pmid,title,authors,citation,first_author,journal,publication_year,create_date,pmcid,nihms_id,doi,url,href,coi,grants,authors_index
30522922,"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","Steven Horwitz 1, Owen A OConnor 2, Barbara Pro 3, Tim Illidge 4, Michelle Fanale 5, Ranjana Advani 6, Nancy L Bartlett 7, Jacob Haaber Christensen 8, Franck Morschhauser 9, Eva Domingo-Domenech 10, Giuseppe Rossi 11, Won Seog Kim 12, Tatyana Feldman 13, Anne Lennard 14, David Belada 15, Árpád Illés 16, Kensei Tobinai 17, Kunihiro Tsukasaki 18, Su-Peng Yeh 19, Andrei Shustov 20, Andreas Hüttmann 21, Kerry J Savage 22, Sam Yuen 23, Swaminathan Iyer 24, Pier Luigi Zinzani 25, Zhaowei Hua 26, Meredith Little 26, Shangbang Rao 27, Joseph Woolery 27, Thomas Manley 27, Lorenz Trümper 28 ; ECHELON-2 Study Group",Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.,Horwitz S,Lancet,2019,2018/12/08,PMC6436818,NIHMS1515984,10.1016/S0140-6736(18)32984-2,https://pubmed.ncbi.nlm.nih.gov/30522922/,/30522922/,"DECLARATION OF INTERESTS Dr. Horwitz reports receiving grant support from Spectrum, grant support and personal fees from Seattle Genetics, Takeda, Kyowa Hakka Kirin, Verastem Oncology, Aileron, ADC Therapeutics, Celgene, and Forty Seven, and personal fees from Portola, Corvus, Miragen, and Innate; Dr. O’Connor, receiving support from Seattle Genetics to conduct the study; Dr. Pro, receiving grant support and personal fees from Seattle Genetics and personal fees from Takeda; Dr. Illidge, receiving personal fees from Takeda; Dr. Fanale, receiving grant support and personal fees from Seattle Genetics during the conduct of the study, grant support, personal fees, and being employed by and holding shares in Seattle Genetics, grant support and personal fees from Takeda, Celgene, Bristol-Myers Squibb, and Merck, grant support from ADC Therapeutics, MedImmune, Gilead, Molecular Templates, and Genentech, and personal fees from Spectrum and Bayer; Dr. Advani, receiving grant support from Agensys, Celgene, Forty Seven, Infinity, Janssen, Kura Oncology, Merck, Millennium, and Regeneron, grant support and consulting and advisory fees from Bristol Myers Squibb, Genentech/Roche, Pharmacyclics, and Seattle Genetics, consulting and advisory fees from Astra Zeneca, Autolus, Bayer Healthcare Pharmaceuticals, Gilead, Juno, Kite, Kyowa Hakko Kirin, NanoString, Spectrum, Sutro Biopharma, and Takeda, and Data Safety Monitoring Board fees from Cell Medica; Dr. Bartlett, receiving research funding from Celgene, Seattle Genetics, Genentech, Kite, Merck, Bristol-Meyers Squibb, Immune Designs, Forty Seven, Affimed, Janssen, Pharmacyclics, Millennium, and Gilead, and advisory board fees from Acerta and Pfizer; Dr. Christensen has nothing to disclose; Dr. Morschhauser, receiving honoraria from Takeda, advisory board fees from Bristol- Myers Squibb, lecture fees from Janssen, advisory board and lecture fees from Celgene and Roche, consultant fees from Epizyme, and consultant, advisory board, and lecture fees from Gilead; Dr. Domingo-Domenech, receiving non-financial support from Seattle Genetics and personal fees from Bristol-Myers Squibb and Takeda; Dr. Rossi, receiving personal fees from Roche, Celgene, Janssen, Amgen, Gilead, Sanofi, Pfizer, AbbVie, Jazz Pharmaceuticals, Novartis, Bristol-Myers Squibb, and Sandoz; Dr. Kim has nothing to disclose; Dr. Feldman, receiving consultant fees from Bristol-Myers Squibb, speaker’s bureau fees and honoraria from Celgene, Pharmacyclis, Janssen, Kite, and AbbVie, and sponsor support, consultant and speaker’s bureau fees, and honoraria from Seattle Genetics; Dr. Lennard has nothing to disclose; Dr. Belada, receiving research support from Seattle Genetics and consultant and advisory board fees from Takeda; Dr. Illés has nothing to disclose; Dr. Tobinai, receiving grant support from GlaxoSmithKline, Servier, and AbbVie, honoraria from Zenyaku Kogyo, and grant support and honoraria from Takeda, Eisai, Celgene, Mundipharma, Janssen, HUYA Bioscience International, Kyowa Hakko Kirin, Chugai Pharma, and Ono Pharma; Dr. Tsukasaki, receiving grant support from Seattle Genetics and Eisai, consultant fees from Ono Pharma and Daiichi-Sankyo, honoraria from Kyowa Hakko Kirin, grant support and honoraria from Celgene and Chugai Pharma, and grant support, consultant fees, and honoraria from HUYA Bioscience International; Dr. Yeh, has nothing to disclose; Dr. Shustov, receiving research funding from Seattle Genetics; Dr. Hüttmann, receiving grant support, honoraria and drug supply for study conduct from Takeda; Dr. Savage, receiving honoraria and advisory board fees from Seattle Genetics, and honoraria from Takeda during the conduct of the study, honoraria and advisory board frees from Bristol-Myers Squibb, Merck, Verastem, Abbvie, and consulting fees from Servier; Dr. Yuen, has nothing to disclose; Dr. Iyer, receiving grant support from Seattle Genetics, Takeda, Roche, Rhizen, Spectrum, Celgene, Gilead, Novarits, Amgen, and Trillium; Dr. Zinzani, receiving advisory board fees and honoraria from Gilead, Sandoz, Johnson & Johnson, Bristol-Myers Squibb, Servier, Takeda, Celtrion, Roche, and Celgene; Dr. Hua has nothing to disclose; Ms. Little, holding shares in and employment with Takeda; Dr. Rao, being employed by and holding shares in Seattle Genetics; Dr. Woolery, being employed by and holding shares in Seattle Genetics; Dr. Manley, being employed by and holding shares in Seattle Genetics and has a patents 62/580,261, 62/739,631, and 62/739,635 licensed to Takeda (all ex-US, except Canada); and Dr. Trümper, receiving grant support from Seattle Genetics and the German Ministry of Education and Research (Bundesministerium für Bildung und Forschung) and grant and non-financial support from Genzyme. No other potential conflict of interest relevant to this article was reported.",Grants and funding P30 CA008748/CA/NCI NIH HHS/United States P30 CA016672/CA/NCI NIH HHS/United States,"Steven Horwitz 1 , Owen A OConnor 2 , Barbara Pro 3 , Tim Illidge 4 , Michelle Fanale 5 , Ranjana Advani 6 , Nancy L Bartlett 7 , Jacob Haaber Christensen 8 , Franck Morschhauser 9 , Eva Domingo-Domenech 10 , Giuseppe Rossi 11 , Won Seog Kim 12 , Tatyana Feldman 13 , Anne Lennard 14 , David Belada 15 , Árpád Illés 16 , Kensei Tobinai 17 , Kunihiro Tsukasaki 18 , Su-Peng Yeh 19 , Andrei Shustov 20 , Andreas Hüttmann 21 , Kerry J Savage 22 , Sam Yuen 23 , Swaminathan Iyer 24 , Pier Luigi Zinzani 25 , Zhaowei Hua 26 , Meredith Little 26 , Shangbang Rao 27 , Joseph Woolery 27 , Thomas Manley 27 , Lorenz Trümper 28 ; ECHELON-2 Study Group"
30312503,"Pediatric asthma: An unmet need for more effective, focused treatments","Nikolaos G Papadopoulos 1 2, Adnan Čustović 3, Michael D Cabana 4, Sharon D Dell 5, Antoine Deschildre 6, Gunilla Hedlin 7 8, Elham Hossny 9, Peter Le Souëf 10, Paolo M Matricardi 11, Antonio Nieto 12, Wanda Phipatanakul 13, Paulo M Pitrez 14, Petr Pohunek 15, Marcela Gavornikova 16, Xavier Jaumont 16, David B Price 17 18",Pediatr Allergy Immunol. 2019 Feb;30(1):7-16. doi: 10.1111/pai.12990. Epub 2018 Nov 15.,Papadopoulos NG,Pediatr Allergy Immunol,2019,2018/10/13,PMC7380053,,10.1111/pai.12990,https://pubmed.ncbi.nlm.nih.gov/30312503/,/30312503/,"Adnan Čustović reports personal fees from Novartis, Regeneron/Sanofi, ALK, Bayer, ThermoFisher, GlaxoSmithKline, and Boehringer Ingelheim. Antoine Deschildre reports personal fees from Novartis, DBV, AImmune, and TEVA and personal fees and congress invitations from ALK, Stallergenes Greer, GlaxoSmithKline, AstraZeneca, and Chiesi. Antonio Nieto reports grants and personal fees from Novartis; clinical trial support from GlaxoSmithKline and AstraZeneca; and lecture honoraria from ThermoFisher. David B. Price reports personal fees from Almirall, Amgen, Cipla, GlaxoSmithKline, Kyorin, Merck, Skyepharma and grants from AKL Research and Development Ltd, British Lung Foundation, Respiratory Effectiveness Group, and UK National Health Service. He reports grants and personal fees from Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva, Theravance, and Zentiva and non‐financial support from the Efficacy and Mechanism Evaluation program and Health Technology Assessment. Dr Price has stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals, and owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore). Gunilla Hedlin reports advisory board participation with Novartis, AstraZeneca and ThermoFisher and lecture honoraria from ThermoFisher. Marcela Gavornikova and Xavier Jaumont are full‐time employees of Novartis Pharma AG, Basel, Switzerland. Michael D. Cabana reports personal fees from Novartis, Genentech, and ThermoFisher. Nikolaos G. Papadopoulos reports personal fees from Novartis, Faes Farma, Biomay, HAL, Nutricia Research, Menarini, MEDA, MSD, Omega Pharma, Abbvie, and Danone and grants from Menarini. Paulo M. Pitrez reports personal fees from Novartis, Boehringer Ingelheim, and AstraZeneca. Petr Pohunek reports personal fees and non‐financial support from Novartis, grants and personal fees from Teva, and personal fees from AstraZeneca and ALK. Sharon D. Dell reports personal fees from Trudell Medical International, AstraZeneca Canada, Novartis Pharmaceuticals, and Vertex Pharmaceuticals. Paolo M. Matricardi reports personal fees and grants from Novartis. All international expert clinicians and scientists received honoraria from Novartis for participation at the advisory board which led to the development of this manuscript.","Grants and funding Novartis Pharma AG, Basel, Switzerland/International","Nikolaos G Papadopoulos 1 2 , Adnan Čustović 3 , Michael D Cabana 4 , Sharon D Dell 5 , Antoine Deschildre 6 , Gunilla Hedlin 7 8 , Elham Hossny 9 , Peter Le Souëf 10 , Paolo M Matricardi 11 , Antonio Nieto 12 , Wanda Phipatanakul 13 , Paulo M Pitrez 14 , Petr Pohunek 15 , Marcela Gavornikova 16 , Xavier Jaumont 16 , David B Price 17 18"
30242544,Optimizing cancer pain management in resource-limited settings,"Sam H Ahmedzai 1, Mary Jocylyn Bautista 2, Kamel Bouzid 3, Rachel Gibson 4, Yuddi Gumara 5, Azza Adel Ibrahim Hassan 6 7, Seiji Hattori 8, Dorothy Keefe 9, Durval Campos Kraychete 10, Dae Ho Lee 11, Kazuo Tamura 12, Jie Jun Wang 13 ; CAncer Pain management in Resource-limited settings (CAPER) Working Group",Support Care Cancer. 2019 Jun;27(6):2113-2124. doi: 10.1007/s00520-018-4471-z. Epub 2018 Sep 21.,Ahmedzai SH,Support Care Cancer,2019,2018/09/23,PMC6499735,,10.1007/s00520-018-4471-z,https://pubmed.ncbi.nlm.nih.gov/30242544/,/30242544/,"MJB, YG, AAIH, SH, DK, DCK, DHL, and JJW received sponsorship from Mundipharma for attending the steering committee meeting. SHA has received payments for conducting research, giving educational lectures, and taking part in advisory boards with Astra Zeneca, Grünenthal, Mundipharma, and Pfizer; for conducting research with Kyowa Kirin; and for giving educational lectures for Menarini. MJB has received remunerations for lectures given for Johnson and Johnson (formerly Janssen Pharmaceuticals) and Fondazione Menarini. RG has received payments for conducting research, giving educational lectures, and taking part in advisory boards with Onyx, Kaleido Biosciences, and Mundipharma. SH has received lecture fees for Shionogi Pharmaceuticals Co., Mundipharma Japan Co., Taiho Pharmaceutical Co., Daiichi Sankyo Co., Hisamitsu Co., and Teikoku Pharmaceutical Co. DK serves on the Advisory Board of Entrinsic Health Solutions. DCK serves on the Latin America Board of the Grünenthal Group and received remunerations for lectures for Cristalia Produtos Químicos e Farmacêuticos. DHL has received honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CJ Healthcare, Eli Lilly, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm, ST Cube, AbbVie, and Takeda for participating in advisory boards. KT has received remunerations for lectures from Kyowa Hakko Kirin Co. Ltd., Ono Pharmaceutical Co., and Eisai Co. JJW has received remunerations for lectures from Eli Lilly, Roche, and Mundipharma. KB, YG, and AAIH have no other conflicts of interest to declare.",,"Sam H Ahmedzai 1 , Mary Jocylyn Bautista 2 , Kamel Bouzid 3 , Rachel Gibson 4 , Yuddi Gumara 5 , Azza Adel Ibrahim Hassan 6 7 , Seiji Hattori 8 , Dorothy Keefe 9 , Durval Campos Kraychete 10 , Dae Ho Lee 11 , Kazuo Tamura 12 , Jie Jun Wang 13 ; CAncer Pain management in Resource-limited settings (CAPER) Working Group"
30457075,Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis,"Rebecca Strawbridge 1, Ben Carter 2, Lindsey Marwood 3, Borwin Bandelow 4, Dimosthenis Tsapekos 5, Viktoriya L Nikolova 6, Rachael Taylor 5, Tim Mantingh 7, Valeria de Angel 8, Fiona Patrick 5, Anthony J Cleare 9, Allan H Young 10",Br J Psychiatry. 2019 Jan;214(1):42-51. doi: 10.1192/bjp.2018.233. Epub 2018 Nov 20.,Strawbridge R,Br J Psychiatry,2019,2018/11/21,,,10.1192/bjp.2018.233,https://pubmed.ncbi.nlm.nih.gov/30457075/,/30457075/,,,"Rebecca Strawbridge 1 , Ben Carter 2 , Lindsey Marwood 3 , Borwin Bandelow 4 , Dimosthenis Tsapekos 5 , Viktoriya L Nikolova 6 , Rachael Taylor 5 , Tim Mantingh 7 , Valeria de Angel 8 , Fiona Patrick 5 , Anthony J Cleare 9 , Allan H Young 10"
29987879,Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma,"Jaco Voorham 1, Xiao Xu 2, David B Price 1 3, Sarowar Golam 4, Jill Davis 5, Joanna Zhi Jie Ling 1, Marjan Kerkhof 1, Mandy Ow 1, Trung N Tran 2",Allergy. 2019 Feb;74(2):273-283. doi: 10.1111/all.13556. Epub 2018 Nov 20.,Voorham J,Allergy,2019,2018/07/11,PMC6587525,,10.1111/all.13556,https://pubmed.ncbi.nlm.nih.gov/29987879/,/29987879/,"Jaco Voorham and Marjan Kerkhof are current employees of the Observational and Pragmatic Research Institute, which has conducted paid research in respiratory disease on behalf of the following organizations in the past 5 years: Aerocrine, AKL Research and Development Ltd, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, Zentiva (a Sanofi company). Joanna Zhi Jie Ling and Mandy Ow were former employees of the Observational and Pragmatic Research Institute at the time of the study. David B. Price has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator‐initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. Xiao Xu, Sarowar Golam, Jill Davis, and Trung N. Tran are employees of AstraZeneca.",Grants and funding AstraZeneca/International,"Jaco Voorham 1 , Xiao Xu 2 , David B Price 1 3 , Sarowar Golam 4 , Jill Davis 5 , Joanna Zhi Jie Ling 1 , Marjan Kerkhof 1 , Mandy Ow 1 , Trung N Tran 2"
30209082,"Prevalence and causes of vision loss in North Africa and Middle\xa0East in 2015: magnitude, temporal trends and projections","Rim Kahloun # 1, Moncef Khairallah # 2, Serge Resnikoff 3 4, Maria Vittoria Cicinelli 5, Seth R Flaxman 6, Aditi Das 7, Jost B Jonas 8, Jill E Keeffe 9, John H Kempen 10 11, Janet Leasher 12, Hans Limburg 13, Kovin Naidoo 3 14, Konrad Pesudovs 15, Alexander J Silvester 16, Nina Tahhan 3 4, Hugh R Taylor 17, Tien Yin Wong 18, Rupert R A Bourne 19 ; Vision Loss Expert Group of the Global Burden of Disease Study",Br J Ophthalmol. 2019 Jul;103(7):863-870. doi: 10.1136/bjophthalmol-2018-312068. Epub 2018 Sep 12.,Kahloun R,Br J Ophthalmol,2019,2018/09/14,,,10.1136/bjophthalmol-2018-312068,https://pubmed.ncbi.nlm.nih.gov/30209082/,/30209082/,"Competing interests: JBJ: consultant for Mundipharma (Cambridge, UK); patent holder with Biocompatibles UK (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and/or antiangiogenic factor; patent number: 20120263794) and patent application with the University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europäische Patentanmeldung 15 000 771.4). JHK: consultant for Gilead and Santen. SR: consultant for Brien Holden Vision Institute.",,"Rim Kahloun # 1 , Moncef Khairallah # 2 , Serge Resnikoff 3 4 , Maria Vittoria Cicinelli 5 , Seth R Flaxman 6 , Aditi Das 7 , Jost B Jonas 8 , Jill E Keeffe 9 , John H Kempen 10 11 , Janet Leasher 12 , Hans Limburg 13 , Kovin Naidoo 3 14 , Konrad Pesudovs 15 , Alexander J Silvester 16 , Nina Tahhan 3 4 , Hugh R Taylor 17 , Tien Yin Wong 18 , Rupert R A Bourne 19 ; Vision Loss Expert Group of the Global Burden of Disease Study"
30209084,"Prevalence and causes of vision\xa0loss in South-east Asia and Oceania in 2015: magnitude, temporal trends and projections","Jill Elizabeth Keeffe 1, Robert J Casson 2, Konrad Pesudovs, Hugh R Taylor 3, Maria Vittoria Cicinelli 4, Aditi Das 5, Seth R Flaxman 6, Jost B Jonas 7, John H Kempen 8 9 10, Janet Leasher 11, Hans Limburg 12, Kovin Naidoo 13, Alexander J Silvester 14, Gretchen A Stevens 15, Nina Tahhan 16 17, Tien Yin Wong 18, Serge Resnikoff 16 17, Rupert R A Bourne 19 ; Vision Loss Expert Group of the Global Burden of Disease Study",Br J Ophthalmol. 2019 Jul;103(7):878-884. doi: 10.1136/bjophthalmol-2018-311946. Epub 2018 Sep 12.,Keeffe JE,Br J Ophthalmol,2019,2018/09/14,,,10.1136/bjophthalmol-2018-311946,https://pubmed.ncbi.nlm.nih.gov/30209084/,/30209084/,"Competing interests: JBJ: Consultant for Mundipharma Co. (Cambridge, UK); Patent holder with Biocompatibles UK Ltd. (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and/or ant-angiogenic factor; Patent number: 20120263794), and Patent application with University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europäische Patentanmeldung 15 000 771.4.",Grants and funding 001/WHO_/World Health Organization/International,"Jill Elizabeth Keeffe 1 , Robert J Casson 2 , Konrad Pesudovs, Hugh R Taylor 3 , Maria Vittoria Cicinelli 4 , Aditi Das 5 , Seth R Flaxman 6 , Jost B Jonas 7 , John H Kempen 8 9 10 , Janet Leasher 11 , Hans Limburg 12 , Kovin Naidoo 13 , Alexander J Silvester 14 , Gretchen A Stevens 15 , Nina Tahhan 16 17 , Tien Yin Wong 18 , Serge Resnikoff 16 17 , Rupert R A Bourne 19 ; Vision Loss Expert Group of the Global Burden of Disease Study"
30428124,Structural correlates of cognitive impairment in normal pressure hydrocephalus,"Katie A Peterson 1 2, Tom B Mole 1, Nicole C H Keong 2, Elise E DeVito 1 2, George Savulich 1, John D Pickard 2, Barbara J Sahakian 1 3",Acta Neurol Scand. 2019 Mar;139(3):305-312. doi: 10.1111/ane.13052. Epub 2018 Dec 3.,Peterson KA,Acta Neurol Scand,2019,2018/11/15,PMC6492129,,10.1111/ane.13052,https://pubmed.ncbi.nlm.nih.gov/30428124/,/30428124/,"Barbara J. Sahakian consults for Cambridge Cognition, Peak (Brainbow), Mundipharma and has share options in Cambridge Cognition. John D. Pickard reports grants from NIHR Senior Investigator Award and grants from NIHR Cambridge Brain Injury HTC. All other authors have nothing to declare.",Grants and funding G0001354/MRC_/Medical Research Council/United Kingdom 13120-10/St Georges University of London (FBMRC) The Wallitt Foundation G00001354/MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute U.S. National Institutes of Health University of Cambridge Human Brain National Institute for Health Research (NIHR) Royal College of Surgeons/Dunhill Medical Trust Fellowship 089589/Z/09/Z/WT_/Wellcome Trust/United Kingdom G9439390/MRC_/Medical Research Council/United Kingdom NIHR Cambridge Biomedical Research Centre (BRC) Eton College G0600986/MRC_/Medical Research Council/United Kingdom G0001237/MRC_/Medical Research Council/United Kingdom G1000183/MRC_/Medical Research Council/United Kingdom Cambridge University Hospitals NHS Foundation Trust NIHR Biomedical Research Centre NIHR Brain Injury MedTech in vitro Diagnostic Co-operative and Van Geest Grant for hydrocephalus research Pinsent Darwin Fund Show all 20 grants,"Katie A Peterson 1 2 , Tom B Mole 1 , Nicole C H Keong 2 , Elise E DeVito 1 2 , George Savulich 1 , John D Pickard 2 , Barbara J Sahakian 1 3"
29974231,Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma,"Dai Maruyama 1, Kunihiro Tsukasaki 2, Toshiki Uchida 3, Yoshinobu Maeda 4, Hirohiko Shibayama 5, Hirokazu Nagai 6, Mitsutoshi Kurosawa 7, Yoko Suehiro 8, Kiyohiko Hatake 9, Kiyoshi Ando 10, Isao Yoshida 11, Michihiro Hidaka 12, Tohru Murayama 13, Yoko Okitsu 14, Norifumi Tsukamoto 15, Masafumi Taniwaki 16, Junji Suzumiya 17, Kazuo Tamura 18, Takahiro Yamauchi 19, Ryuzo Ueda 20, Kensei Tobinai 21",Ann Hematol. 2019 Jan;98(1):131-142. doi: 10.1007/s00277-018-3418-2. Epub 2018 Jul 5.,Maruyama D,Ann Hematol,2019,2018/07/06,PMC6334730,,10.1007/s00277-018-3418-2,https://pubmed.ncbi.nlm.nih.gov/29974231/,/29974231/,"Dai Maruyama reports research funding from Mundipharma K.K., Chugai Pharma, Kyowa Hakko Kirin, Ono Pharmaceutical, Celgene, Janssen, GlaxoSmithKline, Eisai, Takeda, SERVIER, and Abbvie, MSD, and receiving honoraria from Mundipharma K.K., Takeda, Janssen, Eisai, Biomedis International, Celgene, Sanofi, Kyowa Hakko Kirin, Fujifilm, Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical, and Chugai Pharma. Toshiki Uchida reports receiving an honorarium from Janssen. Yoshinobu Maeda reports research funding from Chugai Pharma, Kyowa Hakko Kirin, and Ono Pharmaceutical, and an honorarium from Mundipharma K.K. Hirokazu Nagai reports research funding from Chugai Pharma, Mundipharma K.K., Eisai, Sanofi K.K., Janssen, Takeda, Ono Pharmaceutical, and Kyowa Hakko Kirin. Hirohiko Shibayama reports research funding from Takeda, Janssen, Ono Pharmaceutical, Astellas, Teijin Pharma, Shionogi, Taiho, and Mundipharma KK, and honoraria from Takeda, Celgene, Novartis, Janssen, Kyowa Hakko Kirin, and Mundipharma KK. Kiyoshi Ando reports research funding from Mundipharma K.K. Isao Yoshida reports research funding from Kyowa Hakko Kirin and Chugai Pharma, and receiving honoraria from Mundipharma K.K., Celgene, and Kyowa Hakko Kirin. Michihiro Hidaka reports research funding from Mundipharma K.K. and Chugai Pharma. Tohru Murayama reports research funding from Celltrion, and honoraria from Nippon Shinyaku, Taiho Pharma, Janssen, Siemens, Kyowa Hakko Kirin, Novartis, Celgene, Ono Pharmaceutical, Pfizer, and Bristol-Myers Squibb. Junji Suzumiya reports research funding from Kyowa Hakko Kirin, Chugai-Roche, Shinnipponkagaku-PPD, Astellas, Toyama Chemical, Eisai, Takeda, Sumitomo Dainippon, Shionogi, Taiho, Yakult, and SymBio, and receiving honoraria from Kyowa Hakko Kirin, Chugai-Roche, Janssen, Eisai, Takeda, Sumitomo Dainippon, Otsuka, Celgene, Alexion, Novartis, Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck, Ono Pharmaceutical, Eli Lilly, Shire, Gilead, and Zenyaku. Kazuo Tamura reports receiving honoraria from Ono Pharmaceutical, Kyowa Hakko Kirin, and Eli Lilly. Ryuzo Ueda reports research funding and an honorarium from Kyowa Hakko Kirin, serving as a consultant for Mundipharma K.K. and Terumo, and receiving an honorarium from Chugai Pharma. Kensei Tobinai reports receiving research funding from Mundipharma K.K., Chugai Pharma, Kyowa Hakko Kirin, Ono Pharmaceutical, Celgene, Janssen, GlaxoSmithKline, Eisai, Takeda, Servier, and Abbvie, and honoraria from Zenyaku Kogyo, Eisai, Takeda, Mundipharma K.K., Janssen, HUYA Bioscience International, Kyowa Hakko Kirin, Celgene, Chugai Pharma, and Ono Pharmaceutical. All remaining authors declared that they have no conflicts of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declarations and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in this study.",,"Dai Maruyama 1 , Kunihiro Tsukasaki 2 , Toshiki Uchida 3 , Yoshinobu Maeda 4 , Hirohiko Shibayama 5 , Hirokazu Nagai 6 , Mitsutoshi Kurosawa 7 , Yoko Suehiro 8 , Kiyohiko Hatake 9 , Kiyoshi Ando 10 , Isao Yoshida 11 , Michihiro Hidaka 12 , Tohru Murayama 13 , Yoko Okitsu 14 , Norifumi Tsukamoto 15 , Masafumi Taniwaki 16 , Junji Suzumiya 17 , Kazuo Tamura 18 , Takahiro Yamauchi 19 , Ryuzo Ueda 20 , Kensei Tobinai 21"
29989247,Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting,"Amy Peacock 1 2, Briony Larance 1, Raimondo Bruno 1 2, Sallie-Anne Pearson 3, Nicholas A Buckley 4, Michael Farrell 1, Louisa Degenhardt 1",Addiction. 2019 Mar;114(3):389-399. doi: 10.1111/add.14380. Epub 2018 Sep 7.,Peacock A,Addiction,2019,2018/07/11,PMC6599581,NIHMS1037298,10.1111/add.14380,https://pubmed.ncbi.nlm.nih.gov/29989247/,/29989247/,"Some of the investigators have received investigator-initiated untied educational grants from Reckitt Benckiser/Indivior for studies of buprenorphine-naloxone (BL, LD), buprenorphine depot (BL, LD, MF), naloxone (LD, MF), the development of an opioid-related behavior scale (BL, LD, RB) and a study of opioid substitution therapy uptake among chronic non-cancer pain patients (BL, LD, RB). LD, AP, BL and MF have received an untied educational grant from Seqirus for a post-marketing study of tapentadol, and LD, AP, BL, RB, and MF have received an untied educational grant from Mundipharma for a post-marketing study of oxycodone. SAP and NAB have no conflicts of interest to declare.",Grants and funding R01 DA044170/DA/NIDA NIH HHS/United States,"Amy Peacock 1 2 , Briony Larance 1 , Raimondo Bruno 1 2 , Sallie-Anne Pearson 3 , Nicholas A Buckley 4 , Michael Farrell 1 , Louisa Degenhardt 1"
30357800,Reasons for Long-Term Use of Benzodiazepines and Z-Drugs in Older Patients,"Uwe Verthein 1, Silke Kuhn 1, Rüdiger Holzbach 1 2, Aliaksandra Mokhar 3, Jörg Dirmaier 3, Martin Härter 3, Jens Reimer 1 4",Gesundheitswesen. 2019 Nov;81(11):e180-e191. doi: 10.1055/a-0719-5096. Epub 2018 Oct 24.,Verthein U,Gesundheitswesen,2019,2018/10/26,,,10.1055/a-0719-5096,https://pubmed.ncbi.nlm.nih.gov/30357800/,/30357800/,"Uwe Verthein erhielt innerhalb der letzten 3 Jahre Vortrags- und Beratungshonorar sowie Reisekostenerstattungen von Mundipharma GmbH. Jens Reimer erhielt innerhalb der letzten 3 Jahre Vortrags-, Autoren- und Beratungshonorar, Reisekostenerstattungen sowie Forschungsunterstützung von Indivior, Camurus und Mundipharma GmbH. Die anderen Autoren hatten keine Verbindungen i.o.g. Sinne.",,"Uwe Verthein 1 , Silke Kuhn 1 , Rüdiger Holzbach 1 2 , Aliaksandra Mokhar 3 , Jörg Dirmaier 3 , Martin Härter 3 , Jens Reimer 1 4"
30353942,Burden of non-motor symptoms in Parkinsons disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel,"K Ray Chaudhuri 1 2, A Antonini 3, W Z Robieson 4, O Sanchez-Soliño 4, L Bergmann 4, W Poewe 5 ; GLORIA study co-investigators",Eur J Neurol. 2019 Apr;26(4):581-e43. doi: 10.1111/ene.13847. Epub 2018 Dec 26.,Ray Chaudhuri K,Eur J Neurol,2019,2018/10/25,PMC6590168,,10.1111/ene.13847,https://pubmed.ncbi.nlm.nih.gov/30353942/,/30353942/,"Dr Chaudhuri was a study investigator and has received honorarium from UCB, AbbVie, Britannia, Mundipharma, Boehringer Ingelheim and GSK Pharmaceuticals for lecturing at symposia. He has acted as a consultant for UCB, AbbVie, Britannia, Neuronova and Mundipharma. He has received research funding from Parkinsons UK, NIHR, PDNMG, as well as educational grants from UCB, Britannia, AbbVie, GSK Pharmaceuticals, Boehringer Ingelheim and Neuronova. Dr Chaudhuri receives royalties from Oxford University Press and holds intellectual property rights for the Kings Parkinsons Pain Scale and Parkinsons Disease Sleep Scale 2. Dr Chaudhuri acknowledges independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London, and Maudsley NHS Foundation Trust and Kings College London. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health, UK. A. Antonini was a study investigator and has received compensation for consultancy and speaker‐related activities from UCG, Boston Scientific, Boehringer Ingelheim, AbbVie and Zambon. He has received research support from Mundipharma. W. Poewe was a study investigator and has received compensation from AbbVie, AstraZeneca, Teva, Novartis, GSK, Boehringer Ingelheim, UCB, Orion Pharma, Zambon and Merz Pharmaceuticals (consultancy and lecture fees in relation to clinical drug development programmes for PD) outside the submitted work. He has received royalties from Thieme, Wiley Blackwell and Oxford University Press. W.Z. Robieson, Olga Sanchez‐Solino and L. Bergmann are employees of AbbVie and may hold AbbVie stock and/or stock options. AbbVie contributed to the design, study conduct and financial support for the study. AbbVie participated in the interpretation of data, review and approval of the publication.","Grants and funding AbbVie, Inc./International","K Ray Chaudhuri 1 2 , A Antonini 3 , W Z Robieson 4 , O Sanchez-Soliño 4 , L Bergmann 4 , W Poewe 5 ; GLORIA study co-investigators"
30366909,Definitions of response and remission for the Robarts Histopathology Index,"Rish K Pai 1, Reena Khanna 2 3, Geert R DHaens 2 4, William J Sandborn 2 5, Jenny Jeyarajah 2, Brian G Feagan 2, Niels Vande Casteele 2 6, Vipul Jairath 2 3 7",Gut. 2019 Nov;68(11):2101-2102. doi: 10.1136/gutjnl-2018-317547. Epub 2018 Oct 26.,Pai RK,Gut,2019,2018/10/28,,,10.1136/gutjnl-2018-317547,https://pubmed.ncbi.nlm.nih.gov/30366909/,/30366909/,"Competing interests: RKP has received consulting fees from Seres Therapeutics, Eli Lilly, Protagonist and Genentech outside the submitted work. RK reports fees from Janssen, AbbVie, Shire, Pfizer and Takeda Canada and from Robarts Clinical Trials outside the submitted work. GRD reports consulting fees from Robarts Clinical Trials; personal fees from Ablynx, Amakem, Amgen, AM Pharma, Boehringer-Ingelheim, Bristol Myers Squibb, Cosmo, Celgene, Celtrion, Covidien, Engene, Galapagos, Medimetrics, Mundipharma, Mitsubishi, Novonordisk, Pfizer, Receptos, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Topivert, Versant and Vifor; grants and personal fees from Abbvie, Ferring, Glaxo Smith Kline, Jansen Biologics, Hospira, Merck Sharp Dome, Prometheus Labs, Robarts Clinical Trials, Takeda and Tillotts; and grants from Falk Pharma and Photopill, outside the submitted work. WJS reports consulting fees from University of Western Ontario (previous owner of Robarts Clinical Trials), Abbvie, Akros Pharma, Allergan, Ambrx, Amgen, Ardelyx, Arena Pharmaceuticals, Atlantic Pharmaceuticals, Avaxia, Biogen, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Conatus, Cosmo Technologies, Escalier Biosciences, Ferring, Ferring Research Institute, Forward Pharma, Galapagos, Genentech, Gilead Sciences, Immune Pharmaceuticals, Index Pharmaceuticals, Janssen, Kyowa Hakko Kirin Pharma, Lilly, Medimmune, Mesoblast, Miraca Life Sciences, Nivalis Therapeutics, Novartis, Nutrition Science Partners, Oppilan Pharma, Otsuka, Palatin, Paul Hastings, Pfizer, Precision IBD, Progenity, Prometheus Laboratories, Qu Biologics, Regeneron, Ritter Pharmaceuticals, Robarts Clinical Trials, Salix, Seattle Genetics, Seres Therapeutics, Shire, Sigmoid Biotechnologies, Takeda, Theradiag, Theravance, Tigenix, Tillotts Pharma, UCB Pharma, Vascular Biogenics and Vivelix; research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, Abbvie, Janssen, Takeda, Lilly and Celgene/Receptos; payments for lectures/speaker’s bureau from Abbvie, Janssen and Takeda; and stock/stock options in Escalier Biosciences, Oppilan Pharma, Precision IBD, Progenity and Ritter Pharmaceuticals. JJ is an employee of Robarts Clinical Trials. BGF reports grant/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor, Elan/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix and Wyeth Pharmaceuticals Inc.; consulting fees from Millennium Pharmaceuticals, Merck, Centocor, Elan/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, Astra Zeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging, Salix Pharmaceuticals, Novonordisk, GSK, Actogenix, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, GiCare Pharma and Sigmoid Pharma; and speaker’s bureau fees from UCB, AbbVie and J&J/Janssen outside the submitted work. NVC reports consulting fees from Janssen, Pfizer, Takeda and UCB. VJ has received consulting fees from AbbVie, Sandoz, Takeda, Janssen, Robarts Clinical Trials, Eli Lilly, GlaxoSmithKline, Arena, Topivert; speaker’s fees from Takeda, Janssen, Shire, and Ferring.",,"Rish K Pai 1 , Reena Khanna 2 3 , Geert R DHaens 2 4 , William J Sandborn 2 5 , Jenny Jeyarajah 2 , Brian G Feagan 2 , Niels Vande Casteele 2 6 , Vipul Jairath 2 3 7"
30076171,Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial,"Vipul Jairath 1, Laurent Peyrin-Biroulet 2, Guangyong Zou 1, Mahmoud Mosli 3, Niels Vande Casteele 1, Reetesh K Pai 4, Mark A Valasek 5, Aude Marchal-Bressenot 6, Larry W Stitt 1, Lisa M Shackelton 1, Reena Khanna 1, Geert R DHaens 1, William J Sandborn 1, Allan Olson 7, Brian G Feagan 1, Rish K Pai 8",Gut. 2019 Jul;68(7):1162-1168. doi: 10.1136/gutjnl-2018-316702. Epub 2018 Aug 3.,Jairath V,Gut,2019,2018/08/05,,,10.1136/gutjnl-2018-316702,https://pubmed.ncbi.nlm.nih.gov/30076171/,/30076171/,"Competing interests: VJ reports scientific advisory board fees from Abbvie, Sandoz, Ferring and Janssen; speaker’s fees from Takeda and Ferring; and travel support for conference attendance from Vifor Pharmaceuticals. LP-B reports consulting fees from AbbVie, Amgen, Biogaran, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Ferring, Forward Pharma, Genentech, H.A.C. Pharma, Hospira, Index Pharmaceuticals, Janssen, Lycera, Merck, Lilly, Mitsubishi, Norgine, Pfizer, Pharmacosmos, Pilège, Samsung Bioepis, Sandoz, Takeda, Therakos, Tillots, UCB Pharma and Vifor; and lecture fees from AbbVie, Ferring, H.A.C. Pharma, Janssen, Merck, Mitsubishi, Norgine, Takeda, Therakos, Tillots and Vifor. GZ is an employee of Robarts Clinical Trials, which was the research organisation that conducted this study. NVC reports consulting fees from Janssen, Pfizer, Takeda and UCB. LWS and LMS report consulting fees from Robarts Clinical Trials, which was the research organisation that conducted this study. RK reports fees from Janssen, AbbVie, Shire, Pfizer and Takeda Canada and from Robarts Clinical Trials outside the submitted work. GRD’H reports consulting fees from Robarts Clinical Trials; personal fees from Ablynx, Amakem, Amgen, AM Pharma, Boehringer-Ingelheim, Bristol Myers Squibb, Cosmo, Celgene, Celtrion, Covidien, Engene, Galapagos, Medimetrics, Mundipharma, Mitsubishi, Novonordisk, Pfizer, Receptos, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Topivert, Versant and Vifor; grants and personal fees from Abbvie, Ferring, Glaxo Smith Kline, Jansen Biologics, Hospira, Merck Sharp Dome, Prometheus Labs, Robarts Clinical Trials, Takeda and Tillotts; and grants from Dr Falk Pharma and Photopill, outside the submitted work. WJS reports consulting fees from University of Western Ontario (previous owner of Robarts Clinical Trials, Inc.), Abbvie, Akros Pharma, Allergan, Ambrx Inc., Amgen, Ardelyx, Arena Pharmaceuticals, Atlantic Pharmaceuticals, Avaxia, Biogen, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Conatus, Cosmo Technologies, Escalier Biosciences, Ferring, Ferring Research Institute, Forward Pharma, Galapagos, Genentech, Gilead Sciences, Immune Pharmaceuticals, Index Pharmaceuticals, Janssen, Kyowa Hakko Kirin Pharma, Lilly, Medimmune, Mesoblast, Miraca Life Sciences, Nivalis Therapeutics, Novartis, Nutrition Science Partners, Oppilan Pharma, Otsuka, Palatin, Paul Hastings, Pfizer, Precision IBD, Progenity, Prometheus Laboratories, Qu Biologics, Regeneron, Ritter Pharmaceuticals, Robarts Clinical Trials, Salix, Seattle Genetics, Seres Therapeutics, Shire, Sigmoid Biotechnologies, Takeda, Theradiag, Theravance, Tigenix, Tillotts Pharma, UCB Pharma, Vascular Biogenics and Vivelix; research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, Abbvie, Janssen, Takeda, Lilly and Celgene/Receptos; payments for lectures/speaker’s bureau from Abbvie, Janssen and Takeda; and stock/stock options in Escalier Biosciences, Oppilan Pharma, Precision IBD, Progenity and Ritter Pharmaceuticals. AO is an employee of Celgene Corporation. BGF reports grant/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor Inc., Elan/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix and Wyeth Pharmaceuticals Inc.; consulting fees from Millennium Pharmaceuticals, Merck, Centocor Inc., Elan/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, Astra Zeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging Inc., Salix Pharmaceuticals, Novonordisk, GSK, Actogenix, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, GiCare Pharma Inc. and Sigmoid Pharma; and speaker’s bureau fees from UCB, AbbVie and J&J/Janssen. RKP reports fees from Genentech outside the submitted work.",,"Vipul Jairath 1 , Laurent Peyrin-Biroulet 2 , Guangyong Zou 1 , Mahmoud Mosli 3 , Niels Vande Casteele 1 , Reetesh K Pai 4 , Mark A Valasek 5 , Aude Marchal-Bressenot 6 , Larry W Stitt 1 , Lisa M Shackelton 1 , Reena Khanna 1 , Geert R DHaens 1 , William J Sandborn 1 , Allan Olson 7 , Brian G Feagan 1 , Rish K Pai 8"
30506764,Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis,"Jennifer R Brown 1, Javid Moslehi 2, Michael S Ewer 3, Susan M OBrien 4, Paolo Ghia 5, Florence Cymbalista 6, Tait D Shanafelt 7, Graeme Fraser 8, Simon Rule 9, Steven E Coutre 10, Marie-Sarah Dilhuydy 11, Paula Cramer 12, Ulrich Jaeger 13, Martin Dreyling 14, John C Byrd 15, Steven Treon 16, Emily Y Liu 17, Stephen Chang 17, Amulya Bista 17, Rama Vempati 17, Lisa Boornazian 17, Rudolph Valentino 17, Vijay Reddy 17, Michelle Mahler 18, Huiying Yang 17, Thorsten Graef 17, Jan A Burger 3",Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.,Brown JR,Br J Haematol,2019,2018/12/04,PMC6587776,,10.1111/bjh.15690,https://pubmed.ncbi.nlm.nih.gov/30506764/,/30506764/,"JRB: consultancy/advisory role with Gilead, Verastem, Pharmacyclics LLC, an AbbVie Company, Janssen, Sun Biopharma, AstraZeneca, Genentech, Loxo, Sunesis, AbbVie, BeiGene, Kite Pharma, TG Therapeutics and Pfizer; research funding from Gilead, Loxo Oncology, Verastem and Sun; data safety monitoring board service for MorphoSys and Invectys; JM: consultancy/advisory role with Novartis, Pfizer, Bristol‐Myers Squibb, Takeda/Millennium and Regeneron; research funding from Bristol‐Myers Squibb and Pfizer; MSE: stock or other ownership in AstraZeneca and Bristol‐Myers Squibb; patents with Elsevier; consultancy/advisory role with AstraZeneca, Bayer and Pharmacyclics LLC, an AbbVie Company; travel expenses from Bayer and Pharmacyclics LLC, an AbbVie Company; SOB: honoraria from and consultancy/advisory role with, Janssen, AbbVie and Pharmacyclics LLC, an AbbVie Company; research funding from Pharmacyclics LLC, an AbbVie Company; PG: consultancy/advisory role with AbbVie, Acerta, BeiGene, Gilead, Janssen, Pharmacyclics LLC, an AbbVie Company, and Sunesis; research funding from AbbVie, Gilead, Janssen and Novartis; speakers bureau for Gilead; FC: honoraria from Janssen, Gilead, AbbVie, Sunesis and Roche; consultancy/advisory role with AbbVie; research funding from Sunesis; travel expenses from Roche, Gilead and AbbVie; TS: research funding from Genentech, AbbVie, GlaxoSmithKline, Pharmacyclics LLC, an AbbVie Company, Janssen, Celgene, Hospira and Cephalon; patents, royalties, other intellectual property from Mayo Clinic; GF: honoraria from Janssen and AbbVie; research funding from Janssen and Celgene; consulting or advisory role with Janssen and AbbVie; speakers bureau for Janssen and Lundbeck; SR: consultancy/advisory role with Roche, Janssen, Celgene, Napp, Kite, AstraZeneca and Celltrion; research funding and travel expenses from Roche and Janssen; SC: consultancy/advisory role with AbbVie, Gilead, Novartis, Celgene, Janssen and Pharmacyclics LLC, an AbbVie Company; research funding from AbbVie, Pharmacyclics LLC, an AbbVie Company, Gilead, Celgene and Novartis; M‐SD: honoraria and travel expenses from and consulting/advisory role with Janssen, Gilead and AbbVie; PC: honoraria from, Janssen‐Cilag, AbbVie and AstraZeneca; consulting/advisory role with AbbVie, AstraZeneca, Janssen‐Cilag and Roche; research funding from Roche, Gilead, Janssen‐Cilag, AbbVie and Acerta; travel expenses from Roche, Janssen‐Cilag and AbbVie; speakers’ bureau for Janssen‐Cilag and AbbVie; UJ: honoraria and travel expenses from and consultancy/advisory role with Gilead, Novartis and AbbVie; MD: honoraria from Bayer, Celgene, Gilead, Janssen and Roche; consultancy/advisory role with Bayer, Celgene, Gilead, Janssen, Mundipharma, Roche and Sandoz; research funding from Celgene, Janssen, Mundipharma and Roche; travel expenses from Janssen and Roche; JCB: research funding from Genentech, Acerta, Pharmacyclics LLC, an AbbVie Company and Janssen; ST: consultancy/advisory role with and travel expenses from Pharmacyclics LLC, an AbbVie Company and Janssen; research funding from Pharmacyclics LLC, an AbbVie Company; expert testimony for Johnson & Johnson; EL: employment with Pharmacyclics LLC, an AbbVie Company; equity ownership in AbbVie; SChang: employment with Pharmacyclics LLC, an AbbVie Company; equity ownership in AbbVie, Johnson & Johnson, Portola, Abbott and Ipsen; ARB: employment with Pharmacyclics LLC, an AbbVie Company; equity ownership in AbbVie; RVempati: employment with and travel expenses from Pharmacyclics LLC, an AbbVie Company; equity ownership in AbbVie; LB: employment with Pharmacyclics, an AbbVie Company, GlaxoSmithKline and AstraZeneca; equity ownership in AstraZeneca, GlaxoSmithKline, AbbVie and OncoGenex; RValentino: employment and leadership with Pharmacyclics LLC, an AbbVie Company; equity ownership in AbbVie and Gilead; VR: employment and leadership with Pharmacyclics LLC, an AbbVie Company; travel expenses from Pharmacyclics LLC, an AbbVie Company, and Janssen; equity ownership in AbbVie; MM: employment with and equity ownership in Johnson & Johnson; HY: employment with Pharmacyclics LLC, an AbbVie Company; equity ownership in AbbVie; TG: employment and leadership with Pharmacyclics LLC, an AbbVie Company; equity ownership in AbbVie; patents/royalties/other intellectual property with Pharmacyclics LLC, an AbbVie Company, and AbbVie; JAB: honoraria and travel expenses from Janssen; consultancy/advisory role with Gilead, Pharmacyclics LLC, an AbbVie Company and Janssen; research funding from Pharmacyclics LLC, an AbbVie Company.",Grants and funding P30 CA016672/CA/NCI NIH HHS/United States,"Jennifer R Brown 1 , Javid Moslehi 2 , Michael S Ewer 3 , Susan M OBrien 4 , Paolo Ghia 5 , Florence Cymbalista 6 , Tait D Shanafelt 7 , Graeme Fraser 8 , Simon Rule 9 , Steven E Coutre 10 , Marie-Sarah Dilhuydy 11 , Paula Cramer 12 , Ulrich Jaeger 13 , Martin Dreyling 14 , John C Byrd 15 , Steven Treon 16 , Emily Y Liu 17 , Stephen Chang 17 , Amulya Bista 17 , Rama Vempati 17 , Lisa Boornazian 17 , Rudolph Valentino 17 , Vijay Reddy 17 , Michelle Mahler 18 , Huiying Yang 17 , Thorsten Graef 17 , Jan A Burger 3"
30428493,Efficacy of Disease Management Programs Asthma and COPD? Results of a Cross-Sectional Study,"Frank Kanniess 1, Katja Krockenberger 2 3, Petra Oepen 4 5, Rahel Hedrich 3, Denise Olbrich 3, Nicole Hessler 6, Andreas Ziegler 6 7 8, Birgit Langer-Brauburger 4",Dtsch Med Wochenschr. 2019 Jan;144(2):e12-e20. doi: 10.1055/a-0672-2461. Epub 2018 Nov 14.,Kanniess F,Dtsch Med Wochenschr,2019,2018/11/15,,,10.1055/a-0672-2461,https://pubmed.ncbi.nlm.nih.gov/30428493/,/30428493/,Diese Studie wurde durch die Mundipharma GmbH finanziert. P. O. und B.L-B. sind Mitarbeiterinnen der Mundipharma GmbH. F.K. und A.Z. haben Beraterverträge mit der Mundipharma GmbH. A.Z. ist Mitglied der Schriftleitung der Dtsch Med Wochenschr.,,"Frank Kanniess 1 , Katja Krockenberger 2 3 , Petra Oepen 4 5 , Rahel Hedrich 3 , Denise Olbrich 3 , Nicole Hessler 6 , Andreas Ziegler 6 7 8 , Birgit Langer-Brauburger 4"
30470860,Altered fecal microbiota composition in the Flinders sensitive line rat model of depression,"Sandra Tillmann 1, Anders Abildgaard 2 3, Gudrun Winther 2, Gregers Wegener 2",Psychopharmacology (Berl). 2019 May;236(5):1445-1457. doi: 10.1007/s00213-018-5094-2. Epub 2018 Nov 23.,Tillmann S,Psychopharmacology (Berl),2019,2018/11/25,PMC6599185,,10.1007/s00213-018-5094-2,https://pubmed.ncbi.nlm.nih.gov/30470860/,/30470860/,"Gregers Wegener reported having received lecture/consultancy fees from H. Lundbeck A/S, Servier SA, AstraZeneca AB, Eli Lilly A/S, Sun Pharma Pty Ltd., Pfizer, Inc., Shire A/S, HB Pharma A/S, Arla Foods Amba., Janssen Pharma A/S., and Mundipharma International, Ltd. All other authors report no potential conflicts of interest.",,"Sandra Tillmann 1 , Anders Abildgaard 2 3 , Gudrun Winther 2 , Gregers Wegener 2"
30476356,How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies,"Joanne Neale 1 2, Caral Brown 1, Aimee N C Campbell 3, Jermaine D Jones 3, Verena E Metz 3, John Strang 1, Sandra D Comer 3",Addiction. 2019 Apr;114(4):708-718. doi: 10.1111/add.14510. Epub 2018 Dec 28.,Neale J,Addiction,2019,2018/11/27,PMC6411430,NIHMS999016,10.1111/add.14510,https://pubmed.ncbi.nlm.nih.gov/30476356/,/30476356/,"CONFLICT OF INTEREST/ DISCLOSURES J.N. receives honoraria and some expenses from Addiction journal in her role as Commissioning Editor and Senior Qualitative Editor. J.S. is a researcher and clinician who has advocated for wider pre-provision of take-home naloxone, using several types of naloxone. He has also worked with pharmaceutical companies to seek to identify new or improved treatments (including forms of naloxone) from whom he and his employer (King’s College London) have received honoraria, travel costs and/or consultancy payments. This includes work with, during past 3 years, Martindale, Indivior, MundiPharma, Braeburn/Camurus and trial medication supply from iGen and from Camurus. His employer (King’s College London) has registered intellectual property on a novel buccal naloxone formulation and he has also been named in a patent registration by a Pharma company regarding a concentrated nasal naloxone spray. For a fuller account, see J.S.’s web-page at http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. S.D.C. has received compensation (in the form of partial salary support) from studies supported by Alkermes, Braeburn Pharmaceuticals, Cerecor Inc., Endo Pharmaceuticals, Indivior PLC/Reckitt-Benckiser Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, MediciNova, Omeros, and Schering-Plough Corporation. In addition, S.D.C has received compensation from Grunenthal GmbH to conduct a meta-analysis of drug-induced subjective responses and she served as a consultant to the following companies: Analgesic Solutions, AstraZeneca, BioDelivery Sciences International, Cephalon, Clinilabs, Daiichi Sankyo, Egalet, Endo, Inflexxion, Innovative Science Solutions, Janssen, KemPharm, King, Lightlake (now Opiant), Mallinckrodt, Neuromed, Pfizer, and Salix. C.B., A.N.C.C., J.D.J. and V.E.M. have no disclosures to report.",Grants and funding R01 DA035207/DA/NIDA NIH HHS/United States,"Joanne Neale 1 2 , Caral Brown 1 , Aimee N C Campbell 3 , Jermaine D Jones 3 , Verena E Metz 3 , John Strang 1 , Sandra D Comer 3"
30467809,"Methoxyflurane Versus Standard of Care for Acute Trauma-Related Pain in the Emergency Setting: Protocol for a Randomised, Controlled Study in Italy (MEDITA)","Andrea Fabbri 1, Giuseppe Carpinteri 2, Germana Ruggiano 3, Elisabetta Bonafede 4, Antonella Sblendido 5, Alberto Farina 6, Amedeo Soldi 5 ; MEDITA Study Group",Adv Ther. 2019 Jan;36(1):244-256. doi: 10.1007/s12325-018-0830-x. Epub 2018 Nov 22.,Fabbri A,Adv Ther,2019,2018/11/24,PMC6318254,,10.1007/s12325-018-0830-x,https://pubmed.ncbi.nlm.nih.gov/30467809/,/30467809/,,,"Andrea Fabbri 1 , Giuseppe Carpinteri 2 , Germana Ruggiano 3 , Elisabetta Bonafede 4 , Antonella Sblendido 5 , Alberto Farina 6 , Amedeo Soldi 5 ; MEDITA Study Group"
30467809,"Methoxyflurane Versus Standard of Care for Acute Trauma-Related Pain in the Emergency Setting: Protocol for a Randomised, Controlled Study in Italy (MEDITA)","Andrea Fabbri 1, Giuseppe Carpinteri 2, Germana Ruggiano 3, Elisabetta Bonafede 4, Antonella Sblendido 5, Alberto Farina 6, Amedeo Soldi 5 ; MEDITA Study Group",Adv Ther. 2019 Jan;36(1):244-256. doi: 10.1007/s12325-018-0830-x. Epub 2018 Nov 22.,Fabbri A,Adv Ther,2019,2018/11/24,PMC6318254,,10.1007/s12325-018-0830-x,https://pubmed.ncbi.nlm.nih.gov/30467809/,/30467809/,,Funding: Mundipharma Pharmaceuticals srl.,"Andrea Fabbri 1 , Giuseppe Carpinteri 2 , Germana Ruggiano 3 , Elisabetta Bonafede 4 , Antonella Sblendido 5 , Alberto Farina 6 , Amedeo Soldi 5 ; MEDITA Study Group"
30370636,Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHOs World Mental Health Surveys,"Louisa Degenhardt 1, Chrianna Bharat 1, Raimondo Bruno 2, Meyer D Glantz 3, Nancy A Sampson 4, Luise Lago 1, Sergio Aguilar-Gaxiola 5, Jordi Alonso 6 7 8, Laura Helena Andrade 9, Brendan Bunting 10, Jose Miguel Caldas-de-Almeida 11, Alfredo H Cia 12, Oye Gureje 13, Elie G Karam 14 15 16, Mohammad Khalaf 17, John J McGrath 18 19 20, Jacek Moskalewicz 21, Sing Lee 22, Zeina Mneimneh 23, Fernando Navarro-Mateu 24 25 26, Carmen C Sasu 27, Kate Scott 28, Yolanda Torres 29, Vladimir Poznyak 30, Somnath Chatterji 31, Ronald C Kessler 4 ; WHO World Mental Health Survey Collaborators",Addiction. 2019 Mar;114(3):534-552. doi: 10.1111/add.14482. Epub 2018 Dec 9.,Degenhardt L,Addiction,2019,2018/10/30,PMC7059958,NIHMS1564905,10.1111/add.14482,https://pubmed.ncbi.nlm.nih.gov/30370636/,/30370636/,"Declaration of Interests: In the past three years, LD has received investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma and Seqirus. RK received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. RK is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. VP is a staff member of the World Health Organization involved in the development and field testing of ICD-11 for disorders due to substance use and addictive behaviours. SC is also a staff member of the World Health Organization. MG’s role on this study is through his involvement as a Science Officer on U01-MH60220. He had no involvement in the other cited grants. All other authors declare no competing interests.",Grants and funding R01 DA016558/DA/NIDA NIH HHS/United States 1081984/National Health and Medical Research Council/International R03 TW006481/TW/FIC NIH HHS/United States R01 MH069864/MH/NIMH NIH HHS/United States U01 MH060220/MH/NIMH NIH HHS/United States R01 MH070884/MH/NIMH NIH HHS/United States R01 DA044170/DA/NIDA NIH HHS/United States 001/WHO_/World Health Organization/International R13 MH066849/MH/NIMH NIH HHS/United States Show all 9 grants,"Louisa Degenhardt 1 , Chrianna Bharat 1 , Raimondo Bruno 2 , Meyer D Glantz 3 , Nancy A Sampson 4 , Luise Lago 1 , Sergio Aguilar-Gaxiola 5 , Jordi Alonso 6 7 8 , Laura Helena Andrade 9 , Brendan Bunting 10 , Jose Miguel Caldas-de-Almeida 11 , Alfredo H Cia 12 , Oye Gureje 13 , Elie G Karam 14 15 16 , Mohammad Khalaf 17 , John J McGrath 18 19 20 , Jacek Moskalewicz 21 , Sing Lee 22 , Zeina Mneimneh 23 , Fernando Navarro-Mateu 24 25 26 , Carmen C Sasu 27 , Kate Scott 28 , Yolanda Torres 29 , Vladimir Poznyak 30 , Somnath Chatterji 31 , Ronald C Kessler 4 ; WHO World Mental Health Survey Collaborators"
30756091,DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of neuropathic pain,"Mathilde M V Pascal 1, Andreas C Themistocleous 1, Ralf Baron 2, Andreas Binder 2, Didier Bouhassira 3, Geert Crombez 4, Nanna B Finnerup 5 6, Janne Gierthmühlen 2, Yelena Granovsky 7, Leif Groop 8, Harry L Hebert 9, Troels S Jensen 6, Kristinn Johnsen 10, Mark I McCarthy 11, Weihua Meng 9, Colin N A Palmer 12, Andrew S C Rice 13, Jordi Serra 14, Romà Solà 14, David Yarnitsky 7, Blair H Smith 9, Nadine Attal 3, David L H Bennett 1",Wellcome Open Res. 2019 Feb 1;3:63. doi: 10.12688/wellcomeopenres.14576.2. eCollection 2018.,Pascal MMV,Wellcome Open Res,2019,2019/02/16,PMC6364377,,10.12688/wellcomeopenres.14576.2,https://pubmed.ncbi.nlm.nih.gov/30756091/,/30756091/,"Competing interests: DLB has acted as a consultant on behalf of Oxford Innovation for Abide, Biogen, GSK, Lilly, Mitsubishi Tanabe, Mundipharma and TEVA over the last 3 years. NA received speaker honoraria from Pfizer and reported fees for consultant services from Novartis, Teva, Grünenthal, Mundipharma, Sanofi Pasteur, Aptinyx. ASCR has received funding from Orion Pharma. ASCR undertakes consultancy and advisory board work for Imperial College Consultants—in the past 12 months, this has included remunerated work for: Merck, Galapagos, Toray, Quartet, Lateral, Novartis and Orion. ASCR was the owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued on the acquisition of Spinifex by Novartis in July 2015 and from which future milestone payments may occur. ASCR is named as an inventor on patents: Rice A.S.C., Vandevoorde S. and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain, WO 2005/079771 (Google Patents); Okuse K. et al Methods of treating pain by inhibition of vgf activity, EP13702262.0/WO2013 110945 (Google Patents).",Grants and funding WT_/Wellcome Trust/United Kingdom 202747/Z/16/Z/WT_/Wellcome Trust/United Kingdom,"Mathilde M V Pascal 1 , Andreas C Themistocleous 1 , Ralf Baron 2 , Andreas Binder 2 , Didier Bouhassira 3 , Geert Crombez 4 , Nanna B Finnerup 5 6 , Janne Gierthmühlen 2 , Yelena Granovsky 7 , Leif Groop 8 , Harry L Hebert 9 , Troels S Jensen 6 , Kristinn Johnsen 10 , Mark I McCarthy 11 , Weihua Meng 9 , Colin N A Palmer 12 , Andrew S C Rice 13 , Jordi Serra 14 , Romà Solà 14 , David Yarnitsky 7 , Blair H Smith 9 , Nadine Attal 3 , David L H Bennett 1"
30547712,Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry,"Werner Poewe 1, K Ray Chaudhuri 2, Lars Bergmann 3, Angelo Antonini 4",Neurodegener Dis Manag. 2019 Feb;9(1):39-46. doi: 10.2217/nmt-2018-0034. Epub 2018 Dec 14.,Poewe W,Neurodegener Dis Manag,2019,2018/12/15,PMC6360350,,10.2217/nmt-2018-0034,https://pubmed.ncbi.nlm.nih.gov/30547712/,/30547712/,"Financial & competing interests disclosure This study was supported by AbbVie Inc., North Chicago, IL, USA. AbbVie participated in the study design, research, data collection, analysis and interpretation of data, writing, reviewing and approving the manuscript for publication. W Poewe was a study investigator and has received compensation from AbbVie, Astra Zeneca, Teva, Novartis, BIAL, Biogen, Britannia, Neuroderm, UCB, Orion Pharma, Takeda, Roche, Zambon and Merz Pharmaceuticals (for consultancy and lecture fees in relation to clinical drug development programs for Parkinsons disease) outside the submitted work. He has also received royalties from Thieme, Wiley-Blackwell and Oxford University Press. KR Chaudhuri was a study investigator and has received honorarium from UCB, AbbVie, Britannia, Mundipharma, Boehringer Ingelheim and GSK Pharmaceuticals for lecturing at symposia. He has acted as a consultant for UCB, AbbVie, Britannia, Neuronova and Mundipharma. KRC acknowledges independent research presented in this paper partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. He has also received research funding from Parkinsons UK, PDNMG, EU Horizon 2020 and IMI initiative, as well as educational grants from UCB, Britannia, AbbVie, GSK Pharmaceuticals, Boehringer Ingelheim and Neuronova. In addition, he has received royalties from Oxford University Press and holds intellectual property rights for the Kings Parkinsons Pain Scale and Parkinsons Disease Sleep Scale 2. L Bergmann is an employee of AbbVie and owns stock or stock options. A Antonini was a study investigator and has received compensation for consultancy and speaker-related activities from UCB, Boston Scientific, Boehringer Ingelheim, AbbVie and Zambon. He has received research support from Mundipharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support, funded by AbbVie, was provided by KM Cameron of JB Ashtin, who developed the first draft based on an author-approved outline and assisted in implementing author revisions.",,"Werner Poewe 1 , K Ray Chaudhuri 2 , Lars Bergmann 3 , Angelo Antonini 4"
30479060,"Comparison of the efficacy and safety of povidone-iodine foam dressing (Betafoam), hydrocellular foam dressing (Allevyn), and petrolatum gauze for split-thickness skin graft donor site dressing","Chang Sik Pak 1, Dae Hwan Park 2, Tae Suk Oh 3, Won Jai Lee 4, Young Joon Jun 5, Kyung Ah Lee 6, Kap Sung Oh 7, Kyung Hee Kwak 8, Jong Won Rhie 5",Int Wound J. 2019 Apr;16(2):379-386. doi: 10.1111/iwj.13043. Epub 2018 Nov 26.,Pak CS,Int Wound J,2019,2018/11/28,PMC7379600,,10.1111/iwj.13043,https://pubmed.ncbi.nlm.nih.gov/30479060/,/30479060/,,Grants and funding Mundipharma Korea Ltd,"Chang Sik Pak 1 , Dae Hwan Park 2 , Tae Suk Oh 3 , Won Jai Lee 4 , Young Joon Jun 5 , Kyung Ah Lee 6 , Kap Sung Oh 7 , Kyung Hee Kwak 8 , Jong Won Rhie 5"
29363534,Natural disease course of Crohns disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study,"Johan Burisch 1, Gediminas Kiudelis 2, Limas Kupcinskas 2 3, Hendrika Adriana Linda Kievit 4, Karina Winther Andersen 5, Vibeke Andersen 5 6, Riina Salupere 7, Natalia Pedersen 8, Jens Kjeldsen 9, Renata DIncà 10, Daniela Valpiani 11, Doron Schwartz 12, Selwyn Odes 12, Jóngerð Olsen 13, Kári Rubek Nielsen 13, Zsuzsanna Vegh 14, Peter Laszlo Lakatos 14 15, Alina Toca 16, Svetlana Turcan 16, Konstantinos H Katsanos 17, Dimitrios K Christodoulou 17, Mathurin Fumery 18, Corinne Gower-Rousseau 19 20, Stefania Chetcuti Zammit 21, Pierre Ellul 21, Carl Eriksson 22, Jonas Halfvarson 22, Fernando Jose Magro 23 24, Dana Duricova 25, Martin Bortlik 25 26, Alberto Fernandez 27, Vicent Hernández 28, Sally Myers 29, Shaji Sebastian 29, Pia Oksanen 30 31, Pekka Collin 31, Adrian Goldis 32, Ravi Misra 33, Naila Arebi 33, Ioannis P Kaimakliotis 34, Inna Nikuina 35, Elena Belousova 35, Marko Brinar 36, Silvija Cukovic-Cavka 36, Ebbe Langholz 37, Pia Munkholm 1 ; Epi-IBD group",Gut. 2019 Mar;68(3):423-433. doi: 10.1136/gutjnl-2017-315568. Epub 2018 Jan 23.,Burisch J,Gut,2019,2018/01/25,,,10.1136/gutjnl-2017-315568,https://pubmed.ncbi.nlm.nih.gov/29363534/,/29363534/,"Competing interests: JB: consulting fees from Celgene, Janssen-Cilag, AbbVie A/S and Ferring and lecture fees from Abbvie A/S, Pfizer, MSD and Takeda Pharma A/S. VA: consultancy for Janssen and MSD. RS: consulting fees and/or lecture fees from AbbVie, MSD, Takeda, Janssen-Cilag. RD’I: consulting fees from Abbvie, Biocure and lecture fees from Takeda and Mundipharma. MF: speaker/lecture fees for Abbvie, Ferring, MSD, Takeda, Boehringer and Hospira. CG-R: lecture fees from Takeda, MSD, Ferring and Tillots. CE: lecture fees from Takeda. JH: research grants from Janssen, MSD and Takeda and lecture and/or consultancy fees from Abbvie, Cellgene, Ferring, Hospira, Janssen, Medivir, MSD, Pfizer, Vifor Pharma, Takeda and Tillotts Pharma. EL: lecture or consultancy fees from MSD, Abbvie and Ferring Pharmaceuticals. DD: lecture or consultancy fees from AbbVie, Takeda and Janssen. NA: lecture fees from MSD and Jansen. VH: personal fees, non-financial support and other from MSD, AbbVie, Ferring, Faes Farma, Shire, Falk Pharma, Tillots, Otsuka, Hospira Biologicals, Takeda, Jansen and Kernpharma Biologics. AF: personal fees and non-financial support from MSD, AbbVie, Shire and Tillots. SČ-Č: lecture fees from Takeda, MSD, Abbvie.",,"Johan Burisch 1 , Gediminas Kiudelis 2 , Limas Kupcinskas 2 3 , Hendrika Adriana Linda Kievit 4 , Karina Winther Andersen 5 , Vibeke Andersen 5 6 , Riina Salupere 7 , Natalia Pedersen 8 , Jens Kjeldsen 9 , Renata DIncà 10 , Daniela Valpiani 11 , Doron Schwartz 12 , Selwyn Odes 12 , Jóngerð Olsen 13 , Kári Rubek Nielsen 13 , Zsuzsanna Vegh 14 , Peter Laszlo Lakatos 14 15 , Alina Toca 16 , Svetlana Turcan 16 , Konstantinos H Katsanos 17 , Dimitrios K Christodoulou 17 , Mathurin Fumery 18 , Corinne Gower-Rousseau 19 20 , Stefania Chetcuti Zammit 21 , Pierre Ellul 21 , Carl Eriksson 22 , Jonas Halfvarson 22 , Fernando Jose Magro 23 24 , Dana Duricova 25 , Martin Bortlik 25 26 , Alberto Fernandez 27 , Vicent Hernández 28 , Sally Myers 29 , Shaji Sebastian 29 , Pia Oksanen 30 31 , Pekka Collin 31 , Adrian Goldis 32 , Ravi Misra 33 , Naila Arebi 33 , Ioannis P Kaimakliotis 34 , Inna Nikuina 35 , Elena Belousova 35 , Marko Brinar 36 , Silvija Cukovic-Cavka 36 , Ebbe Langholz 37 , Pia Munkholm 1 ; Epi-IBD group"
29742906,"Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans","Kathrin Kahnert 1, Bertram Jobst 2 3 4, Frank Biertz 5, Jürgen Biederer 2 3 6, Henrik Watz 7, Rudolf M Huber 1, Jürgen Behr 1, Philippe A Grenier 8, Peter Alter 9, Claus F Vogelmeier 9, Hans-Ulrich Kauczor 2 3 4, Rudolf A Jörres 10",Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.,Kahnert K,Chron Respir Dis,2019,2018/05/11,PMC6302978,,10.1177/1479972318775423,https://pubmed.ncbi.nlm.nih.gov/29742906/,/29742906/,"Declaration of conflicting interests: Kathrin Kahnert, Bertram Jobst, Frank Biertz, Jürgen Biederer, Henrik Watz, Rudolf M Huber, Jürgen Behr, Rudolf A Jörres declare no competing interests and have nothing to disclose. Claus F Vogelmeier gave presentations at symposia and/or served on scientific advisory boards sponsored by AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Grifols, Menarini, Mundipharma, Novartis, Teva, Cipla, Omniamed, and MedUpdate. Hans-Ulrich Kauczor declares no competing interests and has nothing to disclose with regard to the content of the article. Philippe A Grenier has nothing to disclose with regard to the content of the article.",,"Kathrin Kahnert 1 , Bertram Jobst 2 3 4 , Frank Biertz 5 , Jürgen Biederer 2 3 6 , Henrik Watz 7 , Rudolf M Huber 1 , Jürgen Behr 1 , Philippe A Grenier 8 , Peter Alter 9 , Claus F Vogelmeier 9 , Hans-Ulrich Kauczor 2 3 4 , Rudolf A Jörres 10"
30858777,Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic,"Olga Růžičková Kirchnerová 1, Tomáš Valena 2, Jakub Novosad 3, Milan Teřl 1 ; Czech eXpeRience Study Group",Postepy Dermatol Alergol. 2019 Feb;36(1):34-43. doi: 10.5114/ada.2018.76606. Epub 2018 Jun 20.,Kirchnerová OR,Postepy Dermatol Alergol,2019,2019/03/13,PMC6409880,,10.5114/ada.2018.76606,https://pubmed.ncbi.nlm.nih.gov/30858777/,/30858777/,"Ruzickova-Kirchnerova O. has been paid lecture fees by Mundipharma and Novartis. Valena T. is an employee of Novartis. Novosad J. has been paid lecture fees by Boehringer Ingelheim, Novartis and AstraZeneca. Terl M. has served on scientific advisory boards for AstraZeneca, GSK, Novartis and TEVA , and has been paid lecture fees by AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, GSK, Novartis, Stallergenes and TEVA.",,"Olga Růžičková Kirchnerová 1 , Tomáš Valena 2 , Jakub Novosad 3 , Milan Teřl 1 ; Czech eXpeRience Study Group"
30428646,Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?,"Shin Hye Yoo 1, Chan-Young Ock 1, Bhumsuk Keam 1, Sung Joon Park 2, Tae Min Kim 1, Jin Ho Kim 3, Yoon Kyung Jeon 4, Eun-Jae Chung 2, Seong Keun Kwon 2, J Hun Hah 2, Tack-Kyun Kwon 2, Kyeong Chun Jung 4, Dong-Wan Kim 1, Hong-Gyun Wu 3, Myung-Whun Sung 2, Dae Seog Heo 1",Korean J Intern Med. 2019 Nov;34(6):1313-1323. doi: 10.3904/kjim.2017.397. Epub 2018 Nov 16.,Yoo SH,Korean J Intern Med,2019,2018/11/16,PMC6823569,,10.3904/kjim.2017.397,https://pubmed.ncbi.nlm.nih.gov/30428646/,/30428646/,"J. Hun Hah has consulted for Mundipharma Pte Ltd., Singapore, and has received research funding from Ildong Pharmaceutical Co., Ltd., Korea. No other potential competing interest exists.",Grants and funding Korea Health Industry Development Institute HI17C2085/Ministry of Health and Welfare,"Shin Hye Yoo 1 , Chan-Young Ock 1 , Bhumsuk Keam 1 , Sung Joon Park 2 , Tae Min Kim 1 , Jin Ho Kim 3 , Yoon Kyung Jeon 4 , Eun-Jae Chung 2 , Seong Keun Kwon 2 , J Hun Hah 2 , Tack-Kyun Kwon 2 , Kyeong Chun Jung 4 , Dong-Wan Kim 1 , Hong-Gyun Wu 3 , Myung-Whun Sung 2 , Dae Seog Heo 1"
30341058,Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy,"Shigeru Kusumoto 1, Luca Arcaini 2 3, Xiaonan Hong 4, Jie Jin 5, Won Seog Kim 6, Yok Lam Kwong 7, Marion G Peters 8, Yasuhito Tanaka 9, Andrew D Zelenetz 10 11, Hiroshi Kuriki 12, Günter Fingerle-Rowson 13, Tina Nielsen 13, Eisuke Ueda 12, Hanna Piper-Lepoutre 13, Gila Sellam 13, Kensei Tobinai 14",Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.,Kusumoto S,Blood,2019,2018/10/21,PMC6337873,,10.1182/blood-2018-04-848044,https://pubmed.ncbi.nlm.nih.gov/30341058/,/30341058/,"Conflict-of-interest disclosure: A.D.Z. reports consulting or advisory roles for Adaptive Biotechnologies, Amgen, Celgene, Genentech, Gilead Sciences, and Dr. Reddys Laboratories and research funding from Bristol-Myers Squibb, Genentech, Gilead Sciences, and Roche. E.U. reports employment and stock ownership from Chugai Pharmaceutical. G.F.-R. reports employment and stock ownership from Roche. G.S. reports employment from Roche. H.K. reports employment and stock ownership from Chugai Pharmaceutical. H.P.-L. reports employment from Roche. K.T. reports consulting fees from HUYA Bioscience International and Zenyaku Kogyo and grants, honoraria, and consulting fees from Celgene; grants and honoraria from Chugai Pharmaceutical, Eisai, Janssen, Kyowa Hakko Kirin, Mundipharma, Ono Pharmaceutical, and Takeda; and grants from AbbVie, GlaxoSmithKline, and Servier. L.A. reports consulting or advisory roles for Bayer, Celgene, Gilead Sciences, Roche, and Sandoz, research funding from Gilead Sciences, and participation in a speakers bureau for Celgene. M.G.P. reports that her spouse is an employee of Roche. S.K. reports honoraria and research funding from Bristol-Myers Squibb, Chugai Pharmaceutical, Roche, and Kyowa Hakko Kirin. T.N. reports employment and stock ownership from Roche. Y.L.K reports advisory roles for Abbvie, Amgen, Bristol-Myers Squibb, Janssen, Novartis, Roche, and Takeda. Y.T. reports honoraria and research funding from Bristol-Myers Squibb, Chugai Pharmaceutical and Gilead Sciences. The remaining authors declare no competing financial interests.",Grants and funding P30 CA008748/CA/NCI NIH HHS/United States,"Shigeru Kusumoto 1 , Luca Arcaini 2 3 , Xiaonan Hong 4 , Jie Jin 5 , Won Seog Kim 6 , Yok Lam Kwong 7 , Marion G Peters 8 , Yasuhito Tanaka 9 , Andrew D Zelenetz 10 11 , Hiroshi Kuriki 12 , Günter Fingerle-Rowson 13 , Tina Nielsen 13 , Eisuke Ueda 12 , Hanna Piper-Lepoutre 13 , Gila Sellam 13 , Kensei Tobinai 14"
30402987,Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals,"Liam J Nestor 1 2, Louise M Paterson 1, Anna Murphy 3, John McGonigle 1, Csaba Orban 1, Laurence Reed 1, Eleanor Taylor 3, Remy Flechais 1, Dana Smith 2 4, Edward T Bullmore 2, Karen D Ersche 2 4, John Suckling 2, Rebecca Elliott 3, Bill Deakin 3, Ilan Rabiner 5, Anne Lingford Hughes 1, Barbara J Sahakian 2 4, Trevor W Robbins 2 4, David J Nutt 1 ; ICCAM Consortium",Eur J Neurosci. 2019 Aug;50(3):2311-2321. doi: 10.1111/ejn.14262. Epub 2018 Nov 26.,Nestor LJ,Eur J Neurosci,2019,2018/11/08,PMC6767584,,10.1111/ejn.14262,https://pubmed.ncbi.nlm.nih.gov/30402987/,/30402987/,"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: David J Nutt is an advisor to British National Formulary, MRC, General Medical Council, Department of Health, is President of the European Brain Council, past President of the British Neuroscience Association and European College of Neuropsychopharmacology, chair of the Independent Scientific Committee on Drugs (UK), is a member of the International Centre for Science in Drug Policy, advisor to Swedish government on drug, alcohol and tobacco research, editor of the Journal of Psychopharmacology, sits on advisory Boards at Lundbeck, MSD, Nalpharm, Orexigen, Shire, has received speaking honoraria (in addition to above) from BMS/Otsuka, GSK, Lilly, Janssen, Servier, is a member of the Lundbeck International Neuroscience Foundation, has received grants or clinical trial payments from P1vital, MRC, NHS, Lundbeck, has share options with P1vital, has been expert witness in a number of legal cases relating to psychotropic drugs, and has edited/written 27 books, some purchased by pharmaceutical companies. Trevor W Robbins has research grants with Eli Lilly and Lundbeck, has received royalties from Cambridge Cognition (CANTAB), has received editorial honoraria from Springer Verlag, Elsevier, Society for Neuroscience; has performed educational lectures for Merck, Sharpe and Dohme and does consultancy work for Cambridge Cognition, Eli Lilly, Lundbeck, Teva and Shire Pharmaceuticals. Barbara J Sahakian consults for Cambridge Cognition, PEAK and Mundipharma. William Deakin currently advises or carries out research funded by Autifony, Sunovion, Lundbeck, AstraZeneca and Servier. All payment is to the University of Manchester. Edward T Bullmore was employed half‐time by the University of Cambridge and half‐time by GSK during some of this work, and is a shareholder in GSK. Liam J Nestor was employed by GSK during some of this work. Eugenii Rabiner worked for GSK until 2011 and is a shareholder in GSK. He is a consultant to GSK, TEVA, Lightlake Therapeutics, AbbVie, and Roche.",Grants and funding WT_/Wellcome Trust/United Kingdom G1000018/MRC_/Medical Research Council/United Kingdom,"Liam J Nestor 1 2 , Louise M Paterson 1 , Anna Murphy 3 , John McGonigle 1 , Csaba Orban 1 , Laurence Reed 1 , Eleanor Taylor 3 , Remy Flechais 1 , Dana Smith 2 4 , Edward T Bullmore 2 , Karen D Ersche 2 4 , John Suckling 2 , Rebecca Elliott 3 , Bill Deakin 3 , Ilan Rabiner 5 , Anne Lingford Hughes 1 , Barbara J Sahakian 2 4 , Trevor W Robbins 2 4 , David J Nutt 1 ; ICCAM Consortium"
30109418,Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ),"Kimberley Wilhelmina Johanna van der Sloot 1 2, Rinse Karel Weersma 3, Gerard Dijkstra 3, Behrooz Zaid Alizadeh 4",J Gastroenterol. 2019 Mar;54(3):238-248. doi: 10.1007/s00535-018-1501-z. Epub 2018 Aug 14.,van der Sloot KWJ,J Gastroenterol,2019,2018/08/16,PMC6394725,,10.1007/s00535-018-1501-z,https://pubmed.ncbi.nlm.nih.gov/30109418/,/30109418/,"KWJS: no disclosures; RKW: unrestricted research grants from Takeda and Ferring Pharmaceutical Company; BZA: no disclosures; GD: unrestricted grants from Abbvie, Takeda and Ferring Pharmaceutcials. Advisory boards for Mundipharma and Pharmacosmos and received speakers fees from Takeda and Janssen Pharmceuticals.","Grants and funding 016.136.308/Nederlandse Organisatie voor Wetenschappelijk Onderzoek 16-22/Rijksuniversiteit Groningen (NL), Junior Scientific Masterclass","Kimberley Wilhelmina Johanna van der Sloot 1 2 , Rinse Karel Weersma 3 , Gerard Dijkstra 3 , Behrooz Zaid Alizadeh 4"
30315239,"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma","G Fraser 1, P Cramer 2, F Demirkan 3, R Santucci Silva 4, S Grosicki 5, A Pristupa 6, A Janssens 7, J Mayer 8, N L Bartlett 9, M-S Dilhuydy 10, H Pylypenko 11, J Loscertales 12, A Avigdor 13, S Rule 14, D Villa 15, O Samoilova 16, P Panagiotidis 17, A Goy 18, M A Pavlovsky 19, C Karlsson 20 21, M Hallek 22, M Mahler 23, M Salman 23, S Sun 23, C Phelps 23, S Balasubramanian 24, A Howes 25, A Chanan-Khan 26",Leukemia. 2019 Apr;33(4):969-980. doi: 10.1038/s41375-018-0276-9. Epub 2018 Oct 12.,Fraser G,Leukemia,2019,2018/10/14,PMC6484712,,10.1038/s41375-018-0276-9,https://pubmed.ncbi.nlm.nih.gov/30315239/,/30315239/,"GF: research support/honoraria: Janssen, Hoffmann-La Roche, Celgene; honoraria: Lundbeck, Abbvie. PC: research grants/honoraria/travel support: F. Hoffmann-La Roche, Janssen-Cilag; research grant/travel support: Gilead; research grant/honoraria: AstraZeneca, Novartis; research support/honoraria: AbbVie; travel support: Astellas, Mundipharma. FD: advisory board honorarium: Amgen; non-financial travel support: Janssen. RSS: research support: Roche Pharmaceuticals, GlaxoSmithKline, Celgene, Merck; personal fees: Novartis. AJ: educational grant: Janssen; travel support: Mundipharma, Abbvie; speakers’ fees: Janssen, Takeda, Roche, Abbvie; consulting fees: Janssen, Roche, Gilead, Abbvie. JM: grants: Janssen, Roche. NLB: advisory board fees: Gilead, Seattle Genetics. M-SD: fees: Janssen, Roche. JL: speakers’ bureaus/advisory boards: Janssen, Gilead, Roche. AA: grant: Janssen. SR: fees: Janssen, Pharmacyclics. DV: honoraria: Janssen, Lundbeck, Celgene, Genentech; research funding: Roche. PP: honoraria: Janssen. AG: speakers’ bureau/advisory board fees: Johnson & Johnson/Pharmacyclics, Takeda; consultancy/advisory board fees: Celgene. MAP: speaking/consulting honoraria: Novartis, Janssen. MH: honoraria/travel funds: Janssen; research funding/speakers’ bureau/advisory role: Roche; advisory role: Gilead Sciences. MM, MS, SS, CP, SB, AH: employees of Janssen. AC-K: institutional funding for this clinical trial. The other authors declare no competing interests.",,"G Fraser 1 , P Cramer 2 , F Demirkan 3 , R Santucci Silva 4 , S Grosicki 5 , A Pristupa 6 , A Janssens 7 , J Mayer 8 , N L Bartlett 9 , M-S Dilhuydy 10 , H Pylypenko 11 , J Loscertales 12 , A Avigdor 13 , S Rule 14 , D Villa 15 , O Samoilova 16 , P Panagiotidis 17 , A Goy 18 , M A Pavlovsky 19 , C Karlsson 20 21 , M Hallek 22 , M Mahler 23 , M Salman 23 , S Sun 23 , C Phelps 23 , S Balasubramanian 24 , A Howes 25 , A Chanan-Khan 26"
30359477,"Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma","Stefania Maraka 1, Morris D Groves 1, Aaron G Mammoser 1, Isaac Melguizo-Gavilanes 1, Charles A Conrad 1, Ivo W Tremont-Lukats 1, Monica E Loghin 1, Barbara J OBrien 1, Vinay K Puduvalli 1, Erik P Sulman 2 3 4, Kenneth R Hess 5, Kenneth D Aldape 1, Mark R Gilbert 1, John F de Groot 1, W K Alfred Yung 1, Marta Penas-Prado 1",Cancer. 2019 Feb 1;125(3):424-433. doi: 10.1002/cncr.31811. Epub 2018 Oct 25.,Maraka S,Cancer,2019,2018/10/26,PMC7180384,NIHMS1048969,10.1002/cncr.31811,https://pubmed.ncbi.nlm.nih.gov/30359477/,/30359477/,"CONFLICT OF INTEREST DISCLOSURES Aaron G. Mammoser reports personal fees from NovoCure outside the submitted work. Ivo W. Tremont-Lukats reports honoraria and travel expenses from Novocure outside the submitted work. Barbara J. O’Brien reports personal fees from AbbVie Central Consultancy Group, nonfinancial support from Kadmon Corporation, and personal fees from Monteris Medical Corporation outside the submitted work. Vinay K. Puduvalli reports other from Gilead Biosciences, personal fees from SK Biosciences, personal fees from Orbus Therapeutics, outside the submitted work; honoraria from Nektar, Orbus Therapeutics, Foundation Medicine, and DePuy Companies SK Biosciences, all outside the submitted work; personal fees from Nektar, Threshold Pharmaceuticals, Novocure, and Ziopharm, all outside the submitted work; and stock and ownership interests in Giliad. Erick P. Sulman reports grants, personal fees, and nonfinancial support from Novocure; and grants and personal fees from AbbVie and Merck, all outside the submitted work. John F. de Groot reports grants from Sanofi-Aventis, AstraZeneca, EMD-Serono, Eli Lilly, Novartis, Deciphera Pharmaceuticals, and Mundipharma, all outside the submitted work; personal fees from Celldex, Deciphera Pharmaceuticals, AbbVie, FivePrime Therapeutics, Inc., GW Pharma, Eli Lilly, Boston Biomedical Inc., Kairos Venture Investments, Syneos Health, Monteris, Genentech, Celldex, Foundation Medicine, Inc., Novogen, Deciphera, AstraZeneca, Insys Therapeutics, Kadmon, Merck), and Eli Lilly, all out-side the submitted work; other financial or material interests in DSMB:VBL Therapeutics, DSMB: Novella, and VBI Vaccines, Inc., all outside the submitted work; employment with and stock ownership in Ziopharm Oncology; and stock ownership in Gilead. Marta Penas-Prado reports travel expenses from AGIOS and Lilly outside the submitted work. The remaining authors made no disclosures.",Grants and funding K24 CA160777/CA/NCI NIH HHS/United States Z99 CA999999/ImNIH/Intramural NIH HHS/United States,"Stefania Maraka 1 , Morris D Groves 1 , Aaron G Mammoser 1 , Isaac Melguizo-Gavilanes 1 , Charles A Conrad 1 , Ivo W Tremont-Lukats 1 , Monica E Loghin 1 , Barbara J OBrien 1 , Vinay K Puduvalli 1 , Erik P Sulman 2 3 4 , Kenneth R Hess 5 , Kenneth D Aldape 1 , Mark R Gilbert 1 , John F de Groot 1 , W K Alfred Yung 1 , Marta Penas-Prado 1"
30455380,Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab,"Anton W Langerak 1, Matthias Ritgen 2, Valentin Goede 3 4, Sandra Robrecht 4, Jasmin Bahlo 4, Kirsten Fischer 4, Michael Steurer 5, Marek Trněný 6, Stephen P Mulligan 7, Ulrich J M Mey 8, Kerstin Trunzer 9, Günter Fingerle-Rowson 9, Kathryn Humphrey 10, Stephan Stilgenbauer 11, Sebastian Böttcher 2 12, Monika Brüggemann 2, Michael Hallek 4 13, Michael Kneba 2, Jacques J M van Dongen 1 14",Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19.,Langerak AW,Blood,2019,2018/11/21,PMC6356981,,10.1182/blood-2018-03-839688,https://pubmed.ncbi.nlm.nih.gov/30455380/,/30455380/,"Conflict-of-interest disclosure: A.W.L. received research funding from Roche and was an advisory board member for AbbVie. V.G. received consulting fees from Roche; was an advisory board member for Roche, Janssen, Gilead Sciences, and AbbVie; and received honoraria from Roche, Janssen, and Gilead Sciences. K.F. received travel grants from Roche. M.S. received consulting fees, research funding, and honoraria from and was an advisory board member for Roche, Janssen, Gilead Sciences, and AbbVie. M.T. received consulting fees and honoraria from Roche, Celgene, Janssen, AbbVie, Bristol-Myers Squibb, Takeda, and Gilead Sciences and research funding from Roche and Celgene. U.J.M.M. received honoraria from and was an advisory board member for Roche. S.S. received consulting fees, speaker honoraria, research funding, and travel support from and was an advisory board member for AbbVie, Celgene, Roche/Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, and Novartis. S.B. received research funding from Roche, Celgene, Janssen, and AbbVie; was an advisory board member for Roche; and received honoraria from Roche, AbbVie, Novartis, and Janssen. M.B. received consulting fees from PRMA, research funding from Amgen, and honoraria from Pfizer and Amgen and was an advisory board member for Incyte and Amgen. M.K. received research funding from Roche. J.J.M.v.D. received research funding from Roche, Amgen, and BD Biosciences. M.H. received honoraria and research funding from and was an advisory board member for AbbVie, Amgen, Celgene, Roche, Gilead Sciences, Janssen, and Mundipharma. M.R. received research funding from and was an advisory board member for Roche. K.T., G.F.-R., and K.H. are employed by F. Hoffmann-La Roche Ltd. The remaining authors declare no competing financial interests.",,"Anton W Langerak 1 , Matthias Ritgen 2 , Valentin Goede 3 4 , Sandra Robrecht 4 , Jasmin Bahlo 4 , Kirsten Fischer 4 , Michael Steurer 5 , Marek Trněný 6 , Stephen P Mulligan 7 , Ulrich J M Mey 8 , Kerstin Trunzer 9 , Günter Fingerle-Rowson 9 , Kathryn Humphrey 10 , Stephan Stilgenbauer 11 , Sebastian Böttcher 2 12 , Monika Brüggemann 2 , Michael Hallek 4 13 , Michael Kneba 2 , Jacques J M van Dongen 1 14"
30421838,Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study,"Andrea L Schaffer 1, Emily A Karanges 1, Nicholas A Buckley 2, Andrew Wilson 3, Louisa Degenhardt 4, Briony Larance 4, Sallie-Anne Pearson 1 3",Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):97-105. doi: 10.1002/pds.4683. Epub 2018 Nov 13.,Schaffer AL,Pharmacoepidemiol Drug Saf,2019,2018/11/14,PMC6687879,NIHMS1037302,10.1002/pds.4683,https://pubmed.ncbi.nlm.nih.gov/30421838/,/30421838/,"Conflict of interest: BL and LD have received investigator-initiated untied educational grants from Reckitt Benckiser/Indivior for studies of buprenorphine-naloxone, buprenorphine depot, naloxone (LD), the development of an opioid-related behaviour scale, and a study of opioid substitution therapy uptake among chronic non-cancer pain patients. BL and LD have received an untied educational grant from Mundipharma Australia to examine the impacts of a tamper-resistant formulation of oxycodone.",Grants and funding R01 DA044170/DA/NIDA NIH HHS/United States,"Andrea L Schaffer 1 , Emily A Karanges 1 , Nicholas A Buckley 2 , Andrew Wilson 3 , Louisa Degenhardt 4 , Briony Larance 4 , Sallie-Anne Pearson 1 3"
31197183,Diabetic neuropathy,"Eva L. Feldman 1, Brian C. Callaghan 1, Rodica Pop-Busui 2, Douglas W. Zochodne 3, Douglas E. Wright 4, David L. Bennett 5, Vera Bril 6 7, James W. Russell 8, Vijay Viswanathan 9",Nat Rev Dis Primers. 2019 Jun 13;5(1):42. doi: 10.1038/s41572-019-0097-9.,Feldman EL,Nat Rev Dis Primers,2019,2019/06/15,PMC7096070,NIHMS1062713,10.1038/s41572-019-0097-9,https://pubmed.ncbi.nlm.nih.gov/31197183/,/31197183/,"Competing interests B.C.C. consults for a Patient-Centered Outcomes Research Institute (PCORI) grant, the Immune Tolerance Network and DynaMed and performs medical legal consultations. D.L.B. has undertaken consultancy work on behalf of Oxford Innovation for Abide, Biogen, GSK, Lilly, Mitsubishi Tanabe, Mundipharma, Teva and Theranexus. All other authors declare no competing interests.",Grants and funding K23 NS079417/NS/NINDS NIH HHS/United States I01 CX001504/CX/CSRD VA/United States I01 RX001030/RX/RRD VA/United States R01 DK115687/DK/NIDDK NIH HHS/United States R24 DK082841/DK/NIDDK NIH HHS/United States R01 DK107956/DK/NIDDK NIH HHS/United States R01 DK107007/DK/NIDDK NIH HHS/United States P30 DK020572/DK/NIDDK NIH HHS/United States WT_/Wellcome Trust/United Kingdom Show all 9 grants,"Eva L. Feldman 1 , Brian C. Callaghan 1 , Rodica Pop-Busui 2 , Douglas W. Zochodne 3 , Douglas E. Wright 4 , David L. Bennett 5 , Vera Bril 6 7 , James W. Russell 8 , Vijay Viswanathan 9"
30586071,The IASP classification of chronic pain for ICD-11: chronic neuropathic pain,"Joachim Scholz 1 2, Nanna B Finnerup 3 4, Nadine Attal 5 6, Qasim Aziz 7, Ralf Baron 8, Michael I Bennett 9, Rafael Benoliel 10, Milton Cohen 11, Giorgio Cruccu 12, Karen D Davis 13 14, Stefan Evers 15 16, Michael First 17, Maria Adele Giamberardino 18, Per Hansson 19 20, Stein Kaasa 21 22 23, Beatrice Korwisi 24, Eva Kosek 25, Patricia Lavandhomme 26, Michael Nicholas 27, Turo Nurmikko 28, Serge Perrot 29, Srinivasa N Raja 30, Andrew S C Rice 31, Michael C Rowbotham 32, Stephan Schug 33, David M Simpson 34, Blair H Smith 35, Peter Svensson 36 37, Johan W S Vlaeyen 38 39, Shuu-Jiun Wang 40 41, Antonia Barke 24, Winfried Rief 24, Rolf-Detlef Treede 42 ; Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG)",Pain. 2019 Jan;160(1):53-59. doi: 10.1097/j.pain.0000000000001365.,Scholz J,Pain,2019,2018/12/27,PMC6310153,NIHMS1502286,10.1097/j.pain.0000000000001365,https://pubmed.ncbi.nlm.nih.gov/30586071/,/30586071/,"Conflict of interest statement Joachim Scholz has received research support from the Thompson Family Foundation and Acetylon, and is now an employee of Biogen. This work was completed before he joined the company. Biogen did not have a role in the design, conduct, analysis, interpretation or funding of the research related to this work. Nanna B. Finnerup has received honoraria for serving on advisory boards or speaker panels from Teva, Novartis, Astellas, Grünenthal, Mitshubishe Tanabe, Novartis and Teva. Nadine Attal has received speaker fees from Pfizer and consultant fees from Aptinyx, Grünenthal, Mundipharma, Novartis, Sanofi Pasteur, and Teva. Ralf Baron reports receiving research grants from Genzyme, Grünenthal, Mundipharma and Pfizer, and honoraria for serving on advisory boards or speakers panels from Abbvie, Allergan, Astellas, AstraZeneca, Bayer, Biogen, Biotest Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Desitin, Eisai, Galapagos NV, Genentech, Genzyme, Glenmark, Grünenthal, Kyowa Kirin, Lilly, Medtronic, Merck MSD, Mundipharma, Novartis, Pfizer, Sanofi Pasteur, Seqirus, TAD, Teva, and Vertex. He is also member of the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Giorgio Cruccu reports grants or personal fees from Alfa Sigma, Angelini, Biogen, Mundipharma, and Pfizer. Michael First reports personal fees from Lundbeck International Neuroscience Foundation, outside the submitted work. Maria Adele Giamberardino reports personal fees from IBSA Institute Biochimique, personal fees from EPITECH Group, personal fees from Helsinn Healthcare, grants from EPITECH Group, grants from Helsinn Healthcare, outside the submitted work. Stein Kaasa reports that he is Eir solution - stockholder. Turo Nurmikko has received personal fees from Abide, Astellas, Mundipharma and Nexstim, and research grants from the Pain Relief Foundation and the National Institute of Health Research in the United Kingdom. Srinivasa N. Raja has received research grants from Medtronic, and serves in the advisory boards of Allergan, Daiichi Sankyo, and Aptinyx. Andrew S.C. Rice has received research funding from Orion, has consulted or participated in advisory boards for Imperial College Consultants, including remunerated work for Abide, Astellas, Galapagos, Lateral, Peter McNaughton from King’s College London and Cambridge University, Merck, Mitsubishi, Novartis, Orion, Pharmaleads, Quartet, and Toray. He owned share options in Spinifex from which personal benefit accrued upon the acquisition of Spinifex by Novartis, and from which future milestone payments may occur. ASCR is also named inventor on patents WO 2005/079771, EP13702262.0, and WO2013/110945. Shuu-Jiun Wang reports personal fees from Eli-Lilly, personal fees from Daiichi-Sankyo, grants and personal fees from Pfizer, Taiwan, personal fees from Eisai, personal fees from Bayer, personal fees from Boehringer Ingelheim, outside the submitted work. Antonia Barke reports personal fees from IASP, during the conduct of the study. Winfried Rief reports grants from IASP, during the conduct of the study; personal fees from Heel, personal fees from Berlin Chemie, outside the submitted work. Rolf-Detlef Treede reports grants from Boehringer Ingelheim, Astellas, AbbVie, Bayer, personal fees from Astellas, Grünenthal, Bauerfeind, Hydra, Bayer, grants from EU, DFG, BMBF, outside the submitted work. The remaining authors have no conflicts of interest to declare.",Grants and funding G0300195/MRC_/Medical Research Council/United Kingdom G0600965/MRC_/Medical Research Council/United Kingdom R01 NS026363/NS/NINDS NIH HHS/United States,"Joachim Scholz 1 2 , Nanna B Finnerup 3 4 , Nadine Attal 5 6 , Qasim Aziz 7 , Ralf Baron 8 , Michael I Bennett 9 , Rafael Benoliel 10 , Milton Cohen 11 , Giorgio Cruccu 12 , Karen D Davis 13 14 , Stefan Evers 15 16 , Michael First 17 , Maria Adele Giamberardino 18 , Per Hansson 19 20 , Stein Kaasa 21 22 23 , Beatrice Korwisi 24 , Eva Kosek 25 , Patricia Lavandhomme 26 , Michael Nicholas 27 , Turo Nurmikko 28 , Serge Perrot 29 , Srinivasa N Raja 30 , Andrew S C Rice 31 , Michael C Rowbotham 32 , Stephan Schug 33 , David M Simpson 34 , Blair H Smith 35 , Peter Svensson 36 37 , Johan W S Vlaeyen 38 39 , Shuu-Jiun Wang 40 41 , Antonia Barke 24 , Winfried Rief 24 , Rolf-Detlef Treede 42 ; Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG)"
30846476,"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019","Dave Singh 1, Alvar Agusti 2, Antonio Anzueto 3, Peter J Barnes 4, Jean Bourbeau 5, Bartolome R Celli 6, Gerard J Criner 7, Peter Frith 8, David M G Halpin 9, Meilan Han 10, M Victorina López Varela 11, Fernando Martinez 12, Maria Montes de Oca 13, Alberto Papi 14, Ian D Pavord 15, Nicolas Roche 16, Donald D Sin 17, Robert Stockley 18, Jørgen Vestbo 19, Jadwiga A Wedzicha 4, Claus Vogelmeier 20",Eur Respir J. 2019 May 18;53(5):1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May.,Singh D,Eur Respir J,2019,2019/03/09,,,10.1183/13993003.00164-2019,https://pubmed.ncbi.nlm.nih.gov/30846476/,/30846476/,"Conflict of interest: D. Singh reports grants and personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, personal fees from Cipla, Genentech and Peptinnovate, outside the submitted work. Conflict of interest: A. Agusti reports personal fees from AstraZeneca, Chiesi and Nuvaira, grants and personal fees from Menarini and GlaxoSmithKline, outside the submitted work. Conflict of interest: A. Anzueto reports grants and personal fees for consultancy from GlaxoSmithKline, personal fees for consultancy from AstraZeneca, Novartis, Boehringer Ingelheim and Sunovion Pharmaceutical, outside the submitted work. Conflict of interest: P.J. Barnes reports grants and personal fees from AstraZeneca and Boehringer Ingelheim, personal fees from Pieris, Novartis and Teva, outside the submitted work. Conflict of interest: J. Bourbeau reports grants from CIHR, Canadian Respiratory Research Network (CRRN), Foundation of the MUHC and Aerocrine, personal fees for consultancy and lecturing from the Canadian Thoracic Society and CHEST, grants and personal fees for advisory work and lecturing from AstraZeneca, Boehringer Ingelheim, Grifols, GlaxoSmithKline, Novartis and Trudell, outside the submitted work. Conflict of interest: B.R. Celli reports grants and research support from AstraZeneca, personal fees for consulting and scientific committee membership from GlaxoSmithKline, personal fees for consulting from Boehringer Ingelheim, Novartis, Sanofi-Aventis and Menarini, outside the submitted work. Conflict of interest: G.J. Criner reports grants and personal fees from GlaxoSmithKline, Boehringer Ingelheim, Chiesi, Mereo, AstraZeneca, Pulmonx, Pneumrx, Olympus, Broncus, Lungpacer, Nuvaira, ResMed, Respironics and Patara, personal fees from Verona, BTG, EOLO and NGM, grants from Alung, Fisher Paykel and Galapagos, outside the submitted work. Conflict of interest: P. Frith reports non-financial support to attend a scientific committee meeting from Global Initiative for Chronic Obstructive Lung Disease (GOLD), during the conduct of the study; personal fees for advisory board membership from AstraZeneca, personal fees and non-financial support for advisory board work, chairing independent conference organising committees and lecturing from Boehringer Ingelheim and Novartis, non-financial support for attending educational meetings from GlaxoSmithKline, non-financial support for attending committee and board meetings from Lung Foundation Australia (LFA), personal fees and non-financial support for advisory board work from CSL Behring, outside the submitted work. Conflict of interest: D.M.G. Halpin reports personal fees and non-financial support from Boehringer Ingelheim and Novartis, personal fees from AstraZeneca, Chiesi, GlaxoSmithKline and Pfizer, outside the submitted work. Conflict of interest: M. Han reports personal fees from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, research support from Novartis and Sunovion, outside the submitted work. Conflict of interest: M.V. López Varela has nothing to disclose. Conflict of interest: F. Martinez reports personal fees for organising CME programmes and non-financial support for travel from the American College of Chest Physicians, Continuing Education, Inova Fairfax Health System, MD Magazine, Miller Communications, National Association for Continuing Education, PeerView Communications, Prime Communications, Puerto Rican Respiratory Society, Potomac, University of Alabama Birmingham, Physicians Education Resource and Canadian Respiratory Network, personal fees for advisory board and steering committee work, and lecturing, and non-financial support for travel from AstraZeneca, personal fees for advisory board and data safety and monitoring board work, and lecturing, non-financial support for travel from Boehringer Ingelheim, non-financial support for advisory board work from ProterrixBio, personal fees for organising CME programmes from Columbia University Integritas, Methodist Hospital Brooklyn, New York University, UpToDate, WebMD/MedScape, Western Connecticut Health Network, Academic CME, PlatformIQ, Rockpointe, Rare Disease Healthcare Communications and France Foundation, personal fees for advisory board work and non-financial support for travel from ConCert, Roche, Sunovion, Theravance and Teva, personal fees for advisory board and data safety and monitoring board work and non-financial support for travel from Genentech, personal fees for advisory board, steering committee and data safety and monitoring board work, and lecturing, and non-financial support for travel from GlaxoSmithKline, personal fees for advisory board work and lecturing, and non-financial support for travel from Novartis and Chiesi, personal fees for advisory board and steering committee work, and non-financial support for travel from Pearl Pharmaceuticals, personal fees for teleconference involvement from Unity, non-financial support for steering committee work from Afferent/Merck, Gilead, Veracyte, Prometic, Bayer and ProMedior, non-financial support for teleconferencing and steering committee work from Nitto, personal fees for consultancy and steering committee work from Patara, non-financial support for data safety and monitoring board work and steering committee from Biogen, personal fees for advisory board work and support for meeting attendance from Zambon, personal fees for editorial board work from the American Thoracic Society, grants from NIH (IPF UO1, COPD UO1/RO1), and non-financial support for consultancy from Bridge Biotherapeutics, outside the submitted work. Conflict of interest: M. Montes de Oca has nothing to disclose. Conflict of interest: A. Papi reports grants, personal fees for board membership, consultancy, lecturing and travel reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and Teva, grants, personal fees for lecturing and travel reimbursement from Menarini, personal fees for lecturing and travel reimbursement from Novartis, Zambon and Sanofi, outside the submitted work. Conflict of interest: I.D. Pavord reports personal fees for lecturing, advisory board work and travel expenses from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and Teva, grants and personal fees for lecturing, advisory board work and travel expenses from Chiesi, personal fees for advisory board work from Sanofi/Regeneron, Merck, Novartis, Knopp and Roche/Genentech, personal fees for lecturing from Circassia and Mundipharma, grants and personal fees for advisory board work from Afferent, outside the submitted work. Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M and Zambon, outside the submitted work. Conflict of interest: D.D. Sin reports grants from Merck, personal fees for advisory meetings from Sanofi-Aventis and Regeneron, grants and personal fees for lecturing and advisory board work from Boehringer Ingelheim and AstraZeneca, personal fees for lecturing and advisory board work from Novartis, outside the submitted work. Conflict of interest: R. Stockley reports personal fees for advisory board membership and lecturing from AstraZeneca, personal fees for advisory board membership from MedImmune, Almirall, Kamada, Baxter, Chiesi and Polyphor, personal fees for lecturing from Nycomed, Takeda and GlaxoSmithKline, personal fees for advisory board membership, lecturing and travel to meetings from Boehringer Ingelheim, grants and personal fees for advisory board membership, lecturing and travel to meetings from CSL Behring, outside the submitted work. Conflict of interest: J. Vestbo reports personal fees for consultancy and lecturing from GlaxoSmithKline, Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis and AstraZeneca, grants from Boehringer Ingelheim, outside the submitted work. Conflict of interest: J.A. Wedzicha reports grants and travel expenses from GlaxoSmithKline, Boehringer Ingelheim, Novartis and AstraZeneca, and grants from Johnson and Johnson, and Chiesi, outside the submitted work. Conflict of interest: C. Vogelmeier reports personal fees from Almirall, Cipla, Berlin-Chemie/Menarini, CSL Behring and Teva, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Mundipharma, Novartis and Takeda, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work.",Grants and funding G0800570/MRC_/Medical Research Council/United Kingdom G1001365/MRC_/Medical Research Council/United Kingdom G1001372/MRC_/Medical Research Council/United Kingdom RP-PG-0109-10056/DH_/Department of Health/United Kingdom,"Dave Singh 1 , Alvar Agusti 2 , Antonio Anzueto 3 , Peter J Barnes 4 , Jean Bourbeau 5 , Bartolome R Celli 6 , Gerard J Criner 7 , Peter Frith 8 , David M G Halpin 9 , Meilan Han 10 , M Victorina López Varela 11 , Fernando Martinez 12 , Maria Montes de Oca 13 , Alberto Papi 14 , Ian D Pavord 15 , Nicolas Roche 16 , Donald D Sin 17 , Robert Stockley 18 , Jørgen Vestbo 19 , Jadwiga A Wedzicha 4 , Claus Vogelmeier 20"
31418093,Diagnosis and management of metabolic acidosis: guidelines from a French expert panel,"Boris Jung 1 2, Mikaël Martinez 3 4, Yann-Erick Claessens 5, Michaël Darmon 6 7 8, Kada Klouche 9 10, Alexandre Lautrette 11 12, Jacques Levraut 13 14, Eric Maury 15 16 17, Mathieu Oberlin 18, Nicolas Terzi 19 20, Damien Viglino 21 22, Youri Yordanov 23 24 25, Pierre-Géraud Claret 26, Naïke Bigé 15 ; Société de Réanimation de Langue Française (SRLF); Société Française de Médecine d’Urgence (SFMU)",Ann Intensive Care. 2019 Aug 15;9(1):92. doi: 10.1186/s13613-019-0563-2.,Jung B,Ann Intensive Care,2019,2019/08/17,PMC6695455,,10.1186/s13613-019-0563-2,https://pubmed.ncbi.nlm.nih.gov/31418093/,/31418093/,"The authors declare the following competing interests: B. Jung: Sedana Medical, Medtronic; M. Martinez: Astra Zeneca, Actélion; YE Claessens: Roche diagnostics, BioMérieux, Sanofi, Pfizer; M. Darmon: Sanofi, Gilead-Kite, Astute Medical, MSD, Astellas; A. Lautrette: Baxter, Frésénius; J. Levraut: LFB, Nova-Biomedical; E. Maury: General Electric Healthcare, Doran International, Vygon, AstraZeneca; N. Terzi: Boehringer Ingelheim, Pfizer; D. Viglino: Astra Zeneca, Mundipharma; Y. Yordanov: Mundipharma, Sanofi; PG Claret: Aspen, AstraZeneca, Daiichi Sankyo, Roche Diagnostics, Sanofi, Thermo Fisher Scientific. The remaining authors declare that they have no competing interests.",,"Boris Jung 1 2 , Mikaël Martinez 3 4 , Yann-Erick Claessens 5 , Michaël Darmon 6 7 8 , Kada Klouche 9 10 , Alexandre Lautrette 11 12 , Jacques Levraut 13 14 , Eric Maury 15 16 17 , Mathieu Oberlin 18 , Nicolas Terzi 19 20 , Damien Viglino 21 22 , Youri Yordanov 23 24 25 , Pierre-Géraud Claret 26 , Naïke Bigé 15 ; Société de Réanimation de Langue Française (SRLF); Société Française de Médecine d’Urgence (SFMU)"
31090937,EUFOREA consensus on biologics for CRSwNP with or without asthma,"Wytske J Fokkens 1 2, Valerie Lund 3, Claus Bachert 2 4 5, Joaquim Mullol 6, Leif Bjermer 7, Jean Bousquet 2 8, Giorgio W Canonica 9 10, Lauren Deneyer 2, Martin Desrosiers 11, Zuzana Diamant 7 12 13, Joseph Han 14, Enrico Heffler 9 10, Claire Hopkins 15, Roger Jankowski 16, Guy Joos 17, Andrew Knill 18, Jivianne Lee 19, Stella E Lee 20, Gert Mariën 2, Benoit Pugin 2 21, Brent Senior 22, Sven F Seys 2 21, Peter W Hellings 1 2 21 23",Allergy. 2019 Dec;74(12):2312-2319. doi: 10.1111/all.13875. Epub 2019 Jul 15.,Fokkens WJ,Allergy,2019,2019/05/16,PMC6972984,,10.1111/all.13875,https://pubmed.ncbi.nlm.nih.gov/31090937/,/31090937/,"Dr. Diamant reports personal fees from AstraZeneca, personal fees from Sanofi‐Genzyme, during the conduct of the study; personal fees from Aquilon, personal fees from ALK, personal fees from Boehringer Ingelheim, personal fees from Gilead, personal fees from Hal Allergy, personal fees from MSD, outside the submitted work; and Apart from my academic affiliations I work at a phase I/II unit performing clinical studies for different biotech and pharma companies. Dr. Bachert reports personal fees from Sanofi, personal fees from GSK, personal fees from Novartis, personal fees from Astra‐Zeneca, during the conduct of the study. Dr. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Dr Han reports to be consultant for Sanofi/Genzyme Regeneron and Astra‐Zeneca. Dr. Hellings reports grants and personal fees from Mylan, during the conduct of the study; personal fees from Sanofi, personal fees from Allergopharma, personal fees from Stallergenes, outside the submitted work. Dr. Hopkins reports personal fees from Advisory Board Participation ‐ Sanofi, personal fees from Advisory Board Participation – Glaxo Smith Kline, personal fees from Advisory Board Participation ‐ Optinose, personal fees from Advisory Board Participation – Smith and Nephew, outside the submitted work. Dr. J. Lee reports grants from Astra‐Zeneca, personal fees from Regeneron Healthcare Solutions, during the conduct of the study. Dr. Jankowski reports personal fees from sanofi regeneron, outside the submitted work. Dr. Joos reports grants and personal fees from AstraZeneca, personal fees from Eureca vzw, grants from Chiesi, grants and personal fees from GlaxoSmithKline, personal fees from Teva, outside the submitted work; all payments were done to his employer. Dr. S. Lee reports grants from Sanofi Regeneron, grants from Allakos Inc, grants from Astra Zeneca, other from Novartis, other from Sanofi Regeneron, outside the submitted work. Dr. Lund reports non‐financial support from GSK, grants from GSK, during the conduct of the study; personal fees from Abbott, personal fees from Kyorin, personal fees from MIMS, personal fees from MSD, personal fees from Elsevier Editor, outside the submitted work. Dr. Mullol reports personal fees and other from SANOFI‐GENZYME & REGENERON, NOVARTIS, and ALLAKOS; grants and personal fees from MYLAN Pharma and URIACH Group; and personal fees from ALK‐Abelló A/S, Menarini, and UCB, outside the submitted work. Dr. Heffler reports grants from AstraZeneca, grants from GSK, grants from Sanofi‐Genzyme, grants from Novartis, grants from Nestlè Purina, grants from Circassia, outside the submitted work. Dr Fokkens reports grants from Sanofi, grants from GSK, grants from Novartis, during the conduct of the study. Dr. Bjermer, Dr. Deneyer, Dr. Desrosiers, Dr. Knill, Dr. Mariën, Dr. Seys, Dr. Senior, Dr. Pugin hava nothing to disclose.",,"Wytske J Fokkens 1 2 , Valerie Lund 3 , Claus Bachert 2 4 5 , Joaquim Mullol 6 , Leif Bjermer 7 , Jean Bousquet 2 8 , Giorgio W Canonica 9 10 , Lauren Deneyer 2 , Martin Desrosiers 11 , Zuzana Diamant 7 12 13 , Joseph Han 14 , Enrico Heffler 9 10 , Claire Hopkins 15 , Roger Jankowski 16 , Guy Joos 17 , Andrew Knill 18 , Jivianne Lee 19 , Stella E Lee 20 , Gert Mariën 2 , Benoit Pugin 2 21 , Brent Senior 22 , Sven F Seys 2 21 , Peter W Hellings 1 2 21 23"
31672337,Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis,"Nicola Black 1, Emily Stockings 1, Gabrielle Campbell 1, Lucy T Tran 1, Dino Zagic 1, Wayne D Hall 2, Michael Farrell 1, Louisa Degenhardt 3",Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28.,Black N,Lancet Psychiatry,2019,2019/11/02,PMC6949116,NIHMS1545883,10.1016/S2215-0366(19)30401-8,https://pubmed.ncbi.nlm.nih.gov/31672337/,/31672337/,"Conflicts of interest MF and LD have been investigators on untied investigator-driven educational grants funded by Reckitt Benckiser, Mundipharma and Seqirus. MF, GC, and LD have been investigators on untied investigator-driven educational grants funded by Indivior.",Grants and funding R01 DA044170/DA/NIDA NIH HHS/United States,"Nicola Black 1 , Emily Stockings 1 , Gabrielle Campbell 1 , Lucy T Tran 1 , Dino Zagic 1 , Wayne D Hall 2 , Michael Farrell 1 , Louisa Degenhardt 3"
30673120,Pregabalin for neuropathic pain in adults,"Sheena Derry 1, Rae Frances Bell, Sebastian Straube, Philip J Wiffen, Dominic Aldington, R Andrew Moore",Cochrane Database Syst Rev. 2019 Jan 23;1(1):CD007076. doi: 10.1002/14651858.CD007076.pub3.,Derry S,Cochrane Database Syst Rev,2019,2019/01/24,PMC6353204,,10.1002/14651858.CD007076.pub3,https://pubmed.ncbi.nlm.nih.gov/30673120/,/30673120/,"SD: none known. RFB: none known. RFB is a retired specialist pain physician who has managed patients with neuropathic pain. SS: none known. Sebastian Straube is a specialist occupational medicine physician. PW: none known. DA has received honoraria from Mundipharma and Grunenthal UK for presentations and expert opinion since 2015. DA is a pain physician who treats patients with neuropathic pain. He also works pro bono for various veterans charities in the UK. RAM has received honoraria from Omega Pharma/Perrigo Pharma (2016, 2017), Futura Pharma (2015, 2016), RB (2015, 2017, 2018), and the Advertising Standards Authority (2016) for providing advice on trial and data analysis methods. He has received honoraria for lectures from Novartis (2016) and RB (2018).",,"Sheena Derry 1 , Rae Frances Bell, Sebastian Straube, Philip J Wiffen, Dominic Aldington, R Andrew Moore"
31626427,Fibromyalgia,Françoise Laroche 1,Rev Prat. 2019 Jun;69(6):649-651.,Laroche F,Rev Prat,2019,2019/10/19,,,,https://pubmed.ncbi.nlm.nih.gov/31626427/,/31626427/,"F. Laroche déclare des liens ponctuels (formations, symposiums, expertises et/ou prise en charge lors de congrès) avec Astellas, Ethypharm, Grünenthal, Kyowa Kirin Pharma, Mundipharma, Novartis, Pfizer, Sanofi et UCB.",,Françoise Laroche 1
30827006,Ulcerative Colitis: Shifting Sands,"Geert R A M DHaens 1, James O Lindsay 2 3, Remo Panaccione 4, Stefan Schreiber 5",Drugs R D. 2019 Jun;19(2):227-234. doi: 10.1007/s40268-019-0263-2.,DHaens GRAM,Drugs R D,2019,2019/03/04,PMC6544716,,10.1007/s40268-019-0263-2,https://pubmed.ncbi.nlm.nih.gov/30827006/,/30827006/,"Geert R.A.M. D’Haens has received consulting fees from AbbVie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmo, Covidien/Medtronics, Dr. Falk Pharma, Engene, Ferring, Galapagos, Gilead, GlaxoSmithKline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millennium/Takeda, Mitsubishi Pharma, MSD, Mundipharma, Novo Nordisk, Pfizer Inc, Prometheus Laboratories/Nestle, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor; research grants from AbbVie, Falk, Ferring, MSD, Mundipharma, and Takeda; and lecture and/or speaker bureau fees from AbbVie, Ferring, Johnson and Johnson, Millennium/Takeda, MSD, Mundipharma, Norgine, Pfizer Inc, Shire, Tillotts, and Vifor. James O. Lindsay has received consulting fees from AbbVie, Celgene, Ferring, Janssen, Merck, Pfizer Inc, Robarts Clinical Trials, Shire, and Takeda; research grants from Pfizer Inc/Hospira, MSD, Shire, and Takeda; lecture and/or speaker bureau fees from AbbVie, Allergan, Ferring, Janssen, MSD, Shire, and Takeda; and advisory board fees from AbbVie, Atlantic Healthcare, Ferring, Hospira, Janssen, MSD, NAP, Pfizer Inc, Shire, Takeda, and Vifor. Remo Panaccione has received consulting fees from AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Biogen, Bristol-Myers Squibb, Celgene, Centocor, Cubist, Eisai, Elan, Ferring, Gilead, GlaxoSmithKline, Janssen, Merck, Pfizer Inc, Robarts Clinical Trials, Salix, Samsung Bioepis, Shire, Takeda, and UCB; research grants from AbbVie, Ferring, Janssen, and Takeda; lecture and/or speaker bureau fees from AbbVie, Aptalis, AstraZeneca, Ferring, Janssen, Merck, Prometheus, Shire, and Takeda; and advisory board fees from Abbott, AbbVie, Amgen, Aptalis, AstraZeneca, Baxter, Bristol-Myers Squibb, Celgene, Centocor, Cubist, Eisai, Elan, Ferring, Genentech, GlaxoSmithKline, Janssen, Merck, Pfizer Inc, Salix, Schering-Plough, Shire, Takeda, and UCB. Stefan Schreiber has received consulting fees from AbbVie, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Janssen, MedImmune, MSD, Pfizer Inc/Hospira, Shire, Takeda, and UCB; and lecture and/or speaker bureau fees from AbbVie, Falk, Ferring, MSD, Takeda, and UCB.",,"Geert R A M DHaens 1 , James O Lindsay 2 3 , Remo Panaccione 4 , Stefan Schreiber 5"
30936704,Unmet needs in asthma,Kevin Gruffydd-Jones 1,Ther Clin Risk Manag. 2019 Mar 14;15:409-421. doi: 10.2147/TCRM.S160327. eCollection 2019.,Gruffydd-Jones K,Ther Clin Risk Manag,2019,2019/04/03,PMC6422410,,10.2147/TCRM.S160327,https://pubmed.ncbi.nlm.nih.gov/30936704/,/30936704/,"Disclosure As a general practitioner, the author has provided a primary care perspective on the review topic. The author has acted as a medical consultant and spoken on behalf of Astra-Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma/Napp, Nutricia, Pfizer, and Teva. The author reports no other conflicts of interest in this work.",,Kevin Gruffydd-Jones 1
31297242,How we treat glioblastoma,"Michael Weller 1, Emilie Le Rhun 2, Matthias Preusser 3, Jörg-Christian Tonn 4, Patrick Roth 5",ESMO Open. 2019 Jun 17;4(Suppl 2):e000520. doi: 10.1136/esmoopen-2019-000520. eCollection 2019.,Weller M,ESMO Open,2019,2019/07/13,PMC6586206,,10.1136/esmoopen-2019-000520,https://pubmed.ncbi.nlm.nih.gov/31297242/,/31297242/,"Competing interests: MW has received research grants from Abbvie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur and Roche and honoraria for lectures or advisory board participation or consulting from Abbvie, Basilea, Bristol Meyer Squibb, Celgene, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen. ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from Abbvie, Daiichi Sankyo, Mundipharma and Novartis. MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dome. JCT has received research grants from BrainLab and honoraria for lectures or consulting from BrainLAb and medac. PR has received honoraria for advisory board participation or lectures from Bristol-Myers Squibb, Covagen, Medac, MSD, Novartis, Novocure, Roche and Virometix.",,"Michael Weller 1 , Emilie Le Rhun 2 , Matthias Preusser 3 , Jörg-Christian Tonn 4 , Patrick Roth 5"
31133026,"Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine","Paola Rogliani 1, Maria Gabriella Matera 2, Clive Page 3, Ermanno Puxeddu 4, Mario Cazzola 4, Luigino Calzetta 4",Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.,Rogliani P,Respir Res,2019,2019/05/29,PMC6537173,,10.1186/s12931-019-1078-y,https://pubmed.ncbi.nlm.nih.gov/31133026/,/31133026/,"PR participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis. Her department was funded by Almirall, Boehringer Ingelheim, Novartis, Zambon and Chiesi Farmaceutici. MGM has participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline and Novartis, and has been a consultant to Chiesi Farmaceutici. CP has acted as a Consultant for Recipharma, ImmunoRegulation, PrEP Biopharma, Ockham Biosciences and Eurodrug. CP also owns equity in Verona Pharma who are developing novel drugs for the treatment of respiratory diseases. EP has no conflict of interest to declare. MC has participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Lallemand, Mundipharma, Novartis, Pfizer, Verona Pharma, and Zambon, and has been a consultant to ABC Farmaceutici, Recipharm, Chiesi Farmaceutici, Lallemand, Novartis, Verona Pharma, and Zambon. His department was funded by Almirall, Boehringer Ingelheim, Novartis, and Zambon. LC has participated as advisor in scientific meetings under the sponsorship of Boehringer Ingelheim and Novartis, received non-financial support by AstraZeneca, received a research grant partially funded by Chiesi Farmaceutici, Boehringer Ingelheim, Novartis, and Almirall, and is or has been a consultant to ABC Farmaceutici, Recipharm, Zambon, Verona Pharma, and Ockham Biotech. His department was funded by Almirall, Boehringer Ingelheim, Novartis, Zambon and Chiesi Farmaceutici.",Grants and funding NA/Edmond Pharma Srl,"Paola Rogliani 1 , Maria Gabriella Matera 2 , Clive Page 3 , Ermanno Puxeddu 4 , Mario Cazzola 4 , Luigino Calzetta 4"
31235526,Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment,"Quentin A Hill 1, Anita Hill 1, Sigbjørn Berentsen 2",Blood Adv. 2019 Jun 25;3(12):1897-1906. doi: 10.1182/bloodadvances.2019000036.,Hill QA,Blood Adv,2019,2019/06/26,PMC6595261,,10.1182/bloodadvances.2019000036,https://pubmed.ncbi.nlm.nih.gov/31235526/,/31235526/,"Conflict-of-interest disclosure: Q.A.H. has received honoraria from Bioverativ and Apellis and research funding from Alexion. A.H. has received honoraria from Bioverativ, Apellis, and Alexion. S.B. has received research funding from Mundipharma and honoraria from Apellis, Bioverativ, Momenta Pharmaceuticals, and True North Therapeutics.",,"Quentin A Hill 1 , Anita Hill 1 , Sigbjørn Berentsen 2"
31666084,Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial,"François Maltais 1, Leif Bjermer 2, Edward M Kerwin 3, Paul W Jones 4, Michael L Watkins 5, Lee Tombs 6, Ian P Naya 4, Isabelle H Boucot 4, David A Lipson 7 8, Chris Compton 4, Mitra Vahdati-Bolouri 9, Claus F Vogelmeier 10",Respir Res. 2019 Oct 30;20(1):238. doi: 10.1186/s12931-019-1193-9.,Maltais F,Respir Res,2019,2019/11/01,PMC6821007,,10.1186/s12931-019-1193-9,https://pubmed.ncbi.nlm.nih.gov/31666084/,/31666084/,"IHB, DAL, CC, MV-B, and PWJ are employees of GSK and hold stocks and shares in GSK. IPN and MLW were employees of GSK at the time of the study. LT is a contingent worker on assignment at GSK. FM has received research grants for participating in multicentre trials for AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, and Novartis, and has received unrestricted research grants and personal fees from Boehringer Ingelheim, Grifols, and Novartis. LB has received honoraria for giving a lecture or attending an advisory board for Airsonett, ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Meda, Novartis and Teva. EMK has served on advisory boards, speaker panels or received travel reimbursement from for Amphastar, AstraZeneca, Boehringer Ingelheim, GSK, Mylan, Novartis, Pearl, Sunovion, Teva, and Theravance and has received consulting fees from Cipia and GSK. CFV has received grants from AstraZeneca, Boehringer Ingelheim, GSK, Grifols, Novartis, Bayer-Schering, MSD, and Pfizer, and has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, GSK, Grifols, Menarini, Mundipharma, Novartis, and Teva. ELLIPTA and DISKUS are owned by/licensed to the GSK group of companies.",,"François Maltais 1 , Leif Bjermer 2 , Edward M Kerwin 3 , Paul W Jones 4 , Michael L Watkins 5 , Lee Tombs 6 , Ian P Naya 4 , Isabelle H Boucot 4 , David A Lipson 7 8 , Chris Compton 4 , Mitra Vahdati-Bolouri 9 , Claus F Vogelmeier 10"
30996039,Dismantling the pathophysiology of asthma using imaging,"Gregory G King 1 2 3, Catherine E Farrow 4 2 3, David G Chapman 2 5",Eur Respir Rev. 2019 Apr 17;28(152):180111. doi: 10.1183/16000617.0111-2018. Print 2019 Jun 30.,King GG,Eur Respir Rev,2019,2019/04/19,PMC9488525,,10.1183/16000617.0111-2018,https://pubmed.ncbi.nlm.nih.gov/30996039/,/30996039/,"Conflict of interest: G.G. King reports grants from CycloMedica and MundiPharma during the conduct of the study; grants, personal fees and other funding from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Menarini and MundiPharma; grants from the National Health and Medical Research Council and Asthma Foundation; other funding from the ATS and ERS; and non-financial support and other funding from Restech, outside the submitted work. Conflict of interest: C. Farrow reports grants from CycloMedica Australia, outside the submitted work. Conflict of interest: D. Chapman reports grants from Cyclomedica during the conduct of the study.",,"Gregory G King 1 2 3 , Catherine E Farrow 4 2 3 , David G Chapman 2 5"
30707761,"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial","Peter Vink 1, Ignacio Delgado Mingorance 2, Constanza Maximiano Alonso 3, Belen Rubio-Viqueira 4, Kyung Hae Jung 5, Juan Francisco Rodriguez Moreno 6, Enrique Grande 7, David Marrupe Gonzalez 8, Sarah Lowndes 9, Javier Puente 10, Hartmut Kristeleit 11, David Farrugia 12, Shelly A McNeil 13, Laura Campora 14, Emmanuel Di Paolo 15, Mohamed El Idrissi 15, Olivier Godeaux 16, Marta López-Fauqued 14, Bruno Salaun 15, Thomas C Heineman 17, Lidia Oostvogels 14 ; Zoster-028 Study Group",Cancer. 2019 Apr 15;125(8):1301-1312. doi: 10.1002/cncr.31909. Epub 2019 Feb 1.,Vink P,Cancer,2019,2019/02/02,PMC6766894,,10.1002/cncr.31909,https://pubmed.ncbi.nlm.nih.gov/30707761/,/30707761/,"Peter Vink, Laura Campora, Emmanuel Di Paolo, Mohamed El Idrissi, Olivier Godeaux, Marta López‐Fauqued, Bruno Salaun, Thomas C. Heineman, and Lidia Oostvogels were employees of the GSK group of companies (GSK) at the time this study was designed, initiated, and/or conducted. Lidia Oostvogels was an employee of CureVacAG as of March 1, 2018, and is an inventor on a patent application related to the vaccine used in this study. Thomas C. Heineman was a paid GSK consultant during manuscript development and is an inventor on a patent application related to the study vaccine. Peter Vink, Laura Campora, Emmanuel Di Paolo, Mohamed El Idrissi, Olivier Godeaux, Bruno Salaun, Thomas C. Heineman, and Lidia Oostvogels hold shares/ stock options in GSK. Hartmut Kristeleit reports fees for consultancy and/or speaker bureau activities from Amgen, Roche, and Eisai. Shelly A. McNeil’s institution has a clinical trial contract with Novartis and has received research grants for conduct of clinical trials by GSK, Merck, Pfizer, and Sanofi Pasteur. Shelly A. McNeil has received honoraria for participation in scientific advisory boards from GSK, Pfizer, Sanofi Pasteur, and Merck and for provision of accredited CME to HCPs on adult immunization and zoster vaccines. Belen Rubio‐Viqueira has received honoraria for scientific advisory board participation from MSD and Lilly and reports personal fees and support from Roche for provision of training and conference attendance. Constanza Maximiano Alonso has received nonfinancial support from Mundipharma, BMS, Pharmamar, Novartis, Janssen‐cilag, MSD, and TEVA and reports personal fees from Sanofi, Pharmamar, Roche, Novartis, Janssen‐cilag, and Bayer. Enrique Grande has received honoraria for ad boards, meetings, and/or lectures from Pfizer, BMS, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi‐Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, and Celgene and has received unrestricted research grants from Pfizer, Astra Zeneca, MTEM/Threshold, Roche, IPSEN and Lexicon. Zostavax is a trademark of Merck Sharpe & Dohme corp. Shingrix is a trademark of the GSK group of companies.",,"Peter Vink 1 , Ignacio Delgado Mingorance 2 , Constanza Maximiano Alonso 3 , Belen Rubio-Viqueira 4 , Kyung Hae Jung 5 , Juan Francisco Rodriguez Moreno 6 , Enrique Grande 7 , David Marrupe Gonzalez 8 , Sarah Lowndes 9 , Javier Puente 10 , Hartmut Kristeleit 11 , David Farrugia 12 , Shelly A McNeil 13 , Laura Campora 14 , Emmanuel Di Paolo 15 , Mohamed El Idrissi 15 , Olivier Godeaux 16 , Marta López-Fauqued 14 , Bruno Salaun 15 , Thomas C Heineman 17 , Lidia Oostvogels 14 ; Zoster-028 Study Group"
31231573,How we treat patients with leptomeningeal metastases,"Emilie Le Rhun 1, Matthias Preusser 2, Martin van den Bent 3, Nicolaus Andratschke 4, Michael Weller 5",ESMO Open. 2019 May 21;4(Suppl 2):e000507. doi: 10.1136/esmoopen-2019-000507. eCollection 2019.,Le Rhun E,ESMO Open,2019,2019/06/25,PMC6555600,,10.1136/esmoopen-2019-000507,https://pubmed.ncbi.nlm.nih.gov/31231573/,/31231573/,"Competing interests: ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from Abbvie, Daiichi Sankyo, Mundipharma and Novartis. MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dohme. MvdB has received research support from AbbVie and declares honoraria from Celgene, BMS, AbbVie, Agios and Boehringer Ingelheim. NA has received grants from Brainlab AG and personal fees from AstraZeneca. MW has received research grants from Abbvie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur and Roche, and honoraria for lectures or advisory board participation or consulting from Abbvie, Basilea, Bristol Meyer Squibb, Celgene, Merck Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen.",,"Emilie Le Rhun 1 , Matthias Preusser 2 , Martin van den Bent 3 , Nicolaus Andratschke 4 , Michael Weller 5"
31278205,Managing cluster headache,"Diana Y Wei 1, Modar Khalil 1 2, Peter J Goadsby 3 4",Pract Neurol. 2019 Dec;19(6):521-528. doi: 10.1136/practneurol-2018-002124. Epub 2019 Jul 5.,Wei DY,Pract Neurol,2019,2019/07/07,PMC6902063,,10.1136/practneurol-2018-002124,https://pubmed.ncbi.nlm.nih.gov/31278205/,/31278205/,"Competing interests: PJG reports, over the last 36 months, grants and personal fees from Amgen and Eli-Lilly and Company, and personal fees from Alder Biopharmaceuticals, Allergan, Autonomic Technologies Inc., Biohaven Pharmaceuticals Inc., Dr Reddys Laboratories, Electrocore LLC, eNeura, Impel Neuropharma, MundiPharma, Novartis, Teva Pharmaceuticals, Trigemina Inc., WL Gore, and personal fees from MedicoLegal work, Massachusetts Medical Society, Up-to-Date, Oxford University Press, and Wolters Kluwer; and a patent magnetic stimulation for headache assigned to eNeura without fee.",,"Diana Y Wei 1 , Modar Khalil 1 2 , Peter J Goadsby 3 4"
31801819,Testing bronchodilator responsiveness,"Christer Janson 1 2, Andrei Malinovschi 3, Andre F S Amaral 2, Simone Accordini 4, Jean Bousquet 5 6 7, A Sonia Buist 8, Judith Garcia-Aymerich 9 10 11, Louisa Gnatiuc 12, Wan Tan 13, Kjell Torén 14, Torsten Zuberbier 7, Peter Burney 2 ; all the authors",Eur Respir J. 2019 Dec 4;54(6):1902104. doi: 10.1183/13993003.02104-2019. Print 2019 Dec.,Janson C,Eur Respir J,2019,2019/12/06,,,10.1183/13993003.02104-2019,https://pubmed.ncbi.nlm.nih.gov/31801819/,/31801819/,"Conflict of interest: C. Janson has nothing to disclose. Conflict of interest: A. Malinovschi has nothing to disclose. Conflict of interest: A.F.S. Amaral has nothing to disclose. Conflict of interest: S. Accordini has nothing to disclose. Conflict of interest: J. Bousquet reports personal fees and other funding from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and other funding from Kyomed, outside the submitted work. Conflict of interest: A.S. Buist has nothing to disclose. Conflict of interest: J. Garcia-Aymerich has nothing to disclose. Conflict of interest: L. Gnatiuc has nothing to disclose. Conflict of interest: W. Tan has nothing to disclose. Conflict of interest: K. Torén has nothing to disclose. Conflict of interest: T. Zuberbier has received consultancy fees from Bayer Health Care, FAES, Novartis and Henkel; has received grants/has grants pensing form Novartis and Henkel, and has received lecture fees from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer HealthCare, Bencradm Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, TEVA, UCB, Henkel, Kryolan and LOreal, outside the submitted work. Conflict of interest: P. Burney has nothing to disclose.",Grants and funding G0901214/MRC_/Medical Research Council/United Kingdom,"Christer Janson 1 2 , Andrei Malinovschi 3 , Andre F S Amaral 2 , Simone Accordini 4 , Jean Bousquet 5 6 7 , A Sonia Buist 8 , Judith Garcia-Aymerich 9 10 11 , Louisa Gnatiuc 12 , Wan Tan 13 , Kjell Torén 14 , Torsten Zuberbier 7 , Peter Burney 2 ; all the authors"
30814138,Women and COPD: do we need more evidence?,"Christophe Gut-Gobert 1, Arnaud Cavaillès 2, Adrien Dixmier 3, Stéphanie Guillot 4, Stéphane Jouneau 5 6, Christophe Leroyer 1, Sylvain Marchand-Adam 7, David Marquette 8, Jean-Claude Meurice 9, Nicolas Desvigne 10, Hugues Morel 3, Christine Person-Tacnet 11, Chantal Raherison 12",Eur Respir Rev. 2019 Feb 27;28(151):180055. doi: 10.1183/16000617.0055-2018. Print 2019 Mar 31.,Gut-Gobert C,Eur Respir Rev,2019,2019/03/01,PMC9488562,,10.1183/16000617.0055-2018,https://pubmed.ncbi.nlm.nih.gov/30814138/,/30814138/,"Conflict of interest: C. Gut-Gobert reports personal fees from Novartis, Chiesi and GSK, outside the submitted work. Conflict of interest: A. Cavailles has nothing to disclose. Conflict of interest: A. Dixmier reports non-financial support from Novartis, outside the submitted work. Conflict of interest: S. Guillot has nothing to disclose. Conflict of interest: S. Jouneau reports grants and personal fees (fees, funding or reimbursement for national and international conferences, boards, expert or opinion groups and research projects) from Actelion, AIRB, AstraZeneca, BMS, Boehringer, Chiesi, Gilead, GSK, LVL, Mundipharma, Novartis, Pfizer, Roche and Savara-Serendex, outside the submitted work. Conflict of interest: C. Leroyer has nothing to disclose. Conflict of interest: S. Marchand-Adam reports personal fees from Novartis, Roche and Boehringer, outside the submitted work. Conflict of interest: D. Marquette has nothing to disclose. Conflict of interest: J-C. Meurice reports grants, personal fees and nonfinancial support from ResMed, grants from Philips, personal fees from Fisher Paykel, and personal fees and nonfinancial support from Novartis and Orkyn, outside the submitted work. Conflict of interest: N. Desvigne reports other fees from Novartis, outside the submitted work. Conflict of interest: H. Morel has nothing to disclose. Conflict of interest: C. Person-Tacnet has nothing to disclose. Conflict of interest: C. Raherison reports personal fees from Novartis, AstraZeneca, Chiesi, GSK and Boeringher Ingelheim, outside the submitted work.",,"Christophe Gut-Gobert 1 , Arnaud Cavaillès 2 , Adrien Dixmier 3 , Stéphanie Guillot 4 , Stéphane Jouneau 5 6 , Christophe Leroyer 1 , Sylvain Marchand-Adam 7 , David Marquette 8 , Jean-Claude Meurice 9 , Nicolas Desvigne 10 , Hugues Morel 3 , Christine Person-Tacnet 11 , Chantal Raherison 12"
31768257,Pharmacological plasticity-How do you hit a moving target?,"Michael J Parnham 1, Gerd Geisslinger 1 2",Pharmacol Res Perspect. 2019 Nov 21;7(6):e00532. doi: 10.1002/prp2.532. eCollection 2019 Dec.,Parnham MJ,Pharmacol Res Perspect,2019,2019/11/27,PMC6868654,,10.1002/prp2.532,https://pubmed.ncbi.nlm.nih.gov/31768257/,/31768257/,"MJP has been a consultant for Leo Pharma and Xellia Pharmaceuticals and was previously an employee of GlaxoSmithKline. GG was a member of the IMI (Innovative Medicine Initiative of the EU) EuroPain collaboration, in which the following industry members are represented: Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Esteve, Gruenenthal, Pfizer, UCB Pharma and Sanofi Aventis. GG has received honoraria as a speaker from Gruenenthal, Mundipharma, and Pfizer. He is a consultant for Abbvie. He has received research funding in the form of a grant from Mundipharma.",,"Michael J Parnham 1 , Gerd Geisslinger 1 2"
30936708,Choosing the right inhaler for your asthma or COPD patient,Omar S Usmani 1,Ther Clin Risk Manag. 2019 Mar 14;15:461-472. doi: 10.2147/TCRM.S160365. eCollection 2019.,Usmani OS,Ther Clin Risk Manag,2019,2019/04/03,PMC6422419,,10.2147/TCRM.S160365,https://pubmed.ncbi.nlm.nih.gov/30936708/,/30936708/,"Disclosure OSU has received industry–academic funding from Boehringer Ingelheim, Chiesi, Edmond Pharma, GlaxoSmithKline, and Mundipharma International, and has received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Edmond Pharma, GlaxoSmithKline, Mundipharma International, Napp, Novartis, Pearl Therapeutics, Roche, Sandoz, Takeda, UCB, Vectura, and Zentiva. The author reports no other conflicts of interest in this work.",,Omar S Usmani 1
32269636,Masterclass in airways disease: course report,"Antonio Spanevello 1, Omar Usmani 2, Batyr R Osmonov 3, Kostiantyn Dmytriiev 4, Kseniia Suska 5",Breathe (Sheff). 2019 Dec;15(4):e132-e134. doi: 10.1183/20734735.0298-2019.,Spanevello A,Breathe (Sheff),2019,2020/04/10,PMC7121875,,10.1183/20734735.0298-2019,https://pubmed.ncbi.nlm.nih.gov/32269636/,/32269636/,"Conflict of interest: A. Spanevello has nothing to disclose. Conflict of interest: O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Takeda, Zentiva, Cipla and Pearl Therapeutics, and grants from GlaxoSmithKline, Prosonix and Edmond Pharma, outside the submitted work. Conflict of interest: B.R.Osmonov has nothing to disclose. Conflict of interest: K. Dmytriiev has nothing to disclose. Conflict of interest: K. Suska reports grants from ERS (bursary to cover the course registration fee), during the conduct of the study.",,"Antonio Spanevello 1 , Omar Usmani 2 , Batyr R Osmonov 3 , Kostiantyn Dmytriiev 4 , Kseniia Suska 5"
31065863,Painful and Painless Diabetic Neuropathies: What Is the Difference?,"Pallai Shillo 1, Gordon Sloan 1, Marni Greig 1, Leanne Hunt 1, Dinesh Selvarajah 2, Jackie Elliott 2, Rajiv Gandhi 1, Iain D Wilkinson 3, Solomon Tesfaye 4 5",Curr Diab Rep. 2019 May 7;19(6):32. doi: 10.1007/s11892-019-1150-5.,Shillo P,Curr Diab Rep,2019,2019/05/09,PMC6505492,,10.1007/s11892-019-1150-5,https://pubmed.ncbi.nlm.nih.gov/31065863/,/31065863/,"Pallai Shillo, Gordon Sloan, Marni Greig, Leanne Hunt, Dinesh Selvarajah, Jackie Elliott, Rajiv Gandhi, and Iain D. Wilkinson declare that they have no conflict of interest. Solomon Tesfaye reports grants from Impeto Medical; personal fees from Neurometrix, Pfizer, Miro, Worwag Pharma, Mundipharma, Merck, and Mitsubishi Pharma; and personal fees and other from Novo Nordisk.",,"Pallai Shillo 1 , Gordon Sloan 1 , Marni Greig 1 , Leanne Hunt 1 , Dinesh Selvarajah 2 , Jackie Elliott 2 , Rajiv Gandhi 1 , Iain D Wilkinson 3 , Solomon Tesfaye 4 5"
31668409,Responding to global stimulant use: challenges and opportunities,"Michael Farrell 1, Natasha K Martin 2, Emily Stockings 3, Annick Bórquez 4, Javier A Cepeda 5, Louisa Degenhardt 3, Robert Ali 6, Lucy Thi Tran 3, Jürgen Rehm 7, Marta Torrens 8, Steve Shoptaw 9, Rebecca McKetin 3",Lancet. 2019 Nov 2;394(10209):1652-1667. doi: 10.1016/S0140-6736(19)32230-5. Epub 2019 Oct 23.,Farrell M,Lancet,2019,2019/11/01,PMC6924572,NIHMS1062649,10.1016/S0140-6736(19)32230-5,https://pubmed.ncbi.nlm.nih.gov/31668409/,/31668409/,"Declaration of interests MF and LD have received investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma, and Seqirus. RA has received untied educational grants from Reckitt Benckiser/Indivior and Mundipharma for studies of opioid substitution and agonist medication treatments in Australia. NKM has received unrestricted research grants to her university from Gilead and Merck unrelated to this work. MT has received educational grants in Spain from Gilead, Merck Sharp & Dohme, Servier, and Lundbeck unrelated to this work. JR has received educational grants from Lundbeck GmbH. SS has received clinical supplies from Alkermes and Medicinova for randomised trials outside of the submitted work. ES, AB, JAC, LTT, and RM report no competing interests.",Grants and funding DP2 DA049295/DA/NIDA NIH HHS/United States P30 MH058107/MH/NIMH NIH HHS/United States R01 AI147490/AI/NIAID NIH HHS/United States P30 AI036214/AI/NIAID NIH HHS/United States T32 DA023356/DA/NIDA NIH HHS/United States K01 DA043421/DA/NIDA NIH HHS/United States Show all 6 grants,"Michael Farrell 1 , Natasha K Martin 2 , Emily Stockings 3 , Annick Bórquez 4 , Javier A Cepeda 5 , Louisa Degenhardt 3 , Robert Ali 6 , Lucy Thi Tran 3 , Jürgen Rehm 7 , Marta Torrens 8 , Steve Shoptaw 9 , Rebecca McKetin 3"
31508197,Pharmacological treatment and current controversies in COPD,"Mario Cazzola 1, Paola Rogliani 1, Daiana Stolz 2, Maria Gabriella Matera 3",F1000Res. 2019 Aug 29;8:F1000 Faculty Rev-1533. doi: 10.12688/f1000research.19811.1. eCollection 2019.,Cazzola M,F1000Res,2019,2019/09/12,PMC6719668,,10.12688/f1000research.19811.1,https://pubmed.ncbi.nlm.nih.gov/31508197/,/31508197/,"Competing interests: MC has participated as a faculty member and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Lallemand, Menarini Group, Mundipharma, Novartis, Pfizer, Teva, Verona Pharma, and Zambon and is or has been a consultant to ABC Farmaceutici, AstraZeneca, Chiesi Farmaceutici, Edmond Pharma, Lallemand, Novartis, Ockham Biotech, Verona Pharma, and Zambon, and his department was funded by Almirall. DS has received research grants from the Swiss National Foundation, AstraZeneca AG, Pan Gas AG, Weinmann AG, Curetis AG, Boston Scientific AG, Circassia Pharmaceuticals, and Lungenliga Switzerland; received payment for lectures, advisory panels, or sponsorship to attend scientific meetings from Novartis AG, AstraZeneca AG, GSK AG, Roche AG, Zambon, Pfizer, and Schwabe Pharma AG; and is the current education council chair of the European Respiratory Society and immediate past president of the European Board for Accreditation in Pneumology and is the current GOLD representative for Switzerland. PR participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, Edmond Pharma, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis, and her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici Novartis, and Zambon. MGM has participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, and Novartis and has been a consultant to ABC Farmaceutici and Chiesi Farmaceutici, and her department was funded by Novartis, Boehringer Ingelheim, Novartis, and Zambon.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.",Grants and funding The author(s) declared that no grants were involved in supporting this work.,"Mario Cazzola 1 , Paola Rogliani 1 , Daiana Stolz 2 , Maria Gabriella Matera 3"
31731307,Typische Verschreibungskaskaden beim multimorbiden Patienten,Hans Jürgen Heppner,Drug Res (Stuttg). 2019 Nov;69(S 01):S21-S22. doi: 10.1055/a-0982-5129. Epub 2019 Nov 15.,Heppner HJ,Drug Res (Stuttg),2019,2019/11/16,,,10.1055/a-0982-5129,https://pubmed.ncbi.nlm.nih.gov/31731307/,/31731307/,"Forschungsunterstützung: ThermoScience, Forschungskolleg Geriatrie der Robert-Bosch-Stiftung, Wissenschaftsforum Geriatrie, Deutsche Bank, Innovationsfonds des G-BA. Vortragshonorare: Pfizer Pharma, Bayer Health Care, Mundipharma, Astellas Pharma, MSD, BLÄK, AO Trauma Europe, Dr. Pfleger GmbH, Grünenthal, Novartis.",,Hans Jürgen Heppner
31414403,Infectious Disease Management and Control with Povidone Iodine,Maren Eggers 1,Infect Dis Ther. 2019 Dec;8(4):581-593. doi: 10.1007/s40121-019-00260-x. Epub 2019 Aug 14.,Eggers M,Infect Dis Ther,2019,2019/08/16,PMC6856232,,10.1007/s40121-019-00260-x,https://pubmed.ncbi.nlm.nih.gov/31414403/,/31414403/,,,Maren Eggers 1
31440986,Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim,"Pere Gascon 1, Andriy Krendyukov 2, Nicola Mathieson 2, Maja Natek 2, Matti Aapro 3",BioDrugs. 2019 Dec;33(6):635-645. doi: 10.1007/s40259-019-00373-2.,Gascon P,BioDrugs,2019,2019/08/24,PMC6875156,,10.1007/s40259-019-00373-2,https://pubmed.ncbi.nlm.nih.gov/31440986/,/31440986/,"MA has been a consultant for Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, GSK, Helsinn, Hospira, Johnson & Johnson, Novartis, Merck, Merck Serono, Mundipharma, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Teva, Vifor, G1 Therapeutics, and Lilly and has received honoraria for lectures at symposia sponsored by Amgen, Bayer Schering, Cephalon, Chugai, Eisai, Genomic Health, GSK, Helsinn, Hospira, Ipsen, Johnson & Johnson, OrthoBiotech, Kyowa Hakko Kirin, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Teva, Vifor, G1 Therapeutics, and Lilly. PG has received consulting fees/honoraria and payment for lectures (including service on speaker’s bureaus) from Amgen, Pfizer, and Sandoz. MN and NM are employees of Hexal AG. AK was an employee of Hexal AG at the time of manuscript development.",,"Pere Gascon 1 , Andriy Krendyukov 2 , Nicola Mathieson 2 , Maja Natek 2 , Matti Aapro 3"
31515397,Defining severe obstructive lung disease in the biologic era: an endotype-based approach,"Richard J Martin 1, Elisabeth H Bel 2, Ian D Pavord 3, David Price 4 5, Helen K Reddel 6",Eur Respir J. 2019 Nov 21;54(5):1900108. doi: 10.1183/13993003.00108-2019. Print 2019 Nov.,Martin RJ,Eur Respir J,2019,2019/09/14,PMC6917363,,10.1183/13993003.00108-2019,https://pubmed.ncbi.nlm.nih.gov/31515397/,/31515397/,"Conflict of interest: R.J. Martin reports grants from NHLBI, MedImmune and Chiesi Farmaceutici SpA, personal fees for steering committee work from AstraZeneca, personal fees for consultancy from PMD Healthcare, personal fees (honorarium) from Regeneron, and personal fees for advisory board work from Boehringer Ingelheim, outside the submitted work; he is a member of the NOVELTY Study Scientific Committee. Conflict of interest: E.H. Bel reports that the study and medical writing support was funded by AstraZeneca, during the conduct of the study; grants and personal fees from AstraZeneca, GSK, Novartis and Teva, and personal fees from Boehringer Ingelheim, Sanofi/Regeneron and Vectura, outside the submitted work; she is a member of the NOVELTY Study Scientific Committee. Conflict of interest: I.D. Pavord reports speakers honoraria, travel expenses and honoraria for attending advisory boards from AstraZeneca, GSK, Boehringer Ingelheim and Teva, grants and speakers honoraria, travel expenses and honoraria for attending advisory boards from Chiesi, personal fees for advisory board work from Sanofi/Regeneron, Merck, Novartis, Knopp and Roche/Genentech, personal fees for lectures from Circassia and Mundipharma, and grants and personal fees for advisory board work from Afferent, outside the submitted work; he is a member of the NOVELTY Study Scientific Committee. Conflict of interest: D. Price reports that the study was funded by AstraZeneca; grants and personal fees for advisory board membership and travel/accommodation/meeting expenses from Aerocrine, grants from AKL Research and Development Ltd, British Lung Foundation, Respiratory Effectiveness Group and UK National Health Service, personal fees for consultancy and lectures from Almirall and GlaxoSmithKline, personal fees for advisory board membership and consultancy from Amgen, grants and personal fees for advisory board membership, consultancy, lectures and travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim and Chiesi, personal fees for lectures from Cipla, Kyorin, Merck and Skyepharma, grants and personal fees for advisory board membership, consultancy and lectures from Mylan, grants and personal fees for advisory board membership, consultancy, lectures, manuscript preparation, educational activities and travel/accommodation/meeting expenses from Mundipharma, grants and personal fees for advisory board membership, consultancy and travel/accommodation/meeting expenses from Napp, grants and personal fees for advisory board membership, consultancy, lectures, patient enrolment or completion of research, development of educational materials and travel/accommodation/meeting expenses from Novartis, grants and personal fees for consultancy and lectures from Pfizer, grants and personal fees for advisory board membership and lectures from Regeneron Pharmaceuticals and Sanofi Genzyme, grants and personal fees for advisory board membership, consultancy, lectures, manuscript preparation, patient enrolment or completion of research and travel/accommodation/meeting expenses from Teva, grants and personal fees for consultancy from Theravance, and grants and personal fees for patient enrolment or completion of research from Zentiva (Sanofi Generics), and has participated in peer review for grant committees for Efficacy and Mechanism Evaluation programme and Health Technology Assessment, outside the submitted work; has stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; and owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); he is a member of the NOVELTY Study Scientific Committee. Conflict of interest: H.K. Reddel reports grants, personal fees and non-financial support from AstraZeneca and GlaxoSmithKline, and personal fees from Boehringer Ingelheim, Merck, Novartis, Teva and Mundipharma, outside the submitted work; she is a member of the NOVELTY Study Scientific Committee.",,"Richard J Martin 1 , Elisabeth H Bel 2 , Ian D Pavord 3 , David Price 4 5 , Helen K Reddel 6"
31048346,Asthma progression and mortality: the role of inhaled corticosteroids,"Paul OByrne 1, Leonardo M Fabbri 2 3, Ian D Pavord 4, Alberto Papi 2, Stefano Petruzzelli 5, Peter Lange 6 7",Eur Respir J. 2019 Jul 18;54(1):1900491. doi: 10.1183/13993003.00491-2019. Print 2019 Jul.,OByrne P,Eur Respir J,2019,2019/05/04,PMC6637285,,10.1183/13993003.00491-2019,https://pubmed.ncbi.nlm.nih.gov/31048346/,/31048346/,"Conflict of interest: L.M. Fabbri reports grants, personal fees and nonfinancial support from Chiesi, personal fees and nonfinancial support from AstraZeneca, GSK, Novartis, Menarini, Boehringer Ingelheim, Zambon, Pearl Therapeutics, nonfinancial support from Dompe, outside the submitted work. Conflict of interest: I.D. Pavord reports speakers honoraria, travel expenses and honoraria for attending advisory boards from AstraZeneca, GSK, Boehringer Ingelheim and Teva, grants and speaker fees, fees for advisory boards and travel expenses for attending international meetings from Chiesi, personal fees for advisory board work from Sanofi/Regeneron, Merck, Novartis, Knopp and Roche/Genentech, personal fees for speaking from Circassia and Mundipharma, grants and personal fees for advisory board work from Afferent, outside the submitted work. Conflict of interest: A. Papi reports board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from Chiesi, AstraZeneca, GSK, Boehringer Ingelheim, Mundipharma and Teva, payment for lectures and travel expenses reimbursement from Menarini, Novartis and Zambon, grants from Sanofi, outside the submitted work. Conflict of interest: S. Petruzzelli is employed by Chiesi Farmaceutici SpA, the sponsor of the studies. Conflict of interest: P. Lange reports grants and personal fees for teaching and advisory board work from AstraZeneca, Boehringer Ingelheim and GSK, personal fees for teaching and advisory board work from Chiesi, outside the submitted work. Conflict of interest: P. OByrne reports receiving speaker fees from AstraZeneca, Chiesi, GSK, Medimmune and Novartis; advisory board membership with AstraZeneca, Medimmune, Novartis, GSK and Chiesi; and grants-in-aid from AstraZeneca, Medimmune, Genentech and Novartis.",,"Paul OByrne 1 , Leonardo M Fabbri 2 3 , Ian D Pavord 4 , Alberto Papi 2 , Stefano Petruzzelli 5 , Peter Lange 6 7"
30464017,Immediate bronchodilator response in\xa0FEV(1) as a diagnostic criterion for adult\xa0asthma,"Leena E Tuomisto 1, Pinja Ilmarinen 1, Lauri Lehtimäki 2 3, Minna Tommola 1, Hannu Kankaanranta 1 2",Eur Respir J. 2019 Feb 14;53(2):1800904. doi: 10.1183/13993003.00904-2018. Print 2019 Feb.,Tuomisto LE,Eur Respir J,2019,2018/11/23,,,10.1183/13993003.00904-2018,https://pubmed.ncbi.nlm.nih.gov/30464017/,/30464017/,"Conflict of interest: L.E. Tuomisto reports non-financial support (costs for attending an international congress) from Chiesi, Boehringer Ingelheim, Orion Pharma and TEVA, and personal fees for lecturing from Astra Zeneca, outside the submitted work. Conflict of interest: P. Ilmarinen reports grants and lecture fees from Astra Zeneca, and lecture fees from MundiPharma and Orion, outside the submitted work. Conflict of interest: L. Lehtimäki reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, OrionPharma, Teva and ALK, outside the submitted work. Conflict of interest: M. Tommola reports personal fees for lecturing from Astra Zeneca, Filha ry, GSK and Pfizer, personal fees for lectures and consulting from Boehringer Ingelheim, and grants from Orion Research Foundation, outside the submitted work. Conflict of interest: H. Kankaanranta reports fees for lectures and consulting, costs for attending an international congress and research grant to institution from AstraZeneca, personal fees for consulting from Chiesi Pharma AB and Roche, fees for lectures and consulting, and costs for attending an international congress from Boehringer Ingelheim, personal fees for lectures and consulting from Novartis, personal fees for lecturing from Mundipharma and Orion Pharma, outside the submitted work.",,"Leena E Tuomisto 1 , Pinja Ilmarinen 1 , Lauri Lehtimäki 2 3 , Minna Tommola 1 , Hannu Kankaanranta 1 2"
31190965,Tapentadol for neuropathic pain: a review of clinical studies,"Ulderico Freo 1, Patrizia Romualdi 2, Hans G Kress 3",J Pain Res. 2019 May 16;12:1537-1551. doi: 10.2147/JPR.S190162. eCollection 2019.,Freo U,J Pain Res,2019,2019/06/14,PMC6529607,,10.2147/JPR.S190162,https://pubmed.ncbi.nlm.nih.gov/31190965/,/31190965/,"UF reports personal fees from Grunenthal, outside the submitted work; HGK has received speaker’s and/or consultancy fees from Bionorica SE, Grunenthal GmbH, Mundipharma Int., TEVA ratiopharm, Mylan, and Pfizer outside the submitted work. HGK reports non-financial support from Grunenthal, during the conduct of the study; personal fees from Bionorica SE, Grunenthal GmbH, Mundipharma Int., TEA ratiopharm, Mylan, Pfizer, outside the submitted work. The authors report no other conflicts on interest in this work.",,"Ulderico Freo 1 , Patrizia Romualdi 2 , Hans G Kress 3"
31285291,Severe T2-high asthma in the biologics era: European experts opinion,"Ian Pavord 1, Thomas Bahmer 2, Fulvio Braido 3, Borja G Cosío 4 5, Marc Humbert 6 7, Marco Idzko 8, Lukasz Adamek 9",Eur Respir Rev. 2019 Jul 8;28(152):190054. doi: 10.1183/16000617.0054-2019. Print 2019 Jun 30.,Pavord I,Eur Respir Rev,2019,2019/07/10,PMC9489011,,10.1183/16000617.0054-2019,https://pubmed.ncbi.nlm.nih.gov/31285291/,/31285291/,"Conflict of interest: I. Pavord reports personal fees (speakers honoraria, travel expenses and honoraria for attending advisory boards) from AstraZeneca, GSK, Boehringer Ingelheim and Teva, personal fees (speaker fees, fees for advisory boards and travel expenses for attending international meetings) from Chiesi, personal fees for advisory boards from Sanofi/Regeneron, Merck, Novartis, Knopp, Afferent and Roche/Genentech, and personal speaker fees from Circassia and Mundipharma, as well as research grants from Chiesi and Afferent, all outside the submitted work. Conflict of interest: T. Bahmer reports personal fees and other support (including compensation for travel expenses) from Chiesi, AstraZeneca, Roche, GlaxoSmithKline and Novartis, outside the submitted work. Conflict of interest: F. Braido reports personal fees (speakers honoraria and travel expenses) from AstraZeneca, outside the submitted work. Conflict of interest: B.G. Cosío reports personal fees from AstraZeneca during the conduct of the study; as well as personal fees from AstraZeneca, Teva and Mundipharma, and grants and personal fees from Chiesi, Boehringer Ingelheim, Menarini and Novartis, outside the submitted work. Conflict of interest: M. Humbert reports personal fees from AstraZeneca, GSK, Novartis, Roche, Sanofi and Teva, during the conduct of the study. Conflict of interest: M. Idzko has nothing to disclose. Conflict of interest: L. Adamek is an employee of AstraZeneca.",,"Ian Pavord 1 , Thomas Bahmer 2 , Fulvio Braido 3 , Borja G Cosío 4 5 , Marc Humbert 6 7 , Marco Idzko 8 , Lukasz Adamek 9"
35005417,Current Status and Future Directions of Pain-Related Outcome Measures for Post-Surgical Pain Trials,"Ian Gilron 1 2 3 4, Henrik Kehlet 5, Esther Pogatzki-Zahn 6",Can J Pain. 2019 Jul 30;3(2):36-43. doi: 10.1080/24740527.2019.1583044. eCollection 2019.,Gilron I,Can J Pain,2019,2022/01/10,PMC8730641,,10.1080/24740527.2019.1583044,https://pubmed.ncbi.nlm.nih.gov/35005417/,/35005417/,"IG has received funding support from Biogen and Adynxx. HK has no conflicts to declare. EPZ has received financial support from Mundipharma GmbH and Grunenthal for research activities, as well as advisory and/or lecture fees and travel support from Grünenthal, MSD Sharp & DOHME GmbH, Mundipharma; Janssen-Cilag GmbH; Fresenius Kabi and AcelRx.","Grants and funding This work was funded, in part, by the CIHR SPOR Chronic Pain Network.","Ian Gilron 1 2 3 4 , Henrik Kehlet 5 , Esther Pogatzki-Zahn 6"
31371934,Personalized medicine for patients with COPD: where are we?,"Frits Me Franssen 1 2, Peter Alter 3, Nadav Bar 4, Birke J Benedikter 5 6, Stella Iurato 7, Dieter Maier 8, Michael Maxheim 3, Fabienne K Roessler 4, Martijn A Spruit 1 2 9, Claus F Vogelmeier 3, Emiel Fm Wouters 1 2, Bernd Schmeck 3 5",Int J Chron Obstruct Pulmon Dis. 2019 Jul 9;14:1465-1484. doi: 10.2147/COPD.S175706. eCollection 2019.,Franssen FM,Int J Chron Obstruct Pulmon Dis,2019,2019/08/03,PMC6636434,,10.2147/COPD.S175706,https://pubmed.ncbi.nlm.nih.gov/31371934/,/31371934/,"FMEF received personal fees for lectures and consultancies from AstraZeneca, Boehringer Ingelheim, Chiesi, TEVA, GlaxoSmithKline, and Novartis, outside of this work. He also received research grants from Novartis and MedImmune. BS received research funding from GlaxoSmithKline. SI reports grants from Austrian Science Fund FWF, during the conduct of the study. DM reports grants from Austrian Science Fund FWF, during the conduct of the study. MM reports grants from German Ministry for Education and Research (BMBF), during the conduct of the study. CFV reports grants and personal fees from AstraZeneca Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Grifols, Menarini, Mundipharma, Novartis, TEVA, Cipla, Bayer Schering, MSD, and Pfizer, outside the submitted work. BS reports grants from BMBF and GlaxoSmithKline, during the conduct of the study. The authors report no other conflicts of interest in this work.",Grants and funding I 3736/FWF_/Austrian Science Fund FWF/Austria,"Frits Me Franssen 1 2 , Peter Alter 3 , Nadav Bar 4 , Birke J Benedikter 5 6 , Stella Iurato 7 , Dieter Maier 8 , Michael Maxheim 3 , Fabienne K Roessler 4 , Martijn A Spruit 1 2 9 , Claus F Vogelmeier 3 , Emiel Fm Wouters 1 2 , Bernd Schmeck 3 5"
31632107,Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement,"Maria Fernanda Delgado 1, Ahmed Mostafa Abdelrahman 2, Malika Terahi 3, Juan Jose Miro Quesada Woll 4, Felix Gil-Carrasco 5, Colin Cook 6, Mohamed Benharbit 7, Sebastien Boisseau 8, Ernestine Chung 8, Yacine Hadjiat 8, José Ap Gomes 9",Clinicoecon Outcomes Res. 2019 Sep 27;11:591-604. doi: 10.2147/CEOR.S218277. eCollection 2019.,Delgado MF,Clinicoecon Outcomes Res,2019,2019/10/22,PMC6776288,,10.2147/CEOR.S218277,https://pubmed.ncbi.nlm.nih.gov/31632107/,/31632107/,"Dr Maria Fernanda Delgado reports personal fees from Mundipharma, personal fees from Allergan, personal fees from Iridex, personal fees from Sophia, outside the submitted work; Dr Mohamed Benharbit reports personal fees from Jamjoom Pharma (AAO Chicago 2016), Mundipharma (WGC Helsinki 2017), ESCRS Lisbon 2017 THEA, SFO 2018 THEA, CGS Montreal 2018 THEA, nothing from ALLERGAN, outside the submitted work. Dr Sebastien Boisseau, Dr Ernestine Chung and Dr Yacine Hadjiat are employees of Mundipharma. Prof. Dr. José AP Gomes reports grants, personal fees, non-financial support from Allergan, grants, personal fees, non-financial support from Alcon, personal fees, non-financial support from Genon, grants, personal fees, non-financial support from Mundipharma, grants, personal fees, non-financial support from Shire, grants, personal fees, non-financial support from Thea, grants, personal fees, non-financial support from Ofta, grants from Fapesp, grants from Cnpq, grants from Capes, outside the submitted work. The authors report no other conflicts of interest in this work.",,"Maria Fernanda Delgado 1 , Ahmed Mostafa Abdelrahman 2 , Malika Terahi 3 , Juan Jose Miro Quesada Woll 4 , Felix Gil-Carrasco 5 , Colin Cook 6 , Mohamed Benharbit 7 , Sebastien Boisseau 8 , Ernestine Chung 8 , Yacine Hadjiat 8 , José Ap Gomes 9"
31523413,Novel insights into the treatment of complement-mediated hemolytic anemias,"Sigbjørn Berentsen 1, Anita Hill 2, Quentin A Hill 2, Tor Henrik Anderson Tvedt 3, Marc Michel 4",Ther Adv Hematol. 2019 Sep 9;10:2040620719873321. doi: 10.1177/2040620719873321. eCollection 2019.,Berentsen S,Ther Adv Hematol,2019,2019/09/17,PMC6734604,,10.1177/2040620719873321,https://pubmed.ncbi.nlm.nih.gov/31523413/,/31523413/,"Conflict of interest statement: The authors did not receive any funding for this work. Outside this work, S. Berentsen has received research funding from Mundipharma, consulting fees from Apellis, Bioverativ, Momenta Pharmaceuticals and True North Therapeutics, and travel grants and lecture honoraria from Alexion, Apellis, Bioverativ and Janssen-Cilag. A. Hill has received honoraria from Alexion, Apellis, Bioverativ, and Novartis. Q.A. Hill has received research support from Alexion and honoraria for lecturing or advisory work from Novartis, Shire, and Bioverativ. T.H.A. Tvedt has received advisory board honoraria from Ablynx and Alexion and lecture honoraria from Alexion and Novartis. M. Michel has advisory board honoraria from Alexion, Apellis, and Rigel.",,"Sigbjørn Berentsen 1 , Anita Hill 2 , Quentin A Hill 2 , Tor Henrik Anderson Tvedt 3 , Marc Michel 4"
31766279,Biological Background of Resistance to Current Standards of Care in Multiple Myeloma,"Pedro Mogollón 1, Andrea Díaz-Tejedor 1, Esperanza M Algarín 1, Teresa Paíno 1, Mercedes Garayoa 1, Enrique M Ocio 2",Cells. 2019 Nov 13;8(11):1432. doi: 10.3390/cells8111432.,Mogollón P,Cells,2019,2019/11/27,PMC6912619,,10.3390/cells8111432,https://pubmed.ncbi.nlm.nih.gov/31766279/,/31766279/,"EM.O. discloses research support from Amgen; Array BioPharma; Celgene; IDP-Pharma; Mundipharma-EDO. Honoraria from Celgene; Janssen; Amgen; MSD; Asofarma; BMS; Takeda. Consultancy from Celgene; Janssen; Amgen; Sanofi; Secura-Bio; Oncopeptides; Mundipharma-EDO; Takeda. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.",,"Pedro Mogollón 1 , Andrea Díaz-Tejedor 1 , Esperanza M Algarín 1 , Teresa Paíno 1 , Mercedes Garayoa 1 , Enrique M Ocio 2"
31810103,"Spacer, Aerosol Therapy through Space and Time","Thomas Voshaar 1, Peter Haidl 2, Rolf Michael Clös 3",Laryngorhinootologie. 2019 Dec;98(12):845-860. doi: 10.1055/a-0960-6519. Epub 2019 Dec 6.,Voshaar T,Laryngorhinootologie,2019,2019/12/07,,,10.1055/a-0960-6519,https://pubmed.ncbi.nlm.nih.gov/31810103/,/31810103/,"Thomas Voshaar: Honorare für Vorträge und Beratung von Chiesi GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Mundipharma, AstraZeneca GmbH, Novartis Deutschland GmbH und Berlin-Chemie AG. Peter Haidl: Honorare für Vorträge und Beratung von AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Chiesi GmbH, Roche Deutschland Holding GmbH, Mundipharma GmbH, Novartis Deutschland GmbH und Teva GmbH. Rolf Michael Clös ist Mitarbeiter der Mundipharma GmbH, Limburg.",,"Thomas Voshaar 1 , Peter Haidl 2 , Rolf Michael Clös 3"
29752633,Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis,"Sophie E Berends 1 2, Anne S Strik 3, Mark Löwenberg 3, Geert R DHaens 3, Ron A A Mathôt 4",Clin Pharmacokinet. 2019 Jan;58(1):15-37. doi: 10.1007/s40262-018-0676-z.,Berends SE,Clin Pharmacokinet,2019,2018/05/13,PMC6326086,,10.1007/s40262-018-0676-z,https://pubmed.ncbi.nlm.nih.gov/29752633/,/29752633/,"Sophie Berends has received lecture fees from Merck Sharp & Dohme, Johnson & Johnson and Tillotts. Anne Strik has received lecture fees from Biogen, Johnson and Johnson, Merck Sharp & Dohme, Mundipharma, Takeda, and Tillotts. Mark Löwenberg has received speaker fees from Abbvie, Covidien, Dr. Falk Pharma, Ferring Pharmaceuticals, Merck Sharp & Dohme, Receptos, Takeda, Tillotts and Tramedico, and has also received research grants from AbbVie, Merck Sharp & Dohme, Achmea Healthcare and ZonMW. Geert D’Haens has served as an advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avax- ia, Biogen, Bristol-Myers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, Dr. Falk Pharma, Engene, Galapagos, Gilead, GlaxoSmithKline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp & Dohme, Mundipharma, Novonordisk, Pfizer, Prometheus Laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor, and has also received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp & Dohme, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts and Vifor. Ron Mathôt has no conflicts of interest to declare.",,"Sophie E Berends 1 2 , Anne S Strik 3 , Mark Löwenberg 3 , Geert R DHaens 3 , Ron A A Mathôt 4"
31111764,"Antidepressants, withdrawal, and addiction; where are we now?","Sameer Jauhar 1, Joseph Hayes 2, Guy M Goodwin 3, David S Baldwin 4, Philip J Cowen 3, David J Nutt 5",J Psychopharmacol. 2019 Jun;33(6):655-659. doi: 10.1177/0269881119845799. Epub 2019 May 21.,Jauhar S,J Psychopharmacol,2019,2019/05/22,PMC7613097,EMS150073,10.1177/0269881119845799,https://pubmed.ncbi.nlm.nih.gov/31111764/,/31111764/,"Declaration of conflicting interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SJ and JH declare no conflicting interests. PJC has no conflicting interests during the last three years. GMG holds shares in P1Vital and has served as consultant, advisor or Continuing Medical Education (CME) speaker for Allergan, Angelini, Compass Pathways, MSD, Lundbeck, Otsuka, Takeda, Medscape, Minervra, P1Vital, Pfizer, Servier, Shire and Sun Pharma. DSB has attracted research funding (between 1994–2018) from the following pharmaceutical and biotechnology companies: AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly Ltd, Glaxo-SmithKline, H. Lundbeck A/S, Pharmacia, Pierre Fabre, Pfizer Ltd, Servier, Vernalis Ltd and Wyeth Ltd. He has attended advisory boards organised by Grunenthal, Liva Nova, Mundipharma, Roche and Sumitomo; and has received personal honoraria for lecture engagements organised by AstraZeneca, Bristol-Myers Squibb, Eli Lilly Ltd, Glaxo-SmithKline, Janssen, H. Lundbeck A/S, Pharmacia, Pierre Fabre, Pfizer Ltd, Servier and Wyeth Ltd. DJN declares the following: advisor – British National Formulary, Medical Research Council (MRC); past president – British Neuroscience Association - European Brain Council; past president – European College of Neuropsychopharmacology; chair – DrugScience (UK); member International Centre for Science in Drug Policy; editor of the Journal of Psychopharmacology; advisory boards – Nalpharm, Mundipharma, Ranvier, Indivior, Opiant; speaking honoraria (in addition to above) Lundbeck BMS/Otsuka, Janssen, Martindale; member of the Lundbeck International Neuroscience Foundation; chair campus editorial board; grants or clinical trial payments: Wellcome Trust, MRC; share options – P1vital, Alcarelle; director Equasy Enterprises; expert witness in a number of legal cases relating to psychotropic drugs; edited/written >32 books – some purchased by pharma companies.",Grants and funding WT_/Wellcome Trust/United Kingdom 211085/WT_/Wellcome Trust/United Kingdom 211085/Z/18/Z/WT_/Wellcome Trust/United Kingdom,"Sameer Jauhar 1 , Joseph Hayes 2 , Guy M Goodwin 3 , David S Baldwin 4 , Philip J Cowen 3 , David J Nutt 5"
31205488,New biologics and small molecules in inflammatory bowel disease: an update,"João Sabino 1, Bram Verstockt 1, Séverine Vermeire 1, Marc Ferrante 2",Therap Adv Gastroenterol. 2019 May 26;12:1756284819853208. doi: 10.1177/1756284819853208. eCollection 2019.,Sabino J,Therap Adv Gastroenterol,2019,2019/06/18,PMC6537282,,10.1177/1756284819853208,https://pubmed.ncbi.nlm.nih.gov/31205488/,/31205488/,"Conflict of interest statement: João Sabino has received speaker fees from AbbVie and Nestle Health Sciences. Bram Verstockt has received financial support for research from Pfizer; lecture fees from AbbVie, Ferring, Takeda Pharmaceuticals, Janssen and R-Biopharm AG; consultancy fees from Janssen. Marc Ferrante has received research grants from Janssen, Pfizer, and Takeda; consultancy fees from AbbVie, Boehringer-Ingelheim, Falk, Ferring, Janssen, Mitsubishi Tanabe, MSD, and Pfizer; speakers fees from AbbVie, Boehringer-Ingelheim, Chiesi, Falk, Ferring, Janssen, Mitsubishi Tanabe, MSD, Pfizer, and Tramedico. Séverine Vermeire has received grant support from AbbVie, MSD, Pfizer, J&J, and Takeda; received speaker fees from AbbVie, MSD, Takeda, Ferring, Dr. Falk Pharma, Hospira, Pfizer Inc., and Tillots; and served as a consultant for AbbVie, MSD, Takeda, Ferring, Genentech/Roche, Robarts Clinical Trials, Gilead, Celgene, Prometheus, Avaxia, Prodigest, Shire, Pfizer Inc, Galapagos, Mundipharma, Hospira, Celgene, Second Genome, and Janssen.",,"João Sabino 1 , Bram Verstockt 1 , Séverine Vermeire 1 , Marc Ferrante 2"
30792985,Research highlights from the 2018 ERS International Congress: interstitial lung diseases,"Tiago M Alfaro 1, Catharina C Moor 2, Veronica Alfieri 3, Florence Jeny 4 5, Michael Kreuter 6, Marlies S Wijsenbeek 2, Elisabetta A Renzoni 7 8 9, Elena Bargagli 10, Hilario Nunes 4 5, Paolo Spagnolo 11, Francesco Bonella 12, Maria Molina-Molina 13 14 15, Katerina Antoniou 16, Venerino Poletti 17 18",ERJ Open Res. 2019 Feb 18;5(1):00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb.,Alfaro TM,ERJ Open Res,2019,2019/02/23,PMC6378342,,10.1183/23120541.00215-2018,https://pubmed.ncbi.nlm.nih.gov/30792985/,/30792985/,"Conflict of interest: T.M. Alfaro reports receiving travel support from Boehringer Ingelheim, Novartis, Astra, Menarini, Mundipharma, Zambon and Roche, and grants from Bayer, outside the submitted work. Conflict of interest: C.C. Moor has nothing to disclose. Conflict of interest: V. Alfieri has nothing to disclose. Conflict of interest: F. Jeny has nothing to disclose. Conflict of interest: M. Kreuter has nothing to disclose. Conflict of interest: M.S. Wijsenbeek reports grants and other support from Boehringer Ingelheim and Hoffman la Roche, and other support from Galapagos, outside the submitted work. Conflict of interest: E.A. Renzoni reports lecture and advisory board fees from Roche and Boehringer Ingelheim, and lecture fees from Mundipharma, outside the submitted work. Conflict of interest: E. Bargagli has nothing to disclose. Conflict of interest: H. Nunes reports consultancy and research support fees from Roche/Genentech and Boehringer Ingelheim, and grants and personal fees as a clinical trial investigator from Sanofi and Gilead. Conflict of interest: P. Spagnolo reports personal fees and nonfinancial support from Roche, Boehringer Ingelheim and Zambon, personal fees from PPM Services, Galapagos and Santhera Pharmaceuticals, outside the submitted work. Conflict of interest: F. Bonella reports personal fees and nonfinancial support from Roche Pharma, Boehringer Ingelheim and Fujrebio, outside the submitted work. Conflict of interest: M. Molina-Molina reports grants from Roche, Boehringer Ingelheim and grants from Esteve-Teijin Healthcare, and personal fees for specialised medical training from Chiesi, outside the submitted work. Conflict of interest: K. Antoniou has nothing to disclose. Conflict of interest: V. Poletti has nothing to disclose.",Grants and funding 20719/VAC_/Versus Arthritis/United Kingdom PB-PG-0712-28073/DH_/Department of Health/United Kingdom,"Tiago M Alfaro 1 , Catharina C Moor 2 , Veronica Alfieri 3 , Florence Jeny 4 5 , Michael Kreuter 6 , Marlies S Wijsenbeek 2 , Elisabetta A Renzoni 7 8 9 , Elena Bargagli 10 , Hilario Nunes 4 5 , Paolo Spagnolo 11 , Francesco Bonella 12 , Maria Molina-Molina 13 14 15 , Katerina Antoniou 16 , Venerino Poletti 17 18"
31861548,Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma,"Francesca Bonello 1, Roberto Mina 1, Mario Boccadoro 1, Francesca Gay 1",Cancers (Basel). 2019 Dec 19;12(1):15. doi: 10.3390/cancers12010015.,Bonello F,Cancers (Basel),2019,2019/12/22,PMC7017131,,10.3390/cancers12010015,https://pubmed.ncbi.nlm.nih.gov/31861548/,/31861548/,"F.B. declares no competing financial interests. R.M. has received honoraria from Amgen, Celgene, Takeda, and Janssen, and served on the advisory boards for Janssen. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie, and has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. F.G. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda, and served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Roche, Takeda, and AbbVie.",,"Francesca Bonello 1 , Roberto Mina 1 , Mario Boccadoro 1 , Francesca Gay 1"
31427843,Blood pressure: at what level is treatment worthwhile?,"Emily R Atkins 1, Vlado Perkovic 1",Aust Prescr. 2019 Aug;42(4):127-130. doi: 10.18773/austprescr.2019.038. Epub 2019 Aug 1.,Atkins ER,Aust Prescr,2019,2019/08/21,PMC6698244,,10.18773/austprescr.2019.038,https://pubmed.ncbi.nlm.nih.gov/31427843/,/31427843/,"Conflicts of interest: Emily Atkins was supported by a postdoctoral fellowship (PdF 101884) from the National Heart Foundation of Australia. Vlado Perkovic has served on steering committees, advisory boards, or given scientific presentations supported by Abbvie, Astellas, Astra Zeneca, Bayer, Baxter, MBS, Boehringer Ingelheim, Dimerix, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Metavant, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Retrophin, Sanofi, Servier, Vifor and Tricida.",,"Emily R Atkins 1 , Vlado Perkovic 1"
31137061,Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview,"John A Mackintosh 1, Anna Stainer 1, Joseph L Barnett 1, Elisabetta A Renzoni 1 2",Semin Respir Crit Care Med. 2019 Apr;40(2):208-226. doi: 10.1055/s-0039-1683431. Epub 2019 May 28.,Mackintosh JA,Semin Respir Crit Care Med,2019,2019/05/29,,,10.1055/s-0039-1683431,https://pubmed.ncbi.nlm.nih.gov/31137061/,/31137061/,"Dr. Renzoni reports lecture fees and advisory board fees from Boeringher Ingelheim and Roche and lecture fees from Mundipharma, outside the submitted work.",Grants and funding 20719/VAC_/Versus Arthritis/United Kingdom,"John A Mackintosh 1 , Anna Stainer 1 , Joseph L Barnett 1 , Elisabetta A Renzoni 1 2"
31544111,Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns,"Yet H Khor 1 2 3 4, Elisabetta A Renzoni 5, Dina Visca 6 7, Christine F McDonald 1 2 4, Nicole S L Goh 1 2 3",ERJ Open Res. 2019 Sep 16;5(3):00118-2019. doi: 10.1183/23120541.00118-2019. eCollection 2019 Jul.,Khor YH,ERJ Open Res,2019,2019/09/24,PMC6745413,,10.1183/23120541.00118-2019,https://pubmed.ncbi.nlm.nih.gov/31544111/,/31544111/,"Conflict of interest: Y.H. Khor reports grants from Boehringer Ingelheim, personal fees from Boehringer Ingelheim and Roche, and in-kind support for a clinical trial from Air Liquide Healthcare, outside the submitted work. Conflict of interest: E.A. Renzoni reports lecture fees and advisory board fees from Boehringer Ingelheim and from Roche, lecture fees from Mundipharma, outside the submitted work. Conflict of interest: D. Visca has nothing to disclose. Conflict of interest: C.F. McDonald reports grants from Boehringer Ingelheim, in-kind support for a clinical trial from Air Liquide Healthcare, and speakers fees paid to her hospital by Menarini and AstraZeneca, outside the submitted work. Conflict of interest: N.S.L. Goh reports personal fees from Roche and AstraZeneca, grants and personal fees from Boehringer Ingelheim, and in-kind support for a clinical trial from Air Liquide Healthcare, outside the submitted work.",Grants and funding 20719/VAC_/Versus Arthritis/United Kingdom PB-PG-0712-28073/DH_/Department of Health/United Kingdom,"Yet H Khor 1 2 3 4 , Elisabetta A Renzoni 5 , Dina Visca 6 7 , Christine F McDonald 1 2 4 , Nicole S L Goh 1 2 3"
31210979,MoM total hip replacements in Europe: a NORE report,"Bart G Pijls 1, Jennifer M T A Meessen 1, Keith Tucker 2, Susanna Stea 3, Liza Steenbergen 4, Anne Marie Fenstad 5, Keijo Mäkelä 6, Ioan Cristian Stoica 7, Maxim Goncharov 8, Søren Overgaard 9, Jorge Arias de la Torre 10 11 12, Anne Lübbeke 13 14, Ola Rolfson 15, Rob G H H Nelissen 1",EFORT Open Rev. 2019 Jun 3;4(6):423-429. doi: 10.1302/2058-5241.4.180078. eCollection 2019 Jun.,Pijls BG,EFORT Open Rev,2019,2019/06/19,PMC6549109,,10.1302/2058-5241.4.180078,https://pubmed.ncbi.nlm.nih.gov/31210979/,/31210979/,"ICMJE Conflict of interest statement: ALW reports that the Division of Orthopaedics and Trauma Surgery at Geneva University Hospitals receives institutional financial support for the Geneva Arthroplasty Registry from the “Fondation pour la recherche ostéoarticulaire”, outside the submitted work. OR reports payment for lectures from ZimmerBiomet, outside the submitted work. SO reports grants from Biomet Denmark and Biomet Inc, grants from DePuy and Protesekompagniet, grants from Zimmer, other from Eli Lilly Denmark, other from MSD, other from Sanofi-Aventis Denmark A/S, other from Mundipharma International Ltd, outside the submitted work. All other authors have nothing to declare.",,"Bart G Pijls 1 , Jennifer M T A Meessen 1 , Keith Tucker 2 , Susanna Stea 3 , Liza Steenbergen 4 , Anne Marie Fenstad 5 , Keijo Mäkelä 6 , Ioan Cristian Stoica 7 , Maxim Goncharov 8 , Søren Overgaard 9 , Jorge Arias de la Torre 10 11 12 , Anne Lübbeke 13 14 , Ola Rolfson 15 , Rob G H H Nelissen 1"
31190966,Tapentadol in the management of cancer pain: current evidence and future perspectives,"Hans G Kress 1, Flaminia Coluzzi 2",J Pain Res. 2019 May 16;12:1553-1560. doi: 10.2147/JPR.S191543. eCollection 2019.,Kress HG,J Pain Res,2019,2019/06/14,PMC6526916,,10.2147/JPR.S191543,https://pubmed.ncbi.nlm.nih.gov/31190966/,/31190966/,"Disclosure HGK has received speaker’s and/or consultancy fees from Bionorica SE, Grunenthal GmbH, Mundipharma Int., TEVA Ratiopharm, Mylan, and Pfizer outside the submit ted work. The authors report no other conflicts of interest in this work.",,"Hans G Kress 1 , Flaminia Coluzzi 2"
31805823,What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape,"Federico Lavorini 1, Christer Janson 2, Fulvio Braido 3, Georgios Stratelis 2 4, Anders Løkke 5",Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619884532. doi: 10.1177/1753466619884532.,Lavorini F,Ther Adv Respir Dis,2019,2019/12/07,PMC6900625,,10.1177/1753466619884532,https://pubmed.ncbi.nlm.nih.gov/31805823/,/31805823/,"Conflict of interest statement: Federico Lavorini has received fees for speaking and grants for research from AstraZeneca, Boehringer Ingelheim, CIPLA, Chiesi, Menarini International, Novartis, Orion and Teva, and has participated in advisory boards arranged by Boehringer Ingelheim, GlaxoSmithKline, Menarini International, Orion and Trudell. Christer Janson has received payments for educational activities from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and Teva, and has participated in advisory boards arranged by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva. Fulvio Braido has received fees for speaking from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Chiesi, Menarini International, Novartis, Teva, Zambon, Dompè and Lallemand, and has participated in advisory boards arranged by Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, Mundipharma, Teva and Chiesi. Georgios Stratelis is a full-time employee of AstraZeneca. Anders Løkke has received fees for lectures and for educational activities from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, GlaxoSmithKline, Mundipharma and Novartis, and has participated in advisory boards arranged by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Pfizer and Novartis. Furthermore, he has received grants for research from Pfizer, Boehringer Ingelheim and Novartis, as well as research-related travel accommodation from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, GlaxoSmithKline, Mundipharma, Orion and Novartis. Anders Løkke has previously been/is currently a principal investigator in pharmaceutical company-sponsored research studies for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Novartis.",,"Federico Lavorini 1 , Christer Janson 2 , Fulvio Braido 3 , Georgios Stratelis 2 4 , Anders Løkke 5"
31190961,Tapentadol: a new option for the treatment of cancer and noncancer pains,"Anthony H Dickenson 1, Hans G Kress 2",J Pain Res. 2019 May 16;12:1509-1511. doi: 10.2147/JPR.S190171. eCollection 2019.,Dickenson AH,J Pain Res,2019,2019/06/14,PMC6526922,,10.2147/JPR.S190171,https://pubmed.ncbi.nlm.nih.gov/31190961/,/31190961/,"Disclosure AHD has received fees from Grünenthal GmbH, Allergan, Janssen, Johnson & Johnson, Teva, and Regeneron. HGK has received speaker’s and/or consultancy fees from Bionorica SE, Grunenthal GmbH, Mundipharma Int., TEVA Ratiopharm, Mylan, and Pfizer outside the submitted work. The authors report no other conflicts of interest in this work.",,"Anthony H Dickenson 1 , Hans G Kress 2"
31847174,Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies,"Mattia DAgostino 1, Luca Bertamini 1, Stefania Oliva 1, Mario Boccadoro 1, Francesca Gay 1",Cancers (Basel). 2019 Dec 13;11(12):2015. doi: 10.3390/cancers11122015.,DAgostino M,Cancers (Basel),2019,2019/12/19,PMC6966449,,10.3390/cancers11122015,https://pubmed.ncbi.nlm.nih.gov/31847174/,/31847174/,"S.O. has received honoraria from Amgen, Celgene, and Janssen; and has served on the advisory boards for Adaptive Biotechnologies, Janssen, Amgen, and Takeda. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; and has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. F.G. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Takeda, and served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Roche, Takeda, and AbbVie. The other authors declare no competing financial interests.",,"Mattia DAgostino 1 , Luca Bertamini 1 , Stefania Oliva 1 , Mario Boccadoro 1 , Francesca Gay 1"
31751545,The Genetics of Neuropathic Pain from Model Organisms to Clinical Application,"Margarita Calvo 1, Alexander J Davies 2, Harry L Hébert 3, Greg A Weir 2, Elissa J Chesler 4, Nanna B Finnerup 5, Roy C Levitt 6, Blair H Smith 3, G Gregory Neely 7, Michael Costigan 8, David L Bennett 9",Neuron. 2019 Nov 20;104(4):637-653. doi: 10.1016/j.neuron.2019.09.018.,Calvo M,Neuron,2019,2019/11/22,PMC6868508,,10.1016/j.neuron.2019.09.018,https://pubmed.ncbi.nlm.nih.gov/31751545/,/31751545/,"D.L.B. acknowledges patent application number PCT/GB2017/052909, D.L.B., J.M. Dawes, G. Weir. Method for the treatment or prevention of pain or excessive neuronal activity or epilepsy. D.L.B. has acted as a consultant on behalf of Oxford Innovation for the following companies: Abide, Amgen, Mitsubishi Tanabe, GSK, TEVA, Biogen, Lilly, Orion, and Theranexus. N.B.F. has served in advisory boards of Grünenthal, Novartis Pharma, Teva Pharmaceuticals, Mitshubishi Tanabe Pharma, Merck, and Mundipharma; has received lecture honoraria from Astellas; and receives a research grant from PAINCARE EU Investigational Medicines Initiative (IMI), where the involved companies are Grunenthal, Bayer, Eli Lilly, Esteve, and Teva. A.J.D. acknowledges patent application number PCT/KR2019/00806. R.C.L. serves as chief scientific officer and board member and is an equity holder Onspira Therapeutics, Inc. and acknowledges patent application number PCT/US18/42122: “Methods for Managing Pain.” G.G.N. acknowledges patent application number AU2018902072A0. M. Costigan receives funding from Amgen.",Grants and funding P50 DA039841/DA/NIDA NIH HHS/United States R01 DA037927/DA/NIDA NIH HHS/United States 202747/Z/16/Z/WT_/Wellcome Trust/United Kingdom U01 HG010230/HG/NHGRI NIH HHS/United States R21 NS105880/NS/NINDS NIH HHS/United States WT_/Wellcome Trust/United Kingdom Show all 6 grants,"Margarita Calvo 1 , Alexander J Davies 2 , Harry L Hébert 3 , Greg A Weir 2 , Elissa J Chesler 4 , Nanna B Finnerup 5 , Roy C Levitt 6 , Blair H Smith 3 , G Gregory Neely 7 , Michael Costigan 8 , David L Bennett 9"
31882734,Applied Precision Cancer Medicine in Neuro-Oncology,"H Taghizadeh 1 2, L Müllauer 3, J Furtner 2 4, J A Hainfellner 2 5, C Marosi 1 2, M Preusser 1 2, G W Prager 6 7",Sci Rep. 2019 Dec 27;9(1):20139. doi: 10.1038/s41598-019-56473-0.,Taghizadeh H,Sci Rep,2019,2019/12/29,PMC6934769,,10.1038/s41598-019-56473-0,https://pubmed.ncbi.nlm.nih.gov/31882734/,/31882734/,"M. Preusser has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dome. G.W. Prager received speaker’s fees from Bayer, Roche, Merck-Serono, Amgen, Servier, Celgene, Shire, MSD, Lilly, and Sanofi-Aventis. M.K. received travel support from Merck, Bayer, Bristol-Myers Squibb, and Roche. All other authors have nothing to declare.",,"H Taghizadeh 1 2 , L Müllauer 3 , J Furtner 2 4 , J A Hainfellner 2 5 , C Marosi 1 2 , M Preusser 1 2 , G W Prager 6 7"
31801821,From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity,"Jean Bousquet 1 2 3 4 5, Josep M Anto 6 7 8, Claus Bachert 9, Sinthia Bosnic-Anticevich 10, Marina Erhola 11, Tari Haahtela 12, Peter W Hellings 13 14, Piotr Kuna 15, Oliver Pfaar 16, Boleslaw Samolinski 17, Holger J Schünemann 18, Aziz Sheikh 19, Dana Wallace 20 ; ARIA study group",Eur Respir J. 2019 Dec 4;54(6):1901023. doi: 10.1183/13993003.01023-2019. Print 2019 Dec.,Bousquet J,Eur Respir J,2019,2019/12/06,,,10.1183/13993003.01023-2019,https://pubmed.ncbi.nlm.nih.gov/31801821/,/31801821/,"Conflict of interest: J. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach (for membership of advisory boards, consultations and honoraria for meeting lectures), and other from KYomed-Innov (shares), outside the submitted work. Conflict of interest: J.M. Anto has nothing to disclose. Conflict of interest: C. Bachert reports consultancy fees from Mylan, Stallergenes, ALK, GSK, Sanofi, Astra-Zeneca and Novartis, outside the submitted work. Conflict of interest: S. Bosnic-Anticevich reports grants from TEVA (unrestricted research grant on inhaler technique), personal fees from TEVA (lecture and advisory board), personal fees from AstraZeneca (lecture and advisory board), personal fees from Boehringer Ingelheim (lecture and advisory board), personal fees from GSK (lecture), personal fees from Sanofi (consultancy), and personal fees from Mylan (consultancy), outside the submitted work. Conflict of interest: M. Erhola has nothing to disclose. Conflict of interest: T. Haahtela reports personal fees from Mundipharma and OrionPharma (lecturing fees), outside the submitted work. Conflict of interest: P.W. Hellings has nothing to disclose. Conflict of interest: P. Kuna has nothing to disclose. Conflict of interest: O. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma and Anergis S.A., grants from Biomay, Nuvo, Circassia and Glaxo Smith Kline, and personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies and Astellas Pharma Global, outside the submitted work. Conflict of interest: B. Samolinski has nothing to disclose. Conflict of interest: H.J. Schünemann has nothing to disclose. Conflict of interest: A. Sheikh reports that he has served as a member of the BTS/SIGN Asthma Guideline and the EAACI Allergen Immunotherapy Guidelines and is currently a member of the GINA Scientific Board. Conflict of interest: D. Wallace is co-chair of the Joint Task Force on Practice Parameters of the AAAAI/ACAAI.",,"Jean Bousquet 1 2 3 4 5 , Josep M Anto 6 7 8 , Claus Bachert 9 , Sinthia Bosnic-Anticevich 10 , Marina Erhola 11 , Tari Haahtela 12 , Peter W Hellings 13 14 , Piotr Kuna 15 , Oliver Pfaar 16 , Boleslaw Samolinski 17 , Holger J Schünemann 18 , Aziz Sheikh 19 , Dana Wallace 20 ; ARIA study group"
31273040,The Global Initiative for Asthma (GINA): 25\u2005years later,"Louis-Philippe Boulet 1, Helen K Reddel 2, Eric Bateman 3, Søren Pedersen 4, J Mark FitzGerald 5, Paul M OByrne 6 7",Eur Respir J. 2019 Aug 29;54(2):1900598. doi: 10.1183/13993003.00598-2019. Print 2019 Aug.,Boulet LP,Eur Respir J,2019,2019/07/06,,,10.1183/13993003.00598-2019,https://pubmed.ncbi.nlm.nih.gov/31273040/,/31273040/,"Conflict of interest: L-P. Boulet reports the following: research grants for participation in multicentre studies from AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi and Takeda; support for research projects introduced by the investigator from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Takeda; consulting fees and advisory board membership for AstraZeneca, Novartis and Methapharm; royalties as co-author of “Up-To-Date” (occupational asthma); non-profit grants for the production of educational materials from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Frosst and Novartis; conference fees from AstraZeneca, GlaxoSmithKline, Merck and Novartis; and support for participation in conferences and meetings from Novartis and Takeda. He is the past president and a member of the Canadian Thoracic Society Respiratory Guidelines Committee and Chair of the Board of Directors of the Global Initiative for Asthma (GINA). Conflict of interest: H. Reddel reports grants and personal fees from AstraZeneca and Novartis; grants, personal fees and non-financial support from GlaxoSmithKline; and personal fees from Merck, Teva, Mundipharma and Boehringer Ingelheim; outside the submitted work. She is Chair of the GINA Scientific Committee. Conflict of interest: E. Bateman is a member of the Science Committee and Board of GINA. He reports personal fees from Novartis, Cipla, Vectura, Menarini, ALK, ICON, Sanofi Regeneron, Boehringer Ingelheim and AstraZeneca, and grants from GlaxoSmithKline, Hoffmann le Roche, Sanofi-Aventis, Novartis, AstraZeneca and Teva, outside the submitted work. Conflict of interest: S. Pedersen reports personal fees from AstraZeneca, ALK and Thermo Fisher, outside the submitted work. Conflict of interest: J.M. FitzGerald reports personal fees for advisory board membership from GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi-Regeneron and Theravance, peer-reviewed funding from CIHR, AllerGen and BC Lung Association, research funding from GSK, AstraZeneca, Amgen, Sanofi-Regeneron and Novarits, all paid directly to UBC; and is a member of the steering committee for the International Severe Asthma Registry and PI for the Canadian Severe Asthma Registry, and a member of the GINA Science and Executive Committees. Conflict of interest: P.M. OByrne has received consultancy fees from AstraZeneca, GSK and Chiesi; has received grants/patents pending from AstraZeneca, Genetech and Novartis; and is a board member for the Joint Oversight Board for LABA safety study.",,"Louis-Philippe Boulet 1 , Helen K Reddel 2 , Eric Bateman 3 , Søren Pedersen 4 , J Mark FitzGerald 5 , Paul M OByrne 6 7"
31196943,IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis,"Malcolm R Starkey 1, Maximilian W Plank 1, Paolo Casolari 2, Alberto Papi 2, Stelios Pavlidis 3, Yike Guo 3, Guy J M Cameron 1, Tatt Jhong Haw 1, Anthony Tam 4 5, Maen Obiedat 4 5, Chantal Donovan 1, Nicole G Hansbro 1 6 7, Duc H Nguyen 1, Prema Mono Nair 1, Richard Y Kim 1, Jay C Horvat 1, Gerard E Kaiko 1, Scott K Durum 8, Peter A Wark 1, Don D Sin 4 5, Gaetano Caramori 9, Ian M Adcock 3, Paul S Foster 1, Philip M Hansbro 10 6 7",Eur Respir J. 2019 Jul 18;54(1):1800174. doi: 10.1183/13993003.00174-2018. Print 2019 Jul.,Starkey MR,Eur Respir J,2019,2019/06/15,PMC8132110,NIHMS1695786,10.1183/13993003.00174-2018,https://pubmed.ncbi.nlm.nih.gov/31196943/,/31196943/,"Conflict of interest: M.R. Starkey has nothing to disclose. Conflict of interest: M.W. Plank is a full-time employee of GlaxoSmithKline. Conflict of interest: P. Casolari has nothing to disclose. Conflict of interest: A. Papi reports board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and TEVA, payment for lectures and travel expenses reimbursement from Menarini, Novartis, Zambon and Sanofi, outside the submitted work. Conflict of interest: S. Pavlidis has nothing to disclose. Conflict of interest: Y Guo has nothing to disclose. Conflict of interest: G.J.M. Cameron has nothing to disclose. Conflict of interest: T.J. Haw has nothing to disclose. Conflict of interest: A. Tam has nothing to disclose. Conflict of interest: M. Obeidat has nothing to disclose. Conflict of interest: C. Donovan has nothing to disclose. Conflict of interest: N.G. Hansbro has nothing to disclose. Conflict of interest: D.H. Nguyen has nothing to disclose. Conflict of interest: P.M. Nair has nothing to disclose. Conflict of interest: R.Y. Kim has nothing to disclose. Conflict of interest: J.C. Horvat has nothing to disclose. Conflict of interest: G.E. Kaiko has nothing to disclose. Conflict of interest: S.K. Durum has nothing to disclose. Conflict of interest: P.A. Wark has nothing to disclose. Conflict of interest: D.D. Sin reports grants from Merck, personal fees for advisory board work from Sanofi-Aventis and Regeneron, grants and personal fees from Boehringer Ingelheim, grants and personal fees for lecturing and advisory board work from AstraZeneca, personal fees for lecturing and advisory board work from Novartis, outside the submitted work. Conflict of interest: G. Caramori has nothing to disclose. Conflict of interest: I.M. Adcock has nothing to disclose. Conflict of interest: P.S. Foster has nothing to disclose. Conflict of interest: P.M. Hansbro reports funding/consultancies from Pharmaxis, AstraZeneca, Sanofi, Pharmakea, Ausbio, and Allakos outside the submitted work.",Grants and funding WT_/Wellcome Trust/United Kingdom Z01 BC009287/ImNIH/Intramural NIH HHS/United States,"Malcolm R Starkey 1 , Maximilian W Plank 1 , Paolo Casolari 2 , Alberto Papi 2 , Stelios Pavlidis 3 , Yike Guo 3 , Guy J M Cameron 1 , Tatt Jhong Haw 1 , Anthony Tam 4 5 , Maen Obiedat 4 5 , Chantal Donovan 1 , Nicole G Hansbro 1 6 7 , Duc H Nguyen 1 , Prema Mono Nair 1 , Richard Y Kim 1 , Jay C Horvat 1 , Gerard E Kaiko 1 , Scott K Durum 8 , Peter A Wark 1 , Don D Sin 4 5 , Gaetano Caramori 9 , Ian M Adcock 3 , Paul S Foster 1 , Philip M Hansbro 10 6 7"
31733651,"Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study","Monia Garofolo 1, Elisa Gualdani 2, Rosa Giannarelli 1, Michele Aragona 1, Fabrizio Campi 1, Daniela Lucchesi 1, Giuseppe Daniele 1, Roberto Miccoli 1, Paolo Francesconi 2, Stefano Del Prato 3, Giuseppe Penno 1",Cardiovasc Diabetol. 2019 Nov 16;18(1):159. doi: 10.1186/s12933-019-0961-7.,Garofolo M,Cardiovasc Diabetol,2019,2019/11/18,PMC6858978,,10.1186/s12933-019-0961-7,https://pubmed.ncbi.nlm.nih.gov/31733651/,/31733651/,"MG has received travel grants from AstraZeneca and Novo Nordisk. MA has received speaker/advisory honoraria from Abbott Laboratories. FC has received travel grants from Novo Nordisk. GD reports past participation in advisory boards from AstraZeneca, Eli Lilly and Co and Novartis Pharmaceuticals. SDP reports past participation in advisory boards and/or receiving research grants from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk, Sanofi, Servier, and Takeda Pharmaceuticals. GP has received travel grants and speaker/advisory honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck Sharp & Dohme, Mundipharma Pharmaceuticals, Novo Nordisk, and Takeda Pharmaceuticals. All other authors (EG, RG, DL, MR, and PF) declare that they have no competing interests.",,"Monia Garofolo 1 , Elisa Gualdani 2 , Rosa Giannarelli 1 , Michele Aragona 1 , Fabrizio Campi 1 , Daniela Lucchesi 1 , Giuseppe Daniele 1 , Roberto Miccoli 1 , Paolo Francesconi 2 , Stefano Del Prato 3 , Giuseppe Penno 1"
31064370,Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview,"Lieven Pouillon 1, Séverine Vermeire 2, Peter Bossuyt 3",BMC Med. 2019 May 8;17(1):89. doi: 10.1186/s12916-019-1323-8.,Pouillon L,BMC Med,2019,2019/05/09,PMC6505179,,10.1186/s12916-019-1323-8,https://pubmed.ncbi.nlm.nih.gov/31064370/,/31064370/,"SV is a senior clinical investigator of the Research Foundation – Flanders (FWO). Not applicable. Not applicable. LP received travel grants from Abvvie, Ferring and Takeda. SV has served as a speaker for AbbVie, MSD, Pfizer, Takeda, Hospira and Ferring; received consultant fees from AbbVie, MSD, Pfizer, Takeda, Hospira, Ferring, Mundipharma, Second Genome, Galapagos, Genentech/Roche, Janssen, Celgene; served as an advisory board member for AbbVie, MSD, Pfizer, Takeda, Hospira, Ferring, Mundipharma, Second Genome, Galapagos, Genentech/Roche, Janssen, Celgene; and received research grants from MSD, AbbVie, Pfizer, Takeda. PB received educational grants from AbbVie, Mundipharma, Pfizer and Janssen; speaker fees from AbbVie, Takeda and Pfizer;and advisory board fees from Hospira, Janssen, MSD, Mundipharma, Roche, Pfizer, Takeda, Sandoz and Pentax. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",,"Lieven Pouillon 1 , Séverine Vermeire 2 , Peter Bossuyt 3"
30815024,Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges,"Shinichi Makita 1, Katsuaki Imaizumi 2, Saiko Kurosawa 3, Kensei Tobinai 1",Drugs Context. 2019 Feb 13;8:212567. doi: 10.7573/dic.212567. eCollection 2019.,Makita S,Drugs Context,2019,2019/03/01,PMC6385623,,10.7573/dic.212567,https://pubmed.ncbi.nlm.nih.gov/30815024/,/30815024/,"Disclosure and potential conflicts of interest: SM, KI, and SK have nothing to disclose. KT received consulting fees and lecture fees from Zenyaku Kogyo, grant support and lecture fees from Eisai, Takeda, Mundipharma International, Janssen, Kyowa Hakko Kirin, Chugai Pharma, and Ono Pharmaceutical, grant support, consulting fees, and lecture fees from HUYA Bioscience International, and grant support from GlaxoSmithKline, Servier, and AbbVie. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2019/01/dic.212567-COI.pdf",,"Shinichi Makita 1 , Katsuaki Imaizumi 2 , Saiko Kurosawa 3 , Kensei Tobinai 1"
31257362,The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars,"Liese Barbier 1, Paul Declerck 2, Steven Simoens 2, Patrick Neven 3, Arnold G Vulto 4, Isabelle Huys 2",Br J Cancer. 2019 Jul;121(3):199-210. doi: 10.1038/s41416-019-0480-z. Epub 2019 Jul 1.,Barbier L,Br J Cancer,2019,2019/07/02,PMC6738325,,10.1038/s41416-019-0480-z,https://pubmed.ncbi.nlm.nih.gov/31257362/,/31257362/,"S.S. is involved in a stakeholder roundtable on biosimilars sponsored by Amgen, Pfizer and MSD, and has participated in an advisory board meeting on biosimilars for Pfizer. A.G.V. is involved in consulting, advisory work and speaking engagements for a number of companies, i.e., AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche, Novartis, Sandoz, Boehringer Ingelheim. PD participated at advisory board meetings for AbbVie, Amgen, Hospira, and Samsung Bioepis and is on the Speakers’ Bureau of AbbVie, Celltrion, Hospira, Merck Serono, and Roche. P.N. and L.B. declare no conflict of interest. The preliminary results of this research were presented at an Amgen sponsored Satellite Symposium at the 22nd Congress of the EAHP (Cannes, France, 2017). LB declares that the research was conducted in the absence of any commercial or financial relationship that could be perceived as a potential conflict of interest.",,"Liese Barbier 1 , Paul Declerck 2 , Steven Simoens 2 , Patrick Neven 3 , Arnold G Vulto 4 , Isabelle Huys 2"
31174279,P2X7 Receptor Signaling in Stress and Depression,"Deidiane Elisa Ribeiro 1, Aline Lulho Roncalho 2 3, Talita Glaser 4, Henning Ulrich 5, Gregers Wegener 6 7, Sâmia Joca 8 9 10",Int J Mol Sci. 2019 Jun 6;20(11):2778. doi: 10.3390/ijms20112778.,Ribeiro DE,Int J Mol Sci,2019,2019/06/09,PMC6600521,,10.3390/ijms20112778,https://pubmed.ncbi.nlm.nih.gov/31174279/,/31174279/,"Gregers Wegener reported having received research support/lecture/consultancy fees from H. Lundbeck A/S, Servier SA, AstraZeneca AB, Eli Lilly A/S, Sun Pharma Pty Ltd., Pfizer, Inc., Shire A/S, HB Pharma A/S, Arla Foods Amba., Janssen Pharma A/S, and Mundipharma International, Ltd. All other authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.",Grants and funding 2015/13345-1; 2012/50880-4; 2018/08426-0/Fundação de Amparo à Pesquisa do Estado de São Paulo 304780/2018-9/Conselho Nacional de Desenvolvimento Científico e Tecnológico 8020-00310B/Danmarks Frie Forskningsfond 754513/Horizon 2020,"Deidiane Elisa Ribeiro 1 , Aline Lulho Roncalho 2 3 , Talita Glaser 4 , Henning Ulrich 5 , Gregers Wegener 6 7 , Sâmia Joca 8 9 10"
30895184,Research highlights from the 2018 European Respiratory Society International Congress: airway disease,"Florence Schleich 1, Andras Bikov 2 3, Alexander G Mathioudakis 2 3, Melissa McDonnell 4, Cecilia Andersson 5, Matteo Bonini 6 7, Lena Uller 8, Marco Idzko 9, Dave Singh 10, Jose Luis Lopez-Campos 11 12, Apostolos Bossios 13 14, Ian M Adcock 7, Omar Usmani 7, Antonio Spanevello 15, Sara J Bonvini 7",ERJ Open Res. 2019 Mar 18;5(1):00225-2018. doi: 10.1183/23120541.00225-2018. eCollection 2019 Feb.,Schleich F,ERJ Open Res,2019,2019/03/22,PMC6421359,,10.1183/23120541.00225-2018,https://pubmed.ncbi.nlm.nih.gov/30895184/,/30895184/,"Conflict of interest: F. Schleich has nothing to disclose. Conflict of interest: A. Bikov has nothing to disclose. Conflict of interest: A.G. Mathioudakis reports grants and personal fees from Boehringer Ingelheim, and personal fees from GlaxoSmithKline, outside the submitted work. Conflict of interest: M. McDonnell reports grants from the Health Research Board, Ireland, outside the submitted work. Conflict of interest: C. Andersson has nothing to disclose. Conflict of interest: M. Bonini has nothing to disclose. Conflict of interest: L. Uller has nothing to disclose. Conflict of interest: M. Idzko has nothing to disclose. Conflict of interest: D. Singh reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, and personal fees from Cipla and Peptinnovate, outside the submitted work. Conflict of interest: J.L. Lopez-Campos reports personal fees and nonfinancial support from Boehringer, Grifols, Novartis, Chiesi, AstraZeneca and GSK, personal fees from Teva, Rovi, Ferrer, Bial, Esteve and Gebro Pharma, and grants, personal fees and nonfinancial support from Menarini, outside the submitted work. Conflict of interest: A. Bossios reports personal fees and other support for consultancy from AstraZeneca, Teva and GSK, outside the submitted work. Conflict of interest: I.M. Adcock has nothing to disclose. Conflict of interest: O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Prosonix, Takeda, Zentiva Cipla and Pearl Therapeutics, and grants from GlaxoSmithKline and Edmond Pharma, outside the submitted work. Conflict of interest: A. Spanevello has nothing to disclose. Conflict of interest: S.J. Bonvini has nothing to disclose.",,"Florence Schleich 1 , Andras Bikov 2 3 , Alexander G Mathioudakis 2 3 , Melissa McDonnell 4 , Cecilia Andersson 5 , Matteo Bonini 6 7 , Lena Uller 8 , Marco Idzko 9 , Dave Singh 10 , Jose Luis Lopez-Campos 11 12 , Apostolos Bossios 13 14 , Ian M Adcock 7 , Omar Usmani 7 , Antonio Spanevello 15 , Sara J Bonvini 7"
30997935,SGLT2 inhibition to address the unmet needs in diabetic nephropathy,"Federica Barutta 1, Sara Bernardi 1, Giuseppe Gargiulo 1, Marilena Durazzo 1, Gabriella Gruden 1",Diabetes Metab Res Rev. 2019 Oct;35(7):e3171. doi: 10.1002/dmrr.3171. Epub 2019 May 9.,Barutta F,Diabetes Metab Res Rev,2019,2019/04/19,PMC6849789,,10.1002/dmrr.3171,https://pubmed.ncbi.nlm.nih.gov/30997935/,/30997935/,Gruden G. has received a speaker fee from MundiPharma.,,"Federica Barutta 1 , Sara Bernardi 1 , Giuseppe Gargiulo 1 , Marilena Durazzo 1 , Gabriella Gruden 1"
31167885,New evidence on the chemoprevention of\xa0inhaled steroids and the risk of lung cancer in COPD,"Luis M Seijo 1 2, Joan B Soriano 2 3, Germán Peces-Barba 2 4",Eur Respir J. 2019 Jun 5;53(6):1900717. doi: 10.1183/13993003.00717-2019. Print 2019 Jun.,Seijo LM,Eur Respir J,2019,2019/06/07,,,10.1183/13993003.00717-2019,https://pubmed.ncbi.nlm.nih.gov/31167885/,/31167885/,"Conflict of interest: L.M. Seijo reports grants from Menarini (funding for lung cancer screening), personal fees from Esteve (speaker fees for a symposium on lung cancer and COPD), personal fees from Roche (speaker fees on lung cancer), personal fees from Medtronic (advisory board fees for speaking on lung cancer screening), travel grants from Chiesi, personal fees from AstraZeneca (speaking fees), personal fees from Suministros Hospitalarios (indwelling pleural catheter symposium), outside the submitted work. Conflict of interest: J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. J.B. Soriano declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates. Conflict of interest: G. Peces-Barba reports grants from GSK (advisory boards, institutional educational programme and research project), Boehringer Ingelheim (institutional educational program), and Chiesi (institutional educational program), outside the submitted work.",,"Luis M Seijo 1 2 , Joan B Soriano 2 3 , Germán Peces-Barba 2 4"
31147425,Supplemental oxygen during exercise training in COPD: full of hot air?,"Jessica A Walsh 1, Matthew Maddocks 2, William D-C Man 1 3",Eur Respir J. 2019 May 30;53(5):1900837. doi: 10.1183/13993003.00837-2019. Print 2019 May.,Walsh JA,Eur Respir J,2019,2019/06/01,,,10.1183/13993003.00837-2019,https://pubmed.ncbi.nlm.nih.gov/31147425/,/31147425/,"Conflict of interest: J.A. Walsh has nothing to disclose. Conflict of interest: M. Maddocks has nothing to disclose. Conflict of interest: W.D-C. Man reports personal fees from Jazz Pharmaceuticals, Mundipharma and Novartis, grants from Pfizer, National Institute for Health Research and British Lung Foundation, non-financial support from GSK, outside the submitted work.",Grants and funding CDF-2017-10-009/DH_/Department of Health/United Kingdom,"Jessica A Walsh 1 , Matthew Maddocks 2 , William D-C Man 1 3"
31015767,"Biliary tract cancers: current knowledge, clinical candidates and future challenges","Noor-Ul-Ain Tariq 1 2, Mairéad G McNamara 1 2, Juan W Valle 1 2",Cancer Manag Res. 2019 Mar 29;11:2623-2642. doi: 10.2147/CMAR.S157092. eCollection 2019.,Tariq NU,Cancer Manag Res,2019,2019/04/25,PMC6446989,,10.2147/CMAR.S157092,https://pubmed.ncbi.nlm.nih.gov/31015767/,/31015767/,"Disclosure Noor-ul-Ain Tariq received honoraria for lecturers, participation in writing guidelines and travel reimbursements in 2014 from Boehringer Ingelheim and received funding from the Timpson fellowship. Boehringer Ingelheim or Timpson have no influence over the contents of this review. Mairéad G McNamara was advisory board member of Ipsen, SHIRE, Celgene and Sirtex, received research support from NuCana BioMed Ltd. and SHIRE, received honoraria for participation in Speaker’s Bureau from Pfizer and Ipsen and received travel expenses from Bayer. Juan W Valle received travel grants from Celgene, Ipsen, Novartis, NuCana for more than 5 years, received honoraria for participation in Speakers’ Bureau for Abbott, Celgene, Ipsen, Novartis, Pfizer and Sir-tex and provided consulting or advisory role for for Abbott, Agios, AstraZeneca, Baxalta, Bioven, Celgene, Delcath, Genoscience Pharma, Incyte, Ipsen, Keocyt, Lilly, Merck, MidaTech, Mundipharma, Novartis, NuCana, PCI Biotech, Pfizer, Pieris Pharmaceuticals and QED Pharmaceuticals. The authors report no other conflicts of interest in this work.",,"Noor-Ul-Ain Tariq 1 2 , Mairéad G McNamara 1 2 , Juan W Valle 1 2"
31698426,TFH lymphomas: the times they aza-changin?,"David M Weinstock 1, Steven M Horwitz 2",Blood. 2019 Oct 24;134(17):1364-1365. doi: 10.1182/blood.2019002806.,Weinstock DM,Blood,2019,2019/11/08,PMC6839955,,10.1182/blood.2019002806,https://pubmed.ncbi.nlm.nih.gov/31698426/,/31698426/,"Conflict-of-interest disclosure: D.M.W. reports advisory board participation for Travera, Mundipharma EDO, Bantam, and Celgene, consulting for Novartis, Genentech/Roche, and Prescient, sponsored research support from Novartis, Astra Zeneca, Aileron, AbbVie, Daiichi Sankyo, Dragonfly, Verastem, and Surface Oncology, and is a cofounder of Travera and Ajax Biosciences. S.M.H. reports consulting for ADC Therapeutics, Aileron, Seattle Genetics, Takeda, Kyowa Hakka Kirin, Verastem, Portola, and Corvus and research funding from Aileron, Celgene, Seattle Genetics, Takeda, Kyowa Hakka Kirin, Verastem, ADCT Therapeutics, and Trillium.",,"David M Weinstock 1 , Steven M Horwitz 2"
31149622,Predictors of prolongation in recent-onset cough,"Anne M Lätti 1 2, Juha Pekkanen 3 4, Heikki O Koskela 1 2",ERJ Open Res. 2019 May 28;5(2):00238-2018. doi: 10.1183/23120541.00238-2018. eCollection 2019 Apr.,Lätti AM,ERJ Open Res,2019,2019/06/01,PMC6536860,,10.1183/23120541.00238-2018,https://pubmed.ncbi.nlm.nih.gov/31149622/,/31149622/,"Conflict of interest: A.M. Lätti reports grants from Kuopion Hengityssäätiö Foundation and Hengityssairauksien Tutkimussäätiö during the conduct of the study, and personal fees from Orion, Boehringer-Ingelheim and Roche to attend international scientific meetings outside the submitted work. Conflict of interest: J. Pekkanen has nothing to disclose. Conflict of interest: H.O. Koskela reports grants from Kuopion Hengityssäätiö Foundation and Hengityssairauksien Tutkimussäätiö during the conduct of the study; and personal fees from Mundipharma Ltd, Orion Pharma Ltd, Oy, Eli Lilly Finland Ltd and Boehringer Ingelheim Finland Ltd as payments for giving scientific lectures at gatherings organised by medical companies, personal fees from Takeda Leiras Ltd, Boehringer Ingelheim Ltd, Mundipharma Ltd and AstraZeneca Ltd to attend international scientific meetings, and owning shares in Orion Pharma Ltd worth €22 000.",,"Anne M Lätti 1 2 , Juha Pekkanen 3 4 , Heikki O Koskela 1 2"
31516692,Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases,"J Jean Bousquet 1 2 3 4, Holger J Schünemann 5, Alkis Togias 6, Marina Erhola 7, Peter W Hellings 3 8 9, Torsten Zuberbier 4 10, Ioana Agache 11, Ignacio J Ansotegui 12, Josep M Anto 13 14 15 16, Claus Bachert 17, Sven Becker 18, Martin Bedolla-Barajas 19, Michael Bewick 20, Sinthia Bosnic-Anticevich 21 22 23, Isabelle Bosse 24, Louis P Boulet 25, Jean Marc Bourrez 26, Guy Brusselle 27, Niels Chavannes 28, Elisio Costa 29, Alvaro A Cruz 30 31, Wienczyslawa Czarlewski 32, Wytske J Fokkens 3 33, Joao A Fonseca 34 35, Mina Gaga 36, Tari Haahtela 37, Maddalena Illario 38, Ludger Klimek 39, Piotr Kuna 40, Violeta Kvedariene 41, L T T Le 42, Desiree Larenas-Linnemann 43, Daniel Laune 44, Olga M Lourenço 45, Enrica Menditto 46, Joaquin Mullol 47 48, Yashitaka Okamoto 49, Nikos Papadopoulos 50 51, Nhân Pham-Thi 52, Robert Picard 53, Hilary Pinnock 54, Nicolas Roche 55, Regina E Roller-Wirnsberger 56, Christine Rolland 57, Boleslaw Samolinski 58, Aziz Sheikh 54, Sanna Toppila-Salmi 37, Ioanna Tsiligianni 59 60, Arunas Valiulis 61, Erkka Valovirta 62, Tuula Vasankari 63, Maria-Teresa Ventura 64, Samantha Walker 65, Sian Williams 62, Cezmi A Akdis 66, Isabella Annesi-Maesano 67, Sylvie Arnavielhe 44, Xavier Basagana 13 14 15 16, Eric Bateman 68, Anna Bedbrook 1, K S Bennoor 69, Samuel Benveniste 70, Karl C Bergmann 4 10, Slawomir Bialek 71, Nils Billo 72, Carsten Bindslev-Jensen 73 74, Leif Bjermer 75, Hubert Blain 76 77, Mateo Bonini 78 79, Philippe Bonniaud 80, Jacques Bouchard 81 82, Vitalis Briedis 83, Christofer E Brightling 84 85, Jan Brozek 5, Roland Buhl 86, Roland Buonaiuto 87, Giorgo W Canonica 88, Victoria Cardona 89, Ana M Carriazo 90, Warner Carr 91, Christine Cartier 92, Thomas Casale 93, Lorenzo Cecchi 94, Alfonso M Cepeda Sarabia 95 96, Eka Chkhartishvili 97, Derek K Chu 3, Cemal Cingi 98, Elaine Colgan 99, Jaime Correia de Sousa 100 101, Anne Lise Courbis 102, Adnan Custovic 103, Biljana Cvetkosvki 21 22 23, Gennaro DAmato 104, Jane da Silva 105, Carina Dantas 106 107, Dejand Dokic 108, Yves Dauvilliers 109, Antoni Dedeu 110 111, Giulia De Feo 112, Philippe Devillier 113, Stefania Di Capua 114, Marc Dykewickz 115, Ruta Dubakiene 116, Motohiro Ebisawa 117, Yaya El-Gamal 118, Esben Eller 73 74, Regina Emuzyte 119, John Farrell 101, Antjie Fink-Wagner 120, Alessandro Fiocchi 121, Jean F Fontaine 122, Bilun Gemicioğlu 123, Peter Schmid-Grendelmeir 124, Amiran Gamkrelidze 125, Judith Garcia-Aymerich 13, Maximiliano Gomez 126, Sandra González Diaz 127, Maia Gotua 128, Nick A Guldemond 129, Maria-Antonieta Guzmán 130, Jawad Hajjam 131, John OB Hourihane 132, Marc Humbert 133, Guido Iaccarino 134, Despo Ierodiakonou 59 62, Maddalena Illario 35, Juan C Ivancevich 135, Guy Joos 25, Ki-Suck Jung 136, Marek Jutel 137, Igor Kaidashev 138, Omer Kalayci 139, Przemyslaw Kardas 140, Thomas Keil 141 142, Mussa Khaitov 143, Nikolai Khaltaev 144, Jorg Kleine-Tebbe 145, Marek L Kowalski 146, Vicky Kritikos 21 22 23, Inger Kull 147 148, Lisa Leonardini 149, Philip Lieberman 150, Brian Lipworth 151, Karin C Lodrup Carlsen 152 153, Claudia C Loureiro 154, Renaud Louis 155, Alpana Mair 156, Gert Marien 3, Bassam Mahboub 157, Joao Malva 107 158, Patrick Manning 159, Esteban De Manuel Keenoy 160, Gailen D Marshall 161, Mohamed R Masjedi 162, Jorge F Maspero 163, Eve Mathieu-Dupas 44, Poalo M Matricardi 164, Eric Melén 148 165, Elisabete Melo-Gomes 166, Eli O Meltzer 167, Enrica Menditto 46, Jacques Mercier 168, Neven Miculinic 169, Florin Mihaltan 170, Branislava Milenkovic 171, Giuliana Moda 172, Maria-Dolores Mogica-Martinez 173, Yousser Mohammad 174 175, Steve Montefort 176, Ricardo Monti 177, Mario Morais-Almeida 178, Ralf Mösges 179 180, Lars Münter 181, Antonella Muraro 182, Ruth Murray 183 184, Robert Naclerio 185, Luigi Napoli 186, Leila Namazova-Baranova 187, Hugo Neffen 188 189, Kristoff Nekam 190, Angelo Neou 191, Enrico Novellino 192, Dieudonné Nyembue 193, Robin OHehir 194, Ken Ohta 195, Kimi Okubo 196, Gabrielle Onorato 1, Solange Ouedraogo 197, Isabella Pali-Schöll 198, Susanna Palkonen 199, Peter Panzner 200, Hae-Sim Park 201, Jean-Louis Pépin 202 203, Ana-Maria Pereira 204 205, Oliver Pfaar 206, Ema Paulino 207, Jim Phillips 208, Robert Picard 53, Davor Plavec 209 210, Ted A Popov 211, Fabienne Portejoie 1, David Price 212 213, Emmanuel P Prokopakis 214, Benoit Pugin 3, Filip Raciborski 58, Rojin Rajabian-Söderlund 215, Sietze Reitsma 3 33, Xavier Rodo 13, Antonino Romano 216 217, Nelson Rosario 218, Menahenm Rottem 219, Dermot Ryan 220, Johanna Salimäki 221, Mario M Sanchez-Borges 222, Juan-Carlos Sisul 223, Dirceu Solé 224, David Somekh 225, Talant Sooronbaev 226, Milan Sova 227, Otto Spranger 120, Cristina Stellato 112, Rafael Stelmach 228, Charlotte Suppli Ulrik 229, Michel Thibaudon 230, Teresa To 231, Ana Todo-Bom 154, Peter V Tomazic 232, Antonio A Valero 233, Rudolph Valenta 234 235 236, Marylin Valentin-Rostan 237, Rianne van der Kleij 238 239, Olivier Vandenplas 240, Giorgio Vezzani 241, Frédéric Viart 92, Giovanni Viegi 242 243, Dana Wallace 244, Martin Wagenmann 245, De Y Wang 246, Susan Waserman 247, Magnus Wickman 248, Dennis M Williams 249, Gary Wong 250, Piotr Wroczynski 71, Panayiotis K Yiallouros 251 252, Arzu Yorgancioglu 253, Osman M Yusuf 254, Heahter J Zar 255 256, Stéphane Zeng 257, Mario Zernotti 258, Luo Zhang 259, Nan S Zhong 260, Mihaela Zidarn 261 ; ARIA Study Group; MASK Study Group",Clin Transl Allergy. 2019 Sep 9;9:44. doi: 10.1186/s13601-019-0279-2. eCollection 2019.,Bousquet JJ,Clin Transl Allergy,2019,2019/09/14,PMC6734297,,10.1186/s13601-019-0279-2,https://pubmed.ncbi.nlm.nih.gov/31516692/,/31516692/,"Competing interestsDr. Ansotegui reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, Astra Zeneca, outside the submitted work. Dr. Bosnic-Anticevich reports grants from TEVA, personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, Sanofi, Mylan, outside the submitted work. Dr. Bousquet reports personal fees and others from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, others from Kyomed, outside the submitted work. Dr. Boulet reports and Disclosure of potential conflicts of interest—last 3 years. Research grants for participation to multicentre studies, AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi, Takeda. Support for research projects introduced by the investigator AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Takeda. Consulting and advisory boards Astra Zeneca, Novartis, Methapharm. Royalties Co-author of “Up-To-Date” (occupational asthma). Nonprofit grants for production of educational materials AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Novartis. Conference fees AstraZeneca, GlaxoSmithKline, Merck, Novartis. Support for participation in conferences and meetings Novartis, Takeda. Other participations Past president and Member of the Canadian Thoracic Society Respiratory Guidelines Committee; Chair of the Board of Directors of the Global Initiative for Asthma (GINA). Chair of Global Initiative for Asthma (GINA) Guidelines Dissemination and Implementation Committee; Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health; Member of scientific committees for the American College of Chest Physicians, American Thoracic Society, European Respiratory Society and the World Allergy Organization; 1st Vice-President of the Global Asthma Organization “InterAsma”. Dr. Casale reports grants and non-financial support from Stallergenes, outside the submitted work. Dr. Cruz reports grants and personal fees from GlaxoSmithKline, personal fees from Boehrinher Ingelheim, AstraZeneca, Novartis, Merk, Sharp & Dohme, MEDA Pharma, EUROFARMA, Sanofi Aventis, outside the submitted work. Dr. Ebisawa reports personal fees from DBV Technologies, Mylan EPD maruho, Shionogi & CO., Ltd., Kyorin Pharmaceutical Co., Ltd., Thermofisher Diagnostics, Pfizer, Beyer, Nippon Chemifar, Takeda Pharmaceutical Co., Ltd., MSD, outside the submitted work. Dr. Ivancevich reports personal fees from Euro Farma Argentina, Faes Farma, non-financial support from Laboratorios Casasco, outside the submitted work. Dr. Haahtela reports personal fees from Mundipharma, Novartis, and Orion Pharma, outside the submitted work. Dr. Klimek reports grants and personal fees from ALK Abelló, Denmark, Novartis, Switzerland, Allergopharma, Germany, Bionorica, Germany, GSK, Great Britain, Lofarma, Italy, personal fees from MEDA, Sweden, Boehringer Ingelheim, Germany, grants from Biomay, Austria, HAL, Netherlands, LETI, Spain, Roxall, Germany, Bencard, Great Britain, outside the submitted work. V.KV has received payment for consultancy from GSK and for lectures from StallergensGreer, Berlin-CHemie and sponsorship from MYLAN for in the following professional training: ARIA masterclass in allergic rhinitis participation. Dr. Larenas Linnemann reports personal fees from GSK, Astrazeneca, MEDA, Boehringer Ingelheim, Novartis, Grunenthal, UCB, Amstrong, Siegfried, DBV Technologies, MSD, Pfizer., grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Chiesi, Boehringer Ingelheim, outside the submitted work. Dr. Mösges reports personal fees from ALK, grants from ASIT biotech, Leti, BitopAG, Hulka, Ursapharm, Optima; personal fees from allergopharma, Nuvo, Meda, Friulchem, Hexal, Servier, Bayer, Johnson & Johnson, Klosterfrau, GSK, MSD, FAES, Stada, UCB, Allergy Therapeutics; grants and personal fees from Bencard, Stallergenes; grants, personal fees and non-financial support from Lofarma; non-financial support from Roxall, Atmos, Bionorica, Otonomy, Ferrero; personal fees and non-financial support from Novartis; Dr. Okamoto reports personal fees from Eizai Co., Ltd., Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, Kyowa Co., Ltd., grants and personal fees from Kyorin Co., Ltd., Tiho Co., Ltd., grants from Yakuruto Co., Ltd., Yamada Bee Farm, outside the submitted work. Dr. Papadopoulos reports grants from Gerolymatos, personal fees from Hal Allergy B.V., Novartis Pharma AG, Menarini, Hal Allergy B.V., outside the submitted work. Dr. Pépin reports grants from AIR LIQUIDE FOUNDATION, AGIR à dom, ASTRA ZENECA, FISHER & PAYKEL, MUTUALIA, PHILIPS, RESMED, VITALAIRE, other from AGIR à dom, ASTRA ZENECA, BOEHRINGER INGELHEIM, JAZZ PHARMACEUTICAL, NIGHT BALANCE, PHILIPS, RESMED, SEFAM, outside the submitted work. Dr. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, ASIT Biotech Tools S.A, Laboratorios LETI/LETI Pharma, Anergis S.A., grants from Nuvo, Circassia, Glaxo Smith Kline, personal fees from Novartis Pharma, MEDA Pharma, Mobile Chamber Experts (a GA2LEN Partner), Pohl-Boskamp, Indoor Biotechnologies, grants from, outside the submitted work. Dr. Todo-Bom reports grants and personal fees from Novartis, Mundipharma, GSK Teva Pharma, personal fees from AstraZeneca, grants from Leti, outside the submitted work. Dr. Tsiligianni reports advisory boards from Boehringer Ingelheim and Novartis and a grant from GSK, outside the submitted work. Dr. Wallace reports and Indicates that she is the co-chair of the Joint Task Force on Practice Parameters, a task force composed of 12 members of the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology. Dr. Waserman reports other from CSL Behring, Shire, AstraZeneca,Teva, Meda, Merck, outside the submitted work. Dr. Zuberbier reports and Organizational affiliations: Commitee member: WHO-Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA). Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI). Head: European Centre for Allergy Research Foundation (ECARF). Secretary General: Global Allergy and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO).",Grants and funding 001/WHO_/World Health Organization/International,"J Jean Bousquet 1 2 3 4 , Holger J Schünemann 5 , Alkis Togias 6 , Marina Erhola 7 , Peter W Hellings 3 8 9 , Torsten Zuberbier 4 10 , Ioana Agache 11 , Ignacio J Ansotegui 12 , Josep M Anto 13 14 15 16 , Claus Bachert 17 , Sven Becker 18 , Martin Bedolla-Barajas 19 , Michael Bewick 20 , Sinthia Bosnic-Anticevich 21 22 23 , Isabelle Bosse 24 , Louis P Boulet 25 , Jean Marc Bourrez 26 , Guy Brusselle 27 , Niels Chavannes 28 , Elisio Costa 29 , Alvaro A Cruz 30 31 , Wienczyslawa Czarlewski 32 , Wytske J Fokkens 3 33 , Joao A Fonseca 34 35 , Mina Gaga 36 , Tari Haahtela 37 , Maddalena Illario 38 , Ludger Klimek 39 , Piotr Kuna 40 , Violeta Kvedariene 41 , L T T Le 42 , Desiree Larenas-Linnemann 43 , Daniel Laune 44 , Olga M Lourenço 45 , Enrica Menditto 46 , Joaquin Mullol 47 48 , Yashitaka Okamoto 49 , Nikos Papadopoulos 50 51 , Nhân Pham-Thi 52 , Robert Picard 53 , Hilary Pinnock 54 , Nicolas Roche 55 , Regina E Roller-Wirnsberger 56 , Christine Rolland 57 , Boleslaw Samolinski 58 , Aziz Sheikh 54 , Sanna Toppila-Salmi 37 , Ioanna Tsiligianni 59 60 , Arunas Valiulis 61 , Erkka Valovirta 62 , Tuula Vasankari 63 , Maria-Teresa Ventura 64 , Samantha Walker 65 , Sian Williams 62 , Cezmi A Akdis 66 , Isabella Annesi-Maesano 67 , Sylvie Arnavielhe 44 , Xavier Basagana 13 14 15 16 , Eric Bateman 68 , Anna Bedbrook 1 , K S Bennoor 69 , Samuel Benveniste 70 , Karl C Bergmann 4 10 , Slawomir Bialek 71 , Nils Billo 72 , Carsten Bindslev-Jensen 73 74 , Leif Bjermer 75 , Hubert Blain 76 77 , Mateo Bonini 78 79 , Philippe Bonniaud 80 , Jacques Bouchard 81 82 , Vitalis Briedis 83 , Christofer E Brightling 84 85 , Jan Brozek 5 , Roland Buhl 86 , Roland Buonaiuto 87 , Giorgo W Canonica 88 , Victoria Cardona 89 , Ana M Carriazo 90 , Warner Carr 91 , Christine Cartier 92 , Thomas Casale 93 , Lorenzo Cecchi 94 , Alfonso M Cepeda Sarabia 95 96 , Eka Chkhartishvili 97 , Derek K Chu 3 , Cemal Cingi 98 , Elaine Colgan 99 , Jaime Correia de Sousa 100 101 , Anne Lise Courbis 102 , Adnan Custovic 103 , Biljana Cvetkosvki 21 22 23 , Gennaro DAmato 104 , Jane da Silva 105 , Carina Dantas 106 107 , Dejand Dokic 108 , Yves Dauvilliers 109 , Antoni Dedeu 110 111 , Giulia De Feo 112 , Philippe Devillier 113 , Stefania Di Capua 114 , Marc Dykewickz 115 , Ruta Dubakiene 116 , Motohiro Ebisawa 117 , Yaya El-Gamal 118 , Esben Eller 73 74 , Regina Emuzyte 119 , John Farrell 101 , Antjie Fink-Wagner 120 , Alessandro Fiocchi 121 , Jean F Fontaine 122 , Bilun Gemicioğlu 123 , Peter Schmid-Grendelmeir 124 , Amiran Gamkrelidze 125 , Judith Garcia-Aymerich 13 , Maximiliano Gomez 126 , Sandra González Diaz 127 , Maia Gotua 128 , Nick A Guldemond 129 , Maria-Antonieta Guzmán 130 , Jawad Hajjam 131 , John OB Hourihane 132 , Marc Humbert 133 , Guido Iaccarino 134 , Despo Ierodiakonou 59 62 , Maddalena Illario 35 , Juan C Ivancevich 135 , Guy Joos 25 , Ki-Suck Jung 136 , Marek Jutel 137 , Igor Kaidashev 138 , Omer Kalayci 139 , Przemyslaw Kardas 140 , Thomas Keil 141 142 , Mussa Khaitov 143 , Nikolai Khaltaev 144 , Jorg Kleine-Tebbe 145 , Marek L Kowalski 146 , Vicky Kritikos 21 22 23 , Inger Kull 147 148 , Lisa Leonardini 149 , Philip Lieberman 150 , Brian Lipworth 151 , Karin C Lodrup Carlsen 152 153 , Claudia C Loureiro 154 , Renaud Louis 155 , Alpana Mair 156 , Gert Marien 3 , Bassam Mahboub 157 , Joao Malva 107 158 , Patrick Manning 159 , Esteban De Manuel Keenoy 160 , Gailen D Marshall 161 , Mohamed R Masjedi 162 , Jorge F Maspero 163 , Eve Mathieu-Dupas 44 , Poalo M Matricardi 164 , Eric Melén 148 165 , Elisabete Melo-Gomes 166 , Eli O Meltzer 167 , Enrica Menditto 46 , Jacques Mercier 168 , Neven Miculinic 169 , Florin Mihaltan 170 , Branislava Milenkovic 171 , Giuliana Moda 172 , Maria-Dolores Mogica-Martinez 173 , Yousser Mohammad 174 175 , Steve Montefort 176 , Ricardo Monti 177 , Mario Morais-Almeida 178 , Ralf Mösges 179 180 , Lars Münter 181 , Antonella Muraro 182 , Ruth Murray 183 184 , Robert Naclerio 185 , Luigi Napoli 186 , Leila Namazova-Baranova 187 , Hugo Neffen 188 189 , Kristoff Nekam 190 , Angelo Neou 191 , Enrico Novellino 192 , Dieudonné Nyembue 193 , Robin OHehir 194 , Ken Ohta 195 , Kimi Okubo 196 , Gabrielle Onorato 1 , Solange Ouedraogo 197 , Isabella Pali-Schöll 198 , Susanna Palkonen 199 , Peter Panzner 200 , Hae-Sim Park 201 , Jean-Louis Pépin 202 203 , Ana-Maria Pereira 204 205 , Oliver Pfaar 206 , Ema Paulino 207 , Jim Phillips 208 , Robert Picard 53 , Davor Plavec 209 210 , Ted A Popov 211 , Fabienne Portejoie 1 , David Price 212 213 , Emmanuel P Prokopakis 214 , Benoit Pugin 3 , Filip Raciborski 58 , Rojin Rajabian-Söderlund 215 , Sietze Reitsma 3 33 , Xavier Rodo 13 , Antonino Romano 216 217 , Nelson Rosario 218 , Menahenm Rottem 219 , Dermot Ryan 220 , Johanna Salimäki 221 , Mario M Sanchez-Borges 222 , Juan-Carlos Sisul 223 , Dirceu Solé 224 , David Somekh 225 , Talant Sooronbaev 226 , Milan Sova 227 , Otto Spranger 120 , Cristina Stellato 112 , Rafael Stelmach 228 , Charlotte Suppli Ulrik 229 , Michel Thibaudon 230 , Teresa To 231 , Ana Todo-Bom 154 , Peter V Tomazic 232 , Antonio A Valero 233 , Rudolph Valenta 234 235 236 , Marylin Valentin-Rostan 237 , Rianne van der Kleij 238 239 , Olivier Vandenplas 240 , Giorgio Vezzani 241 , Frédéric Viart 92 , Giovanni Viegi 242 243 , Dana Wallace 244 , Martin Wagenmann 245 , De Y Wang 246 , Susan Waserman 247 , Magnus Wickman 248 , Dennis M Williams 249 , Gary Wong 250 , Piotr Wroczynski 71 , Panayiotis K Yiallouros 251 252 , Arzu Yorgancioglu 253 , Osman M Yusuf 254 , Heahter J Zar 255 256 , Stéphane Zeng 257 , Mario Zernotti 258 , Luo Zhang 259 , Nan S Zhong 260 , Mihaela Zidarn 261 ; ARIA Study Group; MASK Study Group"
30602182,The stepwise approach of COPD therapy,"Henrik Watz, Anne Kirsten, Timm Greulich",Dtsch Med Wochenschr. 2019 Jan;144(1):15-20. doi: 10.1055/a-0570-3595. Epub 2019 Jan 2.,Watz H,Dtsch Med Wochenschr,2019,2019/01/03,,,10.1055/a-0570-3595,https://pubmed.ncbi.nlm.nih.gov/30602182/,/30602182/,"Henrik Watz: Honorare für Vorträge und Beratung sowie Reisekostenunterstützung von AstraZeneca, Bayer, BerlinChemie, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Menarini, Takeda, Roche.Anne Kirsten: Honorare für Vorträge und Beratung von AstraZeneca Boehringer Ingelheim.Timm Greulich: Honorare für Vorträge, Beratertätigkeiten oder Reiseunterstützung von AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL-Behring, Grifols, GSK, Mundipharma, Novartis, StreamedUp.",,"Henrik Watz, Anne Kirsten, Timm Greulich"
31798382,St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment,"Marija Balic 1, Christoph Thomssen 2, Rachel Würstlein 3, Michael Gnant 4, Nadia Harbeck 3",Breast Care (Basel). 2019 Apr;14(2):103-110. doi: 10.1159/000499931. Epub 2019 Apr 4.,Balic M,Breast Care (Basel),2019,2019/12/05,PMC6886108,,10.1159/000499931,https://pubmed.ncbi.nlm.nih.gov/31798382/,/31798382/,"Marija Balic reports consulting fees, lecture honoraria, advisory board memberships, and travel grants from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Lilly, MSD, Novartis, Pfizer, and Roche, as well as research funding from Eli Lilly and Pfizer. Christoph Thomssen reports receiving honoraria for lectures for advisory boards and lectures: Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Lilly, MSD, NanoString, Novartis, Pfizer, Puma, and Roche, as well as research support from American Diagnostica, Affymetrix, and NanoString. Rachel Würstlein reports receiving lecture and consulting fees, advisory board memberships, travel grants, and research funding by Agenda, Amgen, AstraZeneca, Boehringer Ingelheim, Carl Zeiss, Celgene, Daiichi Sankyo, Essay, Genomic Health, GSK, Hexal, Eli Lilly, MSD, Mundipharma, NanoString, Novartis, Odonate Therapeutics, Paxman, Palleos, Pfizer, Pierre Fabre, Puma Technology, Riemser, Roche, Sandoz/Hexal, Seattle Genetics, TESARO Bio, and Teva. Michael Gnant reports having received personal honoraria, consulting fees, and travel support from: Amgen, AstraZeneca, Celgene, Eisai, Eli Lilly, Ibsen, Madison, Medtronic, Novartis, NanoString Technologies, Pfizer, and Roche/Genentech. An immediate family member is employed by Sandoz. Nadia Harbeck reports honoraria or consultation fees from the following entities: Agendia, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Genomic Health, Lilly, MSD, NanoString, Novartis, Odonate Therapeutics, Pfizer, Roche, Sandoz/Hexal, and Seattle Genetics.",,"Marija Balic 1 , Christoph Thomssen 2 , Rachel Würstlein 3 , Michael Gnant 4 , Nadia Harbeck 3"
31352603,Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine,"John Strang 1 2, Rebecca McDonald 3, Gabrielle Campbell 4, Louisa Degenhardt 4, Suzanne Nielsen 4 5, Alison Ritter 4, Ola Dale 6 7",Drugs. 2019 Sep;79(13):1395-1418. doi: 10.1007/s40265-019-01154-5.,Strang J,Drugs,2019,2019/07/29,PMC6728289,,10.1007/s40265-019-01154-5,https://pubmed.ncbi.nlm.nih.gov/31352603/,/31352603/,"John Strang, through his university, is working with the pharmaceutical industry to identify new or improved treatments and his employer (King’s College London) has received grants, travel costs and/or consultancy payments; this includes investigation of new naloxone formulations and has included work with in the past 3 years, Martindale, Indivior and Mundipharma (all of whom have naloxone products). His employer (King’s College London) has also registered intellectual property on a novel buccal naloxone formulation, naming John Strang et al., and he was earlier named in a patent registration by a pharmaceutical company regarding a concentrated nasal naloxone spray. John Strang et al. have worked as consultants for the United Nations Office on Drugs and Crime, supporting them with a project introducing take-home naloxone to four central and western Asian countries as well as contributing to local take-home naloxone schemes. For a fuller account, see John Strang’s web-page at http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. Rebecca McDonald has undertaken an unpaid student industry placement with Mundipharma Research Ltd. and has received conference-related travel funding and an honorarium from IOTOD (Improving Opioid Outcomes in the Treatment of Opioid Dependence). Rebecca McDonald has been involved in the development of a tablet formulation on which the university (King’s College London) has registered intellectual property. Rebecca McDonald has worked as a consultant for the United Nations Office on Drugs and Crime. Gabrielle Campbell is supported by a National Health and Medical Research Council fellowship (No. 1119992). The National Drug and Alcohol Research Centre at the University of New South Wales is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund. Gabrielle Campbell has received investigator‐initiated untied educational grants from Reckitt Benckiser/Indivior for a study of opioid substitution therapy uptake among patients with chronic non-cancer pain. None of these are directly relevant to the current article. Louisa Degenhardt is supported by National Drug and Alcohol Research Centre research fellowships (No. 1109366 and No. 1041472/No. 1 135 991) and by the National Institutes of Health grant NIDA R01DA1104470. The National Drug and Alcohol Research Centre at the University of New South Wales is supported by funding from the Australian Government under the Drug and Alcohol Program. Louisa Degenhardt has received investigator-initiated untied educational grants from Reckitt Benckiser/Indivior for studies of buprenorphine‐naloxone, buprenorphine depot, naloxone, the development of an opioid‐related behaviour scale and a study of opioid substitution therapy uptake among patients with chronic non‐cancer pain. Louisa Degenhardt has received an untied educational grant from Seqirus for a post‐marketing study of tapentadol and an untied educational grant from Mundipharma for a post‐marketing study of oxycodone. These bodies had no involvement in or knowledge of the current article. Suzanne Nielsen has been a named investigator on untied educational grants from Indivior and Seqirus and has delivered training on opioid dependence for Indivior for which honoraria were paid to her institution. Suzanne Nielsen has participated in an advisory board meeting by Mundipharma relating to naloxone for which she declined a sitting fee. Suzanne Nielsen is a current recipient of a National Health and Medical Research Council Research Fellowship (No. 1163961). Alison Ritter is funded through a National Health and Medical Research Council Research Fellowship (GNT1136944). She has received no funding or untied educational grants from any pharmaceutical company in the last 15 years. This article covers (among others) a naloxone formulation that has been approved by 12 European countries from 16 June, 2018 under the name of Ventizolve® (Respinal® in Sweden), produced by Sanivo Pharma AS. The sponsor of this trial was AS Den Norske Eterfabrikk. Ola Dale was engaged by AS Den Norske Eterfabrikk as the principal investigator in this study, for which Ola Dale receives no personal honorarium. Ola Dale’s employer, the Norwegian University of Science and Technology and its subsidiary Technical Transfer Office have signed cooperation and licensing contracts with DNE PHARMA to seek commercialisation of this nasal naloxone formulation. This regulates potential royalties for Ola Dale through the Norwegian University of Science and Technology. DNE Pharma AS has compensated Ola Dale for business travel from Trondheim to Oslo.",Grants and funding R01 DA044170/DA/NIDA NIH HHS/United States,"John Strang 1 2 , Rebecca McDonald 3 , Gabrielle Campbell 4 , Louisa Degenhardt 4 , Suzanne Nielsen 4 5 , Alison Ritter 4 , Ola Dale 6 7"
31205486,Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience,"Ferdinando DAmico 1, Tommaso Lorenzo Parigi 1, Gionata Fiorino 2, Laurent Peyrin-Biroulet 3, Silvio Danese 4",Therap Adv Gastroenterol. 2019 May 16;12:1756284819848631. doi: 10.1177/1756284819848631. eCollection 2019.,DAmico F,Therap Adv Gastroenterol,2019,2019/06/18,PMC6535722,,10.1177/1756284819848631,https://pubmed.ncbi.nlm.nih.gov/31205486/,/31205486/,"Conflict of interest statement: Gionata Fiorino served as a consultant and a member of Advisory Boards for MSD, Takeda Pharmaceuticals, AbbVie, Pfizer, Celltrion, Amgen, Sandoz, Samsung, and Janssen Pharmaceuticals. Laurent Peyrin-Biroulet received consulting fees from Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Pharmacosmos, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera, Samsung Bioepis, and lecture fees from Merck, Abbvie, Takeda, Janssen, Ferring, Norgine, Tillots, Vifor, Mitsubishi, and HAC-pharma. Silvio Danese has served as a speaker, a consultant and an advisory board member for Abbvie, Ferring, Hospira, Johnson & Johnson, Merck, Millennium Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma, and Vifor. The other authors declare no conflicts of interest.",,"Ferdinando DAmico 1 , Tommaso Lorenzo Parigi 1 , Gionata Fiorino 2 , Laurent Peyrin-Biroulet 3 , Silvio Danese 4"
31315832,Should obesity be recognised as a disease?,"John P H Wilding 1, Vicki Mooney 2, Richard Pile 3",BMJ. 2019 Jul 17;366:l4258. doi: 10.1136/bmj.l4258.,Wilding JPH,BMJ,2019,2019/07/19,,,10.1136/bmj.l4258,https://pubmed.ncbi.nlm.nih.gov/31315832/,/31315832/,"Competing interests: All authors have read and understood BMJ policy on declaration of interests and declare the following interests: JPHW has done consultancy (contracted via and paid to my employer) for Astellas, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceutals, Lilly, Napp, Novo Nordisk, Mundipharma, Sanofi, and Wilmington Healthcare and received institutional research grant support from AstraZeneca and Novo Nordisk. He is has received honorariums and lecture fees from AstraZeneca, Boehringer Ingelheim, Lilly, Napp, Medscape, Mundipharma, Sanofi, and Takeda and support to attend conferences from AstraZeneca, Napp, and Novo Nordisk. He is associate editor of Diabetic Medicine, president elect of the World Obesity Federation, sits on the RCP advisory group on nutrition, weight, and health, a member of the Rank Prize Funds Nutrition Committee and national lead for the metabolic and endocrine speciality group of the NIHR Clinical Research Network. He is also a member of the Association for the Study of Obesity, Diabetes UK, EASD, ADA, and the Society for Endocrinology. VM is a paid consultant for the European Coalition for People living with Obesity (ECPO) and has received honorariums from EASO, Novo Nordisk, Novartis, and Johnson & Johnson for moderating and speaking roles as a patient. RP is a board member leading on prevention for Herts Valleys Clinical Commissioning Group. The CCG has a policy of requiring patients to lose weight or attempt to quit smoking before some types of non-urgent surgery. He works two days a month as a clinical lead for Thrive Tribe, a commercial organisation that provides lifestyle and wellbeing services including smoking cessation, weight management, physical activity, and social prescribing. Most services are commissioned by the NHS or local authorities. He is also a director of Living Life Better, a company set up to provide wellbeing services built around a coaching and partnership working model but has not yet done any paid work for the company.",,"John P H Wilding 1 , Vicki Mooney 2 , Richard Pile 3"
31583033,The Airways Mechanical Stress in Lung Disease: Implications for COPD Pathophysiology and Treatment Evaluation,"Pierachille Santus 1, Matteo Pecchiari 2, Francesco Tursi 3, Vincenzo Valenti 4, Marina Saad 1, Dejan Radovanovic 1",Can Respir J. 2019 Sep 5;2019:3546056. doi: 10.1155/2019/3546056. eCollection 2019.,Santus P,Can Respir J,2019,2019/10/05,PMC6748188,,10.1155/2019/3546056,https://pubmed.ncbi.nlm.nih.gov/31583033/,/31583033/,"PS reports research grants from Chiesi Farmaceutici, Air Liquide, Pfizer, Almirall, and Boehringer Ingelheim and honoraria for lectures and consultancy from AstraZeneca, Boehringer Ingelheim, Novartis, Guidotti, Berlin-Chemie, Mundipharma, Zambon Italia, and Valeas. DR received honoraria for lectures from Boehringer Ingelheim, AstraZeneca, and Neopharmed Gentili and personal fees for participating to advisory boards from AstraZeneca. MP, MS, VV, and FT declare no competing or financial interests.",,"Pierachille Santus 1 , Matteo Pecchiari 2 , Francesco Tursi 3 , Vincenzo Valenti 4 , Marina Saad 1 , Dejan Radovanovic 1"
31004317,Intravenous Oxycodone Versus Other Intravenous Strong Opioids for Acute Postoperative Pain Control: A Systematic Review of Randomized Controlled Trials,"Milton Raff 1, Anissa Belbachir 2, Salah El-Tallawy 3, Kok Yuen Ho 4, Eric Nagtalon 5, Amar Salti 6, Jeong-Hwa Seo 7, Aida Rosita Tantri 8, Hongwei Wang 9, Tianlong Wang 10, Kristal Cielo Buemio 11, Consuelo Gutierrez 11, Yacine Hadjiat 11",Pain Ther. 2019 Jun;8(1):19-39. doi: 10.1007/s40122-019-0122-4. Epub 2019 Apr 19.,Raff M,Pain Ther,2019,2019/04/21,PMC6514019,,10.1007/s40122-019-0122-4,https://pubmed.ncbi.nlm.nih.gov/31004317/,/31004317/,,Grants and funding -/Mundipharma Singapore Holding Pte Ltd,"Milton Raff 1 , Anissa Belbachir 2 , Salah El-Tallawy 3 , Kok Yuen Ho 4 , Eric Nagtalon 5 , Amar Salti 6 , Jeong-Hwa Seo 7 , Aida Rosita Tantri 8 , Hongwei Wang 9 , Tianlong Wang 10 , Kristal Cielo Buemio 11 , Consuelo Gutierrez 11 , Yacine Hadjiat 11"
30819775,Cold agglutinins: fending off the attack,Sigbjørn Berentsen 1,Blood. 2019 Feb 28;133(9):885-886. doi: 10.1182/blood-2019-01-894303.,Berentsen S,Blood,2019,2019/03/02,,,10.1182/blood-2019-01-894303,https://pubmed.ncbi.nlm.nih.gov/30819775/,/30819775/,"Conflict-of-interest disclosure: S.B. has received research support from Mundipharma, travel support from Alexion, lecture honoraria from Bioverativ and Janssen-Cilag, and has consulted for Apellis, Bioverativ, Momenta Pharmaceuticals, and True North Therapeutics.",,Sigbjørn Berentsen 1
31423343,How I treat cancer: treatment of rheumatological side effects of immunotherapy,"Karolina Benesova 1, Hanns-Martin Lorenz 2, Jan Leipe 3, Karin Jordan 2",ESMO Open. 2019 Jul 17;4(Suppl 4):e000529. doi: 10.1136/esmoopen-2019-000529. eCollection 2019.,Benesova K,ESMO Open,2019,2019/08/20,PMC6677979,,10.1136/esmoopen-2019-000529,https://pubmed.ncbi.nlm.nih.gov/31423343/,/31423343/,"Competing interests: KB: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, BMS, Janssen, MSD, Mundipharma, Novartis, Pﬁzer, Roche, UCB. Scientific support: Abbvie, Novartis. H-ML: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly. Scientific support and/or educational seminars and/or clinical studies: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, Thermo Fisher. JL: Consultancy and speaker fees: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Scientific support: Novartis, Pfizer. KJ: Consultancy and/or speaker fees: MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, Pomme-med.",,"Karolina Benesova 1 , Hanns-Martin Lorenz 2 , Jan Leipe 3 , Karin Jordan 2"
31114413,Cold agglutinin disease: current challenges and future prospects,"Sigbjørn Berentsen 1, Alexander Röth 2, Ulla Randen 3, Bernd Jilma 4, Geir E Tjønnfjord 5 6 7",J Blood Med. 2019 Apr 9;10:93-103. doi: 10.2147/JBM.S177621. eCollection 2019.,Berentsen S,J Blood Med,2019,2019/05/23,PMC6497508,,10.2147/JBM.S177621,https://pubmed.ncbi.nlm.nih.gov/31114413/,/31114413/,"S Berentsen has received research support from Mundipharma, travel support from Alexion and Apellis, lecture honoraria from Alexion, Bioverativ, and Janssen-Cilag, and has consulted for Apellis, Bioverativ, Momenta Pharmaceuticals, and True North Therapeutics, outside the submitted work. A Röth has received research support from Alexion and Roche, travel support from Alexion and AbbVie, lecture honoraria from Alexion, Roche, and Novartis, and has consulted for Alexion, Bioverativ, Novartis, and True North Therapeutics, outside the submitted work. U Randen reports no conflicts of interest. B Jilma has received reimbursement for travel for presentations and scientific advice from True North Therapeutics (a Bioverativ Company), outside the submitted work. GE Tjønnfjord has received research support from Mundipharma, Janssen-Cilag and Alexion Pharma, and lecture honoraria from Janssen-Cilag, Alexion Pharma, and Roche Pharma, outside the submitted work.",,"Sigbjørn Berentsen 1 , Alexander Röth 2 , Ulla Randen 3 , Bernd Jilma 4 , Geir E Tjønnfjord 5 6 7"
31604615,Interpreting trends in paediatric opioid prescribing,"Scott E Hadland 1, Louisa Degenhardt 2",Lancet Child Adolesc Health. 2019 Dec;3(12):839-840. doi: 10.1016/S2352-4642(19)30325-6. Epub 2019 Oct 8.,Hadland SE,Lancet Child Adolesc Health,2019,2019/10/13,PMC7061457,NIHMS1567156,10.1016/S2352-4642(19)30325-6,https://pubmed.ncbi.nlm.nih.gov/31604615/,/31604615/,"Conflict of Interest: SEH has no conflicts of interest to declare. LD has received investigator-initiated untied educational grants for studies of new opioid medications in Australia from Indivior, Mundipharma and Seqirus.",Grants and funding K23 DA045085/DA/NIDA NIH HHS/United States L40 DA042434/DA/NIDA NIH HHS/United States R01 DA044170/DA/NIDA NIH HHS/United States,"Scott E Hadland 1 , Louisa Degenhardt 2"
31152254,Physical Activity in the Prevention of Development and Progression of Kidney Disease in Type 1 Diabetes,"Drazenka Pongrac Barlovic 1 2 3 4 5, Heidi Tikkanen-Dolenc 3 4 5, Per-Henrik Groop 6 7 8 9",Curr Diab Rep. 2019 May 31;19(7):41. doi: 10.1007/s11892-019-1157-y.,Pongrac Barlovic D,Curr Diab Rep,2019,2019/06/02,PMC6544601,,10.1007/s11892-019-1157-y,https://pubmed.ncbi.nlm.nih.gov/31152254/,/31152254/,"Drazenka Pongrac Barlovic reports receiving lecture honorariums from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Krka, Merck, MSD, Novo Nordisk, and Sanofi Aventis; and being an advisory board member of Astra Zeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. Per-Henrik Groop reports receiving lecture honorariums from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Novartis, Novo Nordisk, PeerVoice, and Sanofi; and being an advisory board member of AbbVie, Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. Heidi Tikkanen-Dolenc declares that she has no conflict of interest.",,"Drazenka Pongrac Barlovic 1 2 3 4 5 , Heidi Tikkanen-Dolenc 3 4 5 , Per-Henrik Groop 6 7 8 9"
30775373,"European Respiratory Society International Congress, Paris, 2018: highlights from the Clinical Assembly","Lowie E G W Vanfleteren 1, Iñigo Ojanguren 2 3, Claire M Nolan 4, Frits M E Franssen 5, Vasileios Andrianopoulos 6, Aleksandar Grgic 7, Marlies van Dijk 8, Dirk Jan Slebos 8, Luke Daines 9, Janwillem W H Kocks 10 11, Nicolas Kahn 12 13",ERJ Open Res. 2019 Feb 11;5(1):00176-2018. doi: 10.1183/23120541.00176-2018. eCollection 2019 Feb.,Vanfleteren LEGW,ERJ Open Res,2019,2019/02/19,PMC6368995,,10.1183/23120541.00176-2018,https://pubmed.ncbi.nlm.nih.gov/30775373/,/30775373/,"Conflict of interest: L.E.G.W. Vanfleteren reports receiving personal fees from AstraZeneca, Chiesi, PulmonX, GSK and Novartis, outside the submitted work. Conflict of interest: I. Ojanguren reports receiving grants from Mundipharma, speakers fees from Boehringer Ingelheim, AstraZeneca, Teva and Novartis, and consulting fees from GSK, outside the submitted work. Conflict of interest: C.M. Nolan reports that she is co-author on one of the abstracts presented in this article. Conflict of interest: F.M.E. Franssen reports receiving personal fees from AstraZeneca, Chiesi, Boehringer Ingelheim, GSK, Teva and Novartis, outside the submitted work. Conflict of interest: V. Andrianopoulos has nothing to disclose Conflict of interest: A. Grgic has nothing to disclose. Conflict of interest: M. van Dijk has nothing to disclose. Conflict of interest: D.J. Slebos reports receiving reimbursement, devices for treatments for clinical trial trials performed at his institution (NCT01101958, NCT01796392 and NCT02025205), reimbursement for travel expenses, and speakers’ fees for presentations at scientific and educational meetings from PulmonX Inc. (USA); reimbursement for clinical trial trials performed in his institution (NCT02058459 and NCT01483534), devices for treatments, reimbursement for travel expenses, and speakers’ fees for presentations at scientific and educational meetings from Nuvaira Inc. (USA); reimbursement for clinical trial trials performed in his institution, devices for treatments, reimbursement for travel expenses and speakers’ fees for presentations at scientific and educational meetings from, and has acted as a physician advisor to CSA Medical (USA); reimbursement for clinical trial trials performed in his institution (NCT02059057, NCT02179125, NCT01608490, NCT01421082, NCT01328899 and NCT01220908), devices for treatments, reimbursement for travel expenses, speakers’ fees for presentations at scientific and educational meetings from, and has acted as a physician advisor to PneumRx/BTG (USA/UK), outside the submitted work. Conflict of interest: He is co-author on one of the abstracts presented in this article. Conflict of interest: L. Daines has nothing to disclose. Conflict of interest: J.W.H. Kocks reports receiving grants and personal fees from AstraZeneca and Boehringer Ingelheim, personal fees and nonfinancial support from GSK, grants from Chiesi and Mundi Pharma, outside the submitted work. He is an author of one of the presentations mentioned in this article. As Secretary of ERS Assembly 1, he was co-responsible in developing the symposium. Conflict of interest: N. Kahn has nothing to disclose.",,"Lowie E G W Vanfleteren 1 , Iñigo Ojanguren 2 3 , Claire M Nolan 4 , Frits M E Franssen 5 , Vasileios Andrianopoulos 6 , Aleksandar Grgic 7 , Marlies van Dijk 8 , Dirk Jan Slebos 8 , Luke Daines 9 , Janwillem W H Kocks 10 11 , Nicolas Kahn 12 13"
30634565,Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)-Current Considerations for Clinical Practice,"Frederik Trinkmann 1, Joachim Saur 2, Martin Borggrefe 3 4, Ibrahim Akin 5 6",J Clin Med. 2019 Jan 10;8(1):69. doi: 10.3390/jcm8010069.,Trinkmann F,J Clin Med,2019,2019/01/13,PMC6352261,,10.3390/jcm8010069,https://pubmed.ncbi.nlm.nih.gov/30634565/,/30634565/,"Frederik Trinkmann received travel support from Actelion, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma, and TEVA as well as speaker/consultation fees from Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Roche, and Novartis. Joachim Saur received travel support and speaker fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche. Martin Borggrefe received speaker/consultation fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Impulse Dynamics, and Zoll Medical. Ibrahim Akin received travel support as well as speaker/consultation fees Abiomed, Bayer, Boehringer Ingelheim, and St. Jude Medical.",,"Frederik Trinkmann 1 , Joachim Saur 2 , Martin Borggrefe 3 4 , Ibrahim Akin 5 6"
31249010,"The evolution of COPD species; or, something is changing for good in COPD",Joan B Soriano 1 2,Eur Respir J. 2019 Jun 27;53(6):1900762. doi: 10.1183/13993003.00762-2019. Print 2019 Jun.,Soriano JB,Eur Respir J,2019,2019/06/29,,,10.1183/13993003.00762-2019,https://pubmed.ncbi.nlm.nih.gov/31249010/,/31249010/,"Conflict of interest: J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. J.B. Soriano declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates.",,Joan B Soriano 1 2
31572485,Alcohol consumption in Austrian physicians,"Edda Pjrek 1, Leo Silberbauer 1, Siegfried Kasper 1, Dietmar Winkler 1",Ann Gen Psychiatry. 2019 Sep 24;18:22. doi: 10.1186/s12991-019-0246-2. eCollection 2019.,Pjrek E,Ann Gen Psychiatry,2019,2019/10/02,PMC6760098,,10.1186/s12991-019-0246-2,https://pubmed.ncbi.nlm.nih.gov/31572485/,/31572485/,"Competing interestsLS is recipient of a DOC Fellowship of the Austrian Academy of Sciences at the Medical University of Vienna. SK received grants/research support, consulting fees and/or honoraria within the last 3 years from Angelini, AOP Orphan, Celegne, Eli Lilly, Janssen-Cilag, KRKA-Pharma, Lundbeck, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon, and Takeda. DW received lecture fees/authorship honoraria from Angelini, Lundbeck, ProMente Austria, and Medizin Medien Austria. The other authors report no financial or other relationship possibly relevant to the subject of this article.",,"Edda Pjrek 1 , Leo Silberbauer 1 , Siegfried Kasper 1 , Dietmar Winkler 1"
31537804,A qualitative investigation of the allergic rhinitis network from the perspective of the patient,"Biljana Cvetkovski 1, Vicky Kritikos 2, Rachel Tan 2, Kwok Yan 3, Elizabeth Azzi 2, Pamela Srour 2, Sinthia Bosnic-Anticevich 2 4",NPJ Prim Care Respir Med. 2019 Sep 19;29(1):35. doi: 10.1038/s41533-019-0147-5.,Cvetkovski B,NPJ Prim Care Respir Med,2019,2019/09/21,PMC6753105,,10.1038/s41533-019-0147-5,https://pubmed.ncbi.nlm.nih.gov/31537804/,/31537804/,"V.K. has received honoraria from AstraZeneca, GlaxoSmithKline and Pfizer. K.Y. has received honoraria for speaking and consulting from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Meda, Mundipharma and Pfizer. S.B.-A. is a member of the Teva Pharmaceuticals Devices International Key Experts Panel; has received research support from Research in Real Life; has received lecture fees and payment for developing educational presentations from Teva and Mundipharma and has received honoria from AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline for her contribution to advisory boards/key international expert forum. The other authors declare no competing interests.",,"Biljana Cvetkovski 1 , Vicky Kritikos 2 , Rachel Tan 2 , Kwok Yan 3 , Elizabeth Azzi 2 , Pamela Srour 2 , Sinthia Bosnic-Anticevich 2 4"
31404930,Opioid maintenance treatment and Cannabis use,"Udo Schneider 1, Ingo Schäfer 2, Thomas Hillemacher 3, Konrad F Cimander 4, Dirk Wedekind 5, Steffen Weirich 6, Ursula Havemann-Reinecke 5",Fortschr Neurol Psychiatr. 2019 Oct;87(10):548-553. doi: 10.1055/a-0918-5961. Epub 2019 Aug 12.,Schneider U,Fortschr Neurol Psychiatr,2019,2019/08/13,,,10.1055/a-0918-5961,https://pubmed.ncbi.nlm.nih.gov/31404930/,/31404930/,"Prof. Havemann-Reinecke: Vortragshonorare: Sanofi-Aventis, Hexal, lndivior; Advisory boards: lndivior, Sanofi-Aventis; Beteiligung an Fachgesprächen des BMG, Bundesärztekammer, Niedersächsische Ärztekammer, GB-A zur Durchführung der Substitutionsbehandlung, finanzielle Unterstützung durch CNMPB (DFG) für Forschungstätigkeit über Cannabinoide.Prof. Hillemacher: Vortragshonorare: Lundbeck, Otsuka, Servier, Amomed, Janssen-Cilag; Advisory boards: Oberberg-Holding, Mundipharma.Dr. Cimander: Vortragshonorare: Abbivie, Camurus, Gilead, Sanofi-Aventis, Hexal, lndivior, Mundipharma, GL Pharma; Advisory boards: Camurus, lndivior, Sanofi-Aventis, Tilray.Prof. Wedekind: Vortragshonorare: Mundipharma, Pfizer; Beratertätigkeit Servier.",,"Udo Schneider 1 , Ingo Schäfer 2 , Thomas Hillemacher 3 , Konrad F Cimander 4 , Dirk Wedekind 5 , Steffen Weirich 6 , Ursula Havemann-Reinecke 5"
31023866,Electronic clinical decision support system (eCDSS) in the management of asthma: from theory to practice,Jean Bousquet 1 2 3 4 5 6,Eur Respir J. 2019 Apr 25;53(4):1900339. doi: 10.1183/13993003.00339-2019. Print 2019 Apr.,Bousquet J,Eur Respir J,2019,2019/04/27,,,10.1183/13993003.00339-2019,https://pubmed.ncbi.nlm.nih.gov/31023866/,/31023866/,"Conflict of interest: J. Bousquet reports personal fees for advisory board work, consultancy and honoraria for lectures from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and has shares in Kyomed, outside the submitted work.",,Jean Bousquet 1 2 3 4 5 6
30995176,"Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia","Jeff P Sharman 1, Steven E Coutre 2, Richard R Furman 3, Bruce D Cheson 4, John M Pagel 5, Peter Hillmen 6, Jacqueline C Barrientos 7, Andrew D Zelenetz 8, Thomas J Kipps 9, Ian W Flinn 10, Paolo Ghia 11, Herbert Eradat 12, Thomas Ervin 13, Nicole Lamanna 14, Bertrand Coiffier 15 16, Andrew R Pettitt 17, Shuo Ma 18, Eugen Tausch 19, Paula Cramer 20, Julie Huang 21, Siddhartha Mitra 21, Michael Hallek 20, Susan M OBrien 22, Stephan Stilgenbauer 19",J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17.,Sharman JP,J Clin Oncol,2019,2019/04/18,PMC10448866,,10.1200/JCO.18.01460,https://pubmed.ncbi.nlm.nih.gov/30995176/,/30995176/,"The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCOs conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc. Leadership: US Oncology Consulting or Advisory Role: Pharmacyclics, Celgene, TG Therapeutics, Genentech, Abbvie, Acerta Pharma, AstraZeneca Research Funding: Pharmacyclics (Inst), Genentech (Inst), Celgene (Inst), Acerta Pharma (Inst), Gilead Sciences (Inst), Seattle Genetics (Inst), TG Therapeutics (Inst), Merck (Inst), Takeda (Inst) Expert Testimony: Gilead Sciences Stock and Other Ownership Interests: Pharmacyclics (I) Consulting or Advisory Role: Genentech, Roche, Celgene, Pharmacyclics, Gilead Sciences, Abbvie, Novartis, Janssen Oncology, BeiGene Research Funding: Celgene (Inst), Pharmacyclics (Inst), Gilead Sciences (Inst), Abbvie (Inst), Janssen Oncology (Inst), Acerta Pharma (Inst), AstraZeneca (Inst), Millenium Pharmaceuticals (Inst) Travel, Accommodations, Expenses: Celgene, Gilead Sciences, Novartis, Abbvie, Pharmacyclics, Janssen Oncology, BeiGene Honoraria: Janssen, Pharmacyclics, Genentech, Roche Consulting or Advisory Role: Pharmacyclics, Janssen Biotech, Gilead Sciences, Genentech, Roche, Abbvie, Sunesis Pharmaceuticals, Loxo, TG Therapeutics, Verastem, Acerta Pharma, AstraZeneca Research Funding: Acerta Pharma, TG Therapeutics Expert Testimony: Abbvie Other Relationship: Incyte, Janssen Biotech, Abbvie Consulting or Advisory Role: Acerta Pharma, TG Therapeutics, Bayer, Roche, Genentech, Abbvie, Pharmacyclics, Janssen, Morphosys, Sunesis Pharmaceuticals, Celgene Research Funding: Roche (Inst), Genentech (Inst), Acerta Pharma (Inst), Gilead Sciences (Inst), Abbvie (Inst), TG Therapeutics (Inst) Consulting or Advisory Role: Pharmacyclics, Gilead Sciences Honoraria: Janssen, Abbvie, Roche Research Funding: Janssen (Inst), Pharmacyclics (Inst), Roche (Inst), Gilead Sciences (Inst) Travel, Accommodations, Expenses: Janssen, Abbvie Honoraria: Janssen Consulting or Advisory Role: Pharmacyclics, Abbvie, Gilead Sciences, Genentech, Bayer Research Funding: Pharmacyclics (Inst) Travel, Accommodations, Expenses: Janssen Stock and Other Ownership Interests: Adaptive Biotechnologies Honoraria: National Comprehensive Cancer Network, Clinical Care Options, Physician Education Resource, Oncology Information Group Consulting or Advisory Role: Gilead Sciences, Amgen, Genentech, Roche, Celgene, Medscape, AstraZeneca, DAVA Oncology, MorphoSys, BeiGene, Cancer Support Community, Janssen, MEI Pharma, Novartis, Pfizer, Prime Education, TRM Oncology, Vaniam Group, Verastem, Pharmacyclics, Karyopharm Therapeutics Research Funding: Genentech, Roche, Gilead Sciences, MEI Pharma, BeiGene Honoraria: Celgene, Mundipharma, Gilead Sciences, AstraZeneca, Pfizer, Celltrion, Novartis Consulting or Advisory Role: Celgene, Mundipharma, Gilead Sciences, AstraZeneca, Pfizer,Celltrion, Novartis Employment: University of California, San Diego, Health Moores Cancer Center Honoraria: Pharmacyclics, AbbVie, Janssen, Celgene, Genentech, Roche, Gilead, DAVA Oncology Consulting or Advisory Role: AbbVie, Pharmacyclics, Celgene, Genentech, Roche, Janssen, DAVA Oncology, Gilead Sciences Speakers Bureau: Verastem, Pharmacyclics Consulting or Advisory Role: Abbvie (Inst), Seattle Genetics (Inst), TG Therapeutics (Inst), Verastem (Inst) Research Funding : Acerta Pharma (Inst), Agios (Inst), Calithera Biosciences (Inst), Celgene (Inst), Constellation Pharmaceuticals (Inst), Genentech (Inst), Gilead Sciences (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Janssen (Inst), Karyopharm Therapeutics (Inst), Kite Pharma (Inst), Novartis (Inst), Pharmacyclics (Inst), Portola Pharmaceuticals (Inst), Roche (Inst), TG Therapeutics (Inst), Trillium Therapeutics (Inst), Abbvie (Inst), ArQule (Inst), BeiGene (Inst), Curis (Inst), FORMA Therapeutics (Inst), Forty Seven (Inst), Merck (Inst), Pfizer (Inst), Takeda (Inst), Teva (Inst), Verastem (Inst), Gilead Sciences (Inst), AstraZeneca (Inst), Juno Therapeutics (Inst), Unum Therapeutics (Inst), MorphoSys (Inst) Honoraria: Abbvie, BeiGene, Janssen Oncology, Gilead Sciences, Juno Therapeutics, Sunesis Pharmaceuticals, Roche Consulting or Advisory Role: Abbvie, BeiGene, Janssen, Gilead Sciences, Sunesis Pharmaceuticals, Juno Therapeutics Speakers Bureau: Gilead Sciences Research Funding: Abbvie, Janssen Oncology, Gilead Sciences, Sunesis Pharmaceuticals, Novartis Honoraria: Genentech, Roche, Abbvie, Gilead Sciences Consulting or Advisory Role: Genentech, Roche, Abbvie, Gilead Sciences, Pharmacyclics Speakers Bureau: Genentech, Roche, Abbvie, Gilead Sciences, Pharmacyclics Research Funding: Abbvie, Genentech, Roche, Gilead Sciences, Seattle Genetics, Celgene, miRagen, Pharmacyclics Travel, Accommodations, Expenses: Genentech, Roche, Abbvie Consulting or Advisory Role: Celgene, Genentech, Abbvie, ProNAi, Pharmacyclics, Juno Therapeutics, Roche, Janssen, AstraZeneca, Gilead Sciences Research Funding: Genentech (Inst), Abbvie (Inst), Infinity Pharmaceuticals (Inst), Gilead Sciences (Inst), ProNAi (Inst), BeiGene (Inst), AstraZeneca (Inst), Verastem (Inst), Juno Therapeutics (Inst), TG Therapeutics (Inst), Acerta Pharma (Inst), Loxo (Inst) Honoraria: Celgene, Mundipharma, Gilead Sciences, AstraZeneca, Pfizer, Celltrion, Novartis Consulting or Advisory Role: Celgene, Mundipharma, Gilead Sciences, AstraZeneca, Pfizer, Celltrion, Novartis Research Funding: Celgene (Inst), Gilead Sciences (Inst), Roche (Inst), NAPP Pharmaceuticals (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Verastem (Inst) Travel, Accommodations, Expenses: Gilead, Kite, Celgene Consulting or Advisory Role: Genentech, Roche, Gilead Sciences, Abbvie, Novartis, Pharmacyclics, Janssen Oncology, AstraZeneca, Bioverativ, Omniprex Speakers Bureau: Pharmacyclics, Genentech, Roche, Janssen Oncology, AstraZeneca Research Funding: Pharmacyclics (Inst), Gilead Sciences (Inst), Acerta Pharma (Inst), Abbvie (Inst), Novartis (Inst), Incyte (Inst) Consulting or Advisory Role: Roche Speakers Bureau: Roche, Abbvie Travel, Accommodations, Expenses: Abbvie Honoraria: Abbvie, Acerta Pharma, AstraZeneca, Janssen-Cilag Research Funding: Acerta Pharma (Inst), Gilead Sciences (Inst), Janssen-Cilag (Inst), Roche (Inst), Novartis (Inst) Travel, Accommodations, Expenses: Abbvie, Roche, Janssen-Cilag Employment: Gilead Sciences Stock and Other Ownership Interests: Gilead Sciences Employment: Five Prime Therapeutics, Gilead Sciences Stock and Other Ownership Interests: Gilead Sciences, Five Prime Therapeutics Honoraria: Roche, Janssen, Abbvie, Gilead Sciences Consulting or Advisory Role: Janssen, Abbvie, Gilead Sciences, Genentech, Roche Speakers Bureau: Janssen, Abbvie, Gilead Sciences, Roche, Genentech Research Funding: Roche, Abbvie, Janssen, Gilead Sciences Travel, Accommodations, Expenses: Roche, Janssen Employment: University of California, Irvine Honoraria: Celgene, Janssen, Pharmacyclics, Gilead Sciences, Pfizer, Amgen, Astellas Pharma, GlaxoSmithKline, Aptose Biosciences, Vaniam Group, Abbvie, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Loxo, Eisai, TG Therapeutics Consulting or Advisory Role: Amgen, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences, Vaniam Group, Abbvie, Genentech, Sunesis Pharmaceuticals, Alexion Pharmacewuticals, Astellas Pharma, Gilead Sciences, Pharmacyclics, TG Therapeutics, Pfizer Research Funding: Acerta Pharma (Inst), Regeneron (Inst), Gilead Sciences (Inst), Pfizer (Inst), TG Therapeutics (Inst), Pharmacyclics (Inst), Kite Pharma (Inst), Sunesis Pharmaceuticals (Inst) Travel, Accommodations, Expenses: Celgene, Janssen, Gilead Sciences, Regeneron Honoraria: AbbVie, AstraZeneca, Celgene, Gilead, GlaxoSmithKline, Hoffmann La-Roche, Janssen Consulting or Advisory Role: AbbVie, AstraZeneca, Celgene, Gilead, GlaxoSmithKline, Hoffmann La-Roche, Janssen Speakers Bureau: AbbVie, AstraZeneca, Celgene, Gilead, GlaxoSmithKline, Hoffmann La-Roche, Janssen Research Funding: AbbVie, AstraZeneca, Celgene, Gilead, GlaxoSmithKline, Hoffmann La-Roche, Janssen Travel, Accommodations, Expenses: AbbVie, AstraZeneca, Celgene, Gilead, GlaxoSmithKline, Hoffmann La-Roche, Janssen No other potential conflicts of interest were reported.",Grants and funding P30 CA008748/CA/NCI NIH HHS/United States,"Jeff P Sharman 1 , Steven E Coutre 2 , Richard R Furman 3 , Bruce D Cheson 4 , John M Pagel 5 , Peter Hillmen 6 , Jacqueline C Barrientos 7 , Andrew D Zelenetz 8 , Thomas J Kipps 9 , Ian W Flinn 10 , Paolo Ghia 11 , Herbert Eradat 12 , Thomas Ervin 13 , Nicole Lamanna 14 , Bertrand Coiffier 15 16 , Andrew R Pettitt 17 , Shuo Ma 18 , Eugen Tausch 19 , Paula Cramer 20 , Julie Huang 21 , Siddhartha Mitra 21 , Michael Hallek 20 , Susan M OBrien 22 , Stephan Stilgenbauer 19"
30795628,Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?,"Michael Leisch 1 2, Bettina Jansko 3 4 5, Nadja Zaborsky 6 7 8, Richard Greil 9 10 11, Lisa Pleyer 12 13 14",Cancers (Basel). 2019 Feb 21;11(2):252. doi: 10.3390/cancers11020252.,Leisch M,Cancers (Basel),2019,2019/02/24,PMC6406956,,10.3390/cancers11020252,https://pubmed.ncbi.nlm.nih.gov/30795628/,/30795628/,"M.L.: reports receiving travel support from Celgene and Novartis and reports receiving honoraria from Bristol-Myers-Squibb and Novartis. L.P.: has been a consultant for Agios, Celgene, Bristol-Myers Squibb, and Novartis, and reports receiving honoraria and travel support from Agios, Celgene, Novartis. R.G.: reports receiving honoraria from Bristol-Myers-Squibb, Cephalon, Amgen, Eisai, Mundipharma, Merck, Janssen-Cilag, Genentech, Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Roche, and Sanofi Aventis, and research funding from Cephalon, Celgene, Amgen, Mundipharma, Genentech, Pfizer, GSK, and Ratiopharm, and has been a consultant for Bristol-Myers-Squibb, Cephalon, and Celgene. B.J.: none. N.Z.: none.",,"Michael Leisch 1 2 , Bettina Jansko 3 4 5 , Nadja Zaborsky 6 7 8 , Richard Greil 9 10 11 , Lisa Pleyer 12 13 14"
31744832,"International trends in COPD mortality, 1995-2017","Joannie Lortet-Tieulent 1, Isabelle Soerjomataram 2, José Luis López-Campos 3 4, Julio Ancochea 5, Jan Willem Coebergh 6, Joan B Soriano 3 5",Eur Respir J. 2019 Dec 19;54(6):1901791. doi: 10.1183/13993003.01791-2019. Print 2019 Dec.,Lortet-Tieulent J,Eur Respir J,2019,2019/11/21,,,10.1183/13993003.01791-2019,https://pubmed.ncbi.nlm.nih.gov/31744832/,/31744832/,"Conflict of interest: J. Lortet-Tieulent has nothing to disclose. Conflict of interest: I. Soerjomataram has nothing to disclose. Conflict of interest: J.L. López-Campos reports personal fees and non-financial support from AstraZeneca, CSL Behring and Ferrer, and grants, personal fees and non-financial support from Boehringer Ingelheim, Chiesi, Esteve, GebroPharma, GlaxoSmithKline, Grifols, Menarini, Novartis, Rovi and Teva, outside the submitted work. Conflict of interest: J. Ancochea has nothing to disclose. Conflict of interest: J.W. Coebergh has nothing to disclose. Conflict of interest: J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer-Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. J.B. Soriano declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates.",,"Joannie Lortet-Tieulent 1 , Isabelle Soerjomataram 2 , José Luis López-Campos 3 4 , Julio Ancochea 5 , Jan Willem Coebergh 6 , Joan B Soriano 3 5"
31615819,Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering,"Brendon L Neuen 1, David Z Cherney 1, Meg J Jardine 1, Vlado Perkovic 2",CMAJ. 2019 Oct 15;191(41):E1128-E1135. doi: 10.1503/cmaj.190047.,Neuen BL,CMAJ,2019,2019/10/17,PMC6791785,,10.1503/cmaj.190047,https://pubmed.ncbi.nlm.nih.gov/31615819/,/31615819/,"Competing interests: The George Institute for Global Health provides contract research services to Janssen for trials of SGLT2 inhibitors. Brendon Neuen has received travel support from Janssen. David Cherney has received honoraria from Boehringer Ingelheim, Eli Lilly, Merck, AstraZeneca, Sanofi, Merck, Mitsubishi Tanabe, AbbVie, Janssen, Bayer and Prometic, and has received operational funding for clinical trials from Boehringer Ingelheim, Eli Lilly, Merck, Janssen, Sanofi and AstraZeneca. Meg Jardine is responsible for research projects that have received unrestricted funding from Gambro, Baxter, CSL, Amgen, Eli Lilly and Merck; has served on advisory boards sponsored by Akebia, Baxter and Boehringer Ingelheim; and spoken at scientific meetings sponsored by Janssen, Amgen and Roche, with any consultancy, honoraria or travel support paid to her institution. Vlado Perkovic was the chair of a steering committee for a renal outcome study of an SGLT2 inhibitor (canagliflozin), serves on steering committees for AbbVie, Boehringer Ingelheim, GlaxoSmithKline, Janssen and Pfizer; serves on advisory boards or speaks at scientific meetings for AbbVie, Astellas, AstraZeneca, Bayer, Baxter, Bristol–Myers Squibb, Boehringer Ingelheim, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Roche, Sanofi, Servier and Vitae; and has received personal fees for consulting and scientific presentations related to canagliflozin from Mitsubishi Tanabe and Mundipharma.",,"Brendon L Neuen 1 , David Z Cherney 1 , Meg J Jardine 1 , Vlado Perkovic 2"
30651596,ADAM10 mediates malignant pleural mesothelioma invasiveness,"Christelle Sépult 1, Marine Bellefroid 1, Natacha Rocks 1, Kim Donati 1, Catherine Gérard 1, Christine Gilles 1, Andreas Ludwig 2, Bernard Duysinx 3, Agnès Noël 1, Didier Cataldo 4 5",Oncogene. 2019 May;38(18):3521-3534. doi: 10.1038/s41388-018-0669-2. Epub 2019 Jan 16.,Sépult C,Oncogene,2019,2019/01/18,PMC6756017,,10.1038/s41388-018-0669-2,https://pubmed.ncbi.nlm.nih.gov/30651596/,/30651596/,"DC is the founder of Aquilon Pharmaceuticals, received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Mundipharma, Chiesi and GSK and received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Novartis for the participation to advisory boards. None of these activities are related to the therapy of cancer or mesothelioma.",,"Christelle Sépult 1 , Marine Bellefroid 1 , Natacha Rocks 1 , Kim Donati 1 , Catherine Gérard 1 , Christine Gilles 1 , Andreas Ludwig 2 , Bernard Duysinx 3 , Agnès Noël 1 , Didier Cataldo 4 5"
30898837,2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis,"Lisa Ehlers 1, Johan Askling 2, Hans Wj Bijlsma 3, Maria Cinta Cid 4, Maurizio Cutolo 5, Bhaskar Dasgupta 6, Christian Dejaco 7 8, William G Dixon 9, Nils Feltelius 10 11, Axel Finckh 12, Kate Gilbert 13, Sarah Louise Mackie 14, Alfred Mahr 15, Eric L Matteson 16, Lorna Neill 17, Carlo Salvarani 18, Wolfgang A Schmidt 19, Anja Strangfeld 20, Ronald F van Vollenhoven 21, Frank Buttgereit 22",Ann Rheum Dis. 2019 Sep;78(9):1160-1166. doi: 10.1136/annrheumdis-2018-214755. Epub 2019 Mar 21.,Ehlers L,Ann Rheum Dis,2019,2019/03/23,,,10.1136/annrheumdis-2018-214755,https://pubmed.ncbi.nlm.nih.gov/30898837/,/30898837/,"Competing interests: JA has or has had research agreements with Abbvie, BMS, MSD, Pfizer, Roche, Astra-Zeneca, Eli Lilly, Samsung Bioepis and UCB, mainly in the context of safety monitoring of biologics via ARTIS. Karolinska Institutet has received remuneration for JA participating in advisory boards arranged by Pfizer and Eli Lilly. HWJB reported serving as coordinating investigator (Roche and SUN) in GCA and GC trials and consultant and speaker for Roche. MCC reported receiving consultation/lecturing fees from Roche, GSK, Novartis, Boehringer-Ingelheim, Vifor and Abbvie and research funding from Kiniksa. MC reported serving as coordinating investigator (Mundipharma, Horizon) and consultant (Mundipharma, Horizon) in PMR trials. BD reported clinical trials design advisory board consultancies (Roche, Servier, GSK, Mundipharma, Pfizer, Merck, Sobi) and unrestricted grant support from Napp and Roche and speakers honoraria from UCB and Merck. CD reported receiving consultancy fees and honoraria from MSD, Pfizer, UCB, AbbVie, Roche, Novartis, Lilly, Celgene, Merck, Sandoz, clinical trials design advisory board consultancies from GSK and an unrestricted grant support from Pfizer and MSD. WGD reported that the University of Manchester has received remuneration for WGD providing consultancy to Bayer. NF is an employee of the Swedish Medical Products Agency (MPA). AF received speaker honoraria or consultancies within the past 5 years from AbbVie, AB2BIO, BMS, Eli-Lilly, MSD, Pfizer, Roche, not related to the submitted work. KG has received consultancy fees from PMRGCAuk re facilitation of patient engagement with medical research in PMR and GCA. SLM has been an investigator for GCA trials (Roche, GSK), has had medical advisory group consultancies (Roche, Sanofi, Chugai) and is a Patron of the charities PMRGCAuk and PMR and GCA North East. AM reported receiving consultancy fees and honoraria from Roche-Chugai. EM reported serving as coordinating investigator (Novartis) and consultant (Glaxo-Smith-Kline) in PMR trials, consultant (Glaxo-Smith-Kline, Endocyte) and as site investigator in GCA trials (Bristol Meyer Squibb, Hoffman-La Roche, Genentech, Glaxo-Smith-Kline) and editor, contributor for PMR/GCA (UpToDate, Paradigm). CS reported serving as coordinating investigator (Roche) and consultant (Roche) in GCA trials. WAS reported receiving consultancy fees, honoraria and a grant support from Roche, consultancy fees and honoraria from GlaxoSmithKline and consultancy fees from Sanofi. He was principle investigator in a GCA trial (GlaxoSmithKline). AS received speaker honoraria within the past 5 years from AbbVie, BMS, Lilly, MSD, Pfizer, Roche, Sanofi-Aventis and UCB outside the submitted work. RFvV reported receiving research support and grants from AbbVie, BMS, GSK, Pfizer and UCB. He served as consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Roche and UCB. FB reported receiving consultancy fees, honoraria and travel expenses from Horizon Pharma (formerly Nitec Pharma), Mundipharma Int. Ltd, Roche and Galapagos and grant support from Horizon Pharma. He serves as co-principal investigator and site investigator in a Mundipharma sponsored trial in PMR investigating the effects of MR prednisone.",Grants and funding MC_PC_13042/MRC_/Medical Research Council/United Kingdom NIHR-CS-012-016/DH_/Department of Health/United Kingdom G0902272/MRC_/Medical Research Council/United Kingdom MR/K006665/1/MRC_/Medical Research Council/United Kingdom MR/N011775/1/MRC_/Medical Research Council/United Kingdom,"Lisa Ehlers 1 , Johan Askling 2 , Hans Wj Bijlsma 3 , Maria Cinta Cid 4 , Maurizio Cutolo 5 , Bhaskar Dasgupta 6 , Christian Dejaco 7 8 , William G Dixon 9 , Nils Feltelius 10 11 , Axel Finckh 12 , Kate Gilbert 13 , Sarah Louise Mackie 14 , Alfred Mahr 15 , Eric L Matteson 16 , Lorna Neill 17 , Carlo Salvarani 18 , Wolfgang A Schmidt 19 , Anja Strangfeld 20 , Ronald F van Vollenhoven 21 , Frank Buttgereit 22"
30661130,"Diagnostic Criteria, Differential Diagnosis, and Treatment of Minor Motor Activity and Less Well-Known Movement Disorders of Sleep","Ambra Stefani 1, Birgit Högl 2",Curr Treat Options Neurol. 2019 Jan 19;21(1):1. doi: 10.1007/s11940-019-0543-8.,Stefani A,Curr Treat Options Neurol,2019,2019/01/21,PMC6339673,,10.1007/s11940-019-0543-8,https://pubmed.ncbi.nlm.nih.gov/30661130/,/30661130/,"Ambra Stefani reports other from Habel Medizintechnik, Inspire Medical System, OSG, UCB, personal fees from Axovant, outside the submitted work. Birgit Högl reports other from Otsuka, Mundipharma, UCB, Janssen Cilag, Lündbeck, AbbVie, Lilly, Axovant, Benevolent AI, outside the submitted work. This article does not contain any studies with human or animal subjects performed by any of the authors.",,"Ambra Stefani 1 , Birgit Högl 2"
31391053,Evaluation of exacerbations and blood eosinophils in UK and US COPD populations,"Claus F Vogelmeier 1, Konstantinos Kostikas 2, Juanzhi Fang 3, Hengfeng Tian 4, Bethan Jones 5, Christopher Ll Morgan 5, Robert Fogel 3, Florian S Gutzwiller 6, Hui Cao 3",Respir Res. 2019 Aug 7;20(1):178. doi: 10.1186/s12931-019-1130-y.,Vogelmeier CF,Respir Res,2019,2019/08/09,PMC6686508,,10.1186/s12931-019-1130-y,https://pubmed.ncbi.nlm.nih.gov/31391053/,/31391053/,"CFV reports research support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Novartis, Bayer Schering, MSD, Pfizer, consultancy from AstraZeneca, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Grifols, Menarini, Novartis, Teva, Cipla, and honoraria from AstraZeneca, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Grifols, Menarini, Mundipharma, Novartis, Teva, Cipla. KK was an employee of Novartis Pharma AG at the time of the conduct of this study. JF is an employee of Novartis Pharmaceuticals Corporation owning stocks through the employment. HT is employee of KMK Consulting Inc. and providing consulting to Novartis, the sponsor of the study. BJ is an employee of Pharmatelligence who received funding from Novartis to conduct analyses for this study. CM is a consultant of Pharmatelligence who received funding from Novartis to conduct analyses for this study. RF is an employee of Novartis Pharmaceuticals Corporation owning stocks through the employment. FSG is an employee of Novartis Pharma AG owning stocks through the employment. HC is an employee of Novartis Pharmaceuticals Corporation owning stocks through the employment.",Grants and funding N/A/Novartis Pharma AG,"Claus F Vogelmeier 1 , Konstantinos Kostikas 2 , Juanzhi Fang 3 , Hengfeng Tian 4 , Bethan Jones 5 , Christopher Ll Morgan 5 , Robert Fogel 3 , Florian S Gutzwiller 6 , Hui Cao 3"
31554241,Leptin and Associated Mediators of Immunometabolic Signaling: Novel Molecular Outcome Measures for Neurostimulation to Treat Chronic Pain,"Thomas M Kinfe 1, Michael Buchfelder 2, Shafqat R Chaudhry 3, Krishnan V Chakravarthy 4 5, Timothy R Deer 6, Marc Russo 7, Peter Georgius 8, Rene Hurlemann 9, Muhammad Rasheed 10, Sajjad Muhammad 11, Thomas L Yearwood 12",Int J Mol Sci. 2019 Sep 24;20(19):4737. doi: 10.3390/ijms20194737.,Kinfe TM,Int J Mol Sci,2019,2019/09/27,PMC6802360,,10.3390/ijms20194737,https://pubmed.ncbi.nlm.nih.gov/31554241/,/31554241/,"Thomas M. Kinfe works as a consultant for Abbott (formerly St. Jude Medical, Inc.). Sajjad Muhammad has received Neuromodulation and Pain Fellowship by Abbott Inc. (formerly St. Jude Medical). Krishnan Chakravarthy is a consultant to Abbott, Medincaell, Bioness SPR Therapeutics, and founder of Newrom Biomedical, Douleur Therapeutics. Thomas L. Yearwood, works as a consultant for, Boston Scientific Neuromodulation and Neuronano; he is also the CMO of Meghan Medical. Peter Georgius is a consultant to Seqirius Australia, Mundipharma Australia, Abbott Inc., Mainstay Medical and Boston Scientific Inc. Marc Russo is a consultant to Medtronic, Abbott, Boston Scientific, Nevro, Mainstay Medical, Saluda, Stimwave.",,"Thomas M Kinfe 1 , Michael Buchfelder 2 , Shafqat R Chaudhry 3 , Krishnan V Chakravarthy 4 5 , Timothy R Deer 6 , Marc Russo 7 , Peter Georgius 8 , Rene Hurlemann 9 , Muhammad Rasheed 10 , Sajjad Muhammad 11 , Thomas L Yearwood 12"
31602529,"Management of severe asthma exacerbation: guidelines from the Société Française de Médecine dUrgence, the Société de Réanimation de Langue Française and the French Group for Pediatric Intensive Care and Emergencies","Philippe Le Conte 1 2, Nicolas Terzi 3 4, Guillaume Mortamet 5, Fekri Abroug 6, Guillaume Carteaux 7, Céline Charasse 8, Anthony Chauvin 9, Xavier Combes 10, Stéphane Dauger 11, Alexandre Demoule 12, Thibaut Desmettre 13, Stephan Ehrmann 14, Bénédicte Gaillard-Le Roux 15, Valérie Hamel 16, Boris Jung 17, Sabrina Kepka 18, Erwan LHer 19, Mikaël Martinez 20 21, Christophe Milési 22, Élise Morawiec 23, Mathieu Oberlin 24, Patrick Plaisance 25, Robin Pouyau 26, Chantal Raherison 27, Patrick Ray 28, Mathieu Schmidt 29, Arnaud W Thille 30, Jennifer Truchot 9, Guillaume Valdenaire 31, Julien Vaux 32, Damien Viglino 33 34, Guillaume Voiriot 35, Bénédicte Vrignaud 36, Sandrine Jean 37, Eric Mariotte 38, Pierre-Géraud Claret 39",Ann Intensive Care. 2019 Oct 10;9(1):115. doi: 10.1186/s13613-019-0584-x.,Le Conte P,Ann Intensive Care,2019,2019/10/12,PMC6787133,,10.1186/s13613-019-0584-x,https://pubmed.ncbi.nlm.nih.gov/31602529/,/31602529/,"Philippe Le Conte reports personal fees from Novartis, outside the submitted work; Nicolas Terzi reports personal fees from Boehringer Inghelheim, personal fees from Pfizer, outside the submitted work; Guillaume Carteaux reports congress registration expanses from Orkyn, personal fees from Air Liquide Medical System, outside the submitted work; Alexandre Demoule reports personal fees from Medtronic, grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees from Hamilton, personal fees and non-financial support from Fisher & Paykel, grants from French Ministry of Health, personal fees from Getinge, grants and personal fees from Respinor, grants and non-financial support from Lungpacer; Stéphan Ehrmann reports consultancies fees from Aerogen, Baxter healthcare, Bayer medical and La DiffusionTechnique Française, research support from Aerogen, Fisher & Paykel and Hamilton, travel expenses reimbursement from Aerogen and Fisher & Paykel; Bénédicte Gaillard-Le Roux reports non-financial support from BAXTER NUTRITION, non-financial support from FRESENIUS, outside the submitted work; Boris Jung reports travel expenses reimbursement from Sedana Medical; Erwan L’Her reports grants and personal fees from Smiths Medical, General Electrics, Sedana Medical and Oxynov Inc., all outside the submitted work; Mikaël Martinez reports personnal fees from Astra Zeneca and Actélion, outside the submitted work; Chantal Raherison eports personal fees from Mundipharma, grants and personal fees from Astra Zeneca, personal fees from ALK, grants and personal fees from Boehringer Ingelheim, grants from Chiesi, grants and personal fees from Glaxo Smith Kline, grants and personal fees from Novartis, personal fees from Zambon, outside the submitted work; Mathieu Schmidt reports personal fees from Drager, personal fees from Getinge, personal fees from Xenios, outside the submitted work; Arnaud Thille reports personal fees from Fisher&Paykel, personal fees from Covidien, personal fees from Maquet-Getinge, personal fees from GE healthcare, outside the submitted work; Damien Viglino reports grants from Mundipharma, from Astra Zeneca, outside the submitted work; Guillaume Voiriot reports grants, personal fees and non-financial support from Biomérieux, grants from Janssen, grants from SOS Oxygène, outside the submitted work; Eric Mariotte reports personal fees from Sanofi, outside the submitted work; Guillaume Mortamet, Fekri Abroug, Céline Charasse, Anthony Chauvin, Xavier Combes, Stéphane Dauger, Thibaut Desmettre, Valérie Hamel, Sabrina Kepka, Christophe Milési, Élise Morawiec, Mathieu Oberlin, Patrick Plaisance, Robin Pouyau, Patrick Ray, Jennifer Truchot, Guillaume Valdenaire, Julien Vaux, Bénédicte Vrignaud, Sandrine Jean, Pierre-Géraud Claret has nothing to disclose.",Grants and funding 1/CX/CSRD VA/United States 1/CX/CSRD VA/United States,"Philippe Le Conte 1 2 , Nicolas Terzi 3 4 , Guillaume Mortamet 5 , Fekri Abroug 6 , Guillaume Carteaux 7 , Céline Charasse 8 , Anthony Chauvin 9 , Xavier Combes 10 , Stéphane Dauger 11 , Alexandre Demoule 12 , Thibaut Desmettre 13 , Stephan Ehrmann 14 , Bénédicte Gaillard-Le Roux 15 , Valérie Hamel 16 , Boris Jung 17 , Sabrina Kepka 18 , Erwan LHer 19 , Mikaël Martinez 20 21 , Christophe Milési 22 , Élise Morawiec 23 , Mathieu Oberlin 24 , Patrick Plaisance 25 , Robin Pouyau 26 , Chantal Raherison 27 , Patrick Ray 28 , Mathieu Schmidt 29 , Arnaud W Thille 30 , Jennifer Truchot 9 , Guillaume Valdenaire 31 , Julien Vaux 32 , Damien Viglino 33 34 , Guillaume Voiriot 35 , Bénédicte Vrignaud 36 , Sandrine Jean 37 , Eric Mariotte 38 , Pierre-Géraud Claret 39"
31023091,Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic,"Neus Gascon 1, Carmen Almansa 1, Manuel Merlos 1, José Miguel Vela 1, Gregorio Encina 1, Adelaida Morte 1, Kevin Smith 2, Carlos Plata-Salamán 1",Expert Opin Investig Drugs. 2019 May;28(5):399-409. doi: 10.1080/13543784.2019.1612557. Epub 2019 May 3.,Gascon N,Expert Opin Investig Drugs,2019,2019/04/27,,,10.1080/13543784.2019.1612557,https://pubmed.ncbi.nlm.nih.gov/31023091/,/31023091/,,,"Neus Gascon 1 , Carmen Almansa 1 , Manuel Merlos 1 , José Miguel Vela 1 , Gregorio Encina 1 , Adelaida Morte 1 , Kevin Smith 2 , Carlos Plata-Salamán 1"
31659161,Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study,"David B Price 1 2, Jaco Voorham 3, Guy Brusselle 4, Andreas Clemens 5 6, Konstantinos Kostikas 5 7, Jeffrey W Stephens 8, Hye Yun Park 9, Nicolas Roche 10, Robert Fogel 11",NPJ Prim Care Respir Med. 2019 Oct 28;29(1):38. doi: 10.1038/s41533-019-0150-x.,Price DB,NPJ Prim Care Respir Med,2019,2019/10/30,PMC6817865,,10.1038/s41533-019-0150-x,https://pubmed.ncbi.nlm.nih.gov/31659161/,/31659161/,"Professor David Price has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Circassia, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrollment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation program, and Health Technology Assessment. Jaco Voorham is an employee of OPRI, which conducted this study and which has conducted paid research in respiratory disease on behalf of the following organizations in the past 5 years: Aerocrine, AKL Research and Development Ltd, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, Zentiva (a Sanofi company). Guy Brusselle has, within the last 5 years, received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, and Teva; he is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron, and Teva. Andreas Clemens is a full time employee and shareholder of Novartis Pharma AG. Konstantinos Kostikas was an employee and shareholder of Novartis at the time of the study. He has received honoraria for presentations and/or consulting services from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GSK, Innovis, Menarini, and Novartis. Jeffrey W. Stephens has no conflicts of interest in relation to this work. Hye Yun Park has received lecture fees from AstraZeneca, Novartis, and Boehringer Ingelheim. Nicolas Roche reports grants and personal fees from Boehringer Ingelheim, Novartis, Pfizer and personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3 M, Zambon. Robert Fogel is a full time employee and shareholder of Novartis Pharmaceuticals Corporation.",,"David B Price 1 2 , Jaco Voorham 3 , Guy Brusselle 4 , Andreas Clemens 5 6 , Konstantinos Kostikas 5 7 , Jeffrey W Stephens 8 , Hye Yun Park 9 , Nicolas Roche 10 , Robert Fogel 11"
31564957,Practical approach to a patient with chronic pain of uncertain etiology in primary care,"Shaquir Salduker 1, Eugene Allers 2, Sudha Bechan 3, R Eric Hodgson 4, Fanie Meyer 5, Helgard Meyer 6 7, Johan Smuts 8, Eileen Vuong 9, David Webb 10",J Pain Res. 2019 Sep 3;12:2651-2662. doi: 10.2147/JPR.S205570. eCollection 2019.,Salduker S,J Pain Res,2019,2019/10/01,PMC6731975,,10.2147/JPR.S205570,https://pubmed.ncbi.nlm.nih.gov/31564957/,/31564957/,"SB, FM, HM, JS and EV report no conflicts of interest relevant to this article. SS reports grants from Cipla. EA reports grants from Cipla and non-financial support from Psychiatry Management Group (PsychMg) and Glynnview Multiprofessional Practice (GMPP) during the conduct of the study; grants from Aspen Pharmacare, Adcock Ingram, Pfizer, Janssens Pharmaceuticals, Sanofi-Aventis and Litha Pharma, and non-financial support from Rickett Benckiser and Sandoz outside the submitted work; and relationships with Pain SA and with several medical professionals that manage patients with chronic pain to form a virtual pain clinic. REH reports grants or personal fees from Mundipharma, Pfizer, Takeda, Sandoz, Abbvie, Aspen-GSK and Sanofi. DW is a medical writer and reports personal fees from Cipla during the conduct of the study; personal fees from Accord, Adcock Ingram, Alcon, Astra Zeneca, Eli Lilly, Fresenius Kabi, Litha, MSD, Novartis, Novo Nordisk, Pfizer, Pharma Dynamics, Reckitt Benkiser, Sandoz, Sanofi-Aventis, Takeda, MundiPharma and Abbvie outside the submitted work. The authors report no other conflicts of interest in this work.",,"Shaquir Salduker 1 , Eugene Allers 2 , Sudha Bechan 3 , R Eric Hodgson 4 , Fanie Meyer 5 , Helgard Meyer 6 7 , Johan Smuts 8 , Eileen Vuong 9 , David Webb 10"
31439045,Relationship between gender and survival in a real-life cohort of patients with COPD,"Maeva Zysman 1 2 3, Pierre-Régis Burgel 4, Isabelle Court-Fortune 5, Graziella Brinchault-Rabin 6, Pascale Nesme-Meyer 7, Pascale Surpas 8, Gaetan Deslée 9, Thierry Perez 10, Olivier Le Rouzic 10, Gilles Jebrak 11, Pascal Chanez 12, Jean-Louis Paillasseur 13, Denis Caillaud 14, Nicolas Roche 4 ; Initiatives BPCO scientific committee and investigators",Respir Res. 2019 Aug 22;20(1):191. doi: 10.1186/s12931-019-1154-3.,Zysman M,Respir Res,2019,2019/08/24,PMC6704674,,10.1186/s12931-019-1154-3,https://pubmed.ncbi.nlm.nih.gov/31439045/,/31439045/,"MZ reports grants and personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Chiesi, and personal fees from GSK outside the submitted work. PRB reports personal fees from Aptalis, personal fees from Astra-Zeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Novartis, personal fees from Pfizer, personal fees from Vertex, personal fees from Zambon, outside the submitted work. ICF reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, outside the submitted work. GBR reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, personal fees and non-financial support from Chiesi, outside the submitted work. PNM reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from NOVARTIS, personal fees and non-financial support from Chiesi, outside the submitted work. PS reports grants and personal fees from Boehringer Ingelheim outside the submitted work. GD reports personal fees from Novartis, personal fees from Astra Zeneca, personal fees from BTG/PneumRx, personal fees from Chiesi, personal fees from Boehringer Ingelheim, outside the submitted work. TP reports personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from GSK, personal fees from Chiesi, personal fees from Pierre Fabre, outside the submitted work. OLR reports grants and personal fees personal fees and non-financial support from Astra Zeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis; non-financial support from Glaxo Smith Kline, MundiPharma, Pfizer, Teva, Santelys Association, Vertex and Vitalaire, all outside the submitted work. GJ reports personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from Novartis, personal fees from Menarini, personal fees from Astra Zeneca, personal fees from Chiesi, outside the submitted work. PC reports personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from ALK, personal fees from Novartis, personal fees from Teva, personal fees from Astra Zeneca, personal fees from Chiesi, personal fees from Sanofi, personal fees and non-financial support from SNCF, outside the submitted work. JLP reports grants from iBPCO association, during the conduct of the study. DC has nothing to disclose. NRreports grants and personal fees from Boehringe rIngelheim, grants and personal fees from Novartis, personal fees from Teva, personal fees from GSK, personal fees from AstraZeneca, personal fees from Chiesi, personal fees from Mundipharma, personal fees from Cipla, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Sandoz, personal fees from 3 M, personal fees from Zambon, outside the submitted work.",Grants and funding 1/CX/CSRD VA/United States,"Maeva Zysman 1 2 3 , Pierre-Régis Burgel 4 , Isabelle Court-Fortune 5 , Graziella Brinchault-Rabin 6 , Pascale Nesme-Meyer 7 , Pascale Surpas 8 , Gaetan Deslée 9 , Thierry Perez 10 , Olivier Le Rouzic 10 , Gilles Jebrak 11 , Pascal Chanez 12 , Jean-Louis Paillasseur 13 , Denis Caillaud 14 , Nicolas Roche 4 ; Initiatives BPCO scientific committee and investigators"
31656769,The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a transcriptomic compass?,"Melissa Bersanelli 1 2, Alessio Cortellini 3 4, Sebastiano Buti 1",Ann Transl Med. 2019 Sep;7(Suppl 6):S190. doi: 10.21037/atm.2019.07.37.,Bersanelli M,Ann Transl Med,2019,2019/10/29,PMC6789366,,10.21037/atm.2019.07.37,https://pubmed.ncbi.nlm.nih.gov/31656769/,/31656769/,"Conflicts of Interest: S Buti received honoraria as speaker at scientific events and advisory role by Bristol-Myers Squibb (BMS), Pfizer; MSD, Ipsen, Roche, Eli-Lilly, AstraZeneca and Novartis; he also received research funding from Novartis. M Bersanelli received honoraria as speaker at scientific events by Bristol-Myers Squibb (BMS) and Pfizer; as consultant for advisory role by Novartis, Mundipharma, BMS and Pfizer; as medical writer by Mundipharma; she also received research funding from Seqirus, Pfizer, Novartis, BMS and Sanofi. A Cortellini received honoraria as consultant from Bristol-Myers Squibb (BMS).",,"Melissa Bersanelli 1 2 , Alessio Cortellini 3 4 , Sebastiano Buti 1"
31413620,Stratification of patients with unclassified pain in the FabryScan database,"Julia Forstenpointner # 1, Paul Moeller # 1, Manon Sendel 1, Maren Reimer 1, Philipp Hüllemann 1, Ralf Baron 1",J Pain Res. 2019 Jul 23;12:2223-2230. doi: 10.2147/JPR.S206223. eCollection 2019.,Forstenpointner J,J Pain Res,2019,2019/08/16,PMC6662527,,10.2147/JPR.S206223,https://pubmed.ncbi.nlm.nih.gov/31413620/,/31413620/,"The authors declare that the sources of financial support had no influence on data assessment, analysis, and interpretation and disclose the potential conflicts of interest. JF reports grants and personal fees from Sanofi Genzyme GmbH, during the conduct of the study; personal fees and non-financial support from Grünenthal GmbH and Sanofi Genzyme, personal fees from Bayer, non-financial support from Novartis, outside the submitted work. PM reports grants and personal fees from Sanofi Genzyme GmbH, during the conduct of the study. MR received speaking fees and travel expenses from Pfizer, Grünenthal, Astellas, and grant/research support from Mundipharma and Grünenthal. PH reports speaking fees from Pfizer and Genzyme and travel reimbursement from Grünenthal. RB reports personal fees from Sanofi Genzyme GmbH, during the conduct of the study; grants from Pfizer, Genzyme GmbH, Grünenthal GmbH, Mundipharma. RB is a member of the EU Project No 633491: DOLORisk; a member of the IMI “Europain“ collaboration and industry members of this are: Astra Zeneca, Pfizer, Esteve, UCB-Pharma, Sanofi Aventis, Grünenthal GmbH, Eli Lilly and Boehringer Ingelheim Pharma GmbH&Co.KG. German Federal Ministry of Education and Research (BMBF): Member of the ERA_NET NEURON/IM-PAIN Project (01EW1503). German Research Network on Neuropathic Pain (01EM0903), NoPain system biology (0316177C). German Research Foundation (DFG), personal fees from Pfizer, Genzyme GmbH, Grünenthal GmbH, Mundipharma, Sanofi Pasteur, Medtronic Inc. Neuro-modulation, Eisai Co.Ltd., Lilly GmbH, Boehringer Ingelheim Pharma GmbH&Co.KG, Astellas, Desitin, Teva Pharma, Bayer-Schering, MSD GmbH, Seqirus, personal fees from Pfizer, Genzyme GmbH, Grünenthal GmbH, Mundipharma, Allergan, Sanofi Pasteur, Medtronic, Eisai, Lilly GmbH, Boehringer Ingelheim Pharma GmbH&Co.KG, Astellas, Novartis, Bristol-Myers Squibb, Biogenidec, AstraZeneca, Merck, Abbvie, Daiichi Sankyo, Glenmark Pharmaceuticals, Seqirus, Teva Pharma, Genentech, Galapagos NV, Kyowa Kirin GmbH, Vertex Pharmaceuticals Inc., Biotest AG, TAD Pharma GmbH, outside the submitted work. The authors report no other conflicts of interest in this work.",,"Julia Forstenpointner # 1 , Paul Moeller # 1 , Manon Sendel 1 , Maren Reimer 1 , Philipp Hüllemann 1 , Ralf Baron 1"
30717435,What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients,"Angelo G I Maremmani 1 2 3, Matteo Pacini 4, Icro Maremmani 5 6 7",Int J Environ Res Public Health. 2019 Feb 3;16(3):447. doi: 10.3390/ijerph16030447.,Maremmani AGI,Int J Environ Res Public Health,2019,2019/02/06,PMC6388207,,10.3390/ijerph16030447,https://pubmed.ncbi.nlm.nih.gov/30717435/,/30717435/,"The authors declare no conflict of interest. IM served as Board Member for Indivior, Molteni, Mundipharma, D&A Pharma, Lundbeck, Angelini, Camurus, Gilead, MSD and CT Sanremo.",,"Angelo G I Maremmani 1 2 3 , Matteo Pacini 4 , Icro Maremmani 5 6 7"
31770388,"Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records","John Macleod 1, Colin Steer 1, Kate Tilling 1, Rosie Cornish 1, John Marsden 2, Tim Millar 3, John Strang 2, Matthew Hickman 1",PLoS Med. 2019 Nov 26;16(11):e1002965. doi: 10.1371/journal.pmed.1002965. eCollection 2019 Nov.,Macleod J,PLoS Med,2019,2019/11/27,PMC6879111,,10.1371/journal.pmed.1002965,https://pubmed.ncbi.nlm.nih.gov/31770388/,/31770388/,"I have read the journal’s policy and the authors of this manuscript have the following competing interests: In the past three years, JMar declares research grants from the National Institute for Health Research (NIHR; randomised controlled trial of depot naltrexone for OUD, and a randomised controlled trial of acamprosate for alcohol use disorder); and the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Mental Health Foundation Trust (SLaM; randomised controlled trial of novel cognitive therapy for cocaine use disorder). He has worked part-time as the Senior Academic Advisor for the Alcohol, Drugs, Tobacco and Justice Division, Health and Wellbeing Directorate, PHE and he is a clinical academic consultant for the US National Institute on Drug Abuse, Centre for Clinical Trials Network. JM declares an unrestricted research grant at IoPPN and SLaM from Indivior via Action on Addiction for a completed randomised controlled trial of personalised psychosocial intervention in opioid agonist medication for opioid use disorder and, with MK, unrestricted research grant funding at IoPPN and SLaM from Indivior for a three-year, multi-centre, randomised controlled trial of injectable depot buprenorphine for opioid use disorder (2019-2021). He has received honoraria and travel support from Reckitt-Benckiser (2016; treatment of OUD and PCM Scientific and Martindale for the Improving Outcomes in Treatment of Opioid Dependence conference (2018; contribution and chairing). TM has received research funding from the UK National Treatment Agency for Substance Misuse, Public Health England, the Home Office, and Change Grow Live, a 3rd-sector provider of substance misuse services. He has been a member of the organising committee for conferences supported by unrestricted educational grants from Reckitt Benckiser, Lundbeck, Martindale Pharma, and Britannia Pharmaceuticals Ltd, for which he received no personal remuneration. He is a member of the UK Advisory Council on the Misuse of Drugs. JS is a clinician and researcher and has worked extensively with agencies in the addiction treatment fields and addiction-related charities and with government departments and has contributed to clinical guidelines on treatment types and provision. JS’s employer (King’s College London) has received, connected to his work, project grant support and/or honoraria and/or consultancy payments from Department of Health, NTA (National Treatment Agency), PHE (Public Health England), Home Office, NICE (National Institute for Health and Clinical Excellence), and EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) as well as research grants from (last 3 years) NIHR (National Institute on Health Research), MRC (Medical Research Council) and Pilgrim Trust. He has also worked with WHO (World Health Organization), UNODC (United Nations Office on Drugs and Crime), EMCDDA, FDA (US Food and Drug Administration) and NIDA (US National Institute on Drug Abuse) and also other international government agencies. JS’s employer (King’s College London) has also received, connected to his work, research grant support and/or payment of honoraria, consultancy payments and expenses from pharmaceutical companies (including, past 3 years, Martindale, Indivior, MundiPharma, Braeburn/Camurus) and trial medication supply from iGen and Braeburn. JS’s employer (King’s College London) has registered intellectual property on an innovative buccal naloxone with which JS is involved, and JS has been named in a patent registration by a Pharma company as inventor of a potential concentrated naloxone nasal spray. For updated information see http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. MH acknowledges support from NIHR Health Protection Research Unit in Evaluation of Interventions and the NIHR School of Public Health Research. MH has received unrelated unrestricted honoraria from Gilead, Abbvie, Jansen and Merck Serono. No other disclosures by the other authors are reported.",Grants and funding 12/136/105/DH_/Department of Health/United Kingdom,"John Macleod 1 , Colin Steer 1 , Kate Tilling 1 , Rosie Cornish 1 , John Marsden 2 , Tim Millar 3 , John Strang 2 , Matthew Hickman 1"
30723727,Prospective observational study in patients with obstructive lung disease: NOVELTY design,"Helen K Reddel 1, Maria Gerhardsson de Verdier 2, Alvar Agustí 3, Gary Anderson 4, Richard Beasley 5, Elisabeth H Bel 6, Christer Janson 7, Barry Make 8, Richard J Martin 8, Ian Pavord 9, David Price 10, Christina Keen 11, Asparuh Gardev 12, Stephen Rennard 13, Alecka Sveréus 2, Aruna T Bansal 14, Lance Brannman 15, Niklas Karlsson 16, Javier Nuevo 17, Fredrik Nyberg 18, Simon S Young 19, Jørgen Vestbo 20",ERJ Open Res. 2019 Feb 1;5(1):00036-2018. doi: 10.1183/23120541.00036-2018. eCollection 2019 Feb.,Reddel HK,ERJ Open Res,2019,2019/02/07,PMC6355976,,10.1183/23120541.00036-2018,https://pubmed.ncbi.nlm.nih.gov/30723727/,/30723727/,"Conflict of interest: H.K. Reddel reports that this study is funded by AstraZeneca. She received reimbursement from AstraZeneca for time spent working on the study design but not for manuscript preparation. Medical writing support was provided by AstraZeneca, as stated in the support statement. She has served on a data and safety monitoring board (DSMB) and advisory boards, and has received unconditional research grants and honoraria from AstraZeneca and GlaxoSmithKline for providing independent medical education, consulting and studying inhalers. She has served on a DSMB for Merck. She has served on a DSMB and an advisory board for, and received an honorarium from Novartis for providing independent medical education. She has received honoraria from Teva and Mundipharma for providing independent medical education. She has received an honorarium from Boehringer Ingelheim for providing independent medical education from and serving on an advisory board. Conflict of interest: M. Gerhardsson de Verdier is an employee of AstraZeneca. Conflict of interest: A. Agustí reports receiving personal fees from AstraZeneca during the conduct of the study; and grants and personal fees from AstraZeneca and Menarini, and personal fees from Chiesi, Teva and Novartis, outside the submitted work. Conflict of interest: G. Anderson has received honoraria from and serves on an advisory board for Novartis; has received honoraria from, serves on an advisory board for and was employed on a sabbatical basis from 2016 to 2017 by AstraZeneca; and has received honoraria and serves on advisory boards for GlaxoSmithKline, Pieris Pharmaceuticals and Boehringer Ingelheim. Conflict of interest: R. Beasley reports receiving personal fees from Astra Zeneca during the conduct of the study; and grants and personal fees from AstraZeneca, GlaxoSmithKline and the Health Research Council of New Zealand, and grants from Genentech, outside the submitted work. Conflict of interest: E.H. Bel reports receiving grants and personal fees from Novartis, GSK and AstraZeneca, grants from Roche, personal fees from Sanofi Regeneron, Teva, Vectura and Boehringer, outside the submitted work. Conflict of interest: C. Janson reports receiving personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva, outside the submitted work. Conflict of interest: Related to the topic of COPD, B. Make reports funding from the NHLBI for the COPDGene study; grants and personal fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, and Sunovian; personal fees for DSMB from Spiration and Baxalta; CME personal fees from Consensus Medical Education, Integrity Medical Education, WebMD, National Jewish Health, American College of Chest Physicians, Projects in Knowledge, Hybrid Communications, SPIRE Learning, Peer Review Institute, and Medscape; personal fees and other from Mt. Sinai Medical Center; royalties from Up-To-Date; personal fees from Novartis; personal fees from CSL Bering; other from Cleveland Clinic; grants from Pearl (a member of the AstraZeneca Group); and personal fees from Verona, outside the submitted work. Conflict of interest: R.J. Martin reports receiving personal fees from AstraZeneca for service on a steering committee during the conduct of the study; and travel fees from Respiratory Effectiveness Group, consultancy fees from PMD Healthcare, and grants from MedImmune, Chiesi Farmaceutici SpA and NHLBI, outside the submitted work. Conflict of interest: I. Pavord reports receiving speaker fees, advisory board honoraria and sponsorship to attend scientific meetings from AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline, a speaker fee from Aerocrine, speaker fees and advisory board honoraria from Almirall and Novartis, advisory board honoraria from Genentech, Regeneron, Merck & Co., Schering-Plough and Mylan Speciality (Dey Pharma) and Respivert, advisory board honoraria and sponsorship to attend scientific meetings from Napp Pharmaceuticals, outside the submitted work. Conflict of interest: D. Price reports receiving funding from AstraZeneca for the conduct of this study; and board membership (fees paid to Observational and Pragmatic Research Institute) from Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals, consultancy agreements (fees paid to Observational and Pragmatic Research Institute) with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance, grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Teva Pharmaceuticals, Theravance, UK National Health Service and Zentiva, lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) for Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, CIPLA, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, and Teva Pharmaceuticals, manuscript preparation (fees paid to Observational and Pragmatic Research Institute) from Mundipharma and Teva Pharmaceuticals, payment for travel/accommodation/meeting expenses (fees paid to Observational and Pragmatic Research Institute) from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis and Teva Pharmaceuticals, funding for patient enrolment or completion of research (fees paid to Observational and Pragmatic Research Institute) from Chiesi, Novartis, Teva Pharmaceuticals and Zentiva, payment for the development of educational materials (fees paid to Observational and Pragmatic Research Institute) from Mundipharma and Novartis, peer review for grant committees for the Efficacy and Mechanism Evaluation programme and Health Technology Assessment, outside the submitted work; and stock/stock options in AKL Research and Development Ltd, which produces phytopharmaceuticals. He owns 74% of the social enterprise Optimum Patient Care Ltd (Australia, Singapore and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore). Conflict of interest: C. Keen is an employee of AstraZeneca. Conflict of interest: A. Gardev is an employee of AstraZeneca. Conflict of interest: S. Rennard is an employee of AstraZeneca and retains professorship and a part-time appointment at the University of Nebraska Medical Center, Omaha, NE, USA. He reports personal fees from ABIM, Able Associates, Advantage Healthcare, Align2Action, Almirall, APT, ATS, AstraZeneca, Baxter, Boehringer Ingelheim, Cheisi, CIPLA, ClearView Healthcare, the Cleveland Clinic, CME Incite, Complete Medical Group, the COPD Foundation, Cory Paeth, CSA, CSL, CTS Carmel, Dailchi Sankyo, Decision Resources, the Dunn Group, Easton Associates, Elevation Pharma, FirstWord, Forest, the Frankel Group, Gerson, GlaxoSmithKline, Gilead, Grifols, GroupH, Guidepoint Global, Haymarket, HealthStar, Huron Cosulting, Incite, Inthought, IntraMed (Forest), Johnson & Johnson, LEK, McKinsey, Medical Knowledge, MedImmune, the Methodist Health System (Dallas, TX, USA), Navigant, NCI Consulting, Novartis, Nuvis, Pearl (a member of the AstraZeneca Group), Penn Technology, Pfizer, PlanningShop, Prescott, Pro Ed Comm, ProiMed, PSL FirstWord, Pulmatrix, Quadrant, Qwessential, Regeneron, Saatchi and Saatchi, Schlesinger Associates, Strategic North, Synapse, Takeda, Theron, WebMD, NHLBI, the Nebraska DHHS, Otsuka, Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Nycomed, AstraZeneca, Centocor, and Almirall, outside the submitted work. Please note that he has had tobacco industry funding. Specifically, he has received funding from the tobacco industry for studies relating to harm reduction and to the impact of tobacco smoke on stem cells. He has also consulted with R.J. Reynolds, without personal fees, on the topic of harm reduction. He received funding from R.J. Reynolds to evaluate the effect of a harm reduction product in normal smokers (1996) and in subjects with chronic bronchitis (1999) and to assess the effect of smoking cessation on lower respiratory tract inflammation (2000); he participated in a Philip Morris multicentre study to assess biomarkers of smoke exposure (2002); he received funding for a clinical trial from the Institute for Science and Health (2005), which receives support from the tobacco industry, to evaluate biomarkers in exhaled breath associated with smoking cessation and reduction. This study was supplemented with funding from Lorillard and R.J. Reynolds. He has received a grant from the Philip Morris External Research Program (2005) to assess the impact of cigarette smoking on circulating stem cells in the mouse. He has consulted with R.J. Reynolds on the topic of harm reduction until 2007 but did not receive personal remuneration for this. He has no active tobacco industry-funded projects. All ties with tobacco industry companies and entities supported by tobacco companies were terminated in 2007. Conflict of interest: A. Sveréus is an employee of AstraZeneca. Conflict of interest: A.T. Bansal has nothing to disclose. Conflict of interest: L. Brannman is an employee of AstraZeneca. Conflict of interest: N. Karlsson is an employee of AstraZeneca. Conflict of interest: J. Nuevo is an employee of AstraZeneca. Conflict of interest: F. Nyberg is an employee of AstraZeneca. Conflict of interest: S.S. Young is an employee of AstraZeneca. Conflict of interest: J. Vestbo reports receiving an honorarium from AstraZeneca for being a co-principal investigator of the NOVELTY study; and personal fees from GlaxoSmithKline for consultancy for COPD Phase 2 and 3 programme, personal fees from Chiesi Pharmaceuticals, Boeehringer Ingelheim, Novartis and AstraZeneca for consultancy for COPD Phase 2 and 3 programme and payment for lectures including service in speaker bureaus, outside the submitted work.",,"Helen K Reddel 1 , Maria Gerhardsson de Verdier 2 , Alvar Agustí 3 , Gary Anderson 4 , Richard Beasley 5 , Elisabeth H Bel 6 , Christer Janson 7 , Barry Make 8 , Richard J Martin 8 , Ian Pavord 9 , David Price 10 , Christina Keen 11 , Asparuh Gardev 12 , Stephen Rennard 13 , Alecka Sveréus 2 , Aruna T Bansal 14 , Lance Brannman 15 , Niklas Karlsson 16 , Javier Nuevo 17 , Fredrik Nyberg 18 , Simon S Young 19 , Jørgen Vestbo 20"
31798392,"Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)","Diana Lüftner 1, Ingo Bauerfeind 2, Michael Braun 3, Sara Y Brucker 4, Peter A Fasching 5, Ricardo Felberbaum 6, Friederike Hagemann 7, Renate Haidinger 8, Nadia Harbeck 7, Arnd Hönig 9, Jens Huober 10, Christian Jackisch 11, Hans-Christian Kolberg 12, Cornelia Kolberg-Liedtke 13, Thorsten Kühn 14, Nicolai Maass 15, Toralf Reimer 16, Andreas Schneeweiss 17, Eva Schumacher-Wulf 18, Florian Schütz 19, Christoph Thomssen 20, Michael Untch 21, Rachel Wuerstlein 7, Marc Thill 22",Breast Care (Basel). 2019 Oct;14(5):315-324. doi: 10.1159/000502603. Epub 2019 Sep 17.,Lüftner D,Breast Care (Basel),2019,2019/12/05,PMC6883436,,10.1159/000502603,https://pubmed.ncbi.nlm.nih.gov/31798392/,/31798392/,"Prof. Diana Lüftner received honoraria from AstraZeneca, Celgene, Pfizer, Novartis, Amgen, Roche, Loreal, Teva, Tesaro, and Eli Lilly. Dr. med. Ingo Bauerfeind has no conflict of interest. Prof. Michael Braun received honoraria from AstraZeneca, Celgene, Daiichi Sankyo, Genomic Health, GSK, Eisai, Genomic Health, GlaxoSmithKline, Medac, Novartis, Pfizer, Puma Biotechnology, Roche, and Teva. Prof. Sara Y. Brucker received honoraria from Novartis, Pfizer, AstraZeneca, and Roche and research funding from Genomic Health. Prof. Peter A. Fasching received funding from Novartis, Cepheid, and BioNTech and honoraria from Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, Teva, AstraZeneca, Merck Sharp & Dohme, Myelo Therapeutics, MacroGenics, Esai, and Puma. Prof. Ricardo Felberbaum, Dr. med. Friederike Hagemann, and Renate Haidinger have no conflict of interest. Prof. Nadia Harbeck received honoraria from Agendia, Amgen, Celgene, Genomic Health, Lilly, MSD, Nanostring, Novartis, Pfizer, Roche, and Sandoz. Prof. Arnd Hönig received honoraria from Amgen, Astra Zeneca, Celgene, MSD, Pfizer, Roche, and Novartis, research funding from Roche and Genentech, and travel grants from Roche, AstraZeneca, Daiichi Sankyo, and Pfizer. Prof. Jens Huober received honoraria from Celgene, Roche, Novartis, Hexal, Pfizer, AstraZeneca, Lilly, Amgen, Eisai, and MSD, research funding from Celgene and Novartis, and travel grants from Roche, Novartis, Celgene Pfizer, und Daiichi-Sankyo. Prof. Christian Jackisch received honoraria from Celgene, Novartis, Pfizer, AstraZeneca, and Roche and research funding from Genomic Health. Prof. Thorsten Kühn has no conflict of interest. PD Dr. Hans-Christian Kolberg received honoraria from Pfizer, Novartis, Roche, Genomic Health, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GSK, and LIV Pharma and honoraria for consultancy activity from Pfizer, Novartis, SurgVision, Carl Zeiss Meditec, Amgen, and Onkowissen and holds shares in Theraclion SA and Phaon Scientific GmbH; he received travel grants from Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer, and Daiichi Sankyo. Prof. Cornelia Kolberg-Liedtke received honoraria from Roche, AstraZeneca, Celgene, Novartis, Pfizer, Lilly, Hexal, Amgen, Eisai, and SonoScape, honoraria for consultancy from Phaon Scientific, Novartis, Pfizer, and Celgene, research funding from Roche, Novartis, and Pfizer, and travel grants from Novartis and Roche. Prof. Nicolai Maass received honoraria from Amgen, AstraZeneca, Celgene, Lilly, MSD, Pfizer, Roche, Novartis, and Daiichi Sankyo. Prof. Toralf Reimer received honoraria from Novartis, Pfizer, Lilly, Celgene, and AstraZeneca. Prof. Andreas Schneeweiss received honoraria from Celgene, Roche, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, and Lilly, research support from Celgene, Roche, AbbVie, and Molecular Partners, and travel grants from Celgene, Roche, and Pfizer. Eva Schumacher-Wulf has no conflict of interest. Prof. Florian Schütz received honoraria for lectures and consultations from Amgen, AstraZeneca, ClinSol, MSD, Novartis, Pfizer, Riemser, and Roche and travel grants from AstraZeneca, Pfizer, and Roche. PD Dr. Marc Thill received honoraria from Amgen, AstraZeneca, Aurikamed, BiomUp, Celgene, Daiichi Sankyo, Eisai, Genomic Health, Hexal, Lilly, MCI, Medtronic, MSD, Myriad, Neodynamics, Norgine, Novartis, OnkoLive, OmniaMed, pfm Medical, Pfizer, Roche, Tesaro, Teva, RTI Surgical, Onkowissen, Sysmex, and Clovis and research funding from Genomic Health. Prof. Michael Untch received honoraria from the employer (for Ad Board participation, lectures) and travel grants from Amgen, Astra Zeneca, BMS, Celgene, Daiichi Sankyo, Eisai, Janssen Cilag, Johnsen and Johnsen, Lilly Deutschland, Lilly International, MSD Merck, Mundipharma, Myriad Genetics, Odonate, Pfizer, PUMA Biotechnology, Riemser, Roche, Sanofi Aventis, Sividon Diagnostics, and Teva Pharmaceutical Industries Ltd. Dr. med. Rachel Wuerstlein received honoraria from Agendia, Amgen, AstraZeneca, Boehringer Ingelheim, Carl Zeiss, Celgene, Daiichi-Sankyo, Esai, Genomic Health, GSK, Lilly, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, Puma Biotechnology, Riemser, Roche, Sandoz/Hexal, Seattle Genetics, Tesaro Bio, and Teva. Prof. Christoph Thomssen received honoraria from AstraZeneca, Celgene, Genomic Health, Novartis, NanoString, Pfizer, and Roche and research funding from NanoString.",,"Diana Lüftner 1 , Ingo Bauerfeind 2 , Michael Braun 3 , Sara Y Brucker 4 , Peter A Fasching 5 , Ricardo Felberbaum 6 , Friederike Hagemann 7 , Renate Haidinger 8 , Nadia Harbeck 7 , Arnd Hönig 9 , Jens Huober 10 , Christian Jackisch 11 , Hans-Christian Kolberg 12 , Cornelia Kolberg-Liedtke 13 , Thorsten Kühn 14 , Nicolai Maass 15 , Toralf Reimer 16 , Andreas Schneeweiss 17 , Eva Schumacher-Wulf 18 , Florian Schütz 19 , Christoph Thomssen 20 , Michael Untch 21 , Rachel Wuerstlein 7 , Marc Thill 22"
30813226,Decoding the Mechanism of Action of Rapid-Acting Antidepressant Treatment Strategies: Does Gender Matter?,"David P Herzog 1 2, Gregers Wegener 3, Klaus Lieb 4 5, Marianne B Müller 6 7, Giulia Treccani 8 9 10",Int J Mol Sci. 2019 Feb 22;20(4):949. doi: 10.3390/ijms20040949.,Herzog DP,Int J Mol Sci,2019,2019/03/01,PMC6412361,,10.3390/ijms20040949,https://pubmed.ncbi.nlm.nih.gov/30813226/,/30813226/,"D.H., G.T., M.B.M., K.L. report no conflict of interest. G.W. declares having received research support/lecture/consultancy fees from H. Lundbeck A/S, Servier SA, Astra Zeneca AB, Eli Lilly A/S, Sun Pharma Pty Ltd., Pfizer Inc., Shire A/S, HB Pharma A/S, Arla Foods A.m.b.A., Alkermes Inc, Johnson & Johnson Inc. and Mundipharma International Ltd.",Grants and funding Collaborative Research Center 1193/Deutsche Forschungsgemeinschaft DFF-5053-00103/Det Frie Forskningsråd 8020-00310B/Danmarks Frie Forskningsfond AU-IDEAS initiative (eMOOD)/Aarhus Universitets Forskningsfond ExEDE/Horizon 2020 NARSAD Young Investigator 22752/Brain and Behavior Research Foundation Show all 6 grants,"David P Herzog 1 2 , Gregers Wegener 3 , Klaus Lieb 4 5 , Marianne B Müller 6 7 , Giulia Treccani 8 9 10"
30863039,When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals,"S Gaduzo 1, V McGovern 2, J Roberts 3, J E Scullion 4, D Singh 5",Int J Chron Obstruct Pulmon Dis. 2019 Feb 13;14:391-401. doi: 10.2147/COPD.S173901. eCollection 2019.,Gaduzo S,Int J Chron Obstruct Pulmon Dis,2019,2019/03/14,PMC6388781,,10.2147/COPD.S173901,https://pubmed.ncbi.nlm.nih.gov/30863039/,/30863039/,"Disclosure Dr S Gaduzo reports receiving consultancy fees for speaking at and chairing educational meetings and conferences on behalf of AstraZeneca, Boehringer Ingelheim, Chiesi Limited, GlaxoSmithKline, Pfizer, and Novartis. Dr V McGovern reports accepting speaker fees, advisory panel fees, and conference sponsorship from the following pharmaceutical companies: Altana, AstraZeneca, Almirall, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, NAPP, Novartis, Orion Pharma, and Pfizer. J Roberts reports receiving consultancy fees from AstraZeneca, Chiesi Limited, and GlaxoSmithKline. JE Scullion reports accepting honoraria or support from ADMIT, AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, NAPP, Nutricia, Orion Pharma, Roche, Teva, Trudell Medical, and UKIG. Professor D Singh reports receiving sponsorship to attend and speak at international meetings, honoraria for lecturing or attending advisory boards, and research grants from AstraZeneca, Boehringer Ingelheim, Chiesi Limited, Genentech, GlaxoSmithKline, Glenmark, Johnson & Johnson, Merck, NAPP, Novartis, Pfizer, Skypharma, Takeda, Teva, Theravance, and Verona. The authors report no other conflicts of interest in this work.",,"S Gaduzo 1 , V McGovern 2 , J Roberts 3 , J E Scullion 4 , D Singh 5"
31118753,Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review,"Giulia Di Stefano 1, Andrea Di Lionardo 1, Eleonora Galosi 1, Andrea Truini 1, Giorgio Cruccu 1",J Pain Res. 2019 Apr 26;12:1341-1351. doi: 10.2147/JPR.S190231. eCollection 2019.,Di Stefano G,J Pain Res,2019,2019/05/24,PMC6498091,,10.2147/JPR.S190231,https://pubmed.ncbi.nlm.nih.gov/31118753/,/31118753/,"Giorgio Cruccu received a research grant, consulting fees and payments for lectures from Sigma-Tau of Alfasigma Group, and consulting fees from Angelini, Biogen, and Mundipharma. Andrea Truini received consulting fees and payment for lectures from the Sigma-Tau of Alfasigma Group, Angelini, Gruenenthal, and Pfizer. The authors report no other conflicts of interest in this work.",,"Giulia Di Stefano 1 , Andrea Di Lionardo 1 , Eleonora Galosi 1 , Andrea Truini 1 , Giorgio Cruccu 1"
31273036,It is time for the world to take COPD seriously: a statement from the GOLD board of directors,"David M G Halpin 1, Bartolome R Celli 2, Gerard J Criner 3, Peter Frith 4, M Victorina López Varela 5, Sundeep Salvi 6, Claus F Vogelmeier 7, Ronchang Chen 8, Kevin Mortimer 9, Maria Montes de Oca 10, Zaurbek Aisanov 11, Daniel Obaseki 12, Rebecca Decker 13, Alvar Agusti 14",Eur Respir J. 2019 Jul 4;54(1):1900914. doi: 10.1183/13993003.00914-2019. Print 2019 Jul.,Halpin DMG,Eur Respir J,2019,2019/07/06,,,10.1183/13993003.00914-2019,https://pubmed.ncbi.nlm.nih.gov/31273036/,/31273036/,"Conflict of interest: D.M.G. Halpin reports personal fees from AstraZeneca, Chiesi, GlaxoSmithKline and Pfizer, and personal fees and non-financial support from Boehringer Ingelheim and Novartis, outside the submitted work. Conflict of interest: B.R. Celli reports grants and other from Astra Zeneca (research site), personal fees from GlaxoSmithKline (consulting and scientific committee), and personal fees from Boehringer Ingelheim, Novartis, Sanofi-Aventis and Menarini (all for consulting), outside the submitted work. Conflict of interest: G.J. Criner has nothing to disclose. Conflict of interest: P. Frith reports personal fees from Boehringer Ingelheim, Menarini and Novartis (travel compensation and speaker fees), non-financial support from Global Initiative for Chronic Obstructive Lung Disease (travel reimbursement for Board meetings), and non-financial support from Lung Foundation Australia (travel support to Board meetings), outside the submitted work. Conflict of interest: M.V. López Varela has nothing to disclose. Conflict of interest: S. Salvi has nothing to disclose. Conflict of interest: C.F. Vogelmeier reports personal fees from Almirall, Cipla, Berlin Chemie/Menarini, CSL Behring, and Teva; grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Mundipharma, Novartis, and Takeda; grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD, and Pfizer, all outside the submitted work. Conflict of interest: R. Chen reports grants and personal fees from GSK, Astra-Zeneca and Boehringer-Ingelheim, and personal fees from Novartis, during the conduct of the study. Conflict of interest: K. Mortimer reports personal fees from the International Union Against TB and Lung Disease, outside the submitted work. Conflict of interest: M. Montes de Oca has nothing to disclose. Conflict of interest: Z. Aisanov has nothing to disclose. Conflict of interest: D. Obaseki has nothing to disclose. Conflict of interest: R. Decker has nothing to disclose. Conflict of interest: A. Agusti reports personal fees from AstraZeneca, Chiesi and Nuvaira, and grants and personal fees from Menarini and GSK, outside the submitted work.",,"David M G Halpin 1 , Bartolome R Celli 2 , Gerard J Criner 3 , Peter Frith 4 , M Victorina López Varela 5 , Sundeep Salvi 6 , Claus F Vogelmeier 7 , Ronchang Chen 8 , Kevin Mortimer 9 , Maria Montes de Oca 10 , Zaurbek Aisanov 11 , Daniel Obaseki 12 , Rebecca Decker 13 , Alvar Agusti 14"
31096854,Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base,"Anthony D DUrzo 1, Dave Singh 2, James F Donohue 3, Kenneth R Chapman 4",Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619850725. doi: 10.1177/1753466619850725.,DUrzo AD,Ther Adv Respir Dis,2019,2019/05/18,PMC6535700,,10.1177/1753466619850725,https://pubmed.ncbi.nlm.nih.gov/31096854/,/31096854/,"Conflict of interest statement: AD has received research, consulting, and lecturing fees from Almirall, Altana, AstraZeneca, Boehringer Ingelheim (Canada) Ltd, Forest Laboratories, GlaxoSmithKline, KOS Pharmaceuticals, Merck Canada, Methapharm, Novartis Canada/USA, ONO Pharmaceutical Co., Pfizer Canada, Schering-Plough, Sepracor, and SkyePharma. DS has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Apellis, Astra-Zeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Mundipharma, Novartis, Peptin-novate, Pfizer, Pulmatrix, SkyPharma, Teva, Theravance, and Verona. JFD has received consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sunovian, and Theravance. He is a member of the Data Monitoring Committee for AstraZeneca, Gilead, and InsMED. KRC has consulted (in the last 3 years) with AstraZeneca, Baxter, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Grifols, Kamada, Novartis, Roche, and Teva; has undertaken research funded by Amgen, AstraZeneca, Baxter, Boehringer Ingelheim, CSL Behring, Forest Laboratories, GlaxoSmithKline, Grifols, Mereo BioPharma, Novartis, Regeneron, Roche, and Sanofi; and has participated in continuing medical education activities sponsored in whole or in part by AstraZeneca, Boehringer Ingelheim, Glaxo-SmithKline, Grifols, Merck Frosst, Novartis, and Pfizer. He is also participating in research funded by the Canadian Institutes of Health Research operating grant entitled ‘Canadian Cohort Obstructive Lung Disease (CanCOLD)’ and holds the GSK-CIHR Research Chair in Respiratory Health Care Delivery at the University Health Network, Toronto, Ontario, Canada.",,"Anthony D DUrzo 1 , Dave Singh 2 , James F Donohue 3 , Kenneth R Chapman 4"
31537655,The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization,"Nicolas Roche 1 2, Antonio Anzueto 2 3, Sinthia Bosnic Anticevich 2 4 5, Alan Kaplan 2 6, Marc Miravitlles 2 7, Dermot Ryan 2 8, Joan B Soriano 2 9, Omar Usmani 2 10, Nikolaos G Papadopoulos 2 11 12 13, G Walter Canonica 2 14 13 ; Respiratory Effectiveness Group Collaborators",Eur Respir J. 2019 Sep 19;54(3):1901511. doi: 10.1183/13993003.01511-2019. Print 2019 Sep.,Roche N,Eur Respir J,2019,2019/09/21,,,10.1183/13993003.01511-2019,https://pubmed.ncbi.nlm.nih.gov/31537655/,/31537655/,"Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M, Zambon and Trudell, outside the submitted work. Conflict of interest: A. Anzueto reports personal fees for consultancy from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, outside the submitted work. Conflict of interest: S. Bosnic Anticevich reports personal fees for advisory board work from TEVA, personal fees for consultancy from GSK and MEDA, grants from TEVA, personal fees for lectures from TEVA, GSK and AstraZeneca, personal fees for manuscript preparation from MEDA, personal fees for educational activities from GSK, outside the submitted work. Conflict of interest: A. Kaplan reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Pfizer, personal fees from Covis, GSK, Sanofi, Merck Frosst, Novartis, Purdue, Teva, Trudel, Novo Nordisk and Griffols, during the conduct of the study. Conflict of interest: M. Miravitlles reports personal fees for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, CSL Behring, Grifols and Novartis, personal fees for consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols, grants from GlaxoSmithKline and Grifols, outside the submitted work. Conflict of interest: D. Ryan reports personal fees for advisory board work from GSK, BI and Novartis, personal fees for lectures and advisory board work from AZ, personal fees for lectures and meeting attendance from MEDA, outside the submitted work; and was previous president of REG, current vice president of REG and consultant strategic medical adviser, Optimum Patient Care. Conflict of interest: J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, Chest, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. Conflict of interest: O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, grants from GlaxoSmithKline and Edmond Pharma, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Takeda, Zentiva and Cipla, outside the submitted work. Conflict of interest: N. Papadopoulos reports personal fees for advisory board work and lectures from Novartis, Nutricia, HAL, MENARINI/FAES FARMA and MYLAN/MEDA, personal fees for lectures from SANOFI, BIOMAY, MSD, ASIT BIOTECH and Boehringer Ingelheim, personal fees for advisory board work from AstraZeneca and GSK, grants from Gerolymatos International SA and Capricare, outside the submitted work. Conflict of interest: G.W. Canonica has nothing to disclose.",,"Nicolas Roche 1 2 , Antonio Anzueto 2 3 , Sinthia Bosnic Anticevich 2 4 5 , Alan Kaplan 2 6 , Marc Miravitlles 2 7 , Dermot Ryan 2 8 , Joan B Soriano 2 9 , Omar Usmani 2 10 , Nikolaos G Papadopoulos 2 11 12 13 , G Walter Canonica 2 14 13 ; Respiratory Effectiveness Group Collaborators"
31354967,Introducing a new ESMO Open article series: how I treat side effects of immunotherapy,Matthias Preusser 1,ESMO Open. 2019 Jul 5;4(Suppl 4):e000552. doi: 10.1136/esmoopen-2019-000552. eCollection 2019.,Preusser M,ESMO Open,2019,2019/07/30,PMC6615874,,10.1136/esmoopen-2019-000552,https://pubmed.ncbi.nlm.nih.gov/31354967/,/31354967/,"Competing interests: MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo and Merck Sharp & Dome.",,Matthias Preusser 1
30267046,Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies,"Xikun Han 1 2, Emmanuelle Souzeau 3, Jue-Sheng Ong 1 2, Jiyuan An 1, Owen M Siggs 3, Kathryn P Burdon 3 4, Stephen Best 5, Ivan Goldberg 6, Paul R Healey 6 7, Stuart L Graham 6 8, Jonathan B Ruddle 9 10 11, Richard A Mills 3, John Landers 3, Anna Galanopoulos 12, Andrew J R White 7, Robert Casson 12, David A Mackey 4 13, Alex W Hewitt 4 9, Puya Gharahkhani 1, Jamie E Craig 3, Stuart MacGregor 1",JAMA Ophthalmol. 2019 Jan 1;137(1):28-35. doi: 10.1001/jamaophthalmol.2018.4477.,Han X,JAMA Ophthalmol,2019,2018/09/30,PMC6439786,,10.1001/jamaophthalmol.2018.4477,https://pubmed.ncbi.nlm.nih.gov/30267046/,/30267046/,"Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Goldberg reports serving on advisory board for Novartis and Allergan, Mundipharma, and Pfizer, and receiving speakers’ fees from Mundipharma and Pfizer. No other disclosures were reported.",Grants and funding MC_PC_17228/MRC_/Medical Research Council/United Kingdom MC_QA137853/MRC_/Medical Research Council/United Kingdom,"Xikun Han 1 2 , Emmanuelle Souzeau 3 , Jue-Sheng Ong 1 2 , Jiyuan An 1 , Owen M Siggs 3 , Kathryn P Burdon 3 4 , Stephen Best 5 , Ivan Goldberg 6 , Paul R Healey 6 7 , Stuart L Graham 6 8 , Jonathan B Ruddle 9 10 11 , Richard A Mills 3 , John Landers 3 , Anna Galanopoulos 12 , Andrew J R White 7 , Robert Casson 12 , David A Mackey 4 13 , Alex W Hewitt 4 9 , Puya Gharahkhani 1 , Jamie E Craig 3 , Stuart MacGregor 1"
31377695,A protocol for a discrete choice experiment: understanding patient medicine preferences for managing chronic non-cancer pain,"Marian Shanahan 1, Briony Larance 2 3, Suzanne Nielsen 2 4, Milton Cohen 5, Maria Schaffer 2, Gabrielle Campbell 2",BMJ Open. 2019 Aug 2;9(8):e027153. doi: 10.1136/bmjopen-2018-027153.,Shanahan M,BMJ Open,2019,2019/08/05,PMC6687015,,10.1136/bmjopen-2018-027153,https://pubmed.ncbi.nlm.nih.gov/31377695/,/31377695/,"Competing interests: BL and SN report investigator-driven untied educational grants from Reckitt Benckiser/Indivior for studies of buprenorphine-naloxone and buprenorphine depot, the development of an opioid-related behaviour scale and a study of opioid substitution therapy uptake among chronic non-cancer pain patients. BL has also received investigator-initiated untied educational grants for post-marketing surveillance studies of opioids from Mundipharma Limited (a tamper-resistant oxycodone formulation) and Seqirus (tapentadol). These funders had no role in the design, conduct or interpretation of these studies. These studies were unrelated to the current discrete choice experiment protocol or broader pain and opioids in treatment study. SN has provided training around treatment of codeine dependence for which her institution received funding from Indivior. GC reports investigator-driven untied educational grants from Reckitt Benckiser for the development of an opioid-related behaviour scale. MC reports receiving fees from Mundipharma Limited for preparation and presentation of educational material.",,"Marian Shanahan 1 , Briony Larance 2 3 , Suzanne Nielsen 2 4 , Milton Cohen 5 , Maria Schaffer 2 , Gabrielle Campbell 2"
31612359,"Analgesic Efficacy, Practicality and Safety of Inhaled Methoxyflurane Versus Standard Analgesic Treatment for Acute Trauma Pain in the Emergency Setting: A Randomised, Open-Label, Active-Controlled, Multicentre Trial in Italy (MEDITA)","Sebastiano Mercadante 1, Antonio Voza 2, Sossio Serra 3, Germana Ruggiano 4, Giuseppe Carpinteri 5, Gianfilippo Gangitano 6, Fabio Intelligente 2, Elisabetta Bonafede 7, Antonella Sblendido 8, Alberto Farina 8, Amedeo Soldi 8, Andrea Fabbri 9 ; MEDITA Study Group",Adv Ther. 2019 Nov;36(11):3030-3046. doi: 10.1007/s12325-019-01055-9. Epub 2019 Oct 12.,Mercadante S,Adv Ther,2019,2019/10/16,PMC6822789,,10.1007/s12325-019-01055-9,https://pubmed.ncbi.nlm.nih.gov/31612359/,/31612359/,,,"Sebastiano Mercadante 1 , Antonio Voza 2 , Sossio Serra 3 , Germana Ruggiano 4 , Giuseppe Carpinteri 5 , Gianfilippo Gangitano 6 , Fabio Intelligente 2 , Elisabetta Bonafede 7 , Antonella Sblendido 8 , Alberto Farina 8 , Amedeo Soldi 8 , Andrea Fabbri 9 ; MEDITA Study Group"
31230005,Strategies to evaluate healthcare provider trainings in shared decision-making (SDM): a systematic review of evaluation studies,"Evamaria Müller 1, Alena Strukava 1, Isabelle Scholl 1, Martin Härter 1, Ndeye Thiab Diouf 2, France Légaré 2, Angela Buchholz 1",BMJ Open. 2019 Jun 21;9(6):e026488. doi: 10.1136/bmjopen-2018-026488.,Müller E,BMJ Open,2019,2019/06/24,PMC6596948,,10.1136/bmjopen-2018-026488,https://pubmed.ncbi.nlm.nih.gov/31230005/,/31230005/,"Competing interests: EM and AS report grants from Mundipharma GmbH during the conduct of the study. EM, AS, IS, MH and AB conducted SDM communication skills trainings in a project funded by Mundipharma GmbH. NTD and FL have nothing to disclose.",,"Evamaria Müller 1 , Alena Strukava 1 , Isabelle Scholl 1 , Martin Härter 1 , Ndeye Thiab Diouf 2 , France Légaré 2 , Angela Buchholz 1"
31552715,Inhaled Corticosteroids in Asthma and the Risk of Pneumonia,"Min Hye Kim 1, Chin Kook Rhee 2, Ji Su Shim 1, So Young Park 1, Kwang Ha Yoo 3, Bo Yeon Kim 4, Hye Won Bae 4, Yun Su Sim 5, Jung Hyun Chang 1, Young Joo Cho 1, Jin Hwa Lee 6",Allergy Asthma Immunol Res. 2019 Nov;11(6):795-805. doi: 10.4168/aair.2019.11.6.795.,Kim MH,Allergy Asthma Immunol Res,2019,2019/09/26,PMC6761075,,10.4168/aair.2019.11.6.795,https://pubmed.ncbi.nlm.nih.gov/31552715/,/31552715/,"CK Rhee received consulting/lecture fees from MSD, AstraZeneca, Novartis, GSK, Takeda, Mundipharma, Sandoz, Boehringer-Ingelheim, and Teva-Handok. Min-Hye Kim, Kwang Ha Yoo, Bo Yeon Kim, Hye Won Bae, Yun Su Sim, Jung Hyun Chang, Young-Joo Cho, and Jin Hwa Lee have no conflict of interest to declare.",Grants and funding Ewha/Ewha Womans University/Korea 2010-0027945/NRF/National Research Foundation of Korea/Korea,"Min Hye Kim 1 , Chin Kook Rhee 2 , Ji Su Shim 1 , So Young Park 1 , Kwang Ha Yoo 3 , Bo Yeon Kim 4 , Hye Won Bae 4 , Yun Su Sim 5 , Jung Hyun Chang 1 , Young Joo Cho 1 , Jin Hwa Lee 6"
31533630,Impact of training and structured medication review on medication appropriateness and patient-related outcomes in nursing homes: results from the interventional study InTherAKT,"Angelika Mahlknecht 1, Laura Krisch 2, Nadja Nestler 2, Ulrike Bauer 2, Nina Letz 2, Daniel Zenz 3, Jochen Schuler 4, Laura Fährmann 5, Georg Hempel 5, Maria Flamm 4, Jürgen Osterbrink 2",BMC Geriatr. 2019 Sep 18;19(1):257. doi: 10.1186/s12877-019-1263-3.,Mahlknecht A,BMC Geriatr,2019,2019/09/20,PMC6749664,,10.1186/s12877-019-1263-3,https://pubmed.ncbi.nlm.nih.gov/31533630/,/31533630/,"NN: In the last 5 years I have received lecture honoraria from Grünenthal and Mundipharma. GH: In the last 5 years I have received lecture honoraria from Grünenthal. JO: In the last 5 years I have received lecture honoraria from Pfizer, Grünenthal and Mundipharma. All other authors declare to have no competing interests.",,"Angelika Mahlknecht 1 , Laura Krisch 2 , Nadja Nestler 2 , Ulrike Bauer 2 , Nina Letz 2 , Daniel Zenz 3 , Jochen Schuler 4 , Laura Fährmann 5 , Georg Hempel 5 , Maria Flamm 4 , Jürgen Osterbrink 2"
31125359,Pain during exacerbation of chronic obstructive pulmonary disease: A prospective cohort study,"Maxime Maignan 1 2, Jean-Marc Chauny 3, Raoul Daoust 3, Ludivine Duc 1, Prudence Mabiala-Makele 1, Roselyne Collomb-Muret 1, Matthieu Roustit 2 4, Caroline Maindet 5, Jean-Louis Pépin 2 6, Damien Viglino 1 2",PLoS One. 2019 May 24;14(5):e0217370. doi: 10.1371/journal.pone.0217370. eCollection 2019.,Maignan M,PLoS One,2019,2019/05/25,PMC6534306,,10.1371/journal.pone.0217370,https://pubmed.ncbi.nlm.nih.gov/31125359/,/31125359/,"MM reports grants from Mundipharma and Roche diagnostics outside the submitted work. MM also reports personal fees from Mundipharma and Purdue outside the submitted work. JLP is supported by the French National Research Agency in the framework of the Investissements d’avenir” program (ANR-15-IDEX-02). DV reports research grants from AstraZeneca during the conduct of the study, outside the submitted work. All the other authors report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work. These competing interests do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. There are no restrictions to the sharing of data from this study.","Grants and funding This study was funded by the APICIL foundation (http://www.fondation-apicil.org/) and the Agir pour les Maladies Chroniques foundation (http://fonds-apmc.org/), both non-profit organisations (MM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The corresponding author had full access to all the data and had final responsibility for the decision to submit for publication.","Maxime Maignan 1 2 , Jean-Marc Chauny 3 , Raoul Daoust 3 , Ludivine Duc 1 , Prudence Mabiala-Makele 1 , Roselyne Collomb-Muret 1 , Matthieu Roustit 2 4 , Caroline Maindet 5 , Jean-Louis Pépin 2 6 , Damien Viglino 1 2"
31305874,Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial,"Nicholas Lintzeris 1 2, Anjali Bhardwaj 1 2, Llewellyn Mills 1 2, Adrian Dunlop 3 4, Jan Copeland 5, Iain McGregor 6, Raimondo Bruno 7, Jessica Gugusheff 1 2, Nghi Phung 8, Mark Montebello 1, Therese Chan 1, Adrienne Kirby 9, Michelle Hall 3, Meryem Jefferies 8, Jennifer Luksza 8, Marian Shanahan 10, Richard Kevin 3, David Allsop 6 ; Agonist Replacement for Cannabis Dependence (ARCD) study group",JAMA Intern Med. 2019 Sep 1;179(9):1242-1253. doi: 10.1001/jamainternmed.2019.1993.,Lintzeris N,JAMA Intern Med,2019,2019/07/16,PMC6632121,,10.1001/jamainternmed.2019.1993,https://pubmed.ncbi.nlm.nih.gov/31305874/,/31305874/,"Conflict of Interest Disclosures: Dr Lintzeris reported receiving grants from National Health and Medical Research Council of Australia during the conduct of the study; grants from Camurus, personal fees from Indivior and Mundipharma outside the submitted work; and being the Clinical Director of the Lambert Initiative in Cannabinoid Therapeutics at University of Sydney from 2015-2017, involved in a number of studies of medical cannabis, unrelated to this study. Dr McGregor reported receiving grants from National Health and Medical Research Council of Australia and from Lambert Initiative for Cannabinoid Therapeutics during the conduct of the study; having patents to WO2018107216A1, WO2017004674A1, and WO2011038451A1 issued and licensed; and having patents to AU2017904438, AU2017904072, and AU2018901971 pending. No other disclosures were reported.",,"Nicholas Lintzeris 1 2 , Anjali Bhardwaj 1 2 , Llewellyn Mills 1 2 , Adrian Dunlop 3 4 , Jan Copeland 5 , Iain McGregor 6 , Raimondo Bruno 7 , Jessica Gugusheff 1 2 , Nghi Phung 8 , Mark Montebello 1 , Therese Chan 1 , Adrienne Kirby 9 , Michelle Hall 3 , Meryem Jefferies 8 , Jennifer Luksza 8 , Marian Shanahan 10 , Richard Kevin 3 , David Allsop 6 ; Agonist Replacement for Cannabis Dependence (ARCD) study group"
31167884,Artificial intelligence for pulmonary function test interpretation,"Sherif Gonem 1, Salman Siddiqui 2 3",Eur Respir J. 2019 Jun 5;53(6):1900638. doi: 10.1183/13993003.00638-2019. Print 2019 Jun.,Gonem S,Eur Respir J,2019,2019/06/07,,,10.1183/13993003.00638-2019,https://pubmed.ncbi.nlm.nih.gov/31167884/,/31167884/,"Conflict of interest: S. Gonem reports personal fees from 3M and Anaxsys, outside the submitted work. Conflict of interest: S. Siddiqui reports grants from Sir Jules Thorne Trust, NIHR-EME, Anaptys Bio, MRC/EPSRC and Napp, personal fees from AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Mundipharma and Owlstone Medical, outside the submitted work.",,"Sherif Gonem 1 , Salman Siddiqui 2 3"
31417681,"Pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects","Hendrik Wessels 1, Dirk Lehnick 2, Josef Höfler 3, Ruediger Jankowsky 1, Paul Chamberlain 4, Karsten Roth 1",Pharmacol Res Perspect. 2019 Aug 13;7(5):e00507. doi: 10.1002/prp2.507. eCollection 2019 Oct.,Wessels H,Pharmacol Res Perspect,2019,2019/08/17,PMC6691755,,10.1002/prp2.507,https://pubmed.ncbi.nlm.nih.gov/31417681/,/31417681/,"This study was funded by Cinfa Biotech, now part of the Mundipharma network of independent associated companies. KR, HW, and RJ are employees of Cinfa Biotech, now part of Mundipharma. JH is an employee of Staburo GmbH. DL is an employee of the University of Lucerne.",,"Hendrik Wessels 1 , Dirk Lehnick 2 , Josef Höfler 3 , Ruediger Jankowsky 1 , Paul Chamberlain 4 , Karsten Roth 1"
31752560,An innovative corticosteroid/long-acting β(2)-agonist breath-triggered inhaler: facilitating lung delivery of fluticasone propionate/formoterol fumarate for the treatment of asthma,"Omar Usmani 1, Nicolas Roche 2, Jonathan Marshall 3, Helen Danagher 4, David Price 5 6",Expert Opin Drug Deliv. 2019 Dec;16(12):1367-1380. doi: 10.1080/17425247.2019.1689957. Epub 2019 Nov 28.,Usmani O,Expert Opin Drug Deliv,2019,2019/11/23,,,10.1080/17425247.2019.1689957,https://pubmed.ncbi.nlm.nih.gov/31752560/,/31752560/,,,"Omar Usmani 1 , Nicolas Roche 2 , Jonathan Marshall 3 , Helen Danagher 4 , David Price 5 6"
31371974,A case of chronic eosinophilic pneumonia in a patient treated with dupilumab,"Francesco Menzella 1, Gloria Montanari 1, Giulia Patricelli 2, Alberto Cavazza 3, Carla Galeone 1, Patrizia Ruggiero 1, Diego Bagnasco 4, Nicola Facciolongo 1",Ther Clin Risk Manag. 2019 Jul 10;15:869-875. doi: 10.2147/TCRM.S207402. eCollection 2019.,Menzella F,Ther Clin Risk Manag,2019,2019/08/03,PMC6636310,,10.2147/TCRM.S207402,https://pubmed.ncbi.nlm.nih.gov/31371974/,/31371974/,"Francesco Menzella participated in contracted research and clinical trials for Novartis and Sanofi; has received lecture fees and advisory board fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma and Novartis. Nicola Facciolongo served as a consultant for Boston Scientific and has received lecture fees from AstraZeneca and Chiesi. The other authors report no conflicts of interest in this work.",,"Francesco Menzella 1 , Gloria Montanari 1 , Giulia Patricelli 2 , Alberto Cavazza 3 , Carla Galeone 1 , Patrizia Ruggiero 1 , Diego Bagnasco 4 , Nicola Facciolongo 1"
30962222,Targeting CD47 in Sézary syndrome with SIRPαFc,"Lisa D S Johnson 1, Swati Banerjee 2, Oleg Kruglov 2, Natasja Nielsen Viller 1, Steven M Horwitz 3, Alexander Lesokhin 3, Jasmine Zain 4, Christiane Querfeld 4, Robert Chen 4, Craig Okada 5, Ahmed Sawas 6, Owen A OConnor 6, Eric L Sievers 1, Yaping Shou 1, Robert A Uger 1, Mark Wong 1, Oleg E Akilov 2",Blood Adv. 2019 Apr 9;3(7):1145-1153. doi: 10.1182/bloodadvances.2018030577.,Johnson LDS,Blood Adv,2019,2019/04/10,PMC6457236,,10.1182/bloodadvances.2018030577,https://pubmed.ncbi.nlm.nih.gov/30962222/,/30962222/,"Conflict-of-interest disclosure: L.D.S.J., N.N.V., E.L.S., Y.S., R.A.U., and M.W. are employees of Trillium Therapeutics Inc. O.E.A. has received research funding from Trillium Therapeutics Inc. S.M.H., A.L., J.Z., C.Q., R.C., C.O., A.S., O.A.O., and O.E.A. are clinical investigators on a trial sponsored by Trillium Therapeutics Inc. S.M.H. has received both research funding/grant support and honoraria/consulting fees from ADCT Therapeutics, Aileron, Forty-Seven Infinity/Verastem Kyowa-Hakka-Kirin, Millennium/Takeda, and Seattle Genetics; research/grant support from Celgene and Trillium Therapeutics Inc; and honoraria consulting fees from Affimed, Angimmune, Beigene, Corvus, Innate Pharma, Kura, Merck, Miragen, Mundipharma, Portola, and Syros Pharmaceutical. The remaining authors declare no competing financial interests.",Grants and funding P30 CA008748/CA/NCI NIH HHS/United States P50 CA107399/CA/NCI NIH HHS/United States,"Lisa D S Johnson 1 , Swati Banerjee 2 , Oleg Kruglov 2 , Natasja Nielsen Viller 1 , Steven M Horwitz 3 , Alexander Lesokhin 3 , Jasmine Zain 4 , Christiane Querfeld 4 , Robert Chen 4 , Craig Okada 5 , Ahmed Sawas 6 , Owen A OConnor 6 , Eric L Sievers 1 , Yaping Shou 1 , Robert A Uger 1 , Mark Wong 1 , Oleg E Akilov 2"
31819391,Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology,"Martina Veith 1, Andreas Klemmer 1, Iker Anton 2, Rachid El Hamss 2, Noelia Rapun 2, Sabina Janciauskiene 3, Viktor Kotke 1, Christian Herr 4, Robert Bals 4, Claus Franz Vogelmeier 1, Timm Greulich 1",Int J Chron Obstruct Pulmon Dis. 2019 Nov 18;14:2535-2542. doi: 10.2147/COPD.S224221. eCollection 2019.,Veith M,Int J Chron Obstruct Pulmon Dis,2019,2019/12/11,PMC6873957,,10.2147/COPD.S224221,https://pubmed.ncbi.nlm.nih.gov/31819391/,/31819391/,"Martina Veith reports grants from Grifols, during the conduct of the study; grants from Grifols, outside the submitted work. Iker Anton, Rachid El Hamss, and Noelia Rapun are employees of Progenika Biopharma-Grifols. Viktor Kotke reports grants from Grifols, outside the submitted work. Dr. Robert Bals reports grants, personal fees from CSL Behring and Grifols, grants from Boehinger Ingelheim and Novartis, during the conduct of the study. Claus Franz Vogelmeier reports grants, personal fees from AstraZeneca, GlaxoSmithKline, Grifols, Novartis, and Boehringer Ingelheim, personal fees from CSL Behring, Menarini, Mundipharma, Teva, Cipla, Nuvaira, and Chiesi, grants from Bayer Schering Pharma AG, MSD, and Pfizer, outside the submitted work. Timm Greulich reports grants from Grifols, during the conduct of the study; personal fees from AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, CSL-Behring, Grifols, GSK, and Novartis, outside the submitted work. The authors report no other conflicts of interest in this work.",,"Martina Veith 1 , Andreas Klemmer 1 , Iker Anton 2 , Rachid El Hamss 2 , Noelia Rapun 2 , Sabina Janciauskiene 3 , Viktor Kotke 1 , Christian Herr 4 , Robert Bals 4 , Claus Franz Vogelmeier 1 , Timm Greulich 1"
31819561,Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients,"Olga Delgado Sánchez 1, Antonio Gutiérrez 2, Fernando do Pazo 1, Jordi Ginés 1, Clara Martorell 1, Bàrbara Boyeras 1, Leyre Bento 2, Marta Garcia-Recio 2, Antonia Sampol 2",Clinicoecon Outcomes Res. 2019 Nov 18;11:695-701. doi: 10.2147/CEOR.S212257. eCollection 2019.,Delgado Sánchez O,Clinicoecon Outcomes Res,2019,2019/12/11,PMC6874115,,10.2147/CEOR.S212257,https://pubmed.ncbi.nlm.nih.gov/31819561/,/31819561/,"ODS has been speaker to and has provided consultant services for Kern Pharma, Sandoz and Roche. AG discloses research support from Celgene, Janssen, Mundipharma and Roche and Scientific Advisory Boards to Celgene, Janssen, Mundipharma, Pfizer, Roche and Takeda. JG has been the speaker and has provided consultant services for Roche. CM reports personal fees and nonfinancial support from Roche, grants from BMS and personal fees from MSD, during the conduct of the study. The authors report no other conflicts of interest in this work.",,"Olga Delgado Sánchez 1 , Antonio Gutiérrez 2 , Fernando do Pazo 1 , Jordi Ginés 1 , Clara Martorell 1 , Bàrbara Boyeras 1 , Leyre Bento 2 , Marta Garcia-Recio 2 , Antonia Sampol 2"
31244899,Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy,"Kalliopi Pitarokoili 1, Dietrich Sturm 2, Adnan Labedi 3, Tineke Greiner 2, Lynn Eitner 4, Nina Kumowski 4, Elena K Enax-Krumova 2, Anna Lena Fisse 3, Christoph Maier 4, Ralf Gold 3, Martin Tegenthoff 2, Tobias Schmidt-Wilcke 5, Min-Suk Yoon 3",Ther Adv Neurol Disord. 2019 Jun 18;12:1756286419855485. doi: 10.1177/1756286419855485. eCollection 2019.,Pitarokoili K,Ther Adv Neurol Disord,2019,2019/06/28,PMC6582292,,10.1177/1756286419855485,https://pubmed.ncbi.nlm.nih.gov/31244899/,/31244899/,"Conflicts of interest: Nina Kumowski, Lynn Eitner, Tineke Greiner, Anna Lena Fisse and Adnan Labedi report no disclosures. Dietrich Sturm received funding from the Ruhr University, Bochum (FoRUM-Program). Kalliopi Pitarokoili received travel funding and speaker honoraria from Biogen Idec, Novartis and Bayer Schering Pharma and funding from the Ruhr University, Bochum (FoRUM-Program). R. Gold has received consultation fees and speaker honoraria from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and TEVA. He also acknowledges grant support from Bayer Schering, Biogen Idec, Merck Serono, Sanofi-Aventis and TEVA, none related to this manuscript. Elena K. Enax-Krumova is member of the German Research Network on Neuropathic pain e.V. (BMBF, grants 01EM0107 & 01EM0502), members of the European Collaboration, which has received support from the Innovative Medicines Initiative Joint Undertaking, under grant agreement no 11507, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies (AstraZeneca, Pfizer, Esteve, UCB-Pharma, Sanofi-Aventis, Grünenthal, Eli Lilly und Boehringer Ingelheim) inkind contribution, was supported by intramural funding of the Ruhr University Bochum (FoRUM: grant number K046-10, Heinemann Award 2013) and has received a travel grant from Mundipharma GmbH and Bayer Vital GmbH, speaker fees from Grünenthal GmbH and Pfizer GmbH. Christoph Maier has received honoraria for speaking and advisory board membership from Gruenenthal, MSD, Köhler Chemie, Mundipharma, Pfizer, and Wyeth. Martin Tegenthoff has received speaker honoraria from Pfizer, Novartis and Mundipharma. He also acknowledges a grant support from Genzyme, not related to this manuscript. Tobias Schmidt-Wilcke received consulting fees from Daiichi Sankyo. Min-Suk Yoon has received speaker honoraria from CSL Behring and Grifols, a scientific grant from CSL Behring, none related to this manuscript.",,"Kalliopi Pitarokoili 1 , Dietrich Sturm 2 , Adnan Labedi 3 , Tineke Greiner 2 , Lynn Eitner 4 , Nina Kumowski 4 , Elena K Enax-Krumova 2 , Anna Lena Fisse 3 , Christoph Maier 4 , Ralf Gold 3 , Martin Tegenthoff 2 , Tobias Schmidt-Wilcke 5 , Min-Suk Yoon 3"
30578381,Pulmonary rehabilitation in bronchiectasis: a propensity-matched study,"Suhani Patel 1 2 3, Aaron D Cole 2 3, Claire M Nolan 1 2 4, Ruth E Barker 1 2, Sarah E Jones 1 2, Samantha Kon 1 4, Julius Cairn 5, Michael Loebinger 4 6, Robert Wilson 4 6, William D-C Man 1 2 4 5",Eur Respir J. 2019 Jan 17;53(1):1801264. doi: 10.1183/13993003.01264-2018. Print 2019 Jan.,Patel S,Eur Respir J,2019,2018/12/23,,,10.1183/13993003.01264-2018,https://pubmed.ncbi.nlm.nih.gov/30578381/,/30578381/,"Conflict of interest: S. Patel has nothing to disclose. Conflict of interest: A.D. Cole has nothing to disclose. Conflict of interest: C.M. Nolan has nothing to disclose. Conflict of interest: R.E. Barker has nothing to disclose. Conflict of interest: S.E. Jones has nothing to disclose. Conflict of interest: S. Kon has nothing to disclose. Conflict of interest: J. Cairn has nothing to disclose. Conflict of interest: M. Loebinger has nothing to disclose. Conflict of interest: R. Wilson has nothing to disclose. Conflict of interest: W.D-C. Man reports grants from Pfizer, non-financial support from GSK, and personal fees from Mundipharma and Novartis, outside the submitted work.",Grants and funding DHCS/07/07/009/DH_/Department of Health/United Kingdom G1002113/MRC_/Medical Research Council/United Kingdom PB-PG-0213-30003/DH_/Department of Health/United Kingdom PB-PG-0816-20022/DH_/Department of Health/United Kingdom,"Suhani Patel 1 2 3 , Aaron D Cole 2 3 , Claire M Nolan 1 2 4 , Ruth E Barker 1 2 , Sarah E Jones 1 2 , Samantha Kon 1 4 , Julius Cairn 5 , Michael Loebinger 4 6 , Robert Wilson 4 6 , William D-C Man 1 2 4 5"
31291659,Management of adverse effects of opioid therapy,Stefan Wirz,Laryngorhinootologie. 2019 Jul;98(7):473-479. doi: 10.1055/a-0834-4268. Epub 2019 Jul 10.,Wirz S,Laryngorhinootologie,2019,2019/07/11,,,10.1055/a-0834-4268,https://pubmed.ncbi.nlm.nih.gov/31291659/,/31291659/,"Vortrags- und Beratertätigkeiten in den vergangenen fünf Jahren: Astra Zeneca, Dr. Kade, Grünenthal, Indivior, Mundipharma, Pfizer, TEVA. Danksagung. Dieser Artikel entstand mit freundlicher Unterstützung der Astra Zeneca GmbH.",,Stefan Wirz
30634521,Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health,"Barbara Lovrecic 1, Mercedes Lovrecic 2 3, Branko Gabrovec 4, Marco Carli 5, Matteo Pacini 6, Angelo G I Maremmani 7 8, Icro Maremmani 9 10 11",Int J Environ Res Public Health. 2019 Jan 9;16(2):177. doi: 10.3390/ijerph16020177.,Lovrecic B,Int J Environ Res Public Health,2019,2019/01/13,PMC6352208,,10.3390/ijerph16020177,https://pubmed.ncbi.nlm.nih.gov/30634521/,/30634521/,"The authors declare no conflict of interest. I.M. served as Board Member for Indivior, Molteni, Mundipharma, D&A Pharma, Lundbeck, CT Sanremo, Angelini, MDS and Gilead.",,"Barbara Lovrecic 1 , Mercedes Lovrecic 2 3 , Branko Gabrovec 4 , Marco Carli 5 , Matteo Pacini 6 , Angelo G I Maremmani 7 8 , Icro Maremmani 9 10 11"
31741199,RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design,"Andrew D Xia 1, Caroline P Schaefer 2, Agota Szende 3, Elke Jahn 4, Matthew J Hirst 5",Drugs Real World Outcomes. 2019 Dec;6(4):193-203. doi: 10.1007/s40801-019-00167-6.,Xia AD,Drugs Real World Outcomes,2019,2019/11/20,PMC6879703,,10.1007/s40801-019-00167-6,https://pubmed.ncbi.nlm.nih.gov/31741199/,/31741199/,"MH is an employee of Mundibiopharma International Ltd. AX was an employee of Mundibiopharma Ltd. at the time of the content and manuscript development. AS and CS are employees of Covance Market Access Services, which received funding from Mundipharma to conduct this research. EJ is an employee of Covance Phase IV Solutions, which received funding from Mundipharma to conduct this research. The authors report no further potential conflicts of interest.",,"Andrew D Xia 1 , Caroline P Schaefer 2 , Agota Szende 3 , Elke Jahn 4 , Matthew J Hirst 5"
30880943,"Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA","Dave Singh 1, Leonardo M Fabbri 2 3, Stefano Vezzoli 4, Stefano Petruzzelli 4, Alberto Papi 2",Int J Chron Obstruct Pulmon Dis. 2019 Feb 28;14:531-546. doi: 10.2147/COPD.S196383. eCollection 2019.,Singh D,Int J Chron Obstruct Pulmon Dis,2019,2019/03/19,PMC6400232,,10.2147/COPD.S196383,https://pubmed.ncbi.nlm.nih.gov/30880943/,/30880943/,"Disclosure DS is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). DS received personal fees from Chiesi during the conduct of these studies. Outside the submitted work, DS reports grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance, and Verona, and personal fees from Genentech and Skyepharma. LMF reports grants, personal fees, and non-financial support from Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Takeda, AstraZeneca, Novartis, Menarini, Laboratori Guidotti, and Almirall; personal fees and non-financial support from Pearl Therapeutics, Mundipharma, and Boston Scientific; personal fees from Kyorin, Bayer, and Zambon; and grants from Pfizer, Dompè, Malesci, Alfasigma, and Vree Health Italia, all outside the submitted work. SV and SP are employed by Chiesi, the sponsor of the studies. AP reports grants, personal fees, non-financial support, and advisory board membership from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma, and TEVA; personal fees and non-financial support from Menarini, Novartis, and Zambon; and grants from Sanofi, all outside the submitted work. The authors report no other conflicts of interest in this work.",,"Dave Singh 1 , Leonardo M Fabbri 2 3 , Stefano Vezzoli 4 , Stefano Petruzzelli 4 , Alberto Papi 2"
29956215,"Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study","Helen Dooner 1, Gill Mundin 2, Sabine Mersmann 3 4, Carla Bennett 2, Ulrike Lorch 5, Mercedes Encabo 6, Marisol Escriche 6, Gregorio Encina 6, Kevin Smith 2",Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):63-75. doi: 10.1007/s13318-018-0491-9.,Dooner H,Eur J Drug Metab Pharmacokinet,2019,2018/06/30,PMC6394644,,10.1007/s13318-018-0491-9,https://pubmed.ncbi.nlm.nih.gov/29956215/,/29956215/,"UL is an employee of Richmond Pharmacology Ltd. MEn, MEs and GE are employees of Esteve. HD, GM, CB and KS are employees of Mundipharma Research Ltd. SM was an employee of Mundipharma Research GmbH & Co. KG at the time the study was conducted. Esteve and Mundipharma are in collaboration for the development and commercialisation of CTC. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (South Central-Berkshire B Research Ethics Committee, UK; IRAS:188440; REC reference: 15/SC/0549) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.",,"Helen Dooner 1 , Gill Mundin 2 , Sabine Mersmann 3 4 , Carla Bennett 2 , Ulrike Lorch 5 , Mercedes Encabo 6 , Marisol Escriche 6 , Gregorio Encina 6 , Kevin Smith 2"
30677059,ACO: Time to move from the description of different phenotypes to the treatable traits,"Nuria Toledo-Pons 1 2, Job F M van Boven 3, Miguel Román-Rodríguez 4, Noemí Pérez 5, Jose Luis Valera Felices 2, Joan B Soriano 6 7, Borja G Cosío 1 2",PLoS One. 2019 Jan 24;14(1):e0210915. doi: 10.1371/journal.pone.0210915. eCollection 2019.,Toledo-Pons N,PLoS One,2019,2019/01/25,PMC6345463,,10.1371/journal.pone.0210915,https://pubmed.ncbi.nlm.nih.gov/30677059/,/30677059/,"We have read the journal’s policy and the authors of this manuscript have the following competing interests: B. G. C. has received speaker fees from Sanofi, AstraZeneca, Boehringer Ingelheim, Chiesi, Teva, Mundipharma and Menarini, outside the submitted work. M. R.-R. has received personal fees from Astra Zeneca, Boehringer Ingelheim, Mundipharma, Novartis, and TEVA, and grants and personal fees from GSK, outside the submitted work. None declared (J. F. M. v. B., J.L.V., N. T.-P., N.P. and J. B. S.). This does not alter our adherence to PLOS ONE policies on sharing data and materials.","Grants and funding N. T.-P. was a recipient of a SEPAR travel fellowship (478/2017, https://www.separ.es/) aimed to set a collaboration with GRIAC for the purpose of this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","Nuria Toledo-Pons 1 2 , Job F M van Boven 3 , Miguel Román-Rodríguez 4 , Noemí Pérez 5 , Jose Luis Valera Felices 2 , Joan B Soriano 6 7 , Borja G Cosío 1 2"
31276613,Developing in vitro assays to quantitatively evaluate the interactions of dressings with wounds,"Qiaowei Ngo 1, Padmaja Anand 1, Yingting Wang 1, Abhishek Ananthanarayanan 1, Peili Gong 2, Craig S Newby 2, Michael M Mcmillian 1",Wound Repair Regen. 2019 Nov;27(6):715-719. doi: 10.1111/wrr.12746. Epub 2019 Jul 26.,Ngo Q,Wound Repair Regen,2019,2019/07/06,,,10.1111/wrr.12746,https://pubmed.ncbi.nlm.nih.gov/31276613/,/31276613/,,,"Qiaowei Ngo 1 , Padmaja Anand 1 , Yingting Wang 1 , Abhishek Ananthanarayanan 1 , Peili Gong 2 , Craig S Newby 2 , Michael M Mcmillian 1"
30962961,Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology,"Rosa Giuliani 1, Josep Tabernero 2, Fatima Cardoso 3, Keith Hanson McGregor 4, Malvika Vyas 5, Elisabeth G E de Vries 6",ESMO Open. 2019 Mar 6;4(2):e000460. doi: 10.1136/esmoopen-2018-000460. eCollection 2019.,Giuliani R,ESMO Open,2019,2019/04/10,PMC6435239,,10.1136/esmoopen-2018-000460,https://pubmed.ncbi.nlm.nih.gov/30962961/,/30962961/,"Competing interests: JT reports consultancy roles for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics; and institutional grants from Agendia BV, Amgen SA, Debiopharm International SA, Janssen-Cilag SA, Mologen AG, Novartis Farmacéutica SA, Pharma Mar, Roche Farma SA, Laboratorios Servier SL and Symphogen A/S. FC reports consultancy roles for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Seattle Genetics, Samsung Bioepis and Teva. EGEdV reports consultancy/advisory roles for Daiichi Sankyo, Merck, NSABP, Pfizer and Sanofi; and institutional grants from Amgen, AstraZeneca, Bayer, Chugai Pharma, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier and Synthon.",,"Rosa Giuliani 1 , Josep Tabernero 2 , Fatima Cardoso 3 , Keith Hanson McGregor 4 , Malvika Vyas 5 , Elisabeth G E de Vries 6"
30487200,Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study,"Claire M Nolan 1 2, Matthew Maddocks 3, Toby M Maher 2 4, Winston Banya 5, Suhani Patel 1, Ruth E Barker 1 2, Sarah E Jones 1 2, Peter M George 2 4, Paul Cullinan 2, William D-C Man 1 2",Eur Respir J. 2019 Feb 7;53(2):1801186. doi: 10.1183/13993003.01186-2018. Print 2019 Feb.,Nolan CM,Eur Respir J,2019,2018/11/30,,,10.1183/13993003.01186-2018,https://pubmed.ncbi.nlm.nih.gov/30487200/,/30487200/,"Conflict of interest: C.M. Nolan has nothing to disclose. Conflict of interest: M. Maddocks reports fellowship and project grants CDF-2017-10-009 and HSDR 16/02/18 from the NIHR, outside the submitted work. Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GSK R&D and UCB, and has received consultancy or speakers fees from Apellis, AstraZeneca, aTyr Pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Celgene, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB. Conflict of interest: W. Banya has nothing to disclose. Conflict of interest: S. Patel has nothing to disclose. Conflict of interest: R.E. Barker has nothing to disclose. Conflict of interest: S.E. Jones has nothing to disclose. Conflict of interest: P. George reports speaker fees, honoraria and conference attendance support from Boehringer Ingelheim and Roche Pharmaceuticals, outside the submitted work. Conflict of interest: P. Cullinan has nothing to disclose. Conflict of interest: W.D-C. Man reports grants from the NIHR, during the conduct of the study; grants from Pfizer, nonfinancial support from GSK, and personal fees from Mundipharma and Novartis, outside the submitted work.",Grants and funding CDF-2017-10-009/DH_/Department of Health/United Kingdom DRF-2014-07-089/DH_/Department of Health/United Kingdom G1002113/MRC_/Medical Research Council/United Kingdom PB-PG-0213-30003/DH_/Department of Health/United Kingdom,"Claire M Nolan 1 2 , Matthew Maddocks 3 , Toby M Maher 2 4 , Winston Banya 5 , Suhani Patel 1 , Ruth E Barker 1 2 , Sarah E Jones 1 2 , Peter M George 2 4 , Paul Cullinan 2 , William D-C Man 1 2"
31249014,GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents,"Helen K Reddel 1, J Mark FitzGerald 2, Eric D Bateman 3, Leonard B Bacharier 4, Allan Becker 5, Guy Brusselle 6, Roland Buhl 7, Alvaro A Cruz 8, Louise Fleming 9, Hiromasa Inoue 10, Fanny Wai-San Ko 11, Jerry A Krishnan 12, Mark L Levy 13, Jiangtao Lin 14, Søren E Pedersen 15, Aziz Sheikh 16, Arzu Yorgancioglu 17, Louis-Philippe Boulet 18",Eur Respir J. 2019 Jun 27;53(6):1901046. doi: 10.1183/13993003.01046-2019. Print 2019 Jun.,Reddel HK,Eur Respir J,2019,2019/06/29,,,10.1183/13993003.01046-2019,https://pubmed.ncbi.nlm.nih.gov/31249014/,/31249014/,"Conflict of interest: H.K. Reddel reports grants and personal fees for data monitoring committee and advisory board work, and providing independent medical education and consultancy from AstraZeneca, grants, personal fees for data monitoring committee and advisory board work, and providing independent medical education and consultancy, and non-financial support (study medication) from GlaxoSmithKline, personal fees for data monitoring committee work from Merck, grants and personal fees for data monitoring committee and advisory board work, and providing independent medical education from Novartis, personal fees for providing independent medical education from Teva and Mundipharma, personal fees for advisory board work and providing independent medical education from Boehringer Ingelheim, outside the submitted work; and H.K Reddel is Chair of the GINA Scientific Committee. Conflict of interest: J.M. FitzGerald reports grants and personal fees for advisory board work and speaker bureau-related presentations from AstraZeneca, GSK and Sanofi Regeneron, grants from Novartis, Boehringer Ingelheim and TEVA, during the conduct of the study; and is a member of the Executive and Science Committees of GINA. Conflict of interest: E.D. Bateman is a member of the Science Committee and Board of GINA; reports personal fees from ALK, AstraZeneca, Boehringer Ingelheim, Cipla, Menarini, Novartis, Orion, Regeneron, Sanofi Genzyme and Vectura, and grants to his institution from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi-Aventis and TEVA, outside the submitted work. Conflict of interest: L.B. Bacharier reports personal fees for lecturing and consultancy from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Teva, Boehringer Ingelheim and AstraZeneca, personal fees for advisory board work from Merck and Circassia, personal fees for data monitoring committee work from DBV Technologies, personal fees for CME programme development from WebMD/Medscape, personal fees for lecturing and advisory board work from Sanofi/Regeneron, personal fees for consultancy and advisory board work from Vectura, outside the submitted work. Conflict of interest: A. Becker reports personal fees for continuing medical education from AstraZeneca, personal fees for lecturing from Johnson and Johnson, and MSD, personal fees for advisory board work from Novartis, outside the submitted work. Conflict of interest: G. Brusselle reports personal fees for lecturing and advisory board work from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva, personal fees for advisory board work from Sanofi, outside the submitted work. Conflict of interest: R. Buhl reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Novartis, Roche, and Teva, outside the submitted work, as well as grants to Mainz University from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche, also outside the submitted work. Conflict of interest: A.A. Cruz reports grants and personal fees for advisory board work from GSK, grants, personal fees for lecturing and advisory board work and non-financial support for meeting attendance from AstraZeneca, personal fees for lecturing, developing educational materials and advisory board work, and non-financial support for meeting attendance from Boehringer Ingelheim, personal fees for lecturing and non-financial support for meeting attendance from Chiesi, personal fees for lecturing and developing educational materials, and non-financial support for meeting attendance from EUROFARMA and MEDA Pharma, personal fees for lecturing from Novartis, personal fees for consultancy and advisory board work from Sanofi, outside the submitted work. Conflict of interest: L. Fleming reports grants from Asthma UK, and speaker and consutancy fees, all paid direct to her institution, from Boehringer Ingelheim, AstraZeneca, GSK, Sanofi, Respiri and Novartis, outside the submitted work. Conflict of interest: H. Inoue reports grants from Boehringer Ingelheim, Kyorin, MeijiSeikaPharma, Novartis, Ono, Taiho and Teijin-Pharma, personal fees for lecturing and advisory board work from Astellas, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kyorin, Merck Sharp & Dohme, Novartis, Otsuka and Sanofi, outside the submitted work. Conflict of interest: F.W. Ko has nothing to disclose. Conflict of interest: J.A. Krishnan reports research grants from the US National Institutes of Health (current), research contracts from the US Patient Centered Outcomes Research Institute (current), and personal fees from Sanofi to serve on an independent data monitoring committee, outside the submitted work. Conflict of interest: M.L. Levy reports personal fees for consultancy from Clement Clarke International, personal fees for lecturing from Teva and Soar Beyond, personal fees for advisory board work from AstraZeneca, Orion Pharmaceuticals, GlaxoSmithKline and Trudel Pharmaceuticals, non-financial (travel) support from and is a board member of GINA, personal fees for data monitoring committee work and travel support from Chiesi, grants from Conzorcio Futuro In Ricerca, support for meeting attendance from Napp Pharmaceuticals, personal fees for consultancy from National Services for Health Improvement, a company providing services for practices (Nurse asthma reviews), personal fees for lecturing and advisory board work from Novartis Pharmaceuticals, and support from Whole Systems Integrated Care (WSIC) for whom M.L. Levy is lead on asthma and joint lead for COPD in developing dashboards for clinical care for general practitioners in London, outside the submitted work. Conflict of interest: J. Lin has nothing to disclose. Conflict of interest: S.E. Pedersen reports personal fees for lectures and consultancy from Astrazeneca, personal fees for consultancy from ALK and Thermofisher, outside the submitted work. Conflict of interest: A. Sheikh reports support for meeting attendance from GSK, grants from Asthma UK, and other support from the Scottish Allergy and Respiratory Academy (a not-for-profit training initiative for health care professionals supported by a consortium of industry funders), outside the submitted work. Conflict of interest: A. Yorgancioglu reports grants from MSD, personal fees for advisory board work from GSK, personal fees for advisory board work and lecturing from AstraZeneca, Abdi İbrahim, Chiesi, Novartis and Sandoz, outside the submitted work. Conflict of interest: L-P. Boulet reports research grants for participation in multicentre studies from AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi and Takeda; support for research projects from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Takeda; fees for consulting and advisory board work from AstraZeneca, Novartis and Methapharm; royalties as co-author of “Up-To-Date” (occupational asthma); nonprofit grants for production of educational materials from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Frosst and Novartis; conference fees from AstraZeneca, GlaxoSmithKline, Merck and Novartis; support for participation in conferences and meetings from Novartis and Takeda; is past president and member of the Canadian Thoracic Society Respiratory Guidelines Committee; Chair of the Board of Directors of the Global Initiative for Asthma (GINA); Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health; member of scientific committees for the American College of Chest Physicians, American Thoracic Society, European Respiratory Society and the World Allergy Organization; 1st Vice-President of the Global Asthma Organization “InterAsma”.",,"Helen K Reddel 1 , J Mark FitzGerald 2 , Eric D Bateman 3 , Leonard B Bacharier 4 , Allan Becker 5 , Guy Brusselle 6 , Roland Buhl 7 , Alvaro A Cruz 8 , Louise Fleming 9 , Hiromasa Inoue 10 , Fanny Wai-San Ko 11 , Jerry A Krishnan 12 , Mark L Levy 13 , Jiangtao Lin 14 , Søren E Pedersen 15 , Aziz Sheikh 16 , Arzu Yorgancioglu 17 , Louis-Philippe Boulet 18"
31248954,Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry,"Yunus Çolak 1 2 3, Børge G Nordestgaard 1 2 3, Jørgen Vestbo 4, Peter Lange 2 3 5 6, Shoaib Afzal 7 2 3",Eur Respir J. 2019 Sep 19;54(3):1900734. doi: 10.1183/13993003.00734-2019. Print 2019 Sep.,Çolak Y,Eur Respir J,2019,2019/06/29,,,10.1183/13993003.00734-2019,https://pubmed.ncbi.nlm.nih.gov/31248954/,/31248954/,"Conflict of interest: Y. Çolak reports personal fees from Boehringer Ingelheim and AstraZeneca outside the submitted work. Conflict of interest: B.G. Nordestgaard has nothing to disclose. Conflict of interest: J. Vestbo reports personal fees for consultancy from GlaxoSmithKline, Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis, Almirall, AstraZeneca and Bioxydyn, personal fees for lecturing from GlaxoSmithKline, Chiesi Pharmaceuticals, Novartis, AstraZeneca, Boehringer Ingelheim, outside the submitted work. Conflict of interest: P. Lange reports grants and personal fees from Almirall, Boehringer Ingelheim and GlaxoSmithKline, personal fees from AstraZeneca, Novartis, Nycomed, Pfizer and Mundipharma, outside the submitted work. Conflict of interest: S. Afzal has nothing to disclose.",,"Yunus Çolak 1 2 3 , Børge G Nordestgaard 1 2 3 , Jørgen Vestbo 4 , Peter Lange 2 3 5 6 , Shoaib Afzal 7 2 3"
31560179,Validation of a self-completed Dystonia Non-Motor Symptoms Questionnaire,"Lisa Klingelhoefer 1, Kallol R Chaudhuri 2, Christoph Kamm 3 4, Pablo Martinez-Martin 5, Kailash Bhatia 6, Anna Sauerbier 2, Maximilian Kaiser 1, Carmen Rodriguez-Blazquez 5, Bettina Balint 6 7, Robert Untucht 1, Lynsey J Hall 2, Lauritz Mildenstein 3, Miriam Wienecke 1, Davide Martino 8, Olaf Gregor 9, Alexander Storch 3 4, Heinz Reichmann 1",Ann Clin Transl Neurol. 2019 Oct;6(10):2054-2065. doi: 10.1002/acn3.50900. Epub 2019 Sep 27.,Klingelhoefer L,Ann Clin Transl Neurol,2019,2019/09/28,PMC6801169,,10.1002/acn3.50900,https://pubmed.ncbi.nlm.nih.gov/31560179/,/31560179/,"Financial Disclosure/Conflict of Interest concerning the research related to the manuscript: None of the authors reports a financial disclosure/conflict of interest concerning the research performed in this study. Funding sources for this study: None. Financial Disclosures of all authors (for the preceding 12 months) ‐ Information concerning all sources of financial support and funding, regardless of relationship to current manuscript: Lisa Klingelhoefer reports academic grants from EU Horizon 2020, honoraria for lectures from Berlin Partner für Wirtschaft und Technologie GmbH and Desitin. K Ray Chaudhuri reports: Advisory board: AbbVie, UCB, Sunovion, Pfizer, Jazz Pharma, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion. Honoraria for lectures: AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim Neuroderm, Sunovion. Investigator initiated grants: Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial. Aacdemic grants: EU, IMI EU, Parkinsons UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC. K Ray Chaudhuri and Anna Sauerbier acknowledge independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Christoph Kamm has received honoraria for presentations/lectures and travel grants from Merz Pharmaceuticals. Pablo Martinez‐Martin: Honoraria: from National School of Public Health (ISCIII) and Editorial Viguera for lecturing in courses; International Parkinson and Movement Disorder Society for management of the Program on Rating Scales; Air Liquide, Abbvie, Zambon, and HM Hospitales de Madrid for advice in clinical‐epidemiological studies. License fee payments for the King’s Parkinson’s Disease Pain scale. Kailash Bhatia: to be added. Anna Sauerbier reports grants from Parkinson’s UK and Kirby Laing, consultancy and speaker related fees from Britannia, UCB and Bial. Carmen Rodriguez‐Blazquez: financial support from Abbvie for attending national and international meetings. Bettina Balint is supported by the Robert Bosch Foundation. Robert Untucht received a grant from the Stiftung Hochschulmedizin (medical university foundation) in Dresden and discloses support by Merz Pharma and Ipsen for travel costs to conferences. Davide Martino: Honoraria for consultancies from Allergan. Grant research support from Parkinson Association of Alberta. Alexander Storch has received funding from the Deutsche Forschungsgemeinschaft (DFG) and the Helmholtz‐Association; received honoraria for presentations/lectures/consultancies or advisory boards from Desitin, Grünenthal, UCB, Messe Bremen, and AbbVie. He has served on the editorial boards of Stem Cells and Stem Cells International.Heinz Reichmann was acting on Advisory Boards and gave lectures and received research grants from Abbott, Abbvie, Bayer Health Care, Bial, Boehringer/Ingelheim, Brittania, Cephalon, Desitin, GSK, Lundbeck, Medtronic, Merck‐Serono, Novartis, Orion, Pfizer, TEVA, UCB Pharma, Valeant, and Zambon. Maximilian Kaiser, Lynsey J. Hall, Lauritz Mildenstein, Miriam Wienecke and Olaf Gregor report no financial disclosures.",,"Lisa Klingelhoefer 1 , Kallol R Chaudhuri 2 , Christoph Kamm 3 4 , Pablo Martinez-Martin 5 , Kailash Bhatia 6 , Anna Sauerbier 2 , Maximilian Kaiser 1 , Carmen Rodriguez-Blazquez 5 , Bettina Balint 6 7 , Robert Untucht 1 , Lynsey J Hall 2 , Lauritz Mildenstein 3 , Miriam Wienecke 1 , Davide Martino 8 , Olaf Gregor 9 , Alexander Storch 3 4 , Heinz Reichmann 1"
31023700,Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables,"Andrew W Roberts 1 2 3 4, Shuo Ma 5, Thomas J Kipps 6, Steven E Coutre 7, Matthew S Davids 8, Barbara Eichhorst 9, Michael Hallek 10, John C Byrd 11, Kathryn Humphrey 12, Lang Zhou 13, Brenda Chyla 13, Jacqueline Nielsen 13, Jalaja Potluri 13, Su Young Kim 13, Maria Verdugo 13, Stephan Stilgenbauer 14, William G Wierda 15, John F Seymour 1 2 4",Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.,Roberts AW,Blood,2019,2019/04/27,PMC6624969,,10.1182/blood.2018882555,https://pubmed.ncbi.nlm.nih.gov/31023700/,/31023700/,"Conflict-of-interest disclosure: A.W.R. received research funding from AbbVie and Janssen; is an employee of the Walter and Eliza Hall Institute of Medical Research, which receives milestone and royalty payments related to venetoclax (employees of Walter and Eliza Hall Institute also may be eligible for financial benefits related to these payments); and receives a financial benefit as a result of previous research related to venetoclax. S.M. received research funding from AbbVie, Pharmacyclics, Novartis, Gilead, Acerta, and Incyte; is an advisory board member for AbbVie, AstraZeneca, Genentech, Gilead, Janssen, Pharmacyclics; and provides lecturing for Genentech, Pharmacyclics, and Janssen. T.J.K. is a consultant and received research funding from AbbVie. S.E.C. received research funding from AbbVie, Gilead, and Pharmacyclics. M.S.D. is a consultant and/or advisory board member for AbbVie, Genentech, Roche, Pharmacyclics, Janssen, Gilead, Verastem, TG Therapeutics, Acerta, Astra-Zeneca, Sunesis, and MEI Pharma and received institutional research funding from Genentech, Pharmacyclics, TG Therapeutics, Surface Oncology, and Bristol-Myers Squibb. B.E. received research funding, honoraria (consultant or advisory board member), and travel support from AbbVie, Celgene, Gilead, Janssen, Mundipharma, Novartis, and Roche. M.H. received research funding from GlaxoSmithKline, Mundipharma, Janssen, Celgene, Gilead, AbbVie, and Roche, and is a consultant and advisory board member for AbbVie, Roche, and Genentech. J.C.B. received clinical trial support from Pharmacyclics and Acerta and is an unpaid consultant for Genentech, AbbVie, Acerta, Pharmacyclics, and the Leukemia and Lymphoma Society LLC. K.H. is an employee of Roche and may own Roche stock or options. L.Z., B.C., J.N., J.P., S.Y.K., and M.V. are employees of AbbVie and may hold stock or stock options. S.S. received research funding, honoraria (consultant or advisory board member), and travel support from AbbVie, Amgen, Boehringer-Ingelheim, Celgene, Genentech, Genzyme, Gilead, GSK, Janssen, Mundipharma, Novartis, Pharmacyclics, Hoffmann La-Roche, and Sanofi. W.G.W. received research funding from AbbVie and Genentech. J.F.S. received research funding from AbbVie and Genentech and is a consultant and advisory board member to Roche and Genentech.",,"Andrew W Roberts 1 2 3 4 , Shuo Ma 5 , Thomas J Kipps 6 , Steven E Coutre 7 , Matthew S Davids 8 , Barbara Eichhorst 9 , Michael Hallek 10 , John C Byrd 11 , Kathryn Humphrey 12 , Lang Zhou 13 , Brenda Chyla 13 , Jacqueline Nielsen 13 , Jalaja Potluri 13 , Su Young Kim 13 , Maria Verdugo 13 , Stephan Stilgenbauer 14 , William G Wierda 15 , John F Seymour 1 2 4"
31373259,Long-term follow up after endoscopic valve therapy in patients with severe emphysema,"Daniela Gompelmann 1, Tobias Heinhold 2, Matthias Rötting 2, Elena Bischoff 2, Konstantina Kontogianni 3, Ralf Eberhardt 3, Felix J F Herth 3",Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619866101. doi: 10.1177/1753466619866101.,Gompelmann D,Ther Adv Respir Dis,2019,2019/08/03,PMC6681249,,10.1177/1753466619866101,https://pubmed.ncbi.nlm.nih.gov/31373259/,/31373259/,"Conflict of interest statement: DG: Lecture and travel fees from Pulmonx, Olympus, Chiesi, Boehringer Ingelheim, Novartis, Astra Zeneca, Mundipharma, Berlin Chemie and Grifols. TH: No conflicts of interest. MR: No conflicts of interest. EB: No conflicts of interest. KK: No conflicts of interest. RE: Lecture and travel fees from Olympus, Pulmonx and Uptake Medical. FH: Fees for lectures and advisory boards from Astra, Allmirall, Berlin Chemie, Boehringer, Roche, GSK, Pulmonx, BTG, Olympus, PneumRx, Boston Scientific, Medupdate, Grifols, CSL Behring, Omniamed, Lilly, Novartis, Teva, Uptake and Vital Air.",,"Daniela Gompelmann 1 , Tobias Heinhold 2 , Matthias Rötting 2 , Elena Bischoff 2 , Konstantina Kontogianni 3 , Ralf Eberhardt 3 , Felix J F Herth 3"
31417680,"Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects","Karsten Roth 1, Dirk Lehnick 2, Hendrik Wessels 1, Josef Höfler 3, Barbara Gastl 1, Ruediger Jankowsky 1",Pharmacol Res Perspect. 2019 Aug 13;7(5):e00503. doi: 10.1002/prp2.503. eCollection 2019 Oct.,Roth K,Pharmacol Res Perspect,2019,2019/08/17,PMC6691757,,10.1002/prp2.503,https://pubmed.ncbi.nlm.nih.gov/31417680/,/31417680/,"This study was funded by Cinfa Biotech, now part of the Mundipharma network of independent associated companies. KR, HW, and RJ are employees of Cinfa Biotech, now part of the Mundipharma network of independent associated companies. At the time of the study, BG was an employee of Cinfa Biotech. JH is an employee of Staburo GmbH. DL is an employee of the University of Lucerne.",,"Karsten Roth 1 , Dirk Lehnick 2 , Hendrik Wessels 1 , Josef Höfler 3 , Barbara Gastl 1 , Ruediger Jankowsky 1"
31827323,An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD,"Dave Singh 1, Anthony D DUrzo 2, James F Donohue 3, Edward M Kerwin 4, Eduard Molins 5, Ferran Chuecos 5, Anna Ribera 5, Diana Jarreta 5",Int J Chron Obstruct Pulmon Dis. 2019 Dec 6;14:2835-2848. doi: 10.2147/COPD.S217710. eCollection 2019.,Singh D,Int J Chron Obstruct Pulmon Dis,2019,2019/12/13,PMC6902852,,10.2147/COPD.S217710,https://pubmed.ncbi.nlm.nih.gov/31827323/,/31827323/,"DS is supported by the NIHR Manchester Biomedical Research Centre; and has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A, Cipla, Genentech, GlaxoSmithKline, Glenmark, Johnson & Johnson, Mundipharma, Novartis, Peptinnovate Ltd., Pfizer Inc, Pulmatrix, Skyepharma, Teva, Theravance Biopharma, Menarini, and Verona Pharma. ADD has received research, consulting, and lecturing fees from Almirall, Altana, AstraZeneca, Boehringer Ingelheim (Canada) Ltd, Forest Laboratories, GlaxoSmithKline, KOS Pharmaceuticals, Merck Canada, Methapharm, Novartis Canada/USA, ONO Pharmaceutical Co., Pfizer Canada, Schering-Plough, Sepracor, and SkyePharma. JFD has received consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, GSK, Mylan, Theravance, and Sunovion. He is a member of the Data Monitoring Committee for AstraZeneca. EMK has participated in consulting, advisory boards, speaker panels, or received travel reimbursement from Amphastar Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Cipla, Chesi, Forest Laboratories LLC, GSK, Mylan, Novartis, Oriel, Pearl, Sunovion, Teva Pharmaceutical Industries Ltd., and Theravance Biopharma. He has conducted multicenter clinical research trials for ~40 pharmaceutical companies. EM, FC, and DJ are employees of AstraZeneca and former employees of Almirall S.A., Barcelona, Spain. AR is a former employee of Almirall S.A., Barcelona, Spain and was an employee of AstraZeneca at the time the study was conducted. The authors report no other conflicts of interest in this work.",,"Dave Singh 1 , Anthony D DUrzo 2 , James F Donohue 3 , Edward M Kerwin 4 , Eduard Molins 5 , Ferran Chuecos 5 , Anna Ribera 5 , Diana Jarreta 5"
31286970,Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective,"Dave Singh 1, Anthony D DUrzo 2, James F Donohue 3, Edward M Kerwin 4",Respir Res. 2019 Jul 8;20(1):141. doi: 10.1186/s12931-019-1108-9.,Singh D,Respir Res,2019,2019/07/10,PMC6615221,,10.1186/s12931-019-1108-9,https://pubmed.ncbi.nlm.nih.gov/31286970/,/31286970/,"DS has received research, consulting and lecturing fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Therevance, and Verona. AD has received research, consulting and lecturing fees from Boehringer Ingelheim (Canada), and Novartis Canada. JD has received research, consulting and lecturing fees from AstraZeneca, GSK, Mylan, Sunovion, and Theravance. EK has received research, consulting and lecturing fees from Amphastar, AstraZeneca, Boehringer Ingelheim, Crisor LLC Research, GlaxoSmithKline, Mylan, Novartis, Oriel, Pearl, Sunovion, Teva, and Theravance.",Grants and funding N/A/AstraZeneca,"Dave Singh 1 , Anthony D DUrzo 2 , James F Donohue 3 , Edward M Kerwin 4"
30765505,Artificial intelligence outperforms pulmonologists in the interpretation of\xa0pulmonary function tests,"Marko Topalovic 1, Nilakash Das 1, Pierre-Régis Burgel 2, Marc Daenen 3, Eric Derom 4, Christel Haenebalcke 5, Rob Janssen 6, Huib A M Kerstjens 7, Giuseppe Liistro 8, Renaud Louis 9, Vincent Ninane 10, Christophe Pison 11, Marc Schlesser 12, Piet Vercauter 13, Claus F Vogelmeier 14, Emiel Wouters 15, Jokke Wynants 16 17, Wim Janssens 1 ; Pulmonary Function Study Investigators; Pulmonary Function Study Investigators:",Eur Respir J. 2019 Apr 11;53(4):1801660. doi: 10.1183/13993003.01660-2018. Print 2019 Apr.,Topalovic M,Eur Respir J,2019,2019/02/16,,,10.1183/13993003.01660-2018,https://pubmed.ncbi.nlm.nih.gov/30765505/,/30765505/,"Conflict of interest: M. Topalovic has nothing to disclose. Conflict of interest: N. Das has nothing to disclose. Conflict of interest: P-R. Burgel reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, Teva and Vertex, outside the submitted work. Conflict of interest: M. Daenen has nothing to disclose. Conflict of interest: E. Derom has nothing to disclose. Conflict of interest: C. Haenebalcke reports personal fees from Novartis, Chiesi, GSK and AstraZeneca, outside the submitted work. Conflict of interest: R. Janssen has nothing to disclose. Conflict of interest: H.A.M. Kerstjens has nothing to disclose. Conflict of interest: G. Liistro has nothing to disclose. Conflict of interest: R. Louis reports grants and personal fees from GSK and Novartis, personal fees from AstraZeneca, and grants from Chiesi, outside the submitted work. Conflict of interest: V. Ninane has nothing to disclose. Conflict of interest: C. Pison has nothing to disclose. Conflict of interest: M. Schlesser has nothing to disclose. Conflict of interest: P. Vercauter has nothing to disclose. Conflict of interest: C.F. Vogelmeier reports personal fees from Almirall, Cipla, Berlin-Chemie/Menarini, CSL Behring and Teva, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Grifols, Mundipharma, Novartis and Takeda, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work. Conflict of interest: E. Wouters reports personal fees for board membership from Nycomed and Boehringer, grants from AstraZeneca and GSK, and personal fees for lectures from AstraZeneca, GSK, Novartis and Chiesi, outside the submitted work. Conflict of interest: J. Wynants has nothing to disclose. Conflict of interest: W. Janssens has nothing to disclose.",,"Marko Topalovic 1 , Nilakash Das 1 , Pierre-Régis Burgel 2 , Marc Daenen 3 , Eric Derom 4 , Christel Haenebalcke 5 , Rob Janssen 6 , Huib A M Kerstjens 7 , Giuseppe Liistro 8 , Renaud Louis 9 , Vincent Ninane 10 , Christophe Pison 11 , Marc Schlesser 12 , Piet Vercauter 13 , Claus F Vogelmeier 14 , Emiel Wouters 15 , Jokke Wynants 16 17 , Wim Janssens 1 ; Pulmonary Function Study Investigators; Pulmonary Function Study Investigators:"
31313272,A Patient-Centered Description of Severe Asthma: Patient Understanding Leading to Assessment for a Severe Asthma Referral (PULSAR),"Tonya A Winders 1, Andrew M Wilson 2 3 4, Monica J Fletcher 4 5, Anthony McGuinness 6, David B Price 7 8 9",Patient. 2019 Oct;12(5):539-549. doi: 10.1007/s40271-019-00371-0.,Winders TA,Patient,2019,2019/07/18,PMC6697753,,10.1007/s40271-019-00371-0,https://pubmed.ncbi.nlm.nih.gov/31313272/,/31313272/,"TAW is the elected president (voluntary position) of the Global Allergy Asthma Patient Platform, which is a charity. MJF is an employee of GSK, owns stocks/shares in GSK, and is an honorary research fellow at Asthma UK Centre for Applied Research, The University of Edinburgh. AM is a patient advisor for Asthma UK Centre for Applied Research and receives travel and accommodation expenses from AstraZeneca for a voluntary role in a Patient Partnership Program. DBP is an employee of Observational and Pragmatic Research Institute, Singapore, Singapore and Optimum Patient Care Ltd, Oakington, Cambridge, UK. DBP has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrollment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. AMW is an employee at the University of East Anglia and Norfolk and Norwich University Hospital, Norwich, UK. All authors received honoraria and travel costs for attending the PULSAR working group meeting.",,"Tonya A Winders 1 , Andrew M Wilson 2 3 4 , Monica J Fletcher 4 5 , Anthony McGuinness 6 , David B Price 7 8 9"
31584681,Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease,"David E Kleiner 1, Elizabeth M Brunt 2, Laura A Wilson 3, Cynthia Behling 4, Cynthia Guy 5, Melissa Contos 6, Oscar Cummings 7, Matthew Yeh 8, Ryan Gill 9, Naga Chalasani 10, Brent A Neuschwander-Tetri 11, Anna Mae Diehl 12, Srinivasan Dasarathy 13, Norah Terrault 14, Kris Kowdley 15, Rohit Loomba 16, Patricia Belt 3, James Tonascia 3 17, Joel E Lavine 18, Arun J Sanyal 19 ; Nonalcoholic Steatohepatitis Clinical Research Network",JAMA Netw Open. 2019 Oct 2;2(10):e1912565. doi: 10.1001/jamanetworkopen.2019.12565.,Kleiner DE,JAMA Netw Open,2019,2019/10/05,PMC6784786,,10.1001/jamanetworkopen.2019.12565,https://pubmed.ncbi.nlm.nih.gov/31584681/,/31584681/,"Conflict of Interest Disclosures: Dr Brunt reported receiving grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) during the conduct of the study; and is a consulted for Arix, Cymabay, NGM, and Roth Capital Partners outside the submitted work. Ms Wilson reported receiving grants from NIDDK during the conduct of the study. Dr Behling reported receiving grants from the NIDDK during the conduct of the study; and is a consultant for ICON, COVANCE, Eli Lilly, Hologic, and Leica outside the submitted work. Dr Guy reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study and personal fees from CymaBay, NGM Biopharmaceuticals, Madrigal, and Immuron outside the submitted work. Dr Cummings reported receiving grants from the NIDDK during the conduct of the study and is a consultant for Novo-Nordisk outside the submitted work. Dr Gill reported grants from the NIH/NIDDK during the conduct of the study. Dr Chalasani reported receiving personal fees from AbbVie, Shire, Madrigal, Allergan, NuSirt, Afimmune, Siemens, and Genentech, and grants from Exact Sciences, Galectin Therapeutics, and Intercept during the conduct of the study. Dr Neuschwander-Tetri reported receiving grants from the NIDDK during the conduct of the study; grants and personal fees from Allergan, Bristol-Myers Squibb, Enanta, Gilead, Intercept, Madrigal, NGM, and Prometheus; personal fees from Arrowhead, ARTham, Blade, Boehringer Ingleheim, Coherus, Consynance, Durect, Fortress, Gelesis, Lipocine, Medimmune, Merck, Metacrine, Mundipharma, pH-Pharma, Siemens, Karos, and Lexicon; and grants from Cirius, Cymabay, Galectin, and Genfit outside the submitted work. Dr Dasarathy reported receiving grants from the NIH during the conduct of the study. Dr Kowdley reported receiving grants from the NIDDK during the conduct of the study; grants and personal fees from Allergan, Conatus, Enanta, Gilead, Intercept, Merck, NGM, and Biopharma; personal fees from Corcept, Oxford Pharmagenesis, IQVIA Inc, and Verylx; and grants from Galectin, Immuron, and Prometheus outside the submitted work. Ms Belt reported receiving grants from the NIDDK during the conduct of the study. Dr Tonascia reported receiving grants from the NIDDK during the conduct of the study and grants from the National Heart, Lung, and Blood Institute, and National Institute on Aging outside the submitted work. Dr Lavine reported receiving personal fees from Merck, TARGET, Pippin, Novartis, Janssen, Gilead, Bristol-Myers Squibb, and Viking outside the submitted work. Dr Sanyal reported receiving grants from the NIDDK during the conduct of the study, and receiving grants from Bristol-Myers Squibb, Conatus, Galectin, Gilead, Mallinckrodt, Novartis, Salix, and Sequana, serving as president of Sanyal Bio; having stock options in Akarna, Durect, Genfit, Indalo, and Tiziana; serving as a consultant to Ardelyx, Birdrock, Boehringer Ingelheim, ENYO, Exhalenz, GenFit, Hemoshear, Janssen, Lilly, Merck, Nimbus, Nitto Denko, Novo Nordisk, Pfizer, Takeda, Terns, Surrozen, Siemens, Poxel, 89 Bio, and BASF; being an unpaid consultant to Affimmune, Albireo, Chemomab, Ecosens-Sandhill, Fractyl, Immuron, Intercept, and Zydus; and receiving royalties from Elsevier and UpToDate outside the submitted work; and having ongoing unpaid active research collaborations with AMRA, Perspectum, Antaros, Second Genome, and OWL. No other disclosures were reported.",Grants and funding U01 DK061731/DK/NIDDK NIH HHS/United States UL1 TR000006/TR/NCATS NIH HHS/United States UL1 TR000058/TR/NCATS NIH HHS/United States UL1 TR000436/TR/NCATS NIH HHS/United States U01 DK061728/DK/NIDDK NIH HHS/United States UL1 TR000439/TR/NCATS NIH HHS/United States UL1 TR002319/TR/NCATS NIH HHS/United States U01 DK061734/DK/NIDDK NIH HHS/United States U01 DK061737/DK/NIDDK NIH HHS/United States U01 DK061713/DK/NIDDK NIH HHS/United States U01 DK061732/DK/NIDDK NIH HHS/United States UL1 TR002548/TR/NCATS NIH HHS/United States U01 DK061718/DK/NIDDK NIH HHS/United States UL1 TR001442/TR/NCATS NIH HHS/United States U01 DK061730/DK/NIDDK NIH HHS/United States U24 DK061730/DK/NIDDK NIH HHS/United States U01 DK061738/DK/NIDDK NIH HHS/United States UL1 TR000448/TR/NCATS NIH HHS/United States UL1 TR000423/TR/NCATS NIH HHS/United States UL1 TR000100/TR/NCATS NIH HHS/United States UL1 TR002345/TR/NCATS NIH HHS/United States UL1 TR000004/TR/NCATS NIH HHS/United States Show all 22 grants,"David E Kleiner 1 , Elizabeth M Brunt 2 , Laura A Wilson 3 , Cynthia Behling 4 , Cynthia Guy 5 , Melissa Contos 6 , Oscar Cummings 7 , Matthew Yeh 8 , Ryan Gill 9 , Naga Chalasani 10 , Brent A Neuschwander-Tetri 11 , Anna Mae Diehl 12 , Srinivasan Dasarathy 13 , Norah Terrault 14 , Kris Kowdley 15 , Rohit Loomba 16 , Patricia Belt 3 , James Tonascia 3 17 , Joel E Lavine 18 , Arun J Sanyal 19 ; Nonalcoholic Steatohepatitis Clinical Research Network"
30962876,The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies,"Jonathan D Campbell 1, Robert Perry 1, Nikolaos G Papadopoulos 2 3, Jerry Krishnan 4 5, Guy Brusselle 6 7, Alison Chisholm 8, Leif Bjermer 9, Michael Thomas 10, Eric van Ganse 11, Maarten van den Berge 12, Jennifer Quint 13, David Price 14 15, Nicolas Roche 16",Clin Transl Allergy. 2019 Mar 27;9:21. doi: 10.1186/s13601-019-0256-9. eCollection 2019.,Campbell JD,Clin Transl Allergy,2019,2019/04/10,PMC6436213,,10.1186/s13601-019-0256-9,https://pubmed.ncbi.nlm.nih.gov/30962876/,/30962876/,"JC -discloses prior Respiratory Effectiveness Group funding related to this study and has no other conflicts of interests to declare in association with this manuscript. RP has- no conflicts of interest to disclose. NP reports grants from Gerolymatos, personal fees from Hal Allergy B.V., personal fees from Novartis Pharma AG, personal fees from Menarini, personal fees from Hal Allergy B.V., personal fees from Mylan, outside the submitted work. JK has research funding from the U.S. National Institutes of Health and the U.S. Patient Centered Outcomes Research Institute paid to the University for investigator-initiated research. JK does not serve on advisory boards or have other potential conflicts of interest. GB has, within the last 5 years, received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva; he is a member of advisory boards for AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron and Teva. AC and RP have no conflicts of interest to declare in relation to these papers. LB reports no perceived COI. MT nor any member of his close family has any shares in pharmaceutical companies. In the last 3 years he has received speaker’s honoraria for speaking at sponsored meetings or satellite symposia at conferences from the following companies marketing respiratory and allergy products: Aerocrine, GSK, Novartis. He has received honoraria for attending advisory panels with; Aerocrine, Boehringer Inglehiem, GSK, MSD, Novartis, Pfizer. He is a recent a member of the BTS SIGN Asthma guideline steering group and the NICE Asthma Diagnosis and Monitoring guideline development group. EVG reports grants and personal fees from ALK ABELLO, grants and personal fees from Bayer, grants and personal fees from BMS, grants and personal fees from GlaxoSmithKline, grants and personal fees from Merck Sharp and Dohme, personal fees from PELyon, outside the submitted work. MB reports grants from GlaxoSmithKline, TEVA, Chiesi, Genentech, outside the submitted work. JQ’s research group has received funding from The Health Foundation, MRC, Wellcome Trust, BLF, GSK, Insmed, AZ, Bayer and BI for other projects, none of which relate to this work. Dr Quint has received funds from AZ, GSK, Chiesi, Teva and BI for Advisory board participation or travel. DP has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. NR reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, personal fees from Teva, personal fees from GSK, personal fees from AstraZeneca, personal fees from Chiesi, personal fees from Mundipharma, personal fees from Cipla, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Sandoz, personal fees from 3 M, personal fees from Zambon, outside the submitted work.",Grants and funding WT_/Wellcome Trust/United Kingdom,"Jonathan D Campbell 1 , Robert Perry 1 , Nikolaos G Papadopoulos 2 3 , Jerry Krishnan 4 5 , Guy Brusselle 6 7 , Alison Chisholm 8 , Leif Bjermer 9 , Michael Thomas 10 , Eric van Ganse 11 , Maarten van den Berge 12 , Jennifer Quint 13 , David Price 14 15 , Nicolas Roche 16"
31131514,Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences,"Joanne Neale 1 2, Charlotte N E Tompkins 1, John Strang 1 2",Drug Alcohol Rev. 2019 Jul;38(5):510-518. doi: 10.1111/dar.12939. Epub 2019 May 26.,Neale J,Drug Alcohol Rev,2019,2019/05/28,PMC6772117,,10.1111/dar.12939,https://pubmed.ncbi.nlm.nih.gov/31131514/,/31131514/,"JN has received honoraria and research grants from pharmaceutical companies: Camurus AB and Mundipharma International Ltd. JS is a researcher and clinician who has worked with a range of types of treatment and rehabilitation service‐providers. He has also worked with a range of governmental and non‐governmental organisations, and with pharmaceutical companies to seek to identify new or improved treatments from whom he and his employer (Kings College London) have received honoraria, travel costs and/or consultancy payments. This has included discussions with Camurus AB, Indivior and Molteni Farma (all three of whom have developed ultra‐long‐acting buprenorphine formulations) and also an oversight role for the UK part of a safety trial of CAM2038/Buvidal®, the product discussed in this paper. For a fuller account, see John Strangs web‐page at: http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. Charlotte Tompkins received salary support from Camurus AB whilst undertaking this study.",,"Joanne Neale 1 2 , Charlotte N E Tompkins 1 , John Strang 1 2"
31221808,Circadian rhythm of exhaled biomarkers in health and asthma,"Maxim Wilkinson 1, Robert Maidstone 2 3 4, Andrew Loudon 5, John Blaikley 1 6, Iain R White 1 7, Dave Singh 1 8, David W Ray 2 3, Royston Goodacre 9 10, Stephen J Fowler 1 6, Hannah J Durrington 11",Eur Respir J. 2019 Oct 17;54(4):1901068. doi: 10.1183/13993003.01068-2019. Print 2019 Oct.,Wilkinson M,Eur Respir J,2019,2019/06/22,PMC6796150,,10.1183/13993003.01068-2019,https://pubmed.ncbi.nlm.nih.gov/31221808/,/31221808/,"Conflict of interest: M. Wilkinson reports no conflicts of interest. Conflict of interest: R. Maidstone has nothing to disclose. Conflict of interest: A. Loudon has nothing to disclose. Conflict of interest: J. Blaikley reports grants from the Medical Research Council, during the conduct of the study. Conflict of interest: I.R. White has nothing to disclose. Conflict of interest: D. Singh reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, and personal fees from Cipla, Genentech and Peptinnovate, outside the submitted work. Conflict of interest: D.W. Ray has nothing to disclose. Conflict of interest: R. Goodacre has nothing to disclose. Conflict of interest: S.J. Fowler reports personal fees and non-financial support from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Novartis, Teva and Chiesi, outside the submitted work. Conflict of interest: H.J. Durrington has nothing to disclose.",Grants and funding WT_/Wellcome Trust/United Kingdom MR/L006499/1/MRC_/Medical Research Council/United Kingdom MR/P023576/1/MRC_/Medical Research Council/United Kingdom MR/P023576/2/MRC_/Medical Research Council/United Kingdom,"Maxim Wilkinson 1 , Robert Maidstone 2 3 4 , Andrew Loudon 5 , John Blaikley 1 6 , Iain R White 1 7 , Dave Singh 1 8 , David W Ray 2 3 , Royston Goodacre 9 10 , Stephen J Fowler 1 6 , Hannah J Durrington 11"
31826282,Appendicectomy prior to colectomy in ulcerative colitis?,Ulf Helwig 1,Z Gastroenterol. 2019 Dec;57(12):1514. doi: 10.1055/a-0970-2291. Epub 2019 Dec 11.,Helwig U,Z Gastroenterol,2019,2019/12/12,,,10.1055/a-0970-2291,https://pubmed.ncbi.nlm.nih.gov/31826282/,/31826282/,"U. Helwig hat Honorare für Vorträge und/oder Beratung von folgenden Firmen erhalten: AbbVie, Celltrion, Biogen, Amgen, MSD, Ferring, Falk Foundation, Janssen, Norgine, Pfizer, Takeda, Mundipharma, Hospira, Vifor Pharma",,Ulf Helwig 1
31488585,Inhaled corticosteroids and pneumonia mortality in COPD patients,"Pere Almagro 1, Pablo Martinez-Camblor 2, Joan B Soriano 3 4",Eur Respir J. 2019 Sep 5;54(3):1901035. doi: 10.1183/13993003.01035-2019. Print 2019 Sep.,Almagro P,Eur Respir J,2019,2019/09/07,,,10.1183/13993003.01035-2019,https://pubmed.ncbi.nlm.nih.gov/31488585/,/31488585/,"Conflict of interest: P. Almagro reports grants from AstraZeneca and SEPAR, personal fees from Chiesi, Boehringer Ingelheim and GlaxoSmithKline, travel support from Rovi and Esteve, outside the submitted work. Conflict of interest: P. Martinez-Camblor has nothing to disclose. Conflict of interest: J.B. Soriano reports grants from Linde, travel support from Almirall, AstraZeneca, Boehringer Ingelheim, Chest, Chiesi, ERS, Gebro, Grifols, GSK, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda, outside the submitted work.",,"Pere Almagro 1 , Pablo Martinez-Camblor 2 , Joan B Soriano 3 4"
30923181,Transcriptomics of atopy and atopic asthma in white blood cells from children and adolescents,"Yale Jiang 1 2 3, Olena Gruzieva 4 3, Ting Wang 1, Erick Forno 1, Nadia Boutaoui 1, Tao Sun 5, Simon K Merid 4, Edna Acosta-Pérez 6, Inger Kull 4, Glorisa Canino 6, Josep M Antó 7, Jean Bousquet 8 9, Erik Melén 4 10, Wei Chen 1 10, Juan C Celedón 11 10",Eur Respir J. 2019 May 18;53(5):1900102. doi: 10.1183/13993003.00102-2019. Print 2019 May.,Jiang Y,Eur Respir J,2019,2019/03/30,PMC9336185,NIHMS1821820,10.1183/13993003.00102-2019,https://pubmed.ncbi.nlm.nih.gov/30923181/,/30923181/,"Conflict of interest: Y. Jiang has nothing to disclose. Conflict of interest: O. Gruzieva has nothing to disclose. Conflict of interest: T. Wang has nothing to disclose. Conflict of interest: E. Forno has nothing to disclose. Conflict of interest: N. Boutaoui has nothing to disclose. Conflict of interest: T. Sun has nothing to disclose. Conflict of interest: S.K. Merid has nothing to disclose. Conflict of interest: E. Acosta-Pérez has nothing to disclose. Conflict of interest: I. Kull has nothing to disclose. Conflict of interest: G. Canino has nothing to disclose. Conflict of interest: J.M. Antó has nothing to disclose. Conflict of interest: J. Bousquet reports personal fees for advisory board work, consultancy and lectures from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and owns shares in Kyomed, outside the submitted work. Conflict of interest: E. Melén has nothing to disclose. Conflict of interest: W. Chen has nothing to disclose. Conflict of interest: J.C. Celedón has received research materials from GSK, Merck and Pharmavite, outside the submitted work.",Grants and funding K08 HL125666/HL/NHLBI NIH HHS/United States R01 HL079966/HL/NHLBI NIH HHS/United States R01 HL117191/HL/NHLBI NIH HHS/United States R01 MD011764/MD/NIMHD NIH HHS/United States,"Yale Jiang 1 2 3 , Olena Gruzieva 4 3 , Ting Wang 1 , Erick Forno 1 , Nadia Boutaoui 1 , Tao Sun 5 , Simon K Merid 4 , Edna Acosta-Pérez 6 , Inger Kull 4 , Glorisa Canino 6 , Josep M Antó 7 , Jean Bousquet 8 9 , Erik Melén 4 10 , Wei Chen 1 10 , Juan C Celedón 11 10"
31624533,Clinically relevant effect of rupatadine 20\xa0mg and 10\xa0mg in seasonal allergic rhinitis: a pooled responder analysis,"Joaquim Mullol # 1 2 3 4, Iñaki Izquierdo # 5, Kimihiro Okubo 6, Giorgio Walter Canonica 7, Jean Bousquet 8, Antonio Valero 2 4 9",Clin Transl Allergy. 2019 Oct 9;9:50. doi: 10.1186/s13601-019-0293-4. eCollection 2019.,Mullol J,Clin Transl Allergy,2019,2019/10/19,PMC6784348,,10.1186/s13601-019-0293-4,https://pubmed.ncbi.nlm.nih.gov/31624533/,/31624533/,"Competing interestsJM has been member of national and international scientific advisory boards (consulting), received fees for lectures, and grants for research projects from Allakos, ALK-Abelló, Genentech-Roche, Glenmark, GSK, Hartington Pharmaceuticals, Menarini, MSD, Mylan-MEDA Pharma, Novartis, Sanofi-Genzyme-Regeneron, UCB, and Uriach Group. II is an employee of J Uriach y Compañía, S.A. KO received lecture fees from Tanabe Mitsubishi Co, Taiho Pharma, Meiji Pharma, and Torii Pharma. GWC reports having received in the last 3 years research grants as well as lecture or advisory board fees from: Menarini, ALK-Abelló, Allergy Therapeutics, AstraZeneca-Medimmune, Boehringer Ingelheim, Chiesi, Danone, Guidotti-Malesci, GSK, Hal Allergy, MSD, Mundipharma, Novartis, Orion, Sanofi-Genzyme-Regeneron, Stallergenes, Uriach group, and Valeas. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach group, other from KYomed-Innov. AV has previously received honoraria for speaking at sponsored meetings from Uriach group, GSK, AstraZeneca, Chiesi and Novartis, and is a consultant and grants for research for AstraZeneca, Menarini, Uriach group, Novartis, Mylan-MEDA Pharma and Sanofi.",,"Joaquim Mullol # 1 2 3 4 , Iñaki Izquierdo # 5 , Kimihiro Okubo 6 , Giorgio Walter Canonica 7 , Jean Bousquet 8 , Antonio Valero 2 4 9"
31564960,Co-crystals as a new approach to multimodal analgesia and the treatment of pain,"Carmen Almansa 1, Christopher S Frampton 2, José Miguel Vela 1, Steve Whitelock 3, Carlos R Plata-Salamán 4",J Pain Res. 2019 Sep 4;12:2679-2689. doi: 10.2147/JPR.S208082. eCollection 2019.,Almansa C,J Pain Res,2019,2019/10/01,PMC6732512,,10.2147/JPR.S208082,https://pubmed.ncbi.nlm.nih.gov/31564960/,/31564960/,"Carmen Almansa, José Miguel Vela, and Carlos R Plata-Salamán are employees of Esteve Pharmaceuticals S.A. Steve Whitelock is an employee of Mundipharma Research Ltd. Carlos R Plata-Salamán has been named as an inventor in a patent application filed by Laboratorios del Dr Esteve, S.A., entitled “Co-crystals of Tramadol and Coxibs (WO 2011044962). The authors report no other conflicts of interest in this work.",,"Carmen Almansa 1 , Christopher S Frampton 2 , José Miguel Vela 1 , Steve Whitelock 3 , Carlos R Plata-Salamán 4"
31297240,Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion,"Anna S Berghoff 1, Beatriz Bellosillo 2, Christophe Caux 3, Adrianus de Langen 4, Julien Mazieres 5, Nicola Normanno 6, Matthias Preusser 1, Mariano Provencio 7, Federico Rojo 8, Jurgen Wolf 9, Christoph C Zielinski 10 11",ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019.,Berghoff AS,ESMO Open,2019,2019/07/13,PMC6586213,,10.1136/esmoopen-2019-000498,https://pubmed.ncbi.nlm.nih.gov/31297240/,/31297240/,"Competing interests: ASB: Travel support: Daiichi Sankyo, Bristol-Meyers Squibb, Roche, Amgen, Merck, AbbVie; Research Support: Daiichi Sankyo; Advisory Board: Roche. BB: Travel support: Bristol-Meyers Squibb, Roche, Merck; Research support: Roche, Pfizer, Novartis; Advisory Board: Roche, Novartis; Speaker: AstraZeneca, Pfizer, Roche. AJdL: Related to this work: none; in general: Advisor for AstraZeneca, BMS, Boehringer, Pfizer, MSD, Roche; research grants from AstraZeneca, BMS, Merck-Serono, MSD, Roche. JM: Travel support: MSD, MSD, Roche; Research support: Roche, Astra-Zeneca; Advisory Board: Roche, MSD, BMS, Takeda, Astra-Zeneca, Pharmamar, Boehringer. NN: Personal financial interests (speaker’s fee and/or advisory boards): MSD, Qiagen, Biocartis, Incyte, Roche, BMS, MERCK, Thermofisher, Boehringer Ingelheim, Astrazeneca, Sanofi, Eli Lilly; Institutional financial interests (financial support to research projects): MERCK, Sysmex, Thermofisher, QIAGEN, Roche, Astrazeneca, Biocartis; non-financial interests: President, International Quality Network for Pathology (IQN Path); President Elect, Italian Cancer Society (SIC). MP: Personal fees from BMS, Astra Zeneca, Pierre Fabre, Roche, Novartis and Takeda. MP: Received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dome. FR: Travel support: Roche, Merck, Pfizer. Scientific advisor: Genomic Health, Roche, Guardant Health, Merck, Pfizer, Bristol-Meyers Squibb, Abbvie, Astra Zeneca, Novartis. JW: Advisory boards and lecture fees: Abbvie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Ignyta, Lilly, MSD, Novartis, Pfizer, Roche; research support (to institution): BMS, MSD, Novartis, Pfizer. CZ: Roche, Novartis, BMS, MSD, Imugene, Ariad, Pfizer, Merrimack/Shire, Merck KGaA, Fibrogen, AstraZeneca, Tesaro, Gilead, Servier, Eli Lilly, Amgen.",,"Anna S Berghoff 1 , Beatriz Bellosillo 2 , Christophe Caux 3 , Adrianus de Langen 4 , Julien Mazieres 5 , Nicola Normanno 6 , Matthias Preusser 1 , Mariano Provencio 7 , Federico Rojo 8 , Jurgen Wolf 9 , Christoph C Zielinski 10 11"
31626463,Festive use of nitrous oxide: major risks !,Yannick Auffret 1,Rev Prat. 2019 May;69(5):535-536.,Auffret Y,Rev Prat,2019,2019/10/19,,,,https://pubmed.ncbi.nlm.nih.gov/31626463/,/31626463/,"Y. Auffret déclare avoir été pris en charge lors de congrès par Aspen, Mundipharma, Daiichi Sankyo et AstraZeneca.",,Yannick Auffret 1
31576189,Management Of Community-Acquired Pneumonia: An Observational Study In UK Primary Care,"Naomi Launders 1, Dermot Ryan 2, Christopher C Winchester 3, Derek Skinner 4, Priyanka Raju Konduru 4, David B Price 4",Pragmat Obs Res. 2019 Sep 23;10:53-65. doi: 10.2147/POR.S211198. eCollection 2019.,Launders N,Pragmat Obs Res,2019,2019/10/03,PMC6765344,,10.2147/POR.S211198,https://pubmed.ncbi.nlm.nih.gov/31576189/,/31576189/,"CCW is an employee and Director of Oxford PharmaGenesis Ltd and a shareholder and Director of Oxford PharmaGenesis Holdings Ltd. DR is a Consultant Strategic Medical Director of Optimum Patient Care. DBP has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Circassia, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. The authors report no other conflicts of interest in this work.",,"Naomi Launders 1 , Dermot Ryan 2 , Christopher C Winchester 3 , Derek Skinner 4 , Priyanka Raju Konduru 4 , David B Price 4"
31798979,CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion,"Ahmad Awada 1, Joseph Gligorov 2, Guy Jerusalem 3, Matthias Preusser 4, Christian Singer 5, Christoph Zielinski 6 7",ESMO Open. 2019 Nov 13;4(6):e000565. doi: 10.1136/esmoopen-2019-000565. eCollection 2019.,Awada A,ESMO Open,2019,2019/12/05,PMC6863664,,10.1136/esmoopen-2019-000565,https://pubmed.ncbi.nlm.nih.gov/31798979/,/31798979/,"Competing interests: MP: honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo and Merck Sharp & Dome. JG: research support from Eisai, Genomic Health, Novartis, Pfizer and Roche; travel grants from Eisai, Genomic Health, Novartis, Pfizer and Roche; honoraria for advisory boards and speaker fees from Daiichi, Eisai, Genomic Health, Ipsen, Macrogenics, MSD, Novartis, Onxeo, Pfizer and Roche. GJ: grants, personal fees and non-financial support from Novartis and Roche; personal fees and non-financial support from Pfizer, Lilly, Amgen, BMS, Astra-Zeneca; personal fees from Celgene, Puma Technology, Daiichi Sankyo and Abbvie. AA: advisory boards, travel grants, speaker fees: Novartis, Roche, Lilly, Amgen, Eisai, BMS, MSD, LeoPharma, Genomic Health and Ipsen. CS: honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Novartis, Gerson Lehrman Group, Astra-Zeneca, Lilly, Roche, Amgen, Pfitzer, Merck KGaA, and Tesaro. CCZ: honoraria from Roche, Novartis, BMS, MSD, Imugene, Ariad, Pfizer, Merrimack, Merck KGaA, Fibrogen, AstraZeneca, Tesaro, Gilead, Servier and Shire.",,"Ahmad Awada 1 , Joseph Gligorov 2 , Guy Jerusalem 3 , Matthias Preusser 4 , Christian Singer 5 , Christoph Zielinski 6 7"
31699834,The most beautiful COPD chart in the world: all together to end COPD!,"Joan B Soriano 1 2, Julio Ancochea 3 2, Bartolomé R Celli 4",Eur Respir J. 2019 Dec 19;54(6):1902047. doi: 10.1183/13993003.02047-2019. Print 2019 Dec.,Soriano JB,Eur Respir J,2019,2019/11/09,,,10.1183/13993003.02047-2019,https://pubmed.ncbi.nlm.nih.gov/31699834/,/31699834/,"Conflict of interest: J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2015–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda; and declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates. Conflict of interest: Julio Ancochea has received honoraria from Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Linde Healthcare, Menarini, Mundipharma, Novartis, Roche, Rovi,Sandoz and Teva during the period 2014–2019 for speaking at conferences, moderatorships, scientific consultancy services and participating in clinical trials. Conflict of interest: B.R. Celli reports grants and other (research site) from AstraZeneca, personal fees for consultancy and committee work from GlaxoSmithKline, personal fees for consultancy from Boehringer Ingelheim, Sanofi-Aventis, Menarini, Chiesi and Pulmonx, outside the submitted work.",,"Joan B Soriano 1 2 , Julio Ancochea 3 2 , Bartolomé R Celli 4"
31639034,Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis,"Philip G Conaghan 1, Mikkel Østergaard 2, Orrin Troum 3, Michael A Bowes 4, Gwenael Guillard 4, Bethanie Wilkinson 5, Zhiyong Xie 5, John Andrews 6, Amy Stein 7, Douglass Chapman 6, Andrew Koenig 8",Arthritis Res Ther. 2019 Oct 21;21(1):214. doi: 10.1186/s13075-019-2000-1.,Conaghan PG,Arthritis Res Ther,2019,2019/10/23,PMC6805378,,10.1186/s13075-019-2000-1,https://pubmed.ncbi.nlm.nih.gov/31639034/,/31639034/,"PGC has been a consultant for AbbVie, Eli Lilly, Flexion, GlaxoSmithKline, Novartis, Pfizer Inc and Roche, and has been a member of the speakers’ bureau for AbbVie, Novartis and Roche. MØ has received grants or research support from AbbVie, Centocor and Merck, and has been a consultant and/or a member of the speakers’ bureau for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Eli Lilly, GlaxoSmithKline, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer Inc, Regeneron, Roche, Schering-Plough, Takeda, UCB and Wyeth. OT has been a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Horizon, Lilly and Pfizer Inc, has been a member of the speakers’ bureau for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Horizon, Novartis, Pfizer Inc, Sanofi-Genzyme and Takeda, and has received grants or research support from AbbVie, Amgen, Bristol-Myers Squibb, Centocor, Corrona, Novartis and Pfizer Inc. MAB is an employee of Imorphics Ltd, a wholly owned subsidiary of Stryker Corp. GG was an employee of Imorphics Ltd, a wholly owned subsidiary of Stryker Corp, at the time the research was conducted. AS is an employee of IQVIA Inc and has acted as a paid consultant to Pfizer Inc in connection with analysis of study data. BW and AK were employees of Pfizer Inc at the time the research was conducted. ZX, JA and DC are employees and shareholders of Pfizer Inc.",Grants and funding N/A/Pfizer Inc/International,"Philip G Conaghan 1 , Mikkel Østergaard 2 , Orrin Troum 3 , Michael A Bowes 4 , Gwenael Guillard 4 , Bethanie Wilkinson 5 , Zhiyong Xie 5 , John Andrews 6 , Amy Stein 7 , Douglass Chapman 6 , Andrew Koenig 8"
31201476,Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder,"Graham K Murray 1 2 3, Franziska Knolle 4 5, Karen D Ersche 6 7, Kevin J Craig 6 7, Sanja Abbott 7 8 9, Shaila S Shabbir 10, Naomi A Fineberg 11, John Suckling 6 7, Barbara J Sahakian 6 7, Edward T Bullmore 6 7 12, Trevor W Robbins 7 8",Psychopharmacology (Berl). 2019 Aug;236(8):2325-2336. doi: 10.1007/s00213-019-05292-2. Epub 2019 Jun 14.,Murray GK,Psychopharmacology (Berl),2019,2019/06/16,PMC6695357,,10.1007/s00213-019-05292-2,https://pubmed.ncbi.nlm.nih.gov/31201476/,/31201476/,"Dr. Bullmore is employed half-time by GSK and half-time by University of Cambridge. He holds stock in GSK. Dr. Craig was employed by the University of Cambridge at the time the study was initiated; he is now employed by, and holds stock in, Covance, the drug development business of Laboratory Corporation of America® Holdings (LabCorp). Dr. Fineberg reports the following commercial interests, all outside the research work; in the past 2 years, she has received personal fees for giving lectures from Abbott, Otsuka-Lundbeck, RANZCP, BAP, and Wiley; payment for editorial duties from Taylor and Francis; royalties from Oxford University Press; payment for consultancy from the MHRA; research or educational grants from Shire, ECNP, NIHR, MRC, and Wellcome Trust; and non-financial support from Shire, ECNP, BAP, CINP, International Forum of Mood and Anxiety Disorders, International College of Obsessive Compulsive Spectrum Disorders, and RCPsych. Dr. Robbins discloses consultancy with Cambridge Cognition, Lundbeck, Mundipharma, and Unilever; he receives royalties for CANTAB from Cambridge Cognition and editorial honoraria from Springer Verlag and Elsevier. Dr. Sahakian consults for Cambridge Cognition, Peak (Brainbow), and Mundipharma. Ms. Shabbir is employed by GSK. Drs. Abbott, Ersche, Knolle, Murray, and Suckling declare no competing interests.",Grants and funding G0001354/MRC_/Medical Research Council/United Kingdom G0701911/MRC_/Medical Research Council/United Kingdom G1000183/MRC_/Medical Research Council/United Kingdom,"Graham K Murray 1 2 3 , Franziska Knolle 4 5 , Karen D Ersche 6 7 , Kevin J Craig 6 7 , Sanja Abbott 7 8 9 , Shaila S Shabbir 10 , Naomi A Fineberg 11 , John Suckling 6 7 , Barbara J Sahakian 6 7 , Edward T Bullmore 6 7 12 , Trevor W Robbins 7 8"
31842942,Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment,"Jens Reimer 1 2, Tobias Vogelmann 3, Daniel Trümper 4, Norbert Scherbaum 5",Subst Abuse Treat Prev Policy. 2019 Dec 16;14(1):57. doi: 10.1186/s13011-019-0247-9.,Reimer J,Subst Abuse Treat Prev Policy,2019,2019/12/18,PMC6916156,,10.1186/s13011-019-0247-9,https://pubmed.ncbi.nlm.nih.gov/31842942/,/31842942/,"Jens Reimer reports personal fees from Indivior, during the conduct of the study; personal fees from Sanofi-Aventis, personal fees from Hexal, grants and personal fees from Mundipharma, personal fees from Camurus, grants and personal fees from Indivior, outside the submitted work. Norbert Scherbaum reports personal fees from Sanofi-Aventis, personal fees from Indivior, personal fees from AbbVie, personal fees from MSD Pharma, personal fees from Mundipharma, during the conduct of the study. Tobias Vogelmann reports personal fees from Indivior, during the conduct of the study; personal fees from Indivior, outside the submitted work. Daniel Trümper reports personal fees from Indivior.",,"Jens Reimer 1 2 , Tobias Vogelmann 3 , Daniel Trümper 4 , Norbert Scherbaum 5"
31571852,"Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort","Peter Alter 1, Barbara A Mayerhofer 2, Kathrin Kahnert 3, Henrik Watz 4, Benjamin Waschki 5 6, Stefan Andreas 7 8, Frank Biertz 9, Robert Bals 10, Claus F Vogelmeier 1, Rudolf A Jörres 2",Int J Chron Obstruct Pulmon Dis. 2019 Sep 20;14:2163-2172. doi: 10.2147/COPD.S209343. eCollection 2019.,Alter P,Int J Chron Obstruct Pulmon Dis,2019,2019/10/02,PMC6759215,,10.2147/COPD.S209343,https://pubmed.ncbi.nlm.nih.gov/31571852/,/31571852/,"Peter Alter, Barbara A Mayerhofer, Kathrin Kahnert, Henrik Watz, Benjamin Waschki, Frank Biertz, and Rudolf A Jörres report no conflicts of interest in this work. Stefan Andreas report grants and personal fees from Boehringer Ing and Pfizer, and personal fees from Novartis, Astra Zeneca, GSK, Chiesi, and Merini, outside the submitted work. Robert Bals report grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), during the conduct of the study, and grants and personal fees from AstraZeneca, Novartis, and Boehringer Ingelheim, and personal fees from GlaxoSmithKline, Grifols, and CSL Behring, outside the submitted work. Claus F Vogelmeier report grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, and Novartis, personal fees from CSL Behring, Chiesi, Menarini, Mundipharma, Teva, and Cipla, and grants from Bayer Schering Pharma AG, MSD, and Pfizer, outside the submitted work. The authors report no other conflicts of interest regarding this work.",,"Peter Alter 1 , Barbara A Mayerhofer 2 , Kathrin Kahnert 3 , Henrik Watz 4 , Benjamin Waschki 5 6 , Stefan Andreas 7 8 , Frank Biertz 9 , Robert Bals 10 , Claus F Vogelmeier 1 , Rudolf A Jörres 2"
26922805,Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers,"Sharlene Kaye 1, Josep Antoni Ramos-Quiroga 2, Geurt van de Glind 3 4, Frances R Levin 5, Stephen V Faraone 6, Steve Allsop 7, Louisa Degenhardt 1 8, Franz Moggi 9 10, Csaba Barta 11, Maija Konstenius 12, Johan Franck 12, Arvid Skutle 13, Eli-Torild Bu 13, Maarten W J Koeter 4, Zsolt Demetrovics 14, Máté Kapitány-Fövény 14 15, Robert A Schoevers 16, Katelijne van Emmerik-van Oortmerssen 4 17, Pieter-Jan Carpentier 18, Geert Dom 19 20, Sofie Verspreet 19 20, Cleo L Crunelle 4, Jesse T Young 7 8 21, Susan Carruthers 7, Joanne Cassar 1, Melina Fatséas 22, Marc Auriacombe 22, Brian Johnson 6, Matthew Dunn 23, Ortal Slobodin 24, Wim van den Brink 4",J Atten Disord. 2019 Oct;23(12):1438-1453. doi: 10.1177/1087054716629217. Epub 2016 Feb 27.,Kaye S,J Atten Disord,2019,2016/02/29,PMC5002258,NIHMS785816,10.1177/1087054716629217,https://pubmed.ncbi.nlm.nih.gov/26922805/,/26922805/,"Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: G. van de Glind was, on one occasion, a consultant for Shire, for which he refused payment. In 2013, he received an unrestricted travel grant from Neurotech and he is a member (unpaid) of the advisory board of Neurotech. P. J. Carpentier received a fee for speaking at a conference organized by Eli Lilly in 2011. F. R. Levin reports Study Medication provided by US WorldMeds and being a consultant to GW Pharmaceuticals. She served as a consultant to Shire and Eli Lilly from 2005 to 2007. The ICASA Foundation has reimbursed her for airfare to attend the Annual Meeting as a speaker. S. Kaye reports receiving unrestricted travel grants for participation in the World ADHD Federation conference in Berlin (2011) from Shire, Janssen, and Eli Lilly. In the past year, S. V. Faraone received consulting income and/or research support from Shire, Akili Interactive Labs, VAYA Pharma, SynapDx, and Alcobra and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium–hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on advisory boards or participated in continuing medical education programs sponsored by Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. He receives royalties from books published by Guilford Press: Straight Talk About Your Child’s Mental Health and Oxford University Press: Schizophrenia: The Facts. In the last 3 years, J. A. Ramos-Quiroga has been on the speakers’ bureau and/or acted as consultant for Eli Lilly, Janssen-Cilag, Novartis, Shire, and Rubió. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Shire, and Eli Lilly. The ADHD Program chaired by him has received unrestricted educational and research support from Eli Lilly, Janssen-Cilag, Shire, and Rubió in the past 3 years. Z. Demetrovics received reimbursement for participating at symposia organized by Lundbeck (2011). G. Dom acted as a paid consultant for Lundbeck and received a speaker’s fee and reimbursement for symposium attendance from GSK, Janssen Ph., Astra-Zeneca, and Eli Lilly. F. Moggi received a speaker’s fee from Novartis and from Eli Lilly. M. Auriacombe and his institution report unrestricted grants and advisory board activities from RBK Pharmaceutical, Mundipharma, and D&A Pharma. J. Franck declares his research group received an unrestricted research grant from Janssen-Cilag in 2007. The grant was received and administered by his university (Karolinska Institutet). W. van den Brink has received a fee from Eli Lilly for organizing a symposium on the role of impulsivity in psychiatric disorders and a speaker’s fee from Eli Lilly for a presentation on the relationship between ADHD and addiction. Apart from the funding resources described above, the authors declare no other conflicts of interest.",Grants and funding K24 DA029647/DA/NIDA NIH HHS/United States,"Sharlene Kaye 1 , Josep Antoni Ramos-Quiroga 2 , Geurt van de Glind 3 4 , Frances R Levin 5 , Stephen V Faraone 6 , Steve Allsop 7 , Louisa Degenhardt 1 8 , Franz Moggi 9 10 , Csaba Barta 11 , Maija Konstenius 12 , Johan Franck 12 , Arvid Skutle 13 , Eli-Torild Bu 13 , Maarten W J Koeter 4 , Zsolt Demetrovics 14 , Máté Kapitány-Fövény 14 15 , Robert A Schoevers 16 , Katelijne van Emmerik-van Oortmerssen 4 17 , Pieter-Jan Carpentier 18 , Geert Dom 19 20 , Sofie Verspreet 19 20 , Cleo L Crunelle 4 , Jesse T Young 7 8 21 , Susan Carruthers 7 , Joanne Cassar 1 , Melina Fatséas 22 , Marc Auriacombe 22 , Brian Johnson 6 , Matthew Dunn 23 , Ortal Slobodin 24 , Wim van den Brink 4"
31399091,Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD,"Dave Singh 1, Kai Michael Beeh 2, Brendan Colgan 3, Oliver Kornmann 4, Brian Leaker 5, Henrik Watz 6, Germano Lucci 7, Silvia Geraci 7, Aida Emirova 7, Mirco Govoni 8, Marie Anna Nandeuil 7",Respir Res. 2019 Aug 9;20(1):180. doi: 10.1186/s12931-019-1142-7.,Singh D,Respir Res,2019,2019/08/11,PMC6688371,,10.1186/s12931-019-1142-7,https://pubmed.ncbi.nlm.nih.gov/31399091/,/31399091/,"Dave Singh received personal fees from Chiesi during the conduct of this study. Outside the submitted work, he reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance, and Verona, and personal fees from Cipla, Genentech and Peptinnovate. Kai Michael Beeh declares that no personal payments were received from any pharmaceutical entity in the past five years. He is a full time employee of insaf Respiratory Research Institute. The institution has received compensation for services on advisory boards or consulting for Ablynx, Almirall, AstraZeneca, Berlin Chemie, Boehringer, Chiesi, Cytos, Mundipharma, Novartis, Pohl Boskamp, Zentiva. The institution has received compensation for speaker activities in scientific meetings supported by Almirall, AstraZeneca, Berlin Chemie, Boehringer, Cytos, ERT, GSK, Novartis, Pfizer, Pohl Boskamp, Takeda. The institution has received compensation for design and performance of clinical trials from Almirall, Altana/Nycomed, AstraZeneca, Boehringer, Cytos, GSK, Infinity, Medapharma, MSD, Mundipharma, Novartis, Parexel, Pearl Therapeutics, Pfizer, Revotar, Teva, Sterna, and Zentiva. Brendan Colgan has nothing to disclose. Oliver Kornmann’s institution received fees from Chiesi for conducting this study as a participating site. Dr. Kornmann reports personal fees as speaker or Advisory Board member from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi and Novartis. Brian Leaker has nothing to disclose. Henrik Watz reports personal fees from Chiesi during the conduct of the study. Outside the submitted work, Dr. Watz reports personal fees from Bayer, personal fees from GSK, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, personal fees from BerlinChemie, and personal fees from Roche. Germano Lucci, Silvia Geraci, Mirco Govoni, Aida Emirova, and Marie Anna Nandeuil are all employees of Chiesi, the sponsor of this trial.",Grants and funding Not applicable/Chiesi Farmaceutici,"Dave Singh 1 , Kai Michael Beeh 2 , Brendan Colgan 3 , Oliver Kornmann 4 , Brian Leaker 5 , Henrik Watz 6 , Germano Lucci 7 , Silvia Geraci 7 , Aida Emirova 7 , Mirco Govoni 8 , Marie Anna Nandeuil 7"
32206483,Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA(®) trial,"Nobuya Inagaki 1, Wenying Yang 2, Hirotaka Watada 3, Linong Ji 4, Sven Schnaidt 5, Egon Pfarr 6, Tomoo Okamura 7, Odd Erik Johansen 8, Jyothis T George 9, Maximilian von Eynatten 9, Julio Rosenstock 10, Vlado Perkovic 11, Christoph Wanner 12, Mark E Cooper 13, John H Alexander 14, Issei Komuro 15, Masaomi Nangaku 16",Diabetol Int. 2019 Oct 22;11(2):129-141. doi: 10.1007/s13340-019-00412-x. eCollection 2020 Apr.,Inagaki N,Diabetol Int,2019,2020/03/25,PMC7082467,,10.1007/s13340-019-00412-x,https://pubmed.ncbi.nlm.nih.gov/32206483/,/32206483/,"Conflicts of interestN.I. has received honoraria from Kowa company; research funding from Mitsubishi Tanabe, Daiichi Sankyo and AstraZeneca; and subsidies/donations from Takeda, MSD, Ono, Sanofi, Japan Tobacco Inc., Mitsubishi Tanabe, Novartis, Boehringer Ingelheim, Kyowa Kirin, Astellas, Daiichi Sankyo, Kissei Pharmaceutical, Dainippon Pharma, Sanwa kagaku, Eli Lilly, Novo Nordisk, Teijin Pharma, and Taisho-Toyama Pharma. W.Y. has attended advisory boards for Novo Nordisk; received investigator-initiated trial research funds from AstraZeneca; been a speaker for Novo Nordisk, Bayer, Sanofi Aventis, Merck Sharp & Dohme China, AstraZeneca, Eli Lilly, Boehringer Ingelheim, and Servier; and received honorarium and travel support as an advisory board member from Merck & Co., Inc. H.W. has received honoraria from Eli Lilly, Mitsubishi Tanabe Pharma, Sanofi, Takeda Pharmaceutical Company, Novartis Pharma, Nippon Boehringer Ingelheim, Daiichi Sankyo, Ono Pharmaceutical, Astellas Pharma, FUJIFILM Pharma, Terumo Corporation, MSD; research funding from Eli Lilly, Novartis Pharma, Sanwa kagaku; subsidies/donations from Mitsubishi Tanabe Pharma, Kissei Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma, Sumitomo Dainippon Pharma, Sanofi, MSD, Pfizer Japan, Astellas Pharma, Takeda Pharmaceutical Company, Novo Nordisk, Teijin Pharma; and departmental endowments from Takeda Pharmaceutical Company, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Kowa company, and Sanwa kagaku. L.J. has received consulting and lecture fees from Eli Lilly and Company, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, MSD, Takeda, Sanofi, Roche, Boehringer Ingelheim, and AstraZeneca; and research support from Roche, Sanofi, MSD, AstraZeneca, Novartis, and Bristol-Myers Squibb. S.S., E.P., T.O., O.E.J., J.T.G., and M.v.E are employees of Boehringer Ingelheim. J.R. has served on scientific advisory boards and received honoraria or consulting fees from Eli Lilly, Sanofi, Novo Nordisk, Janssen, AstraZeneca, Boehringer Ingelheim, and Intarcia; he has also received grants/research support from Merck, Pfizer, Sanofi, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Genentech, Janssen, Lexicon, Boehringer Ingelheim, and Intarcia. V.P. has received research support from the Australian National Health and Medical Research Council (Project and Program Grant); served on steering committees for trials supported by AbbVie, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Novo Nordisk, Pfizer, Retrophin, and Tricida; and served on advisory boards, spoken at scientific meetings, or both for AbbVie, Astellas Pharma, AstraZeneca, Bayer, Baxter, Bristol-Myers Squibb, Boehringer Ingelheim, Durect Corporation, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Roche, Sanofi, Servier, and Vitae. He has a policy of having honoraria paid to his employer. C.W. has received fees for advisory services to Boehringer Ingelheim and MSD as well as honoraria for lecturing from AstraZeneca, Eli Lilly and Sanofi. M.E.C. has received fees for advisory services and honoraria from Boehringer Ingelheim, Sanofi, Servier, Bayer, Astra Zeneca, Reata, MundiPharma and MSD and a grant from NovoNordisk. J.H.A. has received personal fees from Abbvie, Bristol-Myers Squibb, CSL Behring, Janssen Pharmaceutics, Novo Nordisk, Pfizer, Portola, and Teikoku; and institutional research support from Boehringer Ingelheim, Bristol-Myers Squibb, Cryolife, CSL Behring, Tenax Therapeutics, and VoluMetrix. I.K. has received honororia from Astellas Pharma Inc., MSD K.K., Edwards Laboratories Corporation, Otsuka Pharmaceutical Co. Ltd, Kowa Company, Ltd., Daiichi Sankyo Company, Limited, Taisho Pharma Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Limited, Toa Eiyo Ltd, Bayer Yakuhin, Ltd, Terumo Corporation, Nipro Corporation; research funding from Ono Pharmaceutical Co., Ltd; and subsidies/donations from Actelion Pharmaceuticals Japan Ltd. Astellas Pharma Inc., Amgen Astellas BioPharma K.K., AstraZeneca K.K., MSD K.K., Shionogi & Co., Ltd, Daiichi Sankyo Company, Limited, Takeda Pharmacentical Company Limited, Toa Eiyo Ltd, Nippon Boehringer Ingelheim Co., Ltd, Bayer Yakuhin, Ltd, and Pfizer Japan Inc. M.N. is an advisor for KHK, Astellas, GSK, Daiichi-Sankyo, Mitsubishi-Tanabe, JT, Boehringer-Ingelheim; has received honoraria from KHK, Astellas, AstraZeneca, GSK, Daiichi-Sankyo, Mitubishi-Tanabe, Chugai, Torii, JT; manuscript fees from KHK; research funding from JT, KHK; and subsidies/donations from KHK, Astellas, Ono, Daiichi-Sankyo, Takeda, Mitsubishi-Tanabe, Chugai, Torii, MSD, Otsuka, Dainippon-Sumitomo, JT, and Boehringer Ingelheim.",,"Nobuya Inagaki 1 , Wenying Yang 2 , Hirotaka Watada 3 , Linong Ji 4 , Sven Schnaidt 5 , Egon Pfarr 6 , Tomoo Okamura 7 , Odd Erik Johansen 8 , Jyothis T George 9 , Maximilian von Eynatten 9 , Julio Rosenstock 10 , Vlado Perkovic 11 , Christoph Wanner 12 , Mark E Cooper 13 , John H Alexander 14 , Issei Komuro 15 , Masaomi Nangaku 16"
30737400,Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma,"Simon Wan Yau Ming 1, John Haughney 2, Dermot Ryan 3 4, Shishir Patel 5, Matthias Ochel 5, Martina Stagno dAlcontres 1, Susannah Thornhill 1, Janwillem W H Kocks 1 6, David Price 7 8 9",NPJ Prim Care Respir Med. 2019 Feb 8;29(1):3. doi: 10.1038/s41533-019-0115-0.,Ming SWY,NPJ Prim Care Respir Med,2019,2019/02/10,PMC6368625,,10.1038/s41533-019-0115-0,https://pubmed.ncbi.nlm.nih.gov/30737400/,/30737400/,"D.P. has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. D.R. has received support to attend meetings, delivered educational events on behalf of or provided consultancy to: AZ, Chiesi, TEVA, Trudel Medical, Novartis, BI, Optimum Patient Care, MEDA/Mylan, Stallergenes. J.W.H.K. reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants from Chiesi, grants and personal fees from GSK, grants and personal fees from Novartis, grants from Mundi Pharma, grants from TEVA, outside the submitted work. J.H. reports grants and research supports from Boehringer Ingelheim, GSK, and Teva; and Honoria or consultation fees from AZ, Boehringer Ingelheim, Cipla, Chiesi, Mundipharma, Novartis, Pfizer, Sanofi, and Teva. S.P. and M.O. are employed by Chiesi, the sponsor of the study. S.W.Y.M., M.S.d’.A., and S.T. are past employees of the Observational and Pragmatic Research Institute, which has conducted paid research in respiratory disease on behalf of the following organisations in the past 5 years: Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), GlaxoSmithKline, Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, Zentiva (a Sanofi company).",,"Simon Wan Yau Ming 1 , John Haughney 2 , Dermot Ryan 3 4 , Shishir Patel 5 , Matthias Ochel 5 , Martina Stagno dAlcontres 1 , Susannah Thornhill 1 , Janwillem W H Kocks 1 6 , David Price 7 8 9"
30904980,"Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study","Xiaonan Hong 1, Yuqin Song 2, Huiqiang Huang 3, Bing Bai 3, Huilai Zhang 4, Xiaoyan Ke 5, Yuankai Shi 6, Jun Zhu 7, Guodong Lu 8, Stefan Liebscher 9, Chunxiao Cai 8",Target Oncol. 2019 Apr;14(2):149-158. doi: 10.1007/s11523-019-00630-y.,Hong X,Target Oncol,2019,2019/03/25,PMC6453867,,10.1007/s11523-019-00630-y,https://pubmed.ncbi.nlm.nih.gov/30904980/,/30904980/,"Stefan Liebscher was an employee of Mundipharma Research GmbH at the time the study was conducted. Guodong Lu and Chunxiao Cai are employees of Mundipharma (China) Pharmaceutical Co., Ltd. Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, and Jun Zhu declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.",,"Xiaonan Hong 1 , Yuqin Song 2 , Huiqiang Huang 3 , Bing Bai 3 , Huilai Zhang 4 , Xiaoyan Ke 5 , Yuankai Shi 6 , Jun Zhu 7 , Guodong Lu 8 , Stefan Liebscher 9 , Chunxiao Cai 8"
31804501,A multinational observational study identifying primary care patients at risk of overestimation of asthma control,"Vicky Kritikos 1 2, David Price 3 4 5, Alberto Papi 6, Antonio Infantino 7, Bjorn Ställberg 8, Dermot Ryan 3 9, Federico Lavorini 10, Henry Chrystyn 11, John Haughney 12, Karin Lisspers 8, Kevin Gruffydd-Jones 13, Miguel Román Rodríguez 14, Svein Høegh Henrichsen 15, Thys van der Molen 16, Victoria Carter 3 4, Sinthia Bosnic-Anticevich 17 18 19",NPJ Prim Care Respir Med. 2019 Dec 5;29(1):43. doi: 10.1038/s41533-019-0156-4.,Kritikos V,NPJ Prim Care Respir Med,2019,2019/12/06,PMC6895161,,10.1038/s41533-019-0156-4,https://pubmed.ncbi.nlm.nih.gov/31804501/,/31804501/,"V.K. has received honoraria from AstraZeneca, GlaxoSmithKline and Pfizer, outside the submitted work. D.P. has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. A.P. is on the boards for and has received research and travel support and consultancy and lecture fees from Chiesi Farmaceutici, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp & Dohme, Takeda, Mundipharma Research Limited and Teva; has received lecture fees and travel support from Menarini, Novartis and Zambon; is on the boards for and has received lecture fees and travel support from Pfizer, and has received research support from Sanofi. B. Ställberg has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Meda, MSD, Novartis and Teva, and has served on advisory boards arranged by GlaxoSmithKline, AstraZeneca, Novartis, Meda and Boehringer Ingelheim. D.R. has received consultancy fees from Chiesi, Teva, Novartis and Boehringer Ingelheim; fees from advisory boards from Teva, Chiesi, Boehringer Ingelheim and Novartis; has received lecture fees from Takeda, AstraZeneca and Meda; has received payment for educational presentations from Meda; is European Academy of Allergy and Clinical Immunology chair of primary care interest group; is Director of Respiratory Effectiveness Group; and is Strategic Clinical Director for Optimum Patient Care. F.L. has received honoraria for consultancy and presentations from Cipla, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini International, Teva and Zentiva. H.C. has no shares in any pharmaceutical companies; is employed by RiRL, which is subcontracted by Observational and Pragmatic Research Institute Pte Ltd; has received sponsorship to carry out studies, together with board membership, consultancy agreements, and honoraria for presentation for Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Innovata, Biomed, Meda, Napp Pharmaceuticals, Mundipharma Research Limited, NorPharma, Novartis, Orion, Sanofi, Teva, Truddell Medical International, UCB and Zentiva; and owns 50% of Inhalation Consultancy Ltd. J.H. has received reimbursements for attending symposia, fees for speaking, organising educational events, funds for research or fees for consulting from Cipla, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Sharpe & Dohme, Mundipharma Research Limited and Novartis, and T.K.L. is on the boards for Novartis and Meda; is on the scientific committee for AstraZeneca and Novartis; has received lecture fees from AstraZeneca, GlaxoSmithKline, meda, Nycomed, Boehringer Ingelheim and Novartis; has received payment for developing educational presentations from Novartis; and is on the steering committees for AstraZeneca and Novartis. K.G.-J. declares speaking engagements and consultancy for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and Novartis. M.R.-R. has received personal fees from Almirall, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, Menarini, Mundipharma Research Limited, Novartis, Pfizer, Rovi, Teva and Gebro and has received research support from personal fees from GlaxoSmithKline. T.v.d.M. has received grants for research, travel fees and reimbursement for presentations and advisory boards from AstraZeneca, GlaxoSmithKline, Almirall, Mundipharma Research Limited, Boehringer Ingelheim, Chiesi, Teva and Novartis and is on the Certe Laboratories board. V.C. is an employee of Optimum Patient Care Ltd and Observational and Pragmatic Research Institute Pte Ltd. S.B.-A. has received payment for lectures, expert advice and independent research from Teva, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Mylan and Sanofi, outside the submitted work. The rest of the authors declare no competing interests.",,"Vicky Kritikos 1 2 , David Price 3 4 5 , Alberto Papi 6 , Antonio Infantino 7 , Bjorn Ställberg 8 , Dermot Ryan 3 9 , Federico Lavorini 10 , Henry Chrystyn 11 , John Haughney 12 , Karin Lisspers 8 , Kevin Gruffydd-Jones 13 , Miguel Román Rodríguez 14 , Svein Høegh Henrichsen 15 , Thys van der Molen 16 , Victoria Carter 3 4 , Sinthia Bosnic-Anticevich 17 18 19"
31185885,Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic,"D Y Wei 1, D Moreno-Ajona 1, T Renton 2, P J Goadsby 3 4",J Headache Pain. 2019 Jun 11;20(1):69. doi: 10.1186/s10194-019-1019-7.,Wei DY,J Headache Pain,2019,2019/06/13,PMC6734481,,10.1186/s10194-019-1019-7,https://pubmed.ncbi.nlm.nih.gov/31185885/,/31185885/,"DYW, DMA, TR have nothing to disclose. PJG has no conflict of interest with the submitted work. PJG reports personal fees from Alder Biopharmaceuticals, personal fees from Allergan, grants and personal fees from Amgen, personal fees from Autonomic Technologies Inc., personal fees from Biohaven Pharmaceuticals Inc., personal fees from Dr. Reddy’s Laboratories, grants and personal fees from Eli Lilly and Company, personal fees from Electrocore LLC, personal fees from eNeura Inc., personal fees from MundiPharma, from Novartis, personal fees from Teva Pharmaceuticals, other from Trigemina, outside the submitted work; In addition, PJG has a patent Magnetic stimulation for headache licensed to eNeura without fee and Fees for publishing from Oxford University Press, Massachusetts Medical Society, Wolters Kluwer and for medicolegal work.",,"D Y Wei 1 , D Moreno-Ajona 1 , T Renton 2 , P J Goadsby 3 4"
31720294,Behavioural interventions targeting physical activity improve psychocognitive outcomes in COPD,"Kim L Lavoie 1 2, Maria Sedeno 3, Alan Hamilton 4, Pei-Zhi Li 3, Dorothy De Sousa 4, Thierry Troosters 5, François Maltais 6, Jean Bourbeau 3",ERJ Open Res. 2019 Nov 4;5(4):00013-2019. doi: 10.1183/23120541.00013-2019. eCollection 2019 Oct.,Lavoie KL,ERJ Open Res,2019,2019/11/14,PMC6826247,,10.1183/23120541.00013-2019,https://pubmed.ncbi.nlm.nih.gov/31720294/,/31720294/,"Conflict of interest: K.L. Lavoie reports investigator-initiated research support and speaking fees from Abbvie, consulting fees and speaking fees from Boehringer Ingelheim, Astellas and Novartis, consulting fees from Janssen and AstraZeneca, and speaking fees from Bayer and Mundipharma, outside the submitted work. Conflict of interest: M. Sedeno is an employee of RESPIPLUS and, in this salaried position, works with a variety of companies and receives no payment or honoraria directly from them for services rendered. Conflict of interest: A. Hamilton is an employee of Boehringer Ingelheim (Canada) Ltd. Conflict of interest: P-Z. Li has nothing to disclose. Conflict of interest: D. De Sousa is an employee of Boehringer Ingelheim. Conflict of interest: T. Troosters reports that his institute received speakers’ fees and consultancy fees for activities related to physical activity and exercise in COPD from Boehringer Ingelheim, and for activities around physical activity and exercise from AstraZeneca; and grants from PROactive, during the conduct of the study; and grants from Research Foundation Flanders, outside the submitted work. Conflict of interest: F. Maltais reports personal fees and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, and Griffols, outside the submitted work. Conflict of interest: J. Bourbeau reports grants from McGill University, the Research Institute of the McGill University Health Centre, GlaxoSmithKline, Aerocrine, the Canadian Respiratory Research Network–Canadian Institute of Health Research, Almirall, AstraZeneca, Boehringer Ingelheim and Novartis, outside the submitted work.",,"Kim L Lavoie 1 2 , Maria Sedeno 3 , Alan Hamilton 4 , Pei-Zhi Li 3 , Dorothy De Sousa 4 , Thierry Troosters 5 , François Maltais 6 , Jean Bourbeau 3"
31301742,Difficult-to-treat and severe asthma in general practice: delivery and evaluation of an educational program,"Isla Hains 1, Josh Meyers 2, Kirsten Sterling 2, Jeannie Yoo 2, Helen Reddel 3, Clare Weston 2",BMC Fam Pract. 2019 Jul 13;20(1):99. doi: 10.1186/s12875-019-0991-y.,Hains I,BMC Fam Pract,2019,2019/07/15,PMC6626400,,10.1186/s12875-019-0991-y,https://pubmed.ncbi.nlm.nih.gov/31301742/,/31301742/,"Author HR or her institute have received honoraria for providing independent advice on advisory boards, steering committees and data safety monitoring board for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Novartis; independent consulting for AstraZeneca and GlaxoSmithKline; for providing independent medical education at symposia funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Novartis and Teva. Her institute has received independent research grants from AstraZeneca and GlaxoSmithKline. She has participated in a Novartis-funded severe asthma registry study.",,"Isla Hains 1 , Josh Meyers 2 , Kirsten Sterling 2 , Jeannie Yoo 2 , Helen Reddel 3 , Clare Weston 2"
31695074,Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma,"Pinja Ilmarinen 1, Hind Juboori 2, Leena E Tuomisto 2, Onni Niemelä 3 4, Harri Sintonen 5, Hannu Kankaanranta 2 4",Sci Rep. 2019 Nov 6;9(1):16107. doi: 10.1038/s41598-019-52361-9.,Ilmarinen P,Sci Rep,2019,2019/11/08,PMC6834611,,10.1038/s41598-019-52361-9,https://pubmed.ncbi.nlm.nih.gov/31695074/,/31695074/,"Dr. Sintonen is the developer of the 15D and obtains royalties from its electronic versions. Outside the submitted work, Dr. Ilmarinen reports grants and personal fees from Astra Zeneca, personal fees from Mundipharma, personal fees from GlaxoSmithKline, personal fees from Orion, personal fees from Novartis. Dr. Kankaanranta reports grants, personal fees and non-financial support from AstraZeneca, personal fees from Chiesi Pharma AB, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Novartis, personal fees from Mundipharma, personal fees and non-financial support from Orion Pharma, personal fees from SanofiGenzyme, personal fees from GlaxoSmithKline, outside the submitted work. Dr. Tuomisto reports non-financial support from Chiesi, non-financial support from Boehringer-Ingelheim, personal fees from Astra Zeneca, non-financial support from Orion Pharma, non-financial support from TEVA, other from Novartis, outside the submitted work. Dr. Niemelä and Dr. Juboori declare no potential conflict of interest.",,"Pinja Ilmarinen 1 , Hind Juboori 2 , Leena E Tuomisto 2 , Onni Niemelä 3 4 , Harri Sintonen 5 , Hannu Kankaanranta 2 4"
31519206,Clinical and immune profiling for cancer of unknown primary site,"Koji Haratani 1, Hidetoshi Hayashi 2, Takayuki Takahama 1 3, Yasushi Nakamura 4, Shuta Tomida 5, Takeshi Yoshida 1, Yasutaka Chiba 6, Takahiro Sawada 7, Kazuko Sakai 3, Yoshihiko Fujita 3, Yosuke Togashi 8, Junko Tanizaki 9, Hisato Kawakami 1, Akihiko Ito 4, Kazuto Nishio 3, Kazuhiko Nakagawa 1",J Immunother Cancer. 2019 Sep 13;7(1):251. doi: 10.1186/s40425-019-0720-z.,Haratani K,J Immunother Cancer,2019,2019/09/15,PMC6743146,,10.1186/s40425-019-0720-z,https://pubmed.ncbi.nlm.nih.gov/31519206/,/31519206/,"KH has received honoraria from AstraZeneca K.K. and Ono Pharmaceutical Co. Ltd.; lecture fees from AS ONE Corporation, AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., MSD K.K., and Pfizer Japan Inc.; and research funding from AstraZeneca K.K. HH has received honoraria from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., and Taiho Pharmaceutical Co. Ltd. as well as research funding from AbbVie Inc., AC MEDICAL Inc., Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., EPS Associates Co. Ltd., GlaxoSmithKline K.K., Japan Clinical Research Operations Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Merck Serono Co. Ltd., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., PAREXEL International Corp., Pfizer Japan Inc., PPD-SNBL K.K., Quintiles Transnational Japan K.K., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Yakult Honsha Co. Ltd. TT has received lecture fees from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., and Pfizer Japan Inc. ST has received honoraria from Chugai Pharmaceutical Co. Ltd. as well as lecture fees from AstraZeneca K.K. and Chugai Pharmaceutical Co. Ltd. TY has received lecture fees from Bristol-Myers Squibb Co. Ltd., Daiichi Sankyo Co. Ltd., Hisamitsu Pharmaceutical Co. Inc., MundiPharma K.K., and Shionogi & Co. Ltd. YC has received lecture fees from Chugai Pharmaceutical Co. Ltd. KS has received honoraria from Becton Dickinson Co. Ltd.; and lecture fees from AstraZeneca K.K., Bio-Rad Laboratories, Inc., Roche Diagnostics K.K., SRL, Inc., and Thermo Fisher Scientific K.K. YT has received advisory fees from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., MSD K.K., Novartis Pharma K.K., and Ono Pharmaceutical Co. Ltd.; lecture fees from AstraZeneca K.K., Becton Dickinson Co. Ltd., Bristol-Myers Squibb Co. Ltd., Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Fluidigm Corporation, Illumina, Inc., MSD K.K., Ono Pharmaceutical Co. Ltd., and Shionogi & Co. Ltd.; and research funding from AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., and Ono Pharmaceutical Co. Ltd. JT has received honoraria from AstraZeneca K.K. and Eli Lilly Japan K.K. as well as lecture fees from Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., and MSD K.K. HK has received honoraria from AstraZeneca K.K., Bayer Yakuhin Ltd., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; lecture fees from Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; research funding from Chugai Pharmaceutical Co. Ltd. and Eisai Co. Ltd. A; and consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd. AI has received honoraria from MSD K.K. and Ono Pharmaceutical Co. Ltd. as well as research funding from MSD K.K. KN (Nishio) has received honoraria from Eisai Co. Ltd.; lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., and Sumitomo Bakelite Co. Ltd.; and research funding from Astellas Pharma Inc., Eli Lilly Japan K.K., Ignyta Inc., Korea Otsuka Pharmaceutical Co. Ltd., Life Technologies Japan Ltd., and Nippon Boehringer Ingelheim Co. Ltd. KN (Nakagawa) has received honoraria from Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Clinical Trial Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Nichi-Iko Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Reno. Medical K.K., and Sym Bio Pharmaceuticals Ltd.; research funding from A2 Healthcare Corp., AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., EP-CRSU Co. Ltd., GRITSTONE ONCOLOGY Inc., ICON Japan K.K., inVentiv Health Japan, MSD K.K., Linical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., PAREXEL International Corp., Pfizer Japan Inc., Quintiles Inc., Taiho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; and consulting or advisory fees from Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. All remaining authors have declared no conflicts of interest.",,"Koji Haratani 1 , Hidetoshi Hayashi 2 , Takayuki Takahama 1 3 , Yasushi Nakamura 4 , Shuta Tomida 5 , Takeshi Yoshida 1 , Yasutaka Chiba 6 , Takahiro Sawada 7 , Kazuko Sakai 3 , Yoshihiko Fujita 3 , Yosuke Togashi 8 , Junko Tanizaki 9 , Hisato Kawakami 1 , Akihiko Ito 4 , Kazuto Nishio 3 , Kazuhiko Nakagawa 1"
31221807,Kings Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference,"Claire M Nolan 1 2, Surinder S Birring 3, Matthew Maddocks 4, Toby M Maher 5 6, Suhani Patel 7, Ruth E Barker 7 5, Sarah E Jones 7 5, Jessica A Walsh 7 2, Stephanie C Wynne 7, Peter M George 5 6, William D-C Man 7 2 5",Eur Respir J. 2019 Sep 5;54(3):1900281. doi: 10.1183/13993003.00281-2019. Print 2019 Sep.,Nolan CM,Eur Respir J,2019,2019/06/22,,,10.1183/13993003.00281-2019,https://pubmed.ncbi.nlm.nih.gov/31221807/,/31221807/,"Conflict of interest: C.M. Nolan has nothing to disclose. Conflict of interest: S.S. Birring reports fees paid to Kings College Hospital for use of KBILD from Roche, Boehringer Ingelheim and Galapagos, outside the submitted work. Conflict of interest: M. Maddocks reports grants (CDF-2017-10-009 and HSDR 16/02/18) from NIHR, outside the submitted work. Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB, and has received consultancy or speakers fees from Apellis, AstraZeneca, aTyr Pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Celgene, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB. Conflict of interest: S. Patel has nothing to disclose. Conflict of interest: R.E. Barker has nothing to disclose. Conflict of interest: S.E. Jones has nothing to disclose. Conflict of interest: J.A. Walsh has nothing to disclose. Conflict of interest: S.C. Wynne has nothing to disclose. Conflict of interest: P.M. George reports personal fees for lecturing and nonfinancial support for meeting attendance from Boehringer Ingelheim and Roche Pharmaceuticals, personal fees for lecturing from Teva, outside the submitted work. Conflict of interest: W.D-C. Man reports grants from National Institute for Health Research, during the conduct of the study; grants from Pfizer, nonfinancial support from GlaxoSmithKline, personal fees from Mundipharma and Novartis, outside the submitted work.",Grants and funding CDF-2017-10-009/DH_/Department of Health/United Kingdom DRF-2014-07-089/DH_/Department of Health/United Kingdom PB-PG-0816-20022/DH_/Department of Health/United Kingdom,"Claire M Nolan 1 2 , Surinder S Birring 3 , Matthew Maddocks 4 , Toby M Maher 5 6 , Suhani Patel 7 , Ruth E Barker 7 5 , Sarah E Jones 7 5 , Jessica A Walsh 7 2 , Stephanie C Wynne 7 , Peter M George 5 6 , William D-C Man 7 2 5"
30634202,Optimising infliximab induction dosing for patients with ulcerative colitis,"Erwin Dreesen 1, Ruben Faelens 2, Gert Van Assche 3, Marc Ferrante 3, Séverine Vermeire 3, Ann Gils 1, Thomas Bouillon 2",Br J Clin Pharmacol. 2019 Apr;85(4):782-795. doi: 10.1111/bcp.13859. Epub 2019 Feb 10.,Dreesen E,Br J Clin Pharmacol,2019,2019/01/12,PMC6422726,,10.1111/bcp.13859,https://pubmed.ncbi.nlm.nih.gov/30634202/,/30634202/,"G.V.A., M.F. and S.V. are senior clinical researchers at the Research Foundation Flanders (FWO). G.V.A. received financial support for research from Abbott and Ferring Pharmaceuticals; lecture fees from Janssen, MSD and Abbott; and consultancy fees from PDL BioPharma, UCB Pharma, Sanofi‐Aventis, Abbott, AbbVie, Ferring, Novartis, Biogen Idec, Janssen Biologics, Novo Nordisk, Zealand Pharma A/S, Millenium/Takeda, Shire, Novartis and Bristol Mayer Squibb. M.F. received financial support for research from Takeda; lecture fees from MSD, Janssen, AbbVie, Boehringer‐Ingelheim, Ferring, Chiesi, Tillotts, Zeria and Mitsubishi Tanabe; and consultancy fees from MSD, Janssen, AbbVie, Boehringer‐Ingelheim, and Ferring. S.V. received grant support from MSD, AbbVie, Pfizer and Takeda; lecture fees from AbbVie, MSD, Ferring Pharmaceuticals, Takeda; Hospira and consultancy fees from AbbVie, Takeda, Pfizer, Ferring Pharmaceuticals, Shire Pharmaceuticals Group, MSD, Hospira, Mundipharma, Celgene, Galapagos, Genentech/Roche. A.G. has served as a speaker for MSD, Janssen Biologicals, Pfizer, Takeda and AbbVie; as a consultant for UCB; and has received Investigator Initiated Research Grants from Pfizer and a national grant from Takeda. R.F. is an employee of SGS Exprimo NV. ED and TB declare that they have no conflicts of interest.",,"Erwin Dreesen 1 , Ruben Faelens 2 , Gert Van Assche 3 , Marc Ferrante 3 , Séverine Vermeire 3 , Ann Gils 1 , Thomas Bouillon 2"
31221811,Blood eosinophil counts in COPD patients compared to controls,"Umme Kolsum 1, Thomas Southworth 2 3, Natalie Jackson 3, Dave Singh 2 3",Eur Respir J. 2019 Oct 24;54(4):1900633. doi: 10.1183/13993003.00633-2019. Print 2019 Oct.,Kolsum U,Eur Respir J,2019,2019/06/22,,,10.1183/13993003.00633-2019,https://pubmed.ncbi.nlm.nih.gov/31221811/,/31221811/,"Conflict of interest: U. Kolsum has nothing to disclose. Conflict of interest: T. Southworth is an employee of the Medicines Evaluation Unit. Conflict of interest: N. Jackson has nothing to disclose. Conflict of interest: D. Singh reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, and personal fees from Cipla, Genentech and Peptinnovate, outside the submitted work.",,"Umme Kolsum 1 , Thomas Southworth 2 3 , Natalie Jackson 3 , Dave Singh 2 3"
30993172,Patient safety culture in a university hospital emergency department in Switzerland - a survey study,"Meret E Ricklin 1, Felice Hess 1, Wolf E Hautz 1",GMS J Med Educ. 2019 Mar 15;36(2):Doc14. doi: 10.3205/zma001222. eCollection 2019.,Ricklin ME,GMS J Med Educ,2019,2019/04/18,PMC6446463,,10.3205/zma001222,https://pubmed.ncbi.nlm.nih.gov/30993172/,/30993172/,WEH received speakers honorarium from AO foundation Zürich and sponsoring for a conference he organizes from Mundipharma Medical Basel. All other authors declare that they have no competing interests to report.,,"Meret E Ricklin 1 , Felice Hess 1 , Wolf E Hautz 1"
31499562,Expert Workshop COPD: Lungs and Heart - Quite Often Ill Together,"B Jany 1, R Bals 2, M Dreher 3, M Held 4, L Jany 5, A Rembert Koczulla 6, M Pfeifer 7, W Randerath 8, H Watz 9, H Wilkens 10, G Steinkamp 11",Pneumologie. 2019 Nov;73(11):651-669. doi: 10.1055/a-0914-9566. Epub 2019 Sep 9.,Jany B,Pneumologie,2019,2019/09/10,,,10.1055/a-0914-9566,https://pubmed.ncbi.nlm.nih.gov/31499562/,/31499562/,"B. Jany erhielt Vortragshonorare und Reisekostenerstattung von Boehringer Ingelheim.R. Bals erhielt Forschungsmittel oder persönliche Bezüge von AstraZeneca, CSL Behring, Boehringer Ingelheim, Novartis, German Federal Ministry of Education and Research (BMBF), Competence Network Asthma and COPD (ASCONET), persönliche Bezüge von GlaxoSmithKline, Grifols. Weitere Förderung außerhalb dieser Publikation erfolgte durch die Wilhelm-Sander Stiftung, die Schwiete Stiftung, die Deutsche Krebshilfe und den Mukoviszidose e. V. M. Dreher erhielt Vortragshonorare von Actelion, Astra Zeneca, Bayer, Berlin Chemie, Boehringer, Chiesi, Hamilton, Heinen und Löwenstein, Intermune, Linde, Novartis, Pfizer, Philips Respironics, ResMed, Roche und Weinmann, Beraterhonorare von Almirall, Boehringer, Hamilton, Linde, Novartis, Pfizer, Philips Respironics, ResMed und Roche, Forschungsmittel von Linde, Philips Respironics und ResMed.M. Held gibt an Vortrags- und Beraterhonorare von folgenden Firmen erhalten zu haben: Actelion, Astra Zeneca, Bayer Healthcare, BMS, Boehringer Ingelheim, Berlin Chemie, Daichii Sanyo, MSD, OMT, Pfizer und Forschungsbeihilfen von der Firma Actelion.R. Koczulla hat Honorare von Grifols, CSL, Novartis, Roche, GSK, Boehringer, Astra Zeneca, Berlin Chemie, TEVA, Sanofi, Mundipharma, GSK, Chiesi erhalten.W. Randerath erhielt Vortragshonorare und Reisekosten der Firmen Boehringer Ingelheim, Berlin Chemie, Bayer, Novartis und Roche.H. Watz erhielt Honorare für Vortrags- und Beratungstätigkeit sowie die Durchführung von klinischen Studien und Reisekostenerstattungen von den Firmen AstraZeneca, Bayer, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GlaxoSmithKline, Takeda und SanofiAventis.H. Wilkens erhielt Honorare für Vorträge und/oder Beratertätigkeiten von Actelion, Bayer Health Care, Boehringer Ingelheim, MSD, Pfizer und Roche.G. Steinkamp erhielt Honorare für Medizinisch-wissenschaftliches Publizieren von Boehringer Ingelheim, Gilead Sciences, InfectoPharm, Novartis, Pari GmbH und Alpha1 Deutschland e. V. L. Jany und M. Pfeifer geben an, dass kein Interessenkonflikt besteht.",,"B Jany 1 , R Bals 2 , M Dreher 3 , M Held 4 , L Jany 5 , A Rembert Koczulla 6 , M Pfeifer 7 , W Randerath 8 , H Watz 9 , H Wilkens 10 , G Steinkamp 11"
31164115,A prospective study examining cachexia predictors in patients with incurable cancer,"Ola Magne Vagnildhaug 1 2, Cinzia Brunelli 3 4, Marianne J Hjermstad 4, Florian Strasser 5, Vickie Baracos 6, Andrew Wilcock 7, Maria Nabal 8, Stein Kaasa 4, Barry Laird 9, Tora S Solheim 10 11",BMC Palliat Care. 2019 Jun 4;18(1):46. doi: 10.1186/s12904-019-0429-2.,Vagnildhaug OM,BMC Palliat Care,2019,2019/06/06,PMC6549342,,10.1186/s12904-019-0429-2,https://pubmed.ncbi.nlm.nih.gov/31164115/,/31164115/,"BL has received honoraria from Helsinn. FS has had punctual advisorships (boards, expert meetings) for Danone, Grünenthal, Helsinn, ISIS Global, Mundipharma, Novartis, Novelpharm, Obexia, Ono Pharmaceutical, Psioxus Therapeutics, PrIME Oncology, Sunstone Captial, Vifor. On behalf of his institution, he has received unrestricted industry grants for clinical research from Celgene, Fresenius and Helsinn. He has participated in a clinical cachexia trial lead by Novartis. OMV, CB, MJH, VEB, AW, MN, SK and TSS declare that they have no competing interest.",Grants and funding MCCC-RP-16-A20997/MCCC_/Marie Curie/United Kingdom NA/Helsinn NA/Kreftforeningen 6070/Helse Midt-Norge,"Ola Magne Vagnildhaug 1 2 , Cinzia Brunelli 3 4 , Marianne J Hjermstad 4 , Florian Strasser 5 , Vickie Baracos 6 , Andrew Wilcock 7 , Maria Nabal 8 , Stein Kaasa 4 , Barry Laird 9 , Tora S Solheim 10 11"
31517283,Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler,"Myrna B Dolovich 1, Andreas Kuttler 2, Thomas J Dimke 2, Omar S Usmani 3",Int J Pharm X. 2019 May 30;1:100018. doi: 10.1016/j.ijpx.2019.100018. eCollection 2019 Dec.,Dolovich MB,Int J Pharm X,2019,2019/09/14,PMC6733285,,10.1016/j.ijpx.2019.100018,https://pubmed.ncbi.nlm.nih.gov/31517283/,/31517283/,"Myrna B. Dolovich has no competing interests. Andreas Kuttler and Thomas J. Dimke are employees of Novartis Pharma AG. Omar Usmani has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Napp, MundiPharma, Sandoz, Cipla, Takeda, Zentiva and Trudell Medical; has received grant support from AstraZeneca, Boehringer Ingelheim, Chiesi, and Edmond Pharma; pyaments for lectures (including service on speaker bureas) from Boehringer Ingelheim, Chiesi, Cipla, Napp, MundiPharma, Sandoz and Aerocrine.",,"Myrna B Dolovich 1 , Andreas Kuttler 2 , Thomas J Dimke 2 , Omar S Usmani 3"
31096982,Prevalence and management of chronic breathlessness in COPD in a tertiary care center,"H Carette 1, M Zysman 2 3, C Morelot-Panzini 4, J Perrin 1, E Gomez 1, A Guillaumot 1, P R Burgel 5, G Deslee 6, P Surpas 7, O Le Rouzic 8, T Perez 8, A Chaouat 1, N Roche 5, F Chabot 1 ; Initiatives BPCO (bronchopneumopathie chronique obstructive) Scientific Committee and Investigators",BMC Pulm Med. 2019 May 16;19(1):95. doi: 10.1186/s12890-019-0851-5.,Carette H,BMC Pulm Med,2019,2019/05/18,PMC6524222,,10.1186/s12890-019-0851-5,https://pubmed.ncbi.nlm.nih.gov/31096982/,/31096982/,"HC reports grants and personal fees from France Oxygène, personal fees from RIRL reseau d’insuffisance respiratoire de Lorraine, outside the submitted work. MZ reports grants and personal fees from BoehringerIngelheim, personal fees from Novartis, personal fees from Chiesi, personal fees from GSK outside the submitted work. CMP declares that she have no competing interests. JP declares that she have no competing interests. EG declares that she have no competing interests. AG declares that she have no competing interests. PRB reports personal fees from Aptalis, personal fees from Astra-Zeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Novartis, personal fees from Pfizer, personal fees from Vertex, personal fees from Zambon, outside the submitted work; GD reports personal fees from Novartis, personal fees from Astra Zeneca, personal fees from BTG/PneumRx, personal fees from Chiesi, personal fees from Boehringer Ingelheim, outside the submitted work. PS reports grants and personal fees from Boehringer Ingelheim outside the submitted work. OLR reports grants and personal fees personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis; non-financial support from GlaxoSmithKline, MundiPharma, Pfizer, Teva, Santelys Association, Vertex and Vitalaire, all outside the submitted work. TP reports personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from GSK, personal fees from Chiesi, personal fees from Pierre Fabre, outside the submitted work. AC reports grants and personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Actelion, personal fees from GSK outside the submitted work. NR reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, personal fees from Teva, personal fees from GSK, personal fees from AstraZeneca, personal fees from Chiesi, personal fees from Mundipharma, personal fees from Cipla, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Sandoz, personal fees from 3 M, personal fees from Zambon, outside the submitted work. FC reports grants and personal fees from AGEVIE, grants from ARAIRLOR, grants from Air Liquide, grants from Breas, grants from Covidien, grants from Philips, grants from Resmed, grants from Respironics, grants from Weinman and personal fees from Astra-Zeneca, personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from Novartis, outside the submitted work.",Grants and funding 1/Boehringer Ingelheim (US) 2/Pfizer Foundation,"H Carette 1 , M Zysman 2 3 , C Morelot-Panzini 4 , J Perrin 1 , E Gomez 1 , A Guillaumot 1 , P R Burgel 5 , G Deslee 6 , P Surpas 7 , O Le Rouzic 8 , T Perez 8 , A Chaouat 1 , N Roche 5 , F Chabot 1 ; Initiatives BPCO (bronchopneumopathie chronique obstructive) Scientific Committee and Investigators"
31472683,Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs,"Guntram Schernthaner 1, Avraham Karasik 2, Agnė Abraitienė 3, Alexander S Ametov 4, Zsolt Gaàl 5, Janusz Gumprecht 6, Andrej Janež 7, Susanne Kaser 8, Katarina Lalić 9, Boris N Mankovsky 10, Evgeny Moshkovich 11, Marju Past 12, Martin Prázný 13, Gabriela Radulian 14, Lea Smirčić Duvnjak 15, Ivan Tkáč 16, Kārlis Trušinskis 17",Cardiovasc Diabetol. 2019 Aug 31;18(1):115. doi: 10.1186/s12933-019-0920-3.,Schernthaner G,Cardiovasc Diabetol,2019,2019/09/02,PMC6717330,,10.1186/s12933-019-0920-3,https://pubmed.ncbi.nlm.nih.gov/31472683/,/31472683/,"GS has previously received research grants and honoraria for speaking from Abbot, Amgen, Andromeda, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, DeveloGen, Eli Lilly, GlaxoSmithKline, Janssen, Merck, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Serono, Servier and Takeda. AK has received research support, lecture fees and served as advisory board member for Astra Zeneca, Boehringer Ingelheim and Novo Nordisk. ZG declares receipt of consultation fees from Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca and MSD; and Advisory board fees from Sanofi, Novo Nordisk, and Eli Lilly. JG has received speaker’s or consulting honoraria from Novo Nordisk, Eli Lilly, Servier, MSD, Bioton (Poland), Sanofi, Polpharma (Poland), Polfa Tarchomin (Poland), AstraZeneca and Boehringer Ingelheim. AJ has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk and Sanofi. SK declares research grants from MSD Austria and Boehringer Ingelheim RCV; consultancy fees or honoraria for speaking from AstraZeneca, Boehringer Ingelheim, MSD, Eli Lilly, Novo Nordisk, Sanofi, Takeda and Mundipharma. BNM has been a member of Advisory Boards for Boehringer Ingelheim and AstraZeneca; and a member of a speaker bureau for Boehringer Ingelheim, AstraZeneca and Sanofi. EM is a lecturer for Boehringer Ingelheim, AstraZeneca, Sanofi, Novo Nordisk, MSD and Eli Lilly. MP2 has been a consultant or speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Sanofi, Takeda and Teva. LSD declares receipt of consultation fees or participation in a company-sponsored speaker’s bureau for Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca, Takeda, MSD and Merck. IT declares consultation and lecture fees from Boehringer Ingelheim, Eli Lilly, Mundipharma and Novo Nordisk. KT declares lecture honoraria and conference travel support from Boehringer Ingelheim. AA, ASA, GR, KL and MP1 declare no competing interests in relation to this article.",,"Guntram Schernthaner 1 , Avraham Karasik 2 , Agnė Abraitienė 3 , Alexander S Ametov 4 , Zsolt Gaàl 5 , Janusz Gumprecht 6 , Andrej Janež 7 , Susanne Kaser 8 , Katarina Lalić 9 , Boris N Mankovsky 10 , Evgeny Moshkovich 11 , Marju Past 12 , Martin Prázný 13 , Gabriela Radulian 14 , Lea Smirčić Duvnjak 15 , Ivan Tkáč 16 , Kārlis Trušinskis 17"
31866619,Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma,"Hirohiko Shibayama, Takanori Teshima, Ilseung Choi, Kiyohiko Hatake, Naohiro Sekiguchi, Nozomi Yoshinari",J Clin Exp Hematop. 2019;59(4):179-186. doi: 10.3960/jslrt.19023.,Shibayama H,J Clin Exp Hematop,2019,2019/12/24,PMC6954169,,10.3960/jslrt.19023,https://pubmed.ncbi.nlm.nih.gov/31866619/,/31866619/,"CONFLICTS OF INTEREST: HS has received honoraria from AbbVie, AstraZeneca, Celgene, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Fujimoto, Janssen, Kyowa Hakko Kirin, Mundipharma, Nippon Shinyaku, Novartis, Ono, Otsuka, Sanofi and Takeda; and research funds from Astellas, Celgene, Chugai, Dainippon Sumitomo, Eisai, Fujimoto, Janssen, Kyowa Hakko Kirin, Mundipharma, Nippon Shinyaku, Ono, Otsuka, Shionogi, Taiho, Takeda and Teijin. TT has received honoraria from Bristol-Myers Squibb, Celgene, Chugai, Kyowa Hakko Kirin, Merck Sharp & Dohme Corp, Novartis, Pfizer and Takeda; and research funds from Astellas, Chugai, CMIC Holdings Fuji, IQVIA, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, PPD-SNBL, Sanofi Shionogi, Sumitomo Dainippon SymBio and Takeda. IC has nothing to declare. KH has received personal fees from Celgene, Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, Meiji Seika, Ono and Takeda; and grants from Eisai. NS has received grants from A2 Healthcare, Astellas, Dainippon Sumitomo, Janssen, Merck Sharp & Dohme Corp, Otsuka, Pfizer and PPD-SNBL. NY is an employee of Janssen Pharmaceutical KK.",,"Hirohiko Shibayama, Takanori Teshima, Ilseung Choi, Kiyohiko Hatake, Naohiro Sekiguchi, Nozomi Yoshinari"
30880938,"Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT","Anthony D DUrzo 1, Dave Singh 2, James F Donohue 3, Edward M Kerwin 4, Anna Ribera 5, Eduard Molins 5, Ferran Chuecos 5, Diana Jarreta 5, Esther Garcia Gil 5",Int J Chron Obstruct Pulmon Dis. 2019 Feb 26;14:479-491. doi: 10.2147/COPD.S185502. eCollection 2019.,DUrzo AD,Int J Chron Obstruct Pulmon Dis,2019,2019/03/19,PMC6396834,,10.2147/COPD.S185502,https://pubmed.ncbi.nlm.nih.gov/30880938/,/30880938/,"Disclosure ADD has received research, consulting, and lecturing fees from Almirall S.A., Altana, AstraZeneca (AZ), Boehringer Ingelheim (BI; Canada) Ltd., Forest Laboratories LLC, GlaxoSmithKline (GSK), KOS Pharmaceuticals, Merck Canada, Methapharm, Novartis (Nov; Canada/USA), ONO Pharmaceutical, Pfizer Canada, Schering-Plough, Sepracor Inc., and SkyePharma. DS has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards, and research grants from various pharmaceutical companies including Apellis Pharmaceuticals, AZ, BI, Chiesi Farmaceutici S.p.A, Cipla, Genentech, Glenmark Pharmaceuticals, GSK, Johnson and Johnson, Mundipharma, Nov, Peptinnovate Ltd., Pfizer Inc., Pulmatrix, Skyepharma, Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharma. JFD has received consulting fees from AZ, BI, Circassia, GSK, and Sunovion. He is a member of the Data Monitoring Committee for AZ. EMK has participated in consulting, advisory boards, speaker panels, or received travel reimbursement from Amphastar Pharmaceuticals, AZ, Forest Laboratories LLC, GSK, Mylan, Nov, Oriel, Pearl Therapeutics, Sunovion, Teva Pharmaceutical Industries Ltd., and Theravance Biopharma. He has conducted multicenter clinical research trials for ~40 pharmaceutical companies. AR, EM, FC, DJ, and EGG are employees of AZ and former employees of Almirall S.A., Barcelona, Spain. The authors report no other conflicts of interest in this work.",,"Anthony D DUrzo 1 , Dave Singh 2 , James F Donohue 3 , Edward M Kerwin 4 , Anna Ribera 5 , Eduard Molins 5 , Ferran Chuecos 5 , Diana Jarreta 5 , Esther Garcia Gil 5"
30606188,Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study,"Lisa Strada 1, Christiane Sybille Schmidt 2, Moritz Rosenkranz 1, Uwe Verthein 1, Norbert Scherbaum 3, Jens Reimer 1 4, Bernd Schulte 1",Subst Abuse Treat Prev Policy. 2019 Jan 3;14(1):2. doi: 10.1186/s13011-018-0187-9.,Strada L,Subst Abuse Treat Prev Policy,2019,2019/01/05,PMC6318871,,10.1186/s13011-018-0187-9,https://pubmed.ncbi.nlm.nih.gov/30606188/,/30606188/,"Ethical approval was granted by the Ethics Committee of the Medical Association of Hamburg, Ref. PV4603, and by each local Ethics Committee in Germany. Not applicable; no details on individuals are reported within the manuscript JR received unrestricted educational grants, adviser and/or speakers remuneration from AbbVie, Desitin, Gilead, Janssen-Cilag, Mundipharma, Otsuka-Lundbeck, Hexal. NS received honoraria for several activities (advisory boards, lectures, manuscripts and educational material) by the factories AbbVie, Lundbeck, Medice, Mundipharma, Reckitt-Benckiser/Indivior, and Sanofi-Aventis. During the last three years he participated in clinical trials financed by the pharmaceutical industry. BS, UV, LS, CS, MR declare no potential conflicts of interest. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",,"Lisa Strada 1 , Christiane Sybille Schmidt 2 , Moritz Rosenkranz 1 , Uwe Verthein 1 , Norbert Scherbaum 3 , Jens Reimer 1 4 , Bernd Schulte 1"
31048351,Cumulative effect of smoking on disease burden and multimorbidity in adult-onset asthma,"Minna Tommola 1, Pinja Ilmarinen 2, Leena E Tuomisto 2, Lauri Lehtimäki 3 4, Onni Niemelä 4 5, Pentti Nieminen 6, Hannu Kankaanranta 2 4",Eur Respir J. 2019 Sep 5;54(3):1801580. doi: 10.1183/13993003.01580-2018. Print 2019 Sep.,Tommola M,Eur Respir J,2019,2019/05/04,,,10.1183/13993003.01580-2018,https://pubmed.ncbi.nlm.nih.gov/31048351/,/31048351/,"Conflict of interest: M. Tommola reports personal fees for lectures and consultancy from Boehringer Ingelheim, personal fees for lectures from AstraZeneca, Filha ry, GlaxoSmithKline and Pfizer, grants from Orion research foundation, outside the submitted work. Conflict of interest: P. Ilmarinen reports grants from AstraZeneca, personal fees for lectures from MundiPharma, Orion and AstraZeneca, outside the submitted work. Conflict of interest: L.E. Tuomisto reports non-financial support for attending an international congress from Chiesi, Orion Pharma and TEVA, personal fees for lectures and non-financial support for attending an international congress from Boehringer Ingelheim, personal fees for lectures from AstraZeneca, outside the submitted work. Conflict of interest: L. Lehtimäki reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, OrionPharma, Teva and ALK, outside the submitted work. Conflict of interest: O. Niemelä has nothing to disclose. Conflict of interest: P. Nieminen has nothing to disclose. Conflict of interest: H. Kankaanranta reports grants, personal fees for lectures and consulting, costs for attending an international congress from AstraZeneca, personal fees for consulting from Chiesi Pharma AB and Roche, personal fees for lectures and consulting, costs for attending an international congress from Boehringer Ingelheim, personal fees for lectures and consulting from Novartis, personal fees for lectures from Mundipharma and Orion Pharma, outside the submitted work.",,"Minna Tommola 1 , Pinja Ilmarinen 2 , Leena E Tuomisto 2 , Lauri Lehtimäki 3 4 , Onni Niemelä 4 5 , Pentti Nieminen 6 , Hannu Kankaanranta 2 4"
31656683,Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2),"Jean Bousquet 1 2 3 4 5 6 7 8, Nhân Pham-Thi 9, Anna Bedbrook 2, Ioana Agache 10, Isabella Annesi-Maesano 11, Ignacio Ansotegui 12, Josep M Anto 13 14 15, Claus Bachert 16, Samuel Benveniste 17 18, Mike Bewick 19, Nils Billo 20, Sinthia Bosnic-Anticevich 21, Isabelle Bosse 22, Guy Brusselle 23, Moïses A Calderon 24, G Walter Canonica 25, Luis Caraballo 26, Victoria Cardona 27, Ana Maria Carriazo 28, Eugene Cash 29, Lorenzo Cecchi 30, Derek K Chu 31, Elaine Colgan 32, Elisio Costa 33, Alvaro A Cruz 34, Wienczyslawa Czarlewski 35, Stephen Durham 36, Motohiro Ebisawa 37, Marina Erhola 38, Jean-Luc Fauquert 39, Wytske J Fokkens 8 40, Joao A Fonseca 41, Nick Guldemond 42, Tomohisa Iinuma 43, Maddalena Illario 44, Ludger Klimek 45, Piotr Kuna 46, Violeta Kvedariene 47, Désirée Larenas-Linneman 48, Daniel Laune 49, Lan T T Le 50, Olga Lourenço 51, Joao O Malva 52, Gert Marien 8, Enrica Menditto 53, Joaquim Mullol 54, Lars Münter 55, Yoshitaka Okamoto 43, Gabrielle L Onorato 2, Nikos G Papadopoulos 56 57, Maritta Perala 58, Oliver Pfaar 59, Abigail Phillips 60, Jim Phillips 61, Hilary Pinnock 62, Fabienne Portejoie 2, Pablo Quinones-Delgado 63, Christine Rolland 64, Ulysse Rodts 65, Boleslaw Samolinski 66, Mario Sanchez-Borges 67, Holger J Schünemann 30, Mohamed Shamji 68, David Somekh 69, Alkis Togias 70, Sanna Toppila-Salmi 71, Ioanna Tsiligianni 72, Omar Usmani 73, Samantha Walker 74, Dana Wallace 75, Arunas Valiulis 76, Rianne Van der Kleij 77, Maria Teresa Ventura 78, Sian Williams 79, Arzu Yorgancioglu 80, Torsten Zuberbier 81",J Thorac Dis. 2019 Sep;11(9):4072-4084. doi: 10.21037/jtd.2019.09.38.,Bousquet J,J Thorac Dis,2019,2019/10/29,PMC6790426,,10.21037/jtd.2019.09.38,https://pubmed.ncbi.nlm.nih.gov/31656683/,/31656683/,"Conflicts of Interest: Dr. Ansotegui reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, Astra Zeneca, outside the submitted work. Dr. Bachert reports personal fees from ALK, Stallergen, during the conduct of the study; personal fees from ALK, Stallergen, outside the submitted work. Dr. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov, outside the submitted work. Dr. Calderon reports personal fees from ALK-Abello, ALK-US, Stallergenes Greer, HAL-Allergy, Allergopharma, ASIT-Biotech, outside the submitted work. Dr. Canonica reports grants from ALK ABELLO, Allergy Therapeutics, Anallergo, Hal Allergy, Stallergenes Greer, outside the submitted work. Dr. Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher, Stallergenes, outside the submitted work. Dr. Cecchi reports personal fees from Menarini, Malesci ALK, outside the submitted work. Dr. Cruz reports grants from National Institutes for Health Research (UK), National Institutes of Health (USA), grants and other from National Research Council (Brazil), other from Federal University of Bahia (Brazil), non-financial support from Fundacao ProAR, grants and personal fees from GSK, personal fees from AstraZeneca, Boehringer Ingelheim, CHIESI, Eurofarma, MEDA Pharma. Dr. Durham reports personal fees from Adiga, personal fees from ALK, personal fees from Allergopharma, MedicalUpdate GmBC, UCB, outside the submitted work. Dr. Ebisawa reports personal fees from Mylan, DBV Technologies, Thermofisher, outside the submitted work. Dr. Fokkens reports grants from Mylan, Allergy Therapeutics, GSK, ALK. Dr. Fonseca being a partner in a company developing mobile technologies for monitoring airways diseases. Dr. Klimek reports grants and personal fees from ALK Abelló, Denmark, grants and personal fees from Novartis, Switzerland, Allergopharma, Germany, Bionorica, Sweden, GSK, Great Britain, Lofarma, Italy, personal fees from MEDA, Sweden, Boehringer Ingelheim, Germany, grants from Biomay, Austria, grants from HAL, Netherlands, grants from LETI, Spain, Roxall, Germany, Bencard, Great Britain, outside the submitted work. Dr. Kuna reports personal fees from Adamed, AstraZeneca, Boehringer Ingelheim, Hal, Chiesi, Novartis, Berlin Chemie Menarini, outside the submitted work. Dr. Kvedariene reports personal fees from GSK, non-financial support from StallergenGreer, Mylan, AstraZeneca, Dimuna, Norameda, outside the submitted work. D Larenas Linnemann reports personal fees from GSK, Astrazeneca, MEDA, Boehringer Ingelheim, Novartis, Grunenthal, UCB, Amstrong, Siegfried, DBV Technologies, MSD, Pfizer. grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Chiesi, Boehringer Ingelheim, outside the submitted work. Dr. MULLOL reports personal fees from SANOFI-GenzymeRegeneron, ALK-Abelló A/S, Menarini Group, MSD, GlaxoSmithKline, Novartis, GENENTECH-Roche, grants and personal fees from UCB Pharma, MYLAN-MEDA Pharma, URIACH Group, outside the submitted work. Y Okamoto reports personal fees from Shionogi Co. Ltd., Torii Co. Ltd., GSK, MSD, Kyowa Co. Ltd., from Eizai Co. Ltd., grants and personal fees from Kyorin Co. Ltd., Tiho Co. Ltd., grants from Yakuruto Co. Ltd., Yamada Bee Farm, outside the submitted work. N Papadopoulos reports personal fees from Novartis, Faes Farma, BIOMAY, HAL, Nutricia Research, Menarini, Novartis, MEDA, Abbvie, Novartis, MSD, Omega Pharma Danone, grants from Menarini outside the submitted work. O Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biotech Tools S.A, LETI/LETI Pharma, Anergis S.A. grants from Biomay, Nuvo, Circassia, Glaxo Smith Kline, personal fees from Novartis Pharma, MEDA Pharma, Mobile Chamber Experts (a GA2LEN Partner), Pohl-Boskamp, Indoor Biotechnologies, grants from, outside the submitted work. Dr. Samolinski reports non-financial support from Mylan, during the conduct of the study. Dr. Shamji reports grants and personal fees from ALK, ASIT Biotech, sa, Allergopharma, grants from Regeneron, Merck, Immune Tolerance Network, outside the submitted work. Dr. Tsiligianni reports personal fees from Novartis, GSK, Boehringer Ingelheim, Astra Zeneca, grants from GSK Hellas, outside the submitted work. Dr. Wallace is co-chair of the Joint Task Force on Practice Parameters of the AAAAI/ACAAI. However, it does not feel that this causes any conflict of interest in the writing/review of the document. Zuberbier reports fees from Bayer Health Care, FAES, Novartis, Henkel, Astra Zeneca, AbbVie, ALK, Almirrall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, HAL, Leti, Meda, Menarini, Merck, MSD, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan, l’Oreal; Commitee member: WHO-Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA). Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI). Head: European Centre for Allergy Research Foundation (ECARF). Secretary General: Global Allergy and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). The other authors have no conflicts of interest to declare.",,"Jean Bousquet 1 2 3 4 5 6 7 8 , Nhân Pham-Thi 9 , Anna Bedbrook 2 , Ioana Agache 10 , Isabella Annesi-Maesano 11 , Ignacio Ansotegui 12 , Josep M Anto 13 14 15 , Claus Bachert 16 , Samuel Benveniste 17 18 , Mike Bewick 19 , Nils Billo 20 , Sinthia Bosnic-Anticevich 21 , Isabelle Bosse 22 , Guy Brusselle 23 , Moïses A Calderon 24 , G Walter Canonica 25 , Luis Caraballo 26 , Victoria Cardona 27 , Ana Maria Carriazo 28 , Eugene Cash 29 , Lorenzo Cecchi 30 , Derek K Chu 31 , Elaine Colgan 32 , Elisio Costa 33 , Alvaro A Cruz 34 , Wienczyslawa Czarlewski 35 , Stephen Durham 36 , Motohiro Ebisawa 37 , Marina Erhola 38 , Jean-Luc Fauquert 39 , Wytske J Fokkens 8 40 , Joao A Fonseca 41 , Nick Guldemond 42 , Tomohisa Iinuma 43 , Maddalena Illario 44 , Ludger Klimek 45 , Piotr Kuna 46 , Violeta Kvedariene 47 , Désirée Larenas-Linneman 48 , Daniel Laune 49 , Lan T T Le 50 , Olga Lourenço 51 , Joao O Malva 52 , Gert Marien 8 , Enrica Menditto 53 , Joaquim Mullol 54 , Lars Münter 55 , Yoshitaka Okamoto 43 , Gabrielle L Onorato 2 , Nikos G Papadopoulos 56 57 , Maritta Perala 58 , Oliver Pfaar 59 , Abigail Phillips 60 , Jim Phillips 61 , Hilary Pinnock 62 , Fabienne Portejoie 2 , Pablo Quinones-Delgado 63 , Christine Rolland 64 , Ulysse Rodts 65 , Boleslaw Samolinski 66 , Mario Sanchez-Borges 67 , Holger J Schünemann 30 , Mohamed Shamji 68 , David Somekh 69 , Alkis Togias 70 , Sanna Toppila-Salmi 71 , Ioanna Tsiligianni 72 , Omar Usmani 73 , Samantha Walker 74 , Dana Wallace 75 , Arunas Valiulis 76 , Rianne Van der Kleij 77 , Maria Teresa Ventura 78 , Sian Williams 79 , Arzu Yorgancioglu 80 , Torsten Zuberbier 81"
30740787,Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma,"Kenji Ishitsuka 1, Satoshi Yurimoto 2, Yukie Tsuji 3, Manabu Iwabuchi 3, Takeshi Takahashi 2, Kensei Tobinai 4",Eur J Haematol. 2019 May;102(5):407-415. doi: 10.1111/ejh.13220. Epub 2019 Mar 12.,Ishitsuka K,Eur J Haematol,2019,2019/02/12,PMC6850465,,10.1111/ejh.13220,https://pubmed.ncbi.nlm.nih.gov/30740787/,/30740787/,"KI reports grants and personal fees from Takeda Pharmaceutical; personal fees from Bristol‐Myers Squibb, Celgene, Chugai Pharmaceutical, and Kyowa Hakko Kirin. SY, YT, MI, and TT are employees of Kyowa Hakko Kirin. KT reports grants and personal fees from Ono Pharmaceutical, Celgene, Eisai, Takeda, Mundipharma, Janssen, Kyowa Hakko Kirin, and Chugai Pharmaceutical; personal fees from Zenyaku Kogyo, and HUYA Bioscience International; and grants from GlaxoSmithKline, and AbbVie.","Grants and funding Kyowa Hakko Kirin Co., Ltd.","Kenji Ishitsuka 1 , Satoshi Yurimoto 2 , Yukie Tsuji 3 , Manabu Iwabuchi 3 , Takeshi Takahashi 2 , Kensei Tobinai 4"
31648316,"Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease","Lauren C Bylsma 1, Anne Gulbech Ording 2, Adam Rosenthal 3, Buket Öztürk 2, Jon P Fryzek 1 2, Jaime Morales Arias 3, Alexander Röth 4, Sigbjørn Berentsen 5",Blood Adv. 2019 Oct 22;3(20):2980-2985. doi: 10.1182/bloodadvances.2019000476.,Bylsma LC,Blood Adv,2019,2019/10/25,PMC6849939,,10.1182/bloodadvances.2019000476,https://pubmed.ncbi.nlm.nih.gov/31648316/,/31648316/,"Conflict-of-interest disclosure: S.B. has received research support from Mundipharma, lecture honoraria from Alexion, Sanofi, and Janssen-Cilag, and travel support from Alexion, Apellis, and Celgene and has been an advisory board member for Sanofi; L.C.B. and J.P.F. are employees of EpidStrategies, a Division of ToxStrategies, Inc.; A. Rosenthal and J.M.A. are employees of Sanofi; and A. Röth has received research support from Alexion and Roche, lecture honoraria from Alexion, Novartis, and Sanofi, and travel support from Alexion and has been an advisory board member for Alexion and Sanofi. The remaining authors declare no competing financial interests.",,"Lauren C Bylsma 1 , Anne Gulbech Ording 2 , Adam Rosenthal 3 , Buket Öztürk 2 , Jon P Fryzek 1 2 , Jaime Morales Arias 3 , Alexander Röth 4 , Sigbjørn Berentsen 5"
31221806,Bronchodilator reversibility in asthma and COPD: findings from three large population studies,"Christer Janson 1 2, Andrei Malinovschi 3, Andre F S Amaral 2, Simone Accordini 4, Jean Bousquet 5 6 7, A Sonia Buist 8, Giorgio Walter Canonica 9, Barbro Dahlén 10, Judith Garcia-Aymerich 11 12 13, Louisa Gnatiuc 14, Marek L Kowalski 15, Jaymini Patel 2, Wan Tan 16, Kjell Torén 17, Torsten Zuberbier 7, Peter Burney 2, Deborah Jarvis 2",Eur Respir J. 2019 Sep 5;54(3):1900561. doi: 10.1183/13993003.00561-2019. Print 2019 Sep.,Janson C,Eur Respir J,2019,2019/06/22,,,10.1183/13993003.00561-2019,https://pubmed.ncbi.nlm.nih.gov/31221806/,/31221806/,"Conflict of interest: C. Janson has nothing to disclose. Conflict of interest: A. Malinovschi has nothing to disclose. Conflict of interest: A.F.S. Amaral has nothing to disclose. Conflict of interest: S. Accordini has nothing to disclose. Conflict of interest: J. Bousquet reports personal fees and other funding from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and other funding from Kyomed, outside the submitted work. Conflict of interest: S.A. Buist has nothing to disclose. Conflict of interest: G.W. Canonica has nothing to disclose. Conflict of interest: B. Dahlen has received personal fees from TEVA, Sanofi, GSK and AstraZeneca, outside the submitted work. Conflict of interest: J. Garcia Aymerich has nothing to disclose. Conflict of interest: L. Gnatiuc has nothing to disclose. Conflict of interest: M.L. Kowalski has nothing to disclose. Conflict of interest: J. Patel has nothing to disclose. Conflict of interest: W. Tan has nothing to disclose. Conflict of interest: K. Torén has nothing to disclose. Conflict of interest: T. Zuberbier has received consultancy fees from Bayer Health Care, FAES, Novartis and Henkel; has received grants/has grants pensing form Novartis and Henkel, and has received lecture fees from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer HealthCare, Bencradm Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, TEVA, UCB, Henkel, Kryolan and LOreal, outside the submitted work. Conflict of interest: P. Burney has nothing to disclose. Conflict of interest: D. Jarvis has nothing to disclose.",Grants and funding G0901214/MRC_/Medical Research Council/United Kingdom 085790/Z/08/Z/WT_/Wellcome Trust/United Kingdom,"Christer Janson 1 2 , Andrei Malinovschi 3 , Andre F S Amaral 2 , Simone Accordini 4 , Jean Bousquet 5 6 7 , A Sonia Buist 8 , Giorgio Walter Canonica 9 , Barbro Dahlén 10 , Judith Garcia-Aymerich 11 12 13 , Louisa Gnatiuc 14 , Marek L Kowalski 15 , Jaymini Patel 2 , Wan Tan 16 , Kjell Torén 17 , Torsten Zuberbier 7 , Peter Burney 2 , Deborah Jarvis 2"
31624113,Low agreement between mMRC rated by patients and clinicians: implications for practice,"Magnus Ekström 1 2, Sungwon Chang 2, Miriam J Johnson 2 3, Belinda Fazekas 2, Slavica Kochovska 2, Chao Huang 3, David C Currow 2 3",Eur Respir J. 2019 Dec 19;54(6):1901517. doi: 10.1183/13993003.01517-2019. Print 2019 Dec.,Ekström M,Eur Respir J,2019,2019/10/19,,,10.1183/13993003.01517-2019,https://pubmed.ncbi.nlm.nih.gov/31624113/,/31624113/,"Conflict of interest: M. Ekström has nothing to disclose. Conflict of interest: S. Chang has nothing to disclose. Conflict of interest: M.J. Johnson has nothing to disclose. Conflict of interest: B. Fazekas has nothing to disclose. Conflict of interest: S. Kochovska has nothing to disclose. Conflict of interest: C. Huang has nothing to disclose. Conflict of interest: D.C. Currow received an unrestricted research grant from Mundipharma, is an unpaid member of an advisory board for Helsinn Pharmaceuticals, and has consulted Specialist Therapeutics and Mayne Pharma and received intellectual property payments from Mayne Pharma.",,"Magnus Ekström 1 2 , Sungwon Chang 2 , Miriam J Johnson 2 3 , Belinda Fazekas 2 , Slavica Kochovska 2 , Chao Huang 3 , David C Currow 2 3"
31159350,Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors,"Mie K Eickhoff 1, Claire C J Dekkers 2, Bart J Kramers 3, Gozewijn Dirk Laverman 4, Marie Frimodt-Møller 5, Niklas Rye Jørgensen 6, Jens Faber 7 8, A H Jan Danser 9, Ron T Gansevoort 10, Peter Rossing 11 12, Frederik Persson 13, Hiddo J L Heerspink 14",J Clin Med. 2019 May 31;8(6):779. doi: 10.3390/jcm8060779.,Eickhoff MK,J Clin Med,2019,2019/06/05,PMC6616433,,10.3390/jcm8060779,https://pubmed.ncbi.nlm.nih.gov/31159350/,/31159350/,"C.C.J.D., B.J.K., M.F.M., N.R.J., A.H.J.D., and R.T.G. report no conflicts of interest. M.K.E. has served as an educator for Astra Zeneca (all honoraria to institution). G.D.L. has received lecture fees from Sanofi, Astra Zeneca, and Jansen, and has served as a consultant for Abbvie, Sanofi, Novo Nordisk, Astra Zeneca, Boehringer Ingelheim, and MSD. J.F. has served as a consultant on advisory boards or as an educator for Novo Nordisk, Novartis, AstraZeneca, Eli Lilly, Otsuka, and Boehringer Ingelheim. P.R. has served as a consultant on advisory boards or as an educator for Astra Zeneca, Astellas, AbbVie, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Merck, Bayer (all honoraria to institution), has shares in Novo Nordisk, and has received research grants to institution from Novo Nordisk and Astra Zeneca. F.P. has served as a consultant on advisory boards or as an educator for Astra Zeneca, Novo Nordisk, Sanofi, Mundipharma, MSD, Boehringer Ingelheim, Novartis, and Amgen, and has received research grants to institution from Novo Nordisk, Amgen, and Astra Zeneca. H.J.L.H. is a consultant for and has received honoraria from AbbVie, Astellas, Astra Zeneca, Boehringer Ingelheim, Fresenius, Janssen, and Merck; he has a policy that all honoraria are paid to his employer. Astra Zeneca provided the study medication for both studies, but had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.",,"Mie K Eickhoff 1 , Claire C J Dekkers 2 , Bart J Kramers 3 , Gozewijn Dirk Laverman 4 , Marie Frimodt-Møller 5 , Niklas Rye Jørgensen 6 , Jens Faber 7 8 , A H Jan Danser 9 , Ron T Gansevoort 10 , Peter Rossing 11 12 , Frederik Persson 13 , Hiddo J L Heerspink 14"
30956210,Riociguat for treatment of pulmonary hypertension in COPD: a translational study,"Alexandra Pichl 1 2, Natascha Sommer 1 2, Mariola Bednorz 1, Michael Seimetz 1, Stefan Hadzic 1, Stefan Kuhnert 1, Simone Kraut 1, Elsa T Roxlau 1, Baktybek Kojonazarov 1, Jochen Wilhelm 1, Marija Gredic 1, Henning Gall 1, Khodr Tello 1, Manuel J Richter 1, Oleg Pak 1, Aleksandar Petrovic 1, Matthias Hecker 1, Ralph T Schermuly 1, Friedrich Grimminger 1, Werner Seeger 1 3, Hossein A Ghofrani 1, Norbert Weissmann 4",Eur Respir J. 2019 Jun 27;53(6):1802445. doi: 10.1183/13993003.02445-2018. Print 2019 Jun.,Pichl A,Eur Respir J,2019,2019/04/09,,,10.1183/13993003.02445-2018,https://pubmed.ncbi.nlm.nih.gov/30956210/,/30956210/,"Conflict of interest: A. Pichl has nothing to disclose. Conflict of interest: N. Sommer has nothing to disclose. Conflict of interest: M. Bednorz has nothing to disclose. Conflict of interest: M. Seimetz has nothing to disclose. Conflict of interest: S. Hadzic has nothing to disclose. Conflict of interest: S. Kuhnert reports nonfinancial (travel) support from Teva, Bayer and Astellas, personal fees for advisory board work from Chiesi, personal fees for advisory board work and nonfinancial (travel) support from GSK, personal fees for advisory board work, honoraria and nonfinancial (travel) support from Novartis, honoraria from Berlin-Chemie Menarini and AstraZeneca, outside the submitted work. Conflict of interest: S. Kraut has nothing to disclose. Conflict of interest: E.T. Roxlau has nothing to disclose. Conflict of interest: B. Kojonazarov has nothing to disclose. Conflict of interest: J. Wilhelm has nothing to disclose. Conflict of interest: M. Gredic has nothing to disclose. Conflict of interest: H. Gall reports grants and personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen Cilag, Lilly, MSD, Novartis, Pfizer, and United Therapeutics/OMT, outside the submitted work. Conflict of interest: K. Tello has nothing to disclose. Conflict of interest: M.J. Richter reports grants from United Therapeutics, grants and personal fees for consultancy and lecturing from Bayer, personal fees for lecturing from Actelion, Mundipharma, Roche and OMT, outside the submitted work. Conflict of interest: O. Pak has nothing to disclose. Conflict of interest: A. Petrovic has nothing to disclose. Conflict of interest: M. Hecker has nothing to disclose. Conflict of interest: R.T. Schermuly has nothing to disclose. Conflict of interest: F. Grimminger has nothing to disclose. Conflict of interest: W. Seeger has received honoraria for consultant activities from Bayer, United Therapeutics and Liquidia, outside the submitted work. Conflict of interest: H.A. Ghofrani reports personal fees for advisory board work from Actelion, Bayer, GSK, Novartis and Pfizer, personal fees for consultancy from Actelion, Bayer, GSK, MSD, Novartis and Pfizer, personal fees for lecturing from Actelion, Bayer, GSK, Novartis and Pfizer, personal fees for meeting attendance from Actelion, Bayer, GSK, MSD, Novartis and Pfizer, and grants from Deutsche Forschungsgemeinschaft (DFG), outside the submitted work. Conflict of interest: N. Weissmann has nothing to disclose.",,"Alexandra Pichl 1 2 , Natascha Sommer 1 2 , Mariola Bednorz 1 , Michael Seimetz 1 , Stefan Hadzic 1 , Stefan Kuhnert 1 , Simone Kraut 1 , Elsa T Roxlau 1 , Baktybek Kojonazarov 1 , Jochen Wilhelm 1 , Marija Gredic 1 , Henning Gall 1 , Khodr Tello 1 , Manuel J Richter 1 , Oleg Pak 1 , Aleksandar Petrovic 1 , Matthias Hecker 1 , Ralph T Schermuly 1 , Friedrich Grimminger 1 , Werner Seeger 1 3 , Hossein A Ghofrani 1 , Norbert Weissmann 4"
29247068,Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohns disease (ANDANTE I and II),"Silvio Danese # 1, Séverine Vermeire 2, Paul Hellstern 3, Remo Panaccione 4, Gerhard Rogler 5, Gerald Fraser 6, Anna Kohn 7, Pierre Desreumaux 8, Rupert W Leong 9, Gail M Comer 10, Fabio Cataldi 10, Anindita Banerjee 11, Mary K Maguire 12, Cheryl Li 11, Natalie Rath 12, Jean Beebe 11, Stefan Schreiber # 13",Gut. 2019 Jan;68(1):40-48. doi: 10.1136/gutjnl-2017-314562. Epub 2017 Dec 15.,Danese S,Gut,2019,2017/12/17,PMC6839832,,10.1136/gutjnl-2017-314562,https://pubmed.ncbi.nlm.nih.gov/29247068/,/29247068/,"Competing interests: SD is a speaker, consultant and advisory board member for Abbott Laboratories, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Hospira, Johnson and Johnson, Merck & Co, Millennium Takeda, Mundipharma, Novo Nordisk, Nycomed, Pharmacosmos, Pfizer, Schering-Plough, UCB Pharma and Vifor. SV received research support from AbbVie, MSD and Takeda and received consultancy and/or speaker honoraria from AbbVie, Celgene, Centocor, Ferring, Galapagos, Genentech/Roche, Hospira, MSD, Mundipharma, Pfizer, Shire and Takeda. PH is a consultant and/or advisory board participant for, and/or has received speaker honoraria, research support and/or educational grants from, Cubist, Evoke, Ferring, Forest, Furiex, Gilead, GlaxoSmithKline, Intercept, Ironwood, Menarini, Nature Coast Clinical Research, Pfizer, Rhythm, Salix, Synergy, Takeda, Theravance and Vivus. RP is a consultant for and/or received lecture fees from Abbott, AbbVie, Allergan, Amgen, AstraZeneca, Axcan Pharma, Biogen Idec, Bristol-Myers Squibb, Centocor, ChemoCentryx, Eisai Medical Research, ELAN, Ferring, Genentech, GlaxoSmithKline, Janssen, Millennium, MSD, Ocera Therapeutics, Otsuka America Pharmaceuticals, Pfizer, Shire Pharmaceuticals, Prometheus, Robarts Clinical Trials, Schering-Plough, Synta Pharmaceuticals, Takeda, Teva, UCB Pharma and Warner Chilcott. GR is a consultant for Abbott, AbbVie, Augurix, Boehringer, Calypso, FALK, Ferring, Fisher, Genentech, Essex/MSD, Novartis, Pfizer, Phadia, Roche, Takeda, Tillots, UCB, Vifor, Vital Solutions and Zeller; received speaker honoraria from AstraZeneca, Abbott, AbbVie, FALK, MSD, Phadia, Tillots, UCB and Vifor; and received educational grants and research grants from Abbot, AbbVie, Ardeypharm, Augurix, Calypso, Essex/MSD, FALK, Flamentera, Novartis, Roche, Takeda, Tillots, UCB and Zeller. AK received educational grants from AbbVie, MSD and Takeda. PD participated in advisory boards for, and received fees and grants from, AbbVie, Biofortis, BioMérieux Danone, Ferring, Genfit, Intralytix, Kitozyme, Lesaffre, MSD, Norgine, OmegaPharma International, Pileje, PPM, Roquette, Takeda and TxCell. RWL participated in advisory boards for AbbVie, Aspen, Ferring, Janssen, Hospira and Takeda and received research support from Janssen, NHMRC Career Development Fellowship and Shire. SS received consultancy fees from AbbVie, Bristol-Myers Squibb, Boehringer, Ferring, Genentech/Roche, Pfizer, MSD/Janssen, Takeda and UCB and lecture fees from AbbVie, MSD/Janssen, Takeda and UCB. AB, MKM, CL, NR and JB are all employees of Pfizer Inc and hold stock or options in Pfizer Inc. GMC and FC are former employees of Pfizer Inc and FC is a current employee of Shire Pharmaceuticals. GF has no conflicts of interest to report. GMC has been a consultant for Adare, Albireo, AstraZeneca, CinRx, Cutis, OrphoMed, Second Genome, Strongbridge and Zealand.",,"Silvio Danese # 1 , Séverine Vermeire 2 , Paul Hellstern 3 , Remo Panaccione 4 , Gerhard Rogler 5 , Gerald Fraser 6 , Anna Kohn 7 , Pierre Desreumaux 8 , Rupert W Leong 9 , Gail M Comer 10 , Fabio Cataldi 10 , Anindita Banerjee 11 , Mary K Maguire 12 , Cheryl Li 11 , Natalie Rath 12 , Jean Beebe 11 , Stefan Schreiber # 13"
31632002,The Difficulty Of Improving Quality Of Life In COPD Patients With Depression And Associated Factors,"Jeong Uk Lim # 1, Chan Kwon Park # 2, Tae-Hyung Kim 3, An-Soo Jang 4, Yong Bum Park 5, Chin Kook Rhee 1, Ki Suck Jung 6, Kwang Ha Yoo 7, Won-Yeon Lee 8, Hyoung Kyu Yoon 2",Int J Chron Obstruct Pulmon Dis. 2019 Oct 9;14:2331-2341. doi: 10.2147/COPD.S216746. eCollection 2019.,Lim JU,Int J Chron Obstruct Pulmon Dis,2019,2019/10/22,PMC6790330,,10.2147/COPD.S216746,https://pubmed.ncbi.nlm.nih.gov/31632002/,/31632002/,"Chin Kook Rhee has received consulting/lecture fees from MSD, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, and Bayer. The authors report no other conflicts of interest in this work.",,"Jeong Uk Lim # 1 , Chan Kwon Park # 2 , Tae-Hyung Kim 3 , An-Soo Jang 4 , Yong Bum Park 5 , Chin Kook Rhee 1 , Ki Suck Jung 6 , Kwang Ha Yoo 7 , Won-Yeon Lee 8 , Hyoung Kyu Yoon 2"
30655665,Effects of baseline symptom burden on treatment response in COPD,"Fernando J Martinez 1, Roger A Abrahams 2 3, Gary T Ferguson 4, Leif Bjermer 5, Lars Grönke 6, Florian Voß 7, Dave Singh 8",Int J Chron Obstruct Pulmon Dis. 2019 Jan 4;14:181-194. doi: 10.2147/COPD.S179912. eCollection 2019.,Martinez FJ,Int J Chron Obstruct Pulmon Dis,2019,2019/01/19,PMC6324615,,10.2147/COPD.S179912,https://pubmed.ncbi.nlm.nih.gov/30655665/,/30655665/,"Disclosure FJM reports grants from NHLBI during the conduct of the study, grants from National Institutes of Health, personal fees from Continuing Education, Forest Laboratories, GlaxoSmithKline, Nycomed/Takeda, AstraZeneca, Boehringer Ingelheim, Bellerophon Therapeutics (formerly Ikaria), Genentech, Novartis, Pearl, Roche, Sunovion, Theravance, CME Incite, Annenberg Center for Health Sciences at Eisenhower, Integritas, InThought, National Association for Continuing Education, Paradigm Medical Communications, LLC, PeerVoice, UpToDate, Haymarket Communications, Western Society of Allergy and Immunology, ProterixBio (formerly Bioscale), Unity Biotechnology, Concert Pharmaceuticals, Lucid, Methodist Hospital, Columbia University, Prime Healthcare Ltd, WebMD, PeerView Network, California Society of Allergy and Immunology, Chiesi, and Puerto Rico Thoracic Society, and advisory board participation for Janssen. RA reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline, and grants from Pearl Therapeutics. GTF reports consulting and advisory board fees from Boehringer Ingelheim, AstraZeneca, Pearl Therapeutics, Novartis, Forest, Sunovion, and Verona, consulting fees from Receptos, speaker fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Pearl Therapeutics, Forest, and Sunovion, and research grants from Boehringer Ingelheim, AstraZeneca, Pearl Therapeutics, Sunovion, Novartis, Theravance, Sanofi, Forest, and GlaxoSmithKline. LB reports advisory board participation or personal fees for lectures from ALK, Airsonett, AstraZeneca, Boehringer Ingelheim, Chiesi, Glaxo SmithKline, Novartis, Takeda, and Teva. FV is an employee of Boehringer Ingelheim. LG was an employee at the time of the conduct of the study, and is currently employed by CSL Behring. DS reports personal fees from Apellis, Cipla, Genentech, Peptinnovate, and Vectura (formerly Skyepharma), and grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Theravance, and Verona. The authors report no other conflicts of interest in this work.",,"Fernando J Martinez 1 , Roger A Abrahams 2 3 , Gary T Ferguson 4 , Leif Bjermer 5 , Lars Grönke 6 , Florian Voß 7 , Dave Singh 8"
31332046,Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion,"Michael R Bishop 1, Richard T Maziarz 2, Edmund K Waller 3, Ulrich Jäger 4, Jason R Westin 5, Joseph P McGuirk 6, Isabelle Fleury 7 8, Harald Holte 9, Peter Borchmann 10, Christopher Del Corral 11, Ranjan Tiwari 12, Özlem Anak 13, Rakesh Awasthi 14, Lida Pacaud 11, Vadim V Romanov 11, Stephen J Schuster 15",Blood Adv. 2019 Jul 23;3(14):2230-2236. doi: 10.1182/bloodadvances.2019000151.,Bishop MR,Blood Adv,2019,2019/07/24,PMC6650727,,10.1182/bloodadvances.2019000151,https://pubmed.ncbi.nlm.nih.gov/31332046/,/31332046/,"Conflict-of-interest disclosure: M.R.B. provided consultant services to, was a member of an entity’s board of directors or advisory committees for, and received research funding from Novartis, Kite Pharma, and Juno Therapeutics; provided consultant services to and received honoraria from Novartis, Kite Pharma, Juno Therapeutics, Agios Pharmaceuticals, and CRISPR Therapeutics; was on a speaker’s bureau for, and received travel and honoraria from, Celgene, Kite Pharma, and Agios Pharmaceuticals; and was employed by, provided consultant services to, and received honoraria from Optum. R.T.M. received honoraria from, was a member of an entity’s board of directors or advisory committees for (Scientific Steering Committee for JULIET), and received research funding from Novartis; provided consultant services to and received honoraria from Incyte Inc, Celgene/Juno Therapeutics, and CRISPR Therapeutics; received honoraria from Kite Therapeutics; has patents for and received royalties from Athersys, Inc; was employed by Oregon Health & Science University (OHSU); and provided consultant services to, and received payment from, Novartis (this potential conflict of interest has been reviewed and managed by OHSU). E.K.W. provided consultant services to, was a member of an entity’s board of directors or advisory committees for, and received research funding from Novartis; received travel expenses from European Hematology Association; received research funding from Pharmacyclics and Celldex; provided consultant services to Kalytera; and provided consultant services to and had equity ownership in Cambium Medical Technologies and Cambium Oncology. U.J. provided consultant services to, received honoraria from, was a member of an entity’s board of directors or advisory committees for, and received research funding from Roche and Gilead; provided consultant services to, received honoraria from, and was a member of an entity’s board of directors or advisory committees for Janssen and Celgene; provided consultant services to and received honoraria from AbbVie; was a member of an entity’s board of directors or advisory committees for and received research funding from Novartis; was a member of an entity’s board of directors or advisory committees for Mundipharma, Takeda-Millennium, Amgen, AOP Orphan, GSK, Infinity, and Bioverativ; and research funding from Merck Sharp & Dohme Corporation. J.R.W. was a member of an entity’s board of directors or advisory committees for Novartis, Apotex, Kite Pharma, and Celgene. J.P.M. received honoraria, travel accommodations, and expenses from, and was a speaker for, Kite Pharma; received honoraria from, was a speaker for, and received research funding from Novartis; and received research funding from Fresenius Biotech, Astellas Pharma, Bellicum Pharmaceuticals, Gamida Cell, and Pluristem Ltd. I.F. provided consultant services to AbbVie, Novartis, Merck, Janssen, Seattle Genetics, Gilead, Lundbeck, F. Hoffmann–La Roche Ltd, and Celgene. H.H. was a member of an entity’s board of directors or advisory committees for Novartis, Takeda, Roche, and Celgene, and received research funding from Roche. P.B. provided consultant services to and received honoraria from Novartis. C.d.C., L.P., and V.V.R. were employed by Novartis. R.T. was employed by Novartis Healthcare Private Limited. Ö.A. was employed by Novartis Pharma AG. R.A. was employed by Novartis Institutes for BioMedical Research, and holds equity ownership in Novartis, Cara Therapeutics, Aeterna Zentaris, Exelixis, and Celgene. S.J.S. provided consultant services to, received honoraria from, was a member of an entity’s board of directors or advisory committees for, and received research funding from Celgene; provided consultant services to and received honoraria from Dava Oncology; received honoraria and research funding from Genentech; was a member of an entity’s board of directors or advisory committees for Gilead and Pfizer; provided consultant services to, received honoraria from, and received research funding from Merck; received honoraria from, was a member of an entity’s board of directors or advisory committees for and received research funding from Novartis; provided consultant services to, received honoraria from, and was a member of an entity’s board of directors or advisory committees for Nordic Nanovector; and received honoraria from OncLive and Physician’s Education Source.",,"Michael R Bishop 1 , Richard T Maziarz 2 , Edmund K Waller 3 , Ulrich Jäger 4 , Jason R Westin 5 , Joseph P McGuirk 6 , Isabelle Fleury 7 8 , Harald Holte 9 , Peter Borchmann 10 , Christopher Del Corral 11 , Ranjan Tiwari 12 , Özlem Anak 13 , Rakesh Awasthi 14 , Lida Pacaud 11 , Vadim V Romanov 11 , Stephen J Schuster 15"
30873035,Evolution to a Competency-Based Training Curriculum for Pharmaceutical Medicine Physicians in Switzerland,"Gabriel Schnetzler 1, Markus F Bremgartner 2 3, Regina Grossmann Straessle 4, David Spirk 5 6, Fabian Tay 4, Rahel Troxler Saxer 7, Martin Traber 1",Front Pharmacol. 2019 Feb 27;10:164. doi: 10.3389/fphar.2019.00164. eCollection 2019.,Schnetzler G,Front Pharmacol,2019,2019/03/16,PMC6400888,,10.3389/fphar.2019.00164,https://pubmed.ncbi.nlm.nih.gov/30873035/,/30873035/,,,"Gabriel Schnetzler 1 , Markus F Bremgartner 2 3 , Regina Grossmann Straessle 4 , David Spirk 5 6 , Fabian Tay 4 , Rahel Troxler Saxer 7 , Martin Traber 1"
31412998,Understanding reliever overuse in patients purchasing over-the-counter short-acting beta(2) agonists: an Australian community pharmacy-based survey,"Elizabeth A Azzi 1 2, Vicky Kritikos 3 4, Matthew J Peters 5 6, David B Price 7, Pamela Srour 3 2, Biljana Cvetkovski 3 2, Sinthia Bosnic-Anticevich 3 2",BMJ Open. 2019 Aug 14;9(8):e028995. doi: 10.1136/bmjopen-2019-028995.,Azzi EA,BMJ Open,2019,2019/08/16,PMC6701672,,10.1136/bmjopen-2019-028995,https://pubmed.ncbi.nlm.nih.gov/31412998/,/31412998/,"Competing interests: VK received honoraria from AstraZeneca, GlaxoSmithKline and Pfizer. MJP reports personal fees and non-financial support from AstraZeneca, personal fees from GlaxoSmithKline and personal fees from Boehringer Ingelheim. DBP: a board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis and Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) from UK National Health Service, British Lung Foundation, Aerocrine, AKL Research and Development, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Zentiva and Theravance; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda and Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; payment for the development of educational materials from Novartis and Mundipharma; payment for travel/accommodation/meeting expenses from Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals and AstraZeneca; funding for patient enrolment or completion of research from Chiesi, Teva Pharmaceuticals, Zentiva and Novartis; stock/stock options from AKL Research and Development, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care, UK, and 74% of Observational and Pragmatic Research Institute, Singapore; and is peer reviewer for grant committees of the Medical Research Council, Efficacy and Mechanism Evaluation programme and Health Technology Assessment. SBA: a member of the Teva Pharmaceuticals Devices International Key Experts Panel; received research support from Research in Real Life; payment for lectures/speaking engagements and for developing educational presentations from Teva and Mundipharma; received honoraria from AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline for her contribution to advisory boards/key international expert forum.",,"Elizabeth A Azzi 1 2 , Vicky Kritikos 3 4 , Matthew J Peters 5 6 , David B Price 7 , Pamela Srour 3 2 , Biljana Cvetkovski 3 2 , Sinthia Bosnic-Anticevich 3 2"
31631986,Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort,"Norbert Königsdorfer 1, Rudolf A Jörres 1, Sandra Söhler 2, Tobias Welte 3, Jürgen Behr 4, Joachim H Ficker 5, Robert Bals 6, Henrik Watz 7, Johanna I Lutter 8, Tanja Lucke 1, Frank Biertz 9, Peter Alter 10, Claus F Vogelmeier 10, Kathrin Kahnert 4",Patient Prefer Adherence. 2019 Oct 10;13:1711-1721. doi: 10.2147/PPA.S223438. eCollection 2019.,Königsdorfer N,Patient Prefer Adherence,2019,2019/10/22,PMC6791408,,10.2147/PPA.S223438,https://pubmed.ncbi.nlm.nih.gov/31631986/,/31631986/,"Joachim Ficker reports grants from the COSYCONET study supported by Bundesministerium fuer Bildung und Forschung BMBF, during the conduct of the study. He also received personal fees and nonfinancial support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols and Novartis, grants, personal fees and nonfinancial support from CSL Behring, outside the submitted work. Claus Vogelmeier reports personal fees from Almirall, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Mundipharma, Novartis and Takeda, personal fees from Cipla, Berlin Chemie/Menarini, CSL Behring and Teva, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work. Robert Bals reports grants and personal fees from AstraZeneca, Novartis and Boehringer Ingelheim, personal fees from GlaxoSmithKline and Grifols and CSL Behring, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Sander Stiftung, Schwiete Stiftung and Krebshilfe from Mukoviszidose eV, outside the submitted work. Peter Alter reports grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), and AstraZeneca GmbH, grants and nonfinancial support from Bayer Schering Pharma AG, grants, personal fees and nonfinancial support from Boehringer Ingelheim Pharma GmbH & Co. KG, grants and nonfinancial support from Chiesi GmbH, grants from GlaxoSmithKline, Grifols Deutschland GmbH, and MSD Sharp & Dohme GmbH, grants and personal fees from Mundipharma GmbH, grants, personal fees and nonfinancial support from Novartis Deutschland GmbH, grants from Pfizer Pharma GmbH and Takeda Pharma Vertrieb GmbH & Co. KG, outside the submitted work. Johanna Lutter reports grants from Federal Ministry of Education and Research (grant number 01GI0881), during the conduct of the study. Tobias Welte reports grants from Boehringer, GSK, Novartis, AstraZeneca, during the conduct of the study; personal fees from AstraZeneca, Boehringer, GSK, Novartis, outside the submitted work. The authors report no other conflicts of interest in this work.","Grants and funding This work was supported by BMBF Competence Network Asthma and COPD (ASCONET) and performed in collaboration with the German Center for Lung Research (DZL). The project is funded by the German Federal Ministry of Education and Research (BMBF) with grant number 01 GI 0881; and is funded by unrestricted grants from AstraZeneca GmbH, Bayer Schering Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Chiesi GmbH, GlaxoSmithKline, Grifols Deutschland GmbH, MSD Sharp & Dohme GmbH, Mundipharma GmbH, Novartis Deutschland GmbH, Pfizer Pharma GmbH, Takeda Pharma Vertrieb GmbH & Co. KG for patient investigations and laboratory measurements.","Norbert Königsdorfer 1 , Rudolf A Jörres 1 , Sandra Söhler 2 , Tobias Welte 3 , Jürgen Behr 4 , Joachim H Ficker 5 , Robert Bals 6 , Henrik Watz 7 , Johanna I Lutter 8 , Tanja Lucke 1 , Frank Biertz 9 , Peter Alter 10 , Claus F Vogelmeier 10 , Kathrin Kahnert 4"
31285304,Sensitisation to staphylococcal enterotoxins and asthma severity: a longitudinal study in the EGEA cohort,"Ina Sintobin 1 2, Valerie Siroux 3 2, Gabriële Holtappels 1, Christophe Pison 4 5, Rachel Nadif 6 7, Jean Bousquet 6 7 8 9, Claus Bachert 10 11",Eur Respir J. 2019 Sep 12;54(3):1900198. doi: 10.1183/13993003.00198-2019. Print 2019 Sep.,Sintobin I,Eur Respir J,2019,2019/07/10,,,10.1183/13993003.00198-2019,https://pubmed.ncbi.nlm.nih.gov/31285304/,/31285304/,"Conflict of interest: V. Siroux reports personal fees for lecturing from AstraZeneca, outside the submitted work. Conflict of interest: G. Holtappels has nothing to disclose. Conflict of interest: C. Pison reports non-financial support for meeting attendance from GSK France, AZ France, Boehringer Ingelheim and Novartis, outside the submitted work. Conflict of interest: R. Nadif has nothing to disclose. Conflict of interest: J. Bousquet reports personal fees for advisory board work, consultancy and lecturing from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and owns shares in KYomed-INNOV, outside the submitted work. Conflict of interest: C. Bachert has nothing to disclose. Conflict of interest: I. Sintobin has nothing to disclose.",,"Ina Sintobin 1 2 , Valerie Siroux 3 2 , Gabriële Holtappels 1 , Christophe Pison 4 5 , Rachel Nadif 6 7 , Jean Bousquet 6 7 8 9 , Claus Bachert 10 11"
31684698,Adductor canal blocks for postoperative pain treatment in adults undergoing knee surgery,"Alexander Schnabel 1, Sylvia U Reichl 2, Stephanie Weibel 3, Peter K Zahn 4, Peter Kranke 3, Esther Pogatzki-Zahn 1, Christine H Meyer-Frießem 4",Cochrane Database Syst Rev. 2019 Oct 26;2019(10):CD012262. doi: 10.1002/14651858.CD012262.pub2.,Schnabel A,Cochrane Database Syst Rev,2019,2019/11/06,PMC6814953,,10.1002/14651858.CD012262.pub2,https://pubmed.ncbi.nlm.nih.gov/31684698/,/31684698/,"Alexander Schnabel: none known. Sylvia U Reichl: none known. Stephanie Weibel is an academic researcher. She has received personal payments for consultancies and lecture fees from Genelux Corporation, San Diego, USA (ended March 2014). Genelux Corporation does not produce any products for the intervention of interest in this review. Christine Meyer‐Frießem has no conflicts of interest regarding the topic of this review. She received a sponsorship award for young pain scientists in May 2012 from Janssen‐Cilag GmbH (Eur. 5.000). Further, she received payments for two clinical lectures from OrionPharma in June 2013 (Eur 300) and from the Grünenthal Group in September 2013 (Eur 1000), all unrelated to the current review and relationships in the past. To her knowledge, the product portfolio of these companies has no direct connection to any topic or aim of the current meta‐analysis. Peter K Zahn: none known. Peter Kranke has no conflicts of interest regarding the topic of this review. He has received lecture fees (from FreseniusKabi, MSD, Ratiopharm, Covidien) and has provided consultancy (to MSD, FreseniusKabi, Ratiopharm, Covidien) on topics not related to the current review. He has been involved in the conduct of phase II and phase III clinical trials not related to the current review. Esther Pogatzki‐Zahn received financial support from Mundipharma GmbH and Grunenthal for research activities, advisory and lecture fees from Grünenthal, MSD Sharp & DOHME GmbH, Mundipharma GmbH, Mundipharma International, Janssen‐Cilag GmbH, TEVA, Fresenius Kabi and AcelRx. She receives scientific support from the DFG, the BMBF, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777500. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Funding was not related to the present research.",,"Alexander Schnabel 1 , Sylvia U Reichl 2 , Stephanie Weibel 3 , Peter K Zahn 4 , Peter Kranke 3 , Esther Pogatzki-Zahn 1 , Christine H Meyer-Frießem 4"
30649604,Adaptation and qualitative evaluation of encounter decision aids in breast cancer care,"Pola Hahlweg 1, Isabell Witzel 2, Volkmar Müller 2, Glyn Elwyn 3, Marie-Anne Durand 3, Isabelle Scholl 4",Arch Gynecol Obstet. 2019 Apr;299(4):1141-1149. doi: 10.1007/s00404-018-5035-7. Epub 2019 Jan 16.,Hahlweg P,Arch Gynecol Obstet,2019,2019/01/17,PMC6435605,,10.1007/s00404-018-5035-7,https://pubmed.ncbi.nlm.nih.gov/30649604/,/30649604/,"PH’s institution received the grant from research funding through faculty resources of the University Medical Center Hamburg-Eppendorf (German: Forschungsförderfonds der Medizinischen Fakultät der Universität Hamburg, FFM) for the study at hand (cp. funding). PH gave one scientific presentation on shared decision-making during a lunch symposium, for which she received compensation and travel compensation from GlaxoSmithKline GmbH in 2018. IW and VM declare no conflicts of interest. GE is the director of &think LLC which owns the registered trademark for Option Grid™ patient decision aids. GE currently provides consultancy in the domain of shared decision-making and patient decision aids to Access Community Health Network, Chicago (Federally Qualified Medical Centers) and EBSCO Health Option Grid™ patient decision aids. In the past, GE was a consultant to Emmi Solutions LLC (development of Option Grid™ DAs), to the National Quality Forum (certification of decision support tools), to the Washington State Health Department (certification of decision support tools), and to SciMentum LLC, Amsterdam (workshops for SDM). GE receives royalties from Oxford University Press and Radcliff Press, because he edited and published books that provide royalties on sales by the publishers. The books include Shared Decision Making (Oxford University Press) and Groups. GE initiated the Option Grid Collaborative, tools that are hosted on a website managed by Dartmouth College (http://optiongrid.org/). Existing Option Grids hosted at this website are freely available until the tools have expired. He owns copyright in measures of SDM and care integration, namely CollaboRATE, IntegRATE, and Observer OPTION. These measures are freely available for use. MAD has contributed to the development of Option Grid™ patient decision aids, which are licensed to EBSCO Health. She receives consulting income from EBSCO Health, and may receive royalties in the future. MAD is a consultant to ACCESS Community Health Network. MAD is one of the founding members of the Option Grid Collaborative. IS’s institution received the grant from research funding through faculty resources of the University Medical Center Hamburg-Eppendorf (German: Forschungsförderfonds der Medizinischen Fakultät der Universität Hamburg, FFM) for the study at hand (cp. funding). IS conducted one physician training in shared decision-making for which she received travel compensation from Mundipharma GmbH in 2015. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the Medical Association Hamburg (Germany). Informed consent was obtained from all individual participants included in the study.",Grants and funding NWF 15_10/research funding through faculty resources of the University Medical Center Hamburg-Eppendorf (German: Forschungsförderfonds der Medizinischen Fakultät der Universität Hamburg)/International,"Pola Hahlweg 1 , Isabell Witzel 2 , Volkmar Müller 2 , Glyn Elwyn 3 , Marie-Anne Durand 3 , Isabelle Scholl 4"
31796013,Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial,"Claudia Gregoriano 1 2, Thomas Dieterle 3 4, Anna-Lisa Breitenstein 3, Selina Dürr 3, Amanda Baum 3, Stéphanie Giezendanner 5, Sabrina Maier 3, Anne Leuppi-Taegtmeyer 4 6, Isabelle Arnet 7, Kurt E Hersberger 7, Jörg D Leuppi 3 4",Respir Res. 2019 Dec 3;20(1):273. doi: 10.1186/s12931-019-1219-3.,Gregoriano C,Respir Res,2019,2019/12/05,PMC6892023,,10.1186/s12931-019-1219-3,https://pubmed.ncbi.nlm.nih.gov/31796013/,/31796013/,The authors declare that they have no competing interests.,Grants and funding None/Freiwillige Akademische Gesellschaft () None/Swiss Lung League None/Boehringer Ingelheim GmbH None/Astra Zeneca AG None/Mundipharma AG,"Claudia Gregoriano 1 2 , Thomas Dieterle 3 4 , Anna-Lisa Breitenstein 3 , Selina Dürr 3 , Amanda Baum 3 , Stéphanie Giezendanner 5 , Sabrina Maier 3 , Anne Leuppi-Taegtmeyer 4 6 , Isabelle Arnet 7 , Kurt E Hersberger 7 , Jörg D Leuppi 3 4"
30442715,The potential impact of azithromycin in idiopathic pulmonary fibrosis,"Claudio Macaluso 1 2, Joaquín Maritano Furcada 1 2, Omamah Alzaher 1, Ritesh Chaube 1, Felix Chua 1, Athol U Wells 1, Toby M Maher 1 3, Peter M George 1, Elizabeth A Renzoni 1, Philip L Molyneaux 1 3",Eur Respir J. 2019 Feb 14;53(2):1800628. doi: 10.1183/13993003.00628-2018. Print 2019 Feb.,Macaluso C,Eur Respir J,2019,2018/11/17,,,10.1183/13993003.00628-2018,https://pubmed.ncbi.nlm.nih.gov/30442715/,/30442715/,"Conflict of interest: C. Macaluso has nothing to disclose. Conflict of interest: J. Maritano Furcada has nothing to disclose. Conflict of interest: O. Alzaher has nothing to disclose. Conflict of interest: R. Chaube has nothing to disclose. Conflict of interest: F. Chua has nothing to disclose. Conflict of interest: A.U. Wells reports speakers and consultancy fees from Intermune Roche, Boehringer Ingelheim and Bayer. Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB, and has received consultancy or speakers fees from Apellis, AstraZeneca, aTyr Pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, ProMetic, Roche, Sanumed and UCB. Conflict of interest: P.M. George reports receiving honoraria and speakers fees from Roche Pharmaceuticals and Boehringer Ingelheim, outside the submitted work. Conflict of interest: E.A. Renzoni has received speakers fees from Boehringer Ingelheim, Roche and Mundipharma. Conflict of interest: P.L. Molyneaux has nothing to disclose.",Grants and funding 20719/VAC_/Versus Arthritis/United Kingdom PB-PG-0712-28073/DH_/Department of Health/United Kingdom,"Claudio Macaluso 1 2 , Joaquín Maritano Furcada 1 2 , Omamah Alzaher 1 , Ritesh Chaube 1 , Felix Chua 1 , Athol U Wells 1 , Toby M Maher 1 3 , Peter M George 1 , Elizabeth A Renzoni 1 , Philip L Molyneaux 1 3"
31310600,Intranasal sufentanil versus intravenous morphine for acute severe trauma pain: A double-blind randomized non-inferiority study,"Marc Blancher 1, Maxime Maignan 1 2, Cyrielle Clapé 1, Jean-Louis Quesada 3, Roselyne Collomb-Muret 1, François Albasini 4, François-Xavier Ageron 5, Stephanie Fey 6, Audrey Wuyts 7, Jean-Jacques Banihachemi 8, Barthelemy Bertrand 1, Audrey Lehmann 9, Claire Bollart 10, Guillaume Debaty 1 11, Raphaël Briot 1 11, Damien Viglino 1 2",PLoS Med. 2019 Jul 16;16(7):e1002849. doi: 10.1371/journal.pmed.1002849. eCollection 2019 Jul.,Blancher M,PLoS Med,2019,2019/07/17,PMC6634380,,10.1371/journal.pmed.1002849,https://pubmed.ncbi.nlm.nih.gov/31310600/,/31310600/,"I have read the journals policy and the authors of this manuscript have the following competing interests: MM has received grants and personal fees from MundiPharma and Purdue for speaking at conferences, and support from Roche Diagnostics for research unrelated to that presented here; GD has received personal fees from Zoll Medical for speaking at conferences; DV has received grants from Mundipharma for speaking at conferences, and grants from Astra Zeneca for research unrelated to that presented here. All other authors declare no competing interests.","Grants and funding The study was supported by the foundation Apicil (http://www.fondation-apicil.org/) (MB) and the French Society of Emergency Medicine (http://www.sfmu.org/fr/) (MB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","Marc Blancher 1 , Maxime Maignan 1 2 , Cyrielle Clapé 1 , Jean-Louis Quesada 3 , Roselyne Collomb-Muret 1 , François Albasini 4 , François-Xavier Ageron 5 , Stephanie Fey 6 , Audrey Wuyts 7 , Jean-Jacques Banihachemi 8 , Barthelemy Bertrand 1 , Audrey Lehmann 9 , Claire Bollart 10 , Guillaume Debaty 1 11 , Raphaël Briot 1 11 , Damien Viglino 1 2"
31004075,Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis,"Peter J Goadsby 1, David W Dodick 2, James M Martinez 3, Margaret B Ferguson 3, Tina M Oakes 3, Qi Zhang 4, Vladimir Skljarevski 3, Sheena K Aurora 3",J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):939-944. doi: 10.1136/jnnp-2018-320242. Epub 2019 Apr 19.,Goadsby PJ,J Neurol Neurosurg Psychiatry,2019,2019/04/21,PMC6691875,,10.1136/jnnp-2018-320242,https://pubmed.ncbi.nlm.nih.gov/31004075/,/31004075/,"Competing interests: The studies included in the analyses were sponsored and/or supported by Eli Lilly and Company. VS, MBF, JMM, TMO and SKA are full-time employees of Eli Lilly and Company and/or one of its subsidiaries, and are stockholders. QZ was an employee of Eli Lilly and Company at the time the manuscript was written and is presently an employee of Sanofi and is an Eli Lilly and Company stockholder. PJG reports grants and personal fees from Amgen and Eli Lilly and Company; personal fees from Alder BioPharmaceuticals, Allergan, Autonomic Technologies, Dr Reddy’s Laboratories, Biohaven Pharmaceuticals, Electrocore, eNeura, Novartis,Impel Neuropharma, Mundipharma, Teva Pharmaceuticals and Trigemina; and personal fees from MedicoLegal work, UptoDate, Oxford University Press, Massachusetts Medical Society and Wolters Kluwer; and a patent magnetic stimulation for headache assigned to eNeura without fee. Within the last 12 months, DWD reports personal fees from Amgen, lder, Allergan, Autonomic Technologies, Biohaven, Eli Lilly, eNeura, Foresight Capital, Neurolief, Zosano, WL Gore, Vedanta Associates, Promius Pharma, Nocira, Novartis, Electrocore, Teva, Ipsen, Impel, Satsuma, Charleston Laboratories and Theranica; compensation for activities related to data safety monitoring committee from Axsome; compensation related to CME content development: HealthLogiX, Medicom Worldwide, MedLogix Communications, MedNet, Miller Medical Communications, PeerView Operation Services America, WebMD/Medscape, American Academy of Neurology, American Headache Society, PeerView Institute for Medical Education, Chameleon Communications, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket Medical Education, Global Scientific Communications, UpToDate and Meeting LogiX; royalties from editorial or book publishing: Oxford University Press, Cambridge University Press, Wiley-Blackwell, Sage and Wolters Kluwer Health; consulting use agreement through employer: Neuro Assessment Systems and Myndshft; holds equity in Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health and Epien; and board of directors position: King-Devick Technologies and Ontologics.",,"Peter J Goadsby 1 , David W Dodick 2 , James M Martinez 3 , Margaret B Ferguson 3 , Tina M Oakes 3 , Qi Zhang 4 , Vladimir Skljarevski 3 , Sheena K Aurora 3"
31304177,Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry,"Jaana Kaunisto 1 2, Eija-Riitta Salomaa 2, Ulla Hodgson 3 4, Riitta Kaarteenaho 5 6, Hannu Kankaanranta 7 8, Katri Koli 9, Tero Vahlberg 10, Marjukka Myllärniemi 3 9",ERJ Open Res. 2019 Jul 8;5(3):00170-2018. doi: 10.1183/23120541.00170-2018. eCollection 2019 Jul.,Kaunisto J,ERJ Open Res,2019,2019/07/16,PMC6612605,,10.1183/23120541.00170-2018,https://pubmed.ncbi.nlm.nih.gov/31304177/,/31304177/,"Conflict of interest: J. Kaunisto reports lecture fees from Boehringer and Roche, and support to attend an international conference from Sanofi Genzyme, outside the submitted work. Conflict of interest: E-R. Salomaa has nothing to disclose. Conflict of interest: U. Hodgson has nothing to disclose. Conflict of interest: R. Kaarteenaho reports grants from the Foundation of the Finnish Anti-Tuberculosis Association, the Research Foundation of the Pulmonary Diseases, Jalmari and Rauha Ahokas Foundation and the Research Foundation of North Finland, lecture fees and an advisory board fee from GlaxoSmithKline, Roche and Boehringer-Ingelheim, and conference travel costs from Orion Pharma, outside the submitted work. Conflict of interest: H. Kankaanranta reports fees for lectures and consulting, costs for attending an international conference, and a research grant from AstraZeneca; fees for consulting from Chiesi Pharma AB; fees for lectures and consulting, and costs for attending and international conference from Boehringer-Ingelheim; fees for lectures and consulting from Novartis; fees for lectures from Mundipharma; fees for consulting from GlaxoSmithKline; fees for lectures and consulting from Orion Pharma; and fees for consulting from SanofiGenzyme, all outside the submitted work. Conflict of interest: K. Koli has nothing to disclose. Conflict of interest: T. Vahlberg has nothing to disclose. Conflict of interest: M. Myllärniemi has nothing to disclose.",,"Jaana Kaunisto 1 2 , Eija-Riitta Salomaa 2 , Ulla Hodgson 3 4 , Riitta Kaarteenaho 5 6 , Hannu Kankaanranta 7 8 , Katri Koli 9 , Tero Vahlberg 10 , Marjukka Myllärniemi 3 9"
31433352,A randomized pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling during surgery,"Theresa Wodehouse 1, Mary Demopoulos 1, Robert Petty 2, Farideh Miraki-Moud 2, Alla Belhaj 1, Michael Husband 1, Laura Fulton 1, Nilesh Randive 1, Alexander Oksche 3 4, Vivek Mehta 1, John Gribben 2, Richard Langford 1",Pain. 2019 Dec;160(12):2691-2698. doi: 10.1097/j.pain.0000000000001677.,Wodehouse T,Pain,2019,2019/08/22,,,10.1097/j.pain.0000000000001677,https://pubmed.ncbi.nlm.nih.gov/31433352/,/31433352/,,,"Theresa Wodehouse 1 , Mary Demopoulos 1 , Robert Petty 2 , Farideh Miraki-Moud 2 , Alla Belhaj 1 , Michael Husband 1 , Laura Fulton 1 , Nilesh Randive 1 , Alexander Oksche 3 4 , Vivek Mehta 1 , John Gribben 2 , Richard Langford 1"
31799113,Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports,"Carlo Lombardi 1, Francesco Menzella 2, Giovanni Passalacqua 3",Respir Med Case Rep. 2019 Nov 19;29:100967. doi: 10.1016/j.rmcr.2019.100967. eCollection 2020.,Lombardi C,Respir Med Case Rep,2019,2019/12/05,PMC6881682,,10.1016/j.rmcr.2019.100967,https://pubmed.ncbi.nlm.nih.gov/31799113/,/31799113/,"Carlo Lombardi partecipated has received lecture fee and advisory board fees from GlaxoSmithKline (GSK), AstraZeneca, Novartis, Chiesi, Boehringer Ingelheim, Mylan, Mundipharma. Francesco Menzella participated in contracted research and clinical trials for Novartis and Sanofi, and has received lecture fees and advisory board fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, and Novartis. Passalacqua Giovanni participated in clinical trials, advisory boards and received lecture fees from GSK, AstraZeneca, Novartis, Chiesi, Boehringer Ingelheim, Mylan, Mundipharma, Stallergens, MSD, Thermofisher.",,"Carlo Lombardi 1 , Francesco Menzella 2 , Giovanni Passalacqua 3"
31414562,Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin,"Marjolein Y A M Kroonen 1, Jasper Stevens 1, Dick de Zeeuw 1, Hiddo J L Heerspink 1",Diabetes Obes Metab. 2019 Dec;21(12):2635-2642. doi: 10.1111/dom.13849. Epub 2019 Sep 30.,Kroonen MYAM,Diabetes Obes Metab,2019,2019/08/16,PMC6900110,,10.1111/dom.13849,https://pubmed.ncbi.nlm.nih.gov/31414562/,/31414562/,"The PLANET trials were sponsored by AstraZeneca. MYAMK and JS report no conflicts of interest. DdZ is consultant for and received honoraria from AbbVie, Fresenius, Janssen, Bayer and Mundipharma. HJLH is consultant for and received honoraria from AbbVie, Astellas, Astra Zeneca, Boehringer Ingelheim, Fresenius, Janssen, and Merck and has a policy that all honoraria are paid to his employer.",,"Marjolein Y A M Kroonen 1 , Jasper Stevens 1 , Dick de Zeeuw 1 , Hiddo J L Heerspink 1"
31089155,A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS),"Zachary Veitch 1 2, Alona Zer 1 2, Herbert Loong 1 2, Samer Salah 1 2, Maryam Masood 1, Abha Gupta 1 2, Penelope A Bradbury 1 2, David Hogg 1 2, Andrew Wong 3, Rita Kandel 3 4 5, George S Charames 3 4 5, Albiruni R Abdul Razak 6 7",Sci Rep. 2019 May 14;9(1):7390. doi: 10.1038/s41598-019-43222-6.,Veitch Z,Sci Rep,2019,2019/05/16,PMC6517396,,10.1038/s41598-019-43222-6,https://pubmed.ncbi.nlm.nih.gov/31089155/,/31089155/,"AAR has received research funding from Roche, Genentech, Eli Lilly, Merck, Boehringer Ingleheim, Novartis, Abbvie, Deciphera, Karyopharm, Astra Zeneca, Medimmune, Blueprint, Bristol Myers Squibb, GSK, Entremed/Casi Pharmaceuticals, BetaCat. He also has also served the advisory board for Eli Lilly, Merck, Boehringer Ingleheim. HL has received researching funding from Merck and Mundipharma. He has also served or is currently serving on the advisory boards of Boehringer Ingleheim, Eli Lilly, Novartis, LOXO Pharmaceuticals, Roche/Genentech. He has received speakers’ fees from AbbVie, Bayer, Eisai Pharmaceuticals, Eli-Lilly and Novartis. The following authors have declared no conflicts of interest: ZV, AZ, SS, MM, AG, PB, DH, AW, RK, GC.",,"Zachary Veitch 1 2 , Alona Zer 1 2 , Herbert Loong 1 2 , Samer Salah 1 2 , Maryam Masood 1 , Abha Gupta 1 2 , Penelope A Bradbury 1 2 , David Hogg 1 2 , Andrew Wong 3 , Rita Kandel 3 4 5 , George S Charames 3 4 5 , Albiruni R Abdul Razak 6 7"
31072876,Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!,"Stéphane Jouneau 1 2, Mathieu Lederlin 3, Laurent Vernhet 2, Ronan Thibault 4",Eur Respir J. 2019 May 9;53(5):1900418. doi: 10.1183/13993003.00418-2019. Print 2019 May.,Jouneau S,Eur Respir J,2019,2019/05/11,,,10.1183/13993003.00418-2019,https://pubmed.ncbi.nlm.nih.gov/31072876/,/31072876/,"Conflict of interest: S. Jouneau reports current work on malnutrition and IPF funded by Boehringer Ingelheim and Roche/Genentech, during the conduct of the study; grants for research, personal fees and non-financial support for congress attendance, registration, travel and accommodation, personal fees for advisory board work and consultancy from Actelion, AIRB, AstraZeneca, BMS, Boehringer, Chiesi, Gilead, GSK, LVL, Mundipharma, Novartis, Pfizer, Roche and Savara-Serendex, outside the submitted work. Conflict of interest: M. Lederlin reports current work on malnutrition and IPF funded by Boehringer Ingelheim and Roche/Genentech, during the conduct of the study; personal fees from Boehringer Ingelheim, outside the submitted work. Conflict of interest: L. Vernhet reports current work on malnutrition and IPF funded by Boehringer Ingelheim and Roche/Genentech, during the conduct of the study. Conflict of interest: R. Thibault reports current work on malnutrition and IPF funded by Boehringer Ingelheim and Roche/Genentech, during the conduct of the study; and received royalties from Knoë, Le Kremlin Bicêtre, France for designing the Simplified Evaluation of Food Intake (SEFI) tool.",,"Stéphane Jouneau 1 2 , Mathieu Lederlin 3 , Laurent Vernhet 2 , Ronan Thibault 4"
31649948,Occupational exposures and asthma-COPD overlap in a clinical cohort of adult-onset asthma,"Minna Tommola 1 2, Pinja Ilmarinen 1, Leena E Tuomisto 1, Lauri Lehtimäki 3 4, Hannu Kankaanranta 1 4",ERJ Open Res. 2019 Oct 21;5(4):00191-2019. doi: 10.1183/23120541.00191-2019. eCollection 2019 Oct.,Tommola M,ERJ Open Res,2019,2019/10/26,PMC6801214,,10.1183/23120541.00191-2019,https://pubmed.ncbi.nlm.nih.gov/31649948/,/31649948/,"Conflict of interest: M. Tommola reports personal fees for lectures from AstraZeneca, Filha ry, GlaxoSmithKline, Pfizer and Chiesi, personal fees for lectures and consultation from Boehringer Ingelheim, and grants from the Orion Research Foundation, outside the submitted work. Conflict of interest: P. Ilmarinen reports grants from AstraZeneca, and payment for lectures from Mundipharma, Orion and AstraZeneca, outside the submitted work. Conflict of interest: L.E. Tuomisto reports compensation of costs for attending an international congress from Chiesi, Orion Pharma and Teva, for attending an international congress and costs for lectures from Boehringer Ingelheim, and for lectures from AstraZeneca, outside the submitted work. Conflict of interest: L. Lehtimäki reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, Orion Pharma, Teva and ALK, outside the submitted work. Conflict of interest: H. Kankaanranta reports grants from AstraZeneca, during the conduct of the study; as well as personal fees and non-financial support from AstraZeneca and Boehringer Ingelheim, personal fees from Chiesi Pharma AB, GlaxoSmithKline, Leiras-Takeda, MSD, Novartis, Mundipharma, Roche, Sanofi Genzyme and Orion Pharma, and non-financial support from Intermune, all outside the submitted work.",,"Minna Tommola 1 2 , Pinja Ilmarinen 1 , Leena E Tuomisto 1 , Lauri Lehtimäki 3 4 , Hannu Kankaanranta 1 4"
30740461,Valved holding chamber drug delivery is dependent on breathing pattern and device design,"Péter Csonka 1 2, Lauri Lehtimäki 3 4",ERJ Open Res. 2019 Feb 4;5(1):00158-2018. doi: 10.1183/23120541.00158-2018. eCollection 2019 Feb.,Csonka P,ERJ Open Res,2019,2019/02/12,PMC6360210,,10.1183/23120541.00158-2018,https://pubmed.ncbi.nlm.nih.gov/30740461/,/30740461/,"Conflict of interest: P. Csonka reports personal fees from ThermoFisher, ALK-Abello and OrionPharma, outside the submitted work. Conflict of interest: L. Lehtimäki reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, OrionPharma, Teva and ALK, outside the submitted work.",,"Péter Csonka 1 2 , Lauri Lehtimäki 3 4"
30846468,Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report,"Vanessa M McDonald 1 2, James Fingleton 3 4, Alvar Agusti 5, Sarah A Hiles 1, Vanessa L Clark 6, Anne E Holland 7, Guy B Marks 8 9, Philip P Bardin 10, Richard Beasley 3 4, Ian D Pavord 11, Peter A B Wark 1 2, Peter G Gibson 1 2 ; participants of the Treatable Traits Down Under International Workshop; Treatable Traits Down Under International Workshop participants:",Eur Respir J. 2019 May 9;53(5):1802058. doi: 10.1183/13993003.02058-2018. Print 2019 May.,McDonald VM,Eur Respir J,2019,2019/03/09,,,10.1183/13993003.02058-2018,https://pubmed.ncbi.nlm.nih.gov/30846468/,/30846468/,"Conflict of interest: V.M. McDonald reports grants from GlaxoSmithKline during the conduct of the meeting; and grants and speaker fees from GlaxoSmithKline and AstraZeneca, personal fees for meeting organisation from Menarini, and grants from Cyclopharm Ltd, outside the submitted work. Conflict of interest: J. Fingleton reports travel to the educational event “Treatable Traits Down Under”, at which the ideas contained within this paper were developed, from GlaxoSmithKline; speaker fees for educational events and support to attend educational events from AstraZeneca Ltd and Boehringer Ingelheim, and grants from GlaxoSmithKline and Fisher & Paykel Ltd, New Zealand, outside the submitted work. Conflict of interest: A. Agusti reports grants and personal fees from AstraZeneca and Menarini, and personal fees from Chiesi, GlaxoSmithKline, Nuvaira and Boehringer Ingelheim, outside the submitted work. Conflict of interest: S.A. Hiles’ salary was supported by a grant from GlaxoSmithKline, paid to her institution (University of Newcastle), during the conduct of the meeting. S.A. Hiles also reports salary from a grant from AstraZeneca, paid to her institution, outside the submitted work. Conflict of interest: V.L. Clark receives a fellowship from the National Health and Medical Research Council Centre of Research Excellence in Severe Asthma. Conflict of interest: A.E. Holland has nothing to disclose. Conflict of interest: G.B. Marks reports grants from GlaxoSmithKline (Australia) and from AstraZeneca (Australia), outside the submitted work. Conflict of interest: P.P. Bardin reports personal fees from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, during the conduct of the study. Conflict of interest: R. Beasley reports grants from the Health Research Council of New Zealand, grants and personal fees from AstraZeneca and GlaxoSmithKline, and grants from Genentech, outside the submitted work. Conflict of interest: I.D. Pavord reports personal fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Sanofi/Regeneron, Circassia, Merck, Novartis, Mundipharma, Teva, Knopp and Roche/Genentech, and grants and personal fees from Afferent and Chiesi, outside the submitted work. Conflict of interest: P.A.B. Wark receives grants from The University of Newcastle, John Hunter Hospital Charitable Trust, grants from Hunter Medical Research Institute, grants from National Health and Medical Research Council, during the conduct of the study; he has taken part in advisory boards for AstraZeneca, Boehringer Ingelheim, Novartis and Vertex, and has received personal fees from AstraZeneca, GlaxoSmithKline and Vertex, outside the submitted work. Conflict of interest: P.G. Gibson reports grants and personal fees from AstraZeneca, GlaxoSmithKline and Novartis, and grants from NHMRC (Australian Government), outside the submitted work.",,"Vanessa M McDonald 1 2 , James Fingleton 3 4 , Alvar Agusti 5 , Sarah A Hiles 1 , Vanessa L Clark 6 , Anne E Holland 7 , Guy B Marks 8 9 , Philip P Bardin 10 , Richard Beasley 3 4 , Ian D Pavord 11 , Peter A B Wark 1 2 , Peter G Gibson 1 2 ; participants of the Treatable Traits Down Under International Workshop; Treatable Traits Down Under International Workshop participants:"
31372030,Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain,"Carlos Ferrer Albiach 1, Francisco Villegas Estévez 2, Mª Dolores López Alarcón 3, María de Madariaga 4, Alfonso Carregal 5, Javier Arranz 6, José M Trinidad Martín-Arroyo 7, Antonio Javier Jiménez López 8, Almudena Sanz Yagüe 8",J Pain Res. 2019 Jul 12;12:2125-2135. doi: 10.2147/JPR.S194881. eCollection 2019.,Ferrer Albiach C,J Pain Res,2019,2019/08/03,PMC6636433,,10.2147/JPR.S194881,https://pubmed.ncbi.nlm.nih.gov/31372030/,/31372030/,"CFA and FVE received fees from Kyowa Kirin Farmacéutica, S.L.U., for the design, execution, and coordination of the study. In addition, the following authors declare potential conflicts of interest for individual activities for the industry outside the submitted work: CFA has received payments for consultancies and lecture fees from Astellas Pharma, Janssen, GP-Pharm, and Kyowa Kirin Farmacéutica, S.L.U. FVE has received payments for consultancies and lecture fees from Grünenthal, Gebro Pharma, Menarini, Takeda, Mylan, Esteve, and Ferrer. MDLA has received payments for consultancies and lecture fees from Kyowa Kirin Farmacéutica, S.L.U., Takeda, Gebro Pharma, Esteve, Teva, and Grünenthal. MM has received lecture fees from Kyowa Kirin Farmacéutica, S.L.U., Grünenthal, Mundipharma, Ferrer, and Medtronic. AC has received payments for consultancies and lecture fees from Takeda, Gebro Pharma, Esteve, Teva, Grünenthal, and Kyowa Kirin Farmacéutica, S.L.U. JA has received payments for consultancies and lecture fees from Esteve, Abstral and Kyowa Kirin Farmacéutica, S.L.U. JMTMA has received payments for consultancies and lecture fees from Grünenthal, Boston Scientific, Gebro Pharma, Angellini Farmaceutica, Takeda, Kyowa Kirin Farmacéutica, S.L.U. and Ferrer. AJJL and ASY are employed by Kyowa Kirin Farmacéutica, S.L.U. The authors report no other conflicts of interest in this work.",,"Carlos Ferrer Albiach 1 , Francisco Villegas Estévez 2 , Mª Dolores López Alarcón 3 , María de Madariaga 4 , Alfonso Carregal 5 , Javier Arranz 6 , José M Trinidad Martín-Arroyo 7 , Antonio Javier Jiménez López 8 , Almudena Sanz Yagüe 8"
30670535,Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma,"Neha Mehta-Shah 1 2, Kimiteru Ito 3, Kurt Bantilan 1, Alison J Moskowitz 1, Craig Sauter 4, Steven M Horwitz 1, Heiko Schöder 3",Blood Adv. 2019 Jan 22;3(2):187-197. doi: 10.1182/bloodadvances.2018024075.,Mehta-Shah N,Blood Adv,2019,2019/01/24,PMC6341183,,10.1182/bloodadvances.2018024075,https://pubmed.ncbi.nlm.nih.gov/30670535/,/30670535/,"Conflict-of-interest disclosure: N.M.-S. has research funding from Celgene, Bristol-Myers Squibb, Genentech, and Verastem; and served as a consultant for Kyowa-Kirin. H.S. has served as a consultant for Aileron Therapeutics. S.M.H. has research support from ADC Therapeutics, Aileron, Celgene, Forty-Seven, Infinity/Verastem, Kyowa-Hakka-Kirin, Millennium/Takeda, Seattle Genetics, and Trillium; and consults for Celgene, Millennium/Takeda, Kyowa-Hakka-Kirin, Seattle Genetics, Forty-Seven, Mundipharma, Verastem, Portola, Beigene, Innate Pharma, Miragen, Aileron, and Corvus. C.S. has research funding from Juno Therapeutics and Sanofi-Genzyme; and has served as a consultant for Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Precision Biosciences, Kite, and GlaxoSmithKline. A.J.M. has research funding from Seattle Genetics, Merck, Bristol-Myers Squibb, Incyte, Miragen, and Kyowa-Hakko-Kirin; and has served as a consultant for Kyowa-Hakka-Kirin, Miragen Therapeutics, Takeda Pharmaceuticals, ACD Therapeutics, Seattle Genetics, Cell Medica, Bristol-Myers Squibb, and Erytech Pharma. The remaning authors declare no competing financial interests.",Grants and funding K12 CA167540/CA/NCI NIH HHS/United States P30 CA008748/CA/NCI NIH HHS/United States,"Neha Mehta-Shah 1 2 , Kimiteru Ito 3 , Kurt Bantilan 1 , Alison J Moskowitz 1 , Craig Sauter 4 , Steven M Horwitz 1 , Heiko Schöder 3"
31467120,"ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions","Arnaud Bourdin 1, Leif Bjermer 2, Christopher Brightling 3, Guy G Brusselle 4, Pascal Chanez 5, Kian Fan Chung 6, Adnan Custovic 7, Zuzana Diamant 8 9, Sarah Diver 10, Ratko Djukanovic 11, Dominique Hamerlijnck 12, Ildikó Horváth 13, Sebastian L Johnston 14, Frank Kanniess 15, Nikos Papadopoulos 16 17, Alberto Papi 18, Richard J Russell 19, Dermot Ryan 20 21, Konstantinos Samitas 22, Thomy Tonia 23, Eleftherios Zervas 24, Mina Gaga 25",Eur Respir J. 2019 Sep 28;54(3):1900900. doi: 10.1183/13993003.00900-2019. Print 2019 Sep.,Bourdin A,Eur Respir J,2019,2019/08/31,,,10.1183/13993003.00900-2019,https://pubmed.ncbi.nlm.nih.gov/31467120/,/31467120/,"Conflict of interest: A. Bourdin reports personal and institutional fees for advisory board work from AstraZeneca, Novartis, GSK, Boehringher Ingelheim, Chiesi, Actelion, Pfizer and Teva, outside the submitted work. Conflict of interest: L. Bjermer has nothing to disclose. Conflict of interest: C. Brightling reports grants and personal fees for consultancy from GlaxoSmithKline, AstraZeneca/Medimmune, Novartis, Chiesi, Roche/Genentech and Boehringer Inglheim, personal fees for consultancy from Vectura, Theravance, PreP, Gilead, Sanofi/Regeneron, Teva, Gossamer and 4DPharma, grants from Pfizer and Mologic, outside the submitted work. Conflict of interest: G.G. Brusselle reports personal fees for advisory board work and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva, personal fees for advisory board work from Sanofi, outside the submitted work. Conflict of interest: P. Chanez reports research grants and personal fees for consultancy, advisory board work and lectures from ALK, Almirall, Boehringer Ingelheim, GSK, AstraZeneca, Novartis, TEVA and Chiesi, grants from AMU, outside the submitted work. Conflict of interest: K.F. Chung has received honoraria for participating in advisory board meetings of GSK, AZ, Novartis, Merck, BI and TEVA regarding treatments for asthma and COPD, and has also been renumerated for speaking engagements. Conflict of interest: A. Custovic reports personal fees for consultancy from Novartis, Regeneron/Sanofi, Boehringer Ingelheim and Philips, personal fees for lectures from Thermo Fisher Scientific and Novartis, outside the submitted work. Conflict of interest: Z. Diamant reports personal fees from AstraZeneca and Sanofi-Genzyme, during the conduct of the study; personal fees from Aquilon, ALK, Boehringer Ingelheim, Gilead, Hal Allergy and MSD, outside the submitted work; and in addiction to academic affiliations, also works at a phase I/II unit performing clinical studies for different biotech and pharma companies. Conflict of interest: S. Diver has nothing to disclose. Conflict of interest: R. Djukanovic reports receiving fees for lectures at symposia organised by Novartis, AstraZeneca and TEVA, consultation for TEVA and Novartis as member of advisory boards, and participation in a scientific discussion about asthma organised by GlaxoSmithKline; in addition, is a co-founder and current consultant, and has shares in, Synairgen, a University of Southampton spin out company. Conflict of interest: D. Hamerlijnck has nothing to disclose. Conflict of interest: I. Horvath reports personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GSK, Novartis, CSL-Behring and Roche, outside the submitted work. Conflict of interest: S.L. Johnston reports personal fees for advisory board work from Therapeutic Frontiers and Virtus Respiratory Research, personal fees for consultancy from Myelo Therapeutics GmbH, Concert Pharmaceuticals, Bayer, Gerson Lehrman Group, resTORbio, Bioforce, Materia Medical Holdings, PrepBio Pharma, Pulmotect, Virion Health and Lallemand Pharma, personal and insititutional fees for consultancy from Synairgen, Novartis, Boehringer Ingelheim and Chiesi; and has received personal fees for the following patents planned, issued or pending: transgenic animal models of HRV with human ICAM-1 sequences (UK patent application number 02 167 29.4, and international patent application number PCT/EP2003/007939); anti-virus therapy for respiratory diseases (UK patent application number GB 0405634.7); interferon-beta for anti-virus therapy for respiratory diseases (international patent application number PCT/GB05/50031); interferon lambda therapy for the treatment of respiratory disease (UK patent application number 6779645.9, granted); induction of cross-reactive cellular response against rhinovirus antigens (European patent number 13305152), outside the submitted work. Conflict of interest: F. Kanniess reports personal fees for lectures and advisory board work from AstraZeneca, Novartis, Mundipharma and TEVA, outside the submitted work. Conflict of interest: N. Papadopoulos reports personal fees for advisory board work and lectures from Novartis, Nutricia, HAL, personal fees from Menarini/Faes Farma and Mylan/Meda, personal fees for lectures from Sanofi, Biomay, MSD, ASIT Biotech and Boehringer Ingelheim, personal fees for advisory board work from AstraZeneca and GSK, grants from Gerolymatos International SA and Capricare, outside the submitted work. Conflict of interest: A. Papi reports grants, personal fees for lectures, advisory board work and consultancy, and travel expenses reimbursement from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline and Teva, personal fees for advisory board work and consultancy from Sanofi/Regeneron, personal fees for lectures and travel expenses reimbursement from Zambon and Novartis, personal fees for lectures, advisory board work and consultancy, and travel expenses reimbursement from Mundipharma, personal fees for lectures and advisory board work, and travel expenses reimbursement Almirall, grants, personal fees for lectures and travel expenses reimbursement from Menarini, grants from Fondazione Maugeri, grants from Fondazione Chiesi Farmaceutici, outside the submitted work. Conflict of interest: R.J. Russell has nothing to disclose. Conflict of interest: D. Ryan reports personal fees for advisory board work from GSK and Trudell Medical, personal fees for advisory board work and lectures from AZ, personal fees for lectures from Mylan and Chiesi, personal fees for consultancy from Optimum Patient Care, outside the submitted work. Conflict of interest: K. Samitas has nothing to disclose. Conflict of interest: T. Tonia acts as ERS methodologist. Conflict of interest: E. Zervas reports personal fees consultancy and lectures from Astra, Bristol-Myers Squibb, Chiesi, GSK, Elpen, Merck, MSD, Novartis, Menarini and Pfizer, non-financial support for travel, accommodation and meeting expenses from Astra, Bristol-Myers Squibb, Galenica, Chiesi, Elpen, Novartis, Menarini and Roche, outside the submitted work. Conflict of interest: M. Gaga reports grants and personal fees from AZ, grants from BI, Elpen, Novartis and Menarini, personal fees from BMS, MSD, Chiesi and Pharmaten, outside the submitted work.",,"Arnaud Bourdin 1 , Leif Bjermer 2 , Christopher Brightling 3 , Guy G Brusselle 4 , Pascal Chanez 5 , Kian Fan Chung 6 , Adnan Custovic 7 , Zuzana Diamant 8 9 , Sarah Diver 10 , Ratko Djukanovic 11 , Dominique Hamerlijnck 12 , Ildikó Horváth 13 , Sebastian L Johnston 14 , Frank Kanniess 15 , Nikos Papadopoulos 16 17 , Alberto Papi 18 , Richard J Russell 19 , Dermot Ryan 20 21 , Konstantinos Samitas 22 , Thomy Tonia 23 , Eleftherios Zervas 24 , Mina Gaga 25"
31406171,Tiotropium inhibits proinflammatory microparticle generation by human bronchial and endothelial cells,"Tommaso Neri 1, Valentina Scalise 1, Ilaria Passalacqua 1, Chiara Sanguinetti 1, Stefania Lombardi 2, Laura Pergoli 3, Valentina Bollati 3, Roberto Pedrinelli 1, Pierluigi Paggiaro 1, Alessandro Celi 4",Sci Rep. 2019 Aug 12;9(1):11631. doi: 10.1038/s41598-019-48129-w.,Neri T,Sci Rep,2019,2019/08/14,PMC6691117,,10.1038/s41598-019-48129-w,https://pubmed.ncbi.nlm.nih.gov/31406171/,/31406171/,"A.C. received lectures fees form Boehringer Ingelheim and G.S.K. P.P. received personal and research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, G.S.K., Mundipharma, Novartis and Sanofi.",,"Tommaso Neri 1 , Valentina Scalise 1 , Ilaria Passalacqua 1 , Chiara Sanguinetti 1 , Stefania Lombardi 2 , Laura Pergoli 3 , Valentina Bollati 3 , Roberto Pedrinelli 1 , Pierluigi Paggiaro 1 , Alessandro Celi 4"
30863141,Low-dose methoxyflurane analgesia in adolescent patients with moderate-to-severe trauma pain: a subgroup analysis of the STOP! study,"Stuart Hartshorn 1, Patrick Dissmann 2, Frank Coffey 3, Mark Lomax 4",J Pain Res. 2019 Feb 15;12:689-700. doi: 10.2147/JPR.S188675. eCollection 2019.,Hartshorn S,J Pain Res,2019,2019/03/14,PMC6388743,,10.2147/JPR.S188675,https://pubmed.ncbi.nlm.nih.gov/30863141/,/30863141/,"Disclosure Stuart Hartshorn reports a Chief Investigator grant and personal fees from MDI Limited outside of the submitted work. Patrick Dissmann reports personal fees from Mundipharma International, outside the submitted work. Frank Coffey reports grants from Nottingham University Hospital Trust, during the conduct of the study. Mark Lomax is an employee of Mundipharma Research Limited. The authors report no other conflicts of interest in this work.",,"Stuart Hartshorn 1 , Patrick Dissmann 2 , Frank Coffey 3 , Mark Lomax 4"
30726278,Assessing the clinical practice in specialized outpatient clinics for chronic obstructive pulmonary disease: Analysis of the EPOCONSUL clinical audit,"Myriam Calle Rubio 1 2, Juan José Soler-Cataluña 3, José Luis López-Campos 4 5, Bernardino Alcázar Navarrete 6, José Miguel Rodríguez González-Moro 7, Joan B Soriano 8, Manuel E Fuentes Ferrer 2 9, Juan Luis Rodriguez Hermosa 1 2",PLoS One. 2019 Feb 6;14(2):e0211732. doi: 10.1371/journal.pone.0211732. eCollection 2019.,Calle Rubio M,PLoS One,2019,2019/02/07,PMC6364994,,10.1371/journal.pone.0211732,https://pubmed.ncbi.nlm.nih.gov/30726278/,/30726278/,"This study was partly funded by Boehringer Ingelheim. Myriam Calle Rubio has received speaker fees from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Menarini, and Novartis and consulting fees from GlaxoSmith¬Kline, Gebro Pharma and Novartis. Juan José Soler-Cataluña has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Menarini, Mundipharma, Novartis and and consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, GSK, Mundipharma and Novartis. Jose Luis Lopez Campos has received fees for giving conferences, scientific advising, participation in clinical studies or draft of publications for (alphabetical order): Almirall, AstraZeneca, Bayer, Boehringer Ingelheim, Cantabria Pharma, Chiesi, Esteve, Faes, Ferrer, Gebro Pharma, GlaxoSmithKline, Grifols, Menarini, MSD, Novartis, Pfizer, Rovi, Teva y Takeda. Bernardino Alcázar Navarrete reports personal fees from GSK, grants, personal fees and non-financial support from Novartis AG, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Chiesi, grants, personal fees and nonfinancial support from Laboratorios Menarini, personal fees from Gebro, personal fees from Astra- Zeneca, outside the submitted work. None of these are related to this work. José Miguel Rodríguez González- Moro has received fees for giving conferences from Astra-Zeneca, GSK, Boehringer Ingelheim, Teva, Novartis and Chiesi. J.B. Soriano declares having received grants from 2014 to date from Linde via Hospital Universitario de La Princesa, and has participated in speaking activities, advisory committees and consultancies during the period 2014−2018 sponsored by Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, ERS, Esteve, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda, outside the submitted work. Manuel E. Fuentes Ferrer does not have conflicts of interest Juan Luis Rodriguez Hermosa has received speaker fees from Boehringer Ingelheim and Gebro Pharma. This does not alter our adherence to PLOS ONE policies on sharing data and materials.","Grants and funding This study has been promoted and sponsored by the SEPAR. We thank Boehringer Ingelheim for its financial support to carry out the study. The funders had no role in study design, data collection, analysis, decision to publish or preparation of this manuscript","Myriam Calle Rubio 1 2 , Juan José Soler-Cataluña 3 , José Luis López-Campos 4 5 , Bernardino Alcázar Navarrete 6 , José Miguel Rodríguez González-Moro 7 , Joan B Soriano 8 , Manuel E Fuentes Ferrer 2 9 , Juan Luis Rodriguez Hermosa 1 2"
30868176,Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program,"David R Matthews 1 2, Qiang Li 3, Vlado Perkovic 3 4, Kenneth W Mahaffey 5, Dick de Zeeuw 6, Greg Fulcher 4, Mehul Desai 7, William R Hiatt 8, Mark Nehler 9, Elisa Fabbrini 7, Mary Kavalam 7, Mary Lee 7, Bruce Neal 3 10",Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.,Matthews DR,Diabetologia,2019,2019/03/15,PMC6509073,,10.1007/s00125-019-4839-8,https://pubmed.ncbi.nlm.nih.gov/30868176/,/30868176/,"DRM reports receiving support from Janssen for his role as co-chair of the CANVAS Program steering committee. QL reports being a full-time employee of the George Institute for Global Health. VP reports receiving personal fees for advisory boards or scientific presentations from Retrophin, Janssen, Merck and Servier, serving on steering committees for trials funded by AbbVie, Boehringer Ingelheim, GlaxoSmithKline, Janssen and Pfizer and participating in scientific presentations/advisory boards with AbbVie, Astellas, Astra Zeneca, Bayer, Baxter, Bristol-Myers Squibb, Boehringer Ingelheim, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Novartis, Novo Nordisk, Pharmalink, Relypsa, Sanofi and Vitae, with all fees paid to his employer. KWM reports receiving grants from Afferent, Amgen, Apple Inc., AstraZeneca, Cardiva Medical, Daiichi, Ferring, Google (Verily), Johnson & Johnson, Luitpold, Medtronic, Merck, Novartis, Sanofi, St Jude and Tenax, receiving personal fees from Ablynx, AstraZeneca, Baim Institute, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiometabolic Health Congress, Elsevier, GlaxoSmithKline, Johnson & Johnson, Medscape, Merck, Mitsubishi, Myokardia, Novartis, Oculeve, Portola, Radiometer, Springer Publishing, Theravance, University of California San Francisco and WebMD and having equity in BioPrint Fitness. DdZ reports serving on advisory boards and/or as a speaker for Bayer, Boehringer Ingelheim, Fresenius, Mundipharma and Mitsubishi-Tanabe, being a steering committee member and/or speaker for AbbVie and Janssen and serving on Data Safety and Monitoring Committees for Bayer. GF reports receiving grants from Novo Nordisk and personal fees from Janssen, Novo Nordisk, Boehringer Ingelheim and Merck Sharp & Dohme. MD, EF, MK and ML report being full-time employees of Janssen Research & Development, LLC. MK reports holding stock in Johnson & Johnson. WRH reports receiving grants from Janssen and Bayer. MN reports receiving salary support from CPC Research. BN reports receiving grants and travel costs related to presentation of data from Janssen and serving on advisory boards for Janssen, with any consultancy, honoraria or travel support paid to his institution. No other potential conflicts of interest relevant to this article are reported.",,"David R Matthews 1 2 , Qiang Li 3 , Vlado Perkovic 3 4 , Kenneth W Mahaffey 5 , Dick de Zeeuw 6 , Greg Fulcher 4 , Mehul Desai 7 , William R Hiatt 8 , Mark Nehler 9 , Elisa Fabbrini 7 , Mary Kavalam 7 , Mary Lee 7 , Bruce Neal 3 10"
31497352,Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations,"Junyoung Choi 1 2, Shinkyo Yoon 1, Deokhoon Kim 3, Yong Wha Moon 4, Chang Hoon Lee 5, Seyoung Seo 1, Jaekyung Cheon 6, Yong Song Gho 7, Changhoon Kim 8, Eung Ryoung Lee 8, Soo-Youl Kim 9, Kyoungmin Lee 1, Joo Young Ha 1, Sook Ryun Park 1, Sang-We Kim 1, Kang-Seo Park 1 2, Dae Ho Lee 1",Am J Cancer Res. 2019 Aug 1;9(8):1708-1721. eCollection 2019.,Choi J,Am J Cancer Res,2019,2019/09/10,PMC6726998,,,https://pubmed.ncbi.nlm.nih.gov/31497352/,/31497352/,"Dae Ho Lee declares honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CJ Healthcare, ChongKunDang, Eli Lilly, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm and ST Cube. The other authors declare that they have no conflict of interest.",,"Junyoung Choi 1 2 , Shinkyo Yoon 1 , Deokhoon Kim 3 , Yong Wha Moon 4 , Chang Hoon Lee 5 , Seyoung Seo 1 , Jaekyung Cheon 6 , Yong Song Gho 7 , Changhoon Kim 8 , Eung Ryoung Lee 8 , Soo-Youl Kim 9 , Kyoungmin Lee 1 , Joo Young Ha 1 , Sook Ryun Park 1 , Sang-We Kim 1 , Kang-Seo Park 1 2 , Dae Ho Lee 1"
31440042,"Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study","Kyu Yean Kim 1, Marc Miravitlles 2 3, Pawel Sliwinski 4, Richard Costello 5, Victoria Carter 6 7, Jessica Tan 8, Therese Sophie Lapperre 8 9, Bernardino Alcazar 10, Caroline Gouder 11, Cristina Esquinas 2 12, Juan Luis García-Rivero 13, Anu Kemppinen 6, Augustine Tee 14, Miguel Roman-Rodríguez 15, Juan José Soler-Cataluña 3 16, David Price 6 7 17, Chin Kook Rhee 1",Int J Chron Obstruct Pulmon Dis. 2019 Jul 25;14:1595-1601. doi: 10.2147/COPD.S208245. eCollection 2019.,Kim KY,Int J Chron Obstruct Pulmon Dis,2019,2019/08/24,PMC6664421,,10.2147/COPD.S208245,https://pubmed.ncbi.nlm.nih.gov/31440042/,/31440042/,"Dr Marc Miravitlles received speaker and/or consulting and personal fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Laboratorios Esteve, Ferrer, Gebro Pharma, GlaxoSmithKline, Grifols, Menarini, Mereo Biopharma, Novartis, pH Pharma, Rovi, TEVA, Verona Pharma and Zambon, and research grants from GlaxoSmithKline and Grifols outside the submitted. Professor Pawel Sliwinski received speaker fees and non-financial support from Boehringer Ingelheim, AstraZeneca, Chiesi, GlaxoSmithKline, Grifols, Novartis, Roche and Teva, and consulting fees from Boehringer Ingelheim, GlaxoSmithKline, Chiesi, Grifols, Novartis, and Roche, outside the submitted work. Dr CK Rhee received consulting/lecture fees from MSD, AstraZeneca, Novartis, GSK, Takeda, Mundipharma, Sandoz, Boehringer-Ingelheim, and Teva-Handok. Dr Richard Costelloe has board membership with GSK, Aerogen, Novartis, and Teva Pharmaceuticals; consultancy agreements with, Aerogen, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, and Vitalograph as well as grants and unrestricted funding for investigator-initiated studies from Vitalograph, Aerogen and GlaxoSmithKline. Dr Bernardino Alcazar reports personal fees grants, and non-financial support from Novartis AG, Boehringer-Ingelheim, GSK, personal fees from AztraZeneca, grants and personal fees from Laboratorios Menarini, Laboratorios Rovi, Laboratorios Ferrer, outside the submitted work, in addition, he has a patent WO2018/215686A1 issued. Dr Augustine Tee received research fund from The Respiratory Effectiveness Group, during the conduct of the study; has participated as a member of the local COPD advisory board for AstraZeneca, GlaxoSmithKline, Bayer, Takeda, and Novartis, and has received meeting/conference travel grants from Boehringer Ingelheim, Novartis, AstraZeneca, and GlaxoSmithKline. Ms Victoria Carter reports funding this study by an unrestricted grant from Novartis AG, during the conduct of the study; also she is an employee of the Observational and Pragmatic Research Institute Pte Ltd (OPRI), and Optimum Patient Care. Dr Juan José Soler-Cataluña has received speaker fees from AstraZeneca, grants, personal fees, non-financial support from Boehringer Ingelheim, non-financial support from Chiesi, Esteve, Ferrer, GSK, Menarini, Novartis, and Pfizer, and consulting fees from AirLiquide, Boehringer Ingelheim, Chiesi, GSK, AstraZeneca, Ferrer, and Novartis outside the submitted work. Professor David Price has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. Dr Miguel Roman-Rodríguez has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Gebro Pharma, GlaxoSmithKline, Menarini, Mundipharma, Novartis, Pfizer, and Teva, and consulting/personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis outside the submitted work. The authors report no other conflicts of interest in this work.",,"Kyu Yean Kim 1 , Marc Miravitlles 2 3 , Pawel Sliwinski 4 , Richard Costello 5 , Victoria Carter 6 7 , Jessica Tan 8 , Therese Sophie Lapperre 8 9 , Bernardino Alcazar 10 , Caroline Gouder 11 , Cristina Esquinas 2 12 , Juan Luis García-Rivero 13 , Anu Kemppinen 6 , Augustine Tee 14 , Miguel Roman-Rodríguez 15 , Juan José Soler-Cataluña 3 16 , David Price 6 7 17 , Chin Kook Rhee 1"
31694491,Triple therapy for COPD: a crude analysis from a systematic review of the evidence,"Jose Luis Lopez-Campos 1 2, Laura Carrasco-Hernandez 3 4, Esther Quintana-Gallego 3 4, Carmen Calero-Acuña 3 4, Eduardo Márquez-Martín 3 4, Francisco Ortega-Ruiz 3 4, Joan B Soriano 4 5",Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885522. doi: 10.1177/1753466619885522.,Lopez-Campos JL,Ther Adv Respir Dis,2019,2019/11/08,PMC7000908,,10.1177/1753466619885522,https://pubmed.ncbi.nlm.nih.gov/31694491/,/31694491/,"Conflict of interest statement: JLLC: has received over the last three years honoraria for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Esteve, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, Novartis, Rovi y Teva. JBS participated in speaking activities, advisory committees and consultancies during the period 2014-2019 sponsored by Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. JBS declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates. The rest of the authors declare no conflicts of interest.",,"Jose Luis Lopez-Campos 1 2 , Laura Carrasco-Hernandez 3 4 , Esther Quintana-Gallego 3 4 , Carmen Calero-Acuña 3 4 , Eduardo Márquez-Martín 3 4 , Francisco Ortega-Ruiz 3 4 , Joan B Soriano 4 5"
31719527,Acute anxiety and autonomic arousal induced by CO(2) inhalation impairs prefrontal executive functions in healthy humans,"George Savulich 1 2, Frank H Hezemans 2 3, Sophia van Ghesel Grothe 2, Jessica Dafflon 2, Norah Schulten 2, Annette B Brühl 2, Barbara J Sahakian 1 2, Trevor W Robbins 4 5",Transl Psychiatry. 2019 Nov 12;9(1):296. doi: 10.1038/s41398-019-0634-z.,Savulich G,Transl Psychiatry,2019,2019/11/14,PMC6851177,,10.1038/s41398-019-0634-z,https://pubmed.ncbi.nlm.nih.gov/31719527/,/31719527/,"B.J.S. consults for Cambridge Cognition, Peak and Mundipharma. T.W.R. consults for Cambridge Cognition, Mundipharma and Unilever and receives Royalties for CANTAB. The authors declare that they have no conflict of interest.",Grants and funding G0001354/MRC_/Medical Research Council/United Kingdom G1000183/MRC_/Medical Research Council/United Kingdom 104631/Z/14/Z/Wellcome Trust (Wellcome)/International 093875/Z/10/Z/Wellcome Trust (Wellcome)/International,"George Savulich 1 2 , Frank H Hezemans 2 3 , Sophia van Ghesel Grothe 2 , Jessica Dafflon 2 , Norah Schulten 2 , Annette B Brühl 2 , Barbara J Sahakian 1 2 , Trevor W Robbins 4 5"
30984390,No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors,"Franziska Hopfner 1 2, Stefanie H Müller 1, Dagmar Steppat 3, Joanna Miller 3, Nele Schmidt 1, Klaus-Peter Wandinger 4, Frank Leypoldt 1 4, Daniela Berg 1 5 6, Andre Franke 7, Wolfgang Lieb 8, Lukas Tittmann 8, Monika Balzer-Geldsetzer 9 10, Simon Baudrexel 11 12, Richard Dodel 9 10, Ruediger Hilker-Roggendorf 11 12, Elke Kalbe 13 14, Jan Kassubek 15, Thomas Klockgether 16, Inga Liepelt-Scarfone 5 6, Brit Mollenhauer 17 18, Petra Neuser 19, Kathrin Reetz 20 21, Oliver Riedel 22, Claudia Schulte 5 6, Jörg B Schulz 20 21, Annika Spottke 16, Alexander Storch 23 24 25, Claudia Trenkwalder 17 18, Hans-Ulrich Wittchen 26 27 2, Karsten Witt 1 28 29, Ullrich Wüllner 16, Günther Deuschl 1, Gregor Kuhlenbäumer 1",Transl Neurodegener. 2019 Apr 3;8:11. doi: 10.1186/s40035-019-0153-0. eCollection 2019.,Hopfner F,Transl Neurodegener,2019,2019/04/16,PMC6446289,,10.1186/s40035-019-0153-0,https://pubmed.ncbi.nlm.nih.gov/30984390/,/30984390/,"Ethics committee approval was obtained for all studies involved (Dept. of Neurology of Kiel University, Landscape, popgen).Nothing to report.F. Hopfner received grants from the German Research Council (DFG), Stefanie H. Müller, Dagmar Steppat, Joanna Miller, Nele Schmidt, Claudia Schulte, Petra Neuser, Inga Liepelt-Scarfone, Brit Mollenhauer, Lucas Tittmann, Monika Balzer-Geldsetzer, Simon Baudrexel, Elke Kalbe, Oliver Riedel report no disclosures. Richard Dodel has received lecture fees from Novartis, Lilly, Octapharma, Pfizer and has received research support from the EU Horizon 2020, the AOK Gesundheitskasse Hessen, AOK Gesundheitskasse Sachsen und Thüringen, the M.J.Fox Foundation, the Internationale Parkinson Fonds and the Faber-Stiftung. Frank Leypoldt, Klaus-Peter Wandinger Andre Franke received grants from the German Research Council (DFG). Wolfgang Lieb was supported by a grant from the German Federal Ministry of Education and Research (01EY1103). Daniela Berg is a member of the UCB advisory board and receives grants from Michael J. Fox Foundation, Janssen Pharmaceutica N.V., German Parkinson’s Disease Association (dPV), BMWi, BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, TEVA Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, and Damp foundation. Ruediger Hilker-Roggendorf has received speaker honoraria from Medtronic, Orion, GlaxoSmithKline, TEVA, Cephalon, Solvay, Desitin, Ipsen, Merz, Archimedes Pharma and Boehringer Ingelheim as well as travel funding from Medtronic, Allergan and Cephalon. He has served on a scientific advisory board for Cephalon and has received research funding from the Deutsche Parkinson Vereinigung (dPV), Bundesministerium für Bildung und Forschung and Goethe University Frankfurt. Alexander Storch has received funding from the Deutsche Forschungsgemeinschaft (German Research Association) and the Helmholtz-Association. He has received honoraria for presentations/advisory boards/consultations from AbbVie, Bial, Bayer, Grünenthal, Teva, Desitin and UCB. He has received royalties from Kohlhammer Verlag and Elsevier Press. He serves as an editorial board member of Stem Cells, Stem Cells International, Open Biotechnology Journals, and jbc The Journal of Biological Chemistry. Annika Spottke, Jörg B. Schulz, Karsten Witt and Hans-Ulrich Wittchen report no disclosures. Jan Kassubek has received consulting fees as an advisory board member and honoraria as a speaker from UCB Pharma, Bial, Teva Pharmaceuticals, AbbVie, Zambon, Medtronic, Novartis, Desitin, Boehringer Ingelheim. Thomas Klockgether receives/has received research support from the Deutsche Forschungsgemeinschaft (DFG), the Bundesministerium für Bildung und Forschung (BMBF), the Bundesministerium für Gesundheit (BMG), the Robert Bosch Foundation. the European Union (EU), and the National Institutes of Health (NIH). He serves on the editorial board of The Cerebellum and the Journal of Neurology. He has received consulting fees from Biohaven. Ullrich Wüllner served as consultant and lecturer and on advisory boards for Boehringer-Ingelheim, Glaxo-SmithKline, Pfizer Pharma GmbH, UCB Pharma and received grant/research funding from BMBF, DFG, NAF, dPV and the EU (6th framework). Claudia Trenkwalder reports personal fees from Britannia, during the conduct of the study; grants from Michael J. Fox Foundation, the European Commission Horizon 2020 Program: ‘Propag-Ageing’, MundiPharma, Vifor, personal fees from Britannia, Novartis, UCB, MundiPharma, Vifor, Benevolent, Orion Pharma, Pfizer, personal fees from Grünenthal, UCB and AbbVie., outside the submitted work. Kathrin Reetz is funded by the German Federal Ministry of Education and Research (BMBF 01GQ1402), has received honoraria for presentations from Lilly and research grants from Pfizer, Merck and the Alzheimer Forschung Initiative e.V. (AFI 13812). Günther Deuschl has received lecture fees from UCB, Medtronic and Desitin and has been serving as a consultant for Medtronic, Sapiens, Boston Scientific and Britannica. He received royalties from Thieme publishers. He receives through his institution funding for his research from the German Research Council, the German Ministery of Education and Health and Medtronic. All authors are government employees. Gregor Kuhlenbäumer receives research support from the German Research Council (DFG) and the Christian-Albrechts-University Kiel.",,"Franziska Hopfner 1 2 , Stefanie H Müller 1 , Dagmar Steppat 3 , Joanna Miller 3 , Nele Schmidt 1 , Klaus-Peter Wandinger 4 , Frank Leypoldt 1 4 , Daniela Berg 1 5 6 , Andre Franke 7 , Wolfgang Lieb 8 , Lukas Tittmann 8 , Monika Balzer-Geldsetzer 9 10 , Simon Baudrexel 11 12 , Richard Dodel 9 10 , Ruediger Hilker-Roggendorf 11 12 , Elke Kalbe 13 14 , Jan Kassubek 15 , Thomas Klockgether 16 , Inga Liepelt-Scarfone 5 6 , Brit Mollenhauer 17 18 , Petra Neuser 19 , Kathrin Reetz 20 21 , Oliver Riedel 22 , Claudia Schulte 5 6 , Jörg B Schulz 20 21 , Annika Spottke 16 , Alexander Storch 23 24 25 , Claudia Trenkwalder 17 18 , Hans-Ulrich Wittchen 26 27 2 , Karsten Witt 1 28 29 , Ullrich Wüllner 16 , Günther Deuschl 1 , Gregor Kuhlenbäumer 1"
31412884,Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial,"Luke Sheridan Rains 1, Louise Marston 2, Mark Hinton 3 4, Steven Marwaha 5 6, Thomas Craig 7, David Fowler 8, Michael King 9, Rumana Z Omar 10, Paul McCrone 11, Jonathan Spencer 7, Joanne Taylor 9, Sophie Colman 9, Catherine Harder 9, Eleanor Gilbert 5, Amie Randhawa 5, Kirsty Labuschagne 8, Charlotte Jones 7, Theodora Stefanidou 9, Marina Christoforou 9, Meghan Craig 9, John Strang 12, Tim Weaver 13, Sonia Johnson 9",BMC Med. 2019 Aug 15;17(1):161. doi: 10.1186/s12916-019-1395-5.,Sheridan Rains L,BMC Med,2019,2019/08/16,PMC6694526,,10.1186/s12916-019-1395-5,https://pubmed.ncbi.nlm.nih.gov/31412884/,/31412884/,"This trial was funded by the National Institute for Health Research, Health Technology Assessment programme (09/144/50), and MK is a member of CTUs funded by NIHR and the Rapid Trials and Add-on Studies Board. RM is a member of the HTA General Board. JS is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. JS reports grants from Camurus (Lund, Sweden), Martindale Pharma (now Ethypharm UK, Woodburn Green, UK), Mundipharma (Mundipharma International Limited, Cambridge, UK) and Braeburn Pharma (Braeburn Inc., Plymouth Meeting, PA, USA), and other from Martindale Pharma, Braeburn Pharma outside the submitted work. In addition, John Strang has patents unrelated to the work described in this article: a patent Euro-Celtique issued and a patent King’s College London pending.",Grants and funding 09/144/50/DH_/Department of Health/United Kingdom,"Luke Sheridan Rains 1 , Louise Marston 2 , Mark Hinton 3 4 , Steven Marwaha 5 6 , Thomas Craig 7 , David Fowler 8 , Michael King 9 , Rumana Z Omar 10 , Paul McCrone 11 , Jonathan Spencer 7 , Joanne Taylor 9 , Sophie Colman 9 , Catherine Harder 9 , Eleanor Gilbert 5 , Amie Randhawa 5 , Kirsty Labuschagne 8 , Charlotte Jones 7 , Theodora Stefanidou 9 , Marina Christoforou 9 , Meghan Craig 9 , John Strang 12 , Tim Weaver 13 , Sonia Johnson 9"
30943990,"Prolonged-release opioid agonist therapy: qualitative study exploring patients views of 1-week, 1-month, and 6-month buprenorphine formulations","Joanne Neale 1 2, Charlotte N E Tompkins 3, John Strang 3 4",Harm Reduct J. 2019 Apr 3;16(1):25. doi: 10.1186/s12954-019-0296-4.,Neale J,Harm Reduct J,2019,2019/04/05,PMC6446264,,10.1186/s12954-019-0296-4,https://pubmed.ncbi.nlm.nih.gov/30943990/,/30943990/,"This study received approval from the Psychiatry, Nursing and Midwifery Research Ethics Subcommitttee (PNM RESC), King’s College London (HR-17/18-5957). Not applicable. Joanne Neale has received honoraria and research grants from pharmaceutical companies: Camurus AB and Mundipharma International Ltd. John Strang is a researcher and clinician who has worked with a range of types of treatment and rehabilitation service-providers. He has also worked with a range of governmental and non-governmental organizations, and with pharmaceutical companies to seek to identify new or improved treatments from whom he and his employer (King’s College London) have received honoraria, travel costs, and/or consultancy payments. This has included discussions with Camurus AB, Indivior and Molteni Farma (all three of whom have developed ultra-long-acting buprenorphine formulations) and also an oversight role for the UK part of a safety trial of CAM2038/Buvidal®, the product discussed in this paper. For a fuller account, see John Strang’s web-page at: http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. Charlotte Tompkins received salary support from Camurus AB whilst undertaking this study. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",Grants and funding N/A/Camurus Lipid Research Foundation/International N/A/Pilgrim Trust/International,"Joanne Neale 1 2 , Charlotte N E Tompkins 3 , John Strang 3 4"
31882789,"Meal timing, meal frequency, and breakfast skipping in adult individuals with type 1 diabetes - associations with glycaemic control","Aila J Ahola 1 2 3, Stefan Mutter 1 2 3, Carol Forsblom 1 2 3, Valma Harjutsalo 1 2 3 4, Per-Henrik Groop 5 6 7 8",Sci Rep. 2019 Dec 27;9(1):20063. doi: 10.1038/s41598-019-56541-5.,Ahola AJ,Sci Rep,2019,2019/12/29,PMC6934661,,10.1038/s41598-019-56541-5,https://pubmed.ncbi.nlm.nih.gov/31882789/,/31882789/,"Professor Per-Henrik Groop has received investigator-initiated grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, Astra Zeneca, Boehringer-Ingelheim, Cebix, Eli Lilly, Janssen, MSD, Medscape, Mundipharma, Novartis, Novo Nordisk, and Sanofi. He has received lecture honoraria from Astellas, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, and Sanofi. All other authors declare no conflicts of interest.",,"Aila J Ahola 1 2 3 , Stefan Mutter 1 2 3 , Carol Forsblom 1 2 3 , Valma Harjutsalo 1 2 3 4 , Per-Henrik Groop 5 6 7 8"
31766326,"Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients","Pia S Zeiner 1 2 3 4, Martina Kinzig 5, Iris Divé 1 2 3 4, Gabriele D Maurer 1 2, Katharina Filipski 2 3 6, Patrick N Harter 2 3 4 6, Christian Senft 7, Oliver Bähr 1 8, Elke Hattingen 2 3 9, Joachim P Steinbach 1 2 3 4, Fritz Sörgel 5 10, Martin Voss 1 2 3 4, Eike Steidl 2 3 9, Michael W Ronellenfitsch 1 2 3 4",J Clin Med. 2019 Nov 21;8(12):2031. doi: 10.3390/jcm8122031.,Zeiner PS,J Clin Med,2019,2019/11/27,PMC6947028,,10.3390/jcm8122031,https://pubmed.ncbi.nlm.nih.gov/31766326/,/31766326/,"J.P.S. has received honoraria for lectures or advisory board participation or consulting or travel grants from Abbvie, Roche, Boehringer, Bristol-Myers Squibb, Medac, Mundipharma and UCB. All other authors declare no competing interests.",,"Pia S Zeiner 1 2 3 4 , Martina Kinzig 5 , Iris Divé 1 2 3 4 , Gabriele D Maurer 1 2 , Katharina Filipski 2 3 6 , Patrick N Harter 2 3 4 6 , Christian Senft 7 , Oliver Bähr 1 8 , Elke Hattingen 2 3 9 , Joachim P Steinbach 1 2 3 4 , Fritz Sörgel 5 10 , Martin Voss 1 2 3 4 , Eike Steidl 2 3 9 , Michael W Ronellenfitsch 1 2 3 4"
31114183,Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population,"Jørgen Vestbo 1, Claus F Vogelmeier 2, Mark Small 3, James Siddall 3, Robert Fogel 4, Konstantinos Kostikas 4 5",Int J Chron Obstruct Pulmon Dis. 2019 Apr 16;14:853-861. doi: 10.2147/COPD.S189585. eCollection 2019.,Vestbo J,Int J Chron Obstruct Pulmon Dis,2019,2019/05/23,PMC6489586,,10.2147/COPD.S189585,https://pubmed.ncbi.nlm.nih.gov/31114183/,/31114183/,"JV reports personal fees from AstraZeneca, grants, Boehringer-Ingelheim, Chiesi, and Novartis, outside the submitted work; CV reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, received personal fees from CSL Behring, Chiesi, GlaxoSmithKline, Grifols, Menarini, Mundipharma, Novartis, Teva, Bayer Schering Pharma AG, MSD, and Pfizer, outside the submitted work; MS reports non-personal fees (work by Adelphi from Novartis), during the conduct of the study; and is a full time employee of Adelphi Real World. JS reports nothing from Novartis, during the conduct of the study; and is a full time employee of Adelphi Real World. RF is an employee of and own stock in Novartis Pharmaceuticals Corporation. KK was an employee of Novartis at the time of conduct of this study. The authors report no other conflicts of interest in this work.",,"Jørgen Vestbo 1 , Claus F Vogelmeier 2 , Mark Small 3 , James Siddall 3 , Robert Fogel 4 , Konstantinos Kostikas 4 5"
30962681,"AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD","Sanjay Sethi 1, Edward Kerwin 2, Henrik Watz 3, Gary T Ferguson 4, Robert M Mroz 5 6, Rosa Segarra 7, Eduard Molins 7, Diana Jarreta 7, Esther Garcia Gil 7",Int J Chron Obstruct Pulmon Dis. 2019 Mar 22;14:667-682. doi: 10.2147/COPD.S189138. eCollection 2019.,Sethi S,Int J Chron Obstruct Pulmon Dis,2019,2019/04/10,PMC6435124,,10.2147/COPD.S189138,https://pubmed.ncbi.nlm.nih.gov/30962681/,/30962681/,"Disclosure SS has received grants from AstraZeneca, Dey, and Pearl Therapeutics. He has received personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cempra, CSL Behring, Forest, GlaxoSmithKline, Merck, Pearl Therapeutics, Pulmonx, Reckitt Benckiser, Sunovion, and Theravance. EK has served on advisory boards, speaker panels, or received travel reimbursement from Amphastar, AstraZeneca, GlaxoSmithKline, Mylan, Novartis, Oriel, Pearl Therapeutics, Sunovion, Teva, and Theravance. He has conducted multicenter clinical trials for ~ 40 pharmaceutical companies. HW has received honoraria for consultancies, lectures, and travel support to attend scientific congresses from Almirall, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Takeda. His institution received investigator fees for participation in clinical trials from Almirall, AstraZeneca, Bayer Health Care, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Roche, Sanofi Aventis, and Takeda. GTF reports consulting and advisory board participation for AstraZeneca, Boehringer Ingelheim, Forest Laboratories, Novartis, Pearl Therapeutics, Sunovion, and Verona Pharma; consulting fees from Receptos; speaking engagements for AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Pearl Therapeutics, and Sunovion; and research grants from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Novartis, Pearl Therapeutics, Sanofi, Sunovion, and Theravance Biopharma. RMM has received consulting fees, speaker’s fees, and travel expenses from Boehringer Ingelheim and has also received compensation for participating in advisory boards for Almirall, AstraZeneca, Boehringer Ingelheim, and Novartis. Furthermore, RMM has received compensation for participation in multicenter clinical trials in the past 5 years from several companies including Almirall, AstraZeneca, Boehringer Ingelheim, GSK, Merck Sharp & Dohme, Mundipharma, Novartis, Pearl, Roche, and Takeda. RS, EM, DJ, and EGG are employees of AstraZeneca PLC, Barcelona, Spain. The authors report no other conflicts of interest in this work.",,"Sanjay Sethi 1 , Edward Kerwin 2 , Henrik Watz 3 , Gary T Ferguson 4 , Robert M Mroz 5 6 , Rosa Segarra 7 , Eduard Molins 7 , Diana Jarreta 7 , Esther Garcia Gil 7"
31497610,Comparative effectiveness of triple therapy versus dual bronchodilation in COPD,"Jaco Voorham 1, Massimo Corradi 2, Alberto Papi 3, Claus F Vogelmeier 4, Dave Singh 5, Leonardo M Fabbri 3 6, Marjan Kerkhof 1, Janwillem H Kocks 1 7, Victoria Carter 1, David Price 1 8",ERJ Open Res. 2019 Aug 30;5(3):00106-2019. doi: 10.1183/23120541.00106-2019. eCollection 2019 Jul.,Voorham J,ERJ Open Res,2019,2019/09/10,PMC6715826,,10.1183/23120541.00106-2019,https://pubmed.ncbi.nlm.nih.gov/31497610/,/31497610/,"Conflict of interest: J. Voorham was employed by OPRI, which has conducted paid research in respiratory disease on behalf of the following organisations in the past 5 years: Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), GlaxoSmithKline, Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, Zentiva (a Sanofi company). Conflict of interest: M. Corradi reports grants and personal fees from Chiesi Farmaceutici, outside the submitted work. Conflict of interest: A. Papi reports board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline and Boehringer Ingelheim; payment for lectures and travel expenses reimbursement from Menarini, Novartis and Zambon; board membership, payment for lectures, grants for research and travel expenses reimbursement from Pfizer; Board membership, consultancy, payment for lectures and travel expenses reimbursement from Mundipharma; board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from Teva; and grants for research from Sanofi, outside the submitted work. Conflict of interest: C.F. Vogelmeier reports personal fees from Almirall, Cipla, Berlin Chemie/Menarini, CSL Behring and Teva, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Mundipharma, Novartis and Takeda, and grants from the German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work. Conflict of interest: D. Singh reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, and personal fees from Cipla, Genentech and Peptinnovate, outside the submitted work. Conflict of interest: L.M. Fabbri reports personal fees and nonfinancial support from AstraZeneca, Chiesi, GSK, Novartis, Menarini, Boehringer Ingelheim, Zambon and Pearl Therapeutics, and personal fees from Teva and Verona Pharma, outside the submitted work. Conflict of interest: M. Kerkhof was employed by OPRI, which has conducted paid research in respiratory disease on behalf of the following organizations in the past 5 years: Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), GlaxoSmithKline, Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, Zentiva (a Sanofi company). Conflict of interest: J.H. Kocks was employed by OPRI, which has conducted paid research in respiratory disease on behalf of the following organizations in the past 5 years: Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), GlaxoSmithKline, Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, Zentiva (a Sanofi company). Conflict of interest: V. Carter was employed by OPRI, which has conducted paid research in respiratory disease on behalf of the following organizations in the past 5 years: Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), GlaxoSmithKline, Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, Zentiva (a Sanofi company). Conflict of interest: D. Price reports grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), board membership and payment for travel/accommodation/meeting expenses (fees paid to Observational and Pragmatic Research Institute) from Aerocrine; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) from AKL Research and Development Ltd; consultancy agreements and lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Almirall; board membership and consultancy agreements (fees paid to Observational and Pragmatic Research Institute) from Amgen; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), board membership, consultancy agreements, lectures/speaking engagements and payment for travel/accommodation/meeting expenses (fees paid to Observational and Pragmatic Research Institute) from AstraZeneca; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), board membership, consultancy agreements, lectures/speaking engagements and payment for travel/accommodation/meeting expenses (fees paid to Observational and Pragmatic Research Institute) from Boehringer Ingelheim; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) from British Lung Foundation; Grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute). Board membership; Consultancy agreements; lectures/speaking engagements and funding for patient enrolment or completion of research (fees paid to Observational and Pragmatic Research Institute) from Chiesi; lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Cipla; consultancy agreements and lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from GlaxoSmithKline; lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Kyorin; lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Merck; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), board membership, consultancy agreements and lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Mylan; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), board membership, consultancy agreements, lectures/speaking engagements, manuscript preparation, payment for travel/accommodation/meeting expenses and payment for the development of educational materials (fees paid to Observational and Pragmatic Research Institute) from Mundipharma; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), board membership, consultancy agreements, payment for travel/accommodation/meeting expenses (fees paid to Observational and Pragmatic Research Institute) from Napp; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), board membership, consultancy agreements, lectures/speaking engagements, payment for travel/accommodation/meeting expenses, funding for patient enrolment or completion of research and payment for the development of educational materials (fees paid to Observational and Pragmatic Research Institute) from Novartis; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), consultancy agreements, lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Pfizer; board membership, grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) and lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Regeneron Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) from Respiratory Effectiveness Group; board membership, grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) and lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Sanofi Genzyme; lectures/speaking engagements (fees paid to Observational and Pragmatic Research Institute) from Skyepharma; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute), board membership, consultancy agreements, lectures/speaking engagements, manuscript preparation, payment for travel/accommodation/meeting expenses and funding for patient enrolment or completion of research (fees paid to Observational and Pragmatic Research Institute) from Teva; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) and consultancy agreements (fees paid to Observational and Pragmatic Research Institute) from Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) from UK National Health Service; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) and funding for patient enrolment or completion of research (fees paid to Observational and Pragmatic Research Institute) from Zentiva (Sanofi Generics); and acting as a peer reviewer for grant committees for Efficacy and Mechanism Evaluation programme and Health Technology Assessment, outside the submitted work; and stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; and owning 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore).",,"Jaco Voorham 1 , Massimo Corradi 2 , Alberto Papi 3 , Claus F Vogelmeier 4 , Dave Singh 5 , Leonardo M Fabbri 3 6 , Marjan Kerkhof 1 , Janwillem H Kocks 1 7 , Victoria Carter 1 , David Price 1 8"
30858643,Cocaine-Induced Psychosis and Asenapine as Treatment: A Case Study,"Raul Felipe Palma-Álvarez 1, Elena Ros-Cucurull 1, Josep Antoni Ramos-Quiroga 1, Carlos Roncero 1, Lara Grau-López 1",Psychopharmacol Bull. 2019 Feb 15;49(1):92-97.,Palma-Álvarez RF,Psychopharmacol Bull,2019,2019/03/13,PMC6386431,,,https://pubmed.ncbi.nlm.nih.gov/30858643/,/30858643/,"Conflict of interest Dr. Palma-Álvarez has received fees to give talks for MSD, Mundipharma and Exeltis. Dr. Ros-Cucurull has received fees to give talks for Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Lilly, Servier, Rovi, Juste. She has received financial compensation for projects with Lundbeck, Esteve, Pfizer, Rovi, Exeltis, Servier. She has received financial compensation for her participation as a board member of Janssen-Cilag. She has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict. Dr. Ramos-Quiroga has received fees as speaker from Janssen-Cilag, Shire, Lilly, Ferrer, Medice and Rubió. He has received research funding from Janssen-Cilag, Lilly, Ferrer, Lundbeck and Rubió. Dr. Roncero has received fees to give lectures for Janssen-Cilag, Ferrer-Brainfarma, Pfizer, Indivior, Lundbeck, Otsuka, Servier, GSK, Rovi, Astra, Gilead, MSD, Sanofi and Exeltis. He has received financial compensation for his participation as a board member of JanssenCilag, Lundbeck, Gilead, MSD, Indivior and Mundipharma. He has carried out the PROTEUS project, which was funded by a grant from Reckitt-Benckiser/Indivior. He received a medical education grant for Gilead. Dr. Grau-López has received fees to give talks for Janssen-Cilag, Lundbeck, Servier, Otsuka, and Pfizer.",,"Raul Felipe Palma-Álvarez 1 , Elena Ros-Cucurull 1 , Josep Antoni Ramos-Quiroga 1 , Carlos Roncero 1 , Lara Grau-López 1"
30573712,Accuracy and the role of experience in dynamic computer guided dental implant surgery: An in-vitro study,"A Jorba-García 1, R Figueiredo, A González-Barnadas, O Camps-Font, E Valmaseda-Castellón",Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24(1):e76-e83. doi: 10.4317/medoral.22785.,Jorba-García A,Med Oral Patol Oral Cir Bucal,2019,2018/12/22,PMC6344002,,10.4317/medoral.22785,https://pubmed.ncbi.nlm.nih.gov/30573712/,/30573712/,"Conflict of interest statement:This study was conducted with the support (non-financial aid) of Bonemodels (Castellón de la Plana, Spain) and TiCare (MozoGrau, Vallodolid, Spain). Dr. Figueiredo reports grants, personal fees and non-financial support from Mozo-Grau (Valladolid, Spain), grants from Mundipharma Research (Cambridge, United Kingdom), personal fees from BioHorizons Ibérica (Madrid, Spain), Inibsa Dental (Lliça de Vall, Spain), Dentsply implants Iberia (Barcelona, Spain) and ADIN Implants (Afula, Israel) outside the submitted work. Dr. Valmaseda-Castellón reports grants, personal fees and non-financial support from MozoGrau, personal fees from BioHorizons Ibérica, personal fees from Inibsa Dental, and personal fees from Dentsply implants Iberia outside the submitted work. The authors declare no other conflicts of interest regarding this study. The present research was conducted by the Dental and Maxillofacial Pathology and Therapeutics research group at the IDIBELL Institute.",,"A Jorba-García 1 , R Figueiredo, A González-Barnadas, O Camps-Font, E Valmaseda-Castellón"
31709400,"Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019","David M G Halpin 1 2, Hilda J I de Jong 2, Victoria Carter 2, Derek Skinner 2, David Price 2",EClinicalMedicine. 2019 Jul 24;14:32-41. doi: 10.1016/j.eclinm.2019.07.003. eCollection 2019 Sep.,Halpin DMG,EClinicalMedicine,2019,2019/11/12,PMC6833455,,10.1016/j.eclinm.2019.07.003,https://pubmed.ncbi.nlm.nih.gov/31709400/,/31709400/,"Prof. Halpin reports personal fees from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Chiesi, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees from Pfizer, outside the submitted work. He is also a member of the GOLD Board of Directors and Science Committee. Dr. de Jong, Ms. Carter & Dr. Skinner are employed by the Observational and Pragmatic Research Institute Pte Ltd. (OPRI). Prof. Price reports grants from AKL Research and Development Ltd., personal fees from Amgen, grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants from British Lung Foundation, grants and personal fees from Chiesi, grants and personal fees from Circassia, personal fees from Cipla, personal fees from GlaxoSmithKline, personal fees from Kyorin, personal fees from Merck, grants and personal fees from Mylan, grants and personal fees from Mundipharma, grants and personal fees from Napp, grants and personal fees from Novartis, grants and personal fees from Pfizer, grants and personal fees from Regeneron Pharmaceuticals, grants from Respiratory Effectiveness Group, grants and personal fees from Sanofi Genzyme, grants and personal fees from Teva, grants and personal fees from Theravance, grants from UK National Health Service, grants and personal fees from Zentiva (Sanofi Generics), non-financial support from Efficacy and Mechanism Evaluation programme, non-financial support from Health Technology Assessment, outside the submitted work; and stock/stock options from AKL Research and Development Ltd. which produces phytopharmaceuticals; and owns 74% of the social enterprise Optimum Patient Care Ltd. (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd. (Singapore).",,"David M G Halpin 1 2 , Hilda J I de Jong 2 , Victoria Carter 2 , Derek Skinner 2 , David Price 2"
30702059,Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT,"John Strang 1, Michael Kelleher 2, Soraya Mayet 3, Ed Day 1, Jennifer Hellier 4, Sarah Byford 5, Caroline Murphy 6, Blair McLennan 6, James Shearer 5, Elizabeth Ryan 4, John Marsden 1",Health Technol Assess. 2019 Jan;23(3):1-72. doi: 10.3310/hta23030.,Strang J,Health Technol Assess,2019,2019/02/01,PMC6378535,,10.3310/hta23030,https://pubmed.ncbi.nlm.nih.gov/30702059/,/30702059/,"John Strang reports grants and others from Martindale Pharma, grants and others from Mundipharma, and grants and others from Braeburn Pharma, outside the submitted work. In addition, John Strang has a Euro-Celtique patent issued, and a King’s College London patent pending. Michael Kelleher reports grants from the National Institute for Health Research (NIHR) during the conduct of the study, others from South London and Maudsley NHS Foundation Trust, Public Health England, Braeburn Pharma and Reckitt Benckiser, personal fees from Mundipharma and non-financial support from Cephaid, outside the submitted work. Sarah Byford reports grants from NIHR Health Technology Assessment programme during the conduct of the study. John Marsden reports investigator-led, educational grant funding from Indivior (administered by Action-on-Addiction) for a study of personalised psychosocial intervention for non-response to opioid agonist treatment. He declares consultancy for the US National Institute on Drug Abuse Centre for Clinical Trials Network. In the past 3 years, he received honoraria from Merck Serono (2015; clinical oncology training), Martindale (2017; expert meeting on opioid use disorder), and Indivior (via PCM Scientific) as co-chairperson (2015, 2016) and chairperson (2017) for the conference on Improving Outcomes in Treatment of Opioid Dependence.",Grants and funding HTA/10/46/01/DH_/Department of Health/United Kingdom,"John Strang 1 , Michael Kelleher 2 , Soraya Mayet 3 , Ed Day 1 , Jennifer Hellier 4 , Sarah Byford 5 , Caroline Murphy 6 , Blair McLennan 6 , James Shearer 5 , Elizabeth Ryan 4 , John Marsden 1"
31623403,Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab,"Martin Voss 1 2 3 4, AbdulAziz Batarfi 5, Eike Steidl 6, Marlies Wagner 7, Marie-Thérèse Forster 8, Joachim P Steinbach 9 10 11 12, Claus M Rödel 13, Jörg Bojunga 14, Michael W Ronellenfitsch 15 16 17 18",J Clin Med. 2019 Oct 3;8(10):1608. doi: 10.3390/jcm8101608.,Voss M,J Clin Med,2019,2019/10/19,PMC6832264,,10.3390/jcm8101608,https://pubmed.ncbi.nlm.nih.gov/31623403/,/31623403/,"J.P.S. has received honoraria for lectures or advisory board participation or consulting or travel grants from Abbvie, Roche, Boehringer, Bristol-Myers Squibb, Medac, Mundipharma, and UCB.",,"Martin Voss 1 2 3 4 , AbdulAziz Batarfi 5 , Eike Steidl 6 , Marlies Wagner 7 , Marie-Thérèse Forster 8 , Joachim P Steinbach 9 10 11 12 , Claus M Rödel 13 , Jörg Bojunga 14 , Michael W Ronellenfitsch 15 16 17 18"
31335647,Progesterone relates to enhanced incisional acute pain and pinprick hyperalgesia in the luteal phase of female volunteers,"Esther M Pogatzki-Zahn 1, Christiane Drescher 1, Jan S Englbrecht 1, Thomas Klein 2, Walter Magerl 2, Peter K Zahn 3",Pain. 2019 Aug;160(8):1781-1793. doi: 10.1097/j.pain.0000000000001561.,Pogatzki-Zahn EM,Pain,2019,2019/07/24,,,10.1097/j.pain.0000000000001561,https://pubmed.ncbi.nlm.nih.gov/31335647/,/31335647/,,,"Esther M Pogatzki-Zahn 1 , Christiane Drescher 1 , Jan S Englbrecht 1 , Thomas Klein 2 , Walter Magerl 2 , Peter K Zahn 3"
31673416,Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis,"Ana F Águeda 1, Sara Monti 2 3, Raashid Ahmed Luqmani 4, Frank Buttgereit 5, Maria Cid 6, Bhaskar Dasgupta 7, Christian Dejaco 8 9, Alfred Mahr 10, Cristina Ponte 11 12, Carlo Salvarani 13, Wolfgang Schmidt 14, Bernhard Hellmich 15",RMD Open. 2019 Sep 23;5(2):e001020. doi: 10.1136/rmdopen-2019-001020. eCollection 2019.,Águeda AF,RMD Open,2019,2019/11/02,PMC6803017,,10.1136/rmdopen-2019-001020,https://pubmed.ncbi.nlm.nih.gov/31673416/,/31673416/,"Competing interests: SM received speaker fees and consultancies from Roche and Chugai. FB received grants from Horizon and Mundipharma, and speaker fees and/or consultancies from Horizon, Mundipharma, Roche and Sanofi. MC received lecturing fees from Boehringer Ingelheim and Vifor, consulting fees from Roche, Janssen, AbbVie and GSK, and research agreement from Kiniksa. CD received a grant from Celgene, and speaker fees and/or consultancies from AbbVie, BMS, Lilly, MSD, Pfizer, Novartis, UCB, Roche and Sanofi. WS received a grant from Roche, and speaker fees and consultancies from Chugai, GSK, Novartis, Roche and Sanofi. BH received speaker fees and/or consultancies from AbbVie, Boehringer, Chugai, Celgene, MSD, Pfizer, Novartis and Roche. All other authors have no competing interests.",,"Ana F Águeda 1 , Sara Monti 2 3 , Raashid Ahmed Luqmani 4 , Frank Buttgereit 5 , Maria Cid 6 , Bhaskar Dasgupta 7 , Christian Dejaco 8 9 , Alfred Mahr 10 , Cristina Ponte 11 12 , Carlo Salvarani 13 , Wolfgang Schmidt 14 , Bernhard Hellmich 15"
31343716,Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management,"Tony OBrien 1, Jin Seok Ahn 2, Richard Chye 3, Brian Le 4, Henry Lu 5, Gabriel Olarte 6, Mariana Palladini 7, Amar Salti 8, Yu-Yun Shao 9, Hayati Yaakup 10, Kristal Cielo Buemio 11, Consuelo Gutierrez Colin 11, Yacine Hadjiat 11",J Opioid Manag. 2019 Mar/Apr;15(2):147-158. doi: 10.5055/jom.2019.0496.,OBrien T,J Opioid Manag,2019,2019/07/26,,,10.5055/jom.2019.0496,https://pubmed.ncbi.nlm.nih.gov/31343716/,/31343716/,,,"Tony OBrien 1 , Jin Seok Ahn 2 , Richard Chye 3 , Brian Le 4 , Henry Lu 5 , Gabriel Olarte 6 , Mariana Palladini 7 , Amar Salti 8 , Yu-Yun Shao 9 , Hayati Yaakup 10 , Kristal Cielo Buemio 11 , Consuelo Gutierrez Colin 11 , Yacine Hadjiat 11"
31282424,"Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety","Werner Poewe 1, Lars Bergmann 2, Pavnit Kukreja 2, Weining Z Robieson 2, Angelo Antonini 3",J Parkinsons Dis. 2019;9(3):531-541. doi: 10.3233/JPD-191605.,Poewe W,J Parkinsons Dis,2019,2019/07/09,PMC6700622,,10.3233/JPD-191605,https://pubmed.ncbi.nlm.nih.gov/31282424/,/31282424/,"The study protocol was approved by national and/or local independent ethics committees and health authorities at each participating institution and country. All patients provided written informed consent before enrollment in the registry. We have read the journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. Access is provided to anonymized patient and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports) from AbbVie-sponsored Phase II-IV global interventional clinical trials conducted in patients (completed as of May 2004, for products and indications approved in either the United States or the European Union), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.",,"Werner Poewe 1 , Lars Bergmann 2 , Pavnit Kukreja 2 , Weining Z Robieson 2 , Angelo Antonini 3"
31819397,Prescription Status and Clinical Outcomes of Methylxanthines and Leukotriene Receptor Antagonists in Mild-to-Moderate Chronic Obstructive Pulmonary Disease,"Jung-Kyu Lee 1, Chin Kook Rhee 2, Kyungjoo Kim 2, Seung Won Ra 3, Jae Ha Lee 4, Ki-Suck Jung 5, Kwang Ha Yoo 6, Yoo-Il Kim 7, Deog Kyeom Kim 1",Int J Chron Obstruct Pulmon Dis. 2019 Nov 27;14:2639-2647. doi: 10.2147/COPD.S216326. eCollection 2019.,Lee JK,Int J Chron Obstruct Pulmon Dis,2019,2019/12/11,PMC6885559,,10.2147/COPD.S216326,https://pubmed.ncbi.nlm.nih.gov/31819397/,/31819397/,"C.K.R reports personal fees from MSD, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, and Bayer, outside of the submitted work. The authors report no other conflicts of interest in this work.",,"Jung-Kyu Lee 1 , Chin Kook Rhee 2 , Kyungjoo Kim 2 , Seung Won Ra 3 , Jae Ha Lee 4 , Ki-Suck Jung 5 , Kwang Ha Yoo 6 , Yoo-Il Kim 7 , Deog Kyeom Kim 1"
31651529,Analgesic and Respiratory Depressant Effects of R-dihydroetorphine: A Pharmacokinetic-Pharmacodynamic Analysis in Healthy Male Volunteers,"Erik Olofsen 1, Merel Boom, Elise Sarton, Monique van Velzen, Paul Baily, Kevin J Smith, Alexander Oksche, Albert Dahan, Marieke Niesters",Anesthesiology. 2019 Dec;131(6):1327-1339. doi: 10.1097/ALN.0000000000002991.,Olofsen E,Anesthesiology,2019,2019/10/26,,,10.1097/ALN.0000000000002991,https://pubmed.ncbi.nlm.nih.gov/31651529/,/31651529/,,,"Erik Olofsen 1 , Merel Boom, Elise Sarton, Monique van Velzen, Paul Baily, Kevin J Smith, Alexander Oksche, Albert Dahan, Marieke Niesters"
31452870,Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations,"David B Price 1 2, Sinthia Bosnic-Anticevich 3, Ian D Pavord 4, Nicolas Roche 5, David M G Halpin 6, Leif Bjermer 7, Omar S Usmani 8, Guy Brusselle 9, Simon Wan Yau Ming 1, Sarang Rastogi 10",Clin Transl Allergy. 2019 Aug 21;9:41. doi: 10.1186/s13601-019-0282-7. eCollection 2019.,Price DB,Clin Transl Allergy,2019,2019/08/28,PMC6702739,,10.1186/s13601-019-0282-7,https://pubmed.ncbi.nlm.nih.gov/31452870/,/31452870/,"Competing interestsDP reports grants and/or personal fees from Aerocrine, AKL Research and Development Ltd., Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, the British Lung Foundation, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Merck, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, the Respiratory Effectiveness Group, Sanofi Genzyme, Skyepharma, Teva, Theravance, the UK National Health Service, Zentiva (Sanofi Generics); non-financial support from Efficacy and Mechanism Evaluation Programme and Health Technology Assessment, outside the submitted work; stock/stock options from AKL Research and Development Ltd.; and owns 74% of the social enterprise Optimum Patient Care Ltd. (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd. (Singapore). SB reports grants and personal fees from TEVA, personal fees from Boehringer Ingelheim, AstraZeneca, Sanofi, and Mylan, outside the submitted work. IP has received speaker’s honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, and GlaxoSmithKline, and payments for organising educational events from AstraZeneca and Teva. He has received honoraria for attending advisory panels with Genentech, Regeneron, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva, Merck, Sanofi, Circassia, Chiesi, and Knopp. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Teva, and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. NR reports grants and personal fees from Boehringer Ingelheim, Novartis, Pfizer and personal fees from Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Mundipharma, Cipla, Sanofi, Sandoz, 3 M, and Zambon. DH reports personal fees and/or non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Pfizer, outside the submitted work. LB has nothing to disclose. OU has received grants and/or personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Aerocrine, GlaxoSmithKline, Napp, Mundipharma, Sandoz, Prosonix, Takeda, Zentiva, Edmond Pharma, Cipla, and Pearl Therapeutics. GB reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Sanofi, and Teva, outside the submitted work. SWM reports other from Observational and Pragmatic Research Institute Pte Ltd. (OPRI), outside the submitted work. He was employed by the OPRI at the time the analyses were conducted; OPRI has conducted paid research in respiratory disease on behalf of the following organisations in the past 5 years: Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), GlaxoSmithKline, Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, and Zentiva (a Sanofi company). SR was an employee of AstraZeneca at the time the analyses were conducted.",,"David B Price 1 2 , Sinthia Bosnic-Anticevich 3 , Ian D Pavord 4 , Nicolas Roche 5 , David M G Halpin 6 , Leif Bjermer 7 , Omar S Usmani 8 , Guy Brusselle 9 , Simon Wan Yau Ming 1 , Sarang Rastogi 10"
30994260,Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study,"Christian Kromer 1, Dagmar Wilsmann-Theis 2, Sascha Gerdes 3, Sandra Philipp 4, Marthe-Lisa Schaarschmidt 5, Astrid Schmieder 5, Mohammed Dakna 6, Tobias Arnold 7, Wiebke Katharina Peitsch 8, Rotraut Mössner 1",J Dtsch Dermatol Ges. 2019 May;17(5):503-516. doi: 10.1111/ddg.13834. Epub 2019 Apr 17.,Kromer C,J Dtsch Dermatol Ges,2019,2019/04/18,PMC6850581,,10.1111/ddg.13834,https://pubmed.ncbi.nlm.nih.gov/30994260/,/30994260/,"C. Kromer has received honoraria for presentations from Janssen‐Cilag. D. Wilsmann‐Theis has been advisor and/or received speakers’ honoraria or travel expense reimbursements and/or received grants and/or participated in clinical trials by the companies AbbVie, Almirall, Amgen, Beiersdorf, Biogen, Boehringer‐Ingelheim Pharma, Celgene, Forward Pharma, GlaxoSmithKline, Janssen‐Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme Corp., Novartis, Pfizer, UCB Pharma, and VBL. S. Gerdes has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials by the following companies: Abbott/AbbVie, Almirall‐Hermal, Amgen, Baxalta, Bayer Health Care, Biogen Idec, Bioskin, Boehringer Ingelheim, Celgene, Centocor, Dermira, Eli Lilly, Foamix, Forward Pharma, Galderma, Hexal AG, Isotechnika, Janssen‐Cilag, Leo Pharma, Medac, Merck Serono, Mitsubishi Tanabe, MSD, Novartis, Pfizer, Polichem SA, Regeneron Pharmaceutical, Sandoz Biopharmaceuticals, Schering‐Plough, Takeda, Teva, UCB Pharma, VBL therapeutics, Wyeth Pharma. S. Philipp has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials by the following companies: AbbVie Germany, Almirall, Amgen, Biogen Idec, Boehringer‐Ingelheim, BMS, Celgene, Dermira, Eli Lilly, Forward Pharma, GSK, Hexal, Janssen‐Cilag, Leo Pharma, Maruho, Medac, Merck, MSD, mundipharma, Novartis, Pfizer, UCB Biopharma, VBL Therapeutics. ML. Schaarschmidt conducted clinical trials for Abbvie, Boehringer‐Ingelheim, Celgene, Eli Lilly, Janssen‐Cilag, Merck, Novartis and UCB Pharma; obtained honoraria from Janssen‐Cilag and Novartis; and received financial support for participation in conferences from Abbvie, ALK‐Abello, Biogen Inc., Janssen‐Cilag and MSD. A. Schmieder served as an investigator for Abbvie, Eli Lilly, Janssen‐Cilag, Merck, Novartis and Pfizer; obtained honoraria from Abbvie, Janssen‐Cilag, and Novartis, and received support for conferences from Abbvie, ALK‐Abello, Alma Lasers, ARC Lasers, Asclepion, BMS, GSK, Janssen‐Cilag, L’Oreal, LEO Pharma, Medac, Merck, MSD, Novartis, P&M Cosmetics, and Pfizer. W. K. Peitsch served as an investigator for Abbvie, Boehringer Ingelheim, Eli Lilly, Janssen‐Cilag, Merck, Novartis, Pfizer and UCB Pharma, and was member of an advisory board of Abbvie, Eli Lilly, LEO Pharma, MSD and Novartis. She received speakers honoraria from ALK‐Abello, Abbvie, Janssen‐Cilag, MSD, Novartis and Roche; and received support for conferences from Abbvie, Actelion, ALK‐Abello, Allergika, Alma Lasers, ARC Lasers, Asclepion, Beiersdorf, BMS, Celgene, Dermapharm, Dermasence, Eli Lilly, Galderma, GSK, IGEA, Interlac, Janssen‐Cilag, L’Oreal, La Roche Posay, LEO Pharma, Medac, Merck, MSD, Novartis, Pierre Fabre, P&M Cosmetics, Pfizer, and Roche. R. Mössner has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials by the following companies: Abbott/Abbvie, Allmirall, Biogen Idec GmbH, Böhringer‐Ingelheim, Celgene, Essex Pharma GmbH, Janssen‐Cilag GmbH, Leo Pharma GmbH, Lilly, Merck Serono GmbH, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH and UCB. M. Dakna and T. Arnold declared no conflicts of interest.",,"Christian Kromer 1 , Dagmar Wilsmann-Theis 2 , Sascha Gerdes 3 , Sandra Philipp 4 , Marthe-Lisa Schaarschmidt 5 , Astrid Schmieder 5 , Mohammed Dakna 6 , Tobias Arnold 7 , Wiebke Katharina Peitsch 8 , Rotraut Mössner 1"
31296924,"Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13","Brecht Creyns 1 2, Jonathan Cremer 1 2, Tomoaki Hoshino 3, Karel Geboes 4, Gert de Hertogh 4, Marc Ferrante 2 5, Séverine Vermeire 2 5, Jan L Ceuppens 1, Gert Van Assche 2 5, Christine Breynaert 6 7",Sci Rep. 2019 Jul 11;9(1):10064. doi: 10.1038/s41598-019-46472-6.,Creyns B,Sci Rep,2019,2019/07/13,PMC6624199,,10.1038/s41598-019-46472-6,https://pubmed.ncbi.nlm.nih.gov/31296924/,/31296924/,"M.F. received financial support for research from Pfizer, Takeda and Janssen; lecture fees from Ferring, Boehringer- Ingelheim, Chiesi, Merck Sharpe & Dohme, Tillotts, Janssen Biologics, Abbvie, Takeda, Mitsubishi Tanabe, Zeria; consultancy fees from Abbvie, Boehringer-Ingelheim, Ferring, Merck Sharpe & Dohme, and Janssen Biologics. G.V.A. reports financial support for research from Abbott and Ferring Pharmaceuticals; lecture fees from Janssen, MSD and Abbott; consultancy fees from PDL BioPharma, UCB Pharma, Sanofi-Aventis, Abbott, Abbvie, Ferring, Novartis, Biogen Idec, Janssen Biologics, NovoNordisk, Zealand Pharma A/S, Millenium/Takeda, Shire, Novartis and Bristol Mayer Squibb. SV reports financial support for research: MSD, AbbVie, Takeda, Pfizer, J&J; Lecture fees: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche; Consultancy: MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche, Celgene, Mundipharma, Celltrion, SecondGenome, Prometheus, Shire, Prodigest, Gilead, Galapagos.",,"Brecht Creyns 1 2 , Jonathan Cremer 1 2 , Tomoaki Hoshino 3 , Karel Geboes 4 , Gert de Hertogh 4 , Marc Ferrante 2 5 , Séverine Vermeire 2 5 , Jan L Ceuppens 1 , Gert Van Assche 2 5 , Christine Breynaert 6 7"
30554407,Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis,"C Felice 1, P Leccese 2, L Scudeller 3, E Lubrano 4, F Cantini 5, F Castiglione 6, P Gionchetti 7, A Orlando 8, C Salvarani 9, R Scarpa 10, M Vecchi 11, I Olivieri 2, A Armuzzi 1 ; Italian SpA-IBD Expert Panel Group",Clin Exp Immunol. 2019 Apr;196(1):123-138. doi: 10.1111/cei.13246. Epub 2019 Jan 9.,Felice C,Clin Exp Immunol,2019,2018/12/17,PMC6422654,,10.1111/cei.13246,https://pubmed.ncbi.nlm.nih.gov/30554407/,/30554407/,"C. F. has served as a consultant or advisory member for AbbVie and MSD. F. Cast. has served as a consultant or advisory member for AbbVie, Ferring, Janssen, MSD, Sofar and Takeda. P. G. received honoraria or consultation fees from Janssen, Abbvie, Pfizer, Celgene, Takeda, Ferring, MSD, Alfa Wasserman and Amgen; and participated in a company‐sponsored speakers bureau for Abbvie, Janssen, Takeda, Ferring, Msd, Sofar and Chiesi. A. O. served as advisory board member for AbbVie, Janssen‐Cilag, MSD, Pfizer and Takeda Pharmaceuticals, and received lecture grants from AbbVie, Chiesi, Janssen‐Cilag, MSD, Sofar and Takeda Pharmaceuticals. M. V. participated in the Advisory Board and received lecture fees or support for research from MSD, Hospira, Mundipaharma, Takeda, Abbvie, Chiesi, Zambon, Amgen, Biogen, Jannsen, Pfizer, Sofar and Giuliani. A. A. has served as a consultant or advisory member for AbbVie, Allergan, Amgen, Biogen, Celgene, Celltrion, Ferring, Hospira, Janssen, Lilly, MSD, Mundipharma, Pfizer, Samsung Bioepis, Sofar and Takeda, has received lecture fees from AbbVie, AstraZeneca, Chiesi, Ferring, Hospira, Medtronic, MSD, Mitsubishi Tanabe, Mundipharma, Nikkiso, Otsuka, Pfizer, Samsung Bioepis, Takeda, Tigenix, and Zambon, and has received research funding from MSD and Takeda. All other authors have no conflicts of interest to declare.",,"C Felice 1 , P Leccese 2 , L Scudeller 3 , E Lubrano 4 , F Cantini 5 , F Castiglione 6 , P Gionchetti 7 , A Orlando 8 , C Salvarani 9 , R Scarpa 10 , M Vecchi 11 , I Olivieri 2 , A Armuzzi 1 ; Italian SpA-IBD Expert Panel Group"
31572027,Evaluation of pain relief treatment and timelines in emergency care in six European countries and Australia,"Andrew D Xia 1, Sara L Dickerson 2, Andrew Watson 3, Mika Nokela 4, Sam Colman 5, Agota Szende 6",Open Access Emerg Med. 2019 Sep 17;11:229-240. doi: 10.2147/OAEM.S214396. eCollection 2019.,Xia AD,Open Access Emerg Med,2019,2019/10/02,PMC6756271,,10.2147/OAEM.S214396,https://pubmed.ncbi.nlm.nih.gov/31572027/,/31572027/,"Andrew D Xia was an employee at Mundipharma International Ltd. at the time this study was conducted and is now a consultant to Mundibiopharma Ltd. Sara L Dickerson is an employee of Mundibiopharma Ltd. Mika Nokela, Sam Colman and Agota Szende are employees of Covance Market Access Inc., providing research contracted by Mundipharma. The authors report no other conflicts of interest in this work.",,"Andrew D Xia 1 , Sara L Dickerson 2 , Andrew Watson 3 , Mika Nokela 4 , Sam Colman 5 , Agota Szende 6"
31066001,Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis,"Lawrence F Eichenfield 1 2, Thomas Bieber 3, Lisa A Beck 4, Eric L Simpson 5, Diamant Thaçi 6, Marjolein de Bruin-Weller 7, Mette Deleuran 8, Jonathan I Silverberg 9, Carlos Ferrandiz 10, Regina Fölster-Holst 11, Zhen Chen 12, Neil M H Graham 12, Gianluca Pirozzi 13, Bolanle Akinlade 12, George D Yancopoulos 12, Marius Ardeleanu 12",Am J Clin Dermatol. 2019 Jun;20(3):443-456. doi: 10.1007/s40257-019-00445-7.,Eichenfield LF,Am J Clin Dermatol,2019,2019/05/09,PMC6533236,,10.1007/s40257-019-00445-7,https://pubmed.ncbi.nlm.nih.gov/31066001/,/31066001/,"L. F. Eichenfield has received honoraria for consulting services from Almirall, Celgene, Dermira, Dermavant, Eli Lilly and Company, Forté Pharma, Galderma, L’Oréal, Incyte, MatriSys, Menlo Therapeutics, Otsuka, Novan, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Valeant/Ortho Dermatologics; and study support (to institution) from Celgene, Dermira, Dermavant, Eli Lilly and Company, Galderma, Incyte, Medimetriks, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Valeant. T. Bieber is a speaker for Almirall, Anacor, Astellas, Celgene, Chugai, Galderma, Janssen-Cilag, L’Oréal, Novartis, Oxagen, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi. L. A. Beck has received honoraria as a consultant and research grants as principal investigator for clinical trials from AbbVie, Pfizer, Realm Therapeutics, and Regeneron Pharmaceuticals, Inc.; has received honoraria as a consultant from AbbVie, Astra-Zeneca, Allakos, Boehringer-Ingelheim, Celgene, Eli Lilly and Company, GSK, Leo Pharma, Novan, Novartis, Realm Therapeutics, Regeneron, Sanofi, and UCB; and is a stockholder in Medtronic and Pfizer. E. L. Simpson has received honoraria for consulting services from AbbVie, Anacor, Celgene, Dermira Pharmaceutical Co., Eli Lilly and Company, Galderma, Genentech, Inc., GSK, LEO Pharma, Menlo Therapeutics, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Valeant Pharmaceutical Co.; and has received study support from Anacor, Eli Lilly and Company, GSK, MedImmune, Novartis, Regeneron Pharmaceuticals, Inc., Roivant Sciences, Tioga Pharmaceuticals, Inc., and Vanda Pharmaceuticals, Inc. D. Thaçi has received research support from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Celgene, Dignity, Eli Lilly and Company, GSK, Janssen-Cilag, LEO Pharma, MSD, Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sandoz, and Sanofi; received honoraria and is an independent advisor for AbbVie, Celgene, Janssen, La Roche-Posay, LEO Pharma, Medac, Novartis, Pfizer, Inc., Sun Pharma, and UCB; received honoraria and is a consultant for AbbVie, Celgene, Dignity, Galápagos, Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi, and UCB; and received honoraria and is an advisory board member for AbbVie, Amgen, Celgene, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Mundipharma, Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sandoz, Sanofi, and UCB. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; and a principal investigator and advisory board member for AbbVie. M. Deleuran has received research support, consulting/advisory board agreements, and/or honoraria for lecturing from AbbVie, Eli Lilly and Company, LEO Pharma, Meda, Pierre Fabre, Regeneron Pharmaceuticals, Inc., and Sanofi. J. I. Silverberg has received honoraria for advisory board participation, as a speaker, and for consultancy from AbbVie, Eli Lilly and Company, Galderma, GSK, Kiniksa, LEO Pharma, Menlo Therapeutics, Pfizer, Realm Therapeutics, Regeneron Pharmaceuticals, Inc., Roivant, and Sanofi; and research grants from GSK, Regeneron Pharmaceuticals, Inc., and Sanofi. C. Ferrandiz is a principal investigator in clinical trials for AbbVie, Sanofi, LEO Pharma; and an advisory board participant for Sanofi. R. Fölster-Holst is an investigator for studies, speaker, and consultant for Astellas, Almirall Hermal, Beiersdorf, Johnson & Johnson, La Roche-Posay, LEO Pharma, Neubourg Skin Care GmbH, Novartis, Pierre Fabre, Procter & Gamble, and Regeneron Pharmaceuticals, Inc. Z. Chen, N.M.H. Graham, B. Akinlade, G.D. Yancopoulos, and M. Ardeleanu are employees of and shareholders in Regeneron Pharmaceuticals, Inc. G. Pirozzi is an employee of and may hold stock and/or stock options in Sanofi.",,"Lawrence F Eichenfield 1 2 , Thomas Bieber 3 , Lisa A Beck 4 , Eric L Simpson 5 , Diamant Thaçi 6 , Marjolein de Bruin-Weller 7 , Mette Deleuran 8 , Jonathan I Silverberg 9 , Carlos Ferrandiz 10 , Regina Fölster-Holst 11 , Zhen Chen 12 , Neil M H Graham 12 , Gianluca Pirozzi 13 , Bolanle Akinlade 12 , George D Yancopoulos 12 , Marius Ardeleanu 12"
31154307,"Feasibility, acceptability and preliminary outcomes of a mindfulness-based relapse prevention program in a naturalistic setting among treatment-seeking patients with alcohol use disorder: a prospective observational study","Cora von Hammerstein 1 2, Yasser Khazaal 3, Mathilde Dupuis 2, Henri-Jean Aubin 1, Amine Benyamina 1, Amandine Luquiens 1 4, Lucia Romo 2 5",BMJ Open. 2019 Jun 1;9(5):e026839. doi: 10.1136/bmjopen-2018-026839.,von Hammerstein C,BMJ Open,2019,2019/06/03,PMC6550005,,10.1136/bmjopen-2018-026839,https://pubmed.ncbi.nlm.nih.gov/31154307/,/31154307/,"Competing interests: H-JA has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Bioprojet, D&A Pharma, Ethypharm, Lundbeck, Merck-Serono, Mundipharma, Novartis and Pfizer. LR has received sponsorship to participate in scientific reaserch funded by PMU and FDJ through a convention with the University Paris Ouest Nanterre la Défense. AB has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Bristol-Myers-Squibb, Lundbeck, Merck-Serono and Mylan and is member of the invidor board. AL has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Lundbeck and Indivior.",,"Cora von Hammerstein 1 2 , Yasser Khazaal 3 , Mathilde Dupuis 2 , Henri-Jean Aubin 1 , Amine Benyamina 1 , Amandine Luquiens 1 4 , Lucia Romo 2 5"
30744630,Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study,"Sarah Marietta von Siemens 1, Rudolf A Jörres 1, Jürgen Behr 2, Peter Alter 3, Johanna Lutter 4, Tanja Lucke 1, Sandra Söhler 5, Tobias Welte 6, Henrik Watz 7, Claus F Vogelmeier 3, Franziska Trudzinski 8, Winfried Rief 9, Britta Herbig 1, Kathrin Kahnert 10 ; COSYCONET study group",Respir Res. 2019 Feb 11;20(1):30. doi: 10.1186/s12931-019-0997-y.,von Siemens SM,Respir Res,2019,2019/02/13,PMC6371561,,10.1186/s12931-019-0997-y,https://pubmed.ncbi.nlm.nih.gov/30744630/,/30744630/,"All assessments were approved by the central (Marburg (Ethikkommission FB Medizin Marburg) and local (Bad Reichenhall (Ethikkommission bayerische Landesärztekammer); Berlin (Ethikkommission Ärztekammer Berlin); Bochum (Ethikkommission Medizinische Fakultät der RUB); Borstel (Ethikkommission Universität Lübeck); Coswig (Ethikkommission TU Dresden); Donaustauf (Ethikkommission Universitätsklinikum Regensburg); Essen (Ethikkommission Medizinische Fakultät Duisburg-Essen); Gießen (Ethikkommission Fachbereich Medizin); Greifswald (Ethikkommission Universitätsmedizin Greifswald); Großhansdorf (Ethikkommission Ärztekammer Schleswig-Holstein); Hamburg (Ethikkommission Ärztekammer Hamburg); MHH Hannover / Coppenbrügge (MHH Ethikkommission); Heidelberg Thorax/Uniklinik (Ethikkommission Universität Heidelberg); Homburg (Ethikkommission Saarbrücken); Immenhausen (Ethikkommission Landesärztekammer Hessen); Kiel (Ethikkommission Christian-Albrechts-Universität zu Kiel); Leipzig (Ethikkommission Universität Leipzig); Löwenstein (Ethikkommission Landesärztekammer Baden-Württemberg); Mainz (Ethikkommission Landesärztekammer Rheinland-Pfalz); München LMU/Gauting (Ethikkommission Klinikum Universität München); Nürnberg (Ethikkommission Friedrich-Alexander-Universität Erlangen Nürnberg); Rostock (Ethikkommission Universität Rostock); Berchtesgadener Land (Ethikkommission Land Salzburg); Schmallenberg (Ethikkommission Ärztekammer Westfalen-Lippe); Solingen (Ethikkommission Universität Witten-Herdecke); Ulm (Ethikkommission Universität Ulm); Würzburg (Ethikkommission Universität Würzburg)) ethical committees and written informed consent was obtained from all patients. The study was conducted from September 2011 to December 2013 and comprised 151 patients recruited within the COSYCONET framework (ClinicalTrials.gov, Identifier: NCT01245933). For further information see: Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J, Schulz H, Glaser S, Holle R et al.: The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med 2016, 114:27–37. Within the ethical approval the participants of the study gave their consent to publish the data collected during the study period. The authors declare that they have no competing interests. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",Grants and funding 01 GI 0881/German Federal Ministry of Education and Research not applicable/AstraZeneca GmbH not applicable/Bayer Schering Pharma AG not applicable/Boehringer Ingelheim Pharma GmbH & Co. KG not applicable/Chiesi GmbH not applicable/GlaxoSmithKline not applicable/Grifols Deutschland GmbH not applicable/MSD Sharp & Dohme GmbH not applicable/Mundipharma GmbH not applicable/Novartis Deutschland GmbH not applicable/Pfizer Pharma GmbH not applicable/Takeda Pharma Vertrieb GmbH & Co Show all 12 grants,"Sarah Marietta von Siemens 1 , Rudolf A Jörres 1 , Jürgen Behr 2 , Peter Alter 3 , Johanna Lutter 4 , Tanja Lucke 1 , Sandra Söhler 5 , Tobias Welte 6 , Henrik Watz 7 , Claus F Vogelmeier 3 , Franziska Trudzinski 8 , Winfried Rief 9 , Britta Herbig 1 , Kathrin Kahnert 10 ; COSYCONET study group"
31803269,Changes in FEV(1) over time in COPD and the importance of spirometry reference ranges: the devil is in the detail,"Jane Kirkby 1, Raffaella Nenna 2, Aisling McGowan 3",Breathe (Sheff). 2019 Dec;15(4):337-339. doi: 10.1183/20734735.0252-2019.,Kirkby J,Breathe (Sheff),2019,2019/12/06,PMC6885335,,10.1183/20734735.0252-2019,https://pubmed.ncbi.nlm.nih.gov/31803269/,/31803269/,"Conflict of interest: J. Kirkby has nothing to disclose. Conflict of interest: R. Nenna has nothing to disclose. Conflict of interest: A. McGowan reports honoraria for lectures from Mundipharma, outside the submitted work.",,"Jane Kirkby 1 , Raffaella Nenna 2 , Aisling McGowan 3"
31002021,Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study,"Paolo Solidoro 1, Filippo Patrucco 1, Francesca de Blasio 2, Luisa Brussino 2, Michela Bellocchia 1, Davide Dassetto 1, Emanuele Pivetta 2, Annamaria Riccio 3, Enrico Heffler 4, Walter Canonica 4, Giovanni Rolla 2, Caterina Bucca 5",Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841274. doi: 10.1177/1753466619841274.,Solidoro P,Ther Adv Respir Dis,2019,2019/04/20,PMC6475845,,10.1177/1753466619841274,https://pubmed.ncbi.nlm.nih.gov/31002021/,/31002021/,"Conflict of interest statement: C.B. received lecture fees from AstraZeneca, Guidotti-Malesci, Menarini, Novartis. W.C. received research grants as well as lecture or advisory board fees from A. Menarini, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Mundip-harma, Novartis, Sanofi-Aventis, Teva. G.R. received lecture fees from Allergy Therapeutics.",,"Paolo Solidoro 1 , Filippo Patrucco 1 , Francesca de Blasio 2 , Luisa Brussino 2 , Michela Bellocchia 1 , Davide Dassetto 1 , Emanuele Pivetta 2 , Annamaria Riccio 3 , Enrico Heffler 4 , Walter Canonica 4 , Giovanni Rolla 2 , Caterina Bucca 5"
31807061,Neuroimaging Of Cold Allodynia Reveals A Central Disinhibition Mechanism Of Pain,"Julia Forstenpointner # 1 2, Andreas Binder # 1 2, Rainer Maag 1 2, Oliver Granert 2, Philipp Hüllemann 1 2, Martin Peller 2, Gunnar Wasner 1 2, Stefan Wolff 3, Olav Jansen 3, Hartwig Roman Siebner 2 4 5 6, Ralf Baron 1 2",J Pain Res. 2019 Nov 11;12:3055-3066. doi: 10.2147/JPR.S216508. eCollection 2019.,Forstenpointner J,J Pain Res,2019,2019/12/07,PMC6857664,,10.2147/JPR.S216508,https://pubmed.ncbi.nlm.nih.gov/31807061/,/31807061/,"RB, GW, AB and RM were supported by the German Federal Ministry of Education and Research (BMBF), German Research Foundation DFNS (grant 01 EM 0504) and an unrestricted educational grant from Pfizer, Germany. HS was supported by the BMBF (grant 01 GO 0511). AB reports grants and personal fees from Pfizer, personal fees from Grünenthal, Allergan and Munipharma, during the conduct of the study; honoraria from Astellas, Allergan, Bayer, Boehringer-Ingelheim, Grünenthal, and Pfizer; and he participated in advisory boards of Astellas, Boehringer-Ingelheim, Genzyme, and Grünenthal. RM reports grants and personal fees from Pfizer and personal fees from Grünenthal and Genzyme, during the conduct of the study. JF reports personal fees and non-financial support from Grünenthal GmbH and Sanofi Genzyme, personal fees from Bayer, non-financial support from Novartis, outside the submitted work. PH reports speaking fees from Pfizer and Genzyme; travel reimbursement from Grünenthal; and grants from BMBF and Medoc, outside the submitted work. MP, OG, GW, SW and OJ reports no conflicts of interest in this work. HRS has received honoraria from Novartis, Sanofi-Genzyme, Elsevier Publishers and Springer Publishing; reports grants from Lundbeckfonden, during the conduct of the study. HRS professorship is sponsored by Lundbeckfonden. RB reports personal fees from Pfizer, Genzyme GmbH, Grünenthal GmbH, Mundipharma, Sanofi Pasteur, Medtronic Inc. Neuro-modulation, Eisai Co.Ltd., Lilly GmbH, Boehringer Ingelheim Pharma GmbH&Co.KG, Astellas, Desitin, Teva Pharma, Bayer-Schering, MSD GmbH, Seqirus, Novartis, TAD Pharma GmbH, Allergan, Sanofi Pasteur, Medtronic, Bristol-Myers Squibb, Biogenidec, AstraZeneca, Merck, Abbvie, Daiichi Sankyo, Glenmark Pharmaceuticals, Genentech, Galapagos NV, Kyowa Kirin GmbH, Vertex Pharmaceuticals Inc., Biotest AG, Celgene, Theranexus, Bayer AG, Akcea, and Asahi Kasei Pharma; grants from Pfizer, Genzyme GmbH, Grünenthal GmbH, Mundipharma, German Research Network on Neuropathic Pain (01EM0903), NoPain system biology (0316177C), German Research Foundation (DFG), EU-Project IMI Paincare, Novartis, German Federal Ministry of Education and Research (BMBF): member of the ERA_NET NEURON/IM-PAIN Project (01EW1503). Member of the EU Project No 633491: DOLORisk. Member of the IMI “Europain” collaboration and industry members of this are: Astra Zeneca, Pfizer, Esteve, UCB-Pharma, Sanofi Aventis, Grünenthal GmbH, Eli Lilly and Boehringer Ingelheim Pharma GmbH&Co.KG.",,"Julia Forstenpointner # 1 2 , Andreas Binder # 1 2 , Rainer Maag 1 2 , Oliver Granert 2 , Philipp Hüllemann 1 2 , Martin Peller 2 , Gunnar Wasner 1 2 , Stefan Wolff 3 , Olav Jansen 3 , Hartwig Roman Siebner 2 4 5 6 , Ralf Baron 1 2"
31231974,Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study,"Akihiro Tokoro 1, Hisao Imai 2, Soichi Fumita 3, Toshiyuki Harada 4, Toshio Noriyuki 5, Makio Gamoh 6, Yusaku Akashi 3, Hiroki Sato 7, Yoshiyuki Kizawa 8",Cancer Med. 2019 Aug;8(10):4883-4891. doi: 10.1002/cam4.2341. Epub 2019 Jun 24.,Tokoro A,Cancer Med,2019,2019/06/25,PMC6712473,,10.1002/cam4.2341,https://pubmed.ncbi.nlm.nih.gov/31231974/,/31231974/,"AT has received grants from Shionogi and Daiichi‐Sankyo and personal fees from Daiichi‐Sankyo, Mundipharma, Hisamitsu, Terumo, Sumitomo Dainippon, and Kracie. HI has received travel reimbursement from Shionogi. SF has received honoraria from Merck Serono, Ono Pharmaceutical Co., Bristol‐Myers Squibb, Takeda, and Bayer Yakuhin, and travel reimbursement from BeiGene. TH has received honoraria from Taiho Pharmaceutical, AstraZeneca KK, Boehringer Ingelheim, and Hisamitsu Pharmaceutical Co., Inc. TN has received personal fees from Shionogi, Taiho Pharmaceutical, and Chugai Pharmaceutical, and nonfinancial support from Shionogi. MG has received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Ono Pharmaceutical, Takeda, Daiichi Sankyo, Nippon Kayaku, and Eli Lilly Japan. YA has received honoraria from AstraZeneca KK, Chugai Pharmaceutical Co., Ltd., MDS KK, Bristol‐Myers Squibb KK, Nippon Boehringer Ingelheim Co., Ltd., Pfizer Seiyaku KK, Taiho Pharmaceutical Co., Ltd., and Hisamitsu Pharmaceutical Co., Inc. HS is an employee of Shionogi & Co., Ltd. YK has received grants from Shionogi, Kyowa‐Kirin, and Terumo, and personal fees from Shionogi, Kyowa Kirin, Terumo, Johnson & Johnson, Daiichi‐Sankyo, Pfizer, Mundipharma, Chugai Pharmaceutical.",,"Akihiro Tokoro 1 , Hisao Imai 2 , Soichi Fumita 3 , Toshiyuki Harada 4 , Toshio Noriyuki 5 , Makio Gamoh 6 , Yusaku Akashi 3 , Hiroki Sato 7 , Yoshiyuki Kizawa 8"
31565244,Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study,"Xenofon Baraliakos 1, Juergen Braun 1, Atul Deodhar 2, Denis Poddubnyy 3, Alan Kivitz 4, Hasan Tahir 5, Filip Van den Bosch 6 7, Evie-Maria Delicha 8, Zsolt Talloczy 9, Anke Fierlinger 9",RMD Open. 2019 Sep 3;5(2):e001005. doi: 10.1136/rmdopen-2019-001005. eCollection 2019.,Baraliakos X,RMD Open,2019,2019/10/01,PMC6744073,,10.1136/rmdopen-2019-001005,https://pubmed.ncbi.nlm.nih.gov/31565244/,/31565244/,"Competing interests: XB: Grant/research support from AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen. Consultant for AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen. Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen. JB: Grant/research support from AbbVie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB. Consultant for: AbbVie (Abbott), Amgen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB. Speakers bureau: AbbVie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UC. AD: Honoraria for consulting or speaking for, or has received research grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GlaxoSmithKline (GSK), Janssen, Novartis, Pfizer and UCB. DP: Grant/research support from AbbVie, MSD, Novartis and Pfizer. Consultant for AbbVie, BMS, Celgene, MSD, Novartis, Pfizer and UCB. Speakers bureau: AbbVie, BMS, Janssen, MSD, Novartis, Pfizer, Roche, UCB. AJK: Consultant for AbbVie, Pfizer, Genentech, UCB and Sanofi/Regeneron and Celgene. Speakers bureau: Celgene, Pfizer and Sanofi/Regeneron and Genentech. HT: Speakers bureau: Novartis, Eli Lilly and AbbVie. FVdB: Research grants, consultancy fees or speaker honoraria: AbbVie, BMS, Celgene, Galapagos, Janssen, Lilly, Merck, Novartis, Pfizer and UCB. EMD: Consultant for Novartis. ZT: Employee of Novartis with Novartis Stocks. AF: Employee of Novartis with Novartis Stocks.",,"Xenofon Baraliakos 1 , Juergen Braun 1 , Atul Deodhar 2 , Denis Poddubnyy 3 , Alan Kivitz 4 , Hasan Tahir 5 , Filip Van den Bosch 6 7 , Evie-Maria Delicha 8 , Zsolt Talloczy 9 , Anke Fierlinger 9"
31372003,Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey,"Kevin Gruffydd-Jones 1, Mike Thomas 2, Miguel Roman-Rodríguez 3, Antonio Infantino 4, J Mark FitzGerald 5, Ian Pavord 6, Jennifer M Haddon 7, Ulrich Elsasser 8, Christian Vogelberg 9",J Asthma Allergy. 2019 Jul 11;12:183-194. doi: 10.2147/JAA.S204278. eCollection 2019.,Gruffydd-Jones K,J Asthma Allergy,2019,2019/08/03,PMC6636188,,10.2147/JAA.S204278,https://pubmed.ncbi.nlm.nih.gov/31372003/,/31372003/,"KGJ has spoken on behalf of, and worked as a consultant for, AstraZeneca, Boehringer Ingelheim International GmbH, Chiesi, GlaxoSmithKline, Mundipharma, Napp, Novartis and Pfizer, outside the submitted work. MT has received honoraria from the following companies marketing respiratory and allergy products: Aerocrine, Boehringer Ingelheim International GmbH, GlaxoSmithKline, Merck Sharp & Dohme, Novartis and Pfizer, outside the submitted work; he is also a member of the BTS/SIGN Asthma guideline steering group and the NICE Asthma Diagnosis and Monitoring guideline development group. MRR reports personal fees from AstraZeneca, Boehringer Ingelheim International GmbH, Chiesi, Menarini, Mundipharma, Novartis, Pfizer, Teva and Bial, and grants and personal fees from GlaxoSmithKline, outside the submitted work. JMF reports being a member of advisory boards for AstraZeneca, Boehringer Ingelheim International GmbH, Novartis, Sanofi-Regeneron, Circassia and Teva; has been paid honoraria for lecturing at symposia organized by these companies; and has also undertaken clinical trials through his employer, the University of British Columbia, for these companies and GlaxoSmithKline. Funding was also provided to the University of British Columbia by Boehringer Ingelheim International GmbH during the conduct of this study. In the last 5 years IP has received speaker’s honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim International GmbH, Aerocrine, Almirall, Novartis, Teva, Chiesi and GlaxoSmithKline, and payments for organizing educational events from AstraZeneca and Teva. He has received honoraria for attending advisory panels with Genentech, Regeneron, AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline, Novartis, Teva, Merck, Sanofi, Circassia, Chiesi and Knopp. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim International GmbH, GlaxoSmithKline, AstraZeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. JMH is an employee of Boehringer Ingelheim International GmbH and UE is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. CV has spoken on behalf of, and worked as a consultant for, Boehringer Ingelheim International GmbH and Novartis. The authors report no other conflicts of interest in this work.",,"Kevin Gruffydd-Jones 1 , Mike Thomas 2 , Miguel Roman-Rodríguez 3 , Antonio Infantino 4 , J Mark FitzGerald 5 , Ian Pavord 6 , Jennifer M Haddon 7 , Ulrich Elsasser 8 , Christian Vogelberg 9"
31000665,Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations,"Alberto Papi 1, Stefano Petruzzelli 2, Stefano Vezzoli 2, George Georges 3, Leonardo M Fabbri 4 5",Eur Respir J. 2019 Apr 18;53(4):1900147. doi: 10.1183/13993003.00147-2019. Print 2019 Apr.,Papi A,Eur Respir J,2019,2019/04/20,,,10.1183/13993003.00147-2019,https://pubmed.ncbi.nlm.nih.gov/31000665/,/31000665/,"Conflict of interest: A. Papi reports grants, personal fees, non-financial support and other from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Menarini, Novartis, Zambon, Mundipharma and TEVA, and grants from Sanofi, outside the submitted work. Conflict of interest: S. Petruzzelli is employed by Chiesi Farmaceutici SpA, the sponsor of the studies. Conflict of interest: S. Vezzoli is employed by Chiesi Farmaceutici SpA, the sponsor of the studies. Conflict of interest: G. Georges reports other support from Chiesi USA, Inc., during the conduct of the study; and other support from Chiesi USA, Inc., outside the submitted work. Conflict of interest: L.M. Fabbri reports personal fees and non-financial support from AstraZeneca, GSK, Novartis, Menarini, Boehringer Ingelheim, Zambon and Pearl Therapeutics, non-financial support from Dompe, and grants, personal fees and non-financial support from Chiesi, outside the submitted work.",,"Alberto Papi 1 , Stefano Petruzzelli 2 , Stefano Vezzoli 2 , George Georges 3 , Leonardo M Fabbri 4 5"
31392812,"Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study","Adam Trickey 1 2, Hannah Fraser 1, Aaron G Lim 1, Josephine G Walker 1, Amy Peacock 3, Samantha Colledge 3, Janni Leung 3 4 5, Jason Grebely 5 6, Sarah Larney 3, Natasha K Martin 1 7, Louisa Degenhardt 3, Matthew Hickman 1 2, Margaret T May 1 2 8, Peter Vickerman 1 2",J Viral Hepat. 2019 Dec;26(12):1388-1403. doi: 10.1111/jvh.13187. Epub 2019 Aug 30.,Trickey A,J Viral Hepat,2019,2019/08/09,PMC10401696,NIHMS1919966,10.1111/jvh.13187,https://pubmed.ncbi.nlm.nih.gov/31392812/,/31392812/,"JG is a consultant/advisor and has received research grants from AbbVie, Cepheid, Gilead Sciences and Merck/MSD. In the past 3 years, LD has received investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma, and Seqirus. SL has received investigator initiated untied educational grants from Indivior. AP has received investigator-initiated untied educational grants from Mundipharma and Seqirus. MH reports personal fees from Gilead, Abbvie, and MSD. HF has received an honorarium from MSD. PV has received investigator-initiated untied grants from Gilead and PV has received honorarium from Gilead and Merck. NM has received unrestricted research grants and honoraria from Gilead and Merck.",Grants and funding P30 AI036214/AI/NIAID NIH HHS/United States R01 DA037773/DA/NIDA NIH HHS/United States RP-DG-0610-10055/DH_/Department of Health/United Kingdom RP-PG-0616-20008/DH_/Department of Health/United Kingdom,"Adam Trickey 1 2 , Hannah Fraser 1 , Aaron G Lim 1 , Josephine G Walker 1 , Amy Peacock 3 , Samantha Colledge 3 , Janni Leung 3 4 5 , Jason Grebely 5 6 , Sarah Larney 3 , Natasha K Martin 1 7 , Louisa Degenhardt 3 , Matthew Hickman 1 2 , Margaret T May 1 2 8 , Peter Vickerman 1 2"
31208466,Is atopy a risk indicator of chronic obstructive pulmonary disease in dairy farmers?,"Matthieu Veil-Picard 1, Thibaud Soumagne 1, Rechana Vongthilath 1, Isabella Annesi-Maesano 2, Alicia Guillien 3, Lucie Laurent 1, Pascal Andujar 4 5, Nicolas Roche 6, Stephane Jouneau 7 8, Benoit Cypriani 9, Jean-Jacques Laplante 10, Bruno Degano 11 12, Jean-Charles Dalphin 13 14",Respir Res. 2019 Jun 17;20(1):124. doi: 10.1186/s12931-019-1082-2.,Veil-Picard M,Respir Res,2019,2019/06/19,PMC6580567,,10.1186/s12931-019-1082-2,https://pubmed.ncbi.nlm.nih.gov/31208466/,/31208466/,"Dr. Roche reports grants and personal fees from Boehringer Ingelheim, Pfizer and Novartis, personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Cipla, Sano, Sandoz, 3 M, Zambon, outside the submitted work. Dr. Dalphin reports grants, personal fees and non-financial support from Novartis Pharma, GSK, Chiesi, Intermune, AstraZeneca, Boehringer ingelheim and non-financial support from Stallergenes, outside the submitted work. Dr. Dalphin reports grants, personal fees and non-financial support from Novartis Pharma, personal fees and non-financial support from GSK, personal fees and non-financial support from Chiesi, personal fees and non-financial support from Intermune, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Boehringer ingelheim, non-financial support from Stallergenes, outside the submitted work. The other authors declare that they have no conflict of interest for the submitted work.",,"Matthieu Veil-Picard 1 , Thibaud Soumagne 1 , Rechana Vongthilath 1 , Isabella Annesi-Maesano 2 , Alicia Guillien 3 , Lucie Laurent 1 , Pascal Andujar 4 5 , Nicolas Roche 6 , Stephane Jouneau 7 8 , Benoit Cypriani 9 , Jean-Jacques Laplante 10 , Bruno Degano 11 12 , Jean-Charles Dalphin 13 14"
31017637,"Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial","Barry Greenberg 1, James D Neaton 2, Stefan D Anker 3 4, William M Byra 5, John G F Cleland 6 7, Hsiaowei Deng 5, Min Fu 8, David A La Police 5, Carolyn S P Lam 9 10 11, Mandeep R Mehra 12, Christopher C Nessel 5, Theodore E Spiro 13, Dirk J van Veldhuisen 11, Catherine M Vanden Boom 5, Faiez Zannad 14 15",JAMA Cardiol. 2019 Jun 1;4(6):515-523. doi: 10.1001/jamacardio.2019.1049.,Greenberg B,JAMA Cardiol,2019,2019/04/25,PMC6487904,,10.1001/jamacardio.2019.1049,https://pubmed.ncbi.nlm.nih.gov/31017637/,/31017637/,"Conflict of Interest Disclosures: Dr Greenberg reports personal fees from Janssen Research & Development LLC as a member of the steering committee of the COMMANDER HF trial and consulting fees from Bayer during the conduct of the study; consulting fees from Janssen Research & Development LLC, Bayer, Novartis, Mesoblast, Ionis Pharmaceuticals, Zensun USA, and Cellular Dynamics outside the submitted work; speaker fees from Novartis and Otsuka Pharmaceutical outside the submitted work; and personal fees from AstraZeneca, Actelion, Amgen, EBR Systems, Impulse Dynamics, MyoKardia, Rocket Pharma, Sanofi, and Viking Therapeutics outside the submitted work. Dr Neaton reports personal fees (honoraria) from Johnson & Johnson during the conduct of the study; fees from Janssen Research & Development LLC as a member of the steering committee of the COMMANDER HF trial; and fees from Bristol-Myers Squibb and EBR Systems for serving on data and safety monitoring boards for heart failure trials. Dr Anker reports personal fees from Janssen Research & Development LLC as a member of the steering committee of the COMMANDER HF trial during the conduct of the study; personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Laboratoires Servier, Thermo Fisher Scientific, Vifor Pharma, V-Wave, CVRx, and Impulse Dynamics outside the submitted work; and grants from Vifor Pharma and Abbott Vascular outside the submitted work. Dr Byra reports other support from Janssen Research & Development LLC during the conduct of the study and is employed by and is a shareholder of Johnson & Johnson. Dr Cleland reports personal fees from Janssen Research & Development LLC as a member of the steering committee of the COMMANDER HF trial and research grants and honoraria for speaking, committees, and advisory boards from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Medtronic, MyoKardia, Novartis, Philips Healthcare, Pharmacosmos, Pharma Nord, Sanofi, Laboratoires Servier, Stealth BioTherapeutics, Torrent Pharmaceuticals, and Vifor Pharma. Dr Deng reports other support from Janssen Research & Development LLC during the conduct of the study and outside the submitted work and is employed by and a shareholder of Johnson & Johnson. Dr Fu reports other support from Janssen Research & Development LLC during the conduct of the study and is employed by and a shareholder of Johnson & Johnson. Mr La Police reports other support from Janssen Research & Development LLC during the conduct of the study and is employed by and a shareholder of Johnson & Johnson. Dr Lam reports personal fees from Janssen Research & Development LLC during the conduct of the study; research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; personal fees from serving on the advisory board/steering committee/executive committee/clinical end points committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diagnostics, Corvia Medical, Stealth BioTherapeutics, Jana Care, Biofourmis, Applied Therapeutics Inc, WebMD Global LLC, Radcliffe Group Ltd, Takeda Pharmaceutical Company, and Darma Laboratories outside the submitted work; and support from a Clinician Scientist Award from the National Medical Research Council of Singapore. Dr Mehra reports personal fees from Janssen Research & Development LLC as a member of the steering committee of the COMMANDER HF trial and consulting fees during the conduct of the study and personal fees from Abbott, Medtronic, Portola Pharmaceuticals, Bayer, Mesoblast, Baim Institute for Clinical Research, Xogenex, NupulseCV, and FineHeart outside the submitted work. Dr Nessel reports other support from Janssen Research & Development LLC during the conduct of the study and is employed by and a shareholder of Johnson & Johnson. Dr Spiro is employed by and is a shareholder of Bayer. Dr van Veldhuisen reports personal fees from Johnson & Johnson and Bayer during the conduct of the study and reports receiving board membership fees from Janssen Research & Development LLC as a member of the steering committee of the COMMANDER HF trial. Ms Vanden Boom reports other support from Janssen Research & Development LLC during the conduct of the study and is employed by and a shareholder of Johnson & Johnson. Dr Zannad reports personal fees from Janssen Research & Development LLC and Bayer during the conduct of the study; personal fees from AstraZeneca, Boehringer Ingelheim, LivaNova, GE Healthcare, Amgen, Novartis, Quantum Genomics, Cardior Pharmaceuticals, CardioRenal, CVCT, Merck, CVRx, Vifor Fresenius Medical Care Renal Pharma, NovoNordisk, and MundiPharma outside the submitted work; fees for serving on a steering committee or a safety and data monitoring board from Actelion, Amgen, Bayer, Boehringer Ingelheim, Boston Scientific, CVRx, GE Healthcare, Janssen Research & Development LLC, Novartis, and ResMed; and consulting fees from AstraZeneca, Cardior Pharmaceuticals, CardioRenal, Quantum Genomics, and Vifor Fresenius Medical Care Renal Pharma.",,"Barry Greenberg 1 , James D Neaton 2 , Stefan D Anker 3 4 , William M Byra 5 , John G F Cleland 6 7 , Hsiaowei Deng 5 , Min Fu 8 , David A La Police 5 , Carolyn S P Lam 9 10 11 , Mandeep R Mehra 12 , Christopher C Nessel 5 , Theodore E Spiro 13 , Dirk J van Veldhuisen 11 , Catherine M Vanden Boom 5 , Faiez Zannad 14 15"
31429756,Are there specific clinical characteristics associated with physicians treatment choices in COPD?,"Nicolas Roche 1 2, Anestis Antoniadis 3, David Hess 4, Pei Zhi Li 5, Eric Kelkel 6, Sylvie Leroy 7 8, Christophe Pison 9, Pierre-Régis Burgel 10, Bernard Aguilaniu 11 ; COLIBRI COPD Research Group",Respir Res. 2019 Aug 20;20(1):189. doi: 10.1186/s12931-019-1156-1.,Roche N,Respir Res,2019,2019/08/21,PMC6701115,,10.1186/s12931-019-1156-1,https://pubmed.ncbi.nlm.nih.gov/31429756/,/31429756/,"NR reports grants and personal fees from Boehringer Ingelheim, Novartis, Pfizer and personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Cipla, Sanofi, Sandoz, 3 M, Zambon. PRB reports personal fees from Astra-Zeneca, Boehringer Ingelheim France, Chiesi, GSK, Novartis, Pfizer, Vertex, Zambon, Teva. CP reports grants and personal fees from GSK France, personal fees from Novartis France, BIF and AZ France. AA, BA, EK, SL have nothing to disclose. DH is employed by Association pour la Complémentarité des Connaissances et des Pratiques de la Pneumologie, Grenoble using funds from Agir à Dom, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, PneumRx.",Grants and funding -/Agir à Dom -/AstraZeneca -/Boehringer Ingelheim France -/Chiesi -/GSK -/Novartis -/PneumRX Show all 7 grants,"Nicolas Roche 1 2 , Anestis Antoniadis 3 , David Hess 4 , Pei Zhi Li 5 , Eric Kelkel 6 , Sylvie Leroy 7 8 , Christophe Pison 9 , Pierre-Régis Burgel 10 , Bernard Aguilaniu 11 ; COLIBRI COPD Research Group"
30945206,Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting,"Evelien Moorkens 1, Steven Simoens 1, Per Troein 2, Paul Declerck 1, Arnold G Vulto 3 4, Isabelle Huys 1",BioDrugs. 2019 Jun;33(3):299-306. doi: 10.1007/s40259-019-00346-5.,Moorkens E,BioDrugs,2019,2019/04/05,PMC6533216,,10.1007/s40259-019-00346-5,https://pubmed.ncbi.nlm.nih.gov/30945206/,/30945206/,"SS, IH and AV have conducted biosimilar research sponsored by Hospira (now Pfizer). SS was involved in a stakeholder roundtable on biosimilars sponsored by Amgen, Pfizer and MSD, and has participated in an advisory board meeting for Pfizer. SS currently works with Pfizer, and works with Celltrion as a consultant, to carry out biosimilar research. AGV is involved in consulting, advisory work and speaking engagements for a number of companies, including AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche and Sandoz. PD participated at advisory board meetings for AbbVie, Amgen and Hospira, and is on the Speakers’ Bureau of AbbVie, Celltrion, Hospira, Merck Serono and Roche. PT is employed by IQVIA™. EM declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",,"Evelien Moorkens 1 , Steven Simoens 1 , Per Troein 2 , Paul Declerck 1 , Arnold G Vulto 3 4 , Isabelle Huys 1"
31369144,Repetitive enhancement of serum BDNF subsequent to continuation ECT,"T Vanicek 1, G S Kranz 1 2 3, B Vyssoki 1, A Komorowski 1, G Fugger 1, A Höflich 1, Z Micskei 4, S Milovic 4, R Lanzenberger 1, A Eckert 5, S Kasper 1, R Frey 1",Acta Psychiatr Scand. 2019 Nov;140(5):426-434. doi: 10.1111/acps.13080. Epub 2019 Sep 11.,Vanicek T,Acta Psychiatr Scand,2019,2019/08/02,PMC6856812,,10.1111/acps.13080,https://pubmed.ncbi.nlm.nih.gov/31369144/,/31369144/,"With relevance to this work, there is no conflict of interest to declare. Eckert A. has received grant/research support from Schwabe, Vifor, and Boiron. She has served as a consultant or on advisory boards for Vifor and Schwabe. Frey R. received speaker honoraria from AstraZeneca, Bristol‐Myers Squibb, Eli Lilly, and AOP Orphan. Kasper S. received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen‐Cilag Pharma GmbH, KRKA‐Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Kranz GS received travel grants from Roche, AOP Orphan Pharmaceuticals AG and Pfizer. Lanzenberger R. received conference speaker honorarium within the last three years from Shire and research support from Siemens Healthcare regarding PET/MR. Vanicek T. received travel grants and compensation for workshop participation from Pfizer and Eli Lilly and speaker honorary from Shire. Fugger G., Höflich A., Komorowski A., Milovic S., and Vyssoki B. declared no conflicts of interest.",Grants and funding P 23021/FWF_/Austrian Science Fund FWF/Austria,"T Vanicek 1 , G S Kranz 1 2 3 , B Vyssoki 1 , A Komorowski 1 , G Fugger 1 , A Höflich 1 , Z Micskei 4 , S Milovic 4 , R Lanzenberger 1 , A Eckert 5 , S Kasper 1 , R Frey 1"
31515402,Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension,"Khodr Tello 1, Antonia Dalmer 2, Rebecca Vanderpool 3, Hossein A Ghofrani 2 4 5, Robert Naeije 6, Fritz Roller 7, Werner Seeger 2, Daniel Dumitrescu 8, Natascha Sommer 2, Anne Brunst 2, Henning Gall 2, Manuel J Richter 2",Eur Respir J. 2019 Nov 21;54(5):1900342. doi: 10.1183/13993003.00342-2019. Print 2019 Nov.,Tello K,Eur Respir J,2019,2019/09/14,,,10.1183/13993003.00342-2019,https://pubmed.ncbi.nlm.nih.gov/31515402/,/31515402/,"Conflict of interest: K. Tello reports that this work was funded by the Excellence Cluster Cardio-Pulmonary System (ECCPS) and the Collaborative Research Center (SFB) 1213 - Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (grant from German Research Foundation, Bonn, Germany) and editorial support was funded by University of Giessen, during the conduct of the study; and personal fees for lectures from Actelion and Bayer, outside the submitted work. Conflict of interest: A. Dalmer has nothing to disclose. Conflict of interest: R. Vanderpool has nothing to disclose. Conflict of interest: H.A. Ghofrani reports that this work was funded by the ECCPS and the Collaborative Research Center (SFB) 1213 - Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (grant from German Research Foundation, Bonn, Germany) and editorial support was funded by University of Giessen, during the conduct of the study; and personal fees for consultancy and advisory board work from Bayer and Pfizer, personal fees for consultancy, lectures and advisory board work from Actelion and GSK, personal fees for consultancy from Merck, grants and personal fees for consultancy from Novartis, grants and personal fees for lectures from Bayer HealthCare and Encysive/Pfizer, grants from Aires, German Research Foundation, Excellence Cluster Cardiopulmonary Research and German Ministry for Education and Research, and personal fees for advisory board work from Takeda, outside the submitted work. Conflict of interest: R. Naeije reports grants and personal fees for consultancy and advisory board work from AOP Orphan Pharmaceuticals, Actelion, Bayer, Reata, Lung Biotechnology Corporation and United Therapeutics, outside the submitted work. Conflict of interest: F. Roller has nothing to disclose. Conflict of interest: W. Seeger reports that this work was funded by the ECCPS and the Collaborative Research Center (SFB) 1213 - Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (grant from German Research Foundation, Bonn, Germany) and editorial support was funded by University of Giessen, during the conduct of the study; and personal fees for consultancy and lectures from Pfizer and Bayer Pharma AG, outside the submitted work. Conflict of interest: D. Dumitrescu reports personal fees and advisory board membership from Actelion and Novartis, and personal fees from Bayer Healthcare, GSK, MSD and Servier, outside the submitted work. Conflict of interest: N. Sommer reports personal fees from Actelion, outside the submitted work. Conflict of interest: A. Brunst has nothing to disclose. Conflict of interest: H. Gall reports that this work was funded by the ECCPS and the Collaborative Research Center (SFB) 1213 - Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (grant from German Research Foundation, Bonn, Germany) and editorial support was funded by University of Giessen, during the conduct of the study; and personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer and United Therapeutics, outside the submitted work. Conflict of interest: M.J. Richter reports that this work was funded by the ECCPS and the Collaborative Research Center (SFB) 1213 - Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (grant from German Research Foundation, Bonn, Germany) and editorial support was funded by University of Giessen, during the conduct of the study; and grants from United Therapeutics, grants and personal fees for consultancy and lectures from Bayer, and personal fees for lectures from Actelion, Mundipharma, Roche and OMT, outside the submitted work.",,"Khodr Tello 1 , Antonia Dalmer 2 , Rebecca Vanderpool 3 , Hossein A Ghofrani 2 4 5 , Robert Naeije 6 , Fritz Roller 7 , Werner Seeger 2 , Daniel Dumitrescu 8 , Natascha Sommer 2 , Anne Brunst 2 , Henning Gall 2 , Manuel J Richter 2"
32923868,Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA,"Nora S Sánchez 1, Michael P Kahle 1, Ann Marie Bailey 1, Chetna Wathoo 1, Kavitha Balaji 1, Mehmet Esat Demirhan 1, Dong Yang 1, Milind Javle 1, Ahmed Kaseb 1, Cathy Eng 1, Vivek Subbiah 1, Filip Janku 1, Victoria M Raymond 2, Richard B Lanman 2, Kenna R Mills Shaw 1, Funda Meric-Bernstam 1",JCO Precis Oncol. 2019 Sep 24;3:PO.19.00017. doi: 10.1200/PO.19.00017. eCollection 2019.,Sánchez NS,JCO Precis Oncol,2019,2020/09/14,PMC7448805,,10.1200/PO.19.00017,https://pubmed.ncbi.nlm.nih.gov/32923868/,/32923868/,"The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCOs conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Nora S. SánchezEmployment: Foundation Medicine Stock and Other Ownership Interests: RocheAnn Marie BaileyEmployment: QIAGEN Travel, Accommodations, Expenses: QIAGENKavitha BalajiEmployment: Lexicon Stock and Other Ownership Interests: Lexicon Travel, Accommodations, Expenses: LexiconDong YangEmployment: Molecular HealthMilind JavleConsulting or Advisory Role: QED Therapeutics, Oncosil Medical, Incyte, Mundipharma Other Relationship: Rafael Pharmaceuticals, Incyte, Pieris Pharmaceuticals, Merck, Merck Serono, Novartis, Seattle Genetics, BeiGene, QED Therapeutics, Bayer AGAhmed KasebStock and Other Ownership Interests: Gilead Sciences Honoraria: Merck, Exelixis, Bayer AG, Bristol-Myers Squibb Consulting or Advisory Role: Bayer AG, Bristol-Myers Squibb, Merck, Exelixis Research Funding: Bristol-Myers Squibb, Merck, Bayer AG, Onyx Pharmaceuticals, Genentech Travel, Accommodations, Expenses: Exelixis, Merck, Bayer AG, Onyx Pharmaceuticals, Bristol-Myers SquibbCathy EngHonoraria: Roche, Bayer AG Consulting or Advisory Role: Roche, Genentech, Bayer Schering Pharma, Taiho, Terumo Clinical Supply Travel, Accommodations, Expenses: Genentech, Roche, Bayer AG, Sirtex MedicalVivek SubbiahConsulting or Advisory Role: MedImmune Research Funding: Novartis (Inst), GlaxoSmithKline (Inst), NanoCarrier (Inst), Northwest Biotherapeutics (Inst), Genentech (Inst), Roche (Inst), Berg Pharma (Inst), Bayer AG (Inst), Incyte (Inst), Fujifilm (Inst), PharmaMar (Inst), D3 Oncology Solutions (Inst), Pfizer (Inst), Amgen (Inst), AbbVie (Inst), Multivir (Inst), Blueprint Medicines (Inst), Loxo Oncology (Inst), Vegenics (Inst), Takeda Pharmaceuticals (Inst), Alfasigma (Inst), Agensys (Inst), Idera (Inst), Boston Medical (Inst), Inhibrx (Inst), Exelixis (Inst) Travel, Accommodations, Expenses: PharmaMar, Bayer AGFilip JankuStock and Other Ownership Interests: Trovagene Consulting or Advisory Role: Deciphera, Trovagene, Novartis, Sequenom, Foundation Medicine, Guardant Health, Immunome, Synlogic, Valeant, Dendreon, IFM Therapeutics, Sotio, PureTech Research Funding: Novartis (Inst), BioMed Valley Discoveries (Inst), Roche (Inst), Agios (Inst), Astellas Pharma (Inst), Deciphera (Inst), Plexxikon (Inst), Piqur (Inst), Fujifilm (Inst), Symphogen (Inst), Bristol-Myers Squibb (Inst), Asana Biosciences (Inst), Astex Pharmaceuticals (Inst) Other Relationship: Bio-RadVictoria M. RaymondEmployment: Trovagene, Guardant Health Stock and Other Ownership Interests: Trovagene, Guardant HealthRichard B. LanmanEmployment: Guardant Health, Veracyte Leadership: Guardant Health, Biolase Stock and Other Ownership Interests: Guardant Health, Biolase, Forward Medical Consulting or Advisory Role: Forward Medical Research Funding: Guardant HealthKenna R. Mills ShawResearch Funding: Guardant Health (Inst), Tempus (Inst)Funda Meric-BernstamHonoraria: Sumitomo Group, Dialectica Consulting or Advisory Role: Genentech, Inflection Biosciences, Pieris Pharmaceuticals, Clearlight Diagnostics, Darwin Health, Samsung Bioepis, Spectrum Pharmaceuticals, Aduro Biotech, Origimed, Xencor, Debiopharm Group, Mersana, Seattle Genetics Research Funding: Novartis, AstraZeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm Group, Bayer AG, Aileron Therapeutics, Puma Biotechnology, CytomX Therapeutics, Jounce Therapeutics, Zymeworks, Curis, Pfizer, eFFECTOR Therapeutics, AbbVie, Boehringer Ingelheim (I), Guardant Health (Inst), Daiichi Sankyo, GlaxoSmithKline Speakers’ Bureau: Chugai Biopharmaceuticals No other potential conflicts of interest were reported.",Grants and funding P30 CA016672/CA/NCI NIH HHS/United States UL1 TR000371/TR/NCATS NIH HHS/United States,"Nora S Sánchez 1 , Michael P Kahle 1 , Ann Marie Bailey 1 , Chetna Wathoo 1 , Kavitha Balaji 1 , Mehmet Esat Demirhan 1 , Dong Yang 1 , Milind Javle 1 , Ahmed Kaseb 1 , Cathy Eng 1 , Vivek Subbiah 1 , Filip Janku 1 , Victoria M Raymond 2 , Richard B Lanman 2 , Kenna R Mills Shaw 1 , Funda Meric-Bernstam 1"
31023364,"DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development","H Binder 1, E Willscher 2, H Loeffler-Wirth 2, L Hopp 2, D T W Jones 3 4, S M Pfister 3 5 6, M Kreuz 7, D Gramatzki 8, E Fortenbacher 2, B Hentschel 7, M Tatagiba 9, U Herrlinger 10, H Vatter 10, J Matschke 11, M Westphal 12, D Krex 13, G Schackert 13, J C Tonn 14, U Schlegel 15, H-J Steiger 16, W Wick 17 18, R G Weber 19, M Weller 8, M Loeffler 7",Acta Neuropathol Commun. 2019 Apr 25;7(1):59. doi: 10.1186/s40478-019-0704-8.,Binder H,Acta Neuropathol Commun,2019,2019/04/27,PMC6482573,,10.1186/s40478-019-0704-8,https://pubmed.ncbi.nlm.nih.gov/31023364/,/31023364/,"All patients gave written informed consent for participation in the GGN and its translational research projects. Not applicable. MW has received research grants from Abbvie, Acceleron, Actelion, Bayer, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur, Roche and Tragara, and honoraria for lectures or advisory board participation or consulting from Abbvie, BMS, Celgene, Celldex, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Pfizer, Progenics, Roche, Teva and Tocagen. US has received honoraria for lectures or advisory board participation from medac, GSK, mundipharma, Novartis, Novocure, Roche. DK has received research grants from Novocure, Northwest biotherapeutics, Kyowa, and honoraria for lectures or advisory board participation or consulting from Baxter and Kyowa. WW received study drug for clinical research from Apogenix, Roche and Pfizer. JCT has received research grants BrainLab and honoraria for lectures from BrainLab, Siemens, Merck, Roche and medac. All other authors declare that they have no competing interests. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",,"H Binder 1 , E Willscher 2 , H Loeffler-Wirth 2 , L Hopp 2 , D T W Jones 3 4 , S M Pfister 3 5 6 , M Kreuz 7 , D Gramatzki 8 , E Fortenbacher 2 , B Hentschel 7 , M Tatagiba 9 , U Herrlinger 10 , H Vatter 10 , J Matschke 11 , M Westphal 12 , D Krex 13 , G Schackert 13 , J C Tonn 14 , U Schlegel 15 , H-J Steiger 16 , W Wick 17 18 , R G Weber 19 , M Weller 8 , M Loeffler 7"
31376441,"Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome","Shangru Lyu 1, Mark P DeAndrade 1, Stefan Mueller 2, Alexander Oksche 3, Arthur S Walters 4, Yuqing Li 5",Behav Brain Res. 2019 Nov 18;374:112123. doi: 10.1016/j.bbr.2019.112123. Epub 2019 Jul 31.,Lyu S,Behav Brain Res,2019,2019/08/04,PMC6728912,NIHMS1536880,10.1016/j.bbr.2019.112123,https://pubmed.ncbi.nlm.nih.gov/31376441/,/31376441/,FINANCIAL DISCLOSURES OF ALL AUTHORS: Authors do not report any conflicts of interests.,Grants and funding R01 NS082244/NS/NINDS NIH HHS/United States R21 NS065273/NS/NINDS NIH HHS/United States,"Shangru Lyu 1 , Mark P DeAndrade 1 , Stefan Mueller 2 , Alexander Oksche 3 , Arthur S Walters 4 , Yuqing Li 5"
30772399,High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T,"Gilbert Hangel 1, Saurabh Jain 2, Elisabeth Springer 1, Eva Hečková 1, Bernhard Strasser 3, Michal Považan 4, Stephan Gruber 1, Georg Widhalm 5, Barbara Kiesel 5, Julia Furtner 6, Matthias Preusser 7, Thomas Roetzer 8, Siegfried Trattnig 1, Diana M Sima 2, Dirk Smeets 2, Wolfgang Bogner 9",Neuroimage. 2019 May 1;191:587-595. doi: 10.1016/j.neuroimage.2019.02.023. Epub 2019 Feb 14.,Hangel G,Neuroimage,2019,2019/02/18,PMC7220803,EMS86378,10.1016/j.neuroimage.2019.02.023,https://pubmed.ncbi.nlm.nih.gov/30772399/,/30772399/,"Conflicts of interest M.Pr. personal DOIs MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dome. M.Pr. institutional DOIs MP is responsible investigator for contracted research projects and clinical trials, for which research funding was paid to his institution by the following for-profit companies: Bristol-Myers Squibb, Böhringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dome and Roche.",Grants and funding KLI 646/FWF_/Austrian Science Fund FWF/Austria P 30701/FWF_/Austrian Science Fund FWF/Austria,"Gilbert Hangel 1 , Saurabh Jain 2 , Elisabeth Springer 1 , Eva Hečková 1 , Bernhard Strasser 3 , Michal Považan 4 , Stephan Gruber 1 , Georg Widhalm 5 , Barbara Kiesel 5 , Julia Furtner 6 , Matthias Preusser 7 , Thomas Roetzer 8 , Siegfried Trattnig 1 , Diana M Sima 2 , Dirk Smeets 2 , Wolfgang Bogner 9"
31168922,Type 2 diabetes remission 1\u2009year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial,"Mathias Ried-Larsen 1, Mette Y Johansen 1, Christopher S MacDonald 1 2, Katrine B Hansen 1, Robin Christensen 3 4, Anne-Sophie Wedell-Neergaard 1, Nanna Skytt Pilmark 1, Henning Langberg 2, Allan A Vaag 5, Bente K Pedersen 1, Kristian Karstoft 1 6",Diabetes Obes Metab. 2019 Oct;21(10):2257-2266. doi: 10.1111/dom.13802. Epub 2019 Jun 30.,Ried-Larsen M,Diabetes Obes Metab,2019,2019/06/07,PMC6772176,,10.1111/dom.13802,https://pubmed.ncbi.nlm.nih.gov/31168922/,/31168922/,"A.V. was appointed vice president for AstraZenecas Translational Research and Early Clinical Development during the completion of the study, but remained in the scientific steering committee of this study. R.C. employer, the Parker Institute, Bispebjerg, and Frederiksberg Hospital, is supported by core grant OCAY‐13‐309 from the Oak Foundatian, and he reports receiving personal fees from Abbott, AbbVie, Amgen, Axellus A/S, Bayer HealthCare Pharmaceuticals, Biogen Idec, Bristol‐Myers Squibb, CambridgeWeight Plan, Celgene, Eli Lilly, Hospira, Ipsen, Janssen, Laboratories Expanscience, Merck Sharp & Dohme, Mundipharma, Norpharma, Novartis, Orkla Health, Pfizer, Roche, Rottapharm‐Madaus, Sobi, Takeda and Wyeth, personal fees from employment from Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, and the University of Southern Denmark, grants pending and grant funding from Axellus A/S, AbbVie, Cambridge Weight Plan, Janssen, Merck Sharp & Dohme, Mundipharma, Novartis and Roche, and being involved in many healthcare initiatives and research that could benefit from wide uptake of this publication including Cochrane, Outcome Measures in Rheumatology, International Dermatology Outcome Measures, RADS and the Grading of Recommendations Assessment, Development and Evaluation Working Group. M.R.‐L. has received personal speakers fees from Novo Nordisk A/S. The remaining authors have no conflict of interest to declare.",,"Mathias Ried-Larsen 1 , Mette Y Johansen 1 , Christopher S MacDonald 1 2 , Katrine B Hansen 1 , Robin Christensen 3 4 , Anne-Sophie Wedell-Neergaard 1 , Nanna Skytt Pilmark 1 , Henning Langberg 2 , Allan A Vaag 5 , Bente K Pedersen 1 , Kristian Karstoft 1 6"
31189685,Risk factors for repetitive doctors consultations due to cough: a cross-sectional study in a Finnish employed population,"Heikki O Koskela 1 2, Anne M Lätti 1 2, Juha Pekkanen 3 4",BMJ Open. 2019 Jun 11;9(6):e030945. doi: 10.1136/bmjopen-2019-030945.,Koskela HO,BMJ Open,2019,2019/06/14,PMC6576114,,10.1136/bmjopen-2019-030945,https://pubmed.ncbi.nlm.nih.gov/31189685/,/31189685/,"Competing interests: HOK reports grants from Kuopion Seudun Hengityssäätiö Foundation, grants from Hengityssairauksien Tutkimussäätiö, during the conduct of the study; personal fees from Mundipharma, Orion Pharma, Oy, Eli Lilly Finland, Boehringer Ingelheim Finland as payments for giving scientific lectures in gatherings organised by medical companies, personal fees from Takeda Leiras, Boehringer Ingelheim, Mundipharma and AstraZeneca, to attend international scientific meetings, in addition to owning shares in Orion Pharma worth 22 000€, outside the submitted work. AML reports grants from Kuopion Seudun Hengityssäätiö Foundation, grants from Hengityssairauksien Tutkimussäätiö, during the conduct of the study; personal fees from Orion, Boehringer-Ingelheim, Roche to attend international scientific meetings, outside the submitted work. JP has nothing to disclose.",,"Heikki O Koskela 1 2 , Anne M Lätti 1 2 , Juha Pekkanen 3 4"
30762274,Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial,"G L Goll 1, K K Jørgensen 2, J Sexton 1, I C Olsen 1 3, N Bolstad 4, E A Haavardsholm 1 5, K E A Lundin 5 6 7, K S Tveit 8, M Lorentzen 9, I P Berset 10, B T S Fevang 11, S Kalstad 12, K Ryggen 13, D J Warren 4, R A Klaasen 4, Ø Asak 14, S Baigh 15, I M Blomgren 16, Ø Brenna 17, T J Bruun 12, K Dvergsnes 18, S O Frigstad 19, I M Hansen 20, I S H Hatten 21, G Huppertz-Hauss 22, M Henriksen 23, S S Hoie 24, J Krogh 25, I P Midtgard 26, P Mielnik 27, B Moum 5 28, G Noraberg 29, A Poyan 30, U Prestegård 31, H U Rashid 32, E K Strand 33, K Skjetne 13, K A Seeberg 34, R Torp 35, C M Ystrøm 36, C Vold 37, C C Zettel 38, K Waksvik 39, B Gulbrandsen 40, J Hagfors 41, C Mørk 42, J Jahnsen 2 5, T K Kvien 1 5",J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12.,Goll GL,J Intern Med,2019,2019/02/15,PMC6850326,,10.1111/joim.12880,https://pubmed.ncbi.nlm.nih.gov/30762274/,/30762274/,"GLG reports personal fees from AbbVie, Biogen, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, Orion Pharma, Celltrion and Boehringer Ingelheim. KKJ reports personal fees from Tillott, Intercept and Celltrion. NB reports personal fees received from Orion Pharma, Roche, Napp Pharmaceuticals, Pfizer and Takeda. ICO reports grants from Norwegian Ministry of Health and Care Services during the conduct of the study and personal fees from Pfizer. EAH reports grants from AbbVie, Pfizer, UCB, Roche and MSD. IPB reports personal fees from AbbVie, MSD, Takeda, Hospira and Ferring. KEAL reports grants from MSD and personal fees from Takeda, Orion, AbbVie, Pfizer and MSD. KST reports personal fees and nonfinancial support from AbbVie, Orion, Novartis, Janssen, Celgene, Mundipharma, Pfizer, MSD and Shire and nonfinancial support from CSL Behring. CM reports personal fees from Novartis Norge AS, LEO Pharma AS, ACO Hud Norge AS, Celgene AS, AbbVie and Galderma Nordic AB. JJ reports personal fees from MSD, AbbVie, Celltrion, Orion Pharma, Takeda, Napp Pharm, AstroPharma, Hikma and Pfizer. TKK reports grants from Norwegian Ministry of Health and Care Services during the conduct of the study and personal fees from AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck‐Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB Pharma.",,"G L Goll 1 , K K Jørgensen 2 , J Sexton 1 , I C Olsen 1 3 , N Bolstad 4 , E A Haavardsholm 1 5 , K E A Lundin 5 6 7 , K S Tveit 8 , M Lorentzen 9 , I P Berset 10 , B T S Fevang 11 , S Kalstad 12 , K Ryggen 13 , D J Warren 4 , R A Klaasen 4 , Ø Asak 14 , S Baigh 15 , I M Blomgren 16 , Ø Brenna 17 , T J Bruun 12 , K Dvergsnes 18 , S O Frigstad 19 , I M Hansen 20 , I S H Hatten 21 , G Huppertz-Hauss 22 , M Henriksen 23 , S S Hoie 24 , J Krogh 25 , I P Midtgard 26 , P Mielnik 27 , B Moum 5 28 , G Noraberg 29 , A Poyan 30 , U Prestegård 31 , H U Rashid 32 , E K Strand 33 , K Skjetne 13 , K A Seeberg 34 , R Torp 35 , C M Ystrøm 36 , C Vold 37 , C C Zettel 38 , K Waksvik 39 , B Gulbrandsen 40 , J Hagfors 41 , C Mørk 42 , J Jahnsen 2 5 , T K Kvien 1 5"
31798050,Applications of the European Parkinsons Disease Association sponsored Parkinsons Disease Composite Scale (PDCS),"Roberta Balestrino 1, Carlos Alberto Hurtado-Gonzalez 2, Fabrizio Stocchi 3, Fabiana Giada Radicati 3, K Ray Chaudhuri 4 5, Carmen Rodriguez-Blazquez 6, Pablo Martinez-Martin 6 ; PDCS European Study Group",NPJ Parkinsons Dis. 2019 Nov 27;5:26. doi: 10.1038/s41531-019-0097-1. eCollection 2019.,Balestrino R,NPJ Parkinsons Dis,2019,2019/12/05,PMC6881347,,10.1038/s41531-019-0097-1,https://pubmed.ncbi.nlm.nih.gov/31798050/,/31798050/,"Competing interestsR.B., C.A.H.G., F.S., C.R.B.: no competing interests as defined by Nature Research, or other interests that might be perceived to influence the interpretation of the article. F.G.R.: received a grant from the European Parkinson’s Disease Association for supporting her role as Coordinator in this study. K.R.C.: Advisory board: AbbVie, UCB, Sunovion, Pfizer, Jazz Pharma, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion. Honoraria for lectures: AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim Neuroderm, Sunovion, Grants (Investigator Initiated): Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial, Aacdemic grants: EU, IMI EU, Horizon 2020, Parkinsons UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC. P.M.M.: Honoraria: from National School of Public Health (ISCIII) and Editorial Viguera for lecturing in courses; International Parkinson and Movement Disorder Society for management of the Program on Rating Scales; Abbvie, Zambon, and HM Hospitales de Madrid for advice in clinical-epidemiological studies. License fee payments for the King’s Parkinson’s Disease Pain scale.",,"Roberta Balestrino 1 , Carlos Alberto Hurtado-Gonzalez 2 , Fabrizio Stocchi 3 , Fabiana Giada Radicati 3 , K Ray Chaudhuri 4 5 , Carmen Rodriguez-Blazquez 6 , Pablo Martinez-Martin 6 ; PDCS European Study Group"
31470856,Evaluation of a shared decision-making communication skills training for physicians treating patients with asthma: a mixed methods study using simulated patients,"Evamaria Müller 1, Alice Diesing 2, Anke Rosahl 2, Isabelle Scholl 2, Martin Härter 2, Angela Buchholz 2",BMC Health Serv Res. 2019 Aug 30;19(1):612. doi: 10.1186/s12913-019-4445-y.,Müller E,BMC Health Serv Res,2019,2019/09/01,PMC6716840,,10.1186/s12913-019-4445-y,https://pubmed.ncbi.nlm.nih.gov/31470856/,/31470856/,"The study group received funding from Mundipharma GmbH, a pharmaceutical company, to carry out the study, which may be considered a potential conflict of interest. Mundipharma GmbH was not involved in the design of the study, data collection, data analysis or interpretation, or in the publication of the study results. Mundipharma GmbH provided financial support, recruited training participants, and organized the training settings. AB and MH were heads of the research project. EM AR and AD received funding. IS conducted one training in the project and received travel compensation.",Grants and funding not applicable/Mundipharma GmbH,"Evamaria Müller 1 , Alice Diesing 2 , Anke Rosahl 2 , Isabelle Scholl 2 , Martin Härter 2 , Angela Buchholz 2"
30675511,PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?,"Noam Pondé 1, Richard D Gelber 2, Martine Piccart 1",NPJ Breast Cancer. 2019 Jan 4;5:1. doi: 10.1038/s41523-018-0098-y. eCollection 2019.,Pondé N,NPJ Breast Cancer,2019,2019/01/25,PMC6320365,,10.1038/s41523-018-0098-y,https://pubmed.ncbi.nlm.nih.gov/30675511/,/30675511/,"N.P. has received travelling support from Roche/Genentech, Janssen-Cilag and Mundipharma, as well as speaker’s fees from Mundipharma. The Institute he works for has received AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche-Genentech, Synthon, Radius and Servier. R.G. reports that during the past 3 years, his institutions have received financial support to cover his salary from the following for-profit entities: Roche, AstraZeneca, Merck, Pfizer, Celgene, Ferring, Ipsen, Novartis, GlaxoSmithKline. M.P. is a board member of Radius. She has received honoraria as a consultant from AstraZeneca, Lilly, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Camel-IDS, Crescendo Biologics, Periphagen, Huya, Debiopharm, PharmaMar, G1 Therapeutics, Menarini, Seattle Genetics, Immunomedics, and Oncolytics. Her institute has received research grants from AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche-Genentech, Synthon, Radius and Servier.",,"Noam Pondé 1 , Richard D Gelber 2 , Martine Piccart 1"
31573746,"Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial","Francisco-Javier Peñalver 1, José-Antonio Márquez 2, Soledad Durán 3, Pilar Giraldo 4, Alejandro Martín 5, Carlos Montalbán 6, Juan-Manuel Sancho 7, María-José Ramírez 8, María-José Terol 9, Francisco-Javier Capote 10, Antonio Gutiérrez 11, Blanca Sánchez 12, Andrés López 13, Antonio Salar 12, Gil Rodríguez-Caravaca 14, Miguel Canales 15, María-Dolores Caballero 5 ; GELTAMO (The Spanish Lymphoma Cooperative Group)",Cancer Med. 2019 Nov;8(16):6955-6966. doi: 10.1002/cam4.2555. Epub 2019 Oct 1.,Peñalver FJ,Cancer Med,2019,2019/10/02,PMC6853826,,10.1002/cam4.2555,https://pubmed.ncbi.nlm.nih.gov/31573746/,/31573746/,The authors declare no potential conflict of interest.,Grants and funding Roche Pharma Spain/International Mundipharma Spain/International,"Francisco-Javier Peñalver 1 , José-Antonio Márquez 2 , Soledad Durán 3 , Pilar Giraldo 4 , Alejandro Martín 5 , Carlos Montalbán 6 , Juan-Manuel Sancho 7 , María-José Ramírez 8 , María-José Terol 9 , Francisco-Javier Capote 10 , Antonio Gutiérrez 11 , Blanca Sánchez 12 , Andrés López 13 , Antonio Salar 12 , Gil Rodríguez-Caravaca 14 , Miguel Canales 15 , María-Dolores Caballero 5 ; GELTAMO (The Spanish Lymphoma Cooperative Group)"
31389157,Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial,"Miriam J Johnson 1, Sarah Cockayne 2, David C Currow 1 3, Kerry Bell 2, Kate Hicks 2, Caroline Fairhurst 2, Rhian Gabe 4, David Torgerson 2, Laura Jefferson 2, Stephen Oxberry 5, Justin Ghosh 6, Karen J Hogg 7, Jeremy Murphy 8, Victoria Allgar 9, John G F Cleland 10, Andrew L Clark 11",ESC Heart Fail. 2019 Dec;6(6):1149-1160. doi: 10.1002/ehf2.12498. Epub 2019 Aug 6.,Johnson MJ,ESC Heart Fail,2019,2019/08/08,PMC6989293,,10.1002/ehf2.12498,https://pubmed.ncbi.nlm.nih.gov/31389157/,/31389157/,"D.C.C. has received an unrestricted research grant from Mundipharma, is an unpaid member of an advisory board for Helsinn Pharmaceuticals, and has consulted Mayne Pharma and received intellectual property payments from them. M.J.J. has received consulting payments from Mayne Pharma. No authors have any conflicting interests with the content of this manuscript.",Grants and funding CS/13/2/30584/BHF_/British Heart Foundation/United Kingdom,"Miriam J Johnson 1 , Sarah Cockayne 2 , David C Currow 1 3 , Kerry Bell 2 , Kate Hicks 2 , Caroline Fairhurst 2 , Rhian Gabe 4 , David Torgerson 2 , Laura Jefferson 2 , Stephen Oxberry 5 , Justin Ghosh 6 , Karen J Hogg 7 , Jeremy Murphy 8 , Victoria Allgar 9 , John G F Cleland 10 , Andrew L Clark 11"
31708980,Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair(®) In the Management of Asthma) study,"Delia Colombo 1, Emanuela Zagni 1, Fabio Ferri 2, Giorgio Walter Canonica 3 ; PROXIMA study centers",Allergy Asthma Clin Immunol. 2019 Nov 6;15:65. doi: 10.1186/s13223-019-0380-z. eCollection 2019.,Colombo D,Allergy Asthma Clin Immunol,2019,2019/11/12,PMC6833238,,10.1186/s13223-019-0380-z,https://pubmed.ncbi.nlm.nih.gov/31708980/,/31708980/,"Competing interestsCD is a part-time employee of Novartis Farma Italy and received grants from Allergan and Aventis. ZE is an employee of Novartis Farma Italy. FF is an employee of Medineos Observational Research (Modena, Italy). GWC received research grants as well as lecture or advisory board fees from A. Menarini, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Mundipharma, Novartis, Sanofi-Aventis, Teva.",,"Delia Colombo 1 , Emanuela Zagni 1 , Fabio Ferri 2 , Giorgio Walter Canonica 3 ; PROXIMA study centers"
31391479,Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks,"Marie Spies 1, Manfred Klöbl 1, Anna Höflich 1, Allan Hummer 2, Thomas Vanicek 1, Paul Michenthaler 1, Georg S Kranz 1 3, Andreas Hahn 1, Dietmar Winkler 1, Christian Windischberger 2, Siegfried Kasper 1, Rupert Lanzenberger 4",Sci Rep. 2019 Aug 7;9(1):11484. doi: 10.1038/s41598-019-46702-x.,Spies M,Sci Rep,2019,2019/08/09,PMC6685940,,10.1038/s41598-019-46702-x,https://pubmed.ncbi.nlm.nih.gov/31391479/,/31391479/,"Marie Spies has received travel grants from Janssen-Cilag Pharma GmbH, Eli Lilly, AOP Orphan Pharamceuticals A.G., and Austroplant, speaker honoraria from Janssen-Cilag Pharma GmbH and Austroplant and workshop participation from Eli Lilly. Thomas Vanicek has received travel grants and compensation for workshop participation from Pfizer and Eli Lilly and speaker honoraria from Shire. Georg Kranz has received travel grants from Roche, AOP Orphan Pharmaceuticals A.G. and Pfizer. Dietmar Winkler received lecture fees from Angelini, Lundbeck and Pfizer. Siegfried Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals A.G., Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Rupert Lanzenberger received travel grants and/or conference speaker honoraria from Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, AOP Orphan Pharmaceuticals A.G., Janssen-Cilag Pharma GmbH, and Roche Austria GmbH. All other authors declare no conflict of interest.",Grants and funding KLI 516/FWF_/Austrian Science Fund FWF/Austria,"Marie Spies 1 , Manfred Klöbl 1 , Anna Höflich 1 , Allan Hummer 2 , Thomas Vanicek 1 , Paul Michenthaler 1 , Georg S Kranz 1 3 , Andreas Hahn 1 , Dietmar Winkler 1 , Christian Windischberger 2 , Siegfried Kasper 1 , Rupert Lanzenberger 4"
31412372,Benzodiazepines and Z-Drugs - Analyses of Ambulatory Prescriptions from 2006 to 2015,"Uwe Verthein 1, Sven Buth 1, Rüdiger Holzbach 1 2, Eike Neumann-Runde 1, Marcus-S Martens 1",Psychiatr Prax. 2019 Oct;46(7):399-405. doi: 10.1055/a-0961-2371. Epub 2019 Aug 14.,Verthein U,Psychiatr Prax,2019,2019/08/15,,,10.1055/a-0961-2371,https://pubmed.ncbi.nlm.nih.gov/31412372/,/31412372/,Uwe Verthein erhielt innerhalb der letzten 3 Jahre Vortrags- und Beratungshonorar von Mundipharma GmbH sowie Reisekostenerstattungen von Mundipharma GmbH und CAMURUS GmbH. Die anderen Autoren hatten keine Verbindungen i. o. g. Sinne.,,"Uwe Verthein 1 , Sven Buth 1 , Rüdiger Holzbach 1 2 , Eike Neumann-Runde 1 , Marcus-S Martens 1"
31752937,Respective contribution of intensive care unit-acquired limb muscle and severe diaphragm weakness on weaning outcome and mortality: a post hoc analysis of two cohorts,"Martin Dres 1 2, Boris Jung 3 4, Nicolas Molinari 5, Federico Manna 5, Bruno-Pierre Dubé 1 2, Gerald Chanques 3 6, Thomas Similowski 1 2, Samir Jaber 3 6, Alexandre Demoule 7 8 9",Crit Care. 2019 Nov 21;23(1):370. doi: 10.1186/s13054-019-2650-z.,Dres M,Crit Care,2019,2019/11/23,PMC6873450,,10.1186/s13054-019-2650-z,https://pubmed.ncbi.nlm.nih.gov/31752937/,/31752937/,"Martin Dres reports personal fees from Lungpacer, outside the submitted work. Boris Jung declares no competing interests. Nicolas Molinari declares no competing interests. Federico Manna declares no competing interests. Gerald Chanques reports personal fees from Aspen medical and personal fees from Orion pharma, during the conduct of the study. Samir Jaber declares no competing interests. Thomas Similowski reports receiving personal fees from Almirall France, personal fees from AstraZeneca France, corporate personal fees from Boehringer Ingelheim France, personal fees from GlaxoSmithKline France, personal fees from Invacare, personal fees from Mundipharma, personal fees and nonfinancial support from Novartis France, personal fees from Pfizer France, grants and personal fees from Pierre Fabre Médicaments, personal fees from Takeda, personal fees from Teva Pharma, and personal fees from Lungpacer Medical Inc., all outside the submitted work. Alexandre Demoule reports personal fees from Medtronic; grants, personal fees, and non-financial support from Philips; personal fees from Baxter; personal fees from Hamilton; personal fees and non-financial support from Fisher & Paykel; grants from French Ministry of Health; personal fees from Getinge; grants and personal fees from Respinor; and grants and non-financial support from Lungpacer. Brunop-Pierre Dubé received personal fees from Grifols, Boehringer Ingelheim and Roche, and has signed clinical research contracts with Sanofi, Roche and Boehringer Ingelheim.",Grants and funding 2005 Programme Hospitalier de Recherche Clinique (PHRC)/French Ministry of Health/International bourse de mobilité 2015/Société de Réanimation de Langue Française/International Short Term Fellowship program/European Respiratory Society/International 2015 Bernhard Dräger Award/European Society of Intensive Care Medicine/International FDM 20150734498/Fondation pour la Recherche Médicale/International Globalink Sorbonne Universités/Mitacs/International investissement davenir ANR-10-AIHU 06/French Government./International Show all 7 grants,"Martin Dres 1 2 , Boris Jung 3 4 , Nicolas Molinari 5 , Federico Manna 5 , Bruno-Pierre Dubé 1 2 , Gerald Chanques 3 6 , Thomas Similowski 1 2 , Samir Jaber 3 6 , Alexandre Demoule 7 8 9"
31467044,Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study,"Björn Pasternak 1 2, Peter Ueda 3, Björn Eliasson 4, Ann-Marie Svensson 4 5, Stefan Franzén 5 6, Soffia Gudbjörnsdottir 4 5, Kristian Hveem 7 8, Christian Jonasson 7 8, Viktor Wintzell 3, Mads Melbye 2 9 10, Henrik Svanström 3 2",BMJ. 2019 Aug 29;366:l4772. doi: 10.1136/bmj.l4772.,Pasternak B,BMJ,2019,2019/08/31,PMC6713906,,10.1136/bmj.l4772,https://pubmed.ncbi.nlm.nih.gov/31467044/,/31467044/,"Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: support from the Swedish Heart-Lung Foundation, Novo Nordisk Foundation, and Swedish Society for Medical Research for the submitted work; BE has received personal fees for lectures and serving on advisory boards from Amgen, AstraZeneca, Boerhringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Mundipharma, Navamedic, Novo Nordisk, and RLS Global outside the submitted work, and research grants from Sanofi outside the submitted work; CJ has received personal fees for research consultancy work from Pfizer and Bayer outside of the submitted work; HS has received consulting fees from Celgene and is employed by IQVIA outside of the submitted work; SG has received lecture fees and research grants from AstraZeneca, Boerhringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Novo Nordisk, and Sanofi outside of the submitted work; the other authors did not have any potential competing interests to report.",,"Björn Pasternak 1 2 , Peter Ueda 3 , Björn Eliasson 4 , Ann-Marie Svensson 4 5 , Stefan Franzén 5 6 , Soffia Gudbjörnsdottir 4 5 , Kristian Hveem 7 8 , Christian Jonasson 7 8 , Viktor Wintzell 3 , Mads Melbye 2 9 10 , Henrik Svanström 3 2"
31777575,Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness,"Daisy J A Janssen 1 2, Marieke H J van den Beuken-van Everdingen 2, Cornelia A Verberkt 3, Jacques P H M Creemers 4, Emiel F M Wouters 1 5",Breathe (Sheff). 2019 Sep;15(3):e122-e125. doi: 10.1183/20734735.0183-2019.,Janssen DJA,Breathe (Sheff),2019,2019/11/29,PMC6876137,,10.1183/20734735.0183-2019,https://pubmed.ncbi.nlm.nih.gov/31777575/,/31777575/,"Conflict of interest: D.J.A. Janssen reports personal fees for lectures from Boehringer Ingelheim, Novartis, AstraZeneca and GlaxoSmithKline, outside the submitted work. Conflict of interest: M.H.J. van den Beuken-van Everdingen reports personal fees for lectures from Takeda and Mundipharma, outside the submitted work. Conflict of interest: C.A. Verberkt has nothing to disclose. Conflict of interest: J.P.H.M. Creemers has nothing to disclose. Conflict of interest: E.F.M. Wouters reports personal fees for board membership from Nycomed and Boehringer Ingelheim, personal fees for lectures from AstraZeneca, GlaxoSmithKline, Novartis and Chiesi, and grants from AstraZeneca and GlaxoSmithKline, outside the submitted work.",,"Daisy J A Janssen 1 2 , Marieke H J van den Beuken-van Everdingen 2 , Cornelia A Verberkt 3 , Jacques P H M Creemers 4 , Emiel F M Wouters 1 5"
31240472,Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma,"Ivan Spicka 1, Enrique M Ocio 2, Heather E Oakervee 3, Richard Greil 4, Raymond H Banh 5, Shang-Yi Huang 6, James M DRozario 7, Meletios A Dimopoulos 8, Sara Martínez 9, Sonia Extremera 9, Carmen Kahatt 9, Vicente Alfaro 9, Angelo M Carella 10, Nathalie Meuleman 11, Roman Hájek 12, Argiris Symeonidis 13, Chang-Ki Min 14, Paul Cannell 15, Heinz Ludwig 16, Pieter Sonneveld 17, María Victoria Mateos 18 19",Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25.,Spicka I,Ann Hematol,2019,2019/06/27,PMC6700046,,10.1007/s00277-019-03739-2,https://pubmed.ncbi.nlm.nih.gov/31240472/,/31240472/,"IS has honoraria (Amgen, Takeda, Janssen-Cilag, BMS, Celgene); consulting or advisory role (Amgen, Takeda, Janssen-Cilag, Celgene); speakers’ bureau (Amgen, BMS Celgene, Jansen-Cilag); and travel, accommodation, or expenses (Celgene, Amgen, Jansen-Cilag) to disclose. EMO has honoraria (Novartis, Takeda, Celgene, Amgen, BMS, Janssen); consulting or advisory role (Novartis, Takeda, Celgene, AbbVie, Pharma Mar, Seattle Genetics, Amgen); speakers’ bureau (Takeda); research funding to his institution (Celgene, Amgen, Array, Mundipharma, Sanofi, MSD); patents, royalties, or other intellectual properties (Pharma Mar, Mundipharma, IDP); and travel, accommodation, or expenses (Celgene, Janssen, Takeda) to disclose. HEO has a leadership role (Vertex, Astenas); stock ownership (Vertex); research funding (BMS, Pharma Mar); and travel, accommodation, or expenses (Novartis) to disclose. RG has honoraria (Celgene, Roche, Merck, Takeda, Astra Zeneca, Novartis, Amgen, BMS, MSD, Sandoz); consulting or advisory role (Celgene, Novartis, Roche, BMS, Takeda, AbbVie, Astra Zeneca, Janssen); research funding (Celgene, Roche, Merck, Takeda, Astra Zeneca, Novartis, Amgen, BMS, MSD, Sandoz); and travel, accommodation, or expenses (Roche, Amgen, Janssen, Astra Zeneca) to disclose. RHB has a consulting or advisory role (Specialised Therapeutics, Pharma Mar, BMS); research funding (Acerta, Pharma Mar, Celgene, Gilead, Novotech, Pharmacyclics, Roche); and travel, accommodation, or expenses (Roche, Janssen) to disclose. JMDR has honoraria (Alexion, Roche); consulting or advisory role (Alexion, Roche); and travel, accommodation, or expenses (Pharma Mar, Alexion) to disclose. Meletios A. Dimopoulos has honoraria (Amgen, Takeda, Janssen, Celgene, BMS) to disclose. SM, SE, CK, and VA are employees of Pharma Mar S.A. SE, CK, and VA have stock ownerships (Pharma Mar). RH has honoraria (Amgen, BMS, Takeda, Celgene, Janssen); consulting or advisory role (Amgen, BMS, Takeda, Celgene, Janssen); research funding to his institution (Takeda, Novartis, Amgen, Janssen, Celgene); travel, accommodation, or expenses (Amgen, BMS, Celgene, Janssen, Takeda) to disclose. AS has honoraria (AbbVie, Amgen, Celgene, Janssen, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda, WinMedica); consulting or advisory role (AbbVie, Amgen, Celgene, Janssen, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda); speakers’ bureau (AbbVie, Amgen, Celgene, Janssen, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda, WinMedica); research funding to his institution (AbbVie, Actelion, Alexion, Amgen, Astellas, Bayer, Bristol, Celgene, Demo/ApoPharma, Enorasis, Faran, Gilead, Janssen, MSD, Novartis, Pharmaten, Pfizer, Rafarm, Roche, Sanofi, Takeda, Teva, Vianex, WinMedica); and travel, accommodation, or expenses (AbbVie, Amgen, Celgene, Janssen, Gilead, Roche, Sanofi, Takeda) to disclose. PC has travel, accommodations, or expenses (Amgen, Roche, BMS—conference attendance sponsorship) to disclose. HL has a consulting or advisory role (Pharma Mar); speakers’ bureau (Takeda, Amgen, Celgene, Janssen, BMS); and research funding (Takeda, Amgen) to disclose. PS has honoraria (Janssen, Celgene, Amgen, Takeda); expert testimony (Pharma Mar); and research funding (Janssen, Celgene, Amgen, Takeda) to disclose. MVM has honoraria to disclose from Pharma Mar because of the involvement in advisory boards. All other authors declare that they have no competing interests.",,"Ivan Spicka 1 , Enrique M Ocio 2 , Heather E Oakervee 3 , Richard Greil 4 , Raymond H Banh 5 , Shang-Yi Huang 6 , James M DRozario 7 , Meletios A Dimopoulos 8 , Sara Martínez 9 , Sonia Extremera 9 , Carmen Kahatt 9 , Vicente Alfaro 9 , Angelo M Carella 10 , Nathalie Meuleman 11 , Roman Hájek 12 , Argiris Symeonidis 13 , Chang-Ki Min 14 , Paul Cannell 15 , Heinz Ludwig 16 , Pieter Sonneveld 17 , María Victoria Mateos 18 19"
31745601,Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia,"Gilles Salles 1, Emmanuel Bachy 2, Lukas Smolej 3, Martin Simkovic 3, Lucile Baseggio 2, Anna Panovska 4, Hervé Besson 5, Nollaig Healy 6, Jamie Garside 7, Wafae Iraqi 8, Joris Diels 9, Corinna Pick-Lauer 10, Martin Spacek 11, Renata Urbanova 12, Daniel Lysak 13, Ruben Hermans 14, Jessica Lundbom 14, Evelyne Callet-Bauchu 2, Michael Doubek 4 15",Ann Hematol. 2019 Dec;98(12):2749-2760. doi: 10.1007/s00277-019-03830-8. Epub 2019 Nov 19.,Salles G,Ann Hematol,2019,2019/11/21,PMC6900267,,10.1007/s00277-019-03830-8,https://pubmed.ncbi.nlm.nih.gov/31745601/,/31745601/,"GS received consultancy/honoraria/research funding from Roche/Genentech; consultancy/honoraria from Janssen, Celgene, Novartis, and Amgen; honoraria/research funding from Gilead; honoraria from Mundipharma; EB received consultancy/honoraria/research funding from Roche/Genentech; research funding from Mundipharma; consultancy/honoraria from Sandoz; honoraria from Amgen; LS received consultancy/honoraria/travel grants from Roche/Genentech, Janssen, Gilead, and AbbVie; MS received consultancy/honoraria/travel grants from Roche/Genentech, Janssen, and Gilead; AP, LB, and EC-B declare no competing financial interests; MS received consultancy/honoraria from AbbVie, Gilead, Janssen, and Roche; RU and DL received consultancy/honoraria from Gilead, Janssen, and Roche; HB, RH and JL are employees of IQVIA Real-World Insight Solutions; MD received consultancy/research funding from AbbVie; consultancy/honoraria from Gilead, Janssen, and Roche; NH, JG, WI, and CP-L are employees of Janssen Pharmaceutica NV; HB is a previous employee of Janssen Pharmaceutica NV; JD is an employee and equity owner of Janssen Pharmaceutica NV.",,"Gilles Salles 1 , Emmanuel Bachy 2 , Lukas Smolej 3 , Martin Simkovic 3 , Lucile Baseggio 2 , Anna Panovska 4 , Hervé Besson 5 , Nollaig Healy 6 , Jamie Garside 7 , Wafae Iraqi 8 , Joris Diels 9 , Corinna Pick-Lauer 10 , Martin Spacek 11 , Renata Urbanova 12 , Daniel Lysak 13 , Ruben Hermans 14 , Jessica Lundbom 14 , Evelyne Callet-Bauchu 2 , Michael Doubek 4 15"
31299936,Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients,"Laurie Pahus 1 2 3, Pierre-Régis Burgel 4 5, Nicolas Roche 4 5, Jean-Louis Paillasseur 6, Pascal Chanez 7 8 ; Initiatives BPCO scientific committee",BMC Pulm Med. 2019 Jul 12;19(1):127. doi: 10.1186/s12890-019-0882-y.,Pahus L,BMC Pulm Med,2019,2019/07/14,PMC6625055,,10.1186/s12890-019-0882-y,https://pubmed.ncbi.nlm.nih.gov/31299936/,/31299936/,"LP has no conflicts of interest to report. PRB reports personal fees from Astra Zeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GSK, personal fees from Novartis, personal fees from TEVA, personal fees from Vertex, outside the submitted work. NR reports grants and personal fees from Boehringer Ingelheim, Novartis, Pfizer and personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Cipla, Sanofi, Sandoz, 3 M, Zambon outside the submitted work. JLP has no conflicts of interest to report. PC, as an advisory board member, consultant or lecturer, has previously received honoraria or grants from Boehringer Ingeheim, Almirall, Centocor, GSK, MSD, Astra Zeneca, Novartis, Teva, Chiesi, Shering Plough and Amu. None of the latter participated in or had any influence over the present analysis or manuscript.",Grants and funding NA/Boehringer Ingelheim NA/Pfizer,"Laurie Pahus 1 2 3 , Pierre-Régis Burgel 4 5 , Nicolas Roche 4 5 , Jean-Louis Paillasseur 6 , Pascal Chanez 7 8 ; Initiatives BPCO scientific committee"
30865282,"Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder: Findings From the World Mental Health Surveys","Louisa Degenhardt 1, Chrianna Bharat 1, Meyer D Glantz 2, Nancy A Sampson 3, Ali Al-Hamzawi 4, Jordi Alonso 5 6 7, Laura H Andrade 8, Brendan Bunting 9, Alfredo Cia 10, Giovanni de Girolamo 11, Peter De Jonge 12 13, Koen Demyttenaere 14, Oye Gureje 15, Josep Maria Haro 16, Meredith G Harris 17 18, Yanling He 19, Hristo Hinkov 20, Aimee Nasser Karam 21, Elie G Karam 22 23 21, Andrzej Kiejna 24 25, Viviane Kovess-Masfety 26, Victor Lasebikan 27, Sing Lee 28, Daphna Levinson 29, Maria Elena Medina-Mora 30, Zeina Mneimneh 31, Fernando Navarro-Mateu 32 33 34, Marina Piazza 35, José Posada-Villa 36, Kate Scott 37, Dan J Stein 38 39, Hisateru Tachimori 40, Nathan Tintle 41, Yolanda Torres 42, Ronald C Kessler 3 ; WHO World Mental Health Survey Collaborators",JAMA Psychiatry. 2019 Jul 1;76(7):708-720. doi: 10.1001/jamapsychiatry.2019.0163.,Degenhardt L,JAMA Psychiatry,2019,2019/03/14,PMC6583659,NIHMS1037297,10.1001/jamapsychiatry.2019.0163,https://pubmed.ncbi.nlm.nih.gov/30865282/,/30865282/,"Conflict of Interest Disclosures: Dr Degenhardt reports receiving investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma, and Seqirus. Dr Kessler reports receiving support for his epidemiological studies from Sanofi Aventis; serving as a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, and Takeda; serving on an advisory board for the Johnson & Johnson Services Inc Lake Nona Life Project; and being a coowner of DataStat Inc, a market research firm that carries out healthcare research. Dr Demyttenaere reports having served on advisory boards for Boehringer Ingelheim, Eli Lilly, Lundbeck, Johnson & Johnson, Livanova, and Servier, and receiving research grants from Eli Lilly, Fonds Gavoor Geluk, and Fonds voor Wetenschappelijk Onderzoek Vlaanderen. Dr Stein has received research grants and/or consultancy honoraria from AMBRF/Foundation for Alcohol Research, Biocodex, Cipla, Lundbeck, National Responsible Gambling Foundation, Novartis, Servier, and Sun. Dr Tachimori reports grants from the Japan Agency for Medical Research and Development and the Ministry of Health, Labour and Welfare, Japan, during the conduct of the study. No other disclosures were reported.",Grants and funding R01 DA044170/DA/NIDA NIH HHS/United States R01 MH070884/MH/NIMH NIH HHS/United States R13 MH066849/MH/NIMH NIH HHS/United States R01 MH069864/MH/NIMH NIH HHS/United States R01 DA016558/DA/NIDA NIH HHS/United States R03 TW006481/TW/FIC NIH HHS/United States R01 MH059575/MH/NIMH NIH HHS/United States Show all 7 grants,"Louisa Degenhardt 1 , Chrianna Bharat 1 , Meyer D Glantz 2 , Nancy A Sampson 3 , Ali Al-Hamzawi 4 , Jordi Alonso 5 6 7 , Laura H Andrade 8 , Brendan Bunting 9 , Alfredo Cia 10 , Giovanni de Girolamo 11 , Peter De Jonge 12 13 , Koen Demyttenaere 14 , Oye Gureje 15 , Josep Maria Haro 16 , Meredith G Harris 17 18 , Yanling He 19 , Hristo Hinkov 20 , Aimee Nasser Karam 21 , Elie G Karam 22 23 21 , Andrzej Kiejna 24 25 , Viviane Kovess-Masfety 26 , Victor Lasebikan 27 , Sing Lee 28 , Daphna Levinson 29 , Maria Elena Medina-Mora 30 , Zeina Mneimneh 31 , Fernando Navarro-Mateu 32 33 34 , Marina Piazza 35 , José Posada-Villa 36 , Kate Scott 37 , Dan J Stein 38 39 , Hisateru Tachimori 40 , Nathan Tintle 41 , Yolanda Torres 42 , Ronald C Kessler 3 ; WHO World Mental Health Survey Collaborators"
31190969,Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry,"Michael A Ueberall 1, Ute Essner 2, Gerhard Hh Mueller-Schwefe 3",J Pain Res. 2019 May 20;12:1577-1604. doi: 10.2147/JPR.S192174. eCollection 2019.,Ueberall MA,J Pain Res,2019,2019/06/14,PMC6535492,,10.2147/JPR.S192174,https://pubmed.ncbi.nlm.nih.gov/31190969/,/31190969/,"MAU received financial support and/or expenses in form of research money, consultancy fees, and/or remunerations for lecture activities from Almirall, Archimedes, Aristo pharma, Bene-Arzneimittel, Grünenthal, HAPA Medical, Janssen-Cilag, Kyowa Kirin, Lilly, Menarini, MSD, Mucos, Mundipharma, Omnia Med, Pfizer, PharmAllergan, ProStrakan, Servier, Shionogi, TEVA, and Tilray. UE received financial support and/or expenses in form of consultancy fees from Roche, Almirall, MedDay, and Granzer Regulatory Consulting & Services. GHHM-S received financial support and/or expenses in the form of research money, consultancy fees and/or remunerations for lecture activities from Allergan Ltd., Almirall, Grünenthal, Mundipharma, Pfizer, PharmAllergan, ProStrakan, and TEVA. The authors report no other conflicts of interest in this work.",,"Michael A Ueberall 1 , Ute Essner 2 , Gerhard Hh Mueller-Schwefe 3"
31256021,Thresholds for clinically important deterioration versus improvement in COPD health status: results from a randomised controlled trial in pulmonary rehabilitation and an observational study during routine clinical practice,"Harma Johanna Alma 1 2, Corina de Jong 1 2, Danijel Jelusic 3, Michael Wittmann 3, Michael Schuler 4, Robbert Sanderman 5 6, Konrad Schultz 3, Janwillem Kocks 1 2, Thys van der Molen 1 2",BMJ Open. 2019 Jun 28;9(6):e025776. doi: 10.1136/bmjopen-2018-025776.,Alma HJ,BMJ Open,2019,2019/07/01,PMC6609082,,10.1136/bmjopen-2018-025776,https://pubmed.ncbi.nlm.nih.gov/31256021/,/31256021/,"Competing interests: HJA, CdJ, DJ, MW, MS and RS have nothing to disclose. JK reports personal fees from Novartis; research grants and personal fees from Boehringer Ingelheim; research grants and personal fees from GlaxoSmithKline (GSK); research grants from Stichting Zorgdraad; personal fees from the International Primary Care Respiratory Group (IPCRG); personal fees from Springer Media; and travel arrangements from Chiesi, GSK and IPCRG, all outside the submitted work. KS received lecture fees from Boehringer, AstraZeneca, Berlin-Chemie, Novartis, Chiesi, Mundipharma, Takeda, GSK and MSD, all outside the submitted work. TvdM reports personal reimbursements from GSK, TEVA, AstraZeneca and Boehringer Ingelheim, and study grants from AstraZeneca and GSK. After this study was terminated, he became an employee of GSK. None of these stated conflicts of interest are linked to the current manuscript. TvdM developed the Clinical COPD Questionnaire (CCQ) and holds the copyright.",,"Harma Johanna Alma 1 2 , Corina de Jong 1 2 , Danijel Jelusic 3 , Michael Wittmann 3 , Michael Schuler 4 , Robbert Sanderman 5 6 , Konrad Schultz 3 , Janwillem Kocks 1 2 , Thys van der Molen 1 2"
31824182,Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain,"Maria Cevey 1, Jaime Calvo-Alén 2, Carlos Crespo 3, Angel Robles-Marhuenda 4, Lee Smolen 5, Josefina Cortés-Hernández 6",Clinicoecon Outcomes Res. 2019 Dec 5;11:757-765. doi: 10.2147/CEOR.S218464. eCollection 2019.,Cevey M,Clinicoecon Outcomes Res,2019,2019/12/12,PMC6901000,,10.2147/CEOR.S218464,https://pubmed.ncbi.nlm.nih.gov/31824182/,/31824182/,"This study was funded by GlaxoSmithKline (Study code: HO-17-18309). M Cevey is an employee of GlaxoSmithKline. Jaime Calvo, Carlos Crespo, Angel Robles, Lee Smolen and Josefina Cortés received consulting fees from GlaxoSmithKline during their participation in the study. Dr. Crespo Palomo reports personal fees from GlaxoSmithKline, during the conduct of the study; grants and personal fees from advising outside the submitted work; and he received grants or personal fees from Novartis, Pfizer, Abbvie, Gebro, Takeda, Shire, Mundipharma, Almirall, Boston Scientific, Dexcom, Hospital Clinic of Barcelona, Ferrer, Daichi, Boehringer, Gilead, IESE, Sanofi, Roche, Roche diagnostic, Vifor, EuroQoL, Angellini and Medtronic. Lee J Smolen over the course of the past 36 months Medical Decision Modeling has received financial remuneration from GlaxoSmithKline plc (GSK) for consultant services related to pharmacoeconomic investigations regarding the use of belimumab in the treatment of system lupus erythematosus (SLE). The authors report no other conflicts of interest in this work.",,"Maria Cevey 1 , Jaime Calvo-Alén 2 , Carlos Crespo 3 , Angel Robles-Marhuenda 4 , Lee Smolen 5 , Josefina Cortés-Hernández 6"
31233395,Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohns disease: the LIR!C Trial,"E Joline de Groof # 1 2, Toer W Stevens # 2, Emma J Eshuis 2, Tjibbe J Gardenbroek 1, Judith E Bosmans 3, J M van Dongen 3, Bregje Mol 1, Christianne J Buskens 1, Pieter C F Stokkers 4, Ailsa Hart 5 6, Geert R DHaens 2, Willem A Bemelman # 1, Cyriel Y Ponsioen # 2 ; LIR!C study group",Gut. 2019 Oct;68(10):1774-1780. doi: 10.1136/gutjnl-2018-317539. Epub 2019 Feb 1.,de Groof EJ,Gut,2019,2019/06/25,,,10.1136/gutjnl-2018-317539,https://pubmed.ncbi.nlm.nih.gov/31233395/,/31233395/,"Competing interests: EJdG, TS, JEB, HvD, EJE, TJG, BM, CB, PCFS and WAB declare no conflict of interest. CYP declares a grant from Takeda, Dr Falk Pharma and Abbvie, advisory board fees from Takeda and GSK, as well as speaker’s fees from Takeda, Abbvie, Ferring, MSD and Dr. Falk Pharma. GRAMD’H has served as advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien/Medtronics, Ferring, DrFalk Pharma, Engene, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novonordisk, Otsuka, Pfizer, Prometheus laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor and received speaker fees from Abbvie, Biogen, Ferring, Johnson and Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts and Vifor. AH declares an advisory board fee from MSD.",,"E Joline de Groof # 1 2 , Toer W Stevens # 2 , Emma J Eshuis 2 , Tjibbe J Gardenbroek 1 , Judith E Bosmans 3 , J M van Dongen 3 , Bregje Mol 1 , Christianne J Buskens 1 , Pieter C F Stokkers 4 , Ailsa Hart 5 6 , Geert R DHaens 2 , Willem A Bemelman # 1 , Cyriel Y Ponsioen # 2 ; LIR!C study group"
30978319,Comparison of the antinociceptive profiles of morphine and oxycodone in two models of inflammatory and osteoarthritic pain in rat,"Miguel M Garcia 1, Carlos Goicoechea 1, Martín Avellanal 2, Susana Traseira 3, Ma Isabel Martín 1, Eva Ma Sánchez-Robles 4",Eur J Pharmacol. 2019 Jul 5;854:109-118. doi: 10.1016/j.ejphar.2019.04.011. Epub 2019 Apr 10.,Garcia MM,Eur J Pharmacol,2019,2019/04/13,,,10.1016/j.ejphar.2019.04.011,https://pubmed.ncbi.nlm.nih.gov/30978319/,/30978319/,,,"Miguel M Garcia 1 , Carlos Goicoechea 1 , Martín Avellanal 2 , Susana Traseira 3 , Ma Isabel Martín 1 , Eva Ma Sánchez-Robles 4"
31557239,Resource consumption of multi-substance users in the emergency room: A\xa0neglected patient group,"Laurence Klenk 1, Christina von Rütte 1, Jonathan F Henssler 2, Thomas C Sauter 1 3, Wolf E Hautz 1, Aristomenis K Exadaktylos 1, Martin Müller 1 4",PLoS One. 2019 Sep 26;14(9):e0223118. doi: 10.1371/journal.pone.0223118. eCollection 2019.,Klenk L,PLoS One,2019,2019/09/27,PMC6763017,,10.1371/journal.pone.0223118,https://pubmed.ncbi.nlm.nih.gov/31557239/,/31557239/,"TCS has received research grants or lecture fees from Bayer, Boehringer Ingelheim, and Daiichi-Sankyo and the Gottfried and Julia Bangerter-Rhyner-Foundation. WEH has received speaker fees from the AO Foundation Zürich and research funding from Mundipharma Medical Basel. All other authors have nothing to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials.","Grants and funding This work was funded by the Bangerter Foundation and the Swiss Academy of Medical Sciences through the Young Talents in Clinical Research (grant TCR 14/17) to MM. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","Laurence Klenk 1 , Christina von Rütte 1 , Jonathan F Henssler 2 , Thomas C Sauter 1 3 , Wolf E Hautz 1 , Aristomenis K Exadaktylos 1 , Martin Müller 1 4"
30962875,Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force,"Nicolas Roche 1, Jonathan D Campbell 2, Jerry A Krishnan 3, Guy Brusselle 4, Alison Chisholm 5, Leif Bjermer 6, Mike Thomas 7, Eric van Ganse 8, Maarten van den Berge 9, George Christoff 10, Jennifer Quint 11, Nikolaos G Papadopoulos 12, David Price 13",Clin Transl Allergy. 2019 Mar 27;9:20. doi: 10.1186/s13601-019-0255-x. eCollection 2019.,Roche N,Clin Transl Allergy,2019,2019/04/10,PMC6436229,,10.1186/s13601-019-0255-x,https://pubmed.ncbi.nlm.nih.gov/30962875/,/30962875/,"JC discloses prior Respiratory Effectiveness Group funding related to this study, but has no other conflicts of interests associated with this paper. NP reports grants from Gerolymatos, personal fees from Hal Allergy B.V., personal fees from Novartis Pharma AG, personal fees from Menarini, personal fees from Hal Allergy B.V., personal fees from Mylan, outside the submitted work. JK has research funding from the U.S. National Institutes of Health and the U.S. Patient Centered Outcomes Research Institute paid to the University for investigator-initiated research. JB does not serve on advisory boards or have other potential conflicts of interest. GB has, within the last 5 years, received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva; he is a member of advisory boards for AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Sanofi/Regeneron and Teva. AC and GChave no conflicts of interest to declare in relation to this paper. LB has no perceived COI. MT nor any member of his close family has any shares in pharmaceutical companies. In the last 3 years he has received speaker’s honoraria for speaking at sponsored meetings or satellite symposia at conferences from the following companies marketing respiratory and allergy products: Aerocrine, GSK, Novartis. He has received honoraria for attending advisory panels with; Aerocrine, Boehringer Inglehiem, GSK, MSD, Novartis, Pfizer. He is a recent a member of the BTS SIGN Asthma guideline steering group and the NICE Asthma Diagnosis and Monitoring guideline development group. EVG reports grants and personal fees from ALK ABELLO, grants and personal fees from Bayer, grants and personal fees from BMS, grants and personal fees from GlaxoSmithKline, grants and personal fees from Merck Sharp and Dohme, personal fees from PELyon, outside the submitted work. MB reports grants from GlaxoSmithKline, TEVA, Chiesi, Genentech, outside the submitted work. JQ’sresearch group has received funding from The Health Foundation, MRC, Wellcome Trust, BLF, GSK, Insmed, AZ, Bayer and BI for other projects, none of which relate to this work. Dr Quint has received funds from AZ, GSK, Chiesi, Teva and BI for Advisory board participation or travel. DP has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. NR - Dr. Roche reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, personal fees from Teva, personal fees from GSK, personal fees from AstraZeneca, personal fees from Chiesi, personal fees from Mundipharma, personal fees from Cipla, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Sandoz, personal fees from 3 M, personal fees from Zambon, outside the submitted work. The authors declare that they have no competing interests",Grants and funding WT_/Wellcome Trust/United Kingdom,"Nicolas Roche 1 , Jonathan D Campbell 2 , Jerry A Krishnan 3 , Guy Brusselle 4 , Alison Chisholm 5 , Leif Bjermer 6 , Mike Thomas 7 , Eric van Ganse 8 , Maarten van den Berge 9 , George Christoff 10 , Jennifer Quint 11 , Nikolaos G Papadopoulos 12 , David Price 13"
31692478,Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study,"Faustine Dalon 1, Nicolas Roche 2, Manon Belhassen 1, Maëva Nolin 1, Hervé Pegliasco 3, Gaëtan Deslée 4, Bruno Housset 5, Philippe Devillier 6, Eric Van Ganse 1 7 8",Int J Chron Obstruct Pulmon Dis. 2019 Aug 20;14:1839-1854. doi: 10.2147/COPD.S214061. eCollection 2019.,Dalon F,Int J Chron Obstruct Pulmon Dis,2019,2019/11/07,PMC6708389,,10.2147/COPD.S214061,https://pubmed.ncbi.nlm.nih.gov/31692478/,/31692478/,"EVG is Scientific Advisor of PELyon, he reports personal fees from PELyon, during the conduct of the study; personal fees from PELyon, outside the submitted work. MN, FD and MB (employees of PELyon) conducted the study through sponsorship by Chiesi SAS, and were not paid for manuscript development. NR reports grants and personal fees from Boehringer Ingelheim, Novartis, Pfizer and personal fees from Teva, GSK, AstraZeneca, Mundipharma, Cipla, Sanofi, Sandoz, 3M, Zambon and Chiesi. PD has received consulting fees, honoraria for lectures and/or research funding from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Novartis during the last 3 years. He reports personal fees from Chiesi, during the conduct of the study; personal fees from Astra Zeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Sanofi, outside the submitted work. BH received honorarium from Boehringer Ingelheim, Pfizer, Novartis, Teva, GSK, AstraZeneca and Chiesi for his participation in scientific committees or conferences. He reports personal fees from Chiesi, during the conduct of the study; personal fees from GSK, personal fees from Boehringer Ingelheim, personal fees from Novartis, outside the submitted work. HP received honorarium from Boehringer Ingelheim, Novartis, Teva, GSK, AstraZeneca and Chiesi for his participation in scientific committees or conferences, is on the board for Chiesi and Novartis, and received an invitation to 2019 American Thoracic Society International Conference in Arizona, USA. GD received research funding from BTG/PneumRx and received honorarium from Boehringer Ingelheim, AstraZeneca, Chiesi, Novartis, BTG/PneumRx for his participation in scientific committees or conferences. He reports personal fees from Chiesi, during the conduct of the study; personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from BTG/PneumRx, and personal fees from Nuvaira, outside the submitted work. The authors report no other conflicts of interest in this work.",,"Faustine Dalon 1 , Nicolas Roche 2 , Manon Belhassen 1 , Maëva Nolin 1 , Hervé Pegliasco 3 , Gaëtan Deslée 4 , Bruno Housset 5 , Philippe Devillier 6 , Eric Van Ganse 1 7 8"
31174584,Spinal radiographic progression over 2\xa0years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison,"J Braun 1, H Haibel 2, M de Hooge 3, R Landewé 4, M Rudwaleit 5, T Fox 6, A Readie 7, H B Richards 6, B Porter 7, R Martin 7, D Poddubnyy 2, J Sieper 2, D van der Heijde 3",Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.,Braun J,Arthritis Res Ther,2019,2019/06/09,PMC6555995,,10.1186/s13075-019-1911-1,https://pubmed.ncbi.nlm.nih.gov/31174584/,/31174584/,"J. Braun received a grant/research support from and speaker/consultant for Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plow), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB and a consultant and speakers bureau. M. de Hooge is an employee of MdH Research. R. Landewé received a grant/research support from and a consultant/speaker for Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plow, UCB, and Wyeth and a consultant/speaker for Ablynx, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Merck and an employee of Rheumatology Consultancy BV. M. Rudwaleit is a consultant/speaker for Abbvie, BMS, Celgene, Chugai, Janssen, MSD, Novartis, Pfizer, and UCB. T. Fox, R. Martin, B. Porter, A. Readie, and H. Richards are shareholders and employees of Novartis. D. Poddubny received a grant/research support from and a consultant/speaker for Abbvie, Janssen, MSD, Novartis, and Pfizer and a speaker/consultant for Bristol-Myers Squibb and UCB. J. Sieper received a grant/research support from AbbVie, Boehringer Ingelheim, Janssen, Novartis, Merck, Lilly, Pfizer, and UCB and is a consultant/speaker for Roche and Sun. D. van der Heijde is a consultant for AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB. H. Haibel declared no competing interests.",,"J Braun 1 , H Haibel 2 , M de Hooge 3 , R Landewé 4 , M Rudwaleit 5 , T Fox 6 , A Readie 7 , H B Richards 6 , B Porter 7 , R Martin 7 , D Poddubnyy 2 , J Sieper 2 , D van der Heijde 3"
31588825,"A multicentre survey of pain management in cancer patients and physicians attending radiotherapy clinics in Shandong Province, China","Bingxu Tan 1, Baosheng Li 2, Yongheng An 3, Xuezhen Ma 4, Yuhua Jiang 5, Yipeng Song 6, Xingping Ge 7, Shengli Yuan 8, Liping Liu 9, Yan Dou 10, Yanxia Yu 1, Pu Ji 11, Xia Li 11, Yufeng Cheng 1",J Int Med Res. 2019 Nov;47(11):5711-5722. doi: 10.1177/0300060519867168. Epub 2019 Oct 6.,Tan B,J Int Med Res,2019,2019/10/08,PMC6862914,,10.1177/0300060519867168,https://pubmed.ncbi.nlm.nih.gov/31588825/,/31588825/,,,"Bingxu Tan 1 , Baosheng Li 2 , Yongheng An 3 , Xuezhen Ma 4 , Yuhua Jiang 5 , Yipeng Song 6 , Xingping Ge 7 , Shengli Yuan 8 , Liping Liu 9 , Yan Dou 10 , Yanxia Yu 1 , Pu Ji 11 , Xia Li 11 , Yufeng Cheng 1"
30985279,"Evaluation of Clinical Outcomes and Simultaneous Digital Tracking of Daily Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Protocol for the Observational VENTASTEP Study","Christian Mueller 1, Barbara Stollfuss 1, Alexander Roitenberg 1, Jonas Harder 2, Manuel J Richter 3",JMIR Res Protoc. 2019 Apr 15;8(4):e12144. doi: 10.2196/12144.,Mueller C,JMIR Res Protoc,2019,2019/04/16,PMC6487342,,10.2196/12144,https://pubmed.ncbi.nlm.nih.gov/30985279/,/30985279/,"Conflicts of Interest: JH is an employee of xbird GmbH (Berlin, Germany), which created the study app (for analysis of daily physical activity and heart rate) and the 6MWD app. Bayer selected xbird GmbH to join their accelerator program Grants4Apps in 2016. CM, AR, and BS are employees of Bayer Vital GmbH (Leverkusen, Germany), which is the local representative of the marketing authorization holder for inhaled iloprost in Europe (Bayer AG, Leverkusen, Germany). MJR has received support from United Therapeutics and Bayer Pharma AG and speaker fees from Actelion, Bayer Pharma AG, Mundipharma, Roche, and OMT.",,"Christian Mueller 1 , Barbara Stollfuss 1 , Alexander Roitenberg 1 , Jonas Harder 2 , Manuel J Richter 3"
31703609,Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor,"Jocelyn Joseph 1, Michael J Nathenson 2, Van Anh Trinh 3, Karan Malik 2, Erica Nowell 4, Kristen Carter 4, Shiao-Pei Weathers 5, George D Demetri 2, Dejka Araujo 4, Anthony P Conley 4",J Immunother Cancer. 2019 Nov 8;7(1):296. doi: 10.1186/s40425-019-0759-x.,Joseph J,J Immunother Cancer,2019,2019/11/10,PMC6842215,,10.1186/s40425-019-0759-x,https://pubmed.ncbi.nlm.nih.gov/31703609/,/31703609/,"SPW reports research support from Genentech and Mundipharma. AC receives research support from Ignyta, Iovance, Nektar, and Novartis. All other authors report no disclosures.",Grants and funding UL1 TR003167/TR/NCATS NIH HHS/United States,"Jocelyn Joseph 1 , Michael J Nathenson 2 , Van Anh Trinh 3 , Karan Malik 2 , Erica Nowell 4 , Kristen Carter 4 , Shiao-Pei Weathers 5 , George D Demetri 2 , Dejka Araujo 4 , Anthony P Conley 4"
30616614,Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study,"Nicola Dalbeth 1, Graeme Jones 2, Robert Terkeltaub 3, Dinesh Khanna 4, Maple Fung 5 6, Scott Baumgartner 6 7, Fernando Perez-Ruiz 8",Arthritis Res Ther. 2019 Jan 7;21(1):8. doi: 10.1186/s13075-018-1788-4.,Dalbeth N,Arthritis Res Ther,2019,2019/01/09,PMC6322285,,10.1186/s13075-018-1788-4,https://pubmed.ncbi.nlm.nih.gov/30616614/,/30616614/,"Institutional review boards (IRBs)/ethics committees (ECs) from each country reviewed and approved the protocol. The central IRBs/ECs were Schulman Associates Institutional Review Board, Inc., Cincinnati, OH, USA; Health and Disability Ethics Committees, Wellington, New Zealand; and Komisja Bioetyczna przy Okregowej Izbie Lekarskiej w Gdańsku, Gdańsk, Poland. The study was performed in compliance with the ethical principles of good clinical practice and according to the International Conference on Harmonisation Harmonised Tripartite Guideline. Patients provided written informed consent to participate in the extension study and had the right to withdraw at any time. Not applicable. ND has received grant support from AstraZeneca and Amgen and consulting fees for AstraZeneca, Takeda, Horizon, and Kowa. GJ has received grant support from AbbVie, Ardea, Novartis, and Auxilium and has served on advisory boards for Pfizer, Roche, Hospira, and Janssen and speaker’s bureaus for UCB, Roche, Janssen, AbbVie, Novartis, Mundipharma, Amgen, BMS, and Pfizer. RT has received a research grant from AstraZeneca that was transferred to Ironwood for continued funding and has served as consultant to Selecta, Relburn, and SOBI and on advisory boards for Horizon. DK has no conflicts to report. FPR has received grant support from the Spanish Rheumatology Foundation and Cruces Hospital Rheumatologists Association. FPR is a member of the Pharmacy Advisory Commission of the Health Department, Basque Government. FPR has served on speaker’s bureaus for AstraZeneca and Menarini and advisory boards for Amgen, AstraZeneca, Menarini, Metabolex, Novartis, Pfizer, and SOBI. MF and SB are former employees of Ardea Biosciences, Inc., a member of the AstraZeneca group. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",Grants and funding I01 BX001660/BX/BLRD VA/United States P50 AR060772/AR/NIAMS NIH HHS/United States none/Ardea Biosciences/International,"Nicola Dalbeth 1 , Graeme Jones 2 , Robert Terkeltaub 3 , Dinesh Khanna 4 , Maple Fung 5 6 , Scott Baumgartner 6 7 , Fernando Perez-Ruiz 8"
30850381,Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial,"Andrew D Zelenetz 1, Gilles Salles 2 3, Kylie D Mason 4, Carla Casulo 5, Steven Le Gouill 6, Laurie H Sehn 7, Herve Tilly 8, Guillaume Cartron 9, Martine E D Chamuleau 10, Andre Goy 11, Constantine S Tam 12 13, Pieternella J Lugtenburg 14, Adam M Petrich 15, Arijit Sinha 16, Divya Samineni 17, Sylvia Herter 18, Ellen Ingalla 17, Edith Szafer-Glusman 17, Christian Klein 18, Deepak Sampath 17, Martin Kornacker 19, Mehrdad Mobasher 17, Franck Morschhauser 20",Blood. 2019 May 2;133(18):1964-1976. doi: 10.1182/blood-2018-11-880526. Epub 2019 Mar 8.,Zelenetz AD,Blood,2019,2019/03/10,PMC6497517,,10.1182/blood-2018-11-880526,https://pubmed.ncbi.nlm.nih.gov/30850381/,/30850381/,"Conflict-of-interest disclosure: A.D.Z. serves on advisory committees/consults for Adaptive Biotechnologies, Amgen, Boehringer Ingelheim, Celgene, Roche-Genentech, Gilead, Hospira, NanoString Technologies, Novartis, Pharmacyclics, Portola Pharmaceuticals, and Takeda and has stock holdings in Adaptive Biotechnologies (options, not exercised); G.S. consults for Roche, Gilead, Celgene, Novartis, and Amgen, receives research funding from Roche, and receives honoraria from Roche, BMS, Merck, Servier, Gilead, Celgene, Novartis, Amgen, and Janssen; C.C. consults for Infinity, receives research funding from Celgene, and receives honoraria from Infinity; S.L.G. serves on advisory boards for Roche, Janssen, and Celgene and receives research funding from Roche and Janssen; L.H.S. consults for Roche/Genentech, Amgen, Gilead, Lundbeck, Seattle Genetics, Janssen, AbbVie, TG Therapeutics, and Celgene, and receives honoraria from Seattle Genetics, AbbVie, and TG Therapeutics; H.T. receives honoraria from Roche, BMS, and Servier and serves on advisory committees for Roche and Karyopharm; G.C. consults for Roche and Celgene and receives honoraria from Roche, Celgene, Gilead, and Janssen; M.E.D.C. serves on advisory boards for Roche, Gilead, and Celgene; A.G. consults for Celgene, Pharmacyclics/J&J, Acerta, Takeda, and Infinity, receives research funding from Celgene, Pharmacyclics/J&J, and Genentech, receives honoraria from Celgene, Takeda, Pharmacyclics/J&J, and Acerta, serves on speakers bureaus for Takeda and Pharmacyclics/J&J, and has received writing support from Takeda; C.S.T. receives honoraria from Roche and AbbVie and research funding from Roche; P.J.L. consults for Roche‐Genentech, Celgene, Jansen‐Cilag, Servier, Takeda, and Mundipharma, receives research support from Roche‐Genentech, and receives travel expenses from Roche‐Genentech; A.M.P. is an employee of AbbVie; A.S. is an employee of Roche; D. Samineni is an employee of Genentech; S.H. is an employee of Roche; E.I. is an employee of Genentech; E.S.-G. is an employee of Genentech; C.K. is an employee and equity holder of Roche; D. Sampath is an employee of Genentech; M.K. is an employee and equity holder of Roche; M.M. was an employee of Genentech and is equity holder of Roche; F.M. consults for Celgene and Gilead and receives honoraria from Celgene, Roche, Janssen, Gilead, and BMS; K.D.M. declares no competing financial interests.",Grants and funding P30 CA008748/CA/NCI NIH HHS/United States,"Andrew D Zelenetz 1 , Gilles Salles 2 3 , Kylie D Mason 4 , Carla Casulo 5 , Steven Le Gouill 6 , Laurie H Sehn 7 , Herve Tilly 8 , Guillaume Cartron 9 , Martine E D Chamuleau 10 , Andre Goy 11 , Constantine S Tam 12 13 , Pieternella J Lugtenburg 14 , Adam M Petrich 15 , Arijit Sinha 16 , Divya Samineni 17 , Sylvia Herter 18 , Ellen Ingalla 17 , Edith Szafer-Glusman 17 , Christian Klein 18 , Deepak Sampath 17 , Martin Kornacker 19 , Mehrdad Mobasher 17 , Franck Morschhauser 20"
31308648,Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET,"Danalyn Byng # 1 2, Johanna I Lutter # 1, Margarethe E Wacker 1, Rudolf A Jörres 3, Xiaofei Liu 4, Stefan Karrasch 3 5, Holger Schulz 5, Claus Vogelmeier 6, Rolf Holle 1",Int J Chron Obstruct Pulmon Dis. 2019 Jul 5;14:1423-1439. doi: 10.2147/COPD.S201899. eCollection 2019.,Byng D,Int J Chron Obstruct Pulmon Dis,2019,2019/07/17,PMC6616193,,10.2147/COPD.S201899,https://pubmed.ncbi.nlm.nih.gov/31308648/,/31308648/,"Johanna I Lutter reports grants from German Federal Ministry of Education and Research during the conduct of the study. Stefan Karrasch reports grants from German Federal Ministry of Education and Research (BMBF) during the conduct of the study. Holger Schulz report grants from German Federal Ministry of Education and Research (BMBF), during the conduct of the study. Claus Vogelmeier report grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Grifols, personal fees from Menarini, personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Teva, personal fees from Cipla, grants from Bayer Schering Pharma AG, grants from MSD, and grants from Pfizer outside the submitted work. Rolf Holle report grants from German Federal Ministry of Education and Research, during the conduct of the study. The authors report no other conflicts of interest in this work.",,"Danalyn Byng # 1 2 , Johanna I Lutter # 1 , Margarethe E Wacker 1 , Rudolf A Jörres 3 , Xiaofei Liu 4 , Stefan Karrasch 3 5 , Holger Schulz 5 , Claus Vogelmeier 6 , Rolf Holle 1"
30442714,Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma,"William W Busse 1, Guy G Brusselle 2, Stephanie Korn 3, Piotr Kuna 4, Antoine Magnan 5, David Cohen 6, Karin Bowen 6, Teresa Piechowiak 7, Millie M Wang 8, Gene Colice 6",Eur Respir J. 2019 Jan 31;53(2):1800948. doi: 10.1183/13993003.00948-2018. Print 2019 Feb.,Busse WW,Eur Respir J,2019,2018/11/17,,,10.1183/13993003.00948-2018,https://pubmed.ncbi.nlm.nih.gov/30442714/,/30442714/,"Conflict of interest: W.W. Busse reports personal fees for consultancy from AstraZeneca, during the conduct of the study; personal fees for consultancy from 3M, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi-Regeneron and Teva, personal fees for data and safety monitoring board work from Boston Scientific and Genentech, personal fees (royalties) from Elsevier, personal fees for educational videos from Medscape, personal fees for joint oversight committee work from ICON Clinical Research Limited, and personal fees from Pfizer, Roche, AstraZeneca and Circassia, and grants from NIH-NIAID and NIH-NHLBI, outside the submitted work. Conflict of interest: G.G. Brusselle reports honoraria for advisory boards and/or lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, Sanofi/Regeneron, Teva, UCB and Zambon, during the conduct of the study. Conflict of interest: S. Korn reports consulting and lecture fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Teva and Roche, and grants and personal fees from GlaxoSmithKline and Novartis, during the conduct of the study. Conflict of interest: P. Kuna reports personal fees from Adamed, Allergopharma, ALK, AstraZeneca, Bayer Celon Pharma, Chiesi, FAES, HAL Allergy, Lekam, Polpharma, Pfizer, Sandoz and Teva, during the conduct of the study; and personal fees from Berlin Chemie, Boehringer Ingelheim and Novartis, outside the submitted work. Conflict of interest: A. Magnan reports personal fees and non-financial support from GlaxoSmithKline, Novartis, Boehringer Ingelheim, AstraZeneca, Stallerg nes, ALK, MundiPharma, Teva, Menarini and Meda Pharma, during the the past 5 years. Conflict of interest: D. Cohen is an employee of AstraZeneca. Conflict of interest: K. Bowen is an employee of and own shares in AstraZeneca. Conflict of interest: T. Piechowiak is an employee of and owns stock options in AstraZeneca. Conflict of interest: M.M. Wang is an employee of and owns shares in AstraZeneca. Conflict of interest: G. Colice is an employee of and owns shares and stock options in AstraZeneca.",,"William W Busse 1 , Guy G Brusselle 2 , Stephanie Korn 3 , Piotr Kuna 4 , Antoine Magnan 5 , David Cohen 6 , Karin Bowen 6 , Teresa Piechowiak 7 , Millie M Wang 8 , Gene Colice 6"
31694338,Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis,"Francesca Bonello 1, Stefano Pulini 2, Stelvio Ballanti 3, Massimo Gentile 4, Stefano Spada 1, Ombretta Annibali 5, Paola Omedé 1, Sonia Ronconi 6, Clotilde Cangialosi 7, Luigi Podda 8, Angelo Palmas 9, Alessandra Malfitano 1, Giulia Rivoli 10, Angelo Belotti 11, Fabrizio Ciambelli 12, Iolanda Donatella Vincelli 13, Anna Maria Cafro 14, Vanessa Innao 15, Antonio Palumbo 1, Pieter Sonneveld 16, Andrew Spencer 17, Roman Hájek 18 19, Mario Boccadoro 1, Francesca Gay 1",Cancers (Basel). 2019 Nov 5;11(11):1735. doi: 10.3390/cancers11111735.,Bonello F,Cancers (Basel),2019,2019/11/08,PMC6896192,,10.3390/cancers11111735,https://pubmed.ncbi.nlm.nih.gov/31694338/,/31694338/,"O.A. has received funding from Takeda, Janssen-Cilag, Amgen, Gilead; has served on the advisory boards for Janssen, Celgene, Takeda, and Servier. P.O. has served on the advisory board for Janssen. L.P. has received grants, for his role as discussant, by Janssen, Celgene, and Amgen. A.B. has served on the advisory boards per Celgene, Janssen, and Amgen. A.P. is currently a Takeda employee; data reported here have been generated during his previous Investigator role and are not reflecting any Takeda’s position. He has ownership interests (including stock options) in Takeda. All the following A.P.’s conflicts of interest refer to a period of more than two years ago: he had received honoraria from and undertook consultancy for Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, and Merck; he had received research funding from Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, Merck, and Binding Site; he had served on the Speakers’ Bureau for Bristol-Myers Squibb. P.S. has served on the advisory boards for Amgen, Celgene, Genenta, Janssen, and Seattle Genetics. A.S. has received honoraria and research funding from Celgene. R.H. has received honoraria from Amgen, Bristol-Myers Squibb, Takeda, Celgene, Janssen; has received research funding from Takeda, Novartis, Amgen, Janssen; has had a consultant or advisory relationship with Amgen, Takeda, Bristol-Myers Squibb, Celgene, and Janssen. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, AbbVie, and Bristol-Myers Squibb; has received research funding from Celgene, Janssen, Amgen, Bristol-Myers Squibb, Mundipharma, Novartis, and Sanofi. F.G. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; has served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Roche, Takeda, and AbbVie. The remaining authors declare no competing financial interests.",,"Francesca Bonello 1 , Stefano Pulini 2 , Stelvio Ballanti 3 , Massimo Gentile 4 , Stefano Spada 1 , Ombretta Annibali 5 , Paola Omedé 1 , Sonia Ronconi 6 , Clotilde Cangialosi 7 , Luigi Podda 8 , Angelo Palmas 9 , Alessandra Malfitano 1 , Giulia Rivoli 10 , Angelo Belotti 11 , Fabrizio Ciambelli 12 , Iolanda Donatella Vincelli 13 , Anna Maria Cafro 14 , Vanessa Innao 15 , Antonio Palumbo 1 , Pieter Sonneveld 16 , Andrew Spencer 17 , Roman Hájek 18 19 , Mario Boccadoro 1 , Francesca Gay 1"
30612585,Effectiveness of a hydrogel dressing as an analgesic adjunct to first aid for the treatment of acute paediatric thermal burn injuries: study protocol for a randomised controlled trial,"Maleea D Holbert 1 2, Bronwyn R Griffin 3 4 5, Steven M McPhail 6 7, Robert S Ware 8, Kelly Foster 9, Demi C Bertoni 4, Roy M Kimble 3 4",Trials. 2019 Jan 6;20(1):13. doi: 10.1186/s13063-018-3057-x.,Holbert MD,Trials,2019,2019/01/08,PMC6322255,,10.1186/s13063-018-3057-x,https://pubmed.ncbi.nlm.nih.gov/30612585/,/30612585/,"This trial has being granted ethical approval by The University of Queensland Human Research Ethics Committee (HREC/16/QRCH/322), LCCH (Brisbane) Children’s Health Service District Ethics Committee and the Children’s Health Queensland Human Research Ethics Committee. The study methodology was documented in a protocol and registered with the Australian New Zealand Clinical Trials Registry (ACTRN12617001274369) on 5 September 2017 prior to starting recruitment. All participants will be given verbal and written information about the study and will provide signed consent to participate in the research. The information collected about participants is individually identifiable by members of the research team only. Each participant will be allocated a unique numeric code (ID Number) such that all stored electronic data (e.g., databases, data files) will contain identifiable data until the completion of the study. All confidential information is stored in locked filing cabinets, and only de-identified data will be presented or published. Written informed consent will be obtained from the parent/guardian or participant where applicable for accompanying images in published reports of this study. The consent form is held by the authors and is available for review by the Editor-in-Chief of this journal. It is standard for all clinical trials conducted within the Centre for Children’s Burns and Trauma Research to publish a protocol in Trials, as well as all results of the trial being published in journals and presented at conferences both nationally and internationally. The authors declare that they have no competing interests. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",Grants and funding 2014001961/Mundipharma,"Maleea D Holbert 1 2 , Bronwyn R Griffin 3 4 5 , Steven M McPhail 6 7 , Robert S Ware 8 , Kelly Foster 9 , Demi C Bertoni 4 , Roy M Kimble 3 4"
31122243,Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD,"Mariaelena Occhipinti 1, Matteo Paoletti 2, Brian J Bartholmai 3, Srinivasan Rajagopalan 4, Ronald A Karwoski 4, Cosimo Nardi 5, Riccardo Inchingolo 6, Anna R Larici 7, Gianna Camiciottoli 2, Federico Lavorini 2, Stefano Colagrande 3, Vito Brusasco 8, Massimo Pistolesi 2",Respir Res. 2019 May 23;20(1):101. doi: 10.1186/s12931-019-1049-3.,Occhipinti M,Respir Res,2019,2019/05/25,PMC6533715,,10.1186/s12931-019-1049-3,https://pubmed.ncbi.nlm.nih.gov/31122243/,/31122243/,"Dr. Occhipinti reports personal fees from Imbio LLC, grants from Menarini Foundation, outside the submitted work. Dr. Bartholmai reports personal fees from Promedior, LLC, and from Imbio, LLC, outside the submitted work. Mayo Clinic has received grants from NIH/NHLBI, fees from Imbio, LLC, and Boehringer Ingelheim outside the submitted work. In addition, Dr. Bartholmai has a patent SYSTEMS AND METHODS FOR ANALYZING IN VIVO TISSUE VOLUMES USING MEDICAL IMAGING pending to Mayo Clinic. Dr. Karwoski reports other from Imbio Inc., outside the submitted work. Dr. Lavorini reports personal fees from Chiesi Farmaceutici, grants and personal fees from Menarini International, personal fees from GlaxoSmithKline, personal fees from Boehringer Ingelheim, personal fees from Orion Pharma, personal fees from Novartis, outside the submitted work. Dr. Pistolesi reports grants from MINISTRY OF HEALTH OF ITALY, grants from MINISTRY OF UNIVERSITY AND RESEARCH OF ITALY, during the conduct of the study; personal fees and non-financial support from GSK, grants, personal fees and non-financial support from MENARINI, personal fees and non-financial support from BOEHRINGER IINGELHEIM, personal fees and non-financial support from ASTRAZENECA, personal fees and non-financial support from CHIESI, grants, personal fees and non-financial support from MUNDIPHARMA, personal fees and non-financial support from BIOFUTURA, grants, personal fees and non-financial support from NOVARTIS, personal fees and non-financial support from GUIDOTTI MALESCI, personal fees from MENARINI INTERNATIONAL, grants from SANOFI, grants and personal fees from MSD, personal fees and non-financial support from GRIFOLS, grants from BAYER, outside the submitted work. M Paoletti, SR, CN, ARL, RI, GC, SC have no competing interests.","Grants and funding ---/Ministero dellIstruzione, dellUniversità e della Ricerca ---/Ministero della Salute","Mariaelena Occhipinti 1 , Matteo Paoletti 2 , Brian J Bartholmai 3 , Srinivasan Rajagopalan 4 , Ronald A Karwoski 4 , Cosimo Nardi 5 , Riccardo Inchingolo 6 , Anna R Larici 7 , Gianna Camiciottoli 2 , Federico Lavorini 2 , Stefano Colagrande 3 , Vito Brusasco 8 , Massimo Pistolesi 2"
31243042,Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark,"Justin Taylor 1, Michael Haddadin 1, Vivek A Upadhyay 2 3, Erwin Grussie 1, Neha Mehta-Shah 1, Andrew M Brunner 2, Abner Louissaint Jr 2, Scott B Lovitch 4, Ahmet Dogan 1, Amir T Fathi 2, Richard M Stone 3, Martin S Tallman 1, Raajit K Rampal 1, Donna S Neuberg 3, Kristen E Stevenson 3, Steven M Horwitz 1, Andrew A Lane 3",Blood. 2019 Aug 22;134(8):678-687. doi: 10.1182/blood.2019001144. Epub 2019 Jun 26.,Taylor J,Blood,2019,2019/06/28,PMC6706810,,10.1182/blood.2019001144,https://pubmed.ncbi.nlm.nih.gov/31243042/,/31243042/,"Conflict-of-interest disclosure: N.M.-S. has received research funding from Roche/Genentech, Celgene, Verastem, AstraZeneca, and Bristol-Myers Squibb and is a consultant for Kyowa-Hakka-Kirin. R.K.R. has received research funding from Incyte, Stemline Therapeutics, and Constellation and is a consultant for Incyte, Blueprint, Celgene, Agios, Jazz, BeyondSpring, Apexx, and Partner Therapeutics. S.M.H. has received research funding from Forty-Seven, Aileron, ADCT Therapeutics, Celgene, Infinity/Verastem, Millennium/Takeda, Seattle Genetics, and Trillium, and is a consultant for Kyowa-Hakka-Kirin, Millennium/Takeda, Infinity/Verastem, Seattle Genetics, Celgene, Miragen, Innate Pharma, Portola, Affimed, Kura, Mundipharma, and Astex. A.A.L. has received research funding from AbbVie and Stemline Therapeutics and is a consultant for N-of-One. The remaining authors declare no competing financial interests.",Grants and funding K08 CA230319/CA/NCI NIH HHS/United States P01 CA066996/CA/NCI NIH HHS/United States P30 CA008748/CA/NCI NIH HHS/United States R37 CA225191/CA/NCI NIH HHS/United States,"Justin Taylor 1 , Michael Haddadin 1 , Vivek A Upadhyay 2 3 , Erwin Grussie 1 , Neha Mehta-Shah 1 , Andrew M Brunner 2 , Abner Louissaint Jr 2 , Scott B Lovitch 4 , Ahmet Dogan 1 , Amir T Fathi 2 , Richard M Stone 3 , Martin S Tallman 1 , Raajit K Rampal 1 , Donna S Neuberg 3 , Kristen E Stevenson 3 , Steven M Horwitz 1 , Andrew A Lane 3"
31142617,Ozone-primed neutrophils promote early steps of tumour cell metastasis to lungs by enhancing their NET production,"Natacha Rocks 1, Céline Vanwinge 1, Coraline Radermecker 2 3, Silvia Blacher 1, Christine Gilles 1, Raphael Marée 4, Alison Gillard 1, Brigitte Evrard 5, Christel Pequeux 1, Thomas Marichal 2 3 6, Agnes Noel 1, Didier Cataldo 7 8",Thorax. 2019 Aug;74(8):768-779. doi: 10.1136/thoraxjnl-2018-211990. Epub 2019 May 29.,Rocks N,Thorax,2019,2019/05/31,,,10.1136/thoraxjnl-2018-211990,https://pubmed.ncbi.nlm.nih.gov/31142617/,/31142617/,"Competing interests: DC is the founder of Aquilon Pharmaceuticals, received speaker fees from AstraZeneca, Boehringer-Ingelheim, Novartis, MundiPharma, Chiesi and GSK and received consultancy fees from AstraZeneca, Boehringer-Ingelheim, and Novartis for the participation to advisory boards. None of these activities have any connection with oncology or development of drugs in the field of oncology.",,"Natacha Rocks 1 , Céline Vanwinge 1 , Coraline Radermecker 2 3 , Silvia Blacher 1 , Christine Gilles 1 , Raphael Marée 4 , Alison Gillard 1 , Brigitte Evrard 5 , Christel Pequeux 1 , Thomas Marichal 2 3 6 , Agnes Noel 1 , Didier Cataldo 7 8"
32237643,Opioids crisis in France? Findings and reality,Rodrigue Deleens 1,Rev Prat. 2019 Oct;69(8):826-830.,Deleens R,Rev Prat,2019,2020/04/03,,,,https://pubmed.ncbi.nlm.nih.gov/32237643/,/32237643/,"R. Deleens déclare des liens ponctuels (travaux scientifiques, conférences, colloques, actions de formation et/ou prise en charge lors de congrès) avec Merz, Sanofi, Grunenthal, Mundipharma et Mylan.",,Rodrigue Deleens 1
31149623,High frequency of infection of lung cancer\xa0patients with the parasite Toxoplasma gondii,"Jaroslav Bajnok 1, Muyassar Tarabulsi 1, Helen Carlin 1, Kevin Bown 1, Thomas Southworth 2, Josiah Dungwa 2, Dave Singh 2, Zhao-Rong Lun 1 3, Lucy Smyth 1, Geoff Hide 1",ERJ Open Res. 2019 May 28;5(2):00143-2018. doi: 10.1183/23120541.00143-2018. eCollection 2019 Apr.,Bajnok J,ERJ Open Res,2019,2019/06/01,PMC6536861,,10.1183/23120541.00143-2018,https://pubmed.ncbi.nlm.nih.gov/31149623/,/31149623/,"Conflict of interest: J. Bajnok reports grants from British Society of Parasitology (provision of a travel grant to attend a conference), during the conduct of the study. Conflict of interest: M. Tarabulsi reports grants from Saudi Arabian Cultural Bureau (PhD studentship funding), during the conduct of the study. Conflict of interest: H. Carlin has nothing to disclose. Conflict of interest: K. Bown has nothing to disclose. Conflict of interest: T. Southworth has nothing to disclose. Conflict of interest: J. Dungwa has nothing to disclose. Conflict of interest: D. Singh reports personal fees from Apellis, Cipla, Genentech, Peptinnovate and Skyepharma, grants and personal fees from AstraZeneca, Boehringer Ingleheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Merck, Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Therevance and Verona, all outside the submitted work. Conflict of interest: Z-R. Lun reports their laboratory is supported by a National Key R&D Program of China (2017YFD0500400), outside the submitted work. Conflict of interest: L. Smyth reports grants from Kidscan (charity grant funds for leukaemia research), outside the submitted work. Conflict of interest: G. Hide reports grants from Saudi Arabian Cultural Bureau (provision of funding to cover one of the authors’ PhD fees and research costs. Some of these research costs were used to purchase consumables to support this project. The funding was to support M. Tarabulsi and research consumables used by her and her PhD supervisor (G.Hide), grants from British Society of Parasitology (provision of a travel grant to J. Bajnok for attendance at a conference), during the conduct of the study.",,"Jaroslav Bajnok 1 , Muyassar Tarabulsi 1 , Helen Carlin 1 , Kevin Bown 1 , Thomas Southworth 2 , Josiah Dungwa 2 , Dave Singh 2 , Zhao-Rong Lun 1 3 , Lucy Smyth 1 , Geoff Hide 1"
31667062,An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain,"Sarah Danson 1, Matthew R Mulvey 2, Lesley Turner 1, Janet Horsman 1, KJane Escott 3, Robert E Coleman 1, Sam H Ahmedzai 4, Michael I Bennett 2, David Andrew 5",J Bone Oncol. 2019 Sep 18;19:100261. doi: 10.1016/j.jbo.2019.100261. eCollection 2019 Dec.,Danson S,J Bone Oncol,2019,2019/11/01,PMC6812043,,10.1016/j.jbo.2019.100261,https://pubmed.ncbi.nlm.nih.gov/31667062/,/31667062/,"S Danson has received fees from Amgen for giving lectures. KJ Escott is an employee of AstraZeneca. RE Coleman is co-inventor and patent holder of a bone biomarker under development by Inbiomotion, has received fees for advising on clinical trial protocol development from Amgen, Astellas and Boehringer Ingelheim as well as for independent medical education lectures at symposia supported by Amgen, Genomic Health and Eisai. SH Ahmedzai has received support for undertaking cancer pain studies, giving lectures or for consultancy from Grunenthal, Menarini, Mundipharma and Pfizer The remaining authors have no declaration of interests.",Grants and funding MR/K015052/1/MRC_/Medical Research Council/United Kingdom,"Sarah Danson 1 , Matthew R Mulvey 2 , Lesley Turner 1 , Janet Horsman 1 , KJane Escott 3 , Robert E Coleman 1 , Sam H Ahmedzai 4 , Michael I Bennett 2 , David Andrew 5"
31460865,A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT,"Sonia Johnson 1, Luke Sheridan Rains 1, Steven Marwaha 2, John Strang 3, Thomas Craig 4, Tim Weaver 5, Paul McCrone 6, Michael King 1, David Fowler 7, Stephen Pilling 8, Louise Marston 9, Rumana Z Omar 10, Meghan Craig 1, Jonathan Spencer 4, Mark Hinton 11",Health Technol Assess. 2019 Aug;23(45):1-108. doi: 10.3310/hta23450.,Johnson S,Health Technol Assess,2019,2019/08/29,PMC6732717,,10.3310/hta23450,https://pubmed.ncbi.nlm.nih.gov/31460865/,/31460865/,"Michael King is a member of the Clinical Trial Units funded by the National Institute for Health Research and the Rapid Trials and Add-on Studies Board. Rumana Z Omar is a member of the Health Technology Assessment General Board. John Strang reports grants from Camurus (Lund, Sweden), Martindale Pharma (now Ethypharm UK, Woodburn Green, UK), Mundipharma (Mundipharma International Limited, Cambridge, UK) and Braeburn Pharma (Braeburn Inc., Plymouth Meeting, PA, USA), and other from Martindale Pharma and Braeburn Pharma outside the submitted work. In addition, John Strang has a patent Euro-Celtique SA issued and a patent pending with King’s College London.",Grants and funding 09/144/50/DH_/Department of Health/United Kingdom,"Sonia Johnson 1 , Luke Sheridan Rains 1 , Steven Marwaha 2 , John Strang 3 , Thomas Craig 4 , Tim Weaver 5 , Paul McCrone 6 , Michael King 1 , David Fowler 7 , Stephen Pilling 8 , Louise Marston 9 , Rumana Z Omar 10 , Meghan Craig 1 , Jonathan Spencer 4 , Mark Hinton 11"
30361250,"Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial","David C Currow 1 2, Magnus Ekström 1 3, Sandra Louw 4, Julie Hill 4, Belinda Fazekas 1 2, Katherine Clark 1 5, Patricia M Davidson 1 6, Christine McDonald 7, Dimitar Sajkov 8, Nikki McCaffrey 9, Matthew Doogue 10, Amy P Abernethy 2 11, Meera Agar 1",Eur Respir J. 2019 Jan 17;53(1):1801270. doi: 10.1183/13993003.01270-2018. Print 2019 Jan.,Currow DC,Eur Respir J,2019,2018/10/27,,,10.1183/13993003.01270-2018,https://pubmed.ncbi.nlm.nih.gov/30361250/,/30361250/,"Conflict of interest: D.C. Currow has received an unrestricted research grant from Mundipharma, is an unpaid member of an advisory board for Helsinn Pharmaceuticals and has consulted to Mayne Pharma and received intellectual property payments from them. He is a paid consultant to Specialist Therapeutics. Conflict of interest: M. Ekström has nothing to disclose. Conflict of interest: S. Louw reports personal fees for statistic consultation from Palliative Care Clinical Studies Collaborative, during the conduct of the study. Conflict of interest: J. Hill has nothing to disclose. Conflict of interest: B. Fazekas has nothing to disclose. Conflict of interest: K. Clark has nothing to disclose. Conflict of interest: P.M. Davidson has nothing to disclose. Conflict of interest: C. McDonald reports personal fees for speaking from GSK and Novartis, personal fees for advisory board work from Pfizer, and fees for speaking that were paid directly to the hospital from Menarini, outside the submitted work. Conflict of interest: D. Sajkov has nothing to disclose. Conflict of interest: N. McCaffrey has nothing to disclose. Conflict of interest: M. Doogue has nothing to disclose. Conflict of interest: A.P. Abernethy has nothing to disclose. Conflict of interest: M. Agar has nothing to disclose.",,"David C Currow 1 2 , Magnus Ekström 1 3 , Sandra Louw 4 , Julie Hill 4 , Belinda Fazekas 1 2 , Katherine Clark 1 5 , Patricia M Davidson 1 6 , Christine McDonald 7 , Dimitar Sajkov 8 , Nikki McCaffrey 9 , Matthew Doogue 10 , Amy P Abernethy 2 11 , Meera Agar 1"
31280963,Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction,"David M Kurtz 1, Mohammad S Esfahani 2, Florian Scherer 2, Joanne Soo 2, Michael C Jin 2, Chih Long Liu 2, Aaron M Newman 3, Ulrich Dührsen 4, Andreas Hüttmann 4, Olivier Casasnovas 5, Jason R Westin 6, Matthais Ritgen 7, Sebastian Böttcher 8, Anton W Langerak 9, Mark Roschewski 10, Wyndham H Wilson 10, Gianluca Gaidano 11, Davide Rossi 12, Jasmin Bahlo 13, Michael Hallek 14, Robert Tibshirani 15, Maximilian Diehn 16, Ash A Alizadeh 17",Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.,Kurtz DM,Cell,2019,2019/07/09,PMC7380118,NIHMS1603077,10.1016/j.cell.2019.06.011,https://pubmed.ncbi.nlm.nih.gov/31280963/,/31280963/,"Declaration of Interests Olivier Casasnovas served as a consultant for Roche, Takeda, Gilead, BMS, MSD, Janssen and received research support from Roche, Gilead, and Takeda, outside the submitted work. Anton W. Langerak is a member of the AbbVie advisory board and received research support from Roche-Genentech and Gilead, outside the submitted work. Matthias Ritgen is a member of the Roche advisory board, outside the submitted work. Sebastian Böttcher received research support and personal fees from AbbVie, Janssen, and F Hoffman-La Roche; research support from Celgene and Genentech; and personal fees from Becton Dickinson and Novartis, outside the submitted work. Davide Rossi received research support from Gilead, Janssen, Roche, and AbbVie, outside the submitted work. Michael Hallek received research support from Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, and AbbVie, outside the submitted work. Maximilian Diehn served as a consultant for Roche, AstraZeneca, Novartis, BioNTech, and Quanticell, and received research support from Varian Medical Systems, outside the submitted work. Ash Alizadeh served as a consultant for Roche, Genentech, Janssen, Pharmacyclics, Gilead, Celgene, and Chugai, and received research support from Pfizer, outside the submitted work. He is also a shareholder in FortySeven. Ash Alizadeh, Maximillian Diehn, and Aaron Newman are co-founders of CiberMed. The other authors declare no competing interests.",Grants and funding DP2 CA186569/CA/NCI NIH HHS/United States R25 CA180993/CA/NCI NIH HHS/United States R01 CA229766/CA/NCI NIH HHS/United States U01 CA194389/CA/NCI NIH HHS/United States R01 CA233975/CA/NCI NIH HHS/United States R01 CA244526/CA/NCI NIH HHS/United States K08 CA241076/CA/NCI NIH HHS/United States R01 CA188298/CA/NCI NIH HHS/United States Show all 8 grants,"David M Kurtz 1 , Mohammad S Esfahani 2 , Florian Scherer 2 , Joanne Soo 2 , Michael C Jin 2 , Chih Long Liu 2 , Aaron M Newman 3 , Ulrich Dührsen 4 , Andreas Hüttmann 4 , Olivier Casasnovas 5 , Jason R Westin 6 , Matthais Ritgen 7 , Sebastian Böttcher 8 , Anton W Langerak 9 , Mark Roschewski 10 , Wyndham H Wilson 10 , Gianluca Gaidano 11 , Davide Rossi 12 , Jasmin Bahlo 13 , Michael Hallek 14 , Robert Tibshirani 15 , Maximilian Diehn 16 , Ash A Alizadeh 17"
30741371,"EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research","L J Seppala 1, N van der Velde 2, T Masud 3, H Blain 4, M Petrovic 5, T J van der Cammen 6, K Szczerbińska 7, S Hartikainen 8, R A Kenny 9 10 11, J Ryg 12 13, P Eklund 14, E Topinková 15 16, A Mair 17, L Laflamme 18, H Thaler 19, G Bahat 20, M Gutiérrez-Valencia 21, M A Caballero-Mora 22, F Landi 23, M H Emmelot-Vonk 24 ; EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs; A Cherubini 25, J P Baeyens 26 27, A Correa-Pérez 28, A Gudmundsson 29 30, A Marengoni 31, D OMahony 32 33, N Parekh 34, F E Pisa 35 36, C Rajkumar 37, M Wehling 38, G Ziere 39 40 ; EuGMS Special Interest Group on Pharmacology",Drugs Aging. 2019 Apr;36(4):299-307. doi: 10.1007/s40266-018-0622-7.,Seppala LJ,Drugs Aging,2019,2019/02/12,PMC6435622,,10.1007/s40266-018-0622-7,https://pubmed.ncbi.nlm.nih.gov/30741371/,/30741371/,"Martin Wehling was employed by AstraZeneca R&D, Mölndal, as Director of Discovery Medicine (= translational medicine) from 2004 to 2006 while on sabbatical leave from his professorship at the University of Heidelberg. After returning to this position in January 2007, he received lecturing and consulting fees from Bristol Myers, Bayer, LEO, Boehringer-Ingelheim, Mundipharma, Novartis, Pfizer, Roche, AstraZeneca, Allergan, Polyphor, Helsinn, Sanofi-Aventis, Shire, Otsuka, Lilly, Berlin-Chemie, and Novo-Nordisk. The work of Eva Topinkova was partially supported by grant no. 16-33463A from the Czech Ministry of Health, Czech Republic. LJS, NvdV, TM, HB, MP, TJvdC, KS, SH, RAK, JR, PE, AMair, LL, HT, GB, MG-V, MAC-M, FL, MHE-V, AC, JPB, AC-P, AG, AM, DO, NP, FEP, CR, GZ have no conflicts of interest that are directly relevant to the content of this article.",,"L J Seppala 1 , N van der Velde 2 , T Masud 3 , H Blain 4 , M Petrovic 5 , T J van der Cammen 6 , K Szczerbińska 7 , S Hartikainen 8 , R A Kenny 9 10 11 , J Ryg 12 13 , P Eklund 14 , E Topinková 15 16 , A Mair 17 , L Laflamme 18 , H Thaler 19 , G Bahat 20 , M Gutiérrez-Valencia 21 , M A Caballero-Mora 22 , F Landi 23 , M H Emmelot-Vonk 24 ; EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs; A Cherubini 25 , J P Baeyens 26 27 , A Correa-Pérez 28 , A Gudmundsson 29 30 , A Marengoni 31 , D OMahony 32 33 , N Parekh 34 , F E Pisa 35 36 , C Rajkumar 37 , M Wehling 38 , G Ziere 39 40 ; EuGMS Special Interest Group on Pharmacology"
31760881,"Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study","Marco Contoli 1, Paola Rogliani 2, Fabiano Di Marco 3, Fulvio Braido 4, Angelo G Corsico 5, Christian A Amici 6, Roberto Piro 7, Riccardo Sarzani 8, Patrizia Lessi 9, Carla Scognamillo 9, Nicola Scichilone 10, Pierachille Santus 11 ; SAT Study Group",Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619888128. doi: 10.1177/1753466619888128.,Contoli M,Ther Adv Respir Dis,2019,2019/11/26,PMC6878607,,10.1177/1753466619888128,https://pubmed.ncbi.nlm.nih.gov/31760881/,/31760881/,"Conflict of interest statement: The following authors report personal fees for scientific consultation from Boehringer Ingelheim related to the study: FB, MC, PS, AGC, FDM, PR, NS. FB has received honoraria for lectures at national and international meetings from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dompè, Guidotti/Malesci, GlaxoSmith-Kline, Menarini, Novartis, Lallemand Pharma, Biophutura, Levante Pharma, Merck Sharp & Dohme and Zambon; he has served as consultant for AstraZeneca, Chiesi Farmaceutici, Novartis, Glaxo Smith Kline, Boehringer Ingelheim, Guidotti/MalesciZambon, Csl Behring. MC reports grants for research from AstraZeneca and Chiesi, and reports personal fees for scientific consultations and/or lectures at national and international meetings from Chiesi, Novartis, AstraZeneca, Glaxo Smith Kline, Boehringer Ingelheim, Menarini, Zambon, outside the submitted work. FDM has received honoraria for lectures at national and international meetings from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dompe, Guidotti/Malesci, GlaxoSmithKline, Menarini, Novartis, and Zambon; he has served as consultant for AstraZeneca, Chiesi Farmaceutici, Novartis, and Zambon; he has received financial support for research from Novartis, and Boehringer Ingelheim. PR has participated as a lecturer, speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis; her department has received funding from Almirall, Boehringer Ingelheim, Chiesi, Novartis, and Zambon; she has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. PL and CS are employees of Boehringer Ingelheim Italy. CAA is employee for MediNeos Observational Research, Modena, Italy. MediNeos Observational Research received payment from Boehringer Ingelheim Italy for the following activities related to the submitted work: scientific support, clinical operations, data management, statistical analysis, and manuscript preparation. RP and RS do not report any conflicts of interest.",,"Marco Contoli 1 , Paola Rogliani 2 , Fabiano Di Marco 3 , Fulvio Braido 4 , Angelo G Corsico 5 , Christian A Amici 6 , Roberto Piro 7 , Riccardo Sarzani 8 , Patrizia Lessi 9 , Carla Scognamillo 9 , Nicola Scichilone 10 , Pierachille Santus 11 ; SAT Study Group"
31497295,Use of narrative medicine to identify key factors for effective doctor-patient relationships in severe asthma,"Antonietta Cappuccio 1, Silvia Napolitano 1, Francesco Menzella 2, Guido Pellegrini 3, Alessandro Policreti 4, Girolamo Pelaia 5, Pasquale Alberto Porpiglia 4, Maria Giulia Marini 1 ; SOUND GROUP",Multidiscip Respir Med. 2019 Sep 2;14:26. doi: 10.1186/s40248-019-0190-7. eCollection 2019.,Cappuccio A,Multidiscip Respir Med,2019,2019/09/10,PMC6717986,,10.1186/s40248-019-0190-7,https://pubmed.ncbi.nlm.nih.gov/31497295/,/31497295/,"Competing interestsMenzella, Pellegrini, Cappuccio, Napolitano and Marini have no conflicts of interest to disclose. Pelaia hereby states to have received lecture fees and advisory board fees from: AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi, Dompè, GSK, Guidotti/Malesci, Menarini, Mundipharma, Novartis, TEVA, Zambon. Policreti and Porpiglia are employees of Novartis Italia.",,"Antonietta Cappuccio 1 , Silvia Napolitano 1 , Francesco Menzella 2 , Guido Pellegrini 3 , Alessandro Policreti 4 , Girolamo Pelaia 5 , Pasquale Alberto Porpiglia 4 , Maria Giulia Marini 1 ; SOUND GROUP"
30962424,Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial,"Katja C Weisel 1 2, Christof Scheid 3, Manola Zago 4, Britta Besemer 5, Elias K Mai 6, Mathias Haenel 7, Jan Duerig 8, Markus Munder 9, Hans-Walter Lindemann 10, Anja Seckinger 6, Christina Kunz 11, Axel Benner 11, Dirk Hose 6, Anna Jauch 12, Hans Salwender 13, Hartmut Goldschmidt 6 14",Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8.,Weisel KC,Blood Cancer J,2019,2019/04/10,PMC6453945,,10.1038/s41408-019-0206-8,https://pubmed.ncbi.nlm.nih.gov/30962424/,/30962424/,"K.W. reports research funding from Janssen, Amgen, Sanofi, and Celgene Corporation; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Novartis, Onyx, and Takeda; and advisory board membership for Adaptive Biotech, Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Novartis, Onyx, and Takeda. C.S. reports honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Novartis, Sanofi, Takeda, and advisory board membership for Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Novartis, Sanofi, and Takeda. E.K.M. reports personal fees and other from Janssen Cilag, personal fees and other from Celgene, personal fees and other from Takeda, other from Bristol-Myers Squibb, and other from Mundipharma; M.H. reports honoraria from Novartis and Roche. J.D. reports research funding from Lead Discovery Center. M.M. reports personal fees from Celgene, personal fees and other from Janssen, grants and personal fees from Bristol-Myers Squibb, personal fees and other from Takeda, and personal fees and other from Amgen. H.S. reports research funding from Amgen, Novartis, Janssen, Bristol-Myers Squibb, and Celgene Corporation, honoraria from Novartis, Janssen, Bristol-Myers Squibb, Celgene Corporation, and Takeda, and travel support from Amgen, Celgene Corporation, and Janssen. H.G. reports personal fees and other from Amgen, personal fees and other from Bristol-Myers Squibb, personal fees and other from Celgene, personal fees and other from Chugai, personal fees and other from Janssen, personal fees and other from Sanofi, other from Mundipharma, personal fees and other from Takeda, personal fees and other from Novartis, other from Adaptive Biotechnologies, personal fees from Art Tempi, outside the submitted work. The remaining authors declare that they have no conflict of interest.",,"Katja C Weisel 1 2 , Christof Scheid 3 , Manola Zago 4 , Britta Besemer 5 , Elias K Mai 6 , Mathias Haenel 7 , Jan Duerig 8 , Markus Munder 9 , Hans-Walter Lindemann 10 , Anja Seckinger 6 , Christina Kunz 11 , Axel Benner 11 , Dirk Hose 6 , Anna Jauch 12 , Hans Salwender 13 , Hartmut Goldschmidt 6 14"
30685793,"Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)","Sally Baron-Hay 1, Matti Aapro 2, Alberto Bernareggi 3, Lee Schwartzberg 4",Support Care Cancer. 2019 Apr;27(4):1309-1317. doi: 10.1007/s00520-019-4640-8. Epub 2019 Jan 26.,Baron-Hay S,Support Care Cancer,2019,2019/01/28,PMC6394711,,10.1007/s00520-019-4640-8,https://pubmed.ncbi.nlm.nih.gov/30685793/,/30685793/,"Lee Schwartzberg: consultant for Amgen, Helsinn, NanoString, Napo, Pfizer, Taiho, Genentech/Roche, BMS, Genomic Health, Myriad, AstraZeneca; has received nonfinancial support from AbbVie, AstraZeneca, Helsinn, Merck, Novartis, Bayer, Celgene, Lilly, BMS, Genentech, Pfizer; has received institutional grants from BMS, Novartis, and MedImmune. Matti Aapro: advisor for Eisai, Helsinn, Merck, Mundipharma, Roche, and Tesaro; honoraria from Eisai, Helsinn, Merck, Mundipharma, Roche, and Tesaro; and has received grants from Helsinn, Merck, Roche, and Tesaro. Sally Baron-Hay: honoraria from AstraZeneca, Novartis, and Pfizer; advisor for AstraZeneca, Novartis, and Pfizer. Alberto Bernareggi: Helsinn Healthcare SA employee. For this type of study, formal consent is not required.",,"Sally Baron-Hay 1 , Matti Aapro 2 , Alberto Bernareggi 3 , Lee Schwartzberg 4"
30430456,"Healthcare Experience and their Relationship with Demographic, Disease and Healthcare-Related Variables: A Cross-Sectional Survey of Patients with Chronic Diseases Using the IEXPAC Scale","Domingo Orozco-Beltrán 1, Javier de Toro 2, María J Galindo 3, Ignacio Marín-Jiménez 4, Francesc Casellas 5, María J Fuster-RuizdeApodaca 6, María L García-Vivar 7, Antonio Hormigo-Pozo 8, Mercedes Guilabert 9, Nuria Sánchez-Vega 10, Gonzalo Fernández 10, Luis Cea-Calvo 11",Patient. 2019 Jun;12(3):307-317. doi: 10.1007/s40271-018-0345-1.,Orozco-Beltrán D,Patient,2019,2018/11/16,PMC6525115,,10.1007/s40271-018-0345-1,https://pubmed.ncbi.nlm.nih.gov/30430456/,/30430456/,"Domingo Orozco-Beltrán has provided consultancy services to MSD and Novartis and has lectured for Novartis, Mundipharma, Novo, Sanofi Aventis and Lilly. María J. Galindo has provided consultancy services to Viiv, Abbie, MSD, Gilead and Janssen; her institution has received grants from MSD, Janssen and Gilead and payments for travel to meetings from MSD and for lectures or educational presentations from MSD, Janssen, Gilead and Viiv. Ignacio Marín-Jiménez has received research funding (to his institution) and payment for acting as a consultant, advisory member or speaker from AbbVie, Chiesi, Faes Farma, Falk-Pharma, Ferring, Gebro Pharma, Hospira, Janssen, MSD, Otsuka Pharmaceutical, Pfizer, Shire, Takeda, Tillots and UCB Pharma. Francesc Casellas has received research funding (to his institution) from AbbVie, MSD, Shire, Ferring and Zambon and speaker fees from AbbVie, MSD, Shire, Ferring and Zambon. María J. Fuster-RuizdeApodaca has received research funding (to her institution) from ViiV Healthcare, MSD, Janssen and Gilead and payments for consultancy services (to her institution) from Gilead, ViiV Healthcare and Janssen and for lectures (to her institution) from Gilead and ViiV Healthcare. María L. García-Vivar has provided consultancy services to MSD, BMS and Janssen and expert testimony for AbbVie and Pfizer and has received grants (to her institution) from Roche, MSD and UCB and payments for lectures from Novartis, GSK, Celgene, Lilly, Janssen, AbbVie and Pfizer. Mercedes Guilabert has received consultancy and travel/meeting expenses from MSD. Nuria Sánchez-Vega, Gonzalo Fernández and Luis Cea-Calvo are full-time employees of MSD Spain. Javier de Toro and Antonio Hormigo-Pozo have no conflicts of interest that are directly related to the content of this article.",,"Domingo Orozco-Beltrán 1 , Javier de Toro 2 , María J Galindo 3 , Ignacio Marín-Jiménez 4 , Francesc Casellas 5 , María J Fuster-RuizdeApodaca 6 , María L García-Vivar 7 , Antonio Hormigo-Pozo 8 , Mercedes Guilabert 9 , Nuria Sánchez-Vega 10 , Gonzalo Fernández 10 , Luis Cea-Calvo 11"
31830934,Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice,"Charles Timäus 1, Miriam Meiser 2, Borwin Bandelow 2, Kirsten R Engel 2, Anne M Paschke 2, Jens Wiltfang 2 3 4, Dirk Wedekind 2",BMC Psychiatry. 2019 Dec 12;19(1):393. doi: 10.1186/s12888-019-2377-z.,Timäus C,BMC Psychiatry,2019,2019/12/14,PMC6909459,,10.1186/s12888-019-2377-z,https://pubmed.ncbi.nlm.nih.gov/31830934/,/31830934/,"JW received honoraria for Consulting Activities, Lectures or Advisory Board participation from Pfizer, Eli Lilly, Hoffmann-La-Roche, MSD Sharp & Dome, Janssen-Cilag GmbH, Immungenetics AG, Boehringer Ingelheim. Patents/Royalties: Patent no.: EP1270592B1; patent no.: US 6.849.416 B2; patent no.: EP2095128B1; patent no.: EP3105589A1. In the past 3 years, BB has been on the speakers’ board for Hexal, Janssen, Lilly and Lundbeck and on the Advisory board for Mundipharma and Lundbeck and has received publication honoraria from Servier. Over the past two years, DW has been on the speakers’ board for Servier. CT, MM, KRE, AMP declare that they have no conflict of interest.",,"Charles Timäus 1 , Miriam Meiser 2 , Borwin Bandelow 2 , Kirsten R Engel 2 , Anne M Paschke 2 , Jens Wiltfang 2 3 4 , Dirk Wedekind 2"
31467115,Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD,"Jan Stolk 1, Naveh Tov 2, Kenneth R Chapman 3, Pablo Fernandez 4, William MacNee 5, Nicholas S Hopkinson 6, Eeva Piitulainen 7, Niels Seersholm 8, Claus F Vogelmeier 9, Robert Bals 10, Gerry McElvaney 11, Robert A Stockley 12",Eur Respir J. 2019 Nov 21;54(5):1900673. doi: 10.1183/13993003.00673-2019. Print 2019 Nov.,Stolk J,Eur Respir J,2019,2019/08/31,,,10.1183/13993003.00673-2019,https://pubmed.ncbi.nlm.nih.gov/31467115/,/31467115/,"Conflict of interest: J. Stolk reports personal fees for consultancy from Kamada Ltd, during the conduct of the study, and grants from CSL Behring, outside the submitted work. Conflict of interest: N. Tov reports personal fees for consultancy from Kamada Ltd, during the conduct of the study, and is an employee of Kamada Ltd, outside the submitted work. Conflict of interest: K.R. Chapman reports personal fees for consultancy from Kamada Ltd, during the conduct of the study, and grants from CSL Behring and Grifols, outside the submitted work. Conflict of interest: P. Fernandez reports consultancy fees from Kamada Ltd, during the planning, design, conduct and reporting of the study. Conflict of interest: W. MacNee reports patient recruitment fees from Kamada Ltd, during the conduct of the study; and grants and personal fees from Pfizer and GlaxoSmithKline, and personal fees from Boehringer Ingelheim, AstraZeneca, Novartis, Zambon and Chiesi, outside the submitted work. Conflict of interest: N.S. Hopkinson has nothing to disclose. Conflict of interest: E. Piitulainen has nothing to disclose. Conflict of interest: N. Seersholm has nothing to disclose. Conflict of interest: C.F. Vogelmeier reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols and Novartis, and personal fees from CSL Behring, Chiesi, Menarini, Mundipharma, Teva and Cipla, outside the submitted work. Conflict of interest: R. Bals reports grants from Kamada Ltd, during the conduct of the study; and grants from BMBF, DFG, Schwiete Stiftung, Sander-Stiftung and Boehringer Ingelheim, and personal fees for advisory board work and travel to meetings from GlaxoSmithKline, CSL Behring, Boehringer Ingelheim, Grifols, AstraZeneca and Novartis, outside the submitted work. Conflict of interest: G. McElvaney reports personal fees for advisory board work from CSL Behring, grants and personal fees for advisory board work from Grifols, and grants from Chiesi, outside the submitted work. Conflict of interest: R.A. Stockley reports personal fees for advisory board membership from Kamada Ltd, during the conduct of the study; personal fees for advisory board membership and lectures from AstraZeneca, personal fees for advisory board membership from Medimmune, Almirall, Baxter, Chiesi and Polyphor, personal fees for lectures from Nycomed and Takeda, and personal fees for advisory board membership, lectures and travel to meetings from Boehringer Ingelheim and CSL Behring, outside the submitted work.",,"Jan Stolk 1 , Naveh Tov 2 , Kenneth R Chapman 3 , Pablo Fernandez 4 , William MacNee 5 , Nicholas S Hopkinson 6 , Eeva Piitulainen 7 , Niels Seersholm 8 , Claus F Vogelmeier 9 , Robert Bals 10 , Gerry McElvaney 11 , Robert A Stockley 12"
30635293,Low transmission risk of Pseudomonas aeruginosa in a bronchiectasis clinic based on the knowledge of bacterial population biology,"Nina Cramer 1, Ludwig Sedlacek 2, Burkhard Tümmler 1 3, Tobias Welte 3 4",Eur Respir J. 2019 Mar 28;53(3):1802191. doi: 10.1183/13993003.02191-2018. Print 2019 Mar.,Cramer N,Eur Respir J,2019,2019/01/13,,,10.1183/13993003.02191-2018,https://pubmed.ncbi.nlm.nih.gov/30635293/,/30635293/,"Conflict of interest: N. Cramer has nothing to disclose. Conflict of interest: L. Sedlacek has nothing to disclose. Conflict of interest: B. Tümmler reports grants from the Bundesministerium für Bildung und Forschung during the conduct of the study; and personal fees for consultancy and lectures from, and that he has been an investigator in clinical trials for Vertex Pharmaceuticals, and personal fees for lectures from Gilead, outside the submitted work. Conflict of interest: T. Welte reports grants from the Bundesministerium für Bildung und Forschung during the conduct of the study; and personal fees from AstraZeneca and Basilea, Infectofarm, Boehringer, Berlin Chemie, Mundipharma and Insmed, and grants and personal fees from Bayer, Grifols, Novartis and Pfizer, outside the submitted work.",,"Nina Cramer 1 , Ludwig Sedlacek 2 , Burkhard Tümmler 1 3 , Tobias Welte 3 4"
31074167,"Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study","Alain H Litwin 1 2, Martine Drolet 3, Chizoba Nwankwo 4, Martha Torrens 5, Andrej Kastelic 6, Stephan Walcher 7, Lorenzo Somaini 8, Emily Mulvihill 9, Jochen Ertl 9, Jason Grebely 10",J Viral Hepat. 2019 Sep;26(9):1094-1104. doi: 10.1111/jvh.13119. Epub 2019 Jun 11.,Litwin AH,J Viral Hepat,2019,2019/05/11,PMC6771477,,10.1111/jvh.13119,https://pubmed.ncbi.nlm.nih.gov/31074167/,/31074167/,"JG is a consultant/advisor and has received research grants from AbbVie, Cepheid, Gilead Sciences and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. MT is a consultant/advisor for Gilead Sciences and Merck Sharp & Dohme Corp. AK is a consultant/advisor and/or speaker for Alkaloid, Carso, Eli Lilly, Gillead Sciences, Medis/Mundipharma and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. SW is consultant/advisor for AbbVie, MSD/Merck, Gilead. EM, JE and RL are employees of Kantar Health, paid consultants of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. AL is a consultant/advisor and has received research grants from AbbVie, Gilead Sciences and Merck Pharmaceuticals. JG, MT, AK, SW, LS and AL were consultants/advisors for this study.",,"Alain H Litwin 1 2 , Martine Drolet 3 , Chizoba Nwankwo 4 , Martha Torrens 5 , Andrej Kastelic 6 , Stephan Walcher 7 , Lorenzo Somaini 8 , Emily Mulvihill 9 , Jochen Ertl 9 , Jason Grebely 10"
31364233,Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study,"Mario Luca Morieri 1 2, Mauro Rigato 3, Vera Frison 4, Natalino Simioni 4, Michele DAmbrosio 5, Federica Tadiotto 5, Agostino Paccagnella 3, Annunziata Lapolla 1 6, Angelo Avogaro 1 2, Gian Paolo Fadini 1 2",Diabetes Obes Metab. 2019 Nov;21(11):2542-2552. doi: 10.1111/dom.13840. Epub 2019 Aug 12.,Morieri ML,Diabetes Obes Metab,2019,2019/08/01,PMC6852173,,10.1111/dom.13840,https://pubmed.ncbi.nlm.nih.gov/31364233/,/31364233/,"M. R. received lecture and advisory board fees from AstraZeneca, Boehringer‐Ingelheim, Novo Nordisk and Sanofi Aventis. V. F. served as a consultant for Novo Nordisk. N. S. received lecture or consultancy fees from Astra‐Zeneca, Boehringer‐Lilly, Novartis, Novo Nordisk, Sanofi‐Aventis, Takeda, Merck Sharp & Dohme and Abbott and received research support from Novo Nordisk. A. L. received grant support and lecture or advisory board fees from Novo Nordisk, Sanofi, Abbott and Eli Lilly. A. A. received research grants and lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher‐Ingelheim, Sanofi, Mediolanum, Janssen and Novo Nordisk. G. P. F. received grant support and lecture or advisory board fees from AstraZeneca, Boehringer‐Ingelheim, Eli Lilly, Mundipharma, Novo Nordisk, Sanofi, Genzyme, Abbott, Novartis and Merck Sharp & Dohme. M. L. M., F. T. and M. D. A. declare no conflict of interest.",,"Mario Luca Morieri 1 2 , Mauro Rigato 3 , Vera Frison 4 , Natalino Simioni 4 , Michele DAmbrosio 5 , Federica Tadiotto 5 , Agostino Paccagnella 3 , Annunziata Lapolla 1 6 , Angelo Avogaro 1 2 , Gian Paolo Fadini 1 2"
31649950,"Assessing small airways dysfunction in asthma, asthma remission and healthy controls using particles in exhaled air","Orestes A Carpaij 1 2, Susan Muiser 1, Alex J Bell 3, Huib A M Kerstjens 1 2, Craig J Galban 4, Aleksa B Fortuna 4, Salman Siddiqui 3, Anna-Carin Olin 5, Martijn C Nawijn 1 6, Maarten van den Berge 1 2",ERJ Open Res. 2019 Oct 21;5(4):00202-2019. doi: 10.1183/23120541.00202-2019. eCollection 2019 Oct.,Carpaij OA,ERJ Open Res,2019,2019/10/26,PMC6801216,,10.1183/23120541.00202-2019,https://pubmed.ncbi.nlm.nih.gov/31649950/,/31649950/,"Conflict of interest: O.A. Carpaij has nothing to disclose. Conflict of interest: S. Muiser has nothing to disclose. Conflict of interest: A.J. Bell has nothing to disclose. Conflict of interest: H.A.M. Kerstjens reports an unrestricted research grant and fees for participation in advisory boards from GlaxoSmithKline (the sponsor of this study), as well as from Boehringer Ingelheim and Novartis. He also reports fees for advisory board participation from AstraZeneca and Chiesi, board membership fees from Almirall, and fees per patient for recruitment in trials from GlaxoSmithKline, Novartis and Fluidda. All the above were paid to his institution. Conflict of interest: C.J. Galban reports that Parametric Response Mapping, of which he is a coinventor, is licenced to Imbio, LLC, by the University of Michigan. Conflict of interest: A.B. Fortuna has nothing to disclose. Conflict of interest: S. Siddiqui reports grants from the Chiesi Onulus Foundation, Midlands Asthma and Allergy Research Association, the NIHR Biomedical Research Centre, the Sir Jules Thorne Trust and the Medical Research Council, and personal fees from Chiesi, GlaxoSmithKline, AstraZeneca, Novartis, Owlstone Medical, Napp, Mundipharma, Boehringer Ingelheim and ERT Medical, outside the submitted work. Conflict of interest: A-C. Olin reports that she has patent WO2009045163 (Collection and measurement of exhaled particles) issued and patent WO2013117747 l (A device and method for non-invasive analysis of particles during medical ventilation) pending. Conflict of interest: M.C. Nawijn reports grants from GlaxoSmithKline Ltd and the Ministry of Economic Affairs and Climate Policy during the conduct of the study. Conflict of interest: M. van den Berge reports grants paid to his institution from GlaxoSmithKline, TEVA, AstraZeneca, Chiesi and Genentech, outside the submitted work.",Grants and funding R01 HL139690/HL/NHLBI NIH HHS/United States,"Orestes A Carpaij 1 2 , Susan Muiser 1 , Alex J Bell 3 , Huib A M Kerstjens 1 2 , Craig J Galban 4 , Aleksa B Fortuna 4 , Salman Siddiqui 3 , Anna-Carin Olin 5 , Martijn C Nawijn 1 6 , Maarten van den Berge 1 2"
30718492,Effects of familial risk and stimulant drug use on the anticipation of monetary reward: an fMRI study,"Alanna L Just 1 2, Chun Meng 1 2, Dana G Smith 1 2, Edward T Bullmore 1 2 3 4, Trevor W Robbins 1 2, Karen D Ersche 5 6",Transl Psychiatry. 2019 Feb 4;9(1):65. doi: 10.1038/s41398-019-0399-4.,Just AL,Transl Psychiatry,2019,2019/02/06,PMC6362203,,10.1038/s41398-019-0399-4,https://pubmed.ncbi.nlm.nih.gov/30718492/,/30718492/,"This research was funded by a Medical Research Council (MRC) grant (G0701497), and conducted within the Behavioural and Clinical Neuroscience Institute (BCNI), which is jointly funded by the MRC and Wellcome Trust. A.L.J. was supported by the Gates Cambridge Trust, D.G.S. by a studentship from the Cambridge Overseas Trust, and C.M. by the Wellcome Trust (105602/Z/14/Z) and the NIHR Cambridge Biomedical Research Centre. E.T.B. is employed part-time by GlaxoSmithKline and part-time by the University of Cambridge, and serves as the Head of Research and Development at the Cambridgeshire and Peterborough NHS Foundation Trust. T.W.R. consults for Cambridge Cognition, Lundbeck, Otsuka, and Mundipharma. He also holds a research grant from Shionogi. The authors declare no additional conflict of interests.",Grants and funding MR/J012084/1/MRC_/Medical Research Council/United Kingdom 105602/Z/14/Z/Wellcome Trust/United Kingdom G0701497/MRC_/Medical Research Council/United Kingdom Department of Health/United Kingdom G1000183/MRC_/Medical Research Council/United Kingdom,"Alanna L Just 1 2 , Chun Meng 1 2 , Dana G Smith 1 2 , Edward T Bullmore 1 2 3 4 , Trevor W Robbins 1 2 , Karen D Ersche 5 6"
31423337,Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI,"Markus Kieler 1, Matthias Unseld 1, Daniela Bianconi 1, Fredrik Waneck 2, Robert Mader 1, Fritz Wrba 3, Thorsten Fuereder 1, Christine Marosi 1, Markus Raderer 1, Philipp Staber 4, Walter Berger 5, Maria Sibilia 5, Stephan Polterauer 6, Leonhard Müllauer 3, Matthias Preusser 1, Christoph C Zielinski 1, Gerald W Prager 1",ESMO Open. 2019 Jul 17;4(4):e000538. doi: 10.1136/esmoopen-2019-000538. eCollection 2019.,Kieler M,ESMO Open,2019,2019/08/20,PMC6677998,,10.1136/esmoopen-2019-000538,https://pubmed.ncbi.nlm.nih.gov/31423337/,/31423337/,"Competing interests: MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp and Dome. MK received travel support from Merck, Bayer, Bristol-Myers Squibb and Roche and has participated in advisory board meetings from Bayer and Servier.",,"Markus Kieler 1 , Matthias Unseld 1 , Daniela Bianconi 1 , Fredrik Waneck 2 , Robert Mader 1 , Fritz Wrba 3 , Thorsten Fuereder 1 , Christine Marosi 1 , Markus Raderer 1 , Philipp Staber 4 , Walter Berger 5 , Maria Sibilia 5 , Stephan Polterauer 6 , Leonhard Müllauer 3 , Matthias Preusser 1 , Christoph C Zielinski 1 , Gerald W Prager 1"
31697808,Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy,"Luzalba Sanoja-Flores 1 2 3 4 5, Juan Flores-Montero 1 2 3 4 5, Noemi Puig 1 4 5 6, Teresa Contreras-Sanfeliciano 7, Roberia Pontes 8, Alba Corral-Mateos 1 2 3 4 5, Omar García-Sánchez 1 4 5 6, María Díez-Campelo 1 4 5 6, Roberto José Pessoa de Magalhães 9, Luis García-Martín 10, José María Alonso-Alonso 11, Aranzazú García-Mateo 12, Carlos Aguilar-Franco 13, Jorge Labrador 14, Abelardo Barez-García 15, Angelo Maiolino 9, Bruno Paiva 4 16, Jesús San Miguel 4 16, Elaine Sobral da Costa 8, Marcos González 1 4 5 6, María Victoria Mateos 1 4 5 6, Brian Durie 17, Jacques J M van Dongen 18, Alberto Orfao 1 2 3 4 5",Blood. 2019 Dec 12;134(24):2218-2222. doi: 10.1182/blood.2019002610.,Sanoja-Flores L,Blood,2019,2019/11/08,PMC6966491,,10.1182/blood.2019002610,https://pubmed.ncbi.nlm.nih.gov/31697808/,/31697808/,"Conflict-of-interest disclosure: M.-V.M. declares honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, Takeda, Abbvie, GSK, Adaptive, EDO-Mundipharma, and Pharmamar. The remaining authors declare no competing financial interests.",,"Luzalba Sanoja-Flores 1 2 3 4 5 , Juan Flores-Montero 1 2 3 4 5 , Noemi Puig 1 4 5 6 , Teresa Contreras-Sanfeliciano 7 , Roberia Pontes 8 , Alba Corral-Mateos 1 2 3 4 5 , Omar García-Sánchez 1 4 5 6 , María Díez-Campelo 1 4 5 6 , Roberto José Pessoa de Magalhães 9 , Luis García-Martín 10 , José María Alonso-Alonso 11 , Aranzazú García-Mateo 12 , Carlos Aguilar-Franco 13 , Jorge Labrador 14 , Abelardo Barez-García 15 , Angelo Maiolino 9 , Bruno Paiva 4 16 , Jesús San Miguel 4 16 , Elaine Sobral da Costa 8 , Marcos González 1 4 5 6 , María Victoria Mateos 1 4 5 6 , Brian Durie 17 , Jacques J M van Dongen 18 , Alberto Orfao 1 2 3 4 5"
30681754,Long-term efficacy of opicapone in fluctuating Parkinsons disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions,"J J Ferreira 1 2, A Lees 3, J-F Rocha 4, W Poewe 5, O Rascol 6, P Soares-da-Silva 4 7 8",Eur J Neurol. 2019 Jul;26(7):953-960. doi: 10.1111/ene.13914. Epub 2019 Mar 25.,Ferreira JJ,Eur J Neurol,2019,2019/01/26,PMC6593852,,10.1111/ene.13914,https://pubmed.ncbi.nlm.nih.gov/30681754/,/30681754/,"JJF has held consultancy functions with GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck‐Serono, Merz, Ipsen, Biogen; has received lecture fees from Biogen and BIAL; has received grants from GlaxoSmithKline, Grunenthal, MSD, Allergan, Novartis, Fundação MSD (Portugal) and Teva; has been employed by Faculdade de Medicina de Lisboa and CNS – Campus Neurológico Sénior. AL is funded by the Reta Lila Weston Institute of Neurological Studies, University College London, Institute of Neurology and reports consultancies for Britannia Pharmaceuticals, BIAL. He also reports grants and/or research support from the PSP Association, Weston Trust, the Reta Lila Howard Foundation, and honoraria from Britannia, UCB, Roche, Novartis, Boehringer Ingelheim, Lundbeck, GE Healthcare, Teva, GlaxoSmithKline, Ipsen, Allergan, Orion, BIAL, AbbVie, Nordicinfu Care. WP has received consultancy and lecture fees in relation to clinical drug programmes for PD from AbbVie, AstraZeneca, BIAL, Biogen, Britannia, Grünenthal, Intec, Ipsen, Lundbeck, Novartis, Neuroderm, Orion Pharma, Prexton, Roche, Sunovion, Sun Pharma, Takeda, Teva, UCB and Zambon. Royalties: Thieme, Wiley Blackwell, Oxford University Press and Cambridge University Press. OR reports receiving consulting fees from AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astrazeneca, Bial, Biogen, Britannia, Clevexel, Cynapsus, INC Research, Lundbeck, Merck, MundiPharma, Neuroderm, Novartis, Osmotica, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Takeda, Teva, UCB, XenoPort, Zambon; and grant support from Agence Nationale de la Recherche (ANR), Boehringer Ingelheim, CHU de Toulouse, French Parkinson, GlaxoSmithKline, INSERM‐DHOS, Michael J Fox Foundation, Programme Hospitalier de Recherche Clinique, Recherche Clinique Translationnelle, UCB, Teva and Lundbeck. JFR and PSS are employed by BIAL – Portela & Cª, S.A.",,"J J Ferreira 1 2 , A Lees 3 , J-F Rocha 4 , W Poewe 5 , O Rascol 6 , P Soares-da-Silva 4 7 8"
31577058,"Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia","Nicola R Jones 1, Marian Shanahan 1, Timothy Dobbins 1, Louisa Degenhardt 1, Mark Montebello 1 2, Natasa Gisev 1, Sarah Larney 1",Drug Alcohol Rev. 2019 Sep;38(6):690-698. doi: 10.1111/dar.12976.,Jones NR,Drug Alcohol Rev,2019,2019/10/03,PMC6777861,NIHMS1045296,10.1111/dar.12976,https://pubmed.ncbi.nlm.nih.gov/31577058/,/31577058/,"Declaration of interests SL has received untied education funding from Indivior. LD has received untied educational funding from Indivior, Mundipharma, and Seqirus. MM has received untied educational funding from Pfizer and AbbVie.",Grants and funding R01 DA044170/DA/NIDA NIH HHS/United States,"Nicola R Jones 1 , Marian Shanahan 1 , Timothy Dobbins 1 , Louisa Degenhardt 1 , Mark Montebello 1 2 , Natasa Gisev 1 , Sarah Larney 1"
31068188,Diagnostic error increases mortality and length of hospital stay in patients presenting through the emergency room,"Wolf E Hautz 1 2, Juliane E Kämmer 3 4, Stefanie C Hautz 5, Thomas C Sauter 5 6, Laura Zwaan 7, Aristomenis K Exadaktylos 5, Tanja Birrenbach 5 8, Volker Maier 8, Martin Müller 5, Stefan K Schauber 9 10",Scand J Trauma Resusc Emerg Med. 2019 May 8;27(1):54. doi: 10.1186/s13049-019-0629-z.,Hautz WE,Scand J Trauma Resusc Emerg Med,2019,2019/05/10,PMC6505221,,10.1186/s13049-019-0629-z,https://pubmed.ncbi.nlm.nih.gov/31068188/,/31068188/,"The ethics committee of the canton Berne registered the study as a quality evaluation study under No. 197/15 and waived the requirement for informed patient consent. All patients provided a general consent for the use of their data according to Swiss law. Not applicable. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf . WEH reports grant money from the director of research at Inselspital University Hospital Berne and grants from Mittelbauvereinigung of the University of Berne during the conduct of the study; personal fees from AO Foundation Zurich and other from Mundipharma Medical Basel, outside the submitted work. SCH reports grants from Mittelbauvereinigung of the University of Berne, during the conduct of the study and personal fees from AO Foundation Zurich, outside the submitted work. TCS reports grants from Bangerter-Rhyner-Foundation, grants from Boehringer-Ingelheim, grants and personal fees from Bayer, grants from Daiichi-Sankyo and grants from Bristol-Myers Squibb, outside the submitted work. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",Grants and funding none/Mittelbauvereinigung Universität Bern None/Clinical Trials Unit Inselspital Bern,"Wolf E Hautz 1 2 , Juliane E Kämmer 3 4 , Stefanie C Hautz 5 , Thomas C Sauter 5 6 , Laura Zwaan 7 , Aristomenis K Exadaktylos 5 , Tanja Birrenbach 5 8 , Volker Maier 8 , Martin Müller 5 , Stefan K Schauber 9 10"
31217628,"Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St.\xa0Gallen International Breast Cancer Conference (Vienna 2019)","Michael Untch 1, Christoph Thomssen 2, Ingo Bauerfeind 3, Michael Braun 4, Sara Y Brucker 5, Ricardo Felberbaum 6, Friederike Hagemann 7, Renate Haidinger 8, Arnd Hönig 9, Jens Huober 10, Christian Jackisch 11, Hans-Christian Kolberg 12, Cornelia Kolberg-Liedtke 13, Thorsten Kühn 14, Diana Lüftner 15, Nicolai Maass 16, Toralf Reimer 17, Andreas Schneeweiss 18, Eva Schumacher-Wulf 19, Florian Schütz 20, Marc Thill 21, Rachel Wuerstlein 7, Peter A Fasching 22, Nadia Harbeck 7",Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604. doi: 10.1055/a-0897-6457. Epub 2019 Jun 14.,Untch M,Geburtshilfe Frauenheilkd,2019,2019/06/21,PMC6570611,,10.1055/a-0897-6457,https://pubmed.ncbi.nlm.nih.gov/31217628/,/31217628/,"Conflict of Interest/Interessenkonflikt Prof. Michael Untch: Honoraria to the employer (for AdBoard participation, lectures) as well as travel support from Amgen, AstraZeneca, BMS, Celgene, Daiichi Sankyo, Eisai, Janssen Cilag, Johnson & Johnson, Lilly Deutschland, Lilly International, MSD, Mundipharma, Myriad Genetics, Odonate, Pfizer, Puma Biotechnology, Riemser, Roche, Sanofi Aventis, Sividon Diagnostics, TEVA Pharmaceuticals Ind. Ltd. Prof. Christoph Thomssen received honoraria from AstraZeneca, Celgene, Genomic Health, Novartis, NanoString, Pfizer, Roche and research support from NanoString. Dr. med. Ingo Bauerfeind has no conflict of interest. Prof. Michael Braun received honoraria from AstraZeneca, Celgene, Daiichi Sankyo, Genomic Health, Eisai, Genomic Health, GlaxoSmithKline, Medac, Novartis, Pfizer, PumaBiotechnology, Roche, Teva. Prof. Sara Brucker received honoraria from Novartis, Pfizer, AstraZeneca, Roche and research support from Genomic Health. Prof. Ricardo Felberbaum has no conflict of interest. Dr. med. Friederike Hagemann has no conflict of interest. Renate Haidinger has no conflict of interest. Prof. Arnd Hönig received honoraria from Amgen, Astra Zeneca, Celgene, MSD, Pfizer, Roche, Novartis, as well as research support from Roche and Genentech and travel grants from Roche, AstraZeneca, Daiichi Sankyo, Pfizer. Prof. Jens Huober received honoraria from Celgene, Roche, Novartis, Hexal, Pfizer, AstraZeneca, Lilly, Amgen, Eisai as well as research support from Celgene, Hexal, Novartis and travel grant from Roche, Novartis and Celgene. Prof. Christian Jackisch received honoraria from Celgene, Novartis, Pfizer, AstraZeneca, Roche and research support from Genomic Health. Prof. Thorsten Kühn has no conflict of interest. PD Dr. Hans-Christian Kolberg received honoraria from Pfizer, Novartis, Roche, Genomic Health, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, TEVA, Theraclion, Janssen-Cilag, GSK, LIV Pharma as well as honoraria for consultancy work from Pfizer, Novartis, SurgVision, Carl Zeiss Meditec, Amgen, Onkowissen and owns shares of Theraclion SA, Phaon Scientific GmbH. Travel grant from Carl Zeiss Meditec, LIV Pharam, Novartis, Amgen, Pfizer and Daiichi Sankyo. Prof. Cornelia Kolberg-Liedtke received honoraria from Roche, AstraZeneca, Celgene, Novartis, Pfizer, Lilly, Hexal, Amgen, Eisai, SonoScape as well as honoraria for consultancy work from Phaon Scientific, Novartis, Pfizer, Celgene as well as research support from Roche, Novartis, Pfizer. Travel grant from Novartis and Roche. Prof. Diana Lüftner received honoraria from AstraZeneca, Celgene, Pfizer, Novartis, Amgen, Roche, Loreal, Teva, Tesaro and Eli Lilly. Prof. Nicolai Maass received honoraria from Amgen, AstraZeneca, Celgene, Lilly, MSD, Pfizer, Roche, Novartis, Daiichi Sankyo. Prof. Toralf Reimer received honoraria from Novartis, Pfizer, Lilly, Celgene and AstraZeneca. Prof. Andreas Schneeweiss received honoraria from Celgene, Roche, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly as well as research support from Celgene, Roche, AbbVie, Molecular Partner as well as travel grants from Celgene, Roche and Pfizer. Eva Schumacher-Wulff has no conflict of interest. Prof. Florian Schütz received honoraria for lectures and consultations from Amgen, AstraZeneca, ClinSol, MSD, Novartis, Pfizer, Riemser, Roche as well as a travel grant from AstraZeneca, Pfizer and Roche. PD Dr. Marc Thill received honoraria from Amgen, AstraZeneca, Aurikamed, BiomʼUp, Celgene, Daiichi Sankyo, Eisai, Genomic Health, Hexal, Lilly, MCI, Medtronic, MSD, Myriad, Neodynamics, Norgine, Novartis, OnkoLive, OmniaMed, pfm Medical, Pfizer, Roche, Tesaro, Teva, RTI Surgical, and research support from Genomic Health. Dr. med. Rachel Wuerstlein received honoraria from Agendia, Amgen, AstraZeneca, Boehringer Ingelheim, Carl Zeiss, Celgene, Daiichi-Sankyo, Esai, Genomic Health, GSK, Lilly, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PumaBiotechnology, Riemser, Roche, Sandoz/Hexal, Seattle Genetics, Tesaro Bio, Teva. Prof. Peter A. Fasching reports grants from Novartis, Cepheid and Biontech as well as personal contributions from Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, Teva, AstraZeneca, MSD, Myelo Therapeutics, Macrogenics, Eisai and Puma. Prof. Nadia Harbeck received honoraria from Agendia, Amgen, Celgene, Genomic Health, Lilly, MSD, Nanostring, Novartis, Pfizer, Roche, Sandoz. Prof. Michael Untch: Honoraria an den Arbeitgeber (für AdBoard-Teilnahme, Vorträge) sowie Reiseunterstützung von Amgen, AstraZeneca, BMS, Celgene, Daiichi Sankyo, Eisai, Janssen Cilag, Johnson & Johnson, Lilly Deutschland, Lilly International, MSD, Mundipharma, Myriad Genetics, Odonate, Pfizer, Puma Biotechnology, Riemser, Roche, Sanofi Aventis, Sividon Diagnostics, Teva Pharmaceuticals Ind. Ltd. Prof. Christoph Thomssen erhielt Honoraria von AstraZeneca, Celgene, Genomic Health, Novartis, NanoString, Pfizer, Roche und Forschungsunterstützung von NanoString. Dr. med. Ingo Bauerfeind hat keinen Interessenkonflikt. Prof. Michael Braun erhielt Honoraria von AstraZeneca, Celgene, Daiichi Sankyo, Genomic Health, Eisai, Genomic Health, GlaxoSmithKline, Medac, Novartis, Pfizer, Puma Biotechnology, Roche, Teva. Prof. Sara Brucker erhielt Honoraria von Novartis, Pfizer, AstraZeneca, Roche und Forschungsunterstützung von Genomic Health. Prof. Ricardo Felberbaum hat keinen Interessenkonflikt. Dr. med. Friederike Hagemann hat keinen Interessenkonflikt. Renate Haidinger hat keinen Interessenkonflikt. Prof. Arnd Hönig erhielt Honoraria von Amgen, AstraZeneca, Celgene, MSD, Pfizer, Roche, Novartis, sowie Forschungsunterstützung von Roche und Genentech und Reiseunterstützung von Roche, AstraZeneca, Daiichi Sankyo, Pfizer. Prof. Jens Huober erhielt Honoraria von Celgene, Roche, Novartis, Hexal, Pfizer, AstraZeneca, Lilly, Amgen, Eisai sowie Forschungsunterstützung von Celgene, Hexal, Novartis und Reiseunterstützung von Roche, Novartis und Celgene. Prof. Christian Jackisch erhielt Honoraria von Celgene, Novartis, Pfizer, AstraZeneca, Roche und Forschungsunterstützung von Genomic Health. Prof. Thorsten Kühn hat keinen Interessenkonflikt. PD Dr. Hans-Christian Kolberg erhielt Honoraria von Pfizer, Novartis, Roche, Genomic Health, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, Teva, Theraclion, Janssen-Cilag, GlaxoSmithKline, LIV Pharma sowie Honorare für Beratertätigkeit von Pfizer, Novartis, SurgVision, Carl Zeiss Meditec, Amgen, Onkowissen und hat Aktien von Theraclion SA, Phaon Scientific GmbH. Reiseunterstützung von Carl Zeiss Meditec, LIV Pharma, Novartis, Amgen, Pfizer und Daiichi Sankyo. Prof. Cornelia Kolberg-Liedtke erhielt Honoraria von Roche, AstraZeneca, Celgene, Novartis, Pfizer, Lilly, Hexal, Amgen, Eisai, SonoScape sowie Honorare für Beratertätigkeit von Phaon Scientific, Novartis, Pfizer, Celgene sowie Forschungsunterstützung von Roche, Novartis, Pfizer. Reiseunterstützung von Novartis und Roche. Prof. Diana Lüftner erhielt Honoraria von AstraZeneca, Celgene, Pfizer, Novartis, Amgen, Roche, Loreal, Teva, Tesaro und Eli Lilly. Prof. Nicolai Maass erhielt Honoraria von Amgen, AstraZeneca, Celgene, Lilly, MSD, Pfizer, Roche, Novartis und Daiichi Sankyo. Prof. Toralf Reimer erhielt Honoraria von Novartis, Pfizer, Lilly, Celgene und AstraZeneca. Prof. Andreas Schneeweiss erhielt Honoraria von Celgene, Roche, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly sowie Forschungsunterstützung von Celgene, Roche, AbbVie, Molecular Partner sowie Reiseunterstützung von Celgene, Roche und Pfizer. Eva Schumacher-Wulff hat keinen Interessenkonflikt. Prof. Florian Schütz erhielt Honoraria für Vorträge und Beratungen von Amgen, AstraZeneca, ClinSol, MSD, Novartis, Pfizer, Riemser, Roche sowie Reiseunterstützung von AstraZeneca, Pfizer und Roche. PD Dr. Marc Thill erhielt Honoraria von Amgen, AstraZeneca, Aurikamed, BiomʼUp, Celgene, Daiichi Sankyo, Eisai, Genomic Health, Hexal, Lilly, MCI, Medtronic, MSD, Myriad, Neodynamics, Norgine, Novartis, OnkoLive, OmniaMed, pfm Medical, Pfizer, Roche, Tesaro, Teva, RTI Surgical und Forschungsunterstützung von Genomic Health. Dr. med. Rachel Wuerstlein erhielt Honoraria von Agendia, Amgen, AstraZeneca, Boehringer Ingelheim, Carl Zeiss, Celgene, Daiichi-Sankyo, Esai, Genomic Health, GSK, Lilly, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PumaBiotechnology, Riemser, Roche, Sandoz/Hexal, Seattle Genetics, Tesaro Bio, Teva. Prof. Peter A. Fasching berichtet über Zuschüsse von Novartis, Cepheid und Biontech sowie persönliche Zuwendungen von Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, Teva, AstraZeneca, MSD, Myelo Therapeutics, Macrogenics, Eisai und Puma. Prof. Nadia Harbeck erhielt Honoraria von Agendia, Amgen, Celgene, Genomic Health, Lilly, MSD, Nanostring, Novartis, Pfizer, Roche, Sandoz.",,"Michael Untch 1 , Christoph Thomssen 2 , Ingo Bauerfeind 3 , Michael Braun 4 , Sara Y Brucker 5 , Ricardo Felberbaum 6 , Friederike Hagemann 7 , Renate Haidinger 8 , Arnd Hönig 9 , Jens Huober 10 , Christian Jackisch 11 , Hans-Christian Kolberg 12 , Cornelia Kolberg-Liedtke 13 , Thorsten Kühn 14 , Diana Lüftner 15 , Nicolai Maass 16 , Toralf Reimer 17 , Andreas Schneeweiss 18 , Eva Schumacher-Wulf 19 , Florian Schütz 20 , Marc Thill 21 , Rachel Wuerstlein 7 , Peter A Fasching 22 , Nadia Harbeck 7"
31401601,"Understanding pathways to stimulant use: a mixed-methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe (ATTUNE): study protocol","Moritz Rosenkranz 1, Amy ODonnell 2, Uwe Verthein 3, Heike Zurhold 3, Michelle Addison 4, Nienke Liebregts 5, Magdalena Rowicka 6, Miroslav Barták 7, Benjamin Petruželka 7, Eileen Fs Kaner 2, Marcus-Sebastian Martens 3",BMJ Open. 2019 Aug 10;9(8):e029476. doi: 10.1136/bmjopen-2019-029476.,Rosenkranz M,BMJ Open,2019,2019/08/12,PMC6701668,,10.1136/bmjopen-2019-029476,https://pubmed.ncbi.nlm.nih.gov/31401601/,/31401601/,Competing interests: UV received a speaker’s honoraria and travelling expenses from Mundipharma GmbH. AOD was funded by an NIHR School for Primary Care Research Fellowship between October 2015 and September 2017.,,"Moritz Rosenkranz 1 , Amy ODonnell 2 , Uwe Verthein 3 , Heike Zurhold 3 , Michelle Addison 4 , Nienke Liebregts 5 , Magdalena Rowicka 6 , Miroslav Barták 7 , Benjamin Petruželka 7 , Eileen Fs Kaner 2 , Marcus-Sebastian Martens 3"
31064345,Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries,"Jan Tack 1 2, Vincenzo Stanghellini 3, Fermín Mearin 4, Yan Yiannakou 5, Peter Layer 6, Benoit Coffin 7, Magnus Simren 8, Jonathan Mackinnon 9, Gwen Wiseman 10, Anne Marciniak 10 ; IBIS-C Study group",BMC Gastroenterol. 2019 May 7;19(1):69. doi: 10.1186/s12876-019-0985-1.,Tack J,BMC Gastroenterol,2019,2019/05/09,PMC6505116,,10.1186/s12876-019-0985-1,https://pubmed.ncbi.nlm.nih.gov/31064345/,/31064345/,"The following ethics committees approved the trial protocol and its amendments: Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le domaine de la Santé (Paris, France), Israelitisches Krankenhaus (Hamburg, Germany), University of Bologna (Bologna, Italy), Humanitas Hospital IRCS (Milano, Italy), Floraspe Renzetti Hospital (Lanciano, Italy), Agostino Gemelli University Hospital (Rome, Italy), University of Parma (Parma, Italy), University of Pisa (Pisa, Italy), University of Pescara (Pescara, Italy), Careggi University (Firence, Italy), University of Napoli Federico II (Napoli, Italy), University of L’Aquila (L’Aquila, Italy), University of Messina (Messina, Italy), University of Genoa (Genoa, Italy). Ospedale S. Maria di Ca′ Foncello (Treviso, Italy), Fondazione IRCCS Policlinico San Matteo (Pavia, Italy), Centro médico Teknon (Barcelona, Spain), Hospital Clínico San Carlos (Madrid, Spain), Hospital Universitario 12 de Octubre (Madrid, Spain), Hospital Germans Trias I Pujol (Badalona, Spain), Hospital de Bellvitge (Barcelona, Spain), Consorci Sanitari del Maresme (Mataró, Spain), Hospital Universitario Virgen de la Macarena (Sevilla, Spain), Hospital Universitari Doctor Josep Trueta (Girona, Spain), Hospital Universitari Sant Joan de Reus (Reus, Spain), National Institute for Health Research (London, UK). Not applicable. JT receives grants and/or research support from Abbott, Novartis and Shire; honoraria and/or consultancy fees from Almirall, AstraZeneca, Danone, GI Dyamics, GlaxoSmithKline, Ironwood, Janssen, Menarini, Novartis, Rhythm, Shire, Takeda, Theravance, Tsumura, Will Pharma and Zeria; and speaker fees from Abbott, Almirall, AstraZeneca, Janssen, Menarini, Novartis, Shire, Takeda and Zeria. VS receives grants and/or research support from Alfa Wassermann, Almirall, Aptalis, Italchimici, Norgine, Shire, Takeda, Valeas; honoraria and/or consultancy fees from Abbott, Alfa Wasserman, Almirall, Angelini, Aptalis, CM&D Pharma, Farmaderma, Ironwood, Norgine, Shire, Takeda, Valeas, Vibrant and Zeria. FM receives speaker fees from Almirall. YY receives grants from Shire; Medtronic; and speaker fees from Almirall, Shire, and Sucampo. PL receives financial support from Abbott / Solvay, Almirall, Aptalis / Axcan, Norgine, and Shire. BC receives honoraria and/or consultancy fees from Almirall, Mundipharma, Mayoly Spindler, and Menarini. MS receives unrestricted research grants from Danone, and AstraZeneca; consultant and/or Advisory Board member fees from Danone, Nestlé, Chr Hansen, Almirall, Albireo and Shire; participation fees for company-sponsored speaker’s bureau from Almirall, Shire, Tillotts and Takeda. JM is an employee of TFS Develop S.L, contracted by Almirall S.A to conduct the study. GW and AM are employees of Allergan International. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",,"Jan Tack 1 2 , Vincenzo Stanghellini 3 , Fermín Mearin 4 , Yan Yiannakou 5 , Peter Layer 6 , Benoit Coffin 7 , Magnus Simren 8 , Jonathan Mackinnon 9 , Gwen Wiseman 10 , Anne Marciniak 10 ; IBIS-C Study group"
31136632,New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study,"Matthias Englbrecht 1 2, Rieke Alten 3, Martin Aringer 4, Christoph G Baerwald 5, Harald Burkhardt 6, Nancy Eby 7, Jan-Paul Flacke 8, Gerhard Fliedner 9, Ulf Henkemeier 6, Michael W Hofmann 10, Stefan Kleinert 11 12, Christian Kneitz 13 14, Klaus Krüger 15, Christoph Pohl 3, Georg Schett 2, Marc Schmalzing 12, Anne-Kathrin Tausche 4, Hans-Peter Tony 12, Jörg Wendler 11",PLoS One. 2019 May 28;14(5):e0217412. doi: 10.1371/journal.pone.0217412. eCollection 2019.,Englbrecht M,PLoS One,2019,2019/05/29,PMC6538160,,10.1371/journal.pone.0217412,https://pubmed.ncbi.nlm.nih.gov/31136632/,/31136632/,"This work was funded by Roche Pharma AG and Chugai Pharma Europe Ltd. Besides Dr. Flacke’s and Dr. Hofmann’s support at the study conception phase and the review of the statistical analysis plan by an independent statistician on behalf of Roche, Roche Pharma AG and Chugai Pharma Europe Ltd. had no further direct role in the collection, analysis, or interpretation of the data. AMS Advanced Medical Services GmbH (Mannheim, Germany) was involved in the study as a contract research organization on behalf of the study sponsors conducting the data analysis in collaboration with the scientific project leaders and supporting manuscript preparation. Drs. Englbrecht, Alten, Aringer, Baerwald, Burkhardt, Fliedner, Kleinert, Kneitz, Krueger, Schett, Schmalzing, Tausche, Tony, and Wendler received grants, honoraria, consulting fees, and/or speaking fees (less than $10,000 each) from Roche Pharma AG and Chugai Pharma Europe Ltd. Dr. Englbrecht has received speaker’s fees, compensation for consultancies or board memberships from: AbbVie, Celgene, Lilly, Mundipharma, Novartis, Pfizer, UCB. Dr. Aringer reports AbbVie, Astra Zeneca, Boehringer Ingelheim, Chugai, GSK, HEXAL, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz and Sanofi advisory boards, speaking fees and/or congress support. Dr. Baewald has received travel grants and speaking honoraria or is on advisory boards for Abbvie, Amgen, Biogen, BMS, Janssen, Lilly, MSD, Pfizer and UCB. Dr. Fliedner is on advisory boards for Abbvie, BMS, and Pfizer and has participated in meetings for UBC, Lilly, and Pfizer. Dr. Schett’s work was supported by the Metarthros program of the BMBF. Dr. Schmalzing has received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from: Abbvie, Actelion, BMS, Celgene, Genzyme, Hexal/Sandoz, Janssen‐Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Shire (Baxalta), and UCB. Dr. Wendler is a member of Roche and Chugai advisory boards. Dr. Kneitz has received speaker’s fees, compensation for consultancies or board memberships of: AbbVie, Berlin Chemie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. Dr. Eby received fees from Roche Pharma AG for manuscript preparation and statistical analysis. Dr. Flacke is an employee of Roche Pharma AG. and Dr. Hofmann is an employee of Chugai Pharma Europe Ltd. Editorial assistance for this manuscript was provided by Physicians World Europe (Mannheim, Germany), sponsored by Roche Pharma AG. Funding by corporate entities does not alter our adherence to PLOS ONE policies on sharing data and materials.","Grants and funding This work was supported by Roche Pharma AG and Chugai Pharma Europe Ltd. Drs. Englbrecht, Alten, Aringer, Baerwald, Burkhardt, Fliedner, Kleinert, Kneitz, Krueger, Schett, Schmalzing, Tausche, Tony, and Wendler received funding. Data analysis was done by AMS – Advanced Medical Services GmbH (Mannheim, Germany) and was funded by Roche Pharma AG and Chugai Pharma Europe Ltd.","Matthias Englbrecht 1 2 , Rieke Alten 3 , Martin Aringer 4 , Christoph G Baerwald 5 , Harald Burkhardt 6 , Nancy Eby 7 , Jan-Paul Flacke 8 , Gerhard Fliedner 9 , Ulf Henkemeier 6 , Michael W Hofmann 10 , Stefan Kleinert 11 12 , Christian Kneitz 13 14 , Klaus Krüger 15 , Christoph Pohl 3 , Georg Schett 2 , Marc Schmalzing 12 , Anne-Kathrin Tausche 4 , Hans-Peter Tony 12 , Jörg Wendler 11"
30815927,Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan,"Wataru Munakata 1, Kiyoshi Ando 2, Kiyohiko Hatake 3, Noriko Fukuhara 4, Tomohiro Kinoshita 5, Suguru Fukuhara 1, Yukari Shirasugi 2, Masahiro Yokoyama 3, Satoshi Ichikawa 4, Ken Ohmachi 2, Naokazu Gion 6, Arata Aoi 7, Kensei Tobinai 1",Cancer Sci. 2019 May;110(5):1686-1694. doi: 10.1111/cas.13983. Epub 2019 Mar 28.,Munakata W,Cancer Sci,2019,2019/03/01,PMC6500982,,10.1111/cas.13983,https://pubmed.ncbi.nlm.nih.gov/30815927/,/30815927/,"W. Munakata has received grants from Ono Pharmaceutical Co., Ltd. K. Ando has received grants from Ono Pharmaceutical Co., Ltd. K. Hatake has received grants from Ono Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. N. Fukuhara has received grants from Ono Pharmaceutical Co., Ltd. T. Kinoshita has received grants and/or personal fees from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Solasia Pharma K.K., Ono Pharmaceutical Co., Ltd., Gilead Sciences, Inc., MSD, Zenyaku Kogyo, Bristol‐Myers Squibb, Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., and Janssen Pharmaceutica. S. Fukuhara has received grants from Ono Pharmaceutical Co., Ltd. Y. Shirasugi has received personal fees from Novartis. M. Yokoyama has received grants from Ono Pharmaceutical Co., Ltd. and personal fees from Chugai Pharmaceutical Co., Ltd. S. Ichikawa has received grants from Ono Pharmaceutical Co., Ltd. K. Ohmachi has received grants from Ono Pharmaceutical Co., Ltd. and personal fees from Ono Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Takeda Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd. N. Gion is an employee of Ono Pharmaceutical Co., Ltd., and has received personal fees. A. Aoi is an employee of Ono Pharmaceutical Co., Ltd., and has received personal fees. K. Tobinai has received grants and/or personal fees from Ono Pharmaceutical Co., Ltd., Celgene, Zenyaku Kogyo, HUYA Bioscience International LLC, Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mundipharma, Janssen Pharmaceutical, Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., GlaxoSmithKline, and AbbVie Inc.","Grants and funding Ono Pharmaceutical Co., Ltd","Wataru Munakata 1 , Kiyoshi Ando 2 , Kiyohiko Hatake 3 , Noriko Fukuhara 4 , Tomohiro Kinoshita 5 , Suguru Fukuhara 1 , Yukari Shirasugi 2 , Masahiro Yokoyama 3 , Satoshi Ichikawa 4 , Ken Ohmachi 2 , Naokazu Gion 6 , Arata Aoi 7 , Kensei Tobinai 1"
31656696,Reduced P2X receptor levels are associated with antidepressant effect in the learned helplessness model,"Deidiane Elisa Ribeiro # 1 2 3, Plinio C Casarotto # 4, Laura Staquini 1, Maria Augusta Pinto E Silva 5, Caroline Biojone 4, Gregers Wegener 2, Samia Joca 5 6",PeerJ. 2019 Oct 21;7:e7834. doi: 10.7717/peerj.7834. eCollection 2019.,Ribeiro DE,PeerJ,2019,2019/10/29,PMC6812674,,10.7717/peerj.7834,https://pubmed.ncbi.nlm.nih.gov/31656696/,/31656696/,"Gregers Wegener received lecture/consultancy fees from H. Lundbeck A/S, Servier SA, Astra Zeneca AB, Eli Lilly A/S, Sun Pharma Pty Ltd, Pfizer Inc, Shire A/S, HB Pharma A/S, Arla Foods A.m.b.A., Alkermes Inc, and Mundipharma International Ltd. All other authors declare no conflict of interest.","Grants and funding This study was funded by the State of São Paulo Research Foundation (2013/01737-7) and Aarhus University Research Foundation (AU-UDEAS initiative: eMOOD, and a Mobility Stipend to Deidiane Elisa Ribeiro). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","Deidiane Elisa Ribeiro # 1 2 3 , Plinio C Casarotto # 4 , Laura Staquini 1 , Maria Augusta Pinto E Silva 5 , Caroline Biojone 4 , Gregers Wegener 2 , Samia Joca 5 6"
31164169,A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine (ice) dependence,"Rebecca McKetin 1, Olivia M Dean 2 3 4, Alyna Turner 2 4 5, Peter J Kelly 6, Brendan Quinn 7, Dan I Lubman 8 9, Paul Dietze 7, Gregory Carter 5, Peter Higgs 10, Amanda L Baker 5, Barbara Sinclair 11, David Reid 11, Victoria Manning 8 9, Nina Te Pas 12, Wenbin Liang 12, Tamsin Thomas 6, Ramez Bathish 8 9, Margaret Kent 2, Dayle Raftery 6, Shalini Arunogiri 8 9, Frank Cordaro 11, Harry Hill 13, Michael Berk 2 3 4 14",Trials. 2019 Jun 4;20(1):325. doi: 10.1186/s13063-019-3450-0.,McKetin R,Trials,2019,2019/06/06,PMC6549263,,10.1186/s13063-019-3450-0,https://pubmed.ncbi.nlm.nih.gov/31164169/,/31164169/,"OMD has received grant support from Lilly and ASBDD/Servier and in-kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. MB has received grant support from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, the Meat and Livestock Board, Novartis, Mayne Pharma and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth; and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck and Servier. DIL has provided consultancy advice to Lundbeck and Indivior, and has received travel support and speaker honoraria from Astra Zeneca, Indivior, Janssen, Lundbeck, Servier and Shire. PD has received investigator-initiated funding from Gilead Sciences, an untied educational grant from Indivior and is an unpaid member of an advisory board for Mundipharma for work unrelated to this study.",Grants and funding 1128147/Australian National Health and Medical Research Council,"Rebecca McKetin 1 , Olivia M Dean 2 3 4 , Alyna Turner 2 4 5 , Peter J Kelly 6 , Brendan Quinn 7 , Dan I Lubman 8 9 , Paul Dietze 7 , Gregory Carter 5 , Peter Higgs 10 , Amanda L Baker 5 , Barbara Sinclair 11 , David Reid 11 , Victoria Manning 8 9 , Nina Te Pas 12 , Wenbin Liang 12 , Tamsin Thomas 6 , Ramez Bathish 8 9 , Margaret Kent 2 , Dayle Raftery 6 , Shalini Arunogiri 8 9 , Frank Cordaro 11 , Harry Hill 13 , Michael Berk 2 3 4 14"
30617197,Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL,"Magdalena Klanova 1 2 3, Laurie H Sehn 4, Isabelle Bence-Bruckler 5, Federica Cavallo 6, Jie Jin 7, Maurizio Martelli 8, Douglas Stewart 9, Umberto Vitolo 10, Francesco Zaja 11, Qingyuan Zhang 12, Federico Mattiello 13, Gila Sellam 3, Elizabeth A Punnoose 14, Edith Szafer-Glusman 14, Christopher R Bolen 15, Mikkel Z Oestergaard 16, Guenter R Fingerle-Rowson 3, Tina Nielsen 3, Marek Trneny 1",Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7.,Klanova M,Blood,2019,2019/01/09,PMC6396175,,10.1182/blood-2018-07-862862,https://pubmed.ncbi.nlm.nih.gov/30617197/,/30617197/,"Conflict-of-interest disclosure: M.K. was employed by F. Hoffmann-La Roche Ltd. during the time of the analysis. L.H.S. has acted as a consultant for and received honoraria from Roche/Genentech, Amgen, Janssen, Celgene, AbbVie, and Seattle Genetics. I.B.-B. has served as a member of the advisory board for F. Hoffmann-La Roche Ltd. M.M. has acted as a consultant for F. Hoffmann-La Roche Ltd., Janssen, Sandoz, Takeda, Celgene, and Mundipharma; has served as a member of the speaker’s bureau for F. Hoffman-La Roche Ltd. and Takeda; and has served on the advisory board for F. Hoffmann-La Roche Ltd., Janssen, and Sandoz. D.S. has served on the advisory board for, and received research funding from, as part of a clinical trial, F. Hoffmann-La Roche Ltd. U.V. has received research funding from F. Hoffmann-La Roche Ltd.; has received honoraria from F. Hoffmann-La Roche Ltd., Takeda, and Gilead; and has served as a member of the advisory board for F. Hoffmann-La Roche Ltd., Celgene, and Janssen. F.Z. has acted as a consult or advisor for F. Hoffmann-La Roche Ltd., Janssen, Novartis, and Celgene; has served as a member of the speaker’s bureau for F. Hoffmann-La Roche Ltd., Celgene, Novartis, Gilead, and Takeda; and has received research funding from Celgene and Novartis. F.M., G.S., M.Z.O., G.R.F.-R., and T.N. are employees of F. Hoffmann-La Roche Ltd., and G.R.F.-R. owns stock in F. Hoffmann-La Roche Ltd. E.A.P., E.S.-G., and C.R.B. are employees of Genentech Inc. M.T. has received honoraria, research funding, travel, accommodations and/or expenses from, and has acted as a consultant or advisor to, F. Hoffmann-La Roche Ltd. The remaining authors declare no competing financial interests.",,"Magdalena Klanova 1 2 3 , Laurie H Sehn 4 , Isabelle Bence-Bruckler 5 , Federica Cavallo 6 , Jie Jin 7 , Maurizio Martelli 8 , Douglas Stewart 9 , Umberto Vitolo 10 , Francesco Zaja 11 , Qingyuan Zhang 12 , Federico Mattiello 13 , Gila Sellam 3 , Elizabeth A Punnoose 14 , Edith Szafer-Glusman 14 , Christopher R Bolen 15 , Mikkel Z Oestergaard 16 , Guenter R Fingerle-Rowson 3 , Tina Nielsen 3 , Marek Trneny 1"
30886139,Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature,"Paula Rodríguez-Otero 1, María Victoria Mateos 2, Joaquín Martínez-López 3, Miguel-Teodoro Hernández 4, Enrique M Ocio 2, Laura Rosiñol 5, Rafael Martínez 6, Ana-Isabel Teruel 7, Norma C Gutiérrez 2, Joan Bargay 8, Enrique Bengoechea 9, Yolanda González 10, Jaime Pérez de Oteyza 11, Mercedes Gironella 12, Jorge M Nuñez-Córdoba 13, Cristina Encinas 14, Jesús Martín 15, Carmen Cabrera 16, Luis Palomera 17, Felipe de Arriba 18, María Teresa Cedena 3, Noemí Puig 2, Albert Oriol 19, Bruno Paiva 1, Joan Bladé 6, Juan José Lahuerta 4, Jesús F San Miguel 20",Blood Cancer J. 2019 Mar 18;9(4):36. doi: 10.1038/s41408-019-0176-x.,Rodríguez-Otero P,Blood Cancer J,2019,2019/03/20,PMC6423121,,10.1038/s41408-019-0176-x,https://pubmed.ncbi.nlm.nih.gov/30886139/,/30886139/,"P.R.-O.: has served on the speaker’s bureau and as a member of advisory boards for Janssen, Celgene, BMS, and Takeda. M.V.M.: has declared consultancy for: Janssen, Celgene, Takeda, and Amgen. E.M.O.: has declared consultancy for or honoraria from: Mundipharma, Celgene, Amgen, Novartis, Takeda, AbbVie, BMS, and Janssen. B.P.: has declared grants from Celgene, EngMab, Sanofi, and Takeda, and received honoraria for lectures and advisory boards from Amgen, BMS, Celgene, Janssen, Takeda, Sanofi, and Novartis. J.F.S.M.: received honoraria as part of Advisory boards from Celgene, Novartis, Millenium, Janssen, Amgen, MSD, Sanofi, and BMS. A.O.: has served as a member of advisory boards for Janssen and Celgene. J.B.: received honoraria for lectures and advisory boards from Celgene and Janssen and grant support from Janssen. L.R.: received honoraria from Janssen and Celgene. The remaining authors declare that they have no conflict of interest.",,"Paula Rodríguez-Otero 1 , María Victoria Mateos 2 , Joaquín Martínez-López 3 , Miguel-Teodoro Hernández 4 , Enrique M Ocio 2 , Laura Rosiñol 5 , Rafael Martínez 6 , Ana-Isabel Teruel 7 , Norma C Gutiérrez 2 , Joan Bargay 8 , Enrique Bengoechea 9 , Yolanda González 10 , Jaime Pérez de Oteyza 11 , Mercedes Gironella 12 , Jorge M Nuñez-Córdoba 13 , Cristina Encinas 14 , Jesús Martín 15 , Carmen Cabrera 16 , Luis Palomera 17 , Felipe de Arriba 18 , María Teresa Cedena 3 , Noemí Puig 2 , Albert Oriol 19 , Bruno Paiva 1 , Joan Bladé 6 , Juan José Lahuerta 4 , Jesús F San Miguel 20"
31443252,Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial,"Malgorzata Banys-Paluchowski 1, Sibylle Loibl 2, Isabell Witzel 3, Christoph Mundhenke 4, Bianca Lederer 2, Christine Solbach 5, Thomas Karn 5, Frederik Marmé 6, Valentina Nekljudova 2, Christian Schem 7, Elmar Stickeler 8, Nicholas Willumsen 9, Morten A Karsdal 9, Michael Untch 10, Volkmar Müller 11",Cancers (Basel). 2019 Aug 15;11(8):1186. doi: 10.3390/cancers11081186.,Banys-Paluchowski M,Cancers (Basel),2019,2019/08/25,PMC6721504,,10.3390/cancers11081186,https://pubmed.ncbi.nlm.nih.gov/31443252/,/31443252/,"MBP received lecture honoraria or consultant fees from Roche, Novartis, Eli Lilly, Eisai and Pfizer. VM received lecture honoraria from Amgen, AstraZeneca, Celgene, Daiichi, Eisai, Pfizer, Novartis, served as a consultant/advisor to Hexal, Roche, Pfizer, Amgen, Daiichi, Nektar and Eisai and received research grants from Roche, Novartis, Seattle Genetics and Pfizer. I.W. received honoraria from Roche, Pfizer, Novartis, Pierre Fabre Pharma and Daichii Sankyo. M.U.’s institution/employer has received lecture honoraria and consultant fees from Abbvie, Amgen, Astra Zeneca, Celgene, Daiji Sankyo, Eisai, Lilly, MSD Merck, Mundipharma, Myriad Genetics, Novartis, Pfizer, PUMA Biotechnology, Roche Pharma, Sanofi Aventis, TEVA Pharmaceuticals. FM received honoraria from Roche, AstraZeneca, Clovis, Celgene, Genomic Health, Tesaro, MSD, Pfizer, Eisai and served as a consultant or in an advisory role for MSD, Eisai, Amgen, Roche, AstraZeneca, Novartis, Curevac. C.So. reports personal fees and non-financial support from Olympus Europa, personal fees from Roche, personal fees and non-financial support from Mylan, personal fees from Pfizer, personal fees and non-financial support from Medtronic, personal fees from Astra Zeneca, outside the submitted work. T.K., C.Sc., C.M., B.L., V.N., S.L. and E.S. declare no conflict of interest. N.W. and M.A.K. are employees at Nordic Bioscience A/S. M.A.K. owns stocks at Nordic Bioscience A/S. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.",Grants and funding NCT00567554/Celgene NCT00567554/Roche NCT00567554/Nordic Bioscience,"Malgorzata Banys-Paluchowski 1 , Sibylle Loibl 2 , Isabell Witzel 3 , Christoph Mundhenke 4 , Bianca Lederer 2 , Christine Solbach 5 , Thomas Karn 5 , Frederik Marmé 6 , Valentina Nekljudova 2 , Christian Schem 7 , Elmar Stickeler 8 , Nicholas Willumsen 9 , Morten A Karsdal 9 , Michael Untch 10 , Volkmar Müller 11"
31324936,Computational modelling reveals contrasting effects on reinforcement learning and cognitive flexibility in stimulant use disorder and obsessive-compulsive disorder: remediating effects of dopaminergic D2/3 receptor agents,"Jonathan W Kanen 1 2, Karen D Ersche 3 4, Naomi A Fineberg 4 5 6, Trevor W Robbins 7 3, Rudolf N Cardinal 3 4 8",Psychopharmacology (Berl). 2019 Aug;236(8):2337-2358. doi: 10.1007/s00213-019-05325-w. Epub 2019 Jul 20.,Kanen JW,Psychopharmacology (Berl),2019,2019/07/21,PMC6820481,,10.1007/s00213-019-05325-w,https://pubmed.ncbi.nlm.nih.gov/31324936/,/31324936/,"T.W.R. discloses consultancy with Cambridge Cognition, Lundbeck, Mundipharma and Unilever; he receives royalties for CANTAB from Cambridge Cognition and editorial honoraria from Springer Verlag and Elsevier. N.A.F. reports the following commercial interests, all outside the research work: in the past 2 years, she has received personal fees for giving lectures from Abbott, Otsuka-Lundbeck, RANZCP, BAP and Wiley; payment for editorial duties from Taylor and Francis; royalties from Oxford University Press; payment for consultancy from the MHRA; research or educational grants from Shire, ECNP, NIHR, MRC and Wellcome Trust; nonfinancial support from Shire, ECNP, BAP, CINP, International Forum of Mood and Anxiety Disorders, International College of Obsessive Compulsive Spectrum Disorders and RCPsych. R.N.C. consults for Campden Instruments and receives royalties from Cambridge Enterprise, Routledge, and Cambridge University Press. K.D.E. and J.W.K. declare no conflicts of interest.",Grants and funding MC_PC_17213/MRC_/Medical Research Council/United Kingdom MR/M009041/1/MRC_/Medical Research Council/United Kingdom,"Jonathan W Kanen 1 2 , Karen D Ersche 3 4 , Naomi A Fineberg 4 5 6 , Trevor W Robbins 7 3 , Rudolf N Cardinal 3 4 8"
30945207,Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting,"Evelien Moorkens 1, Steven Simoens 1, Per Troein 2, Paul Declerck 1, Arnold G Vulto 3 4, Isabelle Huys 1",BioDrugs. 2019 Jun;33(3):285-297. doi: 10.1007/s40259-019-00345-6.,Moorkens E,BioDrugs,2019,2019/04/05,PMC6533410,,10.1007/s40259-019-00345-6,https://pubmed.ncbi.nlm.nih.gov/30945207/,/30945207/,"SS, IH and AV have conducted biosimilar research sponsored by Hospira (now Pfizer). SS was involved in a stakeholder roundtable on biosimilars sponsored by Amgen, Pfizer and MSD and has participated in an advisory board meeting for Pfizer. SS currently works with Pfizer, and works with Celltrion as a consultant to carry out biosimilar research. AV is involved in consulting, advisory work and speaking engagements for a number of companies, including AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche and Sandoz. PD participated in advisory board meetings for AbbVie, Amgen and Hospira and is on the speakers’ bureaux of AbbVie, Celltrion, Hospira, Merck Serono and Roche. PT is employed by IQVIA™. EM has no conflicts of interest that are directly relevant to the content of this article. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA™ or any of its affiliated or subsidiary entities.",,"Evelien Moorkens 1 , Steven Simoens 1 , Per Troein 2 , Paul Declerck 1 , Arnold G Vulto 3 4 , Isabelle Huys 1"
30718459,Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study,"Bernhard M Meyer 1, Ulrich Rabl 1, Julia Huemer 2, Lucie Bartova 1, Klaudius Kalcher 3 4, Julian Provenzano 1, Christoph Brandner 1, Patrick Sezen 1, Siegfried Kasper 1, Alan F Schatzberg 5, Ewald Moser 3 4, Gang Chen 6, Lukas Pezawas 7",Transl Psychiatry. 2019 Feb 4;9(1):64. doi: 10.1038/s41398-019-0395-8.,Meyer BM,Transl Psychiatry,2019,2019/02/06,PMC6362173,,10.1038/s41398-019-0395-8,https://pubmed.ncbi.nlm.nih.gov/30718459/,/30718459/,"Siegfried Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Alan F. Schatzberg reports conflicts of interest. Consultant: Bay City Capital, CeNeRx, Cervel, Clintara, Depomed, Eli Lilly, Forum (EnVivo), Genentech, Gilead, Jazz, Lundbeck/Takeda, McKinsey, MSI, Myriad Genetics, Naurex, Neuronetics, One Carbon, Pfizer, PharmaNeuroBoost, Sunovion, Xhale. Intellectual property: Named inventor on pharmacogenetic use patents on prediction of antidepressant response and glucocorticoid antagonists in psychiatry. Equity: Amnestix, CeNeRx, Corcept (co-founder), Forest Labs, Gilead, Incyte, Merck, Neurocrine, Pfizer, PharmaNeuroBoost, Seattle Genetics, Synosia, Titan, Xhale. The remaining authors declare that they have no conflict of interest.",,"Bernhard M Meyer 1 , Ulrich Rabl 1 , Julia Huemer 2 , Lucie Bartova 1 , Klaudius Kalcher 3 4 , Julian Provenzano 1 , Christoph Brandner 1 , Patrick Sezen 1 , Siegfried Kasper 1 , Alan F Schatzberg 5 , Ewald Moser 3 4 , Gang Chen 6 , Lukas Pezawas 7"
31754074,Response: The most fundamental change in asthma management in 30\u2005years?,Helen K Reddel 1 ; members of the GINA Science Committee and Board,Eur Respir J. 2019 Nov 21;54(5):1901860. doi: 10.1183/13993003.01860-2019. Print 2019 Nov.,Reddel HK,Eur Respir J,2019,2019/11/23,,,10.1183/13993003.01860-2019,https://pubmed.ncbi.nlm.nih.gov/31754074/,/31754074/,"Conflict of interest: H. Reddel reports grants and personal fees for data monitoring committee and advisory board work, providing independent medical education, and consultancy from AstraZeneca, grants, personal fees for data monitoring committee and advisory board work, providing independent medical education, and consultancy, and non-financial support (study medication) from GlaxoSmithKline, personal fees for data monitoring committee work from Merck, grants and personal fees for data monitoring committee and advisory board work, and providing independent medical education from Novartis, personal fees for providing independent medical education from Teva and Mundipharma, personal fees for providing independent medical education and advisory board work from Boehringer Ingelheim, personal fees for advisory board work from Sanofi-Genzyme, outside the submitted work; and is Chair of the GINA Scientific Committee.",,Helen K Reddel 1 ; members of the GINA Science Committee and Board
30929187,"Response to A Rigorous Evaluation of Methoxyflurane is Needed: Comment on \Methoxyflurane Versus Standard of Care for Acute Trauma-Related Pain in the Emergency Setting: Protocol for a Randomised, Controlled Study in Italy (MEDITA)\","Andrea Fabbri 1, Giuseppe Carpinteri 2, Germana Ruggiano 3, Elisabetta Bonafede 4, Antonella Sblendido 5, Alberto Farina 6, Amedeo Soldi 5",Adv Ther. 2019 Jun;36(6):1243-1245. doi: 10.1007/s12325-019-00937-2. Epub 2019 Mar 30.,Fabbri A,Adv Ther,2019,2019/04/01,PMC6824380,,10.1007/s12325-019-00937-2,https://pubmed.ncbi.nlm.nih.gov/30929187/,/30929187/,,,"Andrea Fabbri 1 , Giuseppe Carpinteri 2 , Germana Ruggiano 3 , Elisabetta Bonafede 4 , Antonella Sblendido 5 , Alberto Farina 6 , Amedeo Soldi 5"
31033438,A consensus guide to capturing the ability to inhibit actions and impulsive behaviors in the stop-signal task,"Frederick Verbruggen 1, Adam R Aron 2, Guido Ph Band 3, Christian Beste 4, Patrick G Bissett 5, Adam T Brockett 6, Joshua W Brown 7, Samuel R Chamberlain 8, Christopher D Chambers 9, Hans Colonius 10, Lorenza S Colzato 3, Brian D Corneil 11, James P Coxon 12, Annie Dupuis 13, Dawn M Eagle 8, Hugh Garavan 14, Ian Greenhouse 15, Andrew Heathcote 16, René J Huster 17, Sara Jahfari 18, J Leon Kenemans 19, Inge Leunissen 20, Chiang-Shan R Li 21, Gordon D Logan 22, Dora Matzke 23, Sharon Morein-Zamir 24, Aditya Murthy 25, Martin Paré 26, Russell A Poldrack 5, K Richard Ridderinkhof 23, Trevor W Robbins 8, Matthew Roesch 6, Katya Rubia 27, Russell J Schachar 13, Jeffrey D Schall 22, Ann-Kathrin Stock 4, Nicole C Swann 15, Katharine N Thakkar 28, Maurits W van der Molen 23, Luc Vermeylen 1, Matthijs Vink 19, Jan R Wessel 29, Robert Whelan 30, Bram B Zandbelt 31, C Nico Boehler 1",Elife. 2019 Apr 29;8:e46323. doi: 10.7554/eLife.46323.,Verbruggen F,Elife,2019,2019/04/30,PMC6533084,,10.7554/eLife.46323,https://pubmed.ncbi.nlm.nih.gov/31033438/,/31033438/,"FV, GB, PB, AB, JB, CC, HC, LC, BC, JC, AD, DE, HG, IG, AH, RH, SJ, JK, IL, CL, GL, DM, SM, AM, MP, RP, KR, MR, JS, AS, KT, Mv, LV, MV, JW, RW, BZ, CB No competing interests declared, AA, NS Reviewing editor, eLife, CB has received payment for consulting and speakers honoraria from GlaxoSmithKline, Novartis, Genzyme, and Teva. He has recent research grants with Novartis and Genzyme, SC consults for Shire, Ieso Digital Health, Cambridge Cognition, and Promentis. Dr Chamberlains research is funded by Wellcome Trust (110049/Z/15/Z), TR consults for Cambridge Cognition, Mundipharma and Unilever. He receives royalties from Cambridge Cognition (CANTAB) and has recent research grants with Shionogi and SmallPharma, KR has received speakers honoraria and grants for other projects from Eli Lilly and Shire, RS has consulted to Highland Therapeutics, Eli Lilly and Co., and Purdue Pharma. He has commercial interest in a cognitive rehabilitation software company, eHave",Grants and funding U54 HD083211/HD/NICHD NIH HHS/United States UL1 TR001863/TR/NCATS NIH HHS/United States 769595/H2020 European Research Council/International,"Frederick Verbruggen 1 , Adam R Aron 2 , Guido Ph Band 3 , Christian Beste 4 , Patrick G Bissett 5 , Adam T Brockett 6 , Joshua W Brown 7 , Samuel R Chamberlain 8 , Christopher D Chambers 9 , Hans Colonius 10 , Lorenza S Colzato 3 , Brian D Corneil 11 , James P Coxon 12 , Annie Dupuis 13 , Dawn M Eagle 8 , Hugh Garavan 14 , Ian Greenhouse 15 , Andrew Heathcote 16 , René J Huster 17 , Sara Jahfari 18 , J Leon Kenemans 19 , Inge Leunissen 20 , Chiang-Shan R Li 21 , Gordon D Logan 22 , Dora Matzke 23 , Sharon Morein-Zamir 24 , Aditya Murthy 25 , Martin Paré 26 , Russell A Poldrack 5 , K Richard Ridderinkhof 23 , Trevor W Robbins 8 , Matthew Roesch 6 , Katya Rubia 27 , Russell J Schachar 13 , Jeffrey D Schall 22 , Ann-Kathrin Stock 4 , Nicole C Swann 15 , Katharine N Thakkar 28 , Maurits W van der Molen 23 , Luc Vermeylen 1 , Matthijs Vink 19 , Jan R Wessel 29 , Robert Whelan 30 , Bram B Zandbelt 31 , C Nico Boehler 1"
31488584,Misinterpretation of time-to-first event curves can lead to inappropriate treatment,"Benjamin Hartley 1, Gerard J Criner 2, Mark T Dransfield 3, David M G Halpin 4, MeiLan K Han 5, C Elaine Jones 6, Sally Kilbride 7, Peter Lange 8 9, David A Lipson 10 11, David A Lomas 12, Neil Martin 13 14, Fernando J Martinez 15, Dave Singh 16, Robert A Wise 17, Sally Lettis 18",Eur Respir J. 2019 Sep 5;54(3):1900634. doi: 10.1183/13993003.00634-2019. Print 2019 Sep.,Hartley B,Eur Respir J,2019,2019/09/07,,,10.1183/13993003.00634-2019,https://pubmed.ncbi.nlm.nih.gov/31488584/,/31488584/,"Conflict of interest: B. Hartley reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; B. Hartley is a contingent worker on assignment at GlaxoSmithKline, and holds shares in GlaxoSmithKline, outside the submitted work. Conflict of interest: G.J. Criner reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, CSA Medical, Eolo, GlaxoSmithKline, HGE Technologies, Novartis, Nuvaira, Olympus, Pulmonx, Verona and NGM Bio, outside the submitted work. Conflict of interest: M.T. Dransfield reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; grants from Department of Defense and NIH, has received personal fees for consultancy from and undertaken clinical trials for Boehringer Ingelheim, AstraZeneca, PneumRx/BTG, Boston Scientific and GlaxoSmithKline, undertaken clinical trials for Novartis, Yungjin and Pulmonx, personal fees for consultancy from Genentech and Quark Pharmaceuticals, outside the submitted work. Conflict of interest: D.M.G. Halpin reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; personal fees from AstraZeneca, Chiesi, GlaxoSmithKline and Pfizer, personal fees and non-financial support from Boehringer Ingelheim and Novartis, outside the submitted work. Conflict of interest: M.K. Han reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; personal fees from AstraZeneca and Boehringer Ingelheim, grant support from Novartis and Sunovion, outside the submitted work. Conflict of interest: C.E. Jones reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; C.E. Jones is an employee of and holds shares/options in GlaxoSmithKline, outside the submitted work. Conflict of interest: S. Kilbride reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; S. Kilbride is an employee of and holds shares/options in GlaxoSmithKline, outside the submitted work. Conflict of interest: P. Lange reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim and Chiesi, outside the submitted work. Conflict of interest: D.A. Lipson reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; D.A. Lipson is an employee of and holds shares/options in GlaxoSmithKline, outside the submitted work. Conflict of interest: D.A. Lomas reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; grants, personal fees for consultancy and honoraria from GlaxoSmithKline, personal fees for consultancy from Grifols, outside the submitted work. Conflict of interest: N. Martin reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; N. Martin is an employee of and holds shares/options in GlaxoSmithKline, outside the submitted work. Conflict of interest: F.J. Martinez reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; personal fees and travel support for educational activities from American College of Chest Physicians, Inova Fairfax Health System, MD Magazine, Miller Communications, National Association for Continuing Education, PeerView Communications, Prime Communications, Puerto Rican Respiratory Society, Potomac, University of Alabama Birmingham, Physicians Education Resource, Canadian Respiratory Network and Dartmouth, personal fees for advisory board work, steering committee work and lectures, and travel support from AstraZeneca, personal fees for advisory board work, data monitoring committee work and lectures, and travel support from Boehringer Ingelheim and Genentech, non-financial support for advisory board work from ProterrixBio, personal fees for educational activities from Columbia University, Integritas, Methodist Hospital Brooklyn, New York University, UpToDate, WebMD/MedScape, Western Connecticut Health Network, PlatformIQ, Rockpointe, Rare Disease Healthcare Communications and France Foundation, personal fees for advisory board work and travel support from ConCert, Sunovion, Theravance and Teva, personal fees for advisory board work and non-financial support for travel, lecturing, steering committee work and data monitoring committee work from GlaxoSmithKline, personal fees for advisory board work and lectures, and travel support from Novartis, personal fees for advisory board work and non-financial support for steering committee work from Pearl Pharmaceuticals, personal fees for advisory board work and educational activites, and travel support from Chiesi, non-financial support for steering committee work from Afferent/Merck, Gilead, Nitto, Veracyte, Prometic, Bayer and ProMedior, personal fees for consultancy and steering committee work from Patara/Respivant, non-financial support for data monitoring committee and steering committee work from Biogen, non-financial support for lecturing and advisory board work from Zambon, personal fees for journal editorship from American Thoracic Society, grants from NIH, non-financial support for consultancy from Bridge Biotherapeutics, outside the submitted work. Conflict of interest: D. Singh reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, Cipla, Genentech and Peptinnovate, grants and personal fees from AstraZeneca, Boehringer Ingleheim, Chiesi, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, outside the submitted work. Conflict of interest: R.A. Wise reports grant support and medical writing support funded by GlaxoSmithKline, personal fees for data monitoring committee and advisory board work from GlaxoSmithKline, during the conduct of the study; grants and personal fees for data monitoring committee and consultancy work from AstraZeneca/Medimmune and GSK, grants and personal fees for data monitoring and steering committee work from Boehringer Ingelheim, personal fees for clinical end-point committee work from Contrafect, personal fees for data monitoring committee work from Pulmonx, Roche, Merck and AbbVie, personal fees for steering committee work from Spiration, personal fees for workshops and consultancy from Sunovion, grants from Pearl Therapeutics and Sanofi-Aventis, personal fees for consultancy from Circassia, Pneuma, Verona, Denali, Aradigm, Mylan/Theravance and Propelloer Health, personal fees for safety review committee work from Bonti, outside the submitted work. Conflict of interest: S. Lettis reports grant support and medical writing support funded by GlaxoSmithKline, during the conduct of the study; S. Lettis is an employee of and holds shares/options in GlaxoSmithKline, outside the submitted work.",Grants and funding MR/N024842/1/MRC_/Medical Research Council/United Kingdom,"Benjamin Hartley 1 , Gerard J Criner 2 , Mark T Dransfield 3 , David M G Halpin 4 , MeiLan K Han 5 , C Elaine Jones 6 , Sally Kilbride 7 , Peter Lange 8 9 , David A Lipson 10 11 , David A Lomas 12 , Neil Martin 13 14 , Fernando J Martinez 15 , Dave Singh 16 , Robert A Wise 17 , Sally Lettis 18"
30874925,"Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study","Kamel Laribi 1 2, Delphine Badinand 3, Philippe Janoray 4, Khaled Benabed 5 6, Jean-Loup Mouysset 7, Elizabeth Fabre 8, Françoise Monchecourt 9, Rafik Diab 10",Support Care Cancer. 2019 Nov;27(11):4283-4292. doi: 10.1007/s00520-019-04725-0. Epub 2019 Mar 14.,Laribi K,Support Care Cancer,2019,2019/03/16,PMC6803566,,10.1007/s00520-019-04725-0,https://pubmed.ncbi.nlm.nih.gov/30874925/,/30874925/,"K.L. has received grants and personal fees from Novartis and Takeda; grants from Roche, Mundipharma, Hospira, and Teva Santé; and personal fees from Amgen. F.M. is an employee of Teva Santé. All remaining authors have declared no conflicts of interest.",,"Kamel Laribi 1 2 , Delphine Badinand 3 , Philippe Janoray 4 , Khaled Benabed 5 6 , Jean-Loup Mouysset 7 , Elizabeth Fabre 8 , Françoise Monchecourt 9 , Rafik Diab 10"
31883519,Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma,"Richard Beasley 1 2 3, James Harper 4, Grace Bird 4, Harriette Dunphy 4, Alex Semprini 4, Ian D Pavord 5, Alberto Papi 6, Mark Weatherall 7 8",BMC Pulm Med. 2019 Dec 28;19(1):264. doi: 10.1186/s12890-019-1014-4.,Beasley R,BMC Pulm Med,2019,2019/12/30,PMC6935489,,10.1186/s12890-019-1014-4,https://pubmed.ncbi.nlm.nih.gov/31883519/,/31883519/,"RB has participated in advisory boards for AstraZeneca, GlaxoSmithKline and Novartis; received research grants from AstraZeneca, Cephalon, Fisher & Paykel, Genentech, GlaxoSmithKline, Novartis and Sanofi Aventis, and received payment for lectures or support to attend meetings from AstraZeneca and GlaxoSmithKline. IDP has received speaker’s honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Ingelhiem, Aerocrine, Almirall, Novartis, Teva, Chiesi and GSK and payments for organising educational events from AZ and Teva. He has received honoraria for attending advisory panels with Genentech, Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Sanofi, Circassia, Chiesi and Knopp. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chieisi to support a phase 2 clinical trial in Oxford. AP reports grants, personal fees, non-financial support and other from Chiesi, AstraZeneca, GlaxoSmithKilne, Boehringer Ingelheim, Mundipharma and TEVA, personal fees and non-financial support from Menarini, Novartis and Zambon. JH has received sponsorships to attend an international scientific meeting from GSK. The other authors have no conflict of interest to declare.",,"Richard Beasley 1 2 3 , James Harper 4 , Grace Bird 4 , Harriette Dunphy 4 , Alex Semprini 4 , Ian D Pavord 5 , Alberto Papi 6 , Mark Weatherall 7 8"
31278173,Home versus outpatient pulmonary rehabilitation in COPD: a propensity-matched cohort study,"Claire Marie Nolan 1 2, Djeya Kaliaraju 2, Sarah Elizabeth Jones 3 4, Suhani Patel 3, Ruth Barker 3 4, Jessica A Walsh 3 2, Stephanie Wynne 3, William Man 3 2 4",Thorax. 2019 Oct;74(10):996-998. doi: 10.1136/thoraxjnl-2018-212765. Epub 2019 Jul 5.,Nolan CM,Thorax,2019,2019/07/07,,,10.1136/thoraxjnl-2018-212765,https://pubmed.ncbi.nlm.nih.gov/31278173/,/31278173/,"Competing interests: WM reports grants from National Institute for Health Research during the conduct of the study; grants from Pfizer, non-financial support from GSK, personal fees from Mundipharma, personal fees from Novartis, outside the submitted work.",Grants and funding CDRF-2017-03-018/DH_/Department of Health/United Kingdom G1002113/MRC_/Medical Research Council/United Kingdom PB-PG-0816-20022/DH_/Department of Health/United Kingdom DRF-2015-08-004/DH_/Department of Health/United Kingdom PB-PG-0213-30003/DH_/Department of Health/United Kingdom,"Claire Marie Nolan 1 2 , Djeya Kaliaraju 2 , Sarah Elizabeth Jones 3 4 , Suhani Patel 3 , Ruth Barker 3 4 , Jessica A Walsh 3 2 , Stephanie Wynne 3 , William Man 3 2 4"
31641521,Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen,"Jochen Seufert 1, Anja Borck 2, Peter Bramlage 3",BMJ Open Diabetes Res Care. 2019 Oct 1;7(1):e000679. doi: 10.1136/bmjdrc-2019-000679. eCollection 2019.,Seufert J,BMJ Open Diabetes Res Care,2019,2019/10/24,PMC6777409,,10.1136/bmjdrc-2019-000679,https://pubmed.ncbi.nlm.nih.gov/31641521/,/31641521/,"Competing interests: JS has attended Speaker’s Bureaux for AstraZeneca, Bristol-Myers Squibb, Bayer Healthcare, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Lifescan, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Pfizer, Sanofi and Takeda. PB has received research funding and honoraria for consultancy from AstraZeneca, Bristol-Myers Squibb, Novartis and Sanofi. AB is an employee of Sanofi.",,"Jochen Seufert 1 , Anja Borck 2 , Peter Bramlage 3"
30792343,Extrafine triple therapy in patients with symptomatic COPD and history of one\xa0moderate exacerbation,"Dave Singh 1, Leonardo M Fabbri 2 3, Massimo Corradi 4, George Georges 5, Alessandro Guasconi 6, Stefano Vezzoli 6, Stefano Petruzzelli 6, Alberto Papi 2",Eur Respir J. 2019 May 18;53(5):1900235. doi: 10.1183/13993003.00235-2019. Print 2019 May.,Singh D,Eur Respir J,2019,2019/02/23,PMC6853799,,10.1183/13993003.00235-2019,https://pubmed.ncbi.nlm.nih.gov/30792343/,/30792343/,"Conflict of interest: D. Singh reports personal fees from Chiesi, during the conduct of these studies; grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance and Verona, personal fees from Genentech and Skeypharma, outside the submitted work. Conflict of interest: L.M. Fabbri reports personal fees and non-financial support from AstraZeneca, GSK, Novartis, Menarini, Boehringer Ingelheim, Zambon and Pearl Therapeutics, grants, personal fees and non-financial support from Chiesi, non-financial support from Dompe, outside the submitted work. Conflict of interest: M. Corradi reports grants and personal fees from Chiesi Farmaceutici SpA, outside the submitted work. Conflict of interest: G. Georges was an employee of Chiesi USA, Inc., during the conduct of these studies. Conflict of interest: A. Guasconi was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies. Conflict of interest: S. Vezzoli was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies. Conflict of interest: S. Petruzzelli was an employee of Chiesi Farmaceutici S.p.A, during the conduct of these studies. Conflict of interest: A. Papi reports fees for board membership, consultancy, payment for lectures, grants for research and travel expenses reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and TEVA, fees for lectures and travel expenses reimbursement from Menarini, Novartis and Zambon, grants for research from Sanofi, outside the submitted work.",,"Dave Singh 1 , Leonardo M Fabbri 2 3 , Massimo Corradi 4 , George Georges 5 , Alessandro Guasconi 6 , Stefano Vezzoli 6 , Stefano Petruzzelli 6 , Alberto Papi 2"
31559008,High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis,"Ana Sá-Sousa 1, Rute Almeida 1, Ricardo Vicente 2, Nilton Nascimento 2, Henrique Martins 2, Alberto Freitas 1 3, João Almeida Fonseca 1 3 4",Clin Transl Allergy. 2019 Sep 23;9:47. doi: 10.1186/s13601-019-0286-3. eCollection 2019.,Sá-Sousa A,Clin Transl Allergy,2019,2019/09/28,PMC6755705,,10.1186/s13601-019-0286-3,https://pubmed.ncbi.nlm.nih.gov/31559008/,/31559008/,"Competing interestsJAF received personal fees outside the submitted work from AstraZeneca, GSK, Mundipharma, Novartis, Teva. All other authors declare that they have no competing interests.",,"Ana Sá-Sousa 1 , Rute Almeida 1 , Ricardo Vicente 2 , Nilton Nascimento 2 , Henrique Martins 2 , Alberto Freitas 1 3 , João Almeida Fonseca 1 3 4"
31257351,Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma,"Dai Maruyama 1, Hirokazu Nagai 2, Noriko Fukuhara 3, Toshiyuki Kitano 4, Takayuki Ishikawa 5, Tomoaki Nishikawa 6",J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006.,Maruyama D,J Clin Exp Hematop,2019,2019/07/02,PMC6661957,,10.3960/jslrt.19006,https://pubmed.ncbi.nlm.nih.gov/31257351/,/31257351/,"CONFLICT OF INTEREST: Dai Maruyama has received honoraria from Janssen, and has received research funding from Janssen. Hirokazu Nagai has received honoraria from Eisai, Chugai, Mundipharma, and Takeda, and has received research funding from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Mundipharma, Ono, Otsuka, and Takeda. Noriko Fukuhara has received research funding from AbbVie, Bayer, Eisai, Gilead, Janssen, Ono, and Takeda. Toshiyuki Kitano and Takayuki Ishikawa have no conflicts of interest to declare. Tomoaki Nishikawa is an employee of Janssen.",,"Dai Maruyama 1 , Hirokazu Nagai 2 , Noriko Fukuhara 3 , Toshiyuki Kitano 4 , Takayuki Ishikawa 5 , Tomoaki Nishikawa 6"
31423316,HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs,"Andreas Fritsche 1, Helmut Anderten 2, Martin Pfohl 3, Stefan Pscherer 4, Anja Borck 5, Katrin Pegelow 5, Peter Bramlage 6, J Seufert 7",BMJ Open Diabetes Res Care. 2019 Aug 1;7(1):e000668. doi: 10.1136/bmjdrc-2019-000668. eCollection 2019.,Fritsche A,BMJ Open Diabetes Res Care,2019,2019/08/20,PMC6688703,,10.1136/bmjdrc-2019-000668,https://pubmed.ncbi.nlm.nih.gov/31423316/,/31423316/,"Competing interests: AF: Member of Scientific Advisory Boards of Sanofi, Novo Nordisk, Lilly, and Boehringer. HA: Honorary for consultancy: Sanofi, MSD, Lilli, Boehringer Ingelheim and Pfizer. MP: Member of Scientific Advisory Boards of Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. Honorary for talks: Eli Lilly, Novartis, Novo Nordisk and Sanofi. SP: Member of Scientific Advisory Boards of Sanofi. Honorary for talks: Eli Lilly, Novartis, Novo Nordisk, MSD and Sanofi. AB is an employee of Sanofi. KP is an employee of Sanofi. PB: Honorary for consultancy: Sanofi-Aventis, MSD, AstraZeneca, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Novartis and Pfizer. JS received honoraria for talks and/or consultancy and/or research funding from Abbott, Astra Zeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb (BMS), GI-Dynamics, GlaxoSmithKline (GSK), Intarcia, Ipsen, Janssen, LifeScan, Lilly, Merck Sharp Dohme (MSD), MedScape, Mundipharma, Novartis, Novo Nordisk, Omniamed, Pfizer, Roche, Sanofi Aventis, Servier, Takeda and Ypsomed.",,"Andreas Fritsche 1 , Helmut Anderten 2 , Martin Pfohl 3 , Stefan Pscherer 4 , Anja Borck 5 , Katrin Pegelow 5 , Peter Bramlage 6 , J Seufert 7"
31182560,BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient,"Hideki Nakasone 1, Koji Kawamura 1, Kimikazu Yakushijin 2, Akihito Shinohara 3, Masatsugu Tanaka 4, Kazuteru Ohashi 5, Shuichi Ota 6, Naoyuki Uchida 7, Takahiro Fukuda 8, Hirohisa Nakamae 9, Ken-Ichi Matsuoka 10, Junya Kanda 11, Tatsuo Ichinohe 12, Yoshiko Atsuta 13 14, Yoshihiro Inamoto 8, Sachiko Seo 15, Fumihiko Kimura 16, Masao Ogata 17",Blood Adv. 2019 Jun 11;3(11):1750-1760. doi: 10.1182/bloodadvances.2019000077.,Nakasone H,Blood Adv,2019,2019/06/12,PMC6560341,,10.1182/bloodadvances.2019000077,https://pubmed.ncbi.nlm.nih.gov/31182560/,/31182560/,"Conflict-of-interest disclosure: T.I. received research funding from Astellas Pharma, Chugai Pharmaceutical Co., CSL Behring, Eisai Co., Kyowa Hakko Kirin Co., Ono Pharmaceutical Co., Pfizer, Nippon Shinyaku Co., MSD, Otsuka Pharmaceutical Co., Repertoire Genesis Inc., Sumitomo Dainippon Pharma Co., Taiho Pharmaceutical Co., Takeda Pharmaceutical Co., and Zenyaku Kogyo Co., and honoraria from Alexion Pharmaceuticals, Bristol-Myers Squibb, Celgene, JCR Pharmaceuticals, Janssen Pharmaceutical K.K., Mundipharma, and Novartis. The remaining authors declare no competing financial interests.",,"Hideki Nakasone 1 , Koji Kawamura 1 , Kimikazu Yakushijin 2 , Akihito Shinohara 3 , Masatsugu Tanaka 4 , Kazuteru Ohashi 5 , Shuichi Ota 6 , Naoyuki Uchida 7 , Takahiro Fukuda 8 , Hirohisa Nakamae 9 , Ken-Ichi Matsuoka 10 , Junya Kanda 11 , Tatsuo Ichinohe 12 , Yoshiko Atsuta 13 14 , Yoshihiro Inamoto 8 , Sachiko Seo 15 , Fumihiko Kimura 16 , Masao Ogata 17"
31435852,Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine,"Jan-Paul Bohn 1, Vera Reinstadler 2, Georg Pall 3, Günther Stockhammer 4, Michael Steurer 3, Herbert Oberacher 2, Dominik Wolf 3 5",Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):845-851. doi: 10.1007/s13318-019-00572-w.,Bohn JP,Eur J Drug Metab Pharmacokinet,2019,2019/08/23,PMC6828631,,10.1007/s13318-019-00572-w,https://pubmed.ncbi.nlm.nih.gov/31435852/,/31435852/,"Jan-Paul Bohn receives an unrestricted research grant from Mundipharma. Georg Pall, Günther Stockhammer, Michael Steurer, Herbert Oberacher, and Dominik Wolf declare that they have no potential conflict of interest.",,"Jan-Paul Bohn 1 , Vera Reinstadler 2 , Georg Pall 3 , Günther Stockhammer 4 , Michael Steurer 3 , Herbert Oberacher 2 , Dominik Wolf 3 5"
31791384,Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II),"Philip Asherson 1, Lena Johansson 2, Rachel Holland 2, Tom Fahy 2, Andrew Forester 3, Sheila Howitt 4, Stephen Lawrie 4, John Strang 2, Susan Young 5, Sabine Landau 2, Lindsay Thomson 4",Trials. 2019 Dec 2;20(1):663. doi: 10.1186/s13063-019-3705-9.,Asherson P,Trials,2019,2019/12/04,PMC6889577,,10.1186/s13063-019-3705-9,https://pubmed.ncbi.nlm.nih.gov/31791384/,/31791384/,"King’s College London departmental research support account received payments for work by PA: consultancy to Shire, Eli Lilly and Novartis; educational/research awards from Shire, Lilly, Novartis, Vifor Pharma, GW Pharmaceuticals and QbTech; speaker at events sponsored by Shire, Lilly, Novartis, Flynn Pharma and Medicen. PA received personal honoaria for talking at events sponsored by Shire, Flynn Pharma and Medicen. SY has received honoraria for consultation and/or educational talks in the last 5 years from Janssen, HB Pharma and/or Shire. She is author of the ADHD Child Evaluation (ACE) and ACE+ for adults and lead author of R&R2 for ADHD Youths and Adults. In the last 3 years, SL has received personal fees from Janssen, Otsuka and Sunovion and research support from Janssen, all in connection with schizophrenia meetings and trials. JS has worked with several pharmaceutical companies to seek to identify new or improved medications, but they do not have a relationship to the study reported here. This has included research grant support and consultancy payments to King’s College London and travelling and/or accommodation and/or conference expenses (including, in the past 3 years, from Martindale, Indivior, MundiPharma, Camurus/Braeburn). The other authors declare that they have no competing interests.",Grants and funding EME/14/23/17/DH_/Department of Health/United Kingdom 14/23/17/Efficacy and Mechanism Evaluation Programme,"Philip Asherson 1 , Lena Johansson 2 , Rachel Holland 2 , Tom Fahy 2 , Andrew Forester 3 , Sheila Howitt 4 , Stephen Lawrie 4 , John Strang 2 , Susan Young 5 , Sabine Landau 2 , Lindsay Thomson 4"
31044290,Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition,"Thomas R Arkell 1 2 3, Nicholas Lintzeris 3 4, Richard C Kevin 1 2 5, Johannes G Ramaekers 6, Ryan Vandrey 7, Christopher Irwin 8, Paul S Haber 3 9, Iain S McGregor 10 11 12",Psychopharmacology (Berl). 2019 Sep;236(9):2713-2724. doi: 10.1007/s00213-019-05246-8. Epub 2019 May 1.,Arkell TR,Psychopharmacology (Berl),2019,2019/05/03,PMC6695367,,10.1007/s00213-019-05246-8,https://pubmed.ncbi.nlm.nih.gov/31044290/,/31044290/,"Nicholas Lintzeris has received funding for sponsored research studies from Camurus and has provided consultancies for Indivior and Mundipharma for unrelated work. Ryan Vandrey has received consulting fees from Zynerba Pharmaceuticals, Battelle Memorial Institute, and Canopy Health Innovations Inc. and has received compensation for being on the advisory boards for Insys Therapeutics, Brain Solutions Inc., and The Realm of Caring Foundation. Paul Haber has received research funding from Camurus, and has provided consultancies for Indivior, Abbvie, and Gilead for unrelated work. Iain McGregor acts as a consultant to Kinoxis Therapeutics and is an inventor on several patents relating to novel cannabinoid therapeutics. The other authors have no conflicts of interest to disclose.",Grants and funding N/A/The Lambert Initiative for Cannabinoid Therapeutics,"Thomas R Arkell 1 2 3 , Nicholas Lintzeris 3 4 , Richard C Kevin 1 2 5 , Johannes G Ramaekers 6 , Ryan Vandrey 7 , Christopher Irwin 8 , Paul S Haber 3 9 , Iain S McGregor 10 11 12"
31641524,Pharmacovigilance assessment of the association between Fourniers gangrene and other severe genital adverse events with SGLT-2 inhibitors,"Gian Paolo Fadini 1, Mayur Sarangdhar 2, Fabrizio De Ponti 3, Angelo Avogaro 1, Emanuel Raschi 3",BMJ Open Diabetes Res Care. 2019 Oct 4;7(1):e000725. doi: 10.1136/bmjdrc-2019-000725. eCollection 2019.,Fadini GP,BMJ Open Diabetes Res Care,2019,2019/10/24,PMC6777404,,10.1136/bmjdrc-2019-000725,https://pubmed.ncbi.nlm.nih.gov/31641524/,/31641524/,"Competing interests: GPF reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Mundipharma during the conduct of the study; grants, personal fees and non-financial support from Eli Lilly, personal fees and non-financial support from NovoNordisk, personal fees and non-financial support from Sanofi, non-financial support from Genzyme, personal fees and non-financial support from Abbott, personal fees and non-financial support from Novartis, personal fees from Merck Sharp & Dohme, outside the submitted work. AA reports grants, personal fees and non-financial support from AstraZeneca, personal fees from Boehringer-Ingelheim, personal fees from Janssen, during the conduct of the study; personal fees from Merck Sharp & Dome, personal fees and non-financial support from Novartis, personal fees from Sanofi, grants and personal fees from Mediolanum, personal fees from NovoNordisk, personal fees from Lilly, personal fees and non-financial support from Servier, personal fees from Takeda, outside the submitted work.",,"Gian Paolo Fadini 1 , Mayur Sarangdhar 2 , Fabrizio De Ponti 3 , Angelo Avogaro 1 , Emanuel Raschi 3"
30923184,In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is\xa0associated with disease progression and\xa0mortality,"John A Mackintosh 1, Sujal R Desai 1 2, Huzaifa Adamali 3, Kinesh Patel 1, Felix Chua 1, Anand Devaraj 1, Vasilis Kouranos 1, Maria Kokosi 1, George Margaritopoulos 1, Elisabetta A Renzoni 1 2, Athol U Wells 1 2, Philip L Molyneaux 1 2, Sacheen Kumar 4, Toby M Maher 1 2, Peter M George 1 2",Eur Respir J. 2019 May 23;53(5):1802412. doi: 10.1183/13993003.02412-2018. Print 2019 May.,Mackintosh JA,Eur Respir J,2019,2019/03/30,,,10.1183/13993003.02412-2018,https://pubmed.ncbi.nlm.nih.gov/30923184/,/30923184/,"Conflict of interest: J.A. Mackintosh has nothing to disclose. Conflict of interest: S.R. Desai reports personal fees from Boehringer Ingelheim, outside the submitted work. Conflict of interest: H. Adamali has nothing to disclose. Conflict of interest: K. Patel has nothing to disclose. Conflict of interest: F. Chua has nothing to disclose. Conflict of interest: A. Devaraj has nothing to disclose. Conflict of interest: V. Kouranos has nothing to disclose. Conflict of interest: M. Kokosi has nothing to disclose. Conflict of interest: G. Margaritopoulos has nothing to disclose. Conflict of interest: E.A. Renzoni reports lecture fees and advisory board fees from Boeringher Ingelheim and Roche, and lecture fees from Mundipharma, outside the submitted work. Conflict of interest: A.U. Wells reports personal fees for lecturing and advisory board work from Boehringer Ingelheim, Roche and Bayer, outside the submitted work. Conflict of interest: P.L. Molyneaux has, via his institution, received consultancy or speaker fees from Boehringer Ingelheim and Roche. Conflict of interest: S. Kumar has nothing to disclose. Conflict of interest: T.M. Maher reports grants and personal fees from GSK, grants, personal fees and non-financial support from UCB, personal fees and research fees from AstraZeneca, personal fees from Boehringer Ingelheim, Roche, Bayer, Biogen Idec, Prometic, Samumed, Galapagos, Celgene, Indalo and Pliant, stock options from Apellis, outside the submitted work. Conflict of interest: P.M. George reports personal fees and non-financial support from Roche Pharmaceuticals and Boehringer Ingelheim, outside the submitted work.",Grants and funding 20719/VAC_/Versus Arthritis/United Kingdom PB-PG-0712-28073/DH_/Department of Health/United Kingdom,"John A Mackintosh 1 , Sujal R Desai 1 2 , Huzaifa Adamali 3 , Kinesh Patel 1 , Felix Chua 1 , Anand Devaraj 1 , Vasilis Kouranos 1 , Maria Kokosi 1 , George Margaritopoulos 1 , Elisabetta A Renzoni 1 2 , Athol U Wells 1 2 , Philip L Molyneaux 1 2 , Sacheen Kumar 4 , Toby M Maher 1 2 , Peter M George 1 2"
31456143,Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort,"Ariane Steindl 1 2, Franziska Schlieter 1 2, Thomas Klikovits 2 3, Elena Leber 1 2, Brigitte Gatterbauer 2 4, Josa M Frischer 2 4, Karin Dieckmann 2 5, Georg Widhalm 2 4, Sabine Zöchbauer-Müller 1 2, Mir Ali Reza Hoda 2 3, Matthias Preusser 1 2, Anna S Berghoff 6 7",J Neurooncol. 2019 Oct;145(1):85-95. doi: 10.1007/s11060-019-03269-x. Epub 2019 Aug 27.,Steindl A,J Neurooncol,2019,2019/08/29,PMC6775039,,10.1007/s11060-019-03269-x,https://pubmed.ncbi.nlm.nih.gov/31456143/,/31456143/,"Anna Sophie Berghoff has research support from Daiichi Sankyo and honoraria for lectures, consultation or advisory board participation from Roche Bristol-Myers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen and AbbVie. Matthias Preusser has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dome. All other authors report no conflicts of interest.",Grants and funding UE71101084/Daiichi-Sankyo,"Ariane Steindl 1 2 , Franziska Schlieter 1 2 , Thomas Klikovits 2 3 , Elena Leber 1 2 , Brigitte Gatterbauer 2 4 , Josa M Frischer 2 4 , Karin Dieckmann 2 5 , Georg Widhalm 2 4 , Sabine Zöchbauer-Müller 1 2 , Mir Ali Reza Hoda 2 3 , Matthias Preusser 1 2 , Anna S Berghoff 6 7"
31218218,Airway obstruction is associated with reduced variability in specific parts of the tidal breathing flow-volume curve in young children,"Ville-Pekka Seppä 1, Anton Hult 1, Javier Gracia-Tabuenca 2, Marita Paassilta 3, Jari Viik 2, Davor Plavec 4 5, Jussi Karjalainen 3",ERJ Open Res. 2019 Jun 17;5(2):00028-2019. doi: 10.1183/23120541.00028-2019. eCollection 2019 Apr.,Seppä VP,ERJ Open Res,2019,2019/06/21,PMC6571449,,10.1183/23120541.00028-2019,https://pubmed.ncbi.nlm.nih.gov/31218218/,/31218218/,"Conflict of interest: V-P. Seppä has three patents with royalties paid by Revenio Group Inc. and is an employee of Revenio Group Inc., which commercialises impedance pneumography technology. Conflict of interest: A. Hult is an employee of Revenio Group Inc., which commercialises impedance pneumography technology. Conflict of interest: J. Gracia-Tabuenca has nothing to disclose. Conflict of interest: M. Paassilta has nothing to disclose. Conflict of interest: J. Viik has three patents with royalties paid by Revenio Group Inc. Conflict of interest: D. Plavec reports a grant and consultancy fees from Revenio Group during the conduct of the study, and grants from GlaxoSmithKline, Boehringer Ingelheim, Novartis and Chiesi, grants and personal fees from MSD, and personal fees from AbbVie, Sandoz, GlaxoSmithKline, Salveo, Menarini/Berlin Chemie and Salvus, outside the submitted work. Conflict of interest: J. Karjalainen reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Orion Pharma and Teva, outside the submitted work.",,"Ville-Pekka Seppä 1 , Anton Hult 1 , Javier Gracia-Tabuenca 2 , Marita Paassilta 3 , Jari Viik 2 , Davor Plavec 4 5 , Jussi Karjalainen 3"
31299906,Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe),"Raffaele De Caterina 1, Peter Kelly 2, Pedro Monteiro 3, Jean Claude Deharo 4, Carlo de Asmundis 5, Esteban López-de-Sá 6, Thomas W Weiss 7, Johannes Waltenberger 8, Jan Steffel 9, Joris R de Groot 10, Pierre Levy 11, Ameet Bakhai 12, Wolfgang Zierhut 13, Petra Laeis 13, Michael Kerschnitzki 13, Paul-Egbert Reimitz 13, Paulus Kirchhof 14 15 ; ETNA-AF-Europe investigators",BMC Cardiovasc Disord. 2019 Jul 12;19(1):165. doi: 10.1186/s12872-019-1144-x.,De Caterina R,BMC Cardiovasc Disord,2019,2019/07/14,PMC6625115,,10.1186/s12872-019-1144-x,https://pubmed.ncbi.nlm.nih.gov/31299906/,/31299906/,"Raffaele De Caterina co-authored ESC Guidelines on Atrial Fibrillation 2010–2012; acted as a Steering Committee member and National Coordinator for Italy, and co-authored manuscripts published on APPRAISE-2, ARISTOTLE, AVERROES, ENGAGE-AF and Re-DUAL PCI. RDC has received fees, honoraria and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Novartis, Portola, Roche and Merck. Peter Kelly has received speaker’s honoraria for lectures given at meetings sponsored by Daiichi-Sankyo. He is the Lead Investigator of the HRB Stroke Clinical Trials Network Ireland, which has received grant funding from the Irish government, Irish Heart Foundation, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Amgen and A Menarini. Pedro Monteiro is an ETNA-AF investigator, and has received lecture and research fees from Daiichi-Sankyo, Bayer, Boehringer Ingelheim and Pfizer/BMS. Jean Claude Deharo has received honoraria for lectures from Bayer, Boehringer Ingelheim and Bristol-Myers Squibb. JCD has also received research grants from Boston Scientific, Sorin Group, Biotronik and Abbott. Carlo de Asmundis has received compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Atricure, Cardiotek, Biosense Webster and research grants on behalf of the centre from Biotronik, Medtronic, St Jude Medical Abbot, Livanova, Boston Scientific Biosense Webster. Esteban López-de-Sá reports grants and non-financial support from ZOLL Medical Corporation, grants from Boehringer Ingelheim, grants, personal fees and non-financial support from Servier, personal fees and non-financial support from Daiichi Sankyo, personal fees and non-financial support from Rovi, personal fees from BARD, during the conduct of the study. Thomas W. Weiss has received fees, honoraria and research funding from Astra-Zeneca, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Medtronic, Menarini Pharma, Novartis and Sanofi-Aventis. Johannes Waltenberger reports personal fees from Bayer Vital, personal fees from Berlin Chemie, personal fees from Boehringer Ingelheim, personal fees from Daiichi Sankyo, personal fees from Sanofi Aventis, personal fees from Vifor Pharma Deutschland, during the conduct of the study. Jan Steffel has received consultant and / or speaker fees from Abbott, Amgen, Astra-Zeneca, Atricure, Bayer, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic, Merck/MSD, Novartis, Pfizer, Sanofi-Aventis, WebMD, and Zoll. JS reports ownership of CorXL. JS has received grant support through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, and Medtronic. Joris R. de Groot received consultant and/or speaker fees from Servier, Daiichi Sankyo, AtriCure Inc., Bayer, Novartis and Itreas. JRdG received grant support through his institution from St Jude Medical/Abbott, Boston Scientific, Medtronic and AtriCure. JRdG reports ownership of RhythmCARE. Pierre Levy acts as a consultant for AbbVie, Actelion, Amgen, Astellas, Bayer, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Gilead, GSK, Hospira, Impeto Médical, Janssen, MSD, Mundipharma, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi and Sanofi Pasteur MSD. Ameet Bakhai does not hold any stock but is involved in research sponsored by and is a member of advisory panels and speakers’ bureau for Daiichi Sankyo, Pfizer, BMS, Bayer and Boehringer Ingelheim. Wolfgang Zierhut, Petra Laeis, Michael Kerschnitzki and Paul-Egbert Reimitz are employees of Daiichi Sankyo Europe GmbH, Munich, Germany. Paulus Kirchhof receives research support from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783).",,"Raffaele De Caterina 1 , Peter Kelly 2 , Pedro Monteiro 3 , Jean Claude Deharo 4 , Carlo de Asmundis 5 , Esteban López-de-Sá 6 , Thomas W Weiss 7 , Johannes Waltenberger 8 , Jan Steffel 9 , Joris R de Groot 10 , Pierre Levy 11 , Ameet Bakhai 12 , Wolfgang Zierhut 13 , Petra Laeis 13 , Michael Kerschnitzki 13 , Paul-Egbert Reimitz 13 , Paulus Kirchhof 14 15 ; ETNA-AF-Europe investigators"
32914038,Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma,"Brian M Alexander 1 2, Lorenzo Trippa 1, Sarah Gaffey 1, Isabel C Arrillaga-Romany 3, Eudocia Q Lee 1, Mikael L Rinne 2 4, Manmeet S Ahluwalia 5, Howard Colman 6, Geoffrey Fell 1, Evanthia Galanis 7, John de Groot 8, Jan Drappatz 9, Andrew B Lassman 10, David M Meredith 1 2, L Burt Nabors 11, Sandro Santagata 1 2, David Schiff 12, Mary R Welch 10, Keith L Ligon 1 2, Patrick Y Wen 1",JCO Precis Oncol. 2019 Mar 27;3:PO.18.00071. doi: 10.1200/PO.18.00071. eCollection 2019.,Alexander BM,JCO Precis Oncol,2019,2020/09/11,PMC7448806,,10.1200/PO.18.00071,https://pubmed.ncbi.nlm.nih.gov/32914038/,/32914038/,"The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCOs conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Brian M. AlexanderEmployment: Foundation Medicine Consulting or Advisory Role: BMS, Precision Health Economics, AbbVie, Schlesinger AssociatesIsabel C. Arrillaga-RomanyHonoraria: Merck Consulting or Advisory Role: Insys Therapeutics, Karus Therapeutics, AgiosEudocia Q. LeeHonoraria: Medlink, UpToDate Consulting or Advisory Role: Eli LillyMikael L. RinneEmployment: Novartis Institutes for BioMedical Research Consulting or Advisory Role: N-of-OneManmeet S. AhluwaliaStock and Other Ownership Interests: MimiVax Honoraria: Prime Oncology, Elsevier, Itamar Medical (I) Consulting or Advisory Role: Monteris Medical, AstraZeneca, Bristol-Myers Squibb, AbbVie, CBT Pharmaceuticals, Kadmon, VBI Vaccines Research Funding: Novartis, TRACON Pharma, Novocure, Spectrum Pharmaceuticals, Eli Lilly/ImClone, Boehringer Ingelheim, AstraZenecaHoward ColmanHonoraria: Merck Sharp & Dohme Consulting or Advisory Role: Genentech, Roche, Novocure, Omniox, Insys Therapeutics, AbbVie Research Funding: Newlink Genetics, Plexxikon, Kadmon, Orbus Therapeutics, Merck, DNAtrix, AbbVie, BeiGeneEvanthia GalanisConsulting or Advisory Role: Genentech/Roche (Inst), AbbVie (Inst), Oncorus Research Funding: Genentech/Roche (Inst), Merck (Inst)John de GrootEmployment: Helsinn Therapeutics (I), ZIOPHARM Oncology (I) Leadership: ZIOPHARM Oncology (I) Stock and Other Ownership Interests: Gilead Sciences, ZIOPHARM Oncology (I) Consulting or Advisory Role: Celldex, Deciphera, Vascular Biogenics, Foundation Medicine, Genentech/Roche, Omniox, Oxigene, AbbVie, Novogen, Kadmon, Merck, Five Prime Therapeutics, Insys Therapeutics, AstraZeneca, Boston Biomedical, GW Pharmaceuticals, CarThera Research Funding: Deciphera, Novartis, Eli Lilly, Sanofi, EMD Serono, Mundipharma Patents, Royalties, Other Intellectual Property: Sanofi, research support; AstraZeneca, research support; EMD Serono, research support; Eli Lilly, research support; Novartis, research support; Deciphera Pharmaceuticals, research supportJan DrappatzEmployment: Via Oncology Stock and Other Ownership Interests: Exelixis, Bristol-Myers Squibb Honoraria: UpToDate, Via Oncology Consulting or Advisory Role: Oncorus, Immunomix Patents, Royalties, Other Intellectual Property: UpToDateAndrew B. LassmanHonoraria: Prime Oncology, WebMD, American Society of Clinical Oncology, Italian Association for Cancer Research, Focus Forward Incentives, Research America, Gerson Lehrman Group, Guidepoint Global, Health Advisors Bureau/Medefield, RICCA Group, Medsurvey, Olson Research Group, SAI-Med Partners, Schlesinger Associates, Market Strategies International, MSI Survey, Defined Health, marketplusresearch.com, AbbVie Consulting or Advisory Role: BioClinica, AbbVie, Sapience Therapeutics, AstraZeneca, Novocure, Kadmon, Cortice, Celgene, Agios Research Funding: AbbVie (Inst), Novartis (Inst), Karyopharm Therapeutics (Inst), Genentech/Roche (Inst), Novocure (Inst), Aeterna Zentaris (Inst), Pfizer (Inst), Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals (Inst), Agenus (Inst), GlaxoSmithKline (Inst), Stemline Therapeutics (Inst), Northwest Biotherapeutics (Inst), Plexxikon (Inst), Tocagen (Inst), Regeneron (Inst), VBL Therapeutics (Inst), e-Therapeutics (Inst), Bristol-Myers Squibb (Inst), ImmunoCellular Therapeutics (Inst), Merck (Inst), Amgen (Inst), Celldex (Inst), Millennium Pharmaceuticals (Inst), MedImmune (Inst), Boehringer Ingelheim (Inst), Kadmon (Inst), RTOG Foundation (Inst), Boston Biomedical (Inst), BeiGene (Inst), Diffusion Pharmaceuticals (Inst), Agios (Inst), Celgene (Inst), Vascular Biogenics (Inst), Angiochem (Inst), Northwest Biotherapeutics (Inst), Orbus (Inst), VBI Vaccines (Inst) Travel, Accommodations, Expenses: Karyopharm Therapeutics, Tocagen, Radiological Society of North America, AbbVie, Agios, Novocure, NRG Oncology Foundation, Celgene, Kadmon, Bristol-Myers Squibb Other Relationship: Law firms as medical expert in malpractice/disability casesL. Burt NaborsConsulting or Advisory Role: Bristol-Myers Squibb Speakers’ Bureau: Merck/Schering PloughSandro SantagataConsulting or Advisory Role: RareCyteDavid SchiffConsulting or Advisory Role: Orbus Therapeutics, Monteris Medical, Cavion (Inst) Research Funding: Bayer HealthCare Pharmaceuticals (Inst)Mary R. WelchResearch Funding: Boston Biomedical Travel, Accommodations, Expenses: Boston BiomedicalKeith L. LigonStock and Other Ownership Interests: Travera Consulting or Advisory Role: Midatech Research Funding: Plexxikon (Inst), Amgen (Inst), X4 Pharma (Inst), Tragara (Inst), Bristol-Myers Squibb (Inst) Patents, Royalties, Other Intellectual Property: Molecular diagnostics assay patentPatrick Y. WenConsulting or Advisory Role: AbbVie, Genentech/Roche, Agios, AstraZeneca, Karyopharm Therapeutics, Vivus, Monteris Medical, Aurora Biopharma, Vascular Biogenics, Kadmon, ZIOPHARM Oncology, GW Pharmaceuticals, Eli Lilly, Immunomic Therapeutics Speakers’ Bureau: Merck, Agios (Inst), AbbVie (Inst), Angiochem (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst), ImmunoCellular Therapeutics (Inst), Karyopharm Therapeutics (Inst), Merck (Inst), Novartis (Inst), Oncoceutics (Inst), Sanofi (Inst), ARIAD Pharmaceuticals (Inst), Vascular Biogenics (Inst), Eli Lilly No other potential conflicts of interest were reported",Grants and funding R01 CA188228/CA/NCI NIH HHS/United States,"Brian M Alexander 1 2 , Lorenzo Trippa 1 , Sarah Gaffey 1 , Isabel C Arrillaga-Romany 3 , Eudocia Q Lee 1 , Mikael L Rinne 2 4 , Manmeet S Ahluwalia 5 , Howard Colman 6 , Geoffrey Fell 1 , Evanthia Galanis 7 , John de Groot 8 , Jan Drappatz 9 , Andrew B Lassman 10 , David M Meredith 1 2 , L Burt Nabors 11 , Sandro Santagata 1 2 , David Schiff 12 , Mary R Welch 10 , Keith L Ligon 1 2 , Patrick Y Wen 1"
31035904,Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review,"Giorgio Lorenzo Colombo 1, Sergio Di Matteo 2, Chiara Martinotti 2, Martina Oselin 2, Maria Chiara Valentino 2, Giacomo Matteo Bruno 2, Claudia Pitotti 3, Francesco Menzella 4",Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841350. doi: 10.1177/1753466619841350.,Colombo GL,Ther Adv Respir Dis,2019,2019/05/01,PMC6492364,,10.1177/1753466619841350,https://pubmed.ncbi.nlm.nih.gov/31035904/,/31035904/,"Conflict of interest statement: GLC, GMB, SDM, CM, MO and MCV are employees of S.A.V.E. S.r.l and consultants for Novartis. CP is an employee of Novartis Pharma, Origgio, Italy. GLC has received research and educational grants from Amgen, Takeda, Merck Sharp and Dompé, and LEO Pharma. FM participated in contracted research and clinical trials for Novartis and Sanofi and has received lecture fees and advisory board fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, and Novartis. The authors report no other conflicts of interest in this work.",,"Giorgio Lorenzo Colombo 1 , Sergio Di Matteo 2 , Chiara Martinotti 2 , Martina Oselin 2 , Maria Chiara Valentino 2 , Giacomo Matteo Bruno 2 , Claudia Pitotti 3 , Francesco Menzella 4"
31296923,Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial,"Edouard Auclin 1 2 3, Thierry André 4 5, Julien Taieb 1 6, Maria Banzi 7, Jean-Luc Van Laethem 8, Josep Tabernero 9, Tamas Hickish 10, Aimery de Gramont 5 11, Dewi Vernerey 12 13 14",Br J Cancer. 2019 Aug;121(4):312-317. doi: 10.1038/s41416-019-0521-7. Epub 2019 Jul 12.,Auclin E,Br J Cancer,2019,2019/07/13,PMC6738041,,10.1038/s41416-019-0521-7,https://pubmed.ncbi.nlm.nih.gov/31296923/,/31296923/,"Thierry André: Honoraria—AMGEN; Bayer; Bristol-Myers Squibb; PRMA Consulting; Roche/Genentech; Sanofi; SERVIER; Xbiotech. Consulting or Advisory Role—Amgen; Bayer; Bristol-Myers Squibb; Guardant Health; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER. Travel, Accommodations, Expenses—Amgen; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech. Julien Taieb: Consulting or Advisory Role—Amgen; Baxalta; Celgene; Lilly; Merck KGaA; Roche; SERVIER; Sirtex Medical. Speakers’ Bureau—Amgen; Baxalta; Lilly; Merck; Roche/Genentech; Sanofi; SERVIER. Maria Banzi: Honoraria—Merck; Roche (I). Travel, Accommodations, Expenses—Merck; Pfizer; Roche. Josep Tabernero: Consulting or Advisory Role—Amgen; Boehringer Ingelheim; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck; Merck Serono; Millennium; Novartis; Roche/Genentech; Sanofi; Taiho Pharmaceutical. Tamas Hickish: Stock and Other Ownership Interests—Knowledge To Practice. Patents, Royalties, Other Intellectual Property—Bournemouth University (Inst). Travel, Accommodations, Expenses—Philips Healthcare; XBiotech. Aimery De Gramont: Honoraria—Chugai Pharma; Yakult. Dewi Vernerey: Consulting or Advisory Role—HalioDx; Janssen-Cilag; OSE Immunotherapeutics; Prestizia. The remaining authors declare no competing interests.",,"Edouard Auclin 1 2 3 , Thierry André 4 5 , Julien Taieb 1 6 , Maria Banzi 7 , Jean-Luc Van Laethem 8 , Josep Tabernero 9 , Tamas Hickish 10 , Aimery de Gramont 5 11 , Dewi Vernerey 12 13 14"
30586199,Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler,"Dave Singh 1, Frans van den Berg 2, Brian Leaker 3, Massimo Corradi 4, Sunny Jabbal 5, Sara Collarini 6, Valentina Mongelli 6, Luigi Santoro 6, Annalisa Piccinno 6, Sonia Biondaro 6, Brian Lipworth 5",Br J Clin Pharmacol. 2019 Apr;85(4):729-736. doi: 10.1111/bcp.13847. Epub 2019 Feb 3.,Singh D,Br J Clin Pharmacol,2019,2018/12/27,PMC6422816,,10.1111/bcp.13847,https://pubmed.ncbi.nlm.nih.gov/30586199/,/30586199/,"D.S. has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Mundipharma, Novartis, Peptinnovate Pfizer, Pulmatrix, Skypharma, Teva, Therevance and Verona. F.v.d.B. has no competing interests to declare. B.L. has received investigator fees from Chiesi for this and other studies; similar investigator fees were also received from Regeneron Pharmaceuticals, Astra Zeneca, Afimmune, Verona, Moerae Matrix and Hemay Pharmaceutical Pty. Ltd in the last 12 months. M.C. has received grants and honoraria for lectures from Chiesi. S.J. has received personal fees and nonfinancial support from Chiesi, personal fees and nonfinancial support from Pfizer, nonfinancial support and other from Napp, personal fees and nonfinancial support from AstraZeneca, nonfinancial support from Teva, nonfinancial support from Meda, personal fees from Boehringer Ingelheim, outside the submitted work. S.C., V.M., L.S., A.P. and S.B. are full‐time employees at Chiesi Farmaceutici S.p.A.. B.L. and the Scottish Centre for Respiratory Research have received funding in the form of consultancy, advisory boards, research, travel grants, equipment or giving talks from Chiesi Farmaceutici S.p.A., Boerhinger Ingelheim, Teva, Meda Pharma, Mylan, AstraZeneca, Dr Reddys, Cipla, Lupin, Genentech, Sanofi, Jansen, GSK, Novartis, Vectura, Glenmark. The clinical trial was sponsored by Chiesi Farmaceutici S.p.A. D.S., F.v.d.B., B.L. and B.L. were the principal investigators of the four clinical sites where the clinical trial was performed. D.S. also acted as coordinating investigator. S.J. was the co‐investigator at the Scottish Centre for Respiratory Research in Dundee. M.C., S.C., V.M., L.S., A.P. and B.L. were involved in the study design and results interpretation. S.B. and L.S. were involved in data collection and analysis and are responsible for the integrity of the data and accuracy of the data analysis. SGS Belgium NV (Antwerp, Belgium) was responsible for monitoring, data management, statistics, pharmacovigilance and medical writing during the trial. Biomedical Systems (Brussels, Belgium) was responsible for central collection and over‐reading of the lung function data. The manuscript was written by M.C., S.C., L.S. and A.P. and reviewed and approved by all the authors.",,"Dave Singh 1 , Frans van den Berg 2 , Brian Leaker 3 , Massimo Corradi 4 , Sunny Jabbal 5 , Sara Collarini 6 , Valentina Mongelli 6 , Luigi Santoro 6 , Annalisa Piccinno 6 , Sonia Biondaro 6 , Brian Lipworth 5"
31832429,Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis,"Macha Tetart 1, Frederic Wallet 2, Maeva Kyheng 3, Sylvie Leroy 4, Thierry Perez 1, Olivier Le Rouzic 1, Benoit Wallaert 1, Anne Prevotat 1",ERJ Open Res. 2019 Dec 8;5(4):00051-2019. doi: 10.1183/23120541.00051-2019. eCollection 2019 Oct.,Tetart M,ERJ Open Res,2019,2019/12/14,PMC6899338,,10.1183/23120541.00051-2019,https://pubmed.ncbi.nlm.nih.gov/31832429/,/31832429/,"Conflict of interest: M. Tetart has nothing to disclose. Conflict of interest: F. Wallet has nothing to disclose. Conflict of interest: M. Kyheng has nothing to disclose. Conflict of interest: S. Leroy has nothing to disclose. Conflict of interest: T. Perez reports being the principal investigator of a clinical study evaluating a device for chest clearance in cystic fibrosis (Simeox, PhysioAssist). Conflict of interest: O. Le Rouzic reports personal fees and nonfinancial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis, and nonfinancial support from GlaxoSmithKline, MundiPharma, Pfizer, Teva, the Santelys Association, Vertex and Vitalaire, outside the submitted work. Conflict of interest: B. Wallaert reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: A. Prevotat reports personal fees from Vertex and GSK, and congress invitations from Teva and Novartis, outside the submitted work.",,"Macha Tetart 1 , Frederic Wallet 2 , Maeva Kyheng 3 , Sylvie Leroy 4 , Thierry Perez 1 , Olivier Le Rouzic 1 , Benoit Wallaert 1 , Anne Prevotat 1"
31443653,Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease,"Steven J Pascoe 1, Alberto Papi 2, Dawn Midwinter 3, Sally Lettis 3, Neil Barnes 4 5",Respir Res. 2019 Aug 23;20(1):195. doi: 10.1186/s12931-019-1157-0.,Pascoe SJ,Respir Res,2019,2019/08/25,PMC6708190,,10.1186/s12931-019-1157-0,https://pubmed.ncbi.nlm.nih.gov/31443653/,/31443653/,"SP, DM, SL, and NB are employees of, and hold stock in GlaxoSmithKline plc. AP reports grants, personal fees, and/or reimbursement of travel expenses from AstraZeneca, Chiesi, Boehringer Ingelheim, GlaxoSmithKline plc., Menarini, Merck Sharp & Dohme, Mundipharma, Novartis, Teva, Sanofi, and Zambon.",,"Steven J Pascoe 1 , Alberto Papi 2 , Dawn Midwinter 3 , Sally Lettis 3 , Neil Barnes 4 5"
31505701,MRI Brain Changes After Marathon Running: Results of the Berlin Beat of Running Study,"Juliane Herm 1 2, Karl Georg Haeusler 3, Claudia Kunze 2, Matthias Krüll 4 5, Lars Brechtel 6 7, Jürgen Lock 4 5, Peter U Heuschmann 8 9 10, Wilhelm Haverkamp 11, Hauke Heekeren 12, Thomas Liman 1 2, Matthias Endres 1 2 13 14 15, Jochen B Fiebach 2, Gerhard Jan Jungehulsing 16",Int J Sports Med. 2019 Dec;40(13):856-862. doi: 10.1055/a-0958-9548. Epub 2019 Sep 10.,Herm J,Int J Sports Med,2019,2019/09/11,,,10.1055/a-0958-9548,https://pubmed.ncbi.nlm.nih.gov/31505701/,/31505701/,"CK, JH, JL, HH, TL and WH report no conflict of interest. KGH received lecture honoraria from Bayer HealthCare, Sanofi-Aventis, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Medtronic; honoraria for consulting from Edwards Lifesciences, Bayer HealthCare, Pfizer, EIP Pharma as well as research grants from Bayer HealthCare and Sanofi-Aventis. ME report lecture fees and study grants paid to the Charité from Sanofi-Aventis and Bayer Vital GmbH. MK received consulting, lecture and advisory board fees from ALK, Berlin Chemie, Novartis, Mundipharma and Teva. LB reports research support from German Federal Ministry of Research and Education, Else Kröner-Fresenius-Foundation, contract research from the Max Planck Institute for Human Development (Department Lifespan Psychology), Berlin and analyze & realize GmbH, Berlin. PUH reports grants from German Ministry of Research and Education, German Research Foundation, European Union, Federal Joint Committee (G-BA) within the Innovationfond, Charité–Universitätsmedizin Berlin, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert Koch Institute, German Heart Foundation, University Göttingen (within FIND-AF randomized, supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), University Hospital Heidelberg (within RASUNOA-prime, supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), grants from Charité–Universitätsmedizin Berlin (within Mondafis, supported by an unrestricted research grant to the Charité from Bayer), outside the submitted work. JBF has received consulting, lecture, and advisory board fees from BioClinica, Cerevast, Artemida, Brainomix, and Lundbeck. GJJ serves as a consultant for Cipio Partners (Munich, Germany) and Elron (Tel Aviv, Israel).",,"Juliane Herm 1 2 , Karl Georg Haeusler 3 , Claudia Kunze 2 , Matthias Krüll 4 5 , Lars Brechtel 6 7 , Jürgen Lock 4 5 , Peter U Heuschmann 8 9 10 , Wilhelm Haverkamp 11 , Hauke Heekeren 12 , Thomas Liman 1 2 , Matthias Endres 1 2 13 14 15 , Jochen B Fiebach 2 , Gerhard Jan Jungehulsing 16"
31239656,Quantification of inaccurate diagnosis of COPD in primary care medicine: an analysis of the COACH clinical audit,"María Abad-Arranz 1, Ana Moran-Rodríguez 2, Enrique Mascarós Balaguer 3, Carmen Quintana Velasco 4, Laura Abad Polo 5, Sara Núñez Palomo 6, Jaime Gonzálvez Rey 7, Ana María Fernández Vargas 8, Antonio Hidalgo Requena 9, Jose Manuel Helguera Quevedo 10, Marina García Pardo 11, Jose Luis Lopez-Campos 1 12",Int J Chron Obstruct Pulmon Dis. 2019 Jun 6;14:1187-1194. doi: 10.2147/COPD.S199322. eCollection 2019.,Abad-Arranz M,Int J Chron Obstruct Pulmon Dis,2019,2019/06/27,PMC6559770,,10.2147/COPD.S199322,https://pubmed.ncbi.nlm.nih.gov/31239656/,/31239656/,"Dr Enrique Mascarós Balaguer reports personal fees from Pfizer, personal fees from GSK, personal fees from Novartis, grants and personal fees from GRAP, personal fees from semFYC, personal fees from SEPAR, personal fees from Chiesi, personal fees from AstraZeneca, personal fees from TEVA, personal fees from Live-Med Spain, personal fees from Orion, and personal fees from Bial, outside the submitted work. Dr Jaime Gonzálvez Rey reports personal fees from Boehringer Ingelheim, personal fees from ROVI, personal fees from AstraZeneca, personal fees from GSK, personal fees from GRAP, personal fees from 1aria, personal fees from semFYC, personal fees from SEMG, personal fees from Novartis, personal fees from Fundación Colegio Médico Pontevedra, non-financial support from Separ, grants from IPCRG, grants from ISCIII, and grants from Pfizer, outside the submitted work. Dr Antonio Hidalgo Requena reports personal fees from Esteve, personal fees from AstraZeneca, personal fees from GSK, personal fees from Boehringer Inguelheim, personal fees from Menarini, personal fees from Novartis, personal fees from Pfeizer, personal fees from Mundifarma, personal fees from Teva, and personal fees from Rovi, outside the submitted work. Dr Jose Manuel Helguera Quevedo reports personal fees from GSK, non-financial support from Zambon, personal fees from Mundipharma, and personal fees from Novartis, outside the submitted work. Dr Jose Luis Lopez-Campos reports grants, personal fees, non-financial support from Boehringer, grants, personal fees, non-financial support from Novartis, grants and personal fees from AstraZeneca, grants and personal fees from Chiesi, personal fees from Esteve, personal fees from Ferrer, grants and personal fees from GSK, grants, personal fees and non-financial support from Grifols, grants, personal fees and non-financial support from Menarini, and personal fees and non-financial support from Rovi, during the conduct of the study. The authors report no other conflicts of interest in this work.",,"María Abad-Arranz 1 , Ana Moran-Rodríguez 2 , Enrique Mascarós Balaguer 3 , Carmen Quintana Velasco 4 , Laura Abad Polo 5 , Sara Núñez Palomo 6 , Jaime Gonzálvez Rey 7 , Ana María Fernández Vargas 8 , Antonio Hidalgo Requena 9 , Jose Manuel Helguera Quevedo 10 , Marina García Pardo 11 , Jose Luis Lopez-Campos 1 12"
31190905,Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy,"Umberto Restelli 1 2, Davide Croce 1 2, Valeria Pacelli 1, Fabio Ciceri 3 4, Corrado Girmenia 5",Infect Drug Resist. 2019 May 8;12:1127-1138. doi: 10.2147/IDR.S196282. eCollection 2019.,Restelli U,Infect Drug Resist,2019,2019/06/14,PMC6512572,,10.2147/IDR.S196282,https://pubmed.ncbi.nlm.nih.gov/31190905/,/31190905/,"DC declares advisory board fees from Mundipharma, Takeda and Abbvie. CG has received honoraria from Gilead Sciences, Astellas Pharma, Basilea, MSD, Pfizer Pharmaceuticals, and Celgene. UR report grants from MSD, during the conduct of the study; personal fees from Astrazeneca, personal fees from Bayer, personal fees from Italfarmaco, outside the submitted work. The remaining authors report no conflicts of interest in this work.",,"Umberto Restelli 1 2 , Davide Croce 1 2 , Valeria Pacelli 1 , Fabio Ciceri 3 4 , Corrado Girmenia 5"
31847343,Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma,"Pegah Mir Seyed Nazari 1, Christine Marosi 2, Florian Moik 1, Julia Riedl 1, Öykü Özer 1, Anna Sophie Berghoff 2, Matthias Preusser 2, Johannes A Hainfellner 3, Ingrid Pabinger 1, Gerhard J Zlabinger 4, Cihan Ay 1 5",Cancers (Basel). 2019 Dec 14;11(12):2020. doi: 10.3390/cancers11122020.,Mir Seyed Nazari P,Cancers (Basel),2019,2019/12/19,PMC6966639,,10.3390/cancers11122020,https://pubmed.ncbi.nlm.nih.gov/31847343/,/31847343/,"Matthias Preusser has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by MP with payments made to his institution: Böhringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline, AbbVie. Anna Sophie Berghoff has research support from Daiichi Sankyo (≤10,000 €), Roche (>10,000 €) and honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo (all <5000 €) as well as travel support from Roche, Amgen and AbbVie. “The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results”.","Grants and funding F 5405/FWF_/Austrian Science Fund FWF/Austria SFB F5405-B21/Austrian Science Fund Anniversary Fund, project 17828/Oesterreichische Nationalbank","Pegah Mir Seyed Nazari 1 , Christine Marosi 2 , Florian Moik 1 , Julia Riedl 1 , Öykü Özer 1 , Anna Sophie Berghoff 2 , Matthias Preusser 2 , Johannes A Hainfellner 3 , Ingrid Pabinger 1 , Gerhard J Zlabinger 4 , Cihan Ay 1 5"
30815470,Treatment response in COPD: does FEV(1) say it all? A post hoc analysis of the CRYSTAL study,"Konstantinos Kostikas 1, Timm Greulich 2, Alexander J Mackay 3, Nadine S Lossi 4, Maryam Aalamian-Mattheis 5, Xavier Nunez 6, Veronica A Pagano 6, Francesco Patalano 5, Andreas Clemens 5 7 8, Claus F Vogelmeier 2 8",ERJ Open Res. 2019 Feb 25;5(1):00243-2018. doi: 10.1183/23120541.00243-2018. eCollection 2019 Feb.,Kostikas K,ERJ Open Res,2019,2019/03/01,PMC6387992,,10.1183/23120541.00243-2018,https://pubmed.ncbi.nlm.nih.gov/30815470/,/30815470/,"Conflict of interest: K. Kostikas was an employee of Novartis until October 31, 2018. Conflict of interest: T. Greulich reports receiving support from Novartis for participation as a centre in the current the study; and personal fees for lectures and advisory boards from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL Behring, GSK and Novartis, grants and personal fees for lectures and advisory boards from Grifols, and grants from the German Centre for Lung Research (DZL), Marburg, Germany, outside the submitted work. Conflict of interest: A.J. Mackay was a European Respiratory Society Fellow in Industry at Novartis during the preparation of the manuscript. He is a current employee of AstraZeneca and has received speaker fees from Pfizer outside the submitted work. Conflict of interest: N.S. Lossi is currently an employee of Novartis Pharma GmbH. Conflict of interest: M. Aalamian-Mattheis is an employee of Novartis Pharma AG. Conflict of interest: X. Nunez analysed the data in the present study as a statistician employed by TFS. Conflict of interest: V.A. Pagano analysed the data in the present study as a statistician employed by TFS. Conflict of interest: F. Patalano is an employee and a shareholder of Novartis Pharma AG. Conflict of interest: A. Clemens is a full-time employee and shareholder at Novartis Pharma AG. Conflict of interest: C.F. Vogelmeier reports personal fees from Almirall, Cipla, Berlin-Chemie/Menarini, CSL Behring and Teva, grants and personal fees from AstraZeneca, Ingelheim, Chiesi, GSK, Grifols, Mundipharma, Novartis and Takeda, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work.",,"Konstantinos Kostikas 1 , Timm Greulich 2 , Alexander J Mackay 3 , Nadine S Lossi 4 , Maryam Aalamian-Mattheis 5 , Xavier Nunez 6 , Veronica A Pagano 6 , Francesco Patalano 5 , Andreas Clemens 5 7 8 , Claus F Vogelmeier 2 8"
31832814,Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography,"Beatrix Wulkersdorfer 1, Martin Bauer 1, Rudolf Karch 2, Harald Stefanits 3, Cécile Philippe 4, Maria Weber 1, Thomas Czech 3, Marie-Claude Menet 5 6 7, Xavier Declèves 5 6 7, Johannes A Hainfellner 8, Matthias Preusser 9, Marcus Hacker 4, Markus Zeitlinger 1, Markus Müller 1, Oliver Langer 10 11 12",EJNMMI Res. 2019 Dec 12;9(1):110. doi: 10.1186/s13550-019-0581-y.,Wulkersdorfer B,EJNMMI Res,2019,2019/12/14,PMC6908538,,10.1186/s13550-019-0581-y,https://pubmed.ncbi.nlm.nih.gov/31832814/,/31832814/,"Dr. Preusser reports personal fees from Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome., grants from Böhringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline, AbbVie., outside the submitted work. Dr. Müller reports grants from Austrian Science Fund during the conduct of the study. The other authors declare that they have no competing interests.",Grants and funding KLI 139-B00/Austrian Science Fund,"Beatrix Wulkersdorfer 1 , Martin Bauer 1 , Rudolf Karch 2 , Harald Stefanits 3 , Cécile Philippe 4 , Maria Weber 1 , Thomas Czech 3 , Marie-Claude Menet 5 6 7 , Xavier Declèves 5 6 7 , Johannes A Hainfellner 8 , Matthias Preusser 9 , Marcus Hacker 4 , Markus Zeitlinger 1 , Markus Müller 1 , Oliver Langer 10 11 12"
31908789,Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes,"Nicola L Harman 1, John P H Wilding 2, Dave Curry 3, James Harris 3, Jennifer Logue 4, R John Pemberton 3, Leigh Perreault 5 6, Gareth Thompson 3, Sean Tunis 7, Paula R Williamson 1 ; SCORE-IT Study Team",BMJ Open Diabetes Res Care. 2019 Dec 29;7(1):e000700. doi: 10.1136/bmjdrc-2019-000700. eCollection 2019.,Harman NL,BMJ Open Diabetes Res Care,2019,2020/01/08,PMC6936506,,10.1136/bmjdrc-2019-000700,https://pubmed.ncbi.nlm.nih.gov/31908789/,/31908789/,"Competing interests: PRW is a member of the COMET Management Group. JPHW has received funding (grant income, personal fees and consultancy fees) from Astellas, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Napp, Mundipharma, Novo Nordisk, Sanofi, Takeda and Wilmington Healthcare. All other authors declare they have no competing interests.",,"Nicola L Harman 1 , John P H Wilding 2 , Dave Curry 3 , James Harris 3 , Jennifer Logue 4 , R John Pemberton 3 , Leigh Perreault 5 6 , Gareth Thompson 3 , Sean Tunis 7 , Paula R Williamson 1 ; SCORE-IT Study Team"
31314918,Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms,"Wolfgang Knauf 1, Wolfgang Abenhardt 2, Johannes Mohm 3, Jacqueline Rauh 4, Johanna Harde 5, Anja Kaiser-Osterhues 6, Martina Jänicke 7, Norbert Marschner 8 ; TLN-Group (Tumour Registry Lymphatic Neoplasms)",Eur J Haematol. 2019 Nov;103(5):460-471. doi: 10.1111/ejh.13295. Epub 2019 Sep 4.,Knauf W,Eur J Haematol,2019,2019/07/18,,,10.1111/ejh.13295,https://pubmed.ncbi.nlm.nih.gov/31314918/,/31314918/,,Grants and funding Celgene GmbH Mundipharma GmbH Onkovis GmbH Roche Pharma AG,"Wolfgang Knauf 1 , Wolfgang Abenhardt 2 , Johannes Mohm 3 , Jacqueline Rauh 4 , Johanna Harde 5 , Anja Kaiser-Osterhues 6 , Martina Jänicke 7 , Norbert Marschner 8 ; TLN-Group (Tumour Registry Lymphatic Neoplasms)"
31110172,Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse,"Anita Kumar 1, Fushen Sha 2, Ahmed Toure 2, Ahmet Dogan 3, Andy Ni 4, Connie L Batlevi 2, Maria Lia M Palomba 2, Carol Portlock 2, David J Straus 2, Ariela Noy 2, Steven M Horwitz 2, Alison Moskowitz 2, Paul Hamlin 2, Craig H Moskowitz 2, Matthew J Matasar 2, Andrew D Zelenetz 2, Anas Younes 2",Blood Cancer J. 2019 May 20;9(6):50. doi: 10.1038/s41408-019-0209-5.,Kumar A,Blood Cancer J,2019,2019/05/22,PMC6527702,,10.1038/s41408-019-0209-5,https://pubmed.ncbi.nlm.nih.gov/31110172/,/31110172/,"A.K.: research funding from Abbvie Pharmaceuticals, Adaptive Biotechnologies, Celgene, Pharmacyclics, Seattle Genetics; advisory board member for Celgene (April 2016). F.S.: none. A.T.: none. A.D.: consultancy at Novartis, Weill-Cornell Hospital, Celgene, Seattle Genetics, Guidepoint Global Advisors, Pharmacyclics, Oncology Specialty Group, Roche, Peerview Institute, Physicians’ Education Resource, Corvus Pharmaceuticals. A.N.: none. C.L.B.: advisory for GLG, Defined Health; research funding from Novartis, Janssen, Bristol–Myers Squib, Epizyme, MedImmune; honoraria from Dava Oncology. M.L.M.P.: honoraria from Merck, Celgene and Pharmacyclics. C.P.: none. D.J.S.: consultancy at InPractice Elselvier, Seattle Genetics, Onco tracker (2016), Millenium (Takeda), DAVA (2016 and 2017), JUNO (2017), Bayer (2017); speaker’s bureau at ROCH China (2016), Medical Crossfire (2018). A.N.: research funding from Pharmacyclics, NIH, Raphael Pharma; consulting for: Janssen, Pharmacyclics, Medscape, Targeted Oncology. S.M.H.: consultancy at ADCT therapeutics, Aileron, Corvus, Forty-Seven, Innate Pharma, Kyowa-Hakka-Kirin, Millenium/Takeda, Mundipharma, Portola, Seattle Genetics; research funding from ADCT therapeutics, Aileron,Celgene, Forty-Seven, Infinity/Verastem, Kyowa-Hakka-Kirin, Millenium/Takeda, Seattle Genetics, Trillium. A.M.: consultancy at Kyowa Hakko Kirin Pharma, Miragen Therapeutics, Takeda Pharmaceuticals, ADC therapeutics, Seattle Genetics, Cell Medica, Bristol–Myers Squibb, Erytech Pharma; research funding from Incyte, Seattle Genetics, BMS, and Merck. P.H.: consultancy at Portola Pharmaceutics, Celgene, Karyopharm, Juno Therapeutics; research funding from Portola, Molecular Templates, Incyte, J&J Pharmaceuticals. C.H.M.: research funding from Merck, Seattle Genetics, BMS, ADC therapeutics Scientific Advisory Board: Novartis, Seattle Genetics, Takeda, Merck, BMS, Genentech, Astra Zeneca. M.J.M.: research funding from Genentech, Roche, GSK, Spectrum, Pharmacyclics, Seattle Genetics, Janssen; honoraria from Genentech, Roche, Spectrum, Janssen, Seattle Genetics, Rocket. A.D.Z.: consultancy at Genentech/Roche, Gilead, Celgene, Janssen, Amgen, Novartis, Adaptive Biotechnology; research funding MEI Pharma, MorphoSys, Sandoz, Celgene, Roche, Gilead; Board of Directors (DMC Chair) Beigene. A.Y.: research funding from Janssen, Novartis, Curis, Roche, BMS; honoraria or consulting fees from Bayer, Roche, BMS, Celgene, Incyte, Janssen, Curis, Takeda Millenium, Genentect, Merck, Xynomics, Bio-Path, and Epizyme.",Grants and funding P30 CA008748/CA/NCI NIH HHS/United States P50 CA192937/CA/NCI NIH HHS/United States,"Anita Kumar 1 , Fushen Sha 2 , Ahmed Toure 2 , Ahmet Dogan 3 , Andy Ni 4 , Connie L Batlevi 2 , Maria Lia M Palomba 2 , Carol Portlock 2 , David J Straus 2 , Ariela Noy 2 , Steven M Horwitz 2 , Alison Moskowitz 2 , Paul Hamlin 2 , Craig H Moskowitz 2 , Matthew J Matasar 2 , Andrew D Zelenetz 2 , Anas Younes 2"
31686899,The relationship between the reporting of euphoria events and early treatment responses to pregabalin: an exploratory post-hoc analysis,"Bruce Parsons 1, Rainer Freynhagen 2 3, Stephan Schug 4 5, Ed Whalen 1, Marie Ortiz 1, Pritha Bhadra Brown 1, Lloyd Knapp 6",J Pain Res. 2019 Aug 22;12:2577-2587. doi: 10.2147/JPR.S199203. eCollection 2019.,Parsons B,J Pain Res,2019,2019/11/06,PMC6709807,,10.2147/JPR.S199203,https://pubmed.ncbi.nlm.nih.gov/31686899/,/31686899/,"RF reports consultancy and speaker fees in the past 2 years from AOP Orphan Pharmaceuticals, Eli Lilly, Grünenthal, Merck Selbstmedikation, Mitsubishi Tanabe Pharma, Pfizer Inc., and Scilex Pharmaceuticals, outside of the submitted work. SS is an employee of the University of Western Australia (UWA); within the last 2 years his employer has received honoraria, consulting fees and travel support from Andros Pharmaceuticals, Aspen, bioCSL, Eli Lilly, Grünenthal, Invidior, Janssen, Luye Pharma, Mundipharma, Pfizer Inc., Pierre Fabre, Seqirus, and iX Biopharma. BP, EW, MO, PBB, and LK are employees of Pfizer and have stock or stock options with Pfizer. The authors report no other conflicts of interest in this work.",,"Bruce Parsons 1 , Rainer Freynhagen 2 3 , Stephan Schug 4 5 , Ed Whalen 1 , Marie Ortiz 1 , Pritha Bhadra Brown 1 , Lloyd Knapp 6"
31788249,Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report,"Anne S Strik 1, Geert R DHaens 1, Mark Löwenberg 1",Clin Case Rep. 2019 Sep 21;7(11):2049-2053. doi: 10.1002/ccr3.2394. eCollection 2019 Nov.,Strik AS,Clin Case Rep,2019,2019/12/03,PMC6878056,,10.1002/ccr3.2394,https://pubmed.ncbi.nlm.nih.gov/31788249/,/31788249/,"Anne Strik: no conflicts of interest. Mark Löwenberg: has received speaking fees from Abbvie, Covidien, Dr Falk, Ferring Pharmaceuticals, Merck Sharp & Dohme, Receptos, Takesa, Tillotts, and Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Achmea healthcare and ZonMW. Geert D’Haens: has served as advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, DrFALK Pharma, Engene, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novonordisk, Pfizer, Prometheus laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor and received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp & Dohme, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts, and Vifor.",,"Anne S Strik 1 , Geert R DHaens 1 , Mark Löwenberg 1"
30975187,"Nebulized versus intravenous morphine titration for the initial treatment of severe acute pain in the emergency department: study protocol for a multicenter, prospective randomized and controlled trial, CLIN-AEROMORPH","Virginie Eve Lvovschi 1 2, Justine Joly 3, Nicolas Lemaire 3, Maxime Maignan 4, Pauline Canavaggio 5, Anne-Marie Leroi 6, Marie-Pierre Tavolacci 6, Luc-Marie Joly 3",Trials. 2019 Apr 11;20(1):209. doi: 10.1186/s13063-019-3326-3.,Lvovschi VE,Trials,2019,2019/04/13,PMC6458825,,10.1186/s13063-019-3326-3,https://pubmed.ncbi.nlm.nih.gov/30975187/,/30975187/,"The study protocol and patient-informed consent procedures received Ethics Committee approval (SUD-MEDITERRANEE1 approval number 17 32) on 17 May 2017 prior to registration (reference number 2014/009/HP). Authorization for this protocol has also been granted by the ANSM (French Competent Authority) (art. L 1123-8 of French Public Health Code). Thanks to these two centralized procedures, this study has gained ethical approval at both central and local levels for all centers participating in the study. Any modifications to the protocol that may impact the conduct of the study, potential benefit to the patient, or that may affect patient safety will require a formal amendment to the protocol and new approval from the Ethics Committee according to local regulations and a request for authorization by the ANSM (art. L 1123-9). Approval by these two institutional committees is also required for new center recruiting. Information has been provided to the directors and pharmacists of centers participating in the study before the research began (art. L 1123-13 of French Public Health Code). The authors declare that they have no competing interests. However, the authors VEL and NL disclose that they have individually received occasional travel grants for participation in national and international congresses from Mundipharma. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",Grants and funding 760780239/PHRCN,"Virginie Eve Lvovschi 1 2 , Justine Joly 3 , Nicolas Lemaire 3 , Maxime Maignan 4 , Pauline Canavaggio 5 , Anne-Marie Leroi 6 , Marie-Pierre Tavolacci 6 , Luc-Marie Joly 3"
31406261,Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer,"Sumitra Mohan 1, Mahmood Ayub 1, Dominic G Rothwell 1, Sakshi Gulati 1, Bedirhan Kilerci 1, Antoine Hollebecque 1, Hui Sun Leong 2, Nigel K Smith 1, Sudhakar Sahoo 2, Tine Descamps 1, Cong Zhou 1, Richard A Hubner 3, Mairéad G McNamara 3 4, Angela Lamarca 3, Juan W Valle 3 4, Caroline Dive 1, Ged Brady 5",Sci Rep. 2019 Aug 12;9(1):11610. doi: 10.1038/s41598-019-47489-7.,Mohan S,Sci Rep,2019,2019/08/14,PMC6690979,,10.1038/s41598-019-47489-7,https://pubmed.ncbi.nlm.nih.gov/31406261/,/31406261/,"AL received travel and educational support from Ipsen, Pfizer, Bayer, AAA, Sirtex Medical, Novartis, Mylan and Delcath Systems; speaker honoraria from Merck, Pfizer and Ipsen; advisory honoraria from EISAI and Nutricia; she is a member of the Knowledge Network and NETConnect Initiatives funded by Ipsen. JV reports Consulting or Advisory role for Ipsen, Novartis, AstraZeneca, Merck, Delcath Systems, Agios, Pfizer, PCI Biotech, Incyte, Keocyt, QED, Pieris Pharmaceuticals, Genoscience Pharma, Mundipharma EDO; Honoraria from Ipsen; and Speakers’ Bureau for Novartis, Ipsen, Nucana and Imaging Equipment Limited; all outside the scope of this work. CD acts in a consultant or advisory role for Biocartis and AstraZeneca and receives research grants/support from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck AG, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics Inc; all outside the scope of work. MMN has received research grant support from Servier, Ipsen and NuCana. She has received travel and accommodation support from Bayer and Ipsen and speaker honoraria from Pfizer, Ipsen and NuCana. She has served on advisory boards for Celgene, Ipsen, Sirtex and Baxalta; all outside the scope of this work. Other authors have no conflict of interests to declare.",Grants and funding 19278/CRUK_/Cancer Research UK/United Kingdom C480/A25235/CRUK_/Cancer Research UK/United Kingdom A20465/CRUK_/Cancer Research UK/United Kingdom C5759/A25254/CRUK_/Cancer Research UK/United Kingdom C5759/A27412/CRUK_/Cancer Research UK/United Kingdom 29569/CRUK_/Cancer Research UK/United Kingdom Show all 6 grants,"Sumitra Mohan 1 , Mahmood Ayub 1 , Dominic G Rothwell 1 , Sakshi Gulati 1 , Bedirhan Kilerci 1 , Antoine Hollebecque 1 , Hui Sun Leong 2 , Nigel K Smith 1 , Sudhakar Sahoo 2 , Tine Descamps 1 , Cong Zhou 1 , Richard A Hubner 3 , Mairéad G McNamara 3 4 , Angela Lamarca 3 , Juan W Valle 3 4 , Caroline Dive 1 , Ged Brady 5"
31426584,mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohns Disease,"Federica Ungaro 1 2, Valentina Garlatti 2, Luca Massimino 3, Antonino Spinelli 2 4, Michele Carvello 4, Matteo Sacchi 4, Salvatore Spanò 1 2, Gaia Colasante 3, Nicholas Valassina 3, Stefania Vetrano 1 2, Alberto Malesci 5 6, Laurent Peyrin-Biroulet 7, Silvio Danese 1 2, Silvia DAlessio 8 9",Cells. 2019 Aug 18;8(8):924. doi: 10.3390/cells8080924.,Ungaro F,Cells,2019,2019/08/21,PMC6721646,,10.3390/cells8080924,https://pubmed.ncbi.nlm.nih.gov/31426584/,/31426584/,"L.P.B. has served as consultant for Merck, Abbvie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Biogaran, Boerhinger-lngelheim, Lilly, Pfizer, Jndex Pharmaceuticals, Amgen, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestlé, Enterome, Mylan, HAC-Pharma, Tigenix; as speaker for: Merck, Abbvie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Boerhinger-lngelheim, Pfizer, Amgen, Biogen, Samsung Bioepis. S.D. has served as speaker, consultant, and advisory board member for Abbvie, Ferring, Hospira, Johnson and Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim. All other authors disclose no conflicts.",,"Federica Ungaro 1 2 , Valentina Garlatti 2 , Luca Massimino 3 , Antonino Spinelli 2 4 , Michele Carvello 4 , Matteo Sacchi 4 , Salvatore Spanò 1 2 , Gaia Colasante 3 , Nicholas Valassina 3 , Stefania Vetrano 1 2 , Alberto Malesci 5 6 , Laurent Peyrin-Biroulet 7 , Silvio Danese 1 2 , Silvia DAlessio 8 9"
30944519,Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R),"Stefan Christensen 1, Peter Buggisch 2, Stefan Mauss 3, Klaus Hw Böker 4, Tobias Müller 5, Hartwig Klinker 6, Tim Zimmermann 7, Yvonne Serfert 8, Bernd Weber 9, Jens Reimer 10 11, Heiner Wedemeyer 8 12 13 ; German Hepatitis C-Registry",Subst Abuse. 2019 Mar 28;13:1178221819835847. doi: 10.1177/1178221819835847. eCollection 2019.,Christensen S,Subst Abuse,2019,2019/04/05,PMC6440029,,10.1177/1178221819835847,https://pubmed.ncbi.nlm.nih.gov/30944519/,/30944519/,"Declaration of conflicting interest:SC reports personal fees from BMS, AbbVie, Janssen, ViiV, Gilead, and MSD outside the submitted work. PB reports personal fees from AbbVie, BMS, Falk, Gilead, Janssen, Merz Pharma, and MSD Pharma outside the submitted work. SM reports personal fees from AbbVie, Bristol-Meyers-Squibb, Gilead Sciences, Janssen-Cilag, MSD Sharp & Dohme/Merck, and ViiV, outside the submitted work. KHWB reports personal fees from Gilead Sciences, MSD Sharp & Dohme, Merck, AbbVie, and other from Janssen, outside the submitted work. TM reports travel grants from AbbVie, Alexion, MSD, Gilead, MERZ, Intercept, FALK; grants/research support from FALK Foundation, Intercept outside the submitted work. HK reports personal fees from AbbVie, BMS, Gilead, Hexal, Janssen, MSD, Arrowhead, and Novartis; grants/research support from AbbVie, BMS, Gilead, Janssen, MSD, Arrowhead, and Novartis outside the submitted work. TZ reports personal fees, grants, or research support from AbbVie, BMS, Gilead, MSD, Novartis, and Roche outside the submitted work. BW reports personal fees from Camurus GmbH, Indivior, Mundipharma, Gilead, BMS, AbbVie, MSD outside the submitted work. JR reports personal fees, grants/research support from Gilead, AbbVie, Janssen, and BMS outside the submitted work. YS is employee of Leberstiftungs-GmbH Deutschland. HW reports personal fees from Transgene, MSD, Roche, Gilead, Abbott, BMS, Falk, AbbVie, Novartis, GSK, Roche Diagnostics, Eiger, ITF, and MyrGmbH; grants/research support from MSD, Novartis, Gilead, Roche, Abbott, and Roche Diagnostics outside the submitted work.",,"Stefan Christensen 1 , Peter Buggisch 2 , Stefan Mauss 3 , Klaus Hw Böker 4 , Tobias Müller 5 , Hartwig Klinker 6 , Tim Zimmermann 7 , Yvonne Serfert 8 , Bernd Weber 9 , Jens Reimer 10 11 , Heiner Wedemeyer 8 12 13 ; German Hepatitis C-Registry"
31673422,"Canada-Denmark MRI scoring system of the spine in patients with axial spondyloarthritis: updated definitions, scoring rules and inter-reader reliability in a multiple reader setting","Simon Krabbe 1 2, Mikkel Østergaard 1 2, Susanne J Pedersen 1 2, Ulrich Weber 3 4, Georg Kröber 3, Walter Makysmowych 5 6, Robert G W Lambert 7 8",RMD Open. 2019 Oct 13;5(2):e001057. doi: 10.1136/rmdopen-2019-001057. eCollection 2019.,Krabbe S,RMD Open,2019,2019/11/02,PMC6803003,,10.1136/rmdopen-2019-001057,https://pubmed.ncbi.nlm.nih.gov/31673422/,/31673422/,"Competing interests: MØ has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Schering-Plough, Takeda, UCB and Wyeth. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis and UCB, has been an advisory board member for AbbVie and Novartis, and has received research support from AbbVie, MSD and Novartis. UW received speaking fees from AbbVie for serving as convenor for workshops on imaging in SpA. WM has received research support and/or consultancy/speaker fees from AbbVie, Boehringer, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB. RGWL has received consultancy fees from Parexel. The remaining authors declare that they have no competing interests.",,"Simon Krabbe 1 2 , Mikkel Østergaard 1 2 , Susanne J Pedersen 1 2 , Ulrich Weber 3 4 , Georg Kröber 3 , Walter Makysmowych 5 6 , Robert G W Lambert 7 8"
31521192,Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial,"Henriëtte M Y de Jong 1 2, Leonieke J J van Mens 1 2, Michael T Nurmohamed 2 3 4, Marc R Kok 5, Arno W R van Kuijk 2 4, Dominique L P Baeten 1 2, Marleen G H van de Sande 6 7",Arthritis Res Ther. 2019 Sep 14;21(1):208. doi: 10.1186/s13075-019-1998-4.,de Jong HMY,Arthritis Res Ther,2019,2019/09/16,PMC6744710,,10.1186/s13075-019-1998-4,https://pubmed.ncbi.nlm.nih.gov/31521192/,/31521192/,"DB is currently an employee of UCB Pharma. LJJvM and HMdJ declare that they have no competing interest. MGHvdS has been an advisor for Abbvie and Novartis and received research grants from Janssen, Eli Lily, and Novartis. The department of MK is supported by Novartis, Abbvie, Pfizer, Roche, Lilly, and BMS, and MK has been an advisor for Novartis and Abbvie. MTN received research grants, consultation, and/or speaking fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche, Sanofi, and UCB Pharma. AWRvK received speaker fees from Celgene, Novartis, Eli Lilly, and Janssen and received research support from MSD and Janssen.",Grants and funding NA/Merck Sharp and Dohme/International,"Henriëtte M Y de Jong 1 2 , Leonieke J J van Mens 1 2 , Michael T Nurmohamed 2 3 4 , Marc R Kok 5 , Arno W R van Kuijk 2 4 , Dominique L P Baeten 1 2 , Marleen G H van de Sande 6 7"
31362741,"Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA","Frank C Albers 1 2, Alberto Papi 3, Camille Taillé 4, Daniel J Bratton 5, Eric S Bradford 6, Steven W Yancey 6, Namhee Kwon 7",Respir Res. 2019 Jul 30;20(1):169. doi: 10.1186/s12931-019-1134-7.,Albers FC,Respir Res,2019,2019/08/01,PMC6664536,,10.1186/s12931-019-1134-7,https://pubmed.ncbi.nlm.nih.gov/31362741/,/31362741/,"DJB, ESB, SWY and NK are employees of GSK and hold stocks/shares in GSK. FCA was an employee of GSK at the time of this analysis and holds stocks/shares in GSK. AP has received grants, personal fees and non-financial support and other from AstraZeneca, Teva, Mundipharma, GSK, Chiesi and Boehringer Ingelheim; has received personal fees and non-financial support from Novartis, Menarini and Zambon; and has received grants from Sanofi. CT has received fees from GSK, AstraZeneca, Novartis, Teva, Sanofi, Genzyme and Roche (consultancy, advisory boards) and was an investigator in trials involving GSK, AstraZeneca, Novartis, Sanofi, Roche and Boehringer Ingelheim.",,"Frank C Albers 1 2 , Alberto Papi 3 , Camille Taillé 4 , Daniel J Bratton 5 , Eric S Bradford 6 , Steven W Yancey 6 , Namhee Kwon 7"
30736821,Rating the quality of teamwork-a comparison of novice and expert ratings using the Team Emergency Assessment Measure (TEAM) in simulated emergencies,"Julia Freytag 1, Fabian Stroben 2 3, Wolf E Hautz 4 5, Stefan K Schauber 5, Juliane E Kämmer 6 7",Scand J Trauma Resusc Emerg Med. 2019 Feb 8;27(1):12. doi: 10.1186/s13049-019-0591-9.,Freytag J,Scand J Trauma Resusc Emerg Med,2019,2019/02/10,PMC6368771,,10.1186/s13049-019-0591-9,https://pubmed.ncbi.nlm.nih.gov/30736821/,/30736821/,"The ethics committee (EA2/172/16) and the institutional office for data protection (AZ 737/16) at Charité Universitätsmedizin approved the study. All participants and raters consented orally and in written form. Not applicable, since manuscript does not include individual person’s data. WEH received financial compensation for educational consultancy from the AO Foundation, Zurich, Switzerland and research funding from Mundipharma Medical, Basel, Switzerland. All other authors report no competing interests. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",Grants and funding 01PL16036/Bundesministerium für Bildung und Forschung 01PL16036/Bundesministerium für Bildung und Forschung,"Julia Freytag 1 , Fabian Stroben 2 3 , Wolf E Hautz 4 5 , Stefan K Schauber 5 , Juliane E Kämmer 6 7"
30896890,Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry,"Robert N Stuver 1, Niloufer Khan 2, Marc Schwartz 3, Mark Acosta 4, Massimo Federico 5, Christian Gisselbrecht 6, Steven M Horwitz 2, Frederik Lansigan 7, Lauren C Pinter-Brown 8, Barbara Pro 9, Andrei R Shustov 10, Francine M Foss 11, Salvia Jain 1 12",Am J Hematol. 2019 Jun;94(6):641-649. doi: 10.1002/ajh.25463. Epub 2019 Apr 9.,Stuver RN,Am J Hematol,2019,2019/03/22,PMC7928240,NIHMS1638301,10.1002/ajh.25463,https://pubmed.ncbi.nlm.nih.gov/30896890/,/30896890/,"CONFLICT OF INTERESTS Schwartz: (employment); Acosta: Spectrum Pharmaceuticals, Inc. (employment); Pro: Takeda Pharmaceutical Company (honoraria), Portola Pharmaceuticals, Inc. (honoraria), Seattle Genetics (consultancy, research funding), Kyowa Kirin Pharmaceutical Development, Inc. (honoraria); Shustov: Seattle Genetics (research funding); Horwitz: Aileron Therapeutics (consultancy, research funding), Takeda Pharmaceutical Company (consultancy, research funding), Mundipharma (consultancy), ADC Therapeutics (consultancy, research funding), Spectrum Pharmaceuticals, Inc. (research funding), Trillium Therapeutics, Inc. (consultancy), Corvus Pharmaceuticals (consultancy), Forty Seven, Inc. (consultancy, research funding), Seattle Genetics (consultancy, research funding), Celgene (consultancy, research funding), Innate Pharma (consultancy), Infinity Pharmaceuticals, Inc. (consultancy, research funding), Verastem Oncology (consultancy, research funding); Portola Pharmaceuticals, Inc. (consultancy), Kyowa Kirin Pharmaceutical Development, Inc. (consultancy, research funding); Foss: Seattle Genetics (consultancy), Miragen Therapeutics, Inc. (consultancy, speakers bureau), Mallinkrodt (consultancy), Spectru Pharmaceuticals, Inc. (consultancy).","Grants and funding K08 CA230498/CA/NCI NIH HHS/United States P30 CA008748/CA/NCI NIH HHS/United States Spectrum Pharmaceuticals, Inc./International","Robert N Stuver 1 , Niloufer Khan 2 , Marc Schwartz 3 , Mark Acosta 4 , Massimo Federico 5 , Christian Gisselbrecht 6 , Steven M Horwitz 2 , Frederik Lansigan 7 , Lauren C Pinter-Brown 8 , Barbara Pro 9 , Andrei R Shustov 10 , Francine M Foss 11 , Salvia Jain 1 12"
31218428,Dopamine D2-like receptor stimulation blocks negative feedback in visual and spatial reversal learning in the rat: behavioural and computational evidence,"Johan Alsiö 1, Benjamin U Phillips 2 3, Júlia Sala-Bayo 2, Simon R O Nilsson 2 4 5, Teresa C Calafat-Pla 2, Arazo Rizwand 2, Jessica M Plumbridge 2, Laura López-Cruz 2, Jeffrey W Dalley 2 6, Rudolf N Cardinal 2 6 7, Adam C Mar 2 4 5, Trevor W Robbins 2",Psychopharmacology (Berl). 2019 Aug;236(8):2307-2323. doi: 10.1007/s00213-019-05296-y. Epub 2019 Jun 19.,Alsiö J,Psychopharmacology (Berl),2019,2019/06/21,PMC6695374,,10.1007/s00213-019-05296-y,https://pubmed.ncbi.nlm.nih.gov/31218428/,/31218428/,"T.W.R. discloses consultancy with Cambridge Cognition, Lundbeck, Mundipharma, and Unilever; he receives royalties from Cambridge Cognition and editorial honoraria from Springer Verlag and Elsevier. J.S.B. is supported by a studentship from Boehringer Ingelheim. J.A., B.U.P., S.R.O.N., T.C.C.P., A.R., J.M.P., L.L.C., J.W.D., R.N.C., and A.C.M. declare no conflicts of interest.",Grants and funding WT_/Wellcome Trust/United Kingdom G0001354/MRC_/Medical Research Council/United Kingdom G1000183/MRC_/Medical Research Council/United Kingdom MC_PC_17213/MRC_/Medical Research Council/United Kingdom,"Johan Alsiö 1 , Benjamin U Phillips 2 3 , Júlia Sala-Bayo 2 , Simon R O Nilsson 2 4 5 , Teresa C Calafat-Pla 2 , Arazo Rizwand 2 , Jessica M Plumbridge 2 , Laura López-Cruz 2 , Jeffrey W Dalley 2 6 , Rudolf N Cardinal 2 6 7 , Adam C Mar 2 4 5 , Trevor W Robbins 2"
31893088,"Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin","Ritsuko Nakai 1, Suguru Fukuhara 1, Akiko Miyagi Maeshima 2, Sung-Won Kim 3, Yuta Ito 1, Shunsuke Hatta 1, Tomotaka Suzuki 1, Sayako Yuda 1, Shinichi Makita 1, Wataru Munakata 1, Tatsuya Suzuki 1, Dai Maruyama 1, Koji Izutsu 1",Clin Case Rep. 2019 Nov 15;7(12):2500-2504. doi: 10.1002/ccr3.2543. eCollection 2019 Dec.,Nakai R,Clin Case Rep,2019,2020/01/02,PMC6935642,,10.1002/ccr3.2543,https://pubmed.ncbi.nlm.nih.gov/31893088/,/31893088/,"Dr Nakai, Dr Fukuhara, Dr Maeshima, Dr Kim, Dr Ito, Dr Hatta, Dr Tomotaka Suzuki, Dr Yuda, Dr Makita, and Dr Munakata have nothing to disclose. Dr Izutsu reports the following funding outside the submitted work: grants from Eisai, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from MSD, grants and personal fees from Takeda, grants and personal fees from Janssen, personal fees from Bristol Myers Squib, personal fees from Dainihon Sumitomo, grants and personal fees from Mundipharma, personal fees from Nihon Mediphysics, grants and personal fees from Chugai, personal fees from Astra Zeneca, grants and personal fees from Abbvie, grants and personal fees from Bayer, grants and personal fees from Ono, grants from Gilead, grants from Zenyaku, grants and personal fees from Celgene, grants from Solasia, grants from Symbio, grants from Astellas, grants from Astellas Amgen, grants from Daiichi Sankyo. Dr Maruyama reports grants and personal fees from Chugai, grants and personal fees from Takeda during the conduct of the study, and the following funding outside the submitted work: grants from Sanofi, grants and personal fees from Janssen, grants and personal fees from Eisai, grants and personal fees from Celegene, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Ono, grants and personal fees from Mundipharma, grants and personal fees from MSD, grants and personal fees from Zenyaku, personal fees from Sumitomo, personal fees from Asahi Kasei, grants and personal fees from Bristol‐Myers Squibb, grants and personal fees from Daiichi Sankyo, grants and personal fees from AstraZeneca, personal fees from Linical, personal fees from Pharma International, personal fees from Fujimoto, grants from Abbvie, grants from Astellas, grants from Amgen Astellas Biopharma, grants from Otsuka, grants from Novartis, grants from Pfizer, grants from Solasia, grants from Bayer, grants from Symbio, grants from CMIC, grants from Quintiles, grants from IQvia. Dr Tatsuya Suzuki reports personal fees from Chugai Pharmaceutical, outside the submitted work.",,"Ritsuko Nakai 1 , Suguru Fukuhara 1 , Akiko Miyagi Maeshima 2 , Sung-Won Kim 3 , Yuta Ito 1 , Shunsuke Hatta 1 , Tomotaka Suzuki 1 , Sayako Yuda 1 , Shinichi Makita 1 , Wataru Munakata 1 , Tatsuya Suzuki 1 , Dai Maruyama 1 , Koji Izutsu 1"
30927375,Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation,"Sophie E Berends 1 2, Geert R A M DHaens 2, Tiny Schaap 3, Annick de Vries 3, Theo Rispens 4, Karien Bloem 3, Ron A A Mathôt 1",Br J Clin Pharmacol. 2019 Jul;85(7):1544-1551. doi: 10.1111/bcp.13939. Epub 2019 May 11.,Berends SE,Br J Clin Pharmacol,2019,2019/03/31,PMC6595298,,10.1111/bcp.13939,https://pubmed.ncbi.nlm.nih.gov/30927375/,/30927375/,"G.R.A.M.D. has served as advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avax‐ ia, Biogen, Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, DrFALK Pharma, Engene, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novonordisk, Pfizer, Prometheus laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor, and received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp & Dohme, Mundi‐ pharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts and Vifor. T.R. has received honoraria for lectures from Pfizer, Abbvie and Regeneron, and a research grant from Genmab. R.A.A.M. has received unrestricted research grants from Bayer, Shire and Merck Sharpe & Dome and consultancy fees from Bayer and Shire. S.E.B., T.S., A.d.V. and K.B. have no competing interests to declare.",,"Sophie E Berends 1 2 , Geert R A M DHaens 2 , Tiny Schaap 3 , Annick de Vries 3 , Theo Rispens 4 , Karien Bloem 3 , Ron A A Mathôt 1"
31673775,RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group,"Sini Luoma 1, Pekka Anttila 2, Marjaana Säily 3, Tuija Lundan 4, Jouni Heiskanen 2, Timo Siitonen 3, Sakari Kakko 3, Mervi Putkonen 5, Hanna Ollikainen 6, Venla Terävä 7, Marja Sankelo 7, Anu Partanen 8 9, Kirsi Launonen 3 10, Anu Räsänen 11, Anu Sikiö 12, Merja Suominen 13, Piotr Bazia 14, Kristiina Kananen 14, Juha Lievonen 2, Tuomas Selander 15, Tarja-Terttu Pelliniemi 16, Sorella Ilveskero 17, Virva Huotari 16 18, Pentti Mäntymaa 19, Anri Tienhaara 4, Esa Jantunen 8 20 21, Raija Silvennoinen 2 8",Ann Hematol. 2019 Dec;98(12):2781-2792. doi: 10.1007/s00277-019-03815-7. Epub 2019 Oct 31.,Luoma S,Ann Hematol,2019,2019/11/02,PMC6900265,,10.1007/s00277-019-03815-7,https://pubmed.ncbi.nlm.nih.gov/31673775/,/31673775/,"SL has been a lecturer for Amgen and received educational travel grants from Abbvie and Amgen. RS has received research funding from Celgene, Amgen, BMS, and Takeda, and has been a consultant and lecturer for Celgene, Amgen, BMS, Takeda, and Genzyme/Sanofi. EJ reports honoraria from Genzyme/Sanofi and Amgen and has participated in Advisory Boards of Amgen, Takeda, and TEVA. MP has received Advisory Board honoraria from Amgen, Celgene, and Takeda. AR has participated in Advisory Boards organized by Amgen and Roche and received educational travel grants from Gilead, Pfizer, and Roche. TiS has participated in Advisory Boards of Roche and Amgen, has been a lecturer for Amgen and Celgene, and received educational travel grants from Novartis, Pfizer, Gilead, and Amgen. JL has received educational travel grants from Janssen-Cilag, Celgene, Amgen, Novartis, TEVA, Takeda, and Roche, and has been a consultant for Celgene, Amgen, and Novartis. KK has received honoraria from Amgen, Roche, and Fresenius. VT has participated in Advisory Board organized by Amgen and received an educational travel grant from Celgene. JH has received an educational travel grant from and been a lecturer for Sanofi. MaS has received educational travel grants from Celgene, Genzyme, and Pfizer. KL has received educational travel grants from Celgene, Mundipharma, and Novartis. AP reports honoraria from Behring and has participated Medical Advisory Board meeting organized by Abbvie. HO has received educational travel grants from Celgene, Genzyme, and Gilead. The remaining authors declare no conflict of interest.",Grants and funding 5101424/Research Committee of the Kuopio University Hospital catchment area Y1018XPA01/Helsinki University Hospital Comprehensive Cancer Center,"Sini Luoma 1 , Pekka Anttila 2 , Marjaana Säily 3 , Tuija Lundan 4 , Jouni Heiskanen 2 , Timo Siitonen 3 , Sakari Kakko 3 , Mervi Putkonen 5 , Hanna Ollikainen 6 , Venla Terävä 7 , Marja Sankelo 7 , Anu Partanen 8 9 , Kirsi Launonen 3 10 , Anu Räsänen 11 , Anu Sikiö 12 , Merja Suominen 13 , Piotr Bazia 14 , Kristiina Kananen 14 , Juha Lievonen 2 , Tuomas Selander 15 , Tarja-Terttu Pelliniemi 16 , Sorella Ilveskero 17 , Virva Huotari 16 18 , Pentti Mäntymaa 19 , Anri Tienhaara 4 , Esa Jantunen 8 20 21 , Raija Silvennoinen 2 8"
30808625,"Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate","Leonieke J J van Mens 1 2, Henriëtte M de Jong 1 2, Inka Fluri 1 2, Michael T Nurmohamed 2 3, Marleen G H van de Sande 1 2, Marc Kok 4, Arno W R van Kuijk 2 5, Dominique Baeten 6 2",Ann Rheum Dis. 2019 May;78(5):610-616. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.,van Mens LJJ,Ann Rheum Dis,2019,2019/02/28,,,10.1136/annrheumdis-2018-214746,https://pubmed.ncbi.nlm.nih.gov/30808625/,/30808625/,"Competing interests: DB is currently an employee of UCB Pharma. LJJvM, IF and HMdJ have nothing to disclose. MGHvdS has been an advisor for Abbvie and Novartis, and received research grants from Janssen, Eli Lily and Novartis. The department of MK is supported by Novartis, Abbvie, Pfizer, Roche, Lilly and BMS, and MK has been an advisor for Novartis and Abbvie. MTN received research grants, consultation and/or speaking fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche, Sanofi and UCB Pharma. AWRvK received speaker fees from Celgene, Novartis, Eli Lilly and Janssen, and received research support from MSD and Janssen.",,"Leonieke J J van Mens 1 2 , Henriëtte M de Jong 1 2 , Inka Fluri 1 2 , Michael T Nurmohamed 2 3 , Marleen G H van de Sande 1 2 , Marc Kok 4 , Arno W R van Kuijk 2 5 , Dominique Baeten 6 2"
31633999,Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes,"Gian Maria Zaccaria 1, Simone Ferrero 1, Samanta Rosati 2, Marco Ghislieri 2, Elisa Genuardi 1, Andrea Evangelista 3, Rebecca Sandrone 2, Cristina Castagneri 2, Daniela Barbero 1, Mariella Lo Schirico 4, Luca Arcaini 5, Anna Lia Molinari 6, Filippo Ballerini 7, Andres Ferreri 8, Paola Omedè 1, Alberto Zamò 1, Gabriella Balestra 2, Mario Boccadoro 1, Sergio Cortelazzo 9, Marco Ladetto 10",JCO Clin Cancer Inform. 2019 Oct;3:1-15. doi: 10.1200/CCI.19.00049.,Zaccaria GM,JCO Clin Cancer Inform,2019,2019/10/22,PMC6873907,,10.1200/CCI.19.00049,https://pubmed.ncbi.nlm.nih.gov/31633999/,/31633999/,"Consulting or Advisory Role: Janssen-Cilag, EUSA Pharma Speakers Bureau: Janssen-Cilag, Gilead Sciences, SERVIER Research Funding: Gilead Sciences Travel, Accommodations, Expenses: Roche, SERVIER, Sanofi, Janssen-Cilag, EUSA Pharma, Gentili Consulting or Advisory Role: Roche, Celgene, Janssen-Cilag, Verastem Oncology Speakers Bureau: Celgene Research Funding: Gilead Travel, Accommodations, Expenses: Roche, Celgene, Gilead Sciences Consulting or Advisory Role: Kite-Gilead, Celgene, SERVIER Research Funding: Celgene (Inst), Roche (Inst) Travel, Accommodations, Expenses: Gilead Sciences, MolMed, Takeda, Roche Consulting or Advisory Role: Janssen Honoraria: Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, AbbVie Research Funding: Sanofi (Inst), Celgene (Inst), Amgen (Inst), Janssen (Inst), Novartis (Inst), Bristol-Myers Squibb (Inst), Mundipharma (Inst) Honoraria: AbbVie, Acerta Pharma, Amgen, Archigen Biotech, ADC Therapeutics, Celgene, Gilead Sciences, Johnson & Johnson, Jazz Pharmaceuticals, Pfizer, Roche, Sandoz, Takeda No other potential conflicts of interest were reported.",,"Gian Maria Zaccaria 1 , Simone Ferrero 1 , Samanta Rosati 2 , Marco Ghislieri 2 , Elisa Genuardi 1 , Andrea Evangelista 3 , Rebecca Sandrone 2 , Cristina Castagneri 2 , Daniela Barbero 1 , Mariella Lo Schirico 4 , Luca Arcaini 5 , Anna Lia Molinari 6 , Filippo Ballerini 7 , Andres Ferreri 8 , Paola Omedè 1 , Alberto Zamò 1 , Gabriella Balestra 2 , Mario Boccadoro 1 , Sergio Cortelazzo 9 , Marco Ladetto 10"
30881003,Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation,"Ho Cheol Kim 1, Tae Hoon Kim 2, Chin Kook Rhee 3, Minkyu Han 4, Yeon-Mok Oh 1",Ther Clin Risk Manag. 2019 Mar 5;15:377-387. doi: 10.2147/TCRM.S194324. eCollection 2019.,Kim HC,Ther Clin Risk Manag,2019,2019/03/19,PMC6407515,,10.2147/TCRM.S194324,https://pubmed.ncbi.nlm.nih.gov/30881003/,/30881003/,"Disclosure CK Rhee received consulting/lecture fees from MSD, AstraZeneca, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, and Bayer. Other authors have no potential conflicts of interest to disclose in this work.",,"Ho Cheol Kim 1 , Tae Hoon Kim 2 , Chin Kook Rhee 3 , Minkyu Han 4 , Yeon-Mok Oh 1"
31343402,Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT,"Graham Devereux 1, Seonaidh Cotton 2, Shona Fielding 3, Nicola McMeekin 4, Peter J Barnes 5, Andy Briggs 4, Graham Burns 6, Rekha Chaudhuri 7, Henry Chrystyn 8, Lisa Davies 9, Anthony De Soyza 10, Simon Gompertz 11, John Haughney 7, Karen Innes 2, Joanna Kaniewska 2, Amanda Lee 3, Alyn Morice 12, John Norrie 13, Anita Sullivan 11, Andrew Wilson 14, David Price 1 15",Health Technol Assess. 2019 Jul;23(37):1-146. doi: 10.3310/hta23370.,Devereux G,Health Technol Assess,2019,2019/07/26,PMC6689818,,10.3310/hta23370,https://pubmed.ncbi.nlm.nih.gov/31343402/,/31343402/,"Graham Burns reports personal fees from Boehringer Ingelheim GmbH (Ingelheim am Rhein, Germany), Teva Pharmaceutical Industries Ltd (Petah Tikva, Israel), Chiesi Farmaceutici SpA (Parma, Italy), Pfizer Inc. (New York City, NY, USA) and AstraZeneca plc (Cambridge, UK), and non-financial support from Chiesi and Boehringer Ingelheim, outside the submitted work. Rekha Chaudhuri reports personal fees from AstraZeneca, GlaxoSmithKline (GSK) plc (London, UK), Teva and Novartis International AG (Basel, Switzerland) for advisory board meetings, outside the submitted work. Anthony De Soyza reports grants and non-financial support from AstraZeneca and Chiesi, non-financial support from Boehringer Ingelheim, grants and personal fees from GSK, Bayer AG (Leverkusen, Germany) and Pfizer, and grants from Forest Laboratories (New York City, NY, USA)/Teva, outside the submitted work. He is also a member of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Elective and Emergency Specialist Care (EESC) Panel. Simon Gompertz reports personal fees from Pfizer and GSK, outside the submitted work. John Norrie reports grants from the NIHR HTA programme during the conduct of the study, was a member of the NIHR HTA Commissioning Board (2010–16) and is currently Deputy Chairperson of the NIHR HTA General Board (2016–present) and a NIHR Journals Library Editor (2014–present). Andrew Wilson reports grants from F. Hoffmann-La Roche (Basel, Switzerland), outside the submitted work. David Price reports grants and personal fees from Aerocrine AB (Stockholm, Sweden), AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan NV (Canonsburg, PA, USA), Mundipharma International Ltd (Cambridge, UK), Napp Pharmaceuticals Ltd (Cambridge, UK), Novartis, Pfizer, Teva, Theravance Biopharma (San Francisco, CA, USA) and Zentiva Group a.s. (Prague, Czech Republic); personal fees from Almirall SA (Barcelona, Spain), Amgen Inc. (Newbury Park, CA, USA), Cipla Ltd (Mumbai, India), GSK, Kyorin Pharmaceutical Co. Ltd (Tokyo, Japan), Merck Sharp & Dohme (Kenilworth, NJ, USA), Skyepharma Production SAS (Saint-Quentin-Fallavier, France); grants from AKL Research and Development Ltd (Stevenage, UK), the British Lung Foundation, the Respiratory Effectiveness Group and the UK NHS; and non-financial support from the NIHR Efficacy and Mechanism Evaluation and HTA programmes, outside the submitted work. He also reports stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals and owns 74% of the social enterprise Optimum Patient Care Ltd (Cambridge, UK, and Australia and Singapore) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore).",Grants and funding 11/58/15/DH_/Department of Health/United Kingdom HSRU1/CSO_/Chief Scientist Office/United Kingdom,"Graham Devereux 1 , Seonaidh Cotton 2 , Shona Fielding 3 , Nicola McMeekin 4 , Peter J Barnes 5 , Andy Briggs 4 , Graham Burns 6 , Rekha Chaudhuri 7 , Henry Chrystyn 8 , Lisa Davies 9 , Anthony De Soyza 10 , Simon Gompertz 11 , John Haughney 7 , Karen Innes 2 , Joanna Kaniewska 2 , Amanda Lee 3 , Alyn Morice 12 , John Norrie 13 , Anita Sullivan 11 , Andrew Wilson 14 , David Price 1 15"
31749614,The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization,"Arja Viinanen # 1 2, Mariann I Lassenius # 3, Iiro Toppila 3, Antti Karlsson 4 5, Lauri Veijalainen 6, Juhana J Idänpään-Heikkilä 6, Tarja Laitinen 1 2 7",Int J Chron Obstruct Pulmon Dis. 2019 Oct 25;14:2409-2421. doi: 10.2147/COPD.S222581. eCollection 2019.,Viinanen A,Int J Chron Obstruct Pulmon Dis,2019,2019/11/22,PMC6818542,,10.2147/COPD.S222581,https://pubmed.ncbi.nlm.nih.gov/31749614/,/31749614/,"AV has served as a scientific advisory board member for AstraZeneca, GSK and Novartis, has received lecture fees from Astra-Zeneca, Chiesi, Boehringer Ingelheim, Mundipharma, and Novartis, and has participated in congresses and educational lectures with support from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, and Roche. ML and IT are employees of Medaffcon Oy. AK has received lecture fees from Bayer. LV and JI-H are employees of GSK and JI-H holds shares in GSK. TL has served as a scientific advisory board member for GSK, has performed research sponsored by GSK, and has received funding from GSK to participate in a scientific conference. The authors report no other conflicts of interest in this work.",,"Arja Viinanen # 1 2 , Mariann I Lassenius # 3 , Iiro Toppila 3 , Antti Karlsson 4 5 , Lauri Veijalainen 6 , Juhana J Idänpään-Heikkilä 6 , Tarja Laitinen 1 2 7"
31559071,Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1),"Jean Bousquet 1 2 3 4 5 6 7 8, Nhân Pham-Thi 9, Anna Bedbrook 2, Ioana Agache 10, Isabella Annesi-Maesano 11, Ignacio Ansotegui 12, Josep M Anto 13 14 15, Claus Bachert 16, Samuel Benveniste 17 18, Mike Bewick 19, Nils Billo 20, Sinthia Bosnic-Anticevich 21, Isabelle Bosse 22, Guy Brusselle 23, Moïses A Calderon 24, Giorgio W Canonica 25, Luis Caraballo 26, Victoria Cardona 27, Ana Maria Carriazo 28, Eugene Cash 29, Lorenzo Cecchi 30, Derek K Chu 31, Elaine Colgan 32, Elisio Costa 33, Alvaro A Cruz 34, Wienczyslawa Czarlewski 35, Stephen Durham 36, Motohiro Ebisawa 37, Marina Erhola 38, Jean-Luc Fauquert 39, Wytske J Fokkens 8 40, Joao A Fonseca 41, Nick Guldemond 42, Tomohisa Iinuma 43, Maddalena Illario 44, Ludger Klimek 45, Piotr Kuna 46, Violeta Kvedariene 47, Désirée Larenas-Linneman 48, Daniel Laune 49, Lan T T Le 50, Olga Lourenço 51, Joao O Malva 52, Gert Marien 8, Enrica Menditto 53, Joaquim Mullol 54, Lars Münter 55, Yoshitaka Okamoto 43, Gabrielle L Onorato 2, Nikos G Papadopoulos 56 57, Maritta Perala 58, Oliver Pfaar 59, Abigail Phillips 60, Jim Phillips 61, Hilary Pinnock 62, Fabienne Portejoie 2, Pablo Quinones-Delgado 63, Christine Rolland 64, Ulysse Rodts 65, Boleslaw Samolinski 66, Mario Sanchez-Borges 67, Holger J Schünemann 30, Mohamed Shamji 68, David Somekh 69, Alkis Togias 70, Sanna Toppila-Salmi 71, Ioanna Tsiligianni 72, Omar Usmani 73, Samantha Walker 74, Dana Wallace 75, Arunas Valiulis 76, Rianne Van der Kleij 77, Maria Teresa Ventura 78, Sian Williams 79, Arzu Yorgancioglu 80, Torsten Zuberbier 81",J Thorac Dis. 2019 Aug;11(8):3633-3642. doi: 10.21037/jtd.2019.08.64.,Bousquet J,J Thorac Dis,2019,2019/09/28,PMC6753463,,10.21037/jtd.2019.08.64,https://pubmed.ncbi.nlm.nih.gov/31559071/,/31559071/,"Conflicts of Interest: Dr. Ansotegui reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, Astra Zeneca, outside the submitted work. Dr. Bachert reports personal fees from ALK, Stallergen, during the conduct of the study; personal fees from ALK, Stallergen, outside the submitted work. Dr. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov, outside the submitted work. Dr. Calderon reports personal fees from ALK-Abello, ALK-US, Stallergenes Greer, HAL-Allergy, Allergopharma, ASIT-Biotech, outside the submitted work. Dr. Canonica reports grants from ALK ABELLO, Allergy Therapeutics, Anallergo, Hal Allergy, Stallergenes Greer, outside the submitted work. Dr. Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher, Stallergenes, outside the submitted work. Dr. Cecchi reports personal fees from Menarini, Malesci ALK, outside the submitted work. Dr. Cruz reports grants from National Institutes for Health Research (UK), National Institutes of Health (USA), grants and other from National Research Council (Brazil), other from Federal University of Bahia (Brazil), non-financial support from Fundacao ProAR, grants and personal fees from GSK, personal fees from AstraZeneca, Boehringer Ingelheim, CHIESI, Eurofarma, MEDA Pharma. Dr. Durham reports personal fees from Adiga, personal fees from ALK, personal fees from Allergopharma, MedicalUpdate GmBC, UCB, outside the submitted work. Dr. Ebisawa reports personal fees from Mylan, DBV Technologies, Thermofisher, outside the submitted work. Dr. Fokkens reports grants from Mylan, Allergy Therapeutics, GSK, ALK. Dr. Fonseca being a partner in a company developing mobile technologies for monitoring airways diseases. Dr. Klimek reports grants and personal fees from ALK Abelló, Denmark, grants and personal fees from Novartis, Switzerland, Allergopharma, Germany, Bionorica, Sweden, GSK, Great Britain, Lofarma, Italy, personal fees from MEDA, Sweden, Boehringer Ingelheim, Germany, grants from Biomay, Austria, grants from HAL, Netherlands, grants from LETI, Spain, Roxall, Germany, Bencard, Great Britain, outside the submitted work. Dr. Kuna reports personal fees from Adamed, AstraZeneca, Boehringer Ingelheim, Hal, Chiesi, Novartis, Berlin Chemie Menarini, outside the submitted work. Dr. Kvedariene reports personal fees from GSK, non-financial support from StallergenGreer, Mylan, AstraZeneca, Dimuna, Norameda, outside the submitted work. D Larenas Linnemann reports personal fees from GSK, Astrazeneca, MEDA, Boehringer Ingelheim, Novartis, Grunenthal, UCB, Amstrong, Siegfried, DBV Technologies, MSD, Pfizer. grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Chiesi, Boehringer Ingelheim, outside the submitted work. Dr. MULLOL reports personal fees from SANOFI-Genzyme-Regeneron, ALK-Abelló A/S, Menarini Group, MSD, GlaxoSmithKline, Novartis, GENENTECH-Roche, grants and personal fees from UCB Pharma, MYLAN-MEDA Pharma, URIACH Group, outside the submitted work. Y Okamoto reports personal fees from Shionogi Co. Ltd., Torii Co. Ltd., GSK, MSD, Kyowa Co. Ltd., from Eizai Co. Ltd., grants and personal fees from Kyorin Co. Ltd., Tiho Co. Ltd., grants from Yakuruto Co. Ltd., Yamada Bee Farm, outside the submitted work. N Papadopoulos reports personal fees from Novartis, Faes Farma, BIOMAY, HAL, Nutricia Research, Menarini, Novartis, MEDA, Abbvie, Novartis, MSD, Omega Pharma Danone, grants from Menarini outside the submitted work. O Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biotech Tools S.A, LETI/LETI Pharma, Anergis S.A. grants from Biomay, Nuvo, Circassia, Glaxo Smith Kline, personal fees from Novartis Pharma, MEDA Pharma, Mobile Chamber Experts (a GA2LEN Partner), Pohl-Boskamp, Indoor Biotechnologies, grants from, outside the submitted work. Dr. Samolinski reports non-financial support from Mylan, during the conduct of the study. Dr. Shamji reports grants and personal fees from ALK, ASIT Biotech, sa, Allergopharma, grants from Regeneron, Merck, Immune Tolerance Network, outside the submitted work. Dr. Tsiligianni reports personal fees from Novartis, GSK, Boehringer Ingelheim, Astra Zeneca, grants from GSK Hellas, outside the submitted work. Dr. Wallace is co-chair of the Joint Task Force on Practice Parameters of the AAAAI/ACAAI. However, it does not feel that this causes any conflict of interest in the writing/review of the document. Zuberbier reports fees from Bayer Health Care, FAES, Novartis, Henkel, Astra Zeneca, AbbVie, ALK, Almirrall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, HAL, Leti, Meda, Menarini, Merck, MSD, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan, l’Oreal; Commitee member: WHO-Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA). Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI). Head: European Centre for Allergy Research Foundation (ECARF). Secretary General: Global Allergy and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). The other authors have no conflicts of interest to declare.",,"Jean Bousquet 1 2 3 4 5 6 7 8 , Nhân Pham-Thi 9 , Anna Bedbrook 2 , Ioana Agache 10 , Isabella Annesi-Maesano 11 , Ignacio Ansotegui 12 , Josep M Anto 13 14 15 , Claus Bachert 16 , Samuel Benveniste 17 18 , Mike Bewick 19 , Nils Billo 20 , Sinthia Bosnic-Anticevich 21 , Isabelle Bosse 22 , Guy Brusselle 23 , Moïses A Calderon 24 , Giorgio W Canonica 25 , Luis Caraballo 26 , Victoria Cardona 27 , Ana Maria Carriazo 28 , Eugene Cash 29 , Lorenzo Cecchi 30 , Derek K Chu 31 , Elaine Colgan 32 , Elisio Costa 33 , Alvaro A Cruz 34 , Wienczyslawa Czarlewski 35 , Stephen Durham 36 , Motohiro Ebisawa 37 , Marina Erhola 38 , Jean-Luc Fauquert 39 , Wytske J Fokkens 8 40 , Joao A Fonseca 41 , Nick Guldemond 42 , Tomohisa Iinuma 43 , Maddalena Illario 44 , Ludger Klimek 45 , Piotr Kuna 46 , Violeta Kvedariene 47 , Désirée Larenas-Linneman 48 , Daniel Laune 49 , Lan T T Le 50 , Olga Lourenço 51 , Joao O Malva 52 , Gert Marien 8 , Enrica Menditto 53 , Joaquim Mullol 54 , Lars Münter 55 , Yoshitaka Okamoto 43 , Gabrielle L Onorato 2 , Nikos G Papadopoulos 56 57 , Maritta Perala 58 , Oliver Pfaar 59 , Abigail Phillips 60 , Jim Phillips 61 , Hilary Pinnock 62 , Fabienne Portejoie 2 , Pablo Quinones-Delgado 63 , Christine Rolland 64 , Ulysse Rodts 65 , Boleslaw Samolinski 66 , Mario Sanchez-Borges 67 , Holger J Schünemann 30 , Mohamed Shamji 68 , David Somekh 69 , Alkis Togias 70 , Sanna Toppila-Salmi 71 , Ioanna Tsiligianni 72 , Omar Usmani 73 , Samantha Walker 74 , Dana Wallace 75 , Arunas Valiulis 76 , Rianne Van der Kleij 77 , Maria Teresa Ventura 78 , Sian Williams 79 , Arzu Yorgancioglu 80 , Torsten Zuberbier 81"
31073085,A simple echocardiographic estimate of right ventricular-arterial coupling to assess severity and outcome in pulmonary hypertension on chronic lung disease,"Khodr Tello 1, Hossein A Ghofrani 1 2 3, Charlotte Heinze 1, Karsten Krueger 4, Robert Naeije 5, Christina Raubach 1, Werner Seeger 1, Natascha Sommer 1, Henning Gall 1 6, Manuel J Richter 7 6",Eur Respir J. 2019 Sep 12;54(3):1802435. doi: 10.1183/13993003.02435-2018. Print 2019 Sep.,Tello K,Eur Respir J,2019,2019/05/11,,,10.1183/13993003.02435-2018,https://pubmed.ncbi.nlm.nih.gov/31073085/,/31073085/,"Conflict of interest: H.A. Ghofrani reports that this work was funded by the Excellence Cluster Cardio-Pulmonary System (ECCPS) and the Collaborative Research Center (SFB) 1213, Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (German Research Foundation, Bonn, Germany), and received editorial support, funded by the University of Giessen; personal fees for consultancy and advisory board work from Bayer and Pfizer, personal fees for consultancy, advisory board work and lectures from Actelion and GSK, personal fees for consultancy from Merck, grants and personal fees for consultancy from Novartis, grants and personal fees for lectures from Bayer HealthCare and Encysive/Pfizer, grants from Aires, German Research Foundation, Excellence Cluster Cardiopulmonary Research and German Ministry for Education and Research, personal fees for advisory board work from Takeda, outside the submitted work. Conflict of interest: C. Heinze has nothing to disclose. Conflict of interest: K. Krüger has nothing to disclose. Conflict of interest: R. Naeije reports grants and personal fees for consultancy and advisory board work from AOPOrphan Pharmaceuticals, Actelion, Bayer, Reata, Lung Biotechnology Corporation and United Therapeutics, outside the submitted work. Conflict of interest: C. Raubach has nothing to disclose. Conflict of interest: W. Seeger reports that this work was funded by the Excellence Cluster Cardio-Pulmonary System (ECCPS) and the Collaborative Research Center (SFB) 1213, Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (German Research Foundation, Bonn, Germany), and received editorial support, funded by the University of Giessen; personal fees for lectures and consultancy from Pfizer and Bayer Pharma AG, outside the submitted work. Conflict of interest: N. Sommer reports personal fees from Actelion, outside the submitted work. Conflict of interest: H. Gall reports that this work was funded by the Excellence Cluster Cardio-Pulmonary System (ECCPS) and the Collaborative Research Center (SFB) 1213, Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (German Research Foundation, Bonn, Germany), and received editorial support, funded by the University of Giessen; personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer andUnited Therapeutics, outside the submitted work. Conflict of interest: M.J. Richter reports that this work was funded by the Excellence Cluster Cardio-Pulmonary System (ECCPS) and the Collaborative Research Center (SFB) 1213, Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (German Research Foundation, Bonn, Germany), and received editorial support, funded by the University of Giessen; grants from United Therapeutics, grants and personal fees for lectures and consultancy from Bayer, personal fees for lectures from Actelion, Mundipharma, Roche and OMT, outside the submitted work. Conflict of interest: K. Tello reports that this work was funded by the Excellence Cluster Cardio-Pulmonary System (ECCPS) and the Collaborative Research Center (SFB) 1213, Pulmonary Hypertension and Cor Pulmonale, grant number SFB1213/1, project B08 (German Research Foundation, Bonn, Germany), and received editorial support, funded by the University of Giessen; personal fees for lectures from Actelion and Bayer, outside the submitted work.",,"Khodr Tello 1 , Hossein A Ghofrani 1 2 3 , Charlotte Heinze 1 , Karsten Krueger 4 , Robert Naeije 5 , Christina Raubach 1 , Werner Seeger 1 , Natascha Sommer 1 , Henning Gall 1 6 , Manuel J Richter 7 6"
31063477,Diagnostic accuracy of a rapid RT-PCR assay for point-of-care detection of influenza A/B virus at emergency department admission: A prospective evaluation during the 2017/2018 influenza season,"Maxime Maignan 1, Damien Viglino 1, Maud Hablot 1, Nicolas Termoz Masson 1, Anne Lebeugle 1, Roselyne Collomb Muret 1, Prudence Mabiala Makele 1, Valérie Guglielmetti 1, Patrice Morand 2, Julien Lupo 2, Virginie Forget 3, Caroline Landelle 3, Sylvie Larrat 2",PLoS One. 2019 May 7;14(5):e0216308. doi: 10.1371/journal.pone.0216308. eCollection 2019.,Maignan M,PLoS One,2019,2019/05/08,PMC6504036,,10.1371/journal.pone.0216308,https://pubmed.ncbi.nlm.nih.gov/31063477/,/31063477/,"Roche Diagnostics had no role in the study design; collection, analysis, or interpretation of data; writing of the paper; and/or decision to submit for publication. None of the authors received direct funding from this company. MundiPharma and Purdue: These sister companies had no role in this study and are currently working outside the field of influenza diagnosis or treatment. MM and DV received a grant to conduct a trial on pain management in the ED (NCT03380247). MM also received consultant fees as a “pain management expert” from these companies. DV received a grant from AstraZenecca to conducted biological analysis in a subgroup of patients from a larger study investigating exacerbation of Chronic Obstructive Pulmonary Disease (NCT03474575). This company had no role in the present study. DV did not receive fee from this company. These competing interests do not alter our adherence to PLOS ONE policies on sharing data and materials.","Grants and funding This work was partly funded by Roche Diagnostics (http://www.roche-diagnostics.fr/), the industrial company that markets the cobas Liat system. Roche Diagnostics had no access to the data and were not involved in the interpretation of the data or the writing of the manuscript. MM received this grant. There was no additional external funding received for this study.","Maxime Maignan 1 , Damien Viglino 1 , Maud Hablot 1 , Nicolas Termoz Masson 1 , Anne Lebeugle 1 , Roselyne Collomb Muret 1 , Prudence Mabiala Makele 1 , Valérie Guglielmetti 1 , Patrice Morand 2 , Julien Lupo 2 , Virginie Forget 3 , Caroline Landelle 3 , Sylvie Larrat 2"
31618876,Remarkable Reduction of Cocaine Use in Dual Disorder (Adult Attention Deficit Hyperactive Disorder/Cocaine Use Disorder) Patients Treated with Medications for ADHD,"Corrado Manni 1, Giada Cipollone 2, Alessandro Pallucchini 3, Angelo G I Maremmani 4 5 6, Giulio Perugi 7, Icro Maremmani 8 9 10",Int J Environ Res Public Health. 2019 Oct 15;16(20):3911. doi: 10.3390/ijerph16203911.,Manni C,Int J Environ Res Public Health,2019,2019/10/18,PMC6843793,,10.3390/ijerph16203911,https://pubmed.ncbi.nlm.nih.gov/31618876/,/31618876/,"G.P. has acted as consultant of Lundbeck, Angelini, FB-Health. He received grant/research support from Lundbeck and Angelini. He is on the speaker/advisory board of Sanofi-Aventis, Lundbeck, FB-Health, Angelini; I.M. served or is serving as speaker/board member for Angelini, Camurus, CT Sanremo, D & A Pharma, Gilead, Indivior, Lundbeck, Molteni, MSD, and Mundipharma; All other authors declare no conflict of interest.",,"Corrado Manni 1 , Giada Cipollone 2 , Alessandro Pallucchini 3 , Angelo G I Maremmani 4 5 6 , Giulio Perugi 7 , Icro Maremmani 8 9 10"
31060621,Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea,"Ho Cheol Kim 1, Tae Hoon Kim 2, Ye-Jee Kim 3, Chin Kook Rhee 4, Yeon-Mok Oh 5",Respir Res. 2019 May 6;20(1):85. doi: 10.1186/s12931-019-1055-5.,Kim HC,Respir Res,2019,2019/05/08,PMC6503445,,10.1186/s12931-019-1055-5,https://pubmed.ncbi.nlm.nih.gov/31060621/,/31060621/,"The study protocol was approved by the Institutional Review Board of Asan Medical Center (approval number 2016–1028) and written informed consent was waived due to the retrospective nature of the study. Not applicable. YM Oh has received consulting/lecture fees from GSK, MSD, AstraZeneca, Novartis, and Boehringer-Ingelheim. CK Rhee has received consulting/lecture fees from MSD, AstraZeneca, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, and Bayer. Other authors have no financial or other potential conflicts of interest. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","Grants and funding HC16C-2254-010017/Ministry of Health and Welfare, Republic of Korea","Ho Cheol Kim 1 , Tae Hoon Kim 2 , Ye-Jee Kim 3 , Chin Kook Rhee 4 , Yeon-Mok Oh 5"
30674053,Efficacy of Disease Management Programs Asthma and COPD? Results of a Cross-Sectional Study,"Frank Kanniess 1, Katja Krockenberger 2 3, Petra Oepen 4 5, Rahel Hedrich 3, Denise Olbrich 3, Nicole Hessler 6, Andreas Ziegler 6 7 8, Birgit Langer-Brauburger 4",Dtsch Med Wochenschr. 2019 Jan;144(2):e1. doi: 10.1055/a-0837-2602. Epub 2019 Jan 23.,Kanniess F,Dtsch Med Wochenschr,2019,2019/01/24,,,10.1055/a-0837-2602,https://pubmed.ncbi.nlm.nih.gov/30674053/,/30674053/,Diese Studie wurde durch die Mundipharma GmbH finanziert. P. O. und B.L-B. sind Mitarbeiterinnen der Mundipharma GmbH. F.K. und A.Z. haben Beraterverträge mit der Mundipharma GmbH. A.Z. ist Mitglied der Schriftleitung der Dtsch Med Wochenschr.,,"Frank Kanniess 1 , Katja Krockenberger 2 3 , Petra Oepen 4 5 , Rahel Hedrich 3 , Denise Olbrich 3 , Nicole Hessler 6 , Andreas Ziegler 6 7 8 , Birgit Langer-Brauburger 4"
31017657,"Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study","D Thaçi 1, K Papp 2, D Marcoux 3, L Weibel 4, A Pinter 5, P-D Ghislain 6, I Landells 7, P H Hoeger 8, K Unnebrink 9, M M B Seyger 10, D A Williams 11, S Rubant 9, S Philipp 12",Br J Dermatol. 2019 Dec;181(6):1177-1189. doi: 10.1111/bjd.18029. Epub 2019 Jul 25.,Thaçi D,Br J Dermatol,2019,2019/04/25,PMC6916374,,10.1111/bjd.18029,https://pubmed.ncbi.nlm.nih.gov/31017657/,/31017657/,"D.T. has served as a consultant member of advisory boards for AbbVie, BMS, Celgene, Dignity, Galapagos, GlaxoSmithKline, Janssen‐Cilag, Kymab, LEO Pharma, Lilly, Morphosis, Novartis, Regeneron, Samsung, Sandoz, Sanofi‐Aventis, Pfizer and UCB; has served as a speaker for AbbVie, Almirall, Celgene, Janssen‐Cilag, LEO Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Sanofi‐Aventis, Sun Pharma and UCB; and has participated as an investigator in clinical trials (for which the hospital has received support) for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dignity, GlaxoSmithKline, Janssen‐Cilag, LEO Pharma, Lilly, MedImmune, Merck Sharp & Dohme, Novartis, Regeneron, Sandoz, Sanofi‐Aventis, Takeda, Pfizer and UCB. K.P. has received honoraria for participation on advisory boards or panels, and as a consultant and speaker, from AbbVie, Active Biotech, Akesis, Allergan, Amgen, Anacor, Astellas, AstraZeneca, Basilea, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol‐Myers Squibb, CanFite, Cato, Cepheid, Celgene, Centocor, Cipher, Coherus, Dow Pharma, Eli Lilly, Endocyte, Ferring Pharma, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Kythera, LEO Pharma, MedImmune, Meiji Seika Pharma, Merck Sharp & Dohme, Merck Serono, Mylan, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Rigel, Roche, Sanofi‐Genzyme, Sosei, Sun Pharma, Takeda, UBC, Vertex and Wyeth; and has received grants as an investigator from AbbVie, Active Biotech, Akesis, Allergan, Amgen, Anacor, Astellas, AstraZeneca, Basilea, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol‐Myers Squibb, CanFite, Cato, Celgene, Centocor, Cepheid, Cipher, Coherus, Dow Pharma, Eli Lilly, Endocyte, Ferring Pharma, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Kythera, LEO Pharma, MedImmune, Meiji Seika Pharma, Merck Sharp & Dohme, Merck Serono, Mylan, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Rigel, Roche, Sanofi‐Genzyme, Sosei, Sun Pharma, Takeda, UBC, Vertex and Wyeth. D.M. has received honoraria from AbbVie, Johnson & Johnson, Pierre Fabre and Galderma for advisory board, consultant and speaker services; and grants from Celgene, Eli Lilly, LEO, Novartis and Sanofi Regeneron for investigator services. L.W. has received honoraria from AbbVie for participation as an investigator of this study, from Novartis for investigator services, and from Pierre Fabre, Meda, Merz, Sanofi and Pfizer for participation on ad boards, as a speaker and for consultancy. A.P. has worked as an investigator and/or speaker and/or advisor for AbbVie, Almirall, Amgen, Biogen, BMS GmbH, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen‐Cilag, GSK, LEO, MSD, Maruho, Medac, Novartis, Pascoe, Pfizer, Pierre Fabre, Roche, Sanofi‐Aventis, Tigercat and UCB Pharma. P.D.G. has received honoraria from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Fien, Galderma, Janssen, LEO, Maruho, Meda, MSD, Novartis, Pfizer and UCB for participation as a consultant, investigator or speaker, and for participation on ad boards. I.L. has received honoraria from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Merck Serono and Valeant for participation as a consultant, investigator or speaker, and for participation on ad boards. P.H.H. has received honoraria for investigator services from AbbVie, Pierre Fabre and Janssen, and for advisory board, consultant and speaker services from Infectopharm, Pierre Fabre, GSK and Almirall. K.U., S.R. and D.A.W. receive a salary as AbbVie employees, and may also own AbbVie stock or stock options. M.M.B.S. has received grants from and was involved in clinical trials with AbbVie, Almirall, Astellas, Janssen, Eli Lilly, LEO Pharma and Pfizer; has served as a consultant for AbbVie, Almirall, Boehringer Ingelheim, Janssen, Lilly and Pfizer; has served as a speaker for Pfizer; and has received honoraria for travel with AbbVie, Pfizer and LEO Pharma; fees were paid directly to the institution. S.P. has received honoraria or grants for speaker services from AbbVie, Almirall, Amgen, Biogen, BMS GmbH, Boehringer Ingelheim, Celgene, Janssen‐Cilag, MSD, Mundipharma, Novartis and UCB Pharma; for advisory board services from AbbVie, Biogen, Eli Lilly, Janssen‐Cilag, LEO Pharma, Pfizer, MSD and Novartis; and for investigator services from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, GSK, Janssen‐Cilag, LEO Pharma, Maruho, MSD, Novartis, Pfizer, UCB Pharma and VBL Therapeutics.",,"D Thaçi 1 , K Papp 2 , D Marcoux 3 , L Weibel 4 , A Pinter 5 , P-D Ghislain 6 , I Landells 7 , P H Hoeger 8 , K Unnebrink 9 , M M B Seyger 10 , D A Williams 11 , S Rubant 9 , S Philipp 12"
31339847,"Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016",Mohsen Naghavi; Global Burden of Disease Self-Harm Collaborators,BMJ. 2019 Feb 6;364:l94. doi: 10.1136/bmj.l94.,Naghavi M,BMJ,2019,2019/07/25,PMC6598639,,10.1136/bmj.l94,https://pubmed.ncbi.nlm.nih.gov/31339847/,/31339847/,"Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: CAA Antonio reports personal fees from Johnson and Johnson (Philippines), Inc, outside the submitted work. LD reports grants from Seqirus, Indivior, and Mundipharma, outside the submitted work. JMH reports personal fees from Lundbeck, Eli Lilly and Co, and Otsuka, outside the submitted work. JJ reports a grant from VALEANT; personal fees from VALEANT, ALAB Laboratoria, and AMGEN; and non-financial support from MICROLIFE and SERVIER, from outside the submitted work. CK has received authorship royalties from Brazilian publishers Artmed and Manole. SL reports personal fees from Akcea Therapeutics, AMGEN, Berlin-Chemie, MSD Sharp and Dohme, Novo Nordisk, Sanofi-Aventis, Synlab, Unilever, and non-financial support from Preventicus outside the submitted work. WM is currently Program Analyst, Population and Development, in the Peru Country Office of the United Nations Population Fund (UNFPA), the institution does not necessarily endorse this study. CP reports other support from South African National Department of Health during the conduct of the study. MP reports grants and personal fees from various pharmaceutical industries, all outside the submitted work. MP holds stocks in Ingress Health and Pharmacoeconomics Advice Groningen (PAG Ltd) and is advisor to Asc Academics. JS reports consulting activities with Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon, Allergan, Fidia, UBM LLC, WebMD, and the American College of Rheumatology; grants from Takeda and Savient; stocks from Amarin Pharmaceuticals; serves as the principal investigator for an investigator-initiated study funded by Horizon Pharmaceuticals through a grant to DINORA, Inc; and is on the steering committee of OMERACT, which receives funding from 36 pharmaceutical companies. MS reports personal fees from Janssen Pharmaceuticals, Bionomics, Aptinyx, and Neurocrine outside the submitted work.",,Mohsen Naghavi; Global Burden of Disease Self-Harm Collaborators
30835879,Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys,"Meredith G Harris 1 2, Chrianna Bharat 3, Meyer D Glantz 4, Nancy A Sampson 5, Ali Al-Hamzawi 6, Jordi Alonso 7 8, Ronny Bruffaerts 9, José Miguel Caldas de Almeida 10, Alfredo H Cia 11, Giovanni de Girolamo 12, Silvia Florescu 13, Oye Gureje 14, Josep Maria Haro 15, Hristo Hinkov 16, Elie G Karam 17 18 19, Georges Karam 20 21, Sing Lee 22, Jean-Pierre Lépine 23, Daphna Levinson 24, Victor Makanjuola 25, John McGrath 26 27 28, Zeina Mneimneh 29, Fernando Navarro-Mateu 30, Marina Piazza 31, José Posada-Villa 32, Charlene Rapsey 33, Hisateru Tachimori 34, Margreet Ten Have 35, Yolanda Torres 36, Maria Carmen Viana 37, Somnath Chatterji 38, Alan M Zaslavsky 5, Ronald C Kessler 5, Louisa Degenhardt 39 ; World Health Organizations World Mental Health Surveys collaborators",Addiction. 2019 Aug;114(8):1446-1459. doi: 10.1111/add.14599. Epub 2019 Jun 2.,Harris MG,Addiction,2019,2019/03/06,PMC7408310,NIHMS1614375,10.1111/add.14599,https://pubmed.ncbi.nlm.nih.gov/30835879/,/30835879/,"Disclosure/Conflicts of Interest: In the past 3 years, L.D. has received investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma and Seqirus. R.C.K. received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. R.C.K. is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. The views expressed in this report are those of the authors and should not be construed to represent the views or policies of the WHO, other sponsoring organisations, agencies, or governments, and do not necessarily represent the views, official policy, or position of the US. Department of Health and Human Services or any of its affiliated institutions or agencies. M.D.G.’s role on this study is through his involvement as a Science Officer on U01-MH60220. He had no involvement in the other cited grants. All other authors have nothing to disclose.",Grants and funding 1099709/National Health and Medical Research Council/International 1081984/National Health and Medical Research Council/International R03 TW006481/TW/FIC NIH HHS/United States 1007677/National Health and Medical Research Council/International 1081984/Australian National Health and Medical Research Council/International Ortho-McNeil Pharmaceutical Inc./International John D. and Catherine T. MacArthur Foundation/International U01 MH060220/MH/NIMH NIH HHS/United States Australian Government Department of Health under the Drug and Alcohol Program/International R01 DA044170/DA/NIDA NIH HHS/United States GlaxoSmithKline/International Pan American Health Organization/International Eli Lilly and Company/International R01 DA016558/DA/NIDA NIH HHS/United States Bristol-Myers Squibb/International R01 MH069864/MH/NIMH NIH HHS/United States Pfizer Foundation/International R01 MH070884/MH/NIMH NIH HHS/United States 1135991/National Health and Medical Research Council/International 001/WHO_/World Health Organization/International R13 MH066849/MH/NIMH NIH HHS/United States Show all 21 grants,"Meredith G Harris 1 2 , Chrianna Bharat 3 , Meyer D Glantz 4 , Nancy A Sampson 5 , Ali Al-Hamzawi 6 , Jordi Alonso 7 8 , Ronny Bruffaerts 9 , José Miguel Caldas de Almeida 10 , Alfredo H Cia 11 , Giovanni de Girolamo 12 , Silvia Florescu 13 , Oye Gureje 14 , Josep Maria Haro 15 , Hristo Hinkov 16 , Elie G Karam 17 18 19 , Georges Karam 20 21 , Sing Lee 22 , Jean-Pierre Lépine 23 , Daphna Levinson 24 , Victor Makanjuola 25 , John McGrath 26 27 28 , Zeina Mneimneh 29 , Fernando Navarro-Mateu 30 , Marina Piazza 31 , José Posada-Villa 32 , Charlene Rapsey 33 , Hisateru Tachimori 34 , Margreet Ten Have 35 , Yolanda Torres 36 , Maria Carmen Viana 37 , Somnath Chatterji 38 , Alan M Zaslavsky 5 , Ronald C Kessler 5 , Louisa Degenhardt 39 ; World Health Organizations World Mental Health Surveys collaborators"
30670697,Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity,"Tuomas O Kilpeläinen 1 2, Amy R Bentley 3, Raymond Noordam 4, Yun Ju Sung 5, Karen Schwander 5, Thomas W Winkler 6, Hermina Jakupović 7, Daniel I Chasman 8 9, Alisa Manning 10 11, Ioanna Ntalla 12, Hugues Aschard 13 14, Michael R Brown 15, Lisa de Las Fuentes 5 16, Nora Franceschini 17, Xiuqing Guo 18, Dina Vojinovic 19, Stella Aslibekyan 20, Mary F Feitosa 21, Minjung Kho 22, Solomon K Musani 23, Melissa Richard 24, Heming Wang 25, Zhe Wang 15, Traci M Bartz 26, Lawrence F Bielak 22, Archie Campbell 27, Rajkumar Dorajoo 28, Virginia Fisher 29, Fernando P Hartwig 30 31, Andrea R V R Horimoto 32, Changwei Li 33, Kurt K Lohman 34, Jonathan Marten 35, Xueling Sim 36, Albert V Smith 37 38, Salman M Tajuddin 39, Maris Alver 40, Marzyeh Amini 41, Mathilde Boissel 42, Jin Fang Chai 36, Xu Chen 43, Jasmin Divers 44, Evangelos Evangelou 45 46, Chuan Gao 47, Mariaelisa Graff 17, Sarah E Harris 27 48, Meian He 49, Fang-Chi Hsu 44, Anne U Jackson 50, Jing Hua Zhao 51, Aldi T Kraja 21, Brigitte Kühnel 52 53, Federica Laguzzi 54, Leo-Pekka Lyytikäinen 55 56, Ilja M Nolte 41, Rainer Rauramaa 57, Muhammad Riaz 58, Antonietta Robino 59, Rico Rueedi 60 61, Heather M Stringham 50, Fumihiko Takeuchi 62, Peter J van der Most 41, Tibor V Varga 63, Niek Verweij 64, Erin B Ware 65, Wanqing Wen 66, Xiaoyin Li 67, Lisa R Yanek 68, Najaf Amin 19, Donna K Arnett 69, Eric Boerwinkle 15 70, Marco Brumat 71, Brian Cade 25, Mickaël Canouil 42, Yii-Der Ida Chen 18, Maria Pina Concas 59, John Connell 72, Renée de Mutsert 73, H Janaka de Silva 74, Paul S de Vries 15, Ayşe Demirkan 19, Jingzhong Ding 75, Charles B Eaton 76, Jessica D Faul 65, Yechiel Friedlander 77, Kelley P Gabriel 78, Mohsen Ghanbari 19 79, Franco Giulianini 8, Chi Charles Gu 5, Dongfeng Gu 80, Tamara B Harris 81, Jiang He 82 83, Sami Heikkinen 84 85, Chew-Kiat Heng 86 87, Steven C Hunt 88 89, M Arfan Ikram 19 90, Jost B Jonas 91 92, Woon-Puay Koh 36 93, Pirjo Komulainen 57, Jose E Krieger 32, Stephen B Kritchevsky 75, Zoltán Kutalik 61 94, Johanna Kuusisto 85, Carl D Langefeld 44, Claudia Langenberg 51, Lenore J Launer 81, Karin Leander 54, Rozenn N Lemaitre 95, Cora E Lewis 96, Jingjing Liang 67 ; Lifelines Cohort Study; Jianjun Liu 28 97, Reedik Mägi 40, Ani Manichaikul 98, Thomas Meitinger 99 100, Andres Metspalu 40, Yuri Milaneschi 101, Karen L Mohlke 102, Thomas H Mosley Jr 103, Alison D Murray 104, Mike A Nalls 105 106, Ei-Ei Khaing Nang 36, Christopher P Nelson 107 108, Sotoodehnia Nona 109, Jill M Norris 110, Chiamaka Vivian Nwuba 7, Jeff OConnell 111 112, Nicholette D Palmer 113, George J Papanicolau 114, Raha Pazoki 45, Nancy L Pedersen 43, Annette Peters 53 115, Patricia A Peyser 22, Ozren Polasek 116 117 118, David J Porteous 27 48, Alaitz Poveda 63, Olli T Raitakari 119 120, Stephen S Rich 98, Neil Risch 121, Jennifer G Robinson 122, Lynda M Rose 8, Igor Rudan 123, Pamela J Schreiner 124, Robert A Scott 51, Stephen S Sidney 125, Mario Sims 23, Jennifer A Smith 22 65, Harold Snieder 41, Tamar Sofer 11 25, John M Starr 48 126, Barbara Sternfeld 125, Konstantin Strauch 127 128, Hua Tang 129, Kent D Taylor 18, Michael Y Tsai 130, Jaakko Tuomilehto 131 132, André G Uitterlinden 133, M Yldau van der Ende 64, Diana van Heemst 4, Trudy Voortman 19, Melanie Waldenberger 52 53, Patrik Wennberg 134, Gregory Wilson 135, Yong-Bing Xiang 136, Jie Yao 18, Caizheng Yu 49, Jian-Min Yuan 137 138, Wei Zhao 22, Alan B Zonderman 139, Diane M Becker 68, Michael Boehnke 50, Donald W Bowden 113, Ulf de Faire 54, Ian J Deary 48 140, Paul Elliott 45 141, Tõnu Esko 40 142, Barry I Freedman 143, Philippe Froguel 42 144, Paolo Gasparini 59 71, Christian Gieger 52 145, Norihiro Kato 62, Markku Laakso 85, Timo A Lakka 57 84 146, Terho Lehtimäki 55 56, Patrik K E Magnusson 43, Albertine J Oldehinkel 147, Brenda W J H Penninx 101, Nilesh J Samani 107 108, Xiao-Ou Shu 66, Pim van der Harst 64 148 149, Jana V Van Vliet-Ostaptchouk 150, Peter Vollenweider 151, Lynne E Wagenknecht 152, Ya X Wang 92, Nicholas J Wareham 51, David R Weir 65, Tangchun Wu 49, Wei Zheng 66, Xiaofeng Zhu 67, Michele K Evans 39, Paul W Franks 63 134 153 154, Vilmundur Gudnason 37 155, Caroline Hayward 35, Bernardo L Horta 30, Tanika N Kelly 82, Yongmei Liu 156, Kari E North 17, Alexandre C Pereira 32, Paul M Ridker 8 9, E Shyong Tai 36 93 157, Rob M van Dam 36 157, Ervin R Fox 158, Sharon L R Kardia 22, Ching-Ti Liu 29, Dennis O Mook-Kanamori 73 159, Michael A Province 21, Susan Redline 25, Cornelia M van Duijn 19, Jerome I Rotter 18, Charles B Kooperberg 160, W James Gauderman 161, Bruce M Psaty 125 162, Kenneth Rice 163, Patricia B Munroe 12 164, Myriam Fornage 24, L Adrienne Cupples 29 165, Charles N Rotimi 3, Alanna C Morrison 15, Dabeeru C Rao 166, Ruth J F Loos 167 168",Nat Commun. 2019 Jan 22;10(1):376. doi: 10.1038/s41467-018-08008-w.,Kilpeläinen TO,Nat Commun,2019,2019/01/24,PMC6342931,,10.1038/s41467-018-08008-w,https://pubmed.ncbi.nlm.nih.gov/30670697/,/30670697/,"Bruce M. Psaty serves on the DSMB of a clinical trial funded by the manufacturer (Zoll LifeCor) and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Brenda W.J.H. Penninx has received research funding (nonrelated to the work reported here) from Jansen Research and Boehringer Ingelheim. Mike A. Nalls’ participation is supported by a consulting contract between Data Tecnica International and the National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. Dr. Nalls also consults for Illumina Inc, the Michael J. Fox Foundation and University of California Healthcare among others, and has a Commercial affiliation with Data Technica International, Glen Echo, MD, USA. Jost B. Jonas serves as a consultant for Mundipharma Co. (Cambridge, UK), patent holder with Biocompatibles UK Ltd. (Franham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and/or anti-angiogenic factor; Patent number: 20120263794), and is patent applicant with University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europäische Patentanmeldung 15,000 771.4). Paul W. Franks has been a paid consultant in the design of a personalized Nutrition trial (PREDICT) as part of a private-public partnership at Kings College London, UK, and has received research support from several pharmaceutical Companies as part of European Union Innovative Medicines Initiative (IMI) Projects. Terho Lehtimäki is employed by Fimlab Ltd. Ozren Polasek is employed by Gen-info Ltd. The remaining authors declare no competing interests.",Grants and funding MC_UU_12015/1/MRC_/Medical Research Council/United Kingdom R01 HL142302/HL/NHLBI NIH HHS/United States P30 DK020541/DK/NIDDK NIH HHS/United States P30 DK020572/DK/NIDDK NIH HHS/United States BB/F019394/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom R01 DK093757/DK/NIDDK NIH HHS/United States U01 HG007417/HG/NHGRI NIH HHS/United States R01 HL120393/HL/NHLBI NIH HHS/United States R01 HL046380/HL/NHLBI NIH HHS/United States K01 HL136700/HL/NHLBI NIH HHS/United States U01 AG009740/AG/NIA NIH HHS/United States U01 HL120393/HL/NHLBI NIH HHS/United States R01 HL113338/HL/NHLBI NIH HHS/United States R01 DK072193/DK/NIDDK NIH HHS/United States R01 DK107786/DK/NIDDK NIH HHS/United States UM1 CA173640/CA/NCI NIH HHS/United States P30 DK079626/DK/NIDDK NIH HHS/United States P30 DK056341/DK/NIDDK NIH HHS/United States MR/L01341X/1/MRC_/Medical Research Council/United Kingdom R01 DK075787/DK/NIDDK NIH HHS/United States R01 HL119443/HL/NHLBI NIH HHS/United States R01 HL118305/HL/NHLBI NIH HHS/United States R01 DK062370/DK/NIDDK NIH HHS/United States R01 HL105756/HL/NHLBI NIH HHS/United States R35 HL135818/HL/NHLBI NIH HHS/United States MR/R023484/1/MRC_/Medical Research Council/United Kingdom R01 AG055406/AG/NIA NIH HHS/United States MR/L01632X/1/MRC_/Medical Research Council/United Kingdom U01 HL137162/HL/NHLBI NIH HHS/United States M01 RR000032/RR/NCRR NIH HHS/United States MC_UU_00007/10/MRC_/Medical Research Council/United Kingdom U01 DK062370/DK/NIDDK NIH HHS/United States T32 DK091317/DK/NIDDK NIH HHS/United States P01 CA196569/CA/NCI NIH HHS/United States UM1 CA182910/CA/NCI NIH HHS/United States P2C HD050924/HD/NICHD NIH HHS/United States K01 HL135405/HL/NHLBI NIH HHS/United States MR/K026992/1/MRC_/Medical Research Council/United Kingdom Show all 38 grants,"Tuomas O Kilpeläinen 1 2 , Amy R Bentley 3 , Raymond Noordam 4 , Yun Ju Sung 5 , Karen Schwander 5 , Thomas W Winkler 6 , Hermina Jakupović 7 , Daniel I Chasman 8 9 , Alisa Manning 10 11 , Ioanna Ntalla 12 , Hugues Aschard 13 14 , Michael R Brown 15 , Lisa de Las Fuentes 5 16 , Nora Franceschini 17 , Xiuqing Guo 18 , Dina Vojinovic 19 , Stella Aslibekyan 20 , Mary F Feitosa 21 , Minjung Kho 22 , Solomon K Musani 23 , Melissa Richard 24 , Heming Wang 25 , Zhe Wang 15 , Traci M Bartz 26 , Lawrence F Bielak 22 , Archie Campbell 27 , Rajkumar Dorajoo 28 , Virginia Fisher 29 , Fernando P Hartwig 30 31 , Andrea R V R Horimoto 32 , Changwei Li 33 , Kurt K Lohman 34 , Jonathan Marten 35 , Xueling Sim 36 , Albert V Smith 37 38 , Salman M Tajuddin 39 , Maris Alver 40 , Marzyeh Amini 41 , Mathilde Boissel 42 , Jin Fang Chai 36 , Xu Chen 43 , Jasmin Divers 44 , Evangelos Evangelou 45 46 , Chuan Gao 47 , Mariaelisa Graff 17 , Sarah E Harris 27 48 , Meian He 49 , Fang-Chi Hsu 44 , Anne U Jackson 50 , Jing Hua Zhao 51 , Aldi T Kraja 21 , Brigitte Kühnel 52 53 , Federica Laguzzi 54 , Leo-Pekka Lyytikäinen 55 56 , Ilja M Nolte 41 , Rainer Rauramaa 57 , Muhammad Riaz 58 , Antonietta Robino 59 , Rico Rueedi 60 61 , Heather M Stringham 50 , Fumihiko Takeuchi 62 , Peter J van der Most 41 , Tibor V Varga 63 , Niek Verweij 64 , Erin B Ware 65 , Wanqing Wen 66 , Xiaoyin Li 67 , Lisa R Yanek 68 , Najaf Amin 19 , Donna K Arnett 69 , Eric Boerwinkle 15 70 , Marco Brumat 71 , Brian Cade 25 , Mickaël Canouil 42 , Yii-Der Ida Chen 18 , Maria Pina Concas 59 , John Connell 72 , Renée de Mutsert 73 , H Janaka de Silva 74 , Paul S de Vries 15 , Ayşe Demirkan 19 , Jingzhong Ding 75 , Charles B Eaton 76 , Jessica D Faul 65 , Yechiel Friedlander 77 , Kelley P Gabriel 78 , Mohsen Ghanbari 19 79 , Franco Giulianini 8 , Chi Charles Gu 5 , Dongfeng Gu 80 , Tamara B Harris 81 , Jiang He 82 83 , Sami Heikkinen 84 85 , Chew-Kiat Heng 86 87 , Steven C Hunt 88 89 , M Arfan Ikram 19 90 , Jost B Jonas 91 92 , Woon-Puay Koh 36 93 , Pirjo Komulainen 57 , Jose E Krieger 32 , Stephen B Kritchevsky 75 , Zoltán Kutalik 61 94 , Johanna Kuusisto 85 , Carl D Langefeld 44 , Claudia Langenberg 51 , Lenore J Launer 81 , Karin Leander 54 , Rozenn N Lemaitre 95 , Cora E Lewis 96 , Jingjing Liang 67 ; Lifelines Cohort Study; Jianjun Liu 28 97 , Reedik Mägi 40 , Ani Manichaikul 98 , Thomas Meitinger 99 100 , Andres Metspalu 40 , Yuri Milaneschi 101 , Karen L Mohlke 102 , Thomas H Mosley Jr 103 , Alison D Murray 104 , Mike A Nalls 105 106 , Ei-Ei Khaing Nang 36 , Christopher P Nelson 107 108 , Sotoodehnia Nona 109 , Jill M Norris 110 , Chiamaka Vivian Nwuba 7 , Jeff OConnell 111 112 , Nicholette D Palmer 113 , George J Papanicolau 114 , Raha Pazoki 45 , Nancy L Pedersen 43 , Annette Peters 53 115 , Patricia A Peyser 22 , Ozren Polasek 116 117 118 , David J Porteous 27 48 , Alaitz Poveda 63 , Olli T Raitakari 119 120 , Stephen S Rich 98 , Neil Risch 121 , Jennifer G Robinson 122 , Lynda M Rose 8 , Igor Rudan 123 , Pamela J Schreiner 124 , Robert A Scott 51 , Stephen S Sidney 125 , Mario Sims 23 , Jennifer A Smith 22 65 , Harold Snieder 41 , Tamar Sofer 11 25 , John M Starr 48 126 , Barbara Sternfeld 125 , Konstantin Strauch 127 128 , Hua Tang 129 , Kent D Taylor 18 , Michael Y Tsai 130 , Jaakko Tuomilehto 131 132 , André G Uitterlinden 133 , M Yldau van der Ende 64 , Diana van Heemst 4 , Trudy Voortman 19 , Melanie Waldenberger 52 53 , Patrik Wennberg 134 , Gregory Wilson 135 , Yong-Bing Xiang 136 , Jie Yao 18 , Caizheng Yu 49 , Jian-Min Yuan 137 138 , Wei Zhao 22 , Alan B Zonderman 139 , Diane M Becker 68 , Michael Boehnke 50 , Donald W Bowden 113 , Ulf de Faire 54 , Ian J Deary 48 140 , Paul Elliott 45 141 , Tõnu Esko 40 142 , Barry I Freedman 143 , Philippe Froguel 42 144 , Paolo Gasparini 59 71 , Christian Gieger 52 145 , Norihiro Kato 62 , Markku Laakso 85 , Timo A Lakka 57 84 146 , Terho Lehtimäki 55 56 , Patrik K E Magnusson 43 , Albertine J Oldehinkel 147 , Brenda W J H Penninx 101 , Nilesh J Samani 107 108 , Xiao-Ou Shu 66 , Pim van der Harst 64 148 149 , Jana V Van Vliet-Ostaptchouk 150 , Peter Vollenweider 151 , Lynne E Wagenknecht 152 , Ya X Wang 92 , Nicholas J Wareham 51 , David R Weir 65 , Tangchun Wu 49 , Wei Zheng 66 , Xiaofeng Zhu 67 , Michele K Evans 39 , Paul W Franks 63 134 153 154 , Vilmundur Gudnason 37 155 , Caroline Hayward 35 , Bernardo L Horta 30 , Tanika N Kelly 82 , Yongmei Liu 156 , Kari E North 17 , Alexandre C Pereira 32 , Paul M Ridker 8 9 , E Shyong Tai 36 93 157 , Rob M van Dam 36 157 , Ervin R Fox 158 , Sharon L R Kardia 22 , Ching-Ti Liu 29 , Dennis O Mook-Kanamori 73 159 , Michael A Province 21 , Susan Redline 25 , Cornelia M van Duijn 19 , Jerome I Rotter 18 , Charles B Kooperberg 160 , W James Gauderman 161 , Bruce M Psaty 125 162 , Kenneth Rice 163 , Patricia B Munroe 12 164 , Myriam Fornage 24 , L Adrienne Cupples 29 165 , Charles N Rotimi 3 , Alanna C Morrison 15 , Dabeeru C Rao 166 , Ruth J F Loos 167 168"